Stockley’s Herbal Medicines Interactions
Stockley’s Herbal Medicines Interactions

A guide to the interactions of herbal medicines, dietary supplements and nutraceuticals with conventional medicines

Editors

Elizabeth Williamson, BSc, PhD, MRPharmS, FLS
Samuel Driver, BSc
Karen Baxter, BSc, MSc, MRPharmS

Editorial Staff

Mildred Davis, BA, BSc, PhD, MRPharmS
Rebecca E Garner, BSc
C Rhoda Lee, BPharm, PhD, MRPharmS
Alison Marshall, BPharm, DipClinPharm, PGCertClinEd, MRPharmS
Rosalind McLarney, BPharm, MSc, MRPharmS
Jennifer M Sharp, BPharm, DipClinPharm, MRPharmS

Digital Products Team

Julie McGlashan, BPharm, DipInfSc, MRPharmS
Elizabeth King, Dip BTEC PharmSci
Contents

Preface vi
Abbreviations viii

General Considerations 1
   Structure of the publication 1
   Data selection 2
   Nomenclature 2
   Incidence of herbal medicines interactions 2
   Who uses herbal medicines? 3
   Herbal medicine use in specific patient groups 3
   Differences in herbal use in specific population groups 4
   Attitudes to the use of herbal medicines 5

Interactions between herbal medicines and conventional drugs 6
Variability of herbal medicines 6
Mechanisms of interactions 7
Pharmacokinetics 7
Cytochrome P450 isoenzymes 7
Drug transporter proteins 9
Pharmacodynamic interactions 10
Drawing your own conclusions 10

Interaction monographs A to Z by herbal medicinal product 13

Index 403
Preface

This first edition of *Stockley's Herbal Medicines Interactions* is an exciting new addition to the Stockley family of products, and one that has been several years in the planning and execution. When researching *Stockley's Drug Interactions* we had noticed the growing wealth of experimental data on herbal medicines, which does not fall within the brief of Stockley, which is primarily a clinically based reference work. However, it seemed somewhat of an omission to overlook what is obviously valuable information in what can almost be considered a new field of drug interactions. We therefore reached the point where we decided that it was worth producing a book dedicated to this information; however, little did we realise what a journey we’d be taking ourselves on.

As a group dedicated to the study of drug interactions, and the provision of clinically relevant data (aided by the large number of practising pharmacists we have on our team), we felt well equipped to deal with the interactions data. The herbal medicines side of things was, however, not something that we were particularly familiar with, and we were greatly relieved to be approached by Elizabeth Williamson, with a very similar idea to our own, but with a wealth of knowledge on herbal medicines with which to guide us. Liz is widely published in the field of herbal medicines, and is a member of a number of bodies that consider many aspects of herbal medicine use, such as the British Pharmacopoeia Commission. Liz is the Chair of the Expert Advisory Group for Herbal and Complementary Medicines, which advises the BPC on standards for herbal drugs for the pharmaceutical industry. As a team therefore, we feel we have unrivalled experience in assessing herb-drug interactions, and we believe that ours is a unique collaboration.

Herbal medicines are, more than ever, receiving attention, both from the public and healthcare professionals alike, with many countries now undertaking registration schemes for traditional medicines. However, healthcare professionals still freely admit their lack of knowledge in this area, and surveys suggest that patients often rely on friends and family for advice about herbal medicines. Never has there been a more appropriate time to advise healthcare professionals so that they can provide balanced, helpful advice to patients wishing to take herbal medicines with their ‘conventional’ treatments. Our aim, as ever, has therefore been to critically evaluate the published literature and present it in a familiar, easy-to-handle format, so that the busy healthcare professional can quickly access the information and apply it to their clinical situation.

This publication attempts to answer the same questions that we address in *Stockley's Drug Interactions*, namely:

- Are the drugs and substances in question known to interact or is the interaction only theoretical and speculative?
- If they do interact, how serious is it?
- Has it been described many times or only once?
- Are all patients affected or only a few?
- Is it best to avoid these two substances altogether or can the interaction be accommodated in some way?
- And what alternative and safer drugs can be used instead?

*Stockley's Herbal Medicines Interactions* follows the same easy-to-read format as our other publications, with the text organised into a series of individual monographs, all with a common format. In addition, we have included sections on: nomenclature, to help users identify herbal medicines that they or their patients may be familiar with under a different name; uses, so that those less familiar with herbal medicines can put their use into context; and constituents, to allow us to address interactions that occur as a result of a substance common to several plants. A pharmacopoeia section is also included for those herbal medicines, dietary supplements and nutraceuticals that have entries in the latest editions (at time of press) of the *British Pharmacopoeia*, the *European Pharmacopoeia* and the *United States Pharmacopoeia*. An indication of the constituents that the herbal medicine may be standardised for is also provided where necessary, but note that this does not necessarily mean that all marketed products are standardised in this way. In addition, we have added the simple, intuitive ratings system that users of *Stockley’s Interaction Alerts* and *Stockley’s Drug Interactions Pocket Companion* will already be familiar with.

As with all Stockley products, the text is written for a worldwide audience. Terminology has been carefully considered and international terms have been added where it was thought helpful to do so. This and the inclusion of the synonyms and pharmacopoeia sections will, we hope, cater for the needs of healthcare professionals around the world.

As always, the Editorial team have had assistance from many other people in developing this publication, and the Editors gratefully acknowledge the assistance and guidance that they have provided. Of particular note are: the Digital Products Team led by Jane Macintyre; Ithar Malik, Ruchi Birla, Karl Parsons, Tom Whitaker and Darren Searson, who
have worked tirelessly in transforming our data into a usable output. Particular thanks are also due to the editor of *Martindale*, Sean Sweetman, who has acted as our mentor on a number of other projects, and continues to provide invaluable support. Thanks are also due to Tamsin Cousins, who has handled the various aspects of producing this publication in print. We are also grateful for the support of both Paul Weller and Charles Fry. Ivan Stockley remains an important part of all products bearing his name, and we are most grateful for the feedback that he provided on this new project.

*Stockley’s Herbal Medicines Interactions* is available on the Pharmaceutical Press platform, *MedicinesComplete*, and we are indebted to Julie McGlashan and Elizabeth King, and all those involved in the development of these products, for their advice and support. For more details about these digital products please visit: www.pharmpress.com/Stockley

We are always interested in hearing feedback from users of our publications, and have in the past received many useful comments, which help us to develop the product to best meet the needs of the end-user. Anyone who wishes to contact us can do so at the following address: stockley@rpsgb.org

Sam Driver, Karen Baxter and Elizabeth Williamson
London, February 2009
Abbreviations

ACE  angiotensin-converting enzyme
ADP  adenosine diphosphate
AIDS acquired immune deficiency syndrome
ALT  alanine aminotransferase
aPTT activated partial thromboplastin time
AST  aspartate aminotransferase
ATP  adenosine triphosphate
AUC  area under the time–concentration curve
AUC_{0-12} area under the time–concentration curve measured over 0 to 12 hours
AV   atrioventricular
BCRP breast cancer resistance protein
BP   blood pressure
BP British Pharmacopoeia
bpm  beats per minute
CNS  central nervous system
COX  cyclo-oxygenase
CSF  cerebrospinal fluid
CSM  Committee on Safety of Medicines (UK) (now subsumed within the Commission on Human Medicines)
ECG  electrocardiogram
ECT  electroconvulsive therapy
e.g. exempli gratia (for example)
EMEA The European Agency for the Evaluation of Medicinal Products
FDA  Food and Drug Administration (USA)
FSH  follicle-stimulating hormone
g gram(s)
HAART highly active antiretroviral therapy
HIV human immunodeficiency virus
HRT hormone replacement therapy
i.b. ibidem, in the same place (journal or book)
i.e. id est (that is)
INR  international normalised ratio
IU   international units
IUD  intra-uterine device
kg  kilogram(s)
L   litre(s)
LDL low-density lipoprotein
LFT liver function test
LH luteinising hormone
LMWH low-molecular-weight heparin
MAC minimum alveolar concentration
MAO monoamine oxidase
MAOI monoamine oxidase inhibitor
MHRA Medicines and Healthcare products Regulatory Agency (UK)
MID minimum inhibitory concentration
mEq milliequivalent(s)
mg milligram(s)
ml millilitre(s)
mmHg millimetre(s) of mercury
mmol millimole
mol mole
nmol nanomole
NNRTI non-nucleoside reverse transcriptase inhibitor
NRTI nucleoside reverse transcriptase inhibitor
NSAID non-steroidal anti-inflammatory drug
OATP organic anion transporting polypeptide
PCP pneumocystis pneumonia
pH the negative logarithm of the hydrogen ion concentration
Ph Eur European Pharmacopoeia, 6th ed., 2008 and Supplements 6.1, 6.2, 6.3 and 6.4
PPI proton pump inhibitor
ppm parts per million
PTT partial thromboplastin time
sic written exactly as it appears in the original
SNRI serotonin and noradrenaline reuptake inhibitor
SSRI selective serotonin reuptake inhibitor
TSH thyroid-stimulating hormone
UK United Kingdom
USP The United States Pharmacopoeia
US and USA United States of America
WHO World Health Organization
General considerations

Structure of the publication
The basic issues involved in assessing the importance of interactions between herbal medicines (which for the purposes of this book are also taken to include nutritional supplements and some items of food) and drugs are similar to those for interactions between conventional drugs, but for herbal medicines the picture is complicated by their very nature: they are complex mixtures themselves and there is also a lack of reliable information about their occurrence and relevance.

Before using this publication it is advisable to read this short explanatory section so that you know how the drug interaction data have been set out here, and why, as well as the basic philosophy that has been followed in presenting it.

The monographs
This publication includes over 150 herbal medicines, nutraceuticals or dietary supplements. For each of these products there is an introductory section, which includes the following sections where appropriate:

- Synonyms and related species or Types, sources and related compounds
- Pharmacopoeias
- Constituents
- Uses and indications
- Pharmacokinetics
- Interactions overview.

The synonyms, constituents and uses have largely been compiled with reference to a number of standard sources. These include:


More than 550 interactions monographs are included, each with a common format. These are subdivided into the following sections:

- Abstract or summary for quick reading.

- Clinical evidence, detailing the interaction and citing the clinical evidence currently available.

- Experimental evidence. Due to the nature of interactions with herbal medicines much of the data currently available comes from animal and in vitro studies. Although this data doesn’t always extrapolate to the clinical situation it can be used to provide some idea of the likelihood and potential severity of an interaction. It has been deliberately kept separate from the clinical data, because this type of data is a better guide to predicting outcomes in practice.

- Mechanism, to allow an understanding as to why the interaction may occur.

- Importance and management. As with all Stockley products, providing guidance on how to manage an interaction is our key aim. The short discussion is designed to aid rapid clinical decision-making.

- References, a list of all of the relevant references.

Some of the monographs have been compressed into fewer subsections instead of the more usual five, simply where information is limited or where there is little need to be more expansive.

The monographs also carry an adapted form of the drug interaction Hazard/Severity ratings as used in the electronic Stockley Interactions Alerts and Stockley’s Drug Interactions Pocket Companion. Where difficulties arise in applying ratings to monographs that cover multiple pairs of drug–herb interactions, we have chosen to illustrate the worst-case scenario. Reading the Importance and management section will explain which members of the groups are most likely to represent a problem.

The interactions are rated using three separate categories:

- Action: this describes whether or not any action needs to be taken to accommodate the interaction. This category ranges from ‘avoid’ to ‘no action needed’.

- Severity: this describes the likely effect of an unmanaged interaction on the patient. This category ranges from ‘severe’ to ‘nothing expected’.

- Evidence: this describes the weight of evidence behind the interaction. This category ranges from ‘extensive’ to ‘theoretical, weak’.

These ratings are combined to produce one of five symbols:

- ☒ For interactions that have a life-threatening outcome, or where concurrent use is considered to be best avoided.

- ⚠ For interactions where concurrent use may result in a significant hazard to the patient and so dosage adjustment or close monitoring is needed.
For interactions where there is a potentially hazardous outcome, but where, perhaps, the data is poor and conclusions about the interaction are difficult to draw.

For interactions where there is doubt about the outcome of concurrent use, and therefore it may be necessary to give patients some guidance about possible adverse effects, and/or consider some monitoring.

For interactions that are not considered to be of clinical significance, or where no interaction occurs.

We put a lot of thought in to the original design of these symbols, and have deliberately avoided a numerical or colour-coding system as we did not want to imply any relationship between the symbols and colours. Instead we chose internationally recognisable symbols, which in testing were intuitively understood by our target audience of healthcare professionals.

There are also several ‘family monographs’ included. These are for constituents that have been demonstrated to interact in their own right, but which are prevalent in a number of herbal medicines, the most common example of this being the flavonoids. This structure allows us to assess the relevant data in one place, and cross-reference the reader as appropriate. Because so many herbs contain a multitude of these constituents it would not be possible to cover them in each plant monograph.

Data selection

This publication has been produced by the team that writes Stockley’s Drug Interactions, with the help and guidance of an expert in the herbal medicines field. The same rigorous approach that is used to produce Stockley’s Drug Interactions has been applied here, although with some notable differences, particularly in the selection of data for inclusion. The data on interactions are of widely varying quality and reliability, and this is even more the case when considering interactions between herbal medicines and conventional drugs. The best information comes from clinical studies conducted on large numbers of patients under scrupulously controlled conditions; however, with herbal medicines these are sparse. Indeed those that there are have already been included in Stockley’s Drug Interactions. What this publication attempts to do is assess the wealth of data from animal and in vitro studies, which would not normally be considered for inclusion in Stockley’s Drug Interactions.

As with all our publications we undertake extensive literature searching, we consider guidance published by regulatory bodies and we aim to avoid citing secondary literature wherever possible. Some of the studies cited in herb–drug interaction articles or publications are of doubtful quality and some are merely speculation. We have included them because they appear in other reference sources for interactions, but we have attempted to put their results and recommendations in perspective.

The herbal medicines, dietary supplements and nutraceuticals selected for inclusion in this first edition were chosen on the basis of their popularity and/or because they have interaction reports associated them.

Nomenclature

Every care has been taken to correctly identify the herbal medicine involved in interactions. The botanical nomenclature and the vast number of colloquial names used for the plants can be very confusing. We have therefore adopted one name for each herbal medicine that is used consistently throughout the monograph, and indeed across the publication. However, we are aware that we will not always have selected the most appropriate name for some countries and have therefore included a synonyms field to aid users who know the plant by different names. The synonyms come from several well-respected sources and, where botanical names are used, have been cross-checked against the extremely useful database constructed by Kew (Royal Botanic Gardens, Kew (2002). electronic Plant Information Centre. Available at http://epic.kew.org/epic/). Occasionally the same synonym has been used for more than one herbal medicine and, where we are aware of this, we have been careful to highlight the potential for confusion.

We should also point out that we have chosen the phrase ‘conventional medicines’ to distinguish those products that are licensed and commonly used in Western medicine. This nomenclature is not meant to imply any preference, it is just simply a way of being clear about which preparation we are discussing.

Similarly, there is the potential for confusion between the synthetic coumarins used as anticoagulants (e.g. warfarin, acenocoumarol) and those coumarins that occur naturally within plants. We have therefore chosen to use the term ‘coumarins’ for those of synthetic origin, and ‘natural coumarins’ to distinguish those of plant origin.

Incidence of herbal medicines interactions

The incidence of interactions between herbal medicines and nutritional supplements with conventional drugs is not yet fully known, and there is no body of reliable information currently available to draw upon when assessing the scale of any possible problem, or predicting clinical outcomes. Even in the case of St John’s wort, which is now commonly known to interact with a number of drugs, the clinical significance of some reported cases cannot be accurately evaluated due to the variation in the nature of the herb itself and products made from it. In general, the lack of evidence may be due to under-reporting or unrecognised interactions, but there is also the possibility that many herbal medicines have a generally safe profile and do not interact significantly with drugs. Given the poor quality of information available it can be difficult to put the problem into perspective and in the absence of good evidence, speculation has taken its place. Ivan Stockley, a pioneer in the field of drug-interaction investigation, has often maintained that data on interactions are of widely varying quality and reliability, and stated that ‘sometimes they are no more than speculative and theoretical scaremongering guesswork, hallowed by repeated quotation until they become virtually set in stone’. Although these remarks were made in the context of drug interactions, they are even more apposite when applied to herb–drug interactions where anecdotal reports, uncontrolled studies or data based solely on animal studies are the main form of evidence available. These have to be evaluated very carefully before advising patients as to the safety (or not) of combining herbal medicines with either other supplements or conventional drugs. While many publications uncritically use theoretical evidence to advise on this issue, it risks the danger that patients (and their friends and families) who have
already taken supplements and drugs together with no problems will no longer believe even good advice – and subsequently take incompatible combinations to ill effect. It is also noticeable that, whilst anecdotal or theoretical evidence is quite rightly considered unacceptable as evidence of efficacy for herbal products, it seems to be given undue credibility when demonstrating toxicity, and consumers of natural medicines have observed this double standard. Obviously the best answer to this problem is for good and reliable evidence to become available, and for the importance of reports to be based on the nature of the evidence that they provide. In the first instance, it would be most useful to know the extent of the problem and the risk or likelihood of a herb–drug interaction arising. However, even numbers of people taking supplements is not accurately known, although over the past 10 years several studies have been carried out to try to assess this. Some knowledge of not only who, but how and why people are taking herbal medicines can help to identify potential problems or warn of them before they arise.

**Who uses herbal medicines?**

The use of herbal medicines and nutritional supplements is increasing dramatically in many parts of the world, especially in Europe, the US and Australasia, as part of the popularity of complementary and alternative medicine (CAM). It is difficult to measure the extent of the use of herbal products by consumers and patients in a largely unregulated market, especially with so many herbal products being sold over the internet, and survey studies that have attempted to do so have often been criticised for flawed methodology. However, there is no doubt that the issue of people taking herbal and nutritional products at the same time as conventional medicines is significant, and the purpose of this publication is to provide information so that this practice can be carried out as safely as possible.

Some idea of the size of the market and its recent growth can be seen from a series of studies carried out over the past few years in the US. In 1997, the results of a national survey indicated that approximately 12% of the adult responders had taken a herbal remedy in the past year, which was an increase of 380% from 1990, and almost 1 in 5 of those taking prescription drugs were also taking a herbal or vitamin supplement. In 1998 and 1999, a survey of over 2500 adults estimated that 14% of the general population were regularly taking herbal products and, of patients taking prescription drugs, 16% also took a herbal supplement. Data obtained from a separate 1999 survey estimated that 9.6% of US adults used herbal medicines, which was lower than would be expected from the previous study, and illustrates the problems of assessing consumer behaviour accurately, but it is still a significant increase from the 1990 figures. By 2002, figures showed that the annual use of dietary supplements had risen to 18.8%. Although the accuracy of these figures can be questioned, what is also noteworthy is that the studies were carried out in the general population, so it is logical to assume that in the patient population usage could be even higher.

A survey undertaken in the UK in 1994 suggests that the prevalence of alternative medicine use (which included herbal medicines) was 8.5% of the population, whereas in Germany, in 1996, it was much higher, at 65%. The low figure for the UK could be because of national differences, because different types of use were assessed (1-year versus lifetime) or because, at the time, the UK was undergoing a difficult economic period and usually CAM is paid for privately. Useful information about herbal medicinal use can also be obtained from the monetary value of the market. In 2002, French health insurance paid $91 million in partial reimbursements for ginkgo, saw palmetto and pygeum prescriptions, with a total value of $196 million, and, in 2003, German health insurance paid $283 million in reimbursements for prescribed herbal products including ginkgo, St John’s wort, saw palmetto, hawthorn, stinging nettle root and pumpkin seed. These figures do not include non-prescription purchase of herbal remedies, but it is known that, in 2003, European countries spent almost $5 billion (at manufacturers’ prices) on non-prescription herbal medicines, and of course the cost at consumer level would be very much higher.


**Herbal medicine use in specific patient groups**

(a) **Cancer patients**

Certain groups of patients are known, or thought to have, a higher incidence of supplement usage than others. It is generally thought that cancer patients, for example, have an exceptionally high intake of herbal and nutritional supplements. One of the first studies to collate the information available on CAM use in cancer patients was from 1998, when a systematic review of 26 surveys from 13 countries was published. CAM use in adults ranged from 7 to 64%, with an average use of 31.4%. The high degree of variability was thought to be most likely due to different understandings of the term CAM on the part of both investigators and patients, but also illustrates that the results of such surveys must be interpreted very carefully. A subsequent study showed that CAM use (both self-medication and visits to CAM practitioners) had increased significantly from 1998 to 2005 in cancer patients, and it was estimated that more than 80% of all women with breast cancer use CAM, 41% in a specific attempt to manage their breast cancer. The most commonly used herbal products for this purpose in 2005 were flaxseed, green tea and vitamins (C and E). A US survey of outpatients with cancer found that 83.3% had used at least one CAM. Vitamins and herbal medicines were used by 62.6% of patients, and use was greater in women and those of a younger age. These findings were reflected in a 2005 study which confirmed that, of the chemotherapy patients surveyed, 91% reported using at least one form of CAM (most frequently diets, massage and herbal medicine). Of these patients only 57%...
discussed the use of at least one of these therapies with their healthcare provider.4

Herbal medicine use by cancer patients seems to be high in many parts of the world: in New Zealand 49% of cancer patients at a regional centre used CAM (most commonly vitamins, antioxidants, alternative diets and herbal medicines) to improve the quality of life and in the hope of a cure (47% and 30% of CAM users, respectively). CAM was deemed helpful in the management of their cancer by 71% of patients, and 89% felt that CAM was safe. Younger patients tended to use CAM more.5 The different patterns of herbal use between cancer patients undergoing palliative or curative chemotherapy has also been studied, and the results confirmed that both groups frequently use herbal remedies concurrently with chemotherapy (37% and 38%, respectively), but with a slightly different intent. Palliative patients tended to show more frequent herbal use than curative patients (78% versus 67%), whereas curative patients used herbal remedies much more often to relieve adverse effects (31% versus 3%).6

(b) Patients on weight-loss programmes

Other groups of patients known to use supplements regularly are those on weight-loss programmes and most of the weight-loss supplements taken (73.8%) contained stimulants such as ephedra, caffeine and/or bitter orange. An estimated 15.2% of American adults (women 20.6%, men 9.7%) had used a weight-loss supplement at some time: 8.7% within the past year (women 11.3%, men 6%). Women aged 18 to 34 years used weight-loss supplements the most (16.7%), and use was equally prevalent among ethnic groups and education levels. More worryingly, many adults were long-term users and most did not discuss this practice with their doctor.7

(c) Hospital inpatients

A study of herbal medicine use during perioperative care identified the most commonly used medications and assessed their potential for causing adverse events or drug interactions in patients who were having surgical procedures. Their conclusions were that certain herbal medicines posed a potential danger in perioperative care (such as St John’s wort because of its enzyme-inducing effects and valerian because of its sedative effects), but no attempt was made to ascertain the incidence of such events.8 However, in 2007, a study of 299 patients on the medical wards of two hospitals in Israel found that 26.8% of participants took herbal medicines or dietary supplements and, of these, potential interactions were noted in 7.1%. The authors suggested that most patients are not asked specifically about herbal consumption by their medical team.9


Differences in herbal use in specific population groups

(a) The elderly

CAM use is high in those of 65 years of age and over (27.7% according to one US study), but declines among those aged 75 years and over and, overall, more women than men are CAM users. The highest level of use seems to be among Asians (48.6%), followed by Hispanics (31.6%), whites (27.7%) and blacks (20.5%). Data drawn from a 2002 survey that included a supplement on the use of herbal medicines, with the analysis limited to adults aged 65 years and older, showed that herbs were an important component of their own health management. Whereas about 25% of the Asian and Hispanic elderly used herbal medicines, only about 10% of the black and white elderly used them; the herbs used, and the reasons for doing so, also differed according to ethnicity.2

It is also apparent that, in the elderly, the use of herbal medicines with conventional medicines, both prescription and non-prescription, is widespread. The risk for adverse interactions was assessed in a Medicare population, using a retrospective analysis of Cardiovascular Health Study interview data from four different years. Of 5052 participants, the median age at the beginning of the study was 75 years, 60.2% were female, 16.6% were African-American and 83.4% were white. From 1994 to 1999 the number using herbal medicines increased from 6.3% to 15.1%, and the number using herbal medicines concurrently with conventional drugs also increased, from 6% to 14.4%. Combinations thought to be potentially risky were noted in 393 separate interviews, with most (379 reports in 281 patients) involving a risk of bleeding due to use of garlic, ginkgo or ginseng together with aspirin, warfarin, ticlopidine or pentoxifylline. An additional 786 drug-herb combinations were considered to have some (again) theoretical or uncertain risk for an adverse interaction.3

The type of products taken obviously reflect the age group taking them, and the most common products used by the elderly are those concerned with ameliorating degenerative or age-related conditions. In a predominantly white (91%) elderly cohort, the use of dietary supplements was surveyed each year from 1994 to 1999 for an average of 359 male (36%) and female (64%) participants aged 60 to 99 years. By 1999, glucosamine emerged as the most frequently used (non-vitamin, non-mineral) supplement followed by ginkgo, chondroitin and garlic. For women, there was a significant trend of increasing use for black cohosh, starflower oil, evening primrose oil, flaxseed oil, chondroitin, prasterone (dehydroyipandrosterone), garlic, ginkgo, glucosamine, grapeseed extract, hawthorn and St John’s wort. For men, alpha-lipoic acid, ginkgo and grapeseed extract showed a similar trend.4
(b) Children
Surprisingly, herbal medicine and nutritional supplement use in children can also be high, and so is the concurrent use with conventional medicine. A convenience sampling of paediatric emergency department patients in the US was carried out during a 3-month period in 2001, where 153 families participated in the study, with a mean patient age of 5.3 years. Children were given a herbal medicine by 45% of caregivers, and the most common herbal medicines reportedly used were aloe plant or juice (44%), echinacea (33%) and sweet oil (25%).

More recently, 1804 families were interviewed in a study of parents and patients up to 18 years arriving at a large paediatric emergency department in Toronto, Canada. Conventional and herbal medicines or supplements were being used concurrently in 20% of the patients and 15% were receiving more than one herbal medicine simultaneously. The authors of this study identified possible herb–drug or herb–herb interactions in 16% of children.

(c) Gender
Studies usually show that herbal medicine use is higher in women than men, and this is likely to be true for many reasons, despite the unreliability of figures gained in surveys. Women generally live longer than men, and elderly people take more supplements; women tend to be the primary carers for children and the elderly and also purchase most of the everyday remedies used in the home; and women take more weight-loss products than men. In several studies, it is suggested that women are at least twice as likely to take herbal medicines or supplements as men.

(d) Educational level and knowledge of herbal products
People of all levels of educational attainment are likely to take herbal and nutritional supplements. Some studies suggest that usage is similar across most education levels, whereas others have found that college graduates appear to have the highest incidence of herbal use. Despite the generally high levels of education, it is of great concern that consumers do not have a correspondingly high level of knowledge about the products that they are consuming. In a study of caregivers who reported giving their child a herbal medicine or supplements as men.

(e) Rural populations
An Australian postal questionnaire survey found that in people living in rural areas of New South Wales the use of CAM is high, with garlic and echinacea being the most used herbal products. Of those responding, 70.3% reported using one or more CAM and 62.7% had visited a complementary practitioner. In Jamaica, concurrent surveys were carried out in Kingston (an urban parish) and Clarendon (a rural parish) in 743 patients who visited health centres and pharmacies. Herbal medicines were taken with conventional medicines by 80% of respondents and 87% of these did not tell their healthcare provider. In the rural community 92% took herbal medicines with conventional medicines, compared with 70% of the urban community.

Attitudes to the use of herbal medicines
People who use herbal medicines and nutritional supplements report their primary source of information as friends or relatives in 80% of cases, and only 45% of those giving their children herbal products report discussing it with either their doctor or pharmacist. In one study, 44.7% never reported herbal usage to their physician, and 11% did so only rarely. Again, this is a general trend found in other studies, sometimes with even higher levels (e.g. up to 70%) of non-reporting seen. In one study in New Zealand only 41% of patients had discussed their CAM use with their oncologist, and almost one-third had started such medicines before being seen at the cancer treatment centre. In a study of hospital inpatients a great cause for concern was that 94% of the patients had not been asked specifically about herbal
consumption by the medical team and only 23% of the hospital’s medical files of the patients taking herbal medicines or dietary supplements had any record of this fact. In fact, in many studies, even where the question was asked, many patients did not inform their doctor that they were also taking herbal remedies.

This serious under-reporting by patients may probably be because they consider herbal medicines safe, even if taken at the same time as prescription drugs. One study found a significant correlation between the belief that herbal medicines can cause adverse effects and the tendency to report their usage to the family physician. Some patients may fear the disapproval of the physician and, since they consider the medicines to be safe, see no reason for inviting problems by disclosing these practices. Unfortunately, even if patients do report their use of herbal medicines to the physician or pharmacist, there is no guarantee that accurate information or advice will be available. Physicians usually underestimate the extent to which their patients use these remedies and often do not ask for information from the patient. Worse still, in one survey 51% of doctors believed that herbal medicines have no or only mild adverse effects and 75% admitted that they had little or no knowledge about what they are. Pharmacists are equally likely to encounter patients taking supplements together with prescription or non-prescription medicines as they may be asked for advice, or they may actually sell or supply the herbal medicine. Many pharmacists (like many doctors) do not feel that they have enough basic knowledge themselves, or information readily available, to recommend these safely, although, according to a study in an international cohort of pharmacists, 84% have tried CAM at some time in their life, and 81% still felt that they had inadequate skills and knowledge to counsel patients. Personal use of dietary supplements was found to correlate with a twofold increase in the likelihood that a pharmacist would recommend them to a patient.

Interactions between herbal medicines and conventional drugs

An interaction is said to occur when the effects of one drug are changed by the presence of another substance, including herbal medicines, food, drink and environmental chemical agents.

This definition is obviously as true for conventional medicines as it is for herbal medicines. The outcome can be harmful if the interaction causes an increase in the toxicity of the drug. A potential example of this is the experimental increase in toxicity seen when amikacin is given with ginkgo, see Ginkgo + Aminoglycosides, page 209. A reduction in efficacy due to an interaction can sometimes be just as harmful as an increase. For example, the reduction in ciclosporin levels caused by St John’s wort has led to transplant rejection in some cases. See St John’s wort + Ciclosporin, page 368.

As with any publication detailing the adverse effects of drug use it would be very easy to conclude after browsing through this publication that it is extremely risky to treat patients with conventional drugs and herbal medicines, but this would be an over-reaction. Patients can apparently tolerate adverse interactions remarkably well, and many interactions can be accommodated for (for example, through natural dose titration), so that the effects may not consciously be recognised as the result of an interaction.

One of the reasons that it is often difficult to detect an interaction is that, as already mentioned, patient variability is considerable. We now know many of the predisposing and protective factors that determine whether or not an interaction occurs but in practice it is still very difficult to predict what will happen when an individual patient is given two potentially interacting medicines. This effect is compounded when considering the interactions of herbal medicines because they themselves are subject to a degree of variability.

Variability of herbal medicines

Botanical extracts differ from conventional medicines in that they are complicated mixtures of many bioactive compounds. This makes it difficult to assess the contribution of each constituent to the activity of the whole, and this includes evaluating their possible interactions with drugs. Natural products are also liable to a great deal of variation and, even when standardised to one of more of their constituents, there can still be differences in the numerous other compounds present, and different constituents will affect different metabolic enzymes. As well as the source material, the method by which an extract is made will also affect its composition, and thus its interaction potential. This is well illustrated by a study looking at echinacea preparations. This study found that a standardised Swiss-registered Echinacea purpurea extract mildly inhibited the cytochrome P450 isoenzymes CYP1A2, CYP2C19 and CYP3A4, with CYP3A4 being the most affected. However, when this and a number of other products were screened for their ability to inhibit CYP3A4, the inhibitory potencies of the products were found to vary by a factor of 150.¹

Sometimes, the overall effect of a herbal extract has a different effect on cytochrome P450 than that of an isolated constituent contained in the extract. For example, a mixture

of dietary soya isoflavones containing genistein was found to have no effect on rat hepatic CYP1A2 and CYP2E1, whereas isolated genistein was found to inhibit both CYP2E1 and CYP1A2 in experimental studies. Whether this is because of a species difference, a dose-related effect or opposing actions of some constituents within the extract remains to be seen, but it provides another illustration of the dangers of extrapolating results from different types of experiments on individual components to a clinical situation involving a whole mixture.

These brief examples start to illustrate that the mechanisms of drug interactions with herbal medicines bear a great relationship to those of conventional drugs.

Mechanisms of drug interactions
Some drugs interact together in totally unique ways, but, as the many examples in this publication amply illustrate, there are certain mechanisms of interaction that are encountered time and time again. Some of these common mechanisms are discussed here in greater detail than space will allow in the individual monographs, so that only the briefest reference need be made there. This discussion is restricted to those mechanisms that have been extensively investigated with herbal medicines. Readers interested in a more general discussion of mechanisms are referred to Stockley’s Drug Interactions.

Very many drugs that interact do so, not by a single mechanism, but often by two or more mechanisms acting in concert, although for clarity most of the mechanisms are dealt with here as though they occur in isolation. For convenience, the mechanisms of interactions can be subdivided into those that involve the pharmacokinetics of a drug, and those that are pharmacodynamic.

Pharmacokinetic interactions
Pharmacokinetic interactions are those that can affect the processes by which drugs are absorbed, distributed, metabolised and excreted (the so-called ADME interactions). Although all these mechanisms are undoubtedly relevant to interactions with herbal medicines, this discussion will mainly focus on cytochrome P450 and drug transporter proteins. Other enzymes have been shown to play a role in the interactions of herbal medicines, such as UDP-glucuronosyltransferases (UGTs), but less is known about their effects.

Cytochrome P450 isoenzymes
Although a few drugs are cleared from the body simply by being excreted unchanged in the urine, most are chemically altered within the body to less lipid-soluble compounds, which are more easily excreted by the kidneys. If this were not so, many drugs would persist in the body and continue to exert their effects for a long time. Some drug metabolism goes on in the serum, the kidneys, the skin and the intestines, but the greatest proportion is carried out by enzymes that are found in the liver, mainly cytochrome P450. Cytochrome P450 is not a single entity, but is in fact a very large family of related isoenzymes, about 30 of which have been found in human liver tissue. However, in practice, only a few specific subfamilies seem to be responsible for most (about 90%) of the metabolism of the commonly used drugs. The most important isoenzymes are: CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A4. Some of these isoenzymes are also found in the gut wall.

Drugs and herbs affecting or metabolised by the cytochrome P450 isoenzyme CYP1A2

<table>
<thead>
<tr>
<th>Inducers</th>
<th>Substrates*</th>
<th>Inhibitors</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cannabis (modest clinical effects with smoking)</td>
<td>Caffeine</td>
<td>Boswellia (in vitro effects with gum resin)</td>
</tr>
<tr>
<td>Danshen (in vitro effects do not appear to be clinically relevant)</td>
<td>Clomipramine</td>
<td>Chamomile, German (moderate effects with tea given to rats)</td>
</tr>
<tr>
<td>Liquorice (glycyrrhizin constituent studied in mice, effects may be weaker clinically)</td>
<td>Clozapine</td>
<td>Dandelion (moderate to potent effects with tea given to rats)</td>
</tr>
<tr>
<td>St John’s wort (in vitro induction of only minor clinical relevance)</td>
<td>Duloxetine</td>
<td>Feverfew (in vitro evidence only)</td>
</tr>
<tr>
<td></td>
<td>FrovatRIPTAN</td>
<td>Ginkgo (in vitro effects do not appear to be clinically relevant)</td>
</tr>
<tr>
<td></td>
<td>Olanzapine</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Rasagiline</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ropinirole</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Tacrine</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Theophylline</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Tizanidine</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Zolmitriptan</td>
<td></td>
</tr>
</tbody>
</table>

* shown to be clinically relevant in drug–drug interaction studies

† Note that in vitro effects are not necessarily replicated in vivo; findings in vivo often appear weaker than those in vitro. The presence of an in vitro effect suggests that clinical study is warranted.
### Drugs and herbs affecting or metabolised by the cytochrome P450 isoenzyme CYP3A4†

<table>
<thead>
<tr>
<th>Inducers</th>
<th>Substrates*</th>
<th>Inhibitors</th>
</tr>
</thead>
<tbody>
<tr>
<td>Echinacea (in vitro studies supported by clinical data, but any effect modest. Note inhibition also reported)</td>
<td>Antiarrhythmics (Amiodarone, Disopyramide, Lidocaine oral, Propafenone, Quinidine)</td>
<td>Bearberry (in vitro evidence only, effects vary greatly between products)</td>
</tr>
<tr>
<td>Ginkgo (in vitro studies supported by clinical data, but any effect modest. Note inhibition also reported)</td>
<td>Anticholinesterases, centrally acting (Donepezil, Galantamine)</td>
<td>Bitter orange (juice known to have clinically relevant effects, supplement has no effects; difference possibly due to constituents)</td>
</tr>
<tr>
<td>Liquorice (glycyrrhizin constituent studied in mice, effects may be weaker clinically)</td>
<td>Antihistamines (Astemizole, Terfenadine)</td>
<td>Black cohosh (effects in vitro are probably not clinically relevant)</td>
</tr>
<tr>
<td>Rooibos (in vitro studies suggest moderate to potent effects)</td>
<td>Antimigraine drugs (Eletriptan, Ergot derivatives)</td>
<td>Cat's claw (in vitro studies suggest potent effects)</td>
</tr>
<tr>
<td>St John’s wort (clinically established, potency appears to vary with hyperforin content)</td>
<td>Antipsychotics (Pimozide, Quetiapine)</td>
<td>Cranberry (in vitro studies suggest modest effects but studies in humans suggest any effect is not clinically relevant)</td>
</tr>
<tr>
<td>Azoles (itraconazole, Voriconazole)</td>
<td>Antipsychotics (Pimozide, Quetiapine)</td>
<td>Echinacea (in vitro studies supported by clinical data, but any effect modest. Note induction also reported)</td>
</tr>
<tr>
<td>Benzodiazepines and related drugs (Alprazolam, Triazolam, Midazolam; Buspirone, Zolpidem, Zopiclone)</td>
<td>Antipsychotics (Pimozide, Quetiapine)</td>
<td>Feverfew (in vitro evidence only)</td>
</tr>
<tr>
<td>Calcium-channel blockers (Diltiazem, Felodipine, Lercanidipine)</td>
<td>Antipsychotics (Pimozide, Quetiapine)</td>
<td>Garlic (effects in vitro are probably not clinically relevant)</td>
</tr>
<tr>
<td>Corticosteroids (Budesonide, Dexamethasone, Fluticasone, Hydrocortisone, Methylprednisolone)</td>
<td>Antipsychotics (Pimozide, Quetiapine)</td>
<td>Ginseng (ginsenoside constituents studied; in vitro effects are probably not clinically relevant)</td>
</tr>
<tr>
<td>Dopamine agonists (Bromocriptine, Cabergoline)</td>
<td>Antipsychotics (Pimozide, Quetiapine)</td>
<td>Goldenseal (in vitro studies suggest potent effects, but studies in humans suggest only modest clinical effects)</td>
</tr>
<tr>
<td>Hormones (Hormonal contraceptives, Oestrogens, Progestogens)</td>
<td>Antipsychotics (Pimozide, Quetiapine)</td>
<td>Grapefruit (juice has moderate clinical effects; not known if supplements interact similarly)</td>
</tr>
<tr>
<td>Immunosuppressants (Ciclosporin, Sirolimus, Tacrolimus)</td>
<td>Antipsychotics (Pimozide, Quetiapine)</td>
<td>Milk thistle (in vitro studies supported by some clinical data, but any effect modest)</td>
</tr>
<tr>
<td>Opioids (Alfentanil, Buprenorphine, Fentanyl, Methadone)</td>
<td>Antipsychotics (Pimozide, Quetiapine)</td>
<td>Pepper (in vitro piperine (a constituent) has some effect, but ethanolic extracts of the fruit had no clinically significant effects)</td>
</tr>
<tr>
<td>Phosphodiesterase type-5 inhibitors (Sildenafil, Tadalafil, Vardenafil)</td>
<td>Antipsychotics (Pimozide, Quetiapine)</td>
<td>Resveratrol (in vitro studies suggest modest effects)</td>
</tr>
<tr>
<td>Protease inhibitors (Amprenavir, Atazanavir, Darunavir, Fosamprenavir, Indinavir, Nelfinavir, Ritonavir, Saquinavir, Tipranavir)</td>
<td>Antipsychotics (Pimozide, Quetiapine)</td>
<td>Rhodiola (in vitro effects with a root extract)</td>
</tr>
<tr>
<td>Statins (Atorvastatin, Lovastatin, Simvastatin)</td>
<td>Antipsychotics (Pimozide, Quetiapine)</td>
<td>Saw palmetto (effects in vitro are not clinically relevant)</td>
</tr>
<tr>
<td>Miscellaneous (Aprepitant, Bosentan, Carbamazepine, Cilostazol, Cisapride, Delavirdine, Dutasteride, Eplerenone, Maraviroc, Reboxetine, Rifabutin, Sibutramine, Solifenacin, Tolterodine)</td>
<td>Antipsychotics (Pimozide, Quetiapine)</td>
<td>Turmeric (curcumin constituent studied; in vitro effects are potent)</td>
</tr>
</tbody>
</table>

* shown to be clinically relevant in drug–drug interaction studies

† Note that in vitro effects are not necessarily replicated in vivo; findings in vivo often appear weaker than those in vitro. The presence of an in vitro effect suggests that clinical study is warranted.
(a) **Enzyme induction**

Some herbal medicines can have a marked effect on the extent of first-pass metabolism of conventional drugs by inducing the cytochrome P450 isoenzymes in the gut wall or in the liver. A number of herbs have been studied specifically for their effects on these isoenzymes. Those that appear to cause clinically relevant induction of specific isoenzymes are grouped in a series of tables, along with the conventional drugs that are substrates for this isoenzyme. See the tables Drugs and herbs affecting or metabolised by the cytochrome P450 isoenzyme CYP1A2, page 7, and Drugs and herbs affecting or metabolised by the cytochrome P450 isoenzyme CYP3A4, page 8.

The extent of the enzyme induction depends on the herbal medicine, its dosage, and even the specific extract used (see Variability of herbal medicines, page 6). It may take days or even 2 to 3 weeks to develop fully, and may persist for a similar length of time when the enzyme inducer is stopped. This means that enzyme induction interactions can be delayed in onset and slow to resolve. These effects have been seen with St John’s wort, page 362.

If one drug reduces the effects of another by enzyme induction, it may be possible to accommodate the interaction simply by raising the dosage of the drug affected, but this requires good monitoring, and there are obvious hazards if the inducing drug is eventually stopped without remembering to reduce the dosage again. The raised drug dosage may be an overdose when the drug metabolism has returned to normal. This strategy is more complicated with herbal medicines; the intake of a set amount of the herbal medicine would need to be maintained for this approach to work, and this is difficult because the interacting constituent may vary between products, and even between different batches of the same product.

(b) **Enzyme inhibition**

More common than enzyme induction is the inhibition of enzymes. This results in the reduced metabolism of an affected drug, so that it may begin to accumulate within the body, the effect usually being essentially the same as when the dosage is increased. Unlike enzyme induction, which may take several days or even weeks to develop fully, enzyme inhibition can occur within 2 to 3 days, resulting in the rapid development of toxicity. An example is the effect of grapefruit and grapefruit juice, which seem to inhibit the cytochrome P450 isoenzyme CYP3A4, mainly in the gut, and therefore reduce the metabolism of oral calcium-channel blockers. See Grapefruit + Calcium-channel blockers, page 237.

A number of herbs have been studied specifically for their effects on cytochrome P450 isoenzymes. Those that appear to have clinically relevant effects on specific isoenzymes are grouped in a series of tables, along with the conventional drugs that are substrates for this isoenzyme. See the tables Drugs and herbs affecting or metabolised by the cytochrome P450 isoenzyme CYP1A2, page 7, and Drugs and herbs affecting or metabolised by the cytochrome P450 isoenzyme CYP3A4, page 8.

The clinical significance of many enzyme inhibition interactions depends on the extent to which the serum levels of the drug rise. If the serum levels remain within the therapeutic range the interaction may not be clinically important.

(c) **Predicting interactions involving cytochrome P450**

It is interesting to know which particular isoenzyme is responsible for the metabolism of drugs because by doing *in vitro* tests with human liver enzymes it is often possible to explain why and how some drugs interact. For example, ciclosporin is metabolised by CYP3A4, and we know that St John’s wort is a potent inducer of this isoenzyme, so that it comes as no surprise that St John’s wort, page 368, reduces the effects of ciclosporin.

What is very much more important than retrospectively finding out why drugs and herbal medicines interact is the knowledge that such *in vitro* tests can provide about forecasting which other drugs may possibly also interact. This may reduce the numbers of expensive clinical studies in subjects and patients and avoids waiting until significant drug interactions are observed in clinical use. A lot of effort is being put into this area of drug development, and it is particularly important for herbal medicines, where it seems unlikely that expensive clinical studies will be routinely conducted. However, at present such prediction is not always accurate because all of the many variables that can come into play are not known (such as how much of the enzyme is available, the concentration of the drug at the site of metabolism and the affinity of the drug for the enzyme). Remember too that some drugs can be metabolised by more than one cytochrome P450 isoenzyme (meaning that this other isoenzyme may be able to ‘pick up’ more metabolism to compensate for the inhibited pathway), some drugs (and their metabolites) can both induce a particular isoenzyme and be metabolised by it, and some drugs (or their metabolites) can inhibit a particular isoenzyme but not be metabolised by it. With so many factors possibly impinging on the outcome of giving two or more drugs together, it is very easy to lose sight of one of the factors (or not even know about it) so that the sum of 2 plus 2 may not turn out to be the 4 that you have predicted.

**Drug transporter proteins**

Drugs and endogenous substances are known to cross biological membranes, not just by passive diffusion, but also by carrier-mediated processes, often known as transporters. Significant advances in the identification of various transporters have been made, although the contribution of many of these to drug interactions in particular, is still being investigated. The most well-known drug transporter protein is P-glycoprotein.

More and more evidence is accumulating to show that some drug interactions occur because they interfere with the activity of P-glycoprotein. This is an efflux pump found in the membranes of certain cells, which can push metabolites and drugs out of the cells and have an impact on the extent of drug absorption (via the intestine), distribution (to the brain, testis or placenta) and elimination (in the urine and bile). So, for example, the P-glycoprotein in the cells of the gut lining can eject some already-absorbed drug molecules back into the intestine resulting in a reduction in the total amount of drug absorbed. In this way P-glycoprotein acts as a barrier to absorption. The activity of P-glycoprotein in the endothelial...
cells of the blood–brain barrier can also eject certain drugs from the brain, limiting CNS penetration and effects.

The pumping actions of P-glycoprotein can be experimentally induced or inhibited by some herbal medicines. So for example, the induction (or stimulation) of the activity of P-glycoprotein by capsicum, within the lining cells of the gut, causes digoxin to be ejected into the gut more vigorously. This may result in a fall in the plasma levels of digoxin. See Capsicum + Digoxin, page 116. In contrast, some extracts of danshen appear to inhibit the activity of P-glycoprotein, and may therefore increase digoxin levels. See Danshen + Digoxin, page 162.

There is an overlap between CYP3A4 and P-glycoprotein inhibitors, inducers and substrates. Digoxin is an example of one of the few drugs that is a substrate for P-glycoprotein but not CYP3A4. It is for this reason that it is used as a probe substrate for P-glycoprotein activity, and the effects of herbal medicines on this particular drug have been studied.

Other transporters that are involved in some drug interactions are the organic anion transporters (OATs), organic anion-transporting polypeptides (OATPs) and organic cation transporters (OCTs), which are members of the solute carrier superfamily (SLC) of transporters. The best known example of an OAT inhibitor is probenecid, which affects the renal excretion of a number of drugs. However, the effects of many herbal medicines and drugs on these transporters are less well understood than those of P-glycoprotein, and thus, the role of OATs, OATPs and OCTs in drug interactions is still being elucidated.

**Pharmacodynamic interactions**

Pharmacodynamic interactions are those where the effects of one drug are changed by the presence of another drug at its site of action. Sometimes the drugs directly compete for particular receptors but often the reaction is more indirect and involves interference with physiological mechanisms. These interactions are much less easy to classify neatly than those of a pharmacokinetic type.

(a) *Additive or synergistic interactions*

If two drugs that have the same pharmacological effect are given together the effects can be additive. For example, alcohol depresses the CNS and, if taken in moderate amounts with normal therapeutic doses of herbal medicines (e.g. valerian), may increase drowsiness. See Valerian + Alcohol, page 397.

Sometimes the additive effects are solely toxic (e.g. theoretical additive nephrotoxicity, see Ginkgo + Aminoglycosides, page 209). It is common to use the terms ‘additive’, ‘summation’, ‘synergy’ or ‘potentiation’ to describe what happens if two or more drugs behave like this. These words have precise pharmacological definitions but they are often used rather loosely as synonyms because in practice it is often very difficult to know the extent of the increased activity, that is to say whether the effects are greater or smaller than the sum of the individual effects.

One particular additive effect is well known to occur between the herbal medicine St John’s wort, page 362, and conventional medicines. This is serotonin syndrome. The reasons for this effect are not fully understood, but the serotonin syndrome is thought to occur as a result of over-stimulation of the 5-HT_{1A} and 5-HT_{2A} receptors and possibly other serotonin receptors in the CNS (in the brain stem and spinal cord in particular) due to the combined effects of two medicines (herbal or conventional). Serotonin syndrome can occur exceptionally after taking only one substance that causes over-stimulation of these 5-HT receptors, but much more usually it develops when two or more drugs (so-called serotoninergic or serotonimetic drugs) act in concert. The characteristic symptoms fall into three main areas, namely altered mental status (agitation, confusion, mania), autonomic dysfunction (diaphoresis, diarrhoea, fever, shivering) and neuromuscular abnormalities (hyperreflexia, incoordination, myoclonus, tremor).

The syndrome can develop shortly after one serotoninergic drug is added to another, or even if one is replaced by another without allowing a long enough washout period in between, and the problem usually resolves within about 24 hours if both drugs are withdrawn and supportive measures given. Non-specific serotonin antagonists (cyproheptadine, chlorpromazine, methysergide) have also been used for treatment. Most patients recover uneventfully, but there have been a few fatalities.

It is still not at all clear why many patients can take two, or sometimes several, serotoninergic drugs together without problems, while a very small number develop this serious toxic reaction, but it certainly suggests that there are other factors involved that have yet to be identified. The full story is likely to be much more complex than just the simple additive effects of two drugs.

(b) **Antagonistic or opposing interactions**

In contrast to additive interactions, there are some pairs of drugs with activities that are opposed to one another. For example, the coumarins can prolong the blood clotting time by competitively inhibiting the effects of dietary vitamin K. If the intake of vitamin K is increased, the effects of the oral anticoagulant are opposed and the prothrombin time can return to normal, thereby cancelling out the therapeutic benefits of anticoagulant treatment. It has been proposed that the vitamin K content of herbal medicines may be sufficient to provoke this interaction, but in most cases of normal intake of the herb, this seems unlikely. See Alfalfa + Warfarin and related drugs, page 23, for further discussion of this potential interaction.

**Drawing your own conclusions**

The human population is a total mixture, unlike selected batches of laboratory animals (same age, weight, sex, strain, etc.). For this reason human beings do not respond uniformly to one or more drugs or even herbal medicines. Our genetic make-up, ethnic background, sex, renal and hepatic functions, diseases and nutritional states, ages and other factors (the route of administration, for example) all contribute towards the heterogeneity of our responses. This means that the outcome of giving one or more drugs to any individual for the first time is never totally predictable because it is a new and unique ‘experiment’. Even so, some idea of the probable outcome of using a drug or a pair of drugs can be based on what has been seen in other patients: the more extensive the data, the firmer the predictions.

The most difficult decisions concern isolated cases of
interaction, many of which achieved prominence only because they were serious. Do you ignore them as ‘idiosyncratic’ or do you, from that moment onwards, advise against the use of the herbal medicine and conventional drug totally?

There is no simple yes or no answer to these questions, especially as evidence regarding interactions between herbal medicines is often only of an experimental nature. The delicate balance between whether or not to give the drug has then to be set against the actual severity of the reaction reported and weighed up against how essential it is to use the combination in question.

When deciding the possible first-time use of any two drugs in any particular patient, you need to put what is currently known about these drugs against the particular profile of your patient. Read the monograph. Consider the facts and conclusions, and then set the whole against the backdrop of your patient’s unique condition (age, disease, general condition, and so forth) so that what you eventually decide to do is well thought out and soundly based. We do not usually have the luxury of knowing absolutely all the facts, so that an initial conservative approach is often the safest.

It is now quite impossible to remember all the known clinically important interactions and how they occur but there are some broad general principles that are worth remembering:

- Be on the alert with any drugs that have a narrow therapeutic window or where it is necessary to keep serum levels at or above a suitable level (e.g. anticoagulants, antidiabetic drugs, antiepileptics, antihypertensives, anti-infectives, antineoplastic cytotoxics, digitalis glycosides, immunosuppressants, etc.).
- Think about the basic pharmacology of the drugs under consideration so that obvious problems (additive CNS depression, for example) are not overlooked, and try to think what might happen if drugs that affect the same receptors are used together. And don’t forget that many drugs affect more than one type of receptor.
- Keep in mind that the elderly are at risk because of reduced liver and renal function on which drug clearance depends.
Acidophilus

*Lactobacillus acidophilus* (Lactobacillaceae)

**Use and indications**

*Lactobacillus acidophilus* are lactic-acid producing bacterial organisms that are normally present in the human gut. Acidophilus supplements are primarily taken as a probiotic, to restore or maintain healthy microbial flora. Acidophilus has also been used to treat diarrhoea, irritable bowel syndrome, lactose intolerance, urinary tract infections and yeast-based infections (such as those caused by *Candida albicans*), and for general digestive problems. It is available in various forms ranging from capsules to yoghurts.

**Pharmacokinetics**

No relevant pharmacokinetic data found.

**Interactions overview**

Acidophilus is a bacterial organism, and therefore it may lead to systemic infection in immunosuppressed patients, although this effect is expected to be rare. Antibacterials and drugs that are dependent on bacterial degradation to release active constituents, namely sulfasalazine, may also be expected to interact.
Acidophilus + Antibacterials

The interaction between acidophilus and antibacterials is based on experimental evidence only.

Clinical evidence
No interactions found.

Experimental evidence
Lactobacillus acidophilus are Gram-positive, facultative anaerobic bacteria and as such can be inhibited or killed by antibacterials that are effective against this type of bacteria. Ampicillin,1,3 ampicillin with sulbactam,1 benzylpenicillin,2,3 cefalotin,1 chloramphenicol,2,3 clindamycin,1,3,4 erythromycin,2,3 gentamicin,3 linezolid,3 oxytetracycline,1 penicillin,1 quinupristin/dalfopristin,3 streptomycin,2,3 tetracycline2 and vancomycin1 have been found to inhibit acidophilus populations.

Mechanism
Antibacterials kill or inhibit the growth of bacterial populations through various different mechanisms.

Importance and management
Depending on the particular strain of acidophilus and the antibacterial dose, the desired therapeutic effect of acidophilus may be significantly reduced or even abolished by these antibacterials.


Acidophilus + Food

No interactions found. Acidophilus is often present in live yoghurt.

Acidophilus + Herbal medicines; Soya isoflavones

Acidophilus does not generally affect the metabolism of soya isoflavones.

Clinical evidence
In a randomised study 20 women who had been successfully treated for breast cancer and 20 women without a history of cancer were given a soya protein isolate containing 640 micrograms/kg of isoflavones daily (34% daidzein, 57% genistein and 9% glycitein), with three probiotic capsules (DDS Plus), containing Lactobacillus acidophilus and Bifidobacterium longum, daily for 42 days. In general, the probiotics did not affect the plasma isoflavone concentrations, although two of the subjects had altered plasma concentrations of equol, a daidzein metabolite. No adverse effects were reported in the study.1 In another study, the same probiotic did not alter the cholesterol-lowering effects of the isoflavones.2

Experimental evidence
No relevant data found.

Mechanism
The gut bacterial flora metabolises daidzein to equol, which is thought to be responsible for reduced breast cancer risk. The authors hypothesised that increasing the populations of bacteria, by using probiotics, levels of equol would increase.

Importance and management
Increasing the populations of bacteria in the gut does not appear to have a significant effect on the metabolism of soya isoflavones. Note that the metabolism of isoflavones is variable, due to differences in gut flora between individuals, and so the effects of any interaction between acidophilus and isoflavones are likely to differ between individuals. For more information on the interactions of isoflavones in general, see under isoflavones, page 258.


Acidophilus + Immunosuppressants

An isolated case report describes fatal septicaemia in an immunosuppressed woman taking cyclophosphamide and fludrocortisone who ate live yoghurt containing Lactobacillus rhamnosus, which is closely related to acidophilus.

Clinical evidence
A 42-year-old woman taking cyclophosphamide and fludrocortisone for Sjögren’s syndrome developed pneumonia and secondary Lactobacillus rhamnosus septicaemia, which proved to be fatal, after taking a short course of supermarket own-brand live yoghurt for diarrhoea.1 Note that Lactobacillus rhamnosus is a species closely related to Lactobacillus acidophilus.

Experimental evidence
No relevant data found.

Mechanism
The immunosuppressed nature of the patient is thought to have provided a more conducive environment for the introduced bacteria to establish a sufficient population to reach a pathogenic threshold.

Importance and management
Although not a drug interaction in the strictest sense, it would be sensible to assume that introducing bacteria in the form of a probiotic to an immunosuppressed patient should be undertaken with great care or perhaps avoided: note that patients who have undergone a transplantation and who are immunosuppressed are often advised to avoid foods such as live yoghurts.

Remember that, as immunosuppression secondary to corticosteroid use is dependent on numerous factors related to the dosage and duration of intake, not all patients taking corticosteroids are likely to be immunosuppressed and therefore they will not necessarily need to avoid acidophilus-containing products.


Acidophilus + Sulfasalazine

The interaction between acidophilus and sulfasalazine is based on experimental evidence only.

Clinical evidence
No interactions found.
**Experimental evidence**

In an experimental study about 85 to 95% of a dose of sulfasalazine was broken down by several different strains of *Lactobacillus acidophilus*.1

**Mechanism**

The azo link of sulfasalazine is split by anaerobic bacteria in the colon to release sulfapyridine and 5-aminosalicylic acid, the latter being the active metabolite that acts locally in the treatment of inflammatory bowel disease. The lipophilic nature of sulfasalazine is thought to enable it to reach the site of azoreductase activity within the bacterial cell by passive diffusion across the cell membrane.

**Importance and management**

Sulfasalazine is generally thought to be 'activated' by its metabolism to release 5-aminosalicylic acid by bacteria in the colon. By introducing more bacteria, the metabolism could be increased. However, metabolism may also occur earlier, in the small intestine, which could be detrimental as one metabolite, sulfapyridine, is rapidly absorbed from the small intestine and can contribute to renal toxicity.

It should be noted, however, that this is a rather old experimental study that appears to be the only one of its kind in the literature. Also, the pH of the gut is much lower than the pH used in the experimental study and there is a degree of interindividual variability in populations of bacterial flora. Taking all this into account, this interaction seems unlikely to be clinically relevant.

Agnus castus

_Vitex agnus-castus_ L. (Lamiaceae)

**Synonym(s) and related species**
Agni casti, Chasteberry, Chaste tree, Monk’s pepper.

**Pharmacopoeias**
Agnus Castus (BP 2009, Ph Eur 6.4); Chaste Tree (USP 32).

**Constituents**
Agnus castus is usually standardised to the content of the flavonoid casticin (dried ripe fruit and powdered extracts contain a minimum of 0.08%, USP 32), and sometimes also the iridoid glycoside agnuside (dried ripe fruit and powdered extracts contain a minimum of 0.05%, USP 32). Other major constituents are the labdane and clerodane diterpenes (including rotundifuran, 6β,7β-diacetoxy-13-hydroxy-labda-8,14-diene, vitexilactone). Other flavonoids include orientin, apigenin and penduletin.

**Use and indications**
Traditional use of the dried ripe fruit of agnus castus focuses on menstrual disorders in women resulting from corpus luteum deficiency, such as amenorrhea, metrorrhagia and symptoms of premenstrual syndrome, including mastalgia. It has also been used to alleviate some menopausal symptoms and to promote lactation. In men it has been used to suppress libido and treat acne.

**Pharmacokinetics**
No relevant pharmacokinetic data for agnus castus found.

For information on the pharmacokinetics of individual flavonoids present in agnus castus, see under flavonoids, page 186.

**Interactions overview**
A comprehensive systematic review of data from spontaneous adverse event reporting schemes and published clinical studies, post-marketing surveillance studies, surveys and case reports was carried out in September 2004 to investigate the safety of agnus castus extracts. No drug interactions were identified. Agnus castus extracts used in the data reviewed included Agnolyt, Agnuecaston, Strotan and ZE 440.

However, agnus castus has dopamine agonist properties, and may therefore interact with drugs with either dopamine agonist or dopamine antagonist actions.

Agnus castus contains oestrogenic compounds but it is unclear whether the effects of these compounds are additive, or antagonistic, to oestrogens and oestrogen antagonists (e.g. tamoxifen). Although agnus castus binds with opioid receptors, no serious interaction with opioid analgesics would be expected.

For information on the interactions of flavonoids, see under flavonoids, page 186.

Agnus castus + Dopamine agonists or antagonists

Agnus castus has dopamine agonist properties, and may therefore interact with drugs either dopamine agonist or dopamine antagonist actions.

Clinical evidence
In a double-blind study in women suffering from mastalgia, agnus castus extracts reduced serum prolactin levels (by about 4 nanograms/mL compared with about 0.6 nanograms/mL for placebo). The agnus castus extracts used in this study were an oral solution, Mastodynon, and a tablet, MA 1025 E1.1

Experimental evidence
Extracts of agnus castus act as dopamine agonists.2-5 Some dopaminergic compounds (mainly clerodane diterpenes) isolated from agnus castus have almost identical prolactin-suppressive properties at the D2-receptor to dopamine.3

Mechanism
Active compounds of agnus castus and dopaminergics may have additive effects because of their similar pharmacological activity.

Importance and management
While the importance of any potential interaction is difficult to judge, it would be wise to exercise some caution with the concurrent use of agnus castus and dopaminergics that act at the D2-receptor, which is the majority. For dopamine agonists such as bromocriptine and apomorphine, additive effects and toxicity is a theoretical possibility. Conversely, for dopamine antagonists such as antipsychotics and some antiemetics (such as prochlorperazine), antagonistic effects are a theoretical possibility. Conversely, for dopamine antagonists such as antipsychotics and some antiemetics (such as prochlorperazine), antagonistic effects are a theoretical possibility. However, in receptor-binding studies, extracts of agnus castus were found to contain the flavonoids pendenulein, apigenin and vitexin, which are thought to have some oestrogenic effects. Apigenin was identified as the most active, but all were selective for the oestrogen-beta receptor.2,3

Agnus castus + Food
No interactions found.

Agnus castus + Herbal medicines
No interactions found.

Agnus castus + Oestrogens or Oestrogen antagonists

Agnus castus contains oestrogenic compounds. This may result in additive effects with oestrogens or it may oppose the effects of oestrogens. Similarly, agnus castus may have additive effects with oestrogen antagonists or oppose the effects of oestrogen antagonists (e.g. tamoxifen).

Clinical evidence
A 32-year-old woman took a herbal medicine made from agnus castus, on her own initiative, before and in the early follicular phase of her fourth cycle of unstimulated IVF (in vitro fertilisation) treatment in order to try to promote ovarian function. In this cycle, she developed four follicles, and her serum gonadotrophin and ovarian hormone measurements became disordered. The agnus castus was stopped and she experienced symptoms suggestive of mild ovarian hyperstimulation syndrome in the luteal phase. Two subsequent cycles were endocrinologically normal with single follicles, as were the three cycles before she took the herbal preparation.1

It has also been suggested that agnus castus may provide relief from menopausal symptoms, see under Chinese angelica, page 129.

Experimental evidence
In receptor-binding studies, extracts of agnus castus were found to contain the flavonoids pendenulein, apigenin and vitexin, which are thought to have some oestrogenic effects. Apigenin was identified as the most active, but all were selective for the oestrogen-beta receptor.2,3

Mechanism
Active compounds of agnus castus may compete for the same oestrogen receptor as hormonal drugs and treatment. The case report suggests that agnus castus has anti-oestrogenic effects (leading to increased FSH and LH). The in vitro evidence suggests oestrogenic activity.

Importance and management
Evidence is limited and largely speculative, and it is therefore difficult to predict the outcome of using agnus castus with oestrogens or oestrogen antagonists. The evidence suggests that compounds of agnus castus may compete for the same oestrogen receptor as conventional hormonal drugs, with the outcome of either an overall oestrogenic effect, or an overall oestrogen antagonist effect (see also Chinese angelica, page 129). The main compounds in agnus castus that have oestrogenic activity are agnuside, apigenin and rotundifuran and they are found, particularly apigenin, ubiquitously in foods and herbs. Phytoestrogens are generally much less potent than endogenous oestrogens and therefore any potential interaction is likely to be modest. However, note that it is probably inappropriate for patients undergoing IVF treatment to take hormonally active herbal medicines, unless under the advice of an experienced endocrinologist. Further study is needed.


Agnus castus + Opioids
The interaction between agnus castus and opioids is based on experimental evidence only.

Clinical evidence
No interactions found.

Experimental evidence
Various agnus castus extracts have been shown to have an affinity to opioid receptors in an in vitro study.1 Lipophilic extracts of agnus castus produced an inhibition of binding to μ- and κ-opioid receptors and the aqueous fraction produced an inhibition of binding to δ-opioid receptors.
A follow-up study on hamster ovary cells found that extracts of agnus castus acted as agonists at the μ-opioid receptor in a similar way to morphine, another opioid agonist.

**Mechanism**
Active compounds of agnus castus and opioids may have additive effects because of their similar pharmacological activity.

**Importance and management**
The importance of this action on opioid receptors is unknown.

Agnus castus is not known for any strong analgesic effects or for producing opioid-like dependence and, as no clinical interactions have been reported, it seems unlikely that any important interaction will occur with opioids.

Agrimony

*Agrimonia eupatoria* L. (Rosaceae)

**Synonym(s) and related species**
Agrimonia, Cocklebur, Stickwort.

**Pharmacopoeias**
Agrimony (*BP 2009, Ph Eur 6.4*).

**Constituents**
Agrimony may be standardised to a tannin content expressed as pyrogallol 2%. Other constituents include flavonoids, based on quercetin, kaempferol, apigenin, catechins, epicatechins and procyanidins; various phenolic acids; triterpenes including α-amyrin, ursolic and euscadic acids, phytosterols; salicylic and silicic acids.

**Use and indications**
The dried flowering tops are used as a mild astringent and diuretic. They have also been used for diarrhoea in children, mucous colitis, urinary incontinence, cystitis, and as a gargle for sore throats and catarrh.

**Pharmacokinetics**
No relevant pharmacokinetic data found specifically for agrimony, but see under flavonoids, page 186, for more detail on individual flavonoids present in the herb.

**Interactions overview**
Information on the interactions of flavonoid supplements are covered under flavonoids, page 186, but note that it is unlikely that agrimony would be taken in doses large enough to give the levels of individual flavonoids used in the flavonoid studies (e.g. quercetin 100 mg daily and above). Agrimony might have a weak blood-glucose-lowering effect, and has weak diuretic and blood pressure-lowering effects. It may therefore be expected to interact with conventional drugs that have these properties.
Agrimony + Antidiabetics

The interaction between agrimony and antidiabetics is based on experimental evidence only.

Clinical evidence
No interactions found.

Experimental evidence
In various in vitro and animal studies, high-dose agrimony has stimulated insulin secretion and reduced hyperglycaemia.\(^1,2\) This suggests that usual doses used as a herbal medicine might have a weak antidiabetic effect, which could be additive with the effects of antidiabetic drugs.

Mechanism
Additive pharmacological effects.

Importance and management
These experimental studies provide limited evidence of a possible blood-glucose-lowering effect of agrimony extracts. Because of the nature of the evidence, applying these results in a clinical setting is extremely difficult. However, if patients taking antidiabetic drugs want to take agrimony it may be prudent to discuss these potential additive effects, and advise an increase in blood-glucose monitoring, should an interaction be suspected.


Agrimony + Antihypertensives

The interaction between agrimony and antihypertensives is based on experimental evidence only.

Clinical evidence
No interactions found.

Experimental evidence
Agrimony has traditionally been used as a diuretic. One study in rats found that agrimony had little significant diuretic activity,\(^1\) and another in cats found that intravenous agrimony decreased blood pressure over a period of 20 minutes.\(^2\)

Mechanism
It is possible that the herb will have weak antihypertensive effects, and a slight additive reduction in blood pressure could be possible if it is given with antihypertensives.

Importance and management
These experimental studies provide limited evidence of a possible antihypertensive effect of agrimony extracts. Because of the nature of the evidence, applying these results in a clinical setting is extremely difficult and, until more is known, it would be unwise to advise anything other than general caution.


Agrimony + Food

No interactions found.

Agrimony + Herbal medicines

No interactions found.
**Alfalfa**

*Medicago sativa* L. (Fabaceae)

**Synonym(s) and related species**

Lucerne, Medicago, Purple medick.  

**Constituents**

The main active constituents of alfalfa are the isoflavones, which include *biochanin A*, *formononetin*, *daidzein* and *genistein*, and the saponins, based on the aglycones hederagenin, medicaginic acid and soyasapogenols A–E. Other components include the toxic amino acid canavanine; natural coumarins such as coumestrol, lucernol, medicagol, sativol and daphnoretin; the sterols campestrol and beta-sitosterol; and miscellaneous compounds including vitamins (notably vitamin K), porphyrins, alkaloids (e.g. stachydrine), sugars, minerals and trace elements.

**Use and indications**

Alfalfa herb is usually used as a source of nutrients, including vitamins. Alfalfa seeds, when germinated, are popular as salad sprouts. Alfalfa has therapeutic properties including lowering blood cholesterol (the saponins) and oestrogenic activity (see isoflavones, page 258).

A possible association between alfalfa and systemic lupus erythematosus has been reported. This has been attributed to the toxic constituent canavanine, which is a structural analogue of arginine and may interfere with arginine functions.¹

**Pharmacokinetics**

No relevant data for alfalfa found. For information on the pharmacokinetics of its isoflavone constituents genistein, daidzein and biochanin A, see isoflavones, page 258.

**Interactions overview**

Although it has been suggested that alfalfa may interact with antidiabetic medicines and anticoagulants, evidence for this is largely lacking. Alfalfa may interact with immunosuppressants, and has apparently caused transplant rejection in one patient. Potential interactions of specific isoflavone constituents of alfalfa are covered under isoflavones; see antibacterials, page 260, digoxin, page 261, fexofenadine, page 261, nicotine, page 261, paclitaxel, page 261, tamoxifen, page 262, and theophylline, page 263.

### Alfalfa + Antibacterials

No data for alfalfa found. For the theoretical possibility that broad-spectrum antibacterials might reduce the metabolism of the isoflavone constituents of alfalfa, such as daidzein, by colonic bacteria, and so alter their efficacy, see Isoflavones + Antibacterials, page 260.

### Alfalfa + Antidiabetics

An isolated case describes a marked reduction in blood-glucose levels in a diabetic patient who took an alfalfa extract.

**Clinical evidence**

A case report describes a young man with poorly controlled diabetes (reportedly requiring large doses of insulin for even moderately satisfactory control) who had a marked reduction in blood-glucose levels after taking an oral alfalfa aqueous extract. He also had a reduction in his blood-glucose levels in response to oral manganese chloride, but this effect was not seen in 8 other patients with diabetes.1

**Experimental evidence**

In a study in streptozotocin-induced diabetic mice, high levels of alfalfa in the diet (62.5 g/kg) and drinking water (2.5 g/L) resulted in glucose levels that were similar to those in non-diabetic control mice and markedly lower than those in streptozotocin diabetic control mice.2 Insulin-releasing and insulin-like activity was demonstrated for various extracts of alfalfa in vitro.3

**Mechanism**

The authors of the case report (from 1962) concluded that the effect of alfalfa was due to the manganese content,1 but a subsequent in vitro study discounted a major role for manganese.2

**Importance and management**

Evidence is very limited, with just one early case report in an atypical patient and an animal study using very high doses of alfalfa. There are insufficient data to recommend any action, but it appears unlikely that usual herbal doses of alfalfa will have much, if any, effect on diabetic control.


### Alfalfa + Digoxin

No data for alfalfa found. For the possibility that high-dose biochanin A, an isoflavone present in alfalfa, might increase digoxin levels, see Isoflavones + Digoxin, page 261.

### Alfalfa + Fexofenadine

No data for alfalfa found. For the possibility that high-dose biochanin A, an isoflavone present in alfalfa, has been shown to slightly decrease fexofenadine levels in rats, see Isoflavones + Fexofenadine, page 261.

### Alfalfa + Food

No interactions found.

### Alfalfa + Herbal medicines

No interactions found.

### Alfalfa + Immunosuppressants

An isolated report describes acute rejection and vasculitis with alfalfa and/or black cohosh in a renal transplant recipient taking ciclosporin.

**Clinical evidence**

A stable kidney transplant recipient taking azathioprine 50 mg daily and ciclosporin 75 mg twice daily began to take alfalfa and black cohosh supplements (specific products not stated) on medical advice for severe menopausal symptoms. Her serum creatinine rose from between about 97 and 124 micromol/L up to 168 micromol/L after 4 weeks, and to 256 micromol/L after 6 weeks with no associated change in her ciclosporin levels. Biopsy revealed severe acute rejection with vasculitis and she was treated with corticosteroids and anti-T-lymphocyte immunoglobulin with partial improvement in renal function.1

**Experimental evidence**

No relevant data found.

**Mechanism**

Alfalfa has been reported to cause worsening of systemic lupus erythematosus and immunostimulation, and it was suggested that immunostimulation may have contributed to the acute rejection in this patient.1

**Importance and management**

The evidence of an interaction between alfalfa/black cohosh and immunosuppressants is limited, with the mechanism suggesting that alfalfa is the more likely culprit, although an effect of black cohosh cannot be ruled out. As the effects were so severe in this case it would seem prudent to avoid the use of alfalfa supplements in patients receiving immunosuppressants for serious indications, such as organ transplantation. Similarly, it would seem prudent to avoid the use of alfalfa in those taking immunosuppressants for indications such as eczema, psoriasis or rheumatoid arthritis; however, if these patients particularly wish to take alfalfa a short-term trial of concurrent use is likely to be less hazardous, but patients should be counselled about the possible risks (i.e. loss of disease control).


### Alfalfa + Nicotine

For discussion of a study showing that daidzein and genistein present in alfalfa caused a minor decrease in the metabolism of nicotine, see Isoflavones + Nicotine, page 261.

### Alfalfa + Paclitaxel

No data for alfalfa found. For the possibility that biochanin A and genistein present in alfalfa might markedly increase paclitaxel levels, see Isoflavones + Paclitaxel, page 261. Note that paclitaxel is used intravenously, and the effect of biochanin A on intravenous paclitaxel does not appear to have been evaluated.
Alfalfa + Tamoxifen

No data for alfalfa found. Data relating to the use of the isoflavone constituents of alfalfa, such as biochanin A, daidzein and genistein, with tamoxifen are covered under Isoflavones + Tamoxifen, page 262.

Alfalfa + Theophylline

No data for alfalfa found. For the possibility that high doses of daidzein present in alfalfa might modestly increase theophylline levels, see Isoflavones + Theophylline, page 263.

Alfalfa + Warfarin and related drugs

Unintentional and unwanted antagonism of warfarin has occurred in patients who ate exceptionally large amounts of some green vegetables, which can contain significant amounts of vitamin K_1_. It is predicted that alfalfa may contain sufficient vitamin K to provoke a similar reaction.

Evidence

There is no specific clinical or experimental evidence relating to the use of alfalfa with anticoagulants, but alfalfa is predicted to antagonise coumarin anticoagulants based on its vitamin K content. There are some data on the amount of vitamin K in alfalfa, and lots of data on dietary vitamin K and anticoagulant control.

(a) Vitamin K_1_ content of alfalfa

Alfalfa supplements are often promoted on the basis that they contain significant amounts of vitamin K_1_, although packaging rarely gives an amount. Alfalfa greens were used in early studies from the 1930s when vitamin K was first identified. In one such study, the amount of vitamin K activity in dried alfalfa was about half that in dried spinach.1 Green leafy vegetables such as spinach are well known to contain high levels of vitamin K_1_, with modern assay techniques giving values of about 500 micrograms/100 g.2 Conversely, sprouted alfalfa seeds have been shown to contain far more modest amounts of vitamin K_1_ (in the region of 30 micrograms/100 g).2 It is likely that the seeds themselves would contain even less vitamin K_1_. Therefore, the amount of vitamin K_1_ in an alfalfa product is likely to depend on the part of the plant used, and would be highest from the green leaf material and lowest from the seeds.

In addition, the way the product is extracted (vitamin K_1_ is a fat-soluble vitamin) would affect the vitamin K_1_ content. For example, although the leaves of green tea themselves are high in vitamin K_1_, the brew prepared from the leaves contains very little vitamin K_1_. Therefore an aqueous infusion prepared from alfalfa dried herb would be unlikely to contain much vitamin K_1_. Moreover, although the dried herb itself contains high levels of vitamin K_1_, it is taken in modest amounts in the form of supplements when compared with, for example, eating spinach as part of a meal. If a capsule containing 500 mg of powdered alfalfa leaf is taken at a dose of four capsules three times daily, then the daily intake of alfalfa would be 6 g, which might contain in the region of 15 micrograms of vitamin K daily. This amount seems unlikely to generally affect the response to vitamin K antagonist anticoagulants (such as warfarin), and many products contain less alfalfa than this.

(b) Dietary vitamin K and warfarin activity

There is evidence that the average dietary vitamin K_1_ intake is correlated with the efficacy of warfarin. In one study, patients consuming a diet containing more than 250 micrograms daily of vitamin K_1_ had a lower INR 5 days after starting warfarin than patients consuming less dietary vitamin K_1_ (median INR 1.9 versus 3). Also, the group consuming large amounts of vitamin K_1_ needed a higher maintenance warfarin dose (5.7 mg/day versus 3.5 mg/day).4 In another study, multiple regression analysis indicated that, in patients taking warfarin, the INR was altered by 1, by a weekly change in the intake of vitamin K_1_ of 714 micrograms.5 Similarly, for each increase in daily dietary vitamin K_1_ intake of 100 micrograms, the INR decreased by 0.2 in another study.6

In a randomised, crossover study in patients taking warfarin or phenprocoumon, increasing the dietary intake of vitamin K_1_ by 500% relative to the baseline value (from 118 to 591 micrograms daily) for 4 days only modestly decreased the INR from 3.1 to 2.8 on day 4. Decreasing the dietary intake of vitamin K_1_ by 80% (from 118 to 26 micrograms daily) for 4 days increased the INR from 2.6 to 3.3 on day 7.7

There is some evidence that patients with a very low dietary vitamin K_1_ intake are more sensitive to alterations in intake, and have less stable anticoagulant control. For example, in one study, patients with unstable anticoagulant control were found to have a much lower dietary intake of vitamin K_1_, when compared with another group of patients with stable anticoagulant control (29 micrograms daily versus 76 micrograms daily).8 In another study in 10 patients with poor anticoagulant control taking acenocoumarol, a diet with a low, controlled vitamin K_1_ content of 20 to 40 micrograms daily increased the percentage of INR values within the therapeutic range, when compared with a control group of 10 patients not subjected to any dietary restrictions.9

Mechanism

The coumarin and indanedione oral anticoagulants are vitamin K antagonists, which inhibit the enzyme vitamin K epoxide reductase so reducing the synthesis of vitamin K-dependent blood clotting factors by the liver. If the intake of dietary vitamin K_1_ increases, the synthesis of the blood clotting factors begins to return to normal. As a result the prothrombin time also begins to fall to its normal value. Naturally occurring vitamin K_1_ (phytonadione) is found only in plants. The natural coumarins present in alfalfa are not considered to be anticoagulants, because they do not have the structural requirements for this activity.

Importance and management

Patients should be counselled on the effects of dietary vitamin K and the need to avoid dramatic dietary alterations while taking warfarin. It would be prudent to avoid large doses of alfalfa leaf supplements as a precaution when taking warfarin or other coumarin anticoagulants. Available evidence suggests that it is unlikely that infusions prepared with water, or alfalfa seeds, would pose any problem, due to the lower vitamin K_1_ content.

Aloe vera

*Aloe vera* (L.) Burm.f. (Aloaceae)

**Synonym(s) and related species**

Aloe gel, Barbados aloes, Curacao aloes.


**Constituents**

Aloe vera gel is contained in the mucilaginous tissue that is found in the inner leaf, and should not be confused with aloes, page 27, which is the latex stored in tubules along the leaf margin. Aloe vera gel may be produced by a hand-filleted technique to remove the inner leaf, or by a whole-leaf extraction process where the aloes constituents (anthraquinones) are now usually subsequently removed (e.g. by charcoal filtration).

The principal constituents of the gel are polysaccharides consisting mainly of polymannans, of which acemannan is the major one. Other constituents include glycoproteins such as aloctins, and various carboxypeptidases, sterols, saponins, tannins, organic acids, vitamins and minerals. Traces of anthraquinone glycosides may also be present in preparations.

**Use and indications**

Aloe vera is used topically to aid wound healing from cuts and burns, including sunburn, and is used in many cosmetic preparations such as moisturisers. It is reported to possess anti-inflammatory, antitumour, immunomodulatory and antibacterial properties. Internally, aloe vera is thought to be immunostimulatory and to have mild analgesic, antioxidant and antidiabetic effects.

**Pharmacokinetics**

No relevant pharmacokinetic data found.

**Interactions overview**

Aloe vera contains only traces of anthraquinone glycosides, and would therefore not be expected to have any of the interactions of aloes, page 27, or similar herbal medicines, which occur, or are predicted to occur, as a result of their anthraquinone content.

Aloe vera may have blood-glucose-lowering properties and may therefore be expected to interact with conventional drugs that have the same effect. Aloe vera appears to enhance the absorption of some vitamins but the clinical significance of this is not clear.
Aloe vera + Antidiabetics

Aloe vera juice reduces blood-glucose levels in patients with diabetes taking glibenclamide.

Clinical evidence
In placebo-controlled studies, aloe vera juice (80%), one tablespoonful twice daily for 42 days, reduced blood-glucose in patients with diabetes, either taking glibenclamide, or not taking oral antidiabetic drugs, from an average of 14 to 16 mmol/L down to 8 mmol/L over a period of 6 weeks. However, it should be noted that, in the study in patients taking glibenclamide, there was, unexpectedly, no response to the use of glibenclamide alone. In these studies, the aloe vera juice (80%) was prepared from aloe gel and additional flavours and preservatives.

Experimental evidence
There is extensive literature (not cited here) on the possible blood-glucose-lowering effect of various extracts of aloe vera in animal models of diabetes, with some studies showing an effect and others not.

Mechanism
Unknown.

Importance and management
It seems possible that some oral preparations of aloe vera might have a clinically important blood-glucose-lowering effect. Indeed, aloe vera has traditionally been used to treat diabetes. It might therefore be prudent to increase the frequency of blood-glucose monitoring if patients taking antidiabetic medication wish to try oral aloe vera preparations.


Aloe vera + Vitamins

Aloe vera might delay, and enhance, the absorption of vitamin C and vitamin E.

Clinical evidence

(a) Vitamin C
In a single-dose, randomised study in 8 healthy subjects, aloe vera gel extract 60 mL appeared to enhance the absorption of vitamin C 500 mg. The AUC of ascorbate was increased by about threefold. However, this difference was not statistically significant: it was attributed to the large interindividual differences. There was a second maximum plasma ascorbate level at 8 hours with the gel, and plasma ascorbate was still detectable at 24 hours, suggesting that aloe vera gel might delay, as well as enhance, absorption. Conversely, aloe vera whole leaf extract 60 mL had no significant effect on the absorption of vitamin C.

(b) Vitamin E
In a single-dose, randomised study in 10 healthy subjects, aloe vera gel extract 60 mL increased the AUC of vitamin E 420 mg by 3.7-fold. Aloe vera whole leaf extract 60 mL increased the AUC by about twofold. However, the only statistically significant difference was the increase in plasma tocopherol at 8 hours, which occurred with both aloe vera extracts. The time to maximum level was delayed from 4 hours to 8 hours for the gel and to 6 hours for the leaf extract, suggesting that aloe vera might delay, as well as enhance, absorption.

Experimental evidence
No relevant data found.

Mechanism
The authors suggest that the vitamins may be protected from degradation in the intestine by flavonoid antioxidants in the aloe
 Vera extracts and by polysaccharides that may bind to the vitamins, delaying and increasing their absorption.\textsuperscript{1}

**Importance and management**

If confirmed, this appears to be a beneficial interaction, with aloe vera exhibiting the potential to be an adjunct for patients requiring vitamin C and/or E supplementation.

Aloes

*Aloe barbadensis* Mill., *Aloe ferox* Mill., *Aloe perryi* Baker (Aloaceae)

**Synonym(s) and related species**
*Aloe ferox*: Cape aloes.
*Aloe perryi*: Socotrine aloes, Zanzíbar aloes.
Not to be confused with the gel of *Aloe vera*, page 24.

**Pharmacopoeias**
Aloe (*USP 32*); Barbados Aloes (*BP 2009, Ph Eur 6.4*); Cape Aloes (*BP 2009, Ph Eur 6.4*); Standardised Aloes Dry Extract (*BP 2009, Ph Eur 6.4*).

**Constituents**
Not to be confused with *Aloe vera*, page 24, which is the gel contained in the mucilaginous tissue that is found in the inner leaf. Aloes is derived from the latex that is stored in tubules along the margin of the leaf. When the outer leaf is cut, latex exudes from the leaf and this exudate, when dried, is aloes. **Anthraquinone glycosides** are major components of aloes and include barbaloin, a glycoside of aloe-emodin to which it may be standardised, and minor glycosides such as aloinosides A and B. Aloe-emodin, chrysophanol, chromenes including aloesin, aloeresin E, isoaloeresin D and furoaloesone are also present in small amounts, as are resins.

**Use and indications**
Aloes has mainly been used internally as a laxative (although, note that this use has generally been superseded) and, in low concentrations, as a flavouring ingredient in food and drink.

**Pharmacokinetics**
The anthraquinone, emodin, is present in aloes (and similar plants) principally as the inactive glycoside. It travels through the gut, and is then metabolised by microflora to produce the active aglycone emodin, some of which is absorbed. Emodin is genotoxic, and might be metabolised to more toxic metabolites by CYP1A2. However, the relevance of this to the clinical use of drugs (especially CYP1A2 substrates and inducers) is unclear.¹

**Interactions overview**
Although aloes have been predicted to interact with a number of drugs that lower potassium levels (such as the corticosteroids and potassium-depleting diuretics), or drugs where the effects become potentially harmful when potassium is lowered (such as digoxin), there appears to be little or no direct evidence that this occurs in practice.

Aloes + Corticosteroids

Theoretically, the risk of hypokalaemia might be increased in patients taking corticosteroids, who also regularly use, or abuse, anthraquinone-containing substances such as aloes.

Clinical evidence

Chronic diarrhoea as a result of long-term use, or abuse, of stimulant laxatives such as aloes can cause excessive water and potassium loss; this has led to metabolic acidosis in one case. Systemic corticosteroids with mineralocorticoid effects can cause water retention and potassium loss. The effect of the over-use of aloes combined with systemic corticosteroids is not known, but, theoretically at least, the risk of hypokalaemia might be increased. Although this is mentioned in some reviews, there do not appear to be any reports describing clinical cases of this effect.

Experimental evidence

No relevant data found.

Mechanism

In theory the additive loss of potassium, caused by anthraquinone-containing substances and systemic corticosteroids, may result in hypokalaemia.

Importance and management

The interaction between aloes and corticosteroids is theoretical, but be aware of the potential in patients who regularly use, or abuse, anthraquinone-containing substances such as aloes. However, note that, if anthraquinone laxatives are used as recommended (at a dose producing a comfortable soft-formed motion), then this interaction would not be expected to be clinically relevant. See also Senna + Corticosteroids, page 350.

Aloes + Digitalis glycosides

Theoretically, digitalis toxicity could develop if patients regularly use, or abuse, anthraquinone-containing substances such as aloes.

Clinical evidence

Chronic diarrhoea caused by the long-term use, or abuse, of stimulant laxatives such as aloes can cause excessive water and potassium loss, which may cause hypokalaemia that could lead to the development of digitalis toxicity. Although this is often mentioned in reviews, there do not appear to be any reports describing clinical cases of this effect. However, for mention of a case of digitalis toxicity and mild hypokalaemia in a patient stabilised on digitalis and furosemide, who started to take a laxative containing rhubarb and liquorice, see Liquorice + Digitalis glycosides, page 274.

Experimental evidence

No relevant data found.

Mechanism

Possible pharmacodynamic interaction. The risk of development of digitalis toxicity, including cardiac arrhythmias, is increased by hypokalaemia, which can be induced by the excessive use of anthraquinone laxatives.

Importance and management

This is a theoretical interaction, but it may be prudent to exercise caution in patients who are taking digitalis glycosides and who regularly use, or abuse, anthraquinone-containing substances such as aloes. However, note that, if anthraquinone laxatives are used as recommended (at a dose producing a comfortable soft-formed motion), then this interaction would not be expected to be clinically relevant. Consider also Senna + Digitalis glycosides, page 350, for the effects of anthraquinones on digoxin absorption.

Aloes + Diuretics; Potassium-depleting

Theoretically, patients taking potassium-depleting diuretics could experience excessive potassium loss if they also regularly use, or abuse, anthraquinone-containing substances such as aloes.

Clinical evidence

The potassium-depleting diuretics (i.e. loop diuretics and thiazide and related diuretics) may cause potassium depletion. Chronic diarrhoea caused by long-term use, or abuse, of stimulant laxatives such as aloes, may also lead to excessive water loss and potassium deficiency. This, theoretically, could be increased by concurrent use of these diuretics. This interaction is sometimes mentioned in reviews, nevertheless, there is little, if any, direct evidence. There appears to be one case describing a myopathic syndrome related to potassium deficiency (potassium level 1.7 mmol/L) in a patient taking furosemide 80 mg daily and with a history of laxative abuse (laxatives not named). However, even this case may not have occurred as a result of an interaction as the patient also had gastroenteritis, causing profuse diarrhoea.

Experimental evidence

No relevant data found.

Mechanism

Possible pharmacodynamic interaction involving additive loss of potassium and water by anthraquinone-containing substances and potassium-depleting diuretics.

Importance and management

This is a theoretical interaction, but be aware of the potential for hypokalaemia in patients who are taking potassium-depleting diuretics and who regularly use, or abuse, anthraquinone-containing substances such as aloes. However, note that, if anthraquinone laxatives are used as recommended (at a dose producing a comfortable soft-formed motion), then this interaction is not clinically relevant. See also Senna + Diuretics; Potassium-depleting, page 350, for the effects of anthraquinones on furosemide absorption.

<table>
<thead>
<tr>
<th>Aloes + Herbal medicines; Liquorice</th>
<th>Aloes + Quinidine</th>
</tr>
</thead>
<tbody>
<tr>
<td>Consider Liquorice + Laxatives, page 275, for the potential additive effects of anthraquinone-containing laxatives and liquorice.</td>
<td>Consider Senna + Quinidine, page 351 for a potential interaction between anthraquinone-containing laxatives and quinidine.</td>
</tr>
</tbody>
</table>
Andrographis paniculata Nees (Acanthaceae)

Synonym(s) and related species
Bhunimba, Green chiretta, Kalmegh.

Constituents
The whole plant contains diterpene lactone glycosides, collectively termed andrographolides, which are based on the aglycone andrographolide and its derivatives, such as neoandrographolide, deoxyandrographolide, andrographiside, andropaniside and others.

Use and indications
Used in Ayurvedic medicine particularly for jaundice as a general liver and digestive system tonic, and as an immune system stimulant for treatment and prevention of infections. It is also used as an anti-inflammatory and antimalarial, and for cardiovascular disorders and diabetes. When used for the common cold, it is commonly combined with Eleutherococcus senticosus (Siberian ginseng), page 219, or echinacea, page 167.

Pharmacokinetics
Evidence from animal studies suggests that crude extracts of andrographis might induce the cytochrome P450 isoenzymes CYP1A and CYP2B, and might moderately inhibit P-glycoprotein. However, there is no certainty that this evidence can be extrapolated to clinical use, and further study is required to assess its clinical application.

Interactions overview
Andrographis may have antidiabetic and antihypertensive effects, and limited evidence suggests that it may interact with conventional drugs with these properties. Andrographis may also have antiplatelet effects, and so it may interact with conventional antiplatelet drugs and anticoagulants, although evidence is sparse.

References:
The interaction between andrographis and warfarin is based on experimental evidence only.

Clinical evidence
No interactions found.

Experimental evidence
Kan Jang (a standardised fixed combination of extracts from *Andrographis paniculata* and *Eleutherococcus senticosus* (Siberian ginseng), page 219) caused a modest increase in warfarin exposure, but did not alter the effect of warfarin on prothrombin time, in a study in rats. One group of animals was given an aqueous solution of Kan Jang orally for 5 days, at a dose of 17 mg/kg daily of the active principle andrographolide (a dose about 17-fold higher than that recommended for humans). The control group received a similar volume of water only. Sixty minutes after the final daily dose of Kan Jang or water, an aqueous solution of warfarin was given orally, at a dose of 2 mg/kg. The AUC of warfarin was increased by 67%, and its clearance was decreased by 45%, but other pharmacokinetic parameters were similar.1

**Mechanism**
The available evidence suggests that andrographis might have antiplatelet effects (see Andrographis + Antiplatelet drugs below), which may be expected to prolong bleeding time. This may increase the risk or severity of bleeding if over-anticoagulation with warfarin occurs. It is not clear why high doses of andrographis increase warfarin exposure.

**Importance and management**
A very high dose of andrographis does not appear to directly affect prothrombin time, but may modestly increase warfarin exposure. As this study suggested that the pharmacodynamic effects of warfarin were not altered, any pharmacokinetic interaction would not be expected to be clinically relevant. However, if the antiplatelet effects of andrographis are confirmed to be clinically important, then an increased risk of bleeding would be anticipated in patients also taking warfarin, as occurs with low-dose aspirin. Therefore, until more is known, some caution is appropriate if andrographis is given in high doses for a long period of time with any anticoagulant.1


The interaction between andrographis and antidiabetics is based on experimental evidence only.

Clinical evidence
No interactions found.

**Experimental evidence**
Andrographolide1 and an andrographis decoction2 lowered blood-glucose levels in *animal* models of diabetes. In one study, the effect was similar to that of Karela (*Momordica charantia*),2 which has an established antidiabetic effect.

**Mechanism**
Potentially additive pharmacological effects.

**Importance and management**
These experimental studies provide limited evidence of the possible blood-glucose-lowering properties of andrographis, but, because of the nature of the evidence, applying these results in a clinical setting is extremely difficult. However, if a patient taking antidiabetic drugs wants to take andrographis it may be prudent to discuss these potential additive effects, and advise an increase in blood-glucose monitoring should an interaction be suspected.


**Andrographis + Anticoagulants**
Limited evidence suggests that andrographis may have hypotensive properties that may be additive if given with conventional antihypertensives.

**Clinical evidence**
Anecdotal evidence suggests that some patients have experienced hypotensive effects while taking andrographis.3

**Experimental evidence**
*In vitro* and *animal* studies found that extracts of andrographis, and various individual diterpenoid constituents have hypotensive effects.1,2

**Mechanism**
Unknown. Andrographis may have antihypertensive effects, and a slight additive reduction in blood pressure is possible if it is given with conventional antihypertensives.

**Importance and management**
These experimental studies provide limited evidence of the possible hypotensive properties of andrographis. Because of the nature of the evidence, applying these results to a general clinical setting is difficult, and, until more is known, it would be unwise to advise anything other than general caution.


The interaction between andrographis and antiplatelet drugs is based on experimental evidence only.

Clinical evidence
No interactions found.

**Experimental evidence**
In an *in vitro* study, aqueous extracts of andrographis, and two of three individual diterpenoid constituents (all andrographolides), inhibited thrombin-induced platelet aggregation.1 In another study, a preparation of flavones extracted from the root of andrographis, given intravenously, inhibited platelet aggregation and thrombus formation in an experimental model of thrombus production in dogs.2

**Mechanism**
Potentially additive pharmacological effects.
Importance and management
If the antiplatelet effects of andrographis are confirmed to be clinically important, then an increased risk of bleeding would be anticipated in patients taking conventional antiplatelet drugs. Until more is known, this suggests that some caution is appropriate on concurrent use. See also willow, page 399, for more information on herbs that possess antiplatelet properties.


### Andrographis + Food
No interactions found.

### Andrographis + Herbal medicines
No interactions found.
Aniseed
Pimpinella anisum L. (Apiaceae)

Synonym(s) and related species
Anise [not to be confused with Star anise (Illicium verum)], Anisum.
Anisum officinarum Moench., Anisum vulgare Gaertn.

Pharmacopoeia
Aniseed (BP 2009, Ph Eur 6.4).

Constituents
Aniseed fruit contains 2 to 6% of a volatile oil composed mostly of trans-anethole (80 to 95%), with smaller amounts of estragole (methyl chavicol), β-caryophyllene and anise ketone (p-methoxyphenylacetone). Natural coumarins present include scopoletin, umbelliferone, umbelliprenine and bergapten, and there are numerous flavonoids present, including quercetin, apigenin and luteolin.

Use and indications
Aniseed dried fruit, or oil distilled from the fruit, are used mainly for their antispasmodic, carminative and parasiticide effects. Aniseed also is reputed to have mild oestrogenic effects, page 34. In foods, aniseed is used as a spice and flavouring.

Pharmacokinetics
Studies in rats suggested that trans-anethole did not alter cytochrome P450 activity, but increased UDP-glucuronyltransferase activity (a phase II biotransformation reaction).1

In another study in rats, aniseed oil enhanced the absorption of glucose from the gut, probably by increasing the activity of the Na+/K+ ATPase and consequently the sodium gradient needed for glucose transport.2

For information on the pharmacokinetics of individual flavonoids and natural coumarins present in aniseed, see under flavonoids, page 186 and natural coumarins, page 297, respectively.

Interactions overview
Evidence is very limited. Aniseed appears to have some oestrogenic effects, but the clinical relevance of this is unclear. For information on the interactions of individual flavonoids present in aniseed, see under flavonoids, page 186. Although aniseed contains natural coumarins, the quantity of these constituents is not established, and therefore the propensity of aniseed to interact with other drugs because of their presence is unclear. Consider flavonoids, page 186, for further discussion of the interactions of natural coumarin-containing herbs.

Aniseed + Food

No interactions found.

Aniseed + Herbal medicines

No interactions found.

Aniseed + Oestrogens

The interaction between aniseed and oestrogens is based on experimental evidence only.

Clinical evidence

No interactions found.

Experimental evidence

In a yeast oestrogen screen assay, the fruit oil from aniseed was oestrogenic. In another study, an aqueous extract from aniseed had selective oestrogen receptor modulator-like properties (i.e. properties like those of drugs such as raloxifene) in various in vitro assays (stimulation and differentiation of osteoblasts, anti-oestrogenic effect on breast cancer cells, and absence of proliferative effects on cervical adenocarcinoma cells).

Mechanism

Active compounds from aniseed appear to have oestrogenic activity and might compete for the same oestrogen receptor as conventional hormonal drugs and treatment.

Importance and management

These experimental studies provide limited evidence of the possible oestrogenic activity of aniseed. Because of the nature of the evidence, applying these results in a clinical setting is extremely difficult and, until more is known, it would be unwise to advise anything other than general caution.

Aristolochia

*Aristolochia* species (*Aristolochiaceae*)

**Synonym(s) and related species**
The nomenclature of these and related plants has given rise to confusion with other, non-toxic plants. This has been exacerbated by the fact that different Chinese names have been used for each species. Great care is needed.

Birthwort has been used as a collective name for the *Aristolochia* species, but it has also been used for one of the species, *Aristolochia clematitis* L. The Chinese name Mu Tong has been used to refer to some of the *Aristolochia* species.

*Aristolochia clematitis* L. and *Aristolochia fangchi* are the most common species used in herbal medicines, but many others are also used. *Aristolochia fangchi* has been referred to by the Chinese names Fang Chi, Fang Ji, Guang Fang Ji. However, note that *Stephania tetrandra* is also known as Fang Ji.

*Aristolochia reticulata* NUTT., also known as Serpentary, Snakeroat and Texan snakeroot, has been used as a herbal medicine, although note that the term Snakeroat has also been used to describe other species.

**Constituents**
All species contain a range of toxic aristolochic acids and aristolactams.

**Use and indications**
Aristolochic acids and aristolactams are nephrotoxic, carcinogenic and cytotoxic. Numerous deaths have resulted from aristolochic acid nephropathy and associated urothelial cancer, caused by ingestion of aristolochia both medicinally and from contamination of food. All plants of the family *Aristolochiaceae* are banned in Europe and elsewhere, and should be avoided.

**Pharmacokinetics**
No relevant pharmacokinetic data found.

**Interactions overview**
No interactions with aristolochia found.
Arjuna
Terminalia arjuna Wight & Am. (Combretaceae)

Synonym(s) and related species
Arjun myrobalan.
Terminalia cuneata Roth.

Constituents
The main constituents of the bark are triterpenoid saponins including arjunic acid, arjunolic acid, arjungenin and arjunglycosides, and high levels of flavonoids, such as arjunone, arjunolone, luteolin and quercetin. Polyphenols, particularly gallic acid, ellagic acid and oligomeric proanthocyanidins, are also present.

Pharmacopoeias
Terminalia Arjuna Stem Bark (BP 2009).

Use and indications
Arjuna is widely used in Ayurvedic medicine for the treatment of cardiovascular disorders including coronary artery disease, heart failure, hypertension and hypercholesterolaemia. A number of small clinical studies have supported this use.

Interactions overview
Arjuna appears to have some effects on cardiovascular function, which may lead to interactions with conventional drugs used for similar indications. However, if anything, these interactions may be beneficial. Arjuna may also affect thyroid function, which could alter the control of both hyper- and hypothyroidism.

For information on the interactions of individual flavonoids present in arjuna, see under flavonoids, page 186.
Arjuna appears to have some effects on cardiovascular function that may be of benefit when given with conventional cardiovascular drugs.

Clinical evidence

The effect of arjuna on angina pectoris, congestive heart failure, left ventricular mass and hyperlipidaemia has been investigated in a number of small studies in patients with various cardiovascular disorders (these have been the subject of a review). In some of these studies, patients were also taking conventional drugs. For example, in one double-blind, crossover study in 58 patients with stable angina, the addition of powdered stem bark extract (500 mg every 8 hours) for one week decreased the number of angina episodes and the need for nitrate therapy during episodes of angina (about 5.7 mg/week versus 18.2 mg/week with placebo). In another double-blind crossover study in patients with refractory congestive heart failure, the addition of bark extract 500 mg every 8 hours for 2 weeks to conventional therapy (digoxin, maximally tolerated furosemide and spironolactone, vasodilators; ACE inhibitors, nifedipine or nitrates) led to improvements in signs and symptoms of heart failure. This improvement was maintained over long-term evaluation in an open phase, when patients continued the bark extract at the same dosage. The only notable adverse effect was a rise in serum potassium (from about 3.8 to 4.3 mmol/L). Another randomised, placebo-controlled study in patients with coronary heart disease found that adding arjuna bark powder 500 mg daily to existing medication decreased lipid peroxide levels (a marker of atherosclerosis) and caused a significant decrease in cholesterol levels.

Experimental evidence

Numerous pharmacological studies in animals (which have been the subject of a review) have shown that arjuna has cardiotonic activity, positive or negative inotropic effects (depending on the type of extract), causes bradycardia, and has hypotensive effects, antioxidant activity and lipid-lowering effects.

Mechanism

Unknown. Arjuna is purported to have inotropic and hypotensive effects, as well as lipid-lowering effects. These effects might be additive with those of conventional cardiovascular drugs. See Arjuna + Cardiovascular drugs below for the possibility that some of the cardiovascular effects of arjuna might occur via an antithyroid action.

Importance and management

Arjuna has been used in small numbers of patients taking a variety of conventional cardiovascular drugs, apparently without particular problems, and with possible additional benefit.


Arjuna + Cardiovascular drugs

No interactions found.

Arjuna + Food

No interactions found.

Arjuna + Herbal medicines

No interactions found.

Arjuna + Thyroid and Antithyroid drugs

The interaction between arjuna and thyroid or antithyroid drugs is based on experimental evidence only.

Clinical evidence

No interactions found.

Experimental evidence

In a study in animals, arjuna bark extract appeared to inhibit thyroid function. Giving levothyroxine increased the level of thyroid hormones, increased the heart to body weight ratio, as well as increasing cardiac and hepatic lipid peroxidation. When the plant extract was given simultaneously, the level of thyroid hormones, and also the cardiac lipid peroxidation, were decreased. These effects were comparable to those of a standard antithyroid drug, propylthiouracil. When arjuna bark extract was given to euthyroid animals, thyroid hormone levels were decreased, whereas the hepatic lipid peroxidation increased, indicating drug-induced liver toxicity.

Mechanism

Arjuna may deplete thyroid hormones.

Importance and management

Although the evidence is experimental, until more is known, it might be prudent to avoid the use of arjuna in patients requiring levothyroxine (or any thyroid hormone), because of the possibility of reduced efficacy. If patients want to try arjuna, their thyroid function should be monitored more frequently. An additive effect with antithyroid drugs such as propylthiouracil might also occur, and therefore similar caution would seem advisable.

Since, in euthyroid animals, thyroid hormones were decreased and hepatic lipid peroxidation was increased, the authors suggest that high amounts of this plant extract should not be consumed, as hepatotoxicity as well as hypothyroidism may occur.

Artichoke  
*Cynara scolymus* L. (Asteraceae)

**Synonym(s) and related species**
Alcachofa, Bur artichoke, Cynara, Globe artichoke.  
*Cynara cardunculus* Moris.  
Not to be confused with Jerusalem artichoke.

**Pharmacopoeias**
Artichoke Leaf (*BP 2009, Ph Eur 6.4*); Artichoke Leaf Dry Extract (*Ph Eur 6.4*).

**Constituents**
Artichoke leaf is usually standardised to the caffeoylquinic acid derivative, **chlorogenic acid**. Other major constituents are **flavonoid glycosides** based on luteolin, including cynaroside and scolymoside, and sesquiterpene lactones including cynaropicrin.

**Use and indications**
The leaf extract has been traditionally used for liver and digestive disorders, especially dyspepsia and nausea, and to promote bile secretion. Its use now focuses more on hypercholesterolaemia, hyperlipidaemia and irritable bowel syndrome, and some cardiovascular disorders such as atherosclerosis. Artichoke flowers are also used as food and artichoke extracts are used as flavouring agents.

**Pharmacokinetics**
No relevant pharmacokinetic data found. For information on the pharmacokinetics of individual flavonoids present in artichoke, see under flavonoids, page 186.

**Interactions overview**
No interactions with artichoke found. For information on the interactions of individual flavonoids present in artichoke, see under flavonoids, page 186.
Asafoetida

_Ferula asafoetida_ L. (Apiaceae)

**Synonym(s) and related species**
Asafetida, Asant, Devil’s dung, Gum asafetida.

Asafoetida is obtained from various _Ferula_ species, the main sources being _Ferula asafoetida_ L. or _Ferula foetida_ (Bunge) Regel.

Note that Giant fennel (_Ferula communis_ L.), although a species of _Ferula_, contains certain constituents that are distinct from asafoetida and will not be dealt with in this monograph.

**Constituents**
The gum resin contains ferulic acid esters and free ferulic acid, asaresinotannols, farnesiferols A, B and C, natural coumarin derivatives including saradaferin, gummosin, asacoumarins and assafoetidnols, and an essential oil composed of disulfides, polysulfanes, monoterpenes and phenylpropanoids. The sesquiterpene dienones, fetidones A and B, samarcandin and galbanic acid are also present. _Ferula foetida_ also contains foetisulfides and foetithio-phenones.

**Use and indications**
Asafoetida is used for its carminative, antispasmodic and expectorant properties in chronic bronchitis, pertussis, and specifically for intestinal flatulent colic.

**Pharmacokinetics**
Little information is available. Studies in rats fed with asafoetida suggest that, it did not stimulate levels of cytochrome P450, and glucuronyl transferase activity remained unaffected.1

**Interactions overview**
In theory the use of asafoetida with conventional antihypertensives may be expected to produce additive hypotensive effects. Although it has been suggested that asafoetida may interact with anticoagulants, the available data do not appear to support this prediction.1

Asafoetida + Antihypertensives

The interaction between asafoetida and antihypertensives is based on experimental evidence only.

Clinical evidence
No interactions found.

Experimental evidence
In a study in rats, asafoetida gum extract significantly reduced mean arterial blood pressure.¹

Mechanism
In theory the use of asafoetida with conventional antihypertensives may be expected to produce additive hypotensive effects.

Importance and management
Because of the nature of the evidence, applying these results in a clinical setting is extremely difficult and, until more is known, it would be unwise to advise anything other than general caution.


Asafoetida + Food

No interactions found.

Asafoetida + Herbal medicines

No interactions found.

Asafoetida + Warfarin and related drugs

The interaction between asafoetida and warfarin and related drugs is a prediction only.

Clinical evidence
No interactions found.

Experimental evidence
Some reviews¹ and monographs list asafoetida as having the potential to increase the risk of bleeding or potentiate the effects of warfarin.

Mechanism
This appears to be based on the fact that asafoetida contains natural coumarins, but these are not thought to have the structural requirements for anticoagulant activity. For more information, see Natural coumarins + Warfarin and related drugs, page 301.

Importance and management
There appears to be no evidence to support the prediction of an interaction between warfarin and asafoetida, and some data do suggest that an interaction is unlikely to occur. No special precautions therefore appear to be needed if patients taking warfarin or related anticoagulants also wish to take asafoetida.

Ashwagandha

*Withania somnifera* (L.) Dunal (Solanaceae)

**Synonym(s) and related species**
Winter cherry.

*Physalis somnifera* L.

Note that ashwagandha has also been known as Indian ginseng, which should not be confused with the common ginsengs, page 219.

**Constituents**
The major constituents of the root are steroidal lactones, with several series known as the withanolides (designated A–Y to date), glycowithanolides (sitoidosides), the withasomniferols (A–C), withastramonolide and withaferin A. The extract also contains phytosterols and alkaloids such as ashwagandhine, ashwagandhinine, anahygrine, withasomnine, withaninine and others.

**Use and indications**
Use of ashwagandha root originates in Ayurvedic medicine, and it is used as a tonic for debility and as an adaptogen and immune modulator. It has sedative and anti-inflammatory effects and is used for a wide range of conditions including hypercholesterolaemia.

**Pharmacokinetics**
No relevant pharmacokinetic data found.

**Interactions overview**
Although ashwagandha may have blood-glucose-lowering effects, these seem to be mild, and would not generally be expected to affect the control of diabetes with conventional medicines. Ashwagandha may affect the reliability of digoxin assays, and interfere with the control of hypo- and hyperthyroidism.
Ashwagandha + Antidiabetics

Limited evidence suggests that ashwagandha has blood-glucose-lowering effects, which may be additive with conventional antidiabetics.

Clinical evidence
In 6 subjects with mild type 2 diabetes, giving powdered root of ashwagandha 1 g three times daily after meals for 30 days reduced blood-glucose levels by 12% (from 11.5 to 10.1 mmol/L – timing of sample in relation to meals not stated). These subjects discontinued any blood-glucose-lowering drugs before the study, and 6 control subjects continued treatment with glibenclamide. These control subjects also had a reduction in blood-glucose of 12%. This study is difficult to interpret, because there was no placebo group.

Experimental evidence
No interactions found.

Mechanism
Unknown. Additive blood-glucose-lowering effects might be anticipated with antidiabetics.

Importance and management
The limited evidence suggests that ashwagandha might have blood-glucose-lowering effects. Until further information is available, if a patient taking antidiabetic drugs wants to take ashwagandha it may be prudent to discuss these potential additive effects, and advise an increase in blood-glucose monitoring should an interaction be suspected. However, bear in mind that, although ashwagandha has been used for a wide number of complaints, it does not appear to be used for diabetes, suggesting that any effects are mild, and probably not clinically relevant.

Ashwagandha + Digoxin

Ashwagandha has been shown to interfere with some methods of measuring serum digoxin levels; see Ashwagandha + Laboratory tests below.

Ashwagandha + Food

No interactions found.

Ashwagandha + Herbal medicines

No interactions found.

Ashwagandha + Laboratory tests

Digoxin levels might be spuriously elevated when assayed using a fluorescence polarisation immunoassay in patients taking ashwagandha. Ashwagandha does not interfere with in vitro assays for carbamazepine, gentamicin, paracetamol, phenytoin, phenobarbital, procainamide, salicylate, theophylline, tobramycin or valproic acid.

Clinical evidence
No interactions found.

Experimental evidence
No interactions found.

(a) Digoxin
In a study, mice fed two ashwagandha extracts (in quantities that equated to human doses) developed apparent serum digoxin levels of 0.46 nanograms/mL and 0.57 nanograms/mL one hour after feeding, as assessed by a fluorescence polarisation immunoassay (FPIA) of digoxin (Abbott Laboratories). A further ashwagandha extract did not produce detectable digoxin levels by FPIA. No digoxin was detected for any of the three extracts using a monoclonal antibody-based digoxin assay (Beckman) or a microparticle enzyme immunoassay (MEIA, Abbott Laboratories). Similar findings were seen in vitro, with interference seen at lower concentrations of ashwagandha extracts with the FPIA assay, than with the MEIA and Beckman assays. In other similar studies by the same research group, an enzyme-linked chemiluminescent immunosorbent assay (ECLIA) for digoxin (Bayer), and the Tina-quant assay (Roche), were not affected by ashwagandha.

(b) Other drugs
In in vitro tests, ashwagandha extract had no effect on immunoassays (Roche) for carbamazepine, gentamicin, paracetamol, phenytoin, phenobarbital, procainamide, salicylate, theophylline, tobramycin or valproic acid.

Mechanism
Some withanolides (major constituents of ashwagandha) are structurally similar to digoxin, and might therefore interfere with the digoxin immunoassay.

Importance and management
The animal data available suggest that, in patients taking digoxin and ashwagandha, digoxin levels might be spuriously elevated when assayed using a fluorescence polarisation immunoassay. Further clinical study is needed.

Ashwagandha + Thyroid and Antithyroid drugs

Limited evidence suggests that ashwagandha increases thyroid hormone levels and therefore interferes with the control of hyper- and hypothyroidism.

Clinical evidence
A 32-year-old healthy woman developed clinical symptoms of thyrotoxicosis, and was found to have elevated levels of thyroid hormones when she increased the dose of capsules containing ashwagandha herbal extract that she had been taking for chronic fatigue. The symptoms and raised thyroid hormone levels resolved on stopping the product.
**Experimental evidence**
In a study in *mice*, ashwagandha root extract 1.4 g/kg given daily for 20 days by gastric intubation increased serum levels of thyroid hormones, triiodothyronine and thyroxine, by 18% and 111%, respectively.2

**Mechanism**
Unknown. Additive effects with thyroid hormones might be anticipated.

**Importance and management**
Although the evidence is limited, until more is known, it might be prudent to advise caution if patients taking *levothyroxine* (or other thyroid hormones) want to take ashwagandha because of the possibility of an increase in effects. Furthermore, on the basis of this evidence, ashwagandha may be expected to antagonise the effects of antithyroid drugs, such as *propylthiouracil*. In both cases it may be prudent to consider monitoring thyroid function tests if symptoms of hypo- or hyperthyroidism begin to emerge.

Asparagus
Asparagus officinalis L. (Asparagaceae)

Synonym(s) and related species
Sparrowgrass.
Not to be confused with Shatavari, page 353, which is Asparagus racemosus.

Constituents
Asparagus contains saponins called asparagosides, steroidal glycosides, asparagusic acid and its derivatives, flavonoids (including rutin, kaempferol and quercetin) and various amino acids and polysaccharides. Asparagus is also a source of folic acid, vitamin K₁ and other vitamins.

Use and indications
The root and green parts of asparagus have been used as a diuretic, laxative, cardiac tonic and sedative. The young shoots are eaten as a foodstuff. Asparagusic acid may be nematocidal.

Pharmacokinetics
No relevant pharmacokinetic data for asparagus found. For information on the pharmacokinetics of individual flavonoids present in asparagus, see flavonoids, page 186.

Interactions overview
No interactions with asparagus found; however, note that asparagus contains a moderate amount of vitamin K and may therefore reduce the effectiveness of warfarin and other similar anticoagulants if eaten in large quantities. For information on the interactions of individual flavonoids present in asparagus, see under flavonoids, page 186.
Asparagus + Food

No interactions found, but note that asparagus is extensively used as a foodstuff.

Asparagus + Herbal medicines

No interactions found.

Asparagus + Warfarin and related drugs

Patients taking coumarins and indanediones should avoid taking excessive amounts of asparagus because of its vitamin K₁ content.

Evidence, mechanism, importance and management

Asparagus¹ contains a moderate amount of vitamin K₁, which reduces the effect of coumarin and indanedione anticoagulants, which are vitamin K antagonists. Patients taking these anticoagulants are advised to maintain a regular amount of vitamin K from the diet. They should therefore avoid taking excessive amounts of asparagus.

Astragalus

Astragalus membranaceus Bunge (Fabaceae)

Synonym(s) and related species
Huang qi.
Astragalus membranaceus (Fisch.) Bunge var mongolicus (Bunge.) P.K.Hsiao.
Not to be confused with the pharmaceutical excipient, tragacanth (Astragalus gummifer).

Pharmacopoeias
Astragalus Root (BP 2009); Processed Astragalus Root (BP 2009).

 Constituents
The key constituents are triterpene saponins, which include the astragalosides I–VIII and their acetyl derivatives, the agroastragalosides I–IV, the astramembranins I and II and others. Isoflavones are also present, mainly glycosides of calycosin and formononetin, with astrapterocarpan, kumatakenin and numerous hydroxyl and methoxyl derivatives of pterocarpan and isoflavan, and a series of polysaccharides known as astragaloglucans.

Use and indications
Astragalus is traditionally used in Chinese medicine as a tonic to strengthen the immune system, for viral infections, fatigue and loss of blood. It is now used as a liver protectant, an adjunct in chemotherapy and impaired immunity, and for a variety of other conditions such as cardiovascular disease and diabetic complications. Some indications are supported by pharmacological and clinical studies.

Pharmacokinetics
Few data are available, but in a study in one healthy subject, who was given astragalus root decoction orally twice daily before meals of bread and honey for 5 days, urine samples were found to contain calycosin and formononetin and various isoflavonoid glucuronide metabolites. These data, and data from in vitro studies, demonstrate that the isoflavones in astragalus could be absorbed and metabolised by the intestine.\(^1\) For more information about the pharmacokinetics of isoflavones, see under isoflavones, page 258.

Interactions overview
Astragalus appears to alter the immune response, but the effect this has on treatment with interleukins, interferons, antiretrovirals and antineoplastics does not appear to be established. For information about the interactions of individual isoflavones present in astragalus, see under isoflavones, page 258.

Astragalus improved the response to chemotherapy with mitomycin, a vinca alkaloid and cisplatin in one study. Limited experimental data suggest that astragalus may diminish the immunosuppressant effects of cyclophosphamide.

Clinical evidence
In one small randomised clinical study in Chinese patients with non-small cell lung cancer, the addition of an infusion of astragalus to a chemotherapy regimen of mitomycin, vinca alkaloid and cisplatin (MVP) improved response rate (40% versus 36.7%) and median survival (11 months versus 7 months), when compared with a control group receiving MVP alone.1

Experimental evidence
In a study in cyclophosphamide-primed rats, giving a partially purified fraction of astragalus before mononuclear cell grafting markedly enhanced the ability of the rats to reject the graft. This suggests that astragalus reversed the immunosuppressant effect of cyclophosphamide.2 Conversely, in a similar study, astragalus appeared to prolong the life of bone marrow cells transplanted into mice pretreated with cyclophosphamide, as well as promoting blood cell production.3 Furthermore, in another study in rats, pretreatment with astragalus and Ligustrum lucidum (glossy privet) for 12 days had no effect on the degree or duration of myelosuppression (neutrophil and platelet counts) seen after a single dose of cyclophosphamide.4

Mechanism
Unknown, although many in vitro studies have shown that astragalus has immunostimulating effects.

Importance and management
The preclinical and preliminary clinical evidence suggests that astragalus might have immunomodulating activity and effects on blood cell production, and might therefore have beneficial effects if it is given with antineoplastics. Some have interpreted the preclinical data showing increased rejection of a xenograft5 as suggesting that astragalus might decrease the effects of immunosuppressive therapy, and recommend caution with the combination. The evidence is extremely limited, and apparently conflicting; nevertheless it may be prudent to consider the risk–benefit ratio of using the herb, especially in those given immunosuppressant treatment for life-threatening conditions.

No relevant data found.

Mechanism
Unknown, although many in vitro studies have found that astragalus has immunostimulating effects.

Importance and management
Although not an interactions study, the findings provide some evidence that if patients take astragalus concurrently with the NRTIs zidovudine or zalcitabine no major adverse interaction would be expected, and efficacy should not be compromised. Because the herbal product used contained three different herbs, a beneficial effect for a combination of astragalus and antiretroviral drugs is still far from proven.


Astragalus + Cytokines
Preliminary evidence suggests that astragalus may be beneficial when given with interferon-alfa or interleukin-2.

Clinical evidence
In a controlled study in 235 patients, astragalus appeared to act synergistically with interferon-alfa for the topical treatment of chronic cervicitis associated with viral infection. Local application of astragalus extract plus interferon was similar in efficacy to twice the dose of interferon alone, and more effective than astragalus alone.1

Mechanism
Unknown, although many in vitro studies have found that astragalus has immunostimulating effects.

Importance and management
The above preliminary evidence suggests that astragalus might have immunomodulating activity and might therefore be beneficial when given with interferons or interleukin-2.

<table>
<thead>
<tr>
<th>Astragalus + Food</th>
<th>Astragalus + Herbal medicines</th>
</tr>
</thead>
<tbody>
<tr>
<td>No interactions found.</td>
<td>No interactions found.</td>
</tr>
</tbody>
</table>
Avens

*Geum urbanum* L. (Rosaceae)

**Synonym(s) and related species**
Benedict’s herb, Colewort, Geum, Herb bennet, Wood avens.

**Constituents**
The main actives found in the whole plant are the tannins, gallotannins and ellagitannins, including sanguin H6, casuarictin, pedunculagin, potentillin and tellimagrandin. Other polyphenols include gallic, caffeic and chlorogenic acids, gein (a phenolic glycoside of eugenol), flavonoids and volatile oil containing eugenol.

**Use and indications**
Avens has been used as an astringent in diarrhoea, a haemostatic and an anti-inflammatory.

**Pharmacokinetics**
No relevant pharmacokinetic data found.

**Interactions overview**
No interactions with avens found.
Bacopa

*Bacopa monnieri* (L.) Penn. (Scrophulariaceae)

**Synonym(s) and related species**
Brahmi, Thyme leaved gratiola.


**Constituents**
Bacopa contains a wide range of triterpene glycosides, including the bacopa saponins, known as bacosides and bacopasaponins. Cucurbitacins, known as bacobitacins and cucurbitin C, the alkaloids brahmine and herpestine, phenylethanoid glycosides (including the monnierasides and plantioside B), and the flavonoids apigenin and luteolin have also been isolated.

**Use and indications**
Bacopa is an important herb in Ayurvedic medicine, which is increasingly being used in the West. The bacosides have been found, in a number of studies, to enhance the memory and cognitive processes. Bacopa has also been used as an anti-inflammatory, analgesic, antipyretic, sedative, and for the treatment of asthma and bronchitis. Recent toxicological studies suggest that the herb is relatively safe in normal use.

**Pharmacokinetics**
No relevant pharmacokinetic data found. For information on the pharmacokinetics of individual flavonoids present in bacopa, see under flavonoids, page 186.

**Interactions overview**
No interactions with bacopa found. For information on the interactions of individual flavonoids present in bacopa, see under flavonoids, page 186.
Baical skullcap

*Scutellaria baicalensis* Georgi (Lamiaceae)

**Synonym(s) and related species**
Huang qin.

*Scutellaria lanceolaria* Miq., *Scutellaria macrantha* Fisch.

**Constituents**
The major active components of the root are the **flavonoids** baicalein, baicalin (the glucuronide of baicalein), chrysin, oroxylin A, tenaxin I, skullcapflavones I and II, wogonin, wogonoside and many other hydroxylated methoxyflavones.

**Use and indications**
Baical skullcap root has been used traditionally, especially in Chinese medicine, as a remedy for inflammation, infections, dermatitis, allergic diseases, hyperlipidaemia, atherosclerosis and stress-related disorders.

**Pharmacokinetics**
No relevant pharmacokinetic data found specifically for baical skullcap, but see flavonoids, page 186, for information on individual flavonoids present in baical skullcap.

**Interactions overview**
Baical skullcap is the constituent of a number of Chinese medicines, such as sho-saiko-to, saiko-ka-ryukotsu-borei-to and sairei-to; these interactions are covered under bupleurum, page 89. For information on the interactions of individual flavonoids present in the herb, see under flavonoids, page 186, particularly the monograph Flavonoids + Ciclosporin, page 190, where baical skullcap was given as a source of flavonoids.
**Baical skullcap + Caffeine**

For mention that sho-saiko-to (of which baical skullcap is one of 7 constituents) slightly reduces the metabolism of caffeine, see Bupleurum + Caffeine, page 90.

**Baical skullcap + Carbamazepine**

For mention that saiko-ka-ryukotsu-borei-to and sho-saiko-to (of which baical skullcap is one of a number of constituents) do not affect the pharmacokinetics of carbamazepine in animal studies, see Bupleurum + Carbamazepine, page 90.

**Baical skullcap + Ciclosporin**

For mention that baical skullcap, given as a specific source of flavonoids, may affect the pharmacokinetics of ciclosporin, see Flavonoids + Ciclosporin, page 190.

**Baical skullcap + Ofloxacin**

For mention that sairei-to and sho-saiko-to (of which baical skullcap is one of a number of constituents) do not affect the pharmacokinetics of ofloxacin, see Bupleurum + Ofloxacin, page 90.

**Baical skullcap + Tolbutamide**

For conflicting evidence from animal studies that sho-saiko-to (of which baical skullcap is one of 7 constituents) might increase or decrease the rate of absorption of tolbutamide, see Bupleurum + Tolbutamide, page 90.

**Baical skullcap + Food**

No interactions found.

**Baical skullcap + Herbal medicines**

No interactions found.
Balm of Gilead

*Populus × gileadensis* Rouleau and other *Populus* species (Salicaceae)

**Synonym(s) and related species**
Balsam Poplar, Gileadensis, Poplar buds.

Note that Canada Balsam from the fir tree *Abies balsamea* (L.) Mill. is sometimes known as Balm of Gilead. Mecca balsam, a resin from *Commiphora opobalsamum* Engl. (Burseraceae) has also been used as a synonym for Balm of Gilead.

Not to be confused with Poplar bark, which is also from *Populus* species.

**Constituents**
The leaf buds, collected before they open, contain phenolic glycosides including *salicin* (a salicylate) and populin, and a volatile oil consisting of α-caryophyllene as the major component with cineole, bisabolene, farnesene and actophenone. **Flavonoids** present include apigenin, chrysin and others, and some *Populus* species may have constituents that differ slightly.

**Use and indications**
Balm of Gilead has expectorant, stimulant, antipyretic and analgesic activity, and is used mainly in cough mixtures.

**Pharmacokinetics**
No relevant pharmacokinetic data found for Balm of Gilead, but note that salicin, a constituent of Balm of Gilead, is metabolised to salicylic acid in the body. For more information, see willow, page 399. See also flavonoids, page 186 for information on the flavonoid components of Balm of Gilead.

**Interactions overview**
No specific interactions found. Balm of Gilead contains salicin, a precursor of salicylic acid, and clinically relevant levels of this have been achieved by taking some herbs, although this does not necessarily equate to the antiplatelet effect of the herb. For a discussion about the use of herbs with antiplatelet effects in conjunction with antiplatelet drugs and anticoagulants, see willow, page 399.

See also flavonoids, page 186 for information on the interactions of individual flavonoid components of Balm of Gilead.
Bayberry

*Myrica cerifera* L. (Myricaceae)

**Synonym(s) and related species**
Candleberry, Myrica, Southern bayberry, Southern wax myrtle, Waxberry, Wax myrtle.

**Constituents**
The root bark, which is used therapeutically, contains triterpenes including myriceric acid A, myrica acid, myricadiol, myriceron caffeoyl ester, taraxerol and taraxerone, and the flavonoid, myricitrin.

**Use and indications**
Bayberry bark is used for coughs and colds, and for diarrhoea and other gastrointestinal disorders. It is also used topically for wounds and as a douche for vaginal discharge.

**Pharmacokinetics**
No relevant pharmacokinetic data found.

**Interactions overview**
No interactions with bayberry found.
Bearberry

Arctostaphylos uva-ursi (L.) Spreng (Ericaceae)

Synonym(s) and related species
Uva-ursi.

Pharmacopoeias
Bearberry Leaf (BP 2009, Ph Eur 6.4).

Constituents
The major active constituent is arbutin (hydroquinone beta-glucoside), with methylarbutin, 4-hydroxyacetophenone glucoside and galloyl arbutin. Whole or cut dried bearberry leaves may contain not less than 7% anhydrous arbutin (BP 2009, Ph Eur 6.4). Iridoids (such as monotropein), flavonoids (such as myricetin and quercetin), and tannins (including corilagin) are also present.

Use and indications
Bearberry leaves and preparations are traditionally used for urinary tract infections. The use of arbutin and hydroquinone as skin-whitening agents has been investigated.

Pharmacokinetics
After oral ingestion, arbutin is hydrolysed in the urine to hydroquinone, which has antiseptic properties, but in large doses is irritant and cytotoxic. However, it is rapidly conjugated in the urine, mainly as hydroquinone glucuronide and hydroquinone sulfate. The presence of Escherichia coli in an infected urinary tract may enhance hydroquinone levels, by reversing the conjugation process and metabolising them back into free, active hydroquinone. Alkalisation of the urine seems to be unnecessary for improving the antiseptic properties of hydroquinone or arbutin.

In vitro studies suggest that aqueous and ethanol extracts of commercially available bearberry leaf products markedly inhibit CYP3A4 and CYP2C19, whereas methanol extracts appear to have low-to-moderate activity against these isoenzymes. However, the effect on CYP3A4 varied greatly between products. Bearberry alcoholic extracts were also found to inhibit CYP3A4, and interfere with the activity of P-glycoprotein in vitro, causing inhibition after 1 hour of exposure and induction after 18 hours. The clinical significance of these effects is unknown.

Interactions overview
An isolated case of lithium toxicity has been reported in a patient who took a herbal diuretic containing bearberry among other ingredients, see under Parsley + Lithium, page 305. For information on the interactions of individual flavonoid constituents of bearberry, see under flavonoids, page 186.

<table>
<thead>
<tr>
<th>Bearberry + Food</th>
<th>Bearberry + Lithium</th>
</tr>
</thead>
<tbody>
<tr>
<td>No interactions found.</td>
<td>For mention of a case of lithium toxicity in a woman who had been taking a non-prescription herbal diuretic containing corn silk, <em>Equisetum hyemale</em>, juniper, buchu, parsley and bearberry, all of which are believed to have diuretic actions, see under Parsley + Lithium, page 305.</td>
</tr>
</tbody>
</table>
Bee pollen

Synonym(s) and related species
Honeybee pollen.

Bee pollen consists of flower pollen and nectar from male seed flowers, which is mixed with secretions from a worker honey bee. Note that there are products made from pollen alone, such as Cernilton (Rye grass pollen), which will not be dealt with in this monograph.

Constituents
The constituents of bee pollen depend to some extent on the flower species from which it has been harvested. It usually contains phytosterols, essential fatty acids including linoleic and alpha-linolenic acids, flavonoids and other polyphenols, minerals, and small amounts of B vitamins and vitamin C. Coumaroyl spermine and spermidine derivatives have been isolated from Brazilian bee pollen.

Use and indications
Bee pollen has been taken for prostate enlargement and to reduce the risk of atherosclerosis and hypertension, and to improve cognition. Bee pollen from Brassica campestris is widely used in China as a natural food supplement to strengthen the body’s resistance against diseases, including cancer. There is little supporting evidence for any of these uses. It should be avoided by people allergic to bee stings and to pollen because of the risk of a hypersensitivity reaction.

Pharmacokinetics
No relevant pharmacokinetic data found.

Interactions overview
No interactions with bee pollen found.
Berberine

Types, sources and related compounds
Berberine is an isoquinoline alkaloid found in many plants, particularly berberis, page 61, bloodroot, page 76, coptis, page 151, goldenseal, page 230, and greater celandine, page 241.

Use and indications
Berberine is bactericidal, amoebicidal and fungicidal. It has been used for many conditions, such as amoebic dysentery and diarrhoea, inflammation and liver disease. Berberine is also said to possess some antiepileptic, uterine stimulant and hypotensive effects, and is slightly sedative.

Pharmacokinetics
Berberine appears to undergo significant hepatobiliary excretion, including metabolism by cytochrome P450. Its metabolism in rats was partially affected by a known experimental inhibitor of cytochrome P450 isoenzymes. In one in vitro study, berberine appeared to increase CYP3A4 levels. In other in vitro studies, it showed modest inhibition of CYP3A4 activity (see ciclosporin, page 59). It also appears to inhibit CYP2D6, CYP2C8 and CYP2E1, but it does not significantly inhibit CYP2C9, CYP2C19 and CYP1A2. Berberine also appears to be a substrate of P-glycoprotein, as the biliary excretion of berberine in the rat was inhibited by the P-glycoprotein inhibitor ciclosporin, page 59, and both ciclosporin and verapamil, another P-glycoprotein inhibitor, improved berberine absorption. Berberine may also be a substrate of organic cation transporters, as its biliary excretion was inhibited by the organic cation transporter inhibitor quinidine.

Interactions overview
Although a number of studies have used conventional drugs to study berberine metabolism, data on potentially clinically relevant interactions is sparse: the most significant interaction of berberine appears to be its potential to increase ciclosporin levels.

Berberine + Anxiolytics

The interaction between berberine and anxiolytics is based on experimental evidence only.

Clinical evidence
No interactions found.

Experimental evidence
The effect of berberine was investigated using two experimental anxiety models in the mouse. Berberine showed anxiolytic effects in these models at a dose of 100 mg/kg, and sedative effects at a dose of 500 mg/kg. Berberine was found to enhance the anxiolytic effects of buspirone in the elevated plus-maze test, whereas the anxiolytic effects of berberine were not affected by diazepam.1

Mechanism
Berberine may have effects on brain monoamines.

Importance and management
The doses of berberine given in this study were extremely large, compared with those used in clinical studies in humans. Any interactions seem unlikely to be clinically significant.


Berberine + Ciclosporin

Berberine appears to increase the bioavailability and trough blood levels of ciclosporin. Animal studies suggest that ciclosporin may affect the intestinal absorption and elimination of berberine possibly by inhibiting P-glycoprotein.

Clinical evidence
A study in 6 kidney transplant recipients looked at the effects of berberine on the pharmacokinetics of ciclosporin. The patients were taking ciclosporin 3 mg/kg twice daily for an average of 12 days before berberine 200 mg three times daily for 12 days was added. The AUC and trough blood levels of ciclosporin were increased by about 35% and 88%, respectively. The peak ciclosporin level was decreased but this was not statistically significant.1 A clinical study by the same authors in 52 stable kidney transplant recipients taking ciclosporin and given berberine 200 mg three times daily for 3 months found that the ciclosporin trough levels were increased by about 24% when the berberine-treated group was compared with 52 similar patients taking ciclosporin without berberine. The ciclosporin levels in 8 patients fell after berberine was stopped. Creatinine clearance was not significantly altered, and no serious adverse effects were reported.1

A single-dose study in healthy subjects found conflicting results. Six subjects given a single 6-mg/kg dose of ciclosporin daily found that berberine 300 mg twice daily, taken for 10 days before the dose of ciclosporin, had no significant effects on the pharmacokinetics of ciclosporin. However, a separate study in another 6 subjects given a single 3-mg/kg dose of ciclosporin found that a single 300 mg dose of berberine increased the AUC of ciclosporin by 19.2%. No adverse events were reported in this study.2

Experimental evidence
A study in rats found that intravenous ciclosporin 20 mg/kg did not significantly affect the AUC of intravenous berberine 10 to 20 mg/kg in the blood, but ciclosporin did decrease the AUC of berberine in the liver and the bile.3 Another study in rats also found that ciclosporin increased the intestinal absorption of berberine.4

Mechanism
The mechanism for the increase in ciclosporin levels seen in the clinical studies is unclear, although it has been suggested that it may be due to inhibition of CYP3A by berberine.

Animal studies suggest that ciclosporin may also affect the handling of berberine possibly by inhibiting P-glycoprotein, therefore affecting its intestinal absorption and its distribution into the bile and liver.

Importance and management
Although the increase in ciclosporin levels is not sufficiently severe to suggest that the concurrent use of berberine should be avoided, it may make ciclosporin levels less stable. If concurrent use is undertaken, ciclosporin levels should be well monitored, and the dose of ciclosporin adjusted accordingly.


Berberine + Hyoscine (Scopolamine)

The interaction between berberine and hyoscine (scopolamine) is based on experimental evidence only.

Clinical evidence
No interactions found.

Experimental evidence
Berberine 100 and 500 mg/kg, given orally for 7 to 14 days significantly improved hyoscine-induced amnesia in rats, measured using a step-through passive avoidance task. This antiamnesic effect of berberine was completely reversed by hyoscine methobromide, implying that the antiamnesic action of berberine may be through the peripheral rather than central nervous system.1

Mechanism
The authors suggest that the mechanism may partially be through alpha2-adrenoceptor blockade by berberine, leading to an increase in the release of adrenaline (epinephrine) and a subsequent increase in glucose supply to the brain.

Importance and management
The experimental evidence for this interaction is very limited and there appears to be no data to suggest that berberine may improve memory or reverse the effects of drugs that affect memory, such as hyoscine, in humans. This is unlikely to be a clinically significant
interaction, especially as the doses used in the study were many times those used in human studies of berberine.


**Berberine + Paclitaxel**

The interaction between berberine and paclitaxel is based on experimental evidence only.

**Clinical evidence**

No interactions found.

**Experimental evidence**

An *in vitro* study found that pre-treatment with berberine blocked the anticancer effects of paclitaxel in six cancer cell line cultures (oral cancer, gastric cancer and colon cancer).1

**Mechanism**

Unknown.

**Importance and management**

This appears to be the only published study of an antagonistic effect between berberine and paclitaxel. Further study is required to confirm these *in vitro* results, and to explore their clinical relevance.

**Berberis**

*Berberis vulgaris* L. and *Berberis aristata* DC. (Berberidaceae)

**Synonym(s) and related species**
Barberry, Berberidis, Pipperidge bush.

**Constituents**
The root and stem of all species contain isoquinoline alkaloids such as berberine, berbamine, jatrorrhizine, oxyberberine, palmatine, magnoflorine, oxyacanthine and others.

**Use and indications**
Used for many conditions, especially infective, such as amoebic dysentery and diarrhoea, inflammation and liver disease. The main constituent berberine is bactericidal, amoebicidal and fungicidal. It has some antiepileptic, uterine stimulant and hypotensive effects and is slightly sedative, as are jatrorrhizine and palmatine.

**Pharmacokinetics**
No relevant pharmacokinetic data found specifically for berberis, but see berberine, page 58, for information on this constituent of berberis.

**Interactions overview**
No interactions with berberis found. For information on the interactions of one of its constituents, berberine, see under berberine, page 58.
Betacarotene

**Types, sources and related compounds**
Provitamin A.

**Pharmacopoeias**
Betacarotene (BP 2009, Ph Eur 6.4); Beta Carotene (USP 32); Beta Carotene Capsules (USP 32).

**Use and indications**
Betacarotene is a carotenoid precursor to vitamin A (retinol). It is a natural pigment found in many plants including fruit and vegetables (such as carrots) and is therefore eaten as part of a healthy diet, and is also used as a food colouring. Betacarotene supplements are usually taken for the prevention of vitamin A deficiency and for reducing photosensitivities in patients with erythropoietic protoporphyria. It is also used for age-related macular degeneration and has been investigated for possible use in cardiovascular disease and cancer prevention.

**Pharmacokinetics**
Betacarotene is the most studied carotenoid of the hundreds that exist in nature. It is a fat-soluble precursor of vitamin A (retinol) and a large part of the metabolism to vitamin A takes place in the gastrointestinal mucosa where its absorption may be sensitive to changes in gastric pH, see proton pump inhibitors, page 64. This could be a contributing factor to the large interindividual variation seen in betacarotene absorption. As betacarotene intake increases, vitamin A production from the carotenoid is reduced.\(^1\)

Betacarotene potentiated the induction of the cytochrome P450 isoenzyme CYP2E1 by alcohol in rats;\(^2\) however, it did not significantly affect CYP1A1/2.

**Interactions overview**
Orlistat reduces betacarotene absorption, heavy long-term alcohol intake may interfere with the conversion of betacarotene to vitamin A, and the desired effect of betacarotene supplementation may be reduced by colchicine and omeprazole. Betacarotene reduces the benefits that combined simvastatin and niacin have on cholesterol, and reduces ciclosporin levels. Combined use with colestyramine or probucol modestly reduces dietary betacarotene absorption. Clinically relevant interactions are unlikely between betacarotene and tobacco, but note that smokers are advised against taking betacarotene. For the interactions of betacarotene with food or lycopene, see Lycopene + Food, page 280, and Lycopene + Herbal medicines; Betacarotene, page 280.

Betacarotene + Alcohol

Heavy consumption of alcohol may interfere with the conversion of betacarotene to vitamin A.

Clinical evidence
In the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study (ATBC), an almost 7-year-long, large, randomised, placebo-controlled study in men, an alcohol intake of more than 12.9 g daily by 109 heavy drinkers reduced the serum concentrations of betacarotene 20 mg daily by up to 13%. These findings were independent of dietary carotenoid intake.1

Experimental evidence
In an experimental study in baboons fed alcohol for 2 to 5 years and given 30 mg/L and then 45 mg/L doses of betacarotene (Solatene capsules) daily for 33 days and 29 days respectively, the serum levels of betacarotene were higher in those fed alcohol than those that were not fed alcohol. When betacarotene was stopped, its clearance was delayed in the baboons fed alcohol. Betacarotene was also found to potentiate the hepatotoxicity of alcohol.2

Mechanism
This interaction is complex. Betacarotene and alcohol may share similar biochemical pathways; one experimental study in rats found that betacarotene potentiated the induction of the cytochrome P450 isoenzyme CYP2E1 by alcohol.1 Alcohol also reduces the levels of vitamin A, of which betacarotene is the precursor. It has therefore been suggested that alcohol interferes with the conversion of betacarotene to vitamin A.3

Importance and management
Information about an interaction between betacarotene and alcohol is limited, and the effects in animals and humans are conflicting. It appears that the long-term intake of alcohol causes some changes in betacarotene disposition, and it would therefore seem sensible to try to limit alcohol intake if betacarotene supplementation is necessary.


Betacarotene + Ciclosporin

A study in 10 kidney transplant recipients found that an antioxidant vitamin supplement containing betacarotene modestly reduced ciclosporin blood levels.

Clinical evidence
A randomised placebo-controlled study, in 10 kidney transplant recipients taking ciclosporin, found that the addition of an antioxidant vitamin supplement for 6 months containing vitamin C 500 mg, vitamin E 400 units and betacarotene 6 mg daily reduced the ciclosporin blood level by 24%. An associated improvement in renal function, indicated by an increase in glomerular filtration rate of 17%, was also seen and may have been associated with reduced ciclosporin levels.1

Experimental evidence
No relevant data found.

Mechanism
Unknown.

Betacarotene + Cimetidine

An interaction between betacarotene and cimetidine is based on experimental evidence only.

Clinical evidence
No interactions found.

Experimental evidence
In an animal study, rats were given intragastric alcohol to induce mucosal damage. When the rats were pretreated with betacarotene 1 mg/kg, the number of mucosal lesions was decreased by 63%. However, when cimetidine 50 mg/kg was given with the betacarotene, 30 minutes before the alcohol, the damaging effects of the alcohol appeared to be enhanced.1

Mechanism
The exact mechanism is unclear.

Importance and management
This is a relatively old study and there do not appear to be any clinical reports in the literature. Furthermore the dose of betacarotene used is roughly 10-fold greater than the recommended daily intake of betacarotene. Therefore a clinically relevant interaction with cimetidine seems unlikely.


Betacarotene + Colchicine

The desired effect of betacarotene supplementation may be reduced in those taking colchicine.

Clinical evidence
Divided doses of colchicine 1.9 mg to 3.9 mg daily reduced the serum levels of betacarotene 10,000 units daily (about 6 mg) in 5 obese subjects. Levels returned to normal when colchicine was stopped.1 However, in another study, long-term use of colchicine 1 mg to 2 mg daily for 3 years had no effect on the serum levels of diet-derived carotene in 12 patients with familial Mediterranean fever.2

Experimental evidence
No relevant data found.

Mechanism
The mechanism is unclear. Colchicine causes reversible malabsorption in the gastrointestinal tract by disturbing epithelial cell function.
and inhibiting cell proliferation. It also lowered the serum levels of cholesterol in the first study. All these factors could have an effect on the absorption of betacarotene, which largely takes place in the gastrointestinal mucosa and the distribution of which is dependent on the presence of lipoproteins.

**Importance and management**

The evidence for a possible interaction between betacarotene and colchicine is limited to two relatively old studies. While supplemental betacarotene absorption appears to be reduced, betacarotene ingested as part of the normal diet appears to be unaffected. Based on these two findings, and the fact that there is large interindividual variation in betacarotene absorption, it is difficult to recommend a clinical course of action other than to be aware that the desired effect of betacarotene supplementation may be reduced in those taking colchicine.


**Betacarotene + Food**

See under Lycopene + Food, page 280.

**Betacarotene + Herbal medicines; Lycopene**

Betacarotene may alter the absorption of lycopene, see Lycopene + Herbal medicines; Betacarotene, page 280.

**Betacarotene + Lipid regulating drugs**

Betacarotene reduces the benefits that combined simvastatin and nicotinic acid have on HDL-cholesterol. Colestyramine and probucol reduce the serum levels of betacarotene eaten as part of a normal diet.

**Clinical evidence**

In a 3-year study in 146 patients with clinical coronary disease, an antioxidant regimen consisting of betacarotene 25 mg, vitamin E 800 units, vitamin C 1 g and selenium 100 micrograms daily halved the beneficial rise of high-density lipoprotein-cholesterol (HDL2) caused by combined treatment with simvastatin 10 to 20 mg and nicotinic acid (niacin) 2 to 4 g daily.1

There do not appear to be any studies on the effect of lipid regulating drugs on the absorption of betacarotene from supplements; however, a 3-year study of 303 hypercholesterolemic subjects given colestyramine in doses of 8 g to 16 g daily, according to tolerance, found that the serum levels of dietary-derived betacarotene were reduced by about 40% after 2 months. Probucol 500 mg twice daily was then added, and 2 months later the serum levels of betacarotene were reduced by an additional 39% (representing an overall decrease of 65%).2

**Experimental evidence**

No relevant data found.

**Mechanism**

Unknown. Betacarotene is a fat-soluble substance, and therefore its absorption and distribution are dependent on the presence of lipoproteins, which might be reduced by colestyramine.

**Betacarotene + Orlistat**

Orlistat decreases the absorption of supplemental betacarotene.

**Clinical evidence**

A randomised study in healthy subjects found that about two-thirds of a supplemental dose of betacarotene was absorbed in the presence of orlistat. The study included 48 patients in 4 groups, given placebo, or betacarotene in doses of 30 mg, 60 mg or 120 mg. The betacarotene was given within about 30 minutes of the orlistat.1

**Experimental evidence**

No relevant data found.

**Mechanism**

Orlistat reduces dietary fat absorption by inhibiting gastrointestinal lipase. Consequently, it reduces the absorption of fat-soluble vitamins.

**Importance and management**

Evidence is limited to one study, but what is known suggests that orlistat decreases the absorption of supplemental betacarotene. To maximise vitamin absorption, the manufacturers recommend that any multivitamin preparations should be taken at least 2 hours before or after orlistat, such as at bedtime.2 The US manufacturers suggest that patients taking orlistat should be advised to take multivitamins, because of the possibility of reduced vitamin levels.3


**Betacarotene + Proton pump inhibitors**

The desired effect of betacarotene supplementation may be reduced in those taking proton pump inhibitors.
**Clinical evidence**

In a study in 10 healthy subjects the AUC of a single 120-mg dose of betacarotene was halved by pretreatment with omeprazole 20 mg twice daily for 7 days.\(^1\)

**Experimental evidence**

No relevant data found.

**Mechanism**

The exact mechanism is unclear. Betacarotene is absorbed in the small intestine by a simple passive-diffusion process. It has been suggested that omeprazole may retard this diffusion,\(^1\) and that delayed gastric emptying may also contribute.\(^2\)

**Importance and management**

Evidence for an interaction between betacarotene and omeprazole is limited, and as there is large interindividual variability in betacarotene absorption, the true bioavailability of the carotenoid can vary greatly even before omeprazole is taken. Coupled with the fact that betacarotene is a normal part of the healthy diet, it is very difficult to assess the true clinical importance of this interaction. Be aware that the desired effect of betacarotene supplements may be reduced or abolished by the concurrent use of omeprazole. If the suggested mechanism is correct, other proton pump inhibitors are likely to affect betacarotene absorption similarly.


---

**Betacarotene + Tobacco**

There is a slight increased risk of lung cancer in smokers taking betacarotene supplements.

---

**Clinical evidence**

In the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study (ATBC), an almost 7-year-long, large, randomised, placebo-controlled study in men, tobacco smoking did not significantly affect the serum concentrations of betacarotene 20 mg daily. These findings were independent of dietary carotenoid intake.\(^1\) However, in this study, the risk of lung cancer was slightly, but significantly, increased in those patients receiving betacarotene supplements (18% increase).\(^2\)

**Experimental evidence**

No relevant data found.

**Mechanism**

Unknown.

**Importance and management**

Evidence for an interaction between tobacco smoking and betacarotene is limited, but a clinically significant effect of tobacco smoking on absorption of betacarotene supplementation seems unlikely. However, unexpectedly, well-designed studies have found a slight increased risk of lung cancer in smokers taking betacarotene supplements. There is no clear explanation for this, and there is much debate about whether this is a true effect. Until more is known it may be prudent for smokers to avoid betacarotene supplements, and to counsel the patient on smoking cessation and the health benefits of consuming five portions of fruit and vegetables daily as part of a balanced diet. Note that the Food Standards Agency in the UK advises people who smoke not to take betacarotene supplements because of an increased risk of lung cancer.\(^3\)

**Bilberry**

*Vaccinium myrtillus* L. (Ericaceae)

---

**Synonym(s) and related species**  
Blaeberry, Bogberry, Huckleberry, Hurtleberry, Myrtillus, Whortleberry.

Note that the synonym Blueberry has also been used, but the name Blueberry is the more commonly accepted name for the North American native plants such as *Vaccinium angustifolium* Aiton (Lowbush Blueberry) and *Vaccinium corymbosum* L. (Northern Highbush Blueberry).

**Pharmacopoeias**  

**Constituents**  
The berries contain anthocyanins, mainly glucosides of cyanidin, delphinidin, malvidin, petunidin and peonidin. Standardised extracts containing not less than 0.3% of anthocyanins, expressed as cyanidin-3-glucoside chloride (dried drug), or not less than 1% tannins, expressed as pyrogallol (dried drug), are often used (*BP 2009, Ph Eur 6.4*). Bilberry berries also contain flavonoids (including catechins, quercetin-3-glucuronide and hyperoside), and vitamin C.

**Use and indications**  
Traditionally bilberry has been used to treat diarrhoea, haemorrhoids and venous insufficiency, gastrointestinal inflammation and urinary complaints. It has now found a more specific use in improving visual acuity, by improving blood flow to the retina, and for its vasoprotective properties as an anti-atherosclerotic.

**Pharmacokinetics**  
For general information about the pharmacokinetics of anthocyanins, see under flavonoids, page 186.

An *in vitro* study investigated the effects of bilberry extract (at a concentration likely to be attainable in the human intestine) on the uptake of estrone-3-sulfate by the transporter protein OATP-B. Estrone-3-sulfate was used as it is known to be an OATP-B substrate. The bilberry extract inhibited estrone-3-sulfate uptake by about 75%, which was considered to be a potent effect.\(^1\) OATP-B is known to have a role in the absorption of drugs such as fexofenadine, glibenclamide and pravastatin, and therefore this study suggests that bilberry extract may decrease the absorption of these drugs, which could result in a reduction in their effects. However, no clinical reports of an interaction between bilberry and these or other drugs appear to have been published.

**Interactions overview**  
No interactions with bilberry found. For information on the interactions of individual flavonoids found in bilberry, see under flavonoids, page 186.

**Bistort**

*Polygonum bistorta* L. (Polygonaceae)

**Synonym(s) and related species**
Adderwort, Dragonwort, English Serpentary, Osterick, Snakeweed.


**Pharmacopoeias**
Bistort Rhizome (*BP 2009, Ph Eur 6.4*).

**Constituents**
The bistort root and rhizome contain polyphenolic compounds, mainly flavonoids (e.g. catechins and quercetin), ellagic acid, and the triterpenes, friedelanol and 5-glutinen-3-one.

**Use and indications**
Bistort is traditionally used as an astringent and anti-inflammatory agent.

**Pharmacokinetics**
No relevant pharmacokinetic data found. For information on the pharmacokinetics of individual flavonoids found in bistort, see under flavonoids, page 186.

**Interactions overview**
No interactions with bistort found. For information on the interactions of individual flavonoids found in bistort, see under flavonoids, page 186.
Bitter orange  
*Citrus aurantium* var *amara* L. (Rutaceae)

**Synonym(s) and related species**
Bigaradier, Pomeranze, Seville orange.

**Pharmacopoeias**
Bitter-orange Epicarp and Mesocarp (*Ph Eur* 6.4); Bitter-orange Epicarp and Mesocarp Tincture (*Ph Eur* 6.4); Bitter-orange Flower (*BP* 2009, *Ph Eur* 6.4); Bitter-orange Flower Oil (*Ph Eur* 6.4); Dried Bitter-orange Peel (*BP* 2009); Neroli Oil (*Ph Eur* 6.4).

**Constituents**
Bitter orange contains the sympathomimetic alkaloid oxedrine (*synephrine*), flavonoids (hesperidin, naringenin, tangeretin and others; often referred to as citrus bioflavonoids), and natural coumarins (umbelliferone, 6,7-dimethoxycoumarin, and the furanocoumarins 6,7-dihydroxybergamottin and bergapten). The volatile oil is mostly composed of limonene. Some sources standardise the flowers to flavonoid content, expressed as naringin, and the peel to essential oil content.

**Use and indications**
Bitter orange is traditionally used as a carminative and for other digestive disorders. It is also said to possess antihypertensive, anti-inflammatory, analgesic and antibacterial properties. Bitter-orange extract is included in some herbal anorectic preparations as it contains oxedrine, which is claimed to increase metabolism; however, cardiovascular adverse effects are associated with this constituent (see under Caffeine + Herbal medicines; Bitter orange, page 101). Interestingly bitter orange has also been promoted as an appetite stimulant. The flowers have been used as a sedative, and the peel and the oils are used widely as flavourings in foods and conventional medicines. Bitter orange is used to make marmalade. The juice of bitter orange has been used in studies of drug metabolism as a comparator to grapefruit juice, but it is not used as a medicine or beverage.

**Pharmacokinetics**
A bitter orange supplement (containing oxedrine but no 6,7-dihydroxybergamottin) did not inhibit the cytochrome P450 isoenzymes CYP1A2 (see caffeine, page 101), CYP2E1 (see chloroxazone, page 69) or CYP2D6 (as assessed with debrisoquine) in clinical studies.

The effects of bitter orange on CYP3A4 are uncertain. A bitter orange supplement (containing oxedrine but no 6,7-dihydroxybergamottin) did not inhibit CYP3A4 (see midazolam, page 70). However, the juice of bitter orange (containing the furanocoumarins bergapten and 6,7-dihydroxybergamottin) inhibited intestinal CYP3A4 (see felodipine, page 70), but probably has no effect on hepatic CYP3A4 (see indinavir, page 70). The juice may also inhibit P-glycoprotein transport (see dextromethorphan, page 69). Differences in active constituents might be part of the explanation for the differences in effects seen on CYP3A4.

For information on the pharmacokinetics of individual flavonoids present in bitter orange, see flavonoids, page 186, and for the pharmacokinetics of individual furanocoumarins, see under natural coumarins, page 297.

**Interactions overview**
The juice of bitter orange has been used in some drug interaction studies (as a comparator to grapefruit juice, page 235). Information from these studies has been included here, but note that it should not be directly extrapolated to herbal medicines containing bitter orange, because some differences in interaction potential have been seen.

A bitter orange decoction increased ciclosporin levels in animals, whereas the juice of bitter orange does not appear to interact clinically. A bitter orange supplement does not appear to affect the pharmacokinetics of chloroxazone, debrisoquine or midazolam, suggesting a lack of interaction with substrates of the cytochrome P450 isoenzymes CYP2E1, CYP2D6 and CYP3A4, respectively. The juice of bitter orange does not appear to affect the pharmacokinetics of indinavir, but it may raise dextromethorphan and felodipine levels.

For a possible interaction of supplements containing bitter orange with caffeine, resulting in adverse cardiac effects, see Caffeine + Herbal medicines; Bitter orange, page 101.

For specific interactions of citrus flavonoids such as naringenin, see flavonoids, page 186, and for citrus furanocoumarins such as bergapten, see natural coumarins, page 297.

Bitter orange + Chlorzoxazone

A bitter orange supplement did not alter the metabolism of chlorzoxazone in one study and is therefore unlikely to alter the pharmacokinetics of drugs that are metabolised by CYP2E1.

Clinical evidence
In a study in 12 healthy subjects, a bitter orange supplement, standardised to synephrine 4%, was given at a dose of 350 mg twice daily for 28 days with a single 250-mg dose of chlorzoxazone given before and at the end of the treatment with bitter orange. The metabolism of chlorzoxazone was not affected by the concurrent use of bitter orange. The supplement was analysed and found to contain the stated amount of synephrine (equivalent to a daily dose of about 30 mg), and none of the furocoumarin, 6,7-dihydroxybergamottin. The supplement was analysed and found to contain the stated amount of synephrine (equivalent to a daily dose of about 30 mg), and none of the furocoumarin, 6,7-dihydroxybergamottin.

Experimental evidence
No relevant data found.

Mechanism
No mechanism expected.

Importance and management
Chlorzoxazone is used as a probe drug for CYP1E2 activity, and therefore these results also suggest that a pharmacokinetic interaction between this bitter orange supplement and other CYP1E2 substrates is unlikely.

Bitter orange + Dextromethorphan

Bitter orange juice increases the absorption of dextromethorphan.

Clinical evidence
In a study, 11 healthy subjects were given a single 30-mg dose of dextromethorphan hydrobromide at bedtime, followed by 200 mL of water or freshly squeezed bitter orange juice. Measurement of the amount of dextromethorphan and its metabolites in the urine indicated that the bioavailability of dextromethorphan was increased by more than fourfold by bitter orange juice. Dextromethorphan levels were still raised 3 days later, indicating a sustained effect of the juice. The effects were similar to those of grapefruit juice.

Experimental evidence
No relevant data found.

Mechanism
It was suggested that these fruit juices increased the absorption of dextromethorphan by inhibiting the cytochrome P450 isoenzyme CYP3A and P-glycoprotein in the gut wall, although the authors note that other transporter proteins may be involved. Note that dextromethorphan is commonly used as a probe substrate for CYP2D6; however, in this study, analysis of the metabolites demonstrated that the metabolism of dextromethorphan by CYP2D6 in the liver was not affected. Similarly, a bitter orange supplement did not alter CYP2D6 activity as assessed by debrisoquine metabolism.

Importance and management
While the study discussed shows a clear pharmacokinetic interaction, it has no direct clinical relevance to bitter orange supplements (it was used in the study as a comparator to assess the likely mechanisms of the effect of grapefruit juice). How the effects of the juice of bitter orange relate to the peel of bitter orange, which is one of the parts used medicinally, is unclear. However, note that the effects of grapefruit juice are thought to be in part related to 'contamination' with constituents of the peel, so some interaction might occur. Further study is needed.

Note that it is important not to extrapolate the interaction seen with the juice to other CYP2D6 substrates since inhibition of CYP2D6 was not thought to be the mechanism.

Bitter orange + Ciclosporin

Bitter orange juice does not appear to affect the pharmacokinetics of ciclosporin in humans. However, a bitter orange decoction increased ciclosporin levels in animals.

Clinical evidence
In a randomised, crossover study, 7 healthy subjects were given a single 7.5-mg/kg dose of ciclosporin 30 minutes after consuming about 240 mL of bitter orange juice. Bitter orange juice did not affect the AUC or the maximum serum levels of ciclosporin, although it appeared to delay the absorption of ciclosporin in some subjects. This was in contrast to the effects of grapefruit juice. The bitter orange juice was prepared by squeezing fresh fruit and freezing it until needed (up to 6 weeks). It was determined to contain 6,7-dihydroxybergamottin at a concentration of about 30 micro-mol/L.

Experimental evidence
In a study in pigs, 200 mL of a decoction of bitter orange increased the maximum levels and AUC of ciclosporin 10 mg/kg by 64% and 46%, respectively. One of the 5 animals used in the study developed ciclosporin toxicity. The decoction was prepared by boiling the crude drug with water for about 2 hours. Each 200 mL dose was prepared from the equivalent of 20 g of crude drug, and was determined to contain 1.12 mmol/L of flavonoids, mostly naringin. It was not assayed for furocoumarin content.

Mechanism
The results of an animal study suggested that bitter orange alters the absorption of ciclosporin, possibly by affecting intestinal P-glycoprotein. It is possible that the differing findings in humans represent differing absorption characteristics between species, but it also seems likely that they could be related to the different preparations of bitter orange (juice and a decoction) used in the studies. Note that, in the clinical study, the furocoumarin 6,7-dihydroxybergamottin did not interact. In the animal study, the extent of the interaction was not related to the flavonoid content.

Importance and management
There only appear to be two studies investigating an interaction between bitter orange and ciclosporin, one of them using the juice in humans and another using a decoction in animals. What is known suggests that the juice of bitter orange is unlikely to affect the pharmacokinetics of ciclosporin. However, the animal study suggests that a decoction of bitter orange may increase ciclosporin levels and therefore some caution may be warranted if patients taking ciclosporin wish to take bitter orange supplements. Careful consideration should be given to the risks of using the supplement; in patients receiving ciclosporin for severe indications, such as transplantation, it seems unlikely that the benefits will outweigh the risks. If concurrent use is undertaken then close monitoring of ciclosporin levels seems warranted.

Bitter orange

Bitter orange juice increased the exposure to felodipine in one study.

Clinical evidence
In a randomised study, 10 healthy subjects were given a single 10-mg dose of felodipine with 240 mL of bitter orange juice or orange juice (as a control). The AUC and maximum serum levels of felodipine were increased by 76% and 61%, respectively, when compared with orange juice. The effects were similar in magnitude to those of grapefruit juice. The bitter orange juice was prepared by squeezing fresh fruit and freezing it until needed. It was analysed and found to contain the furanocoumarins bergapten, 6,7-dihydroxybergamottin and bergamottin.

Experimental evidence
No relevant data found.

Mechanism
It was suggested that bitter orange juice inhibited the metabolism of felodipine (a drug that undergoes high first-pass metabolism) by the cytochrome P450 isoenzyme CYP3A4 in the intestine. This is similar to the effect seen with grapefruit juice, for which the furanocoumarins are known to be required for an interaction to occur.

Importance and management
There appears to be only one study investigating the effect of bitter orange on the pharmacokinetics of felodipine, and it relates to the juice, so has no direct clinical relevance to bitter orange supplements. The effects seen in the study were similar, although slightly smaller, than those seen with grapefruit juice. Felodipine should not be given with the juice or peel of grapefruit juice because of the increased effects on blood pressure that may result, and some extend this advice to other grapefruit products. See grapefruit juice–felodipine interaction: comparison with dilute grapefruit juice and involvement of furanocoumarins. 

No mechanism expected. The authors suggest that bitter orange juice and peel or flowers of bitter orange, which are the parts used medicinally. Orange comes from one study, which used the juice rather than the peel or flowers of bitter orange, which are the parts used medicinally. However, this information, and what is known about midazolam, see below, suggests that bitter orange supplements are unlikely to affect the metabolism of midazolam.

Importance and management
Evidence regarding an interaction between midazolam and bitter orange comes from one study, which used the juice rather than the peel or flowers of bitter orange, which are the parts used medicinally. However, this information, and what is known about midazolam, see below, suggests that bitter orange supplements are unlikely to affect the metabolism of midazolam.


Bitter orange + Indinavir

Bitter orange juice did not alter indinavir pharmacokinetics in one study.

Clinical evidence
In a study in 13 healthy subjects, about 200 mL of freshly squeezed bitter orange juice had no effect on the pharmacokinetics of indinavir. In this study indinavir 800 mg was given every 8 hours for 4 doses; with water or bitter orange juice given with the last 2 doses. Grapefruit juice also had no effect. The juices were determined to contain 6,7-dihydroxybergamottin at a concentration of about 40 micromol/L.

Experimental evidence
No relevant data found.

Mechanism
No mechanism expected. The authors suggest that bitter orange juice does not affect the metabolism of indinavir by the cytochrome P450 isoenzyme CYP3A4 in the intestine, as has been seen with other drugs. See felodipine, above. This may be because the first-pass metabolism of indinavir is low.

Importance and management
Evidence regarding an interaction between indinavir and bitter orange comes from one study, which used the juice rather than the peel or flowers of bitter orange, which are the parts used medicinally. However, this information, and what is known about midazolam, see below, suggests that bitter orange supplements are unlikely to affect the metabolism of midazolam.

Bitter orange + Food

No interactions found. Note that bitter orange is commonly used as a flavouring, and in marmalade, but this is not expected to result in a high dietary intake.

Bitter orange + Herbal medicines; Caffeine-containing

For an interaction between bitter orange and the caffeine content of some herbs resulting in adverse cardiac effects, see Caffeine + Herbal medicines; Bitter orange, page 101.

Bitter orange + Indinavir

A bitter orange supplement did not alter the metabolism of midazolam in one study.

Clinical evidence
In a study in 12 healthy subjects, bitter orange (Citrus aurantium) 350 mg, standardised to 4% synephrine, was given twice daily for 28 days with a single 8-mg oral dose of midazolam before and at the end of this period. The metabolism of midazolam was not affected by the concurrent use of bitter orange. The supplement was analysed and found to contain the stated amount of synephrine (equivalent to a daily dose of about 30 mg), and none of the furanocoumarin, 6,7-dihydroxybergamottin.

Experimental evidence
No relevant data found.

Mechanism
No mechanism expected. The bitter orange supplement used here may not have interacted because of a lack of furanocoumarins. In the study here, the bitter orange supplement used did not contain the one furanocoumarin tested for, 6,7-dihydroxybergamottin.

Importance and management
Direct evidence about an interaction between midazolam and bitter orange appears to be limited to one clinical study.

70 Bitter orange


However, its findings suggest that this bitter orange supplement is unlikely to affect the metabolism of midazolam. Midazolam is used as a probe drug for CYP3A4 activity, and therefore these results also suggest that a pharmacokinetic interaction between bitter orange supplements and other substrates of CYP3A4 is unlikely. Bearing in mind the proposed mechanisms, it is possible that this applies only to supplements that do not contain furanocoumarins.

Black cohosh

*Actaea racemosa* (L.) Nutt. (Ranunculaceae)

**Synonym(s) and related species**
Black snakeroot, Bugbane, Cimicifuga, Macrotys actaea, Rattleroot, Rattleweed, Squawroot.


**Pharmacopoeias**
Black cohosh (*USP 32*); Black cohosh fluid extract (*USP 32*); Black cohosh tablets (*USP 32*); Powdered black cohosh (*USP 32*); Powdered black cohosh extract (*USP 32*).

**Constituents**
The main active constituents are triterpene glycosides (to which it may be standardised) including actein, and several series of related compounds such as the cimicifugosides, the cimicaracemosides, cimigenol and its derivatives, 26-deoxyactein and many others. Phenylpropanoid esters such as the cimiracemates A-D, isoferulic and ferulic acids, and methylcaffeate are present, as are the quinolizidine alkaloids including cytisine and N-methylcytisine. The presence of the oestrogenic isoflavone formononetin is disputed.

**Use and indications**
Black cohosh is widely used to treat peri- and postmenopausal symptoms. It is also used as an antirheumatic, antitussive and sedative, and for the treatment of dysmenorrhea and premenstrual disorders.

**Pharmacokinetics**
An in vitro study isolated six triterpene glycosides with inhibitory activity against the cytochrome P450 isoenzyme CYP3A4 from a powdered preparation of black cohosh. However, the CYP3A4-inhibitory activity of these compounds was very weak, and the clinical data using midazolam, page 74, as a probe drug for CYP3A4 suggests that this activity is not clinically relevant. Similarly, two clinical studies using debrisoquine as a probe substrate of CYP2D6 suggested that black cohosh (standardised to 0.2% or 2.5% triterpene glycosides) has no clinically relevant effect on this isoenzyme.

Black cohosh root extract had no clinically relevant effects on the activity of CYP1A2 or CYP2E1, see caffeine, page 73, and chlorzoxazone, page 73, respectively.

Studies with digoxin, page 73, suggest that black cohosh does not affect P-glycoprotein activity.

**Interactions overview**
Black cohosh does not appear to interact with caffeine, chlorzoxazone, digoxin or midazolam. Limited data suggest that black cohosh may antagonise the activity of cisplatin. For a case report describing transplant rejection in a patient taking a supplement containing alfalfa and black cohosh, see Alfalfa + Immunosuppressants, page 22.

The interaction between black cohosh and antineoplastics is based on experimental evidence only.

Clinical evidence
No interactions found.

Experimental evidence
An in vitro study using mouse mammary tumour cells found that liquid extracts of black cohosh caused a small reduction in the cytotoxicity of cisplatin. The extracts were standardised to 3% triterpene glycosides and were given in doses of 100 times the expected human dose.

Mechanism
Unknown.

Importance and management
Evidence is extremely limited. These data cannot reasonably be extrapolated to patients being treated with an antineoplastic regimen for breast cancer, because the dose of black cohosh used was much higher than the usual human dose, and the same study found that black cohosh may have potentiated the effects of other antineoplastics (such as docetaxel and doxorubicin).

Probably of more clinical relevance are the potential oestrogenic effects of black cohosh. Although these effects are not fully understood, they may have an important impact on the outcome of treatment for oestrogen-dependent breast cancer (see also Oestrogens or Oestrogen antagonists, page 74).


Black cohosh does not significantly affect the pharmacokinetics of chloroxazone.

Clinical evidence
In a study in 12 healthy subjects, black cohosh root extract 1.09 g twice daily (standardised to 0.2% triterpene glycosides) for 28 days, did not significantly affect the pharmacokinetics of chloroxazone 250 mg.

Experimental evidence
No relevant data found.

Mechanism
These studies investigated whether black cohosh had any effect on the cytochrome P450 isoenzyme CYP2E1 by which chloroxazone is metabolised.

Importance and management
Evidence appears to be limited to this one study, which suggests that black cohosh does not raise chloroxazone levels.

Chloroxazone is used as a probe drug for CYP2E1 activity, and therefore these results also suggest that a pharmacokinetic interaction between black cohosh and other CYP2E1 substrates is unlikely.


A standardised black cohosh extract did not alter the pharmacokinetics of digoxin in one study.

Clinical evidence
In a randomised study, 16 healthy subjects were given a black cohosh extract 20 mg twice daily (standardised to 2.5% triterpene glycosides) for 14 days with a single 400-microgram oral dose of digoxin on day 14. There were no significant changes in the pharmacokinetics of digoxin, and no serious adverse effects were reported.

Experimental evidence
No relevant data found.

Mechanism
Digoxin is used as a probe drug to assess the effects of other substances on P-glycoprotein.

Importance and management
This study suggests that black cohosh does not interact with digoxin, and is unlikely to interact with other drugs that are transported by P-glycoprotein.


No interactions found.
### Black cohosh + Herbal medicines

No interactions found.

### Black cohosh + Immunosuppressants

For a case report describing transplant rejection in a patient taking a supplement containing alfalfa and black cohosh, see Alfalfa + Immunosuppressants, page 22.

### Black cohosh + Midazolam

Black cohosh does not affect the pharmacokinetics of midazolam.

**Clinical evidence**

In a study in 19 healthy subjects given black cohosh extract (standardised to triterpene glycosides 2.5%) 40 mg twice daily for 28 days with a single 8-mg oral dose of midazolam on day 28, there was no change in the pharmacokinetics of midazolam. In addition, black cohosh had no effect on the duration of midazolam-induced sleep. Similarly, in another study in 12 non-smoking healthy subjects given black cohosh root extract (standardised to triterpene glycosides 0.2%) 1090 mg twice daily for 28 days, there was no significant change in the pharmacokinetics of a single 8-mg oral dose of midazolam.

**Experimental evidence**

No relevant data found.

**Mechanism**

These studies investigated whether black cohosh had any effect on the cytochrome P450 isoenzyme CYP3A4 by which midazolam is metabolised.

**Importance and management**

Black cohosh is unlikely to interact with midazolam and, as midazolam is used as a probe drug for CYP3A4 activity, black cohosh is also unlikely to induce or inhibit the metabolism of other CYP3A4 substrates.


### Black cohosh + Oestrogens or Oestrogen antagonists

Black cohosh contains oestrogenic compounds. This may result in additive effects with oestrogens or it may oppose the effects of oestrogens. Similarly, black cohosh may have additive effects with oestrogen antagonists or oppose the effects of oestrogen antagonists (e.g. tamoxifen). See Chinese angelica + Oestrogens or Oestrogen antagonists, page 130, for more information.
Black haw
Viburnum prunifolium L. (Caprifoliaceae)

Synonym(s) and related species
American sloe, Nanny bush, Stagbush.

Constituents
The stem and root bark of black haw contain iridoid glycosides based on penstemide, with patrinoside and others. They also contain natural coumarins, such as scopoletin and aesculetin, and triterpenes, including oleanolic and ursolic acids.

Use and indications
Traditionally black haw has been used as a uterine tonic, for preventing miscarriage in the latter stages of pregnancy, to reduce pain and bleeding after childbirth, and for dysmenorrhoea.

Pharmacokinetics
No relevant pharmacokinetic data found. For information on the pharmacokinetics of individual natural coumarins present in black haw, see under coumarins, page 297.

Interactions overview
No interactions with black haw found. Although black haw contains natural coumarins, the quantity of these constituents is not established, and therefore the propensity of black haw to interact with other drugs because of their presence is unclear. Consider coumarins, page 297, for further discussion of the interactions of coumarin-containing herbs.
**Bloodroot**

*Sanguinaria canadensis* L. (Papaveraceae)

**Synonym(s) and related species**
Red Indian paint, Red puccoon, Red root, Sanguinaria, Tetterwort.

Note that *Sanguinaria australis* Greene, *Sanguinaria canadensis* var. *rotundifolia* (Greene) Fedde and *Sanguinaria dilleniana* Greene have also been referred to as bloodroot.

**Constituents**
The rhizome contains isoquinoline alkaloids including sanguinarine, chelerythrine, sanguidardine, oxysanguinaridine, berberine, coptisine, protopine and others.

**Use and indications**
Bloodroot is found in cough preparations and topical preparations used to treat skin infections and burns. Bloodroot extracts are also used as an antiplaque agent in some toothpastes and mouthwashes.

**Pharmacokinetics**
No relevant pharmacokinetic data found specifically for bloodroot, but see berberine, page 58, for more details on this constituent.

**Interactions overview**
No interactions with bloodroot found. However, for the interactions of one of its constituents, berberine, see under berberine, page 58.
Bogbean

*Menyanthes trifoliata* L. (Menyanthaceae)

**Synonym(s) and related species**
Buckbean, Marsh trefoil, Menyanthes.

The name Bog myrtle, most commonly used for *Myrica gale* (Myricaceae), has also been used for *Menyanthes trifoliata*.

**Pharmacopoeias**
Bogbean Leaf (*BP 2009, Ph Eur 6.4*).

**Constituents**
Bogbean leaf contains the iridoids foliamethin, 7',8'-dihydrofoliamethin, loganin, menthiafolin and sweroside; polyphenolics such as caffeic, chlorogenic, protocatechuic and ferulic acids, and flavonoids, including hyperin, kaempferol, quercetin, rutin and trifolioside. Other constituents include: the pyridine alkaloids gentianine and gentianinidine; triterpenes including lupeol, betulin and betulinic acid; carotenoids, such as carotene and loliolide; and the natural coumarins, scopoletin and braylin.

**Use and indications**
Bogbean has been used for rheumatism, rheumatoid arthritis and other inflammatory diseases, and as a bitter tonic.

**Pharmacokinetics**
No relevant pharmacokinetic data for bogbean found, but see under flavonoids, page 186, for information on individual flavonoids present in bogbean.

**Interactions overview**
No interactions with bogbean found. Some have suggested that bogbean may interact with anticoagulants, presumably based on its natural coumarin content, but the coumarins present are not known to possess the structural requirements necessary for anticoagulant activity. For more information, see Natural coumarins + Warfarin and related drugs, page 301. For information on the interactions of individual flavonoids present in bogbean, see under flavonoids, page 186.
**Boldo**

*Peumus boldus* Molina (Monimiaceae)

**Synonym(s) and related species**

Boldus, Boldi folium, Peumus.


**Pharmacopoeias**

Boldo Leaf (*BP 2009, Ph Eur 6.4*); Boldo Leaf Dry Extract (*BP 2009, Ph Eur 6.4*).

** Constituents**

Alkaloids are the main constituents of boldo leaf and these include **boldine**, isoboldine and dehydroboldine among others. Extracts may be standardised to contain a minimum of 0.1% of total alkaloids (dried extracts), or 0.5% of total alkaloids (aqueous extracts), expressed as **boldine** (*BP 2009, Ph Eur 6.4*). Boldo also contains **coumarin**. Volatile oils present include low levels of ascaridole, which is toxic: it is this constituent that has led to the suggestion that the dose and duration of treatment with boldo should be restricted.

**Use and indications**

Boldo is used as an aid to slimming, although there is little or no evidence to support this use. It is also traditionally used for dyspepsia, digestive disturbances, constipation, gallstones, liver disorders, cystitis and rheumatism. Recent research has shown boldine to be a potent antioxidant.

**Pharmacokinetics**

No relevant pharmacokinetic data found.

**Interactions overview**

There are few data regarding boldo. One case report suggests that it may interact with warfarin.
**Boldo + Food**

No interactions found.

**Boldo + Herbal medicines**

No interactions found.

**Boldo + Warfarin and related drugs**

A report describes a woman taking warfarin whose INR rose modestly when she began to take boldo and fenugreek.

**Clinical evidence**

A woman taking warfarin for atrial fibrillation whose INR was normally within the range 2 to 3 had a modest rise in her INR to 3.4, apparently due to the use of 10 drops of boldo after meals and one capsule of fenugreek before meals. A week after stopping these two herbal medicines her INR had fallen to 2.6. When she restarted them, her INR rose to 3.1 after a week, and to 3.4 after 2 weeks. Her INR was later restabilised in her normal range, while continuing to take these two herbs, by reducing the warfarin dosage by 15%. The patient had no undesirable reactions (e.g. bruising or bleeding).

**Experimental evidence**

No relevant data found.

**Mechanism**

The mechanism of this apparent interaction remains unknown, and it is not known whether both herbs or just one was responsible for what happened. Both boldo and fenugreek have been reported to contain natural coumarins, but it is unclear whether they have any anticoagulant activity. See natural coumarins, page 297 for more information on the interactions of coumarin-containing herbs.

**Importance and management**

Evidence is limited to one isolated case. Because of the many other factors influencing anticoagulant control, it is not possible to reliably ascribe a change in INR specifically to a drug interaction in a single case report without other supporting evidence. It may be better to advise patients to discuss the use of any herbal products that they wish to try, and to increase monitoring if this is thought advisable. Cases of uneventful use should be reported, as they are as useful as possible cases of adverse effects.

Boneset

Eupatorium perfoliatum L. (Asteraceae)

Synonym(s) and related species
Common boneset, Feverwort, Thoroughwort.
   Eupatorium chapmanii Small.
   Note that the name boneset has also been used for Symphytum officinale (Boraginaceae).

Constituents
Sesquiterpene lactones present in the herb include helenalin, euperoxin, euperfolin, eufoliatin, eufoliatorin and euperfolide. Diterpenes such as dendroidinic acid and hebeclinolide have been reported, as well as the phytosterols sitosterol and stigmasterol, and the flavonoids kaempferol, quercetin, astragalin, hyperoside, rutin and eupatorin. A series of immunostimulatory polysaccharides (mainly 4-O-methylglucuroxyrans) have also been described.

Use and indications
Boneset is traditionally used for influenza, acute bronchitis and nasopharyngeal catarrh.

Pharmacokinetics
No relevant pharmacokinetic data found. For information on the pharmacokinetics of individual flavonoids present in boneset, see under flavonoids, page 186.

Interactions overview
No interactions with boneset found. For information on the interactions of individual flavonoids present in boneset, see under flavonoids, page 186.
Synonym(s) and related species
The gum resin obtained from *Boswellia serrata* is known as Indian frankincense, Indian olibanum or Salai guggul.
Not to be confused with other types of frankincense, which are extracted from other *Boswellia* species and used for their aromatic properties.

Pharmacopoeias
Indian Frankincense (*BP 2009, Ph Eur 6.4*).

Constituents
The main active constituents are the *boswellic acids*, which are lipophilic pentacyclic triterpene acids. The keto derivatives, 11-keto-beta-boswellic acid and acetyl-11-keto-beta-boswellic acid, are thought to be particularly potent anti-inflammatory agents. The volatile oils of *Boswellia serrata* characteristically contain the diterpenes isoincensole and isoincensole acetate.

Use and indications
*Boswellia serrata* is used for inflammatory disorders including collagenous colitis (a cause of chronic diarrhoea), peritumoral oedema, rheumatoid arthritis and other chronic conditions. There is mounting clinical evidence to support its use. The boswellic acids have immunomodulatory effects and are anti-inflammatory via a number of mechanisms.

Pharmacokinetics
In an *in vitro* study, aqueous extracts of *Boswellia serrata* did not inhibit common cytochrome P450 drug-metabolising enzymes. However, the gum resin was found to have some inhibitory effects on the cytochrome P450 isoenzymes CYP1A2 and CYP2D6, and more potent inhibitory effects on CYP2C8, CYP2C9, CYP2C19 and CYP3A4, although the clinical relevance of these effects is not clear. It was established that cytochrome P450 inhibition occurs irrespective of boswellic acid content, and the constituents responsible for this effect are not removed during the manufacturing of a commercially available product tested in the study (*Boswellia serrata* extract, *H15*).

Another *in vitro* study found that keto derivatives of boswellic acids (from a *Boswellia serrata* extract, *H15*) inhibited P-glycoprotein in a dose-dependent manner. It was suggested that the low bioavailability of some of the boswellic acid derivatives means that boswellia is unlikely to have a clinically significant effect on P-glycoprotein at the blood–brain barrier, but that it may inhibit gastrointestinal P-glycoprotein at clinically relevant doses.

Interactions overview
Some evidence suggests that food may beneficially increase the bioavailability of boswellic acids, but other interaction data are generally lacking. It seems possible that boswellia may interact with conventional drugs by inhibiting P-glycoprotein and/or cytochrome P450 isoenzymes (see Pharmacokinetics, above), but the data are too sparse to make any meaningful predictions.

Boswellia + Conventional drugs

No interactions found.

Boswellia + Food

Food appears to beneficially increase the bioavailability of boswellic acids.

Clinical evidence
In a crossover study, 12 healthy subjects, after fasting for 10 hours, were given a single 786-mg dose of dry extract (gum resin) of Boswellia serrata (standardised to 55% boswellic acids) with a high-fat meal. The plasma AUCs of the boswellic acids were increased by between about 1.8- and 5-fold by the high-fat meal, and the maximum plasma levels were increased by up to 6-fold. No serious adverse events were noted.¹

Experimental evidence
No relevant data found.

Mechanism
Unknown.

Importance and management
These data show that food intake can significantly increase the bioavailability of boswellic acids, and suggest that Boswellia serrata extracts should be taken with meals, as therapeutic levels may not be achieved when taken on an empty stomach.


Boswellia + Herbal medicines

No interactions found.
Bromelain

Ananas comosus (L.) Merr. (Bromeliaceae)

**Synonym(s) and related species**
Ananase, Pineapple.

**Pharmacopoeias**
Bromelains (BP 2009).

**Constituents**
Bromelain is a crude, aqueous extract obtained from the pineapple plant, containing a number of proteolytic enzymes. The most common type is stem bromelain, which is extracted from the stem of the pineapple.

**Use and indications**
There is some clinical evidence for anti-arthritic and anti-inflammatory effects of bromelain, and it is sometimes used as an alternative to NSAIDs. It is also used to treat bruising, swollen and painful joints, as an analgesic and wound-healing agent, and as a skin debrider for the treatment of burns. It possesses anti-oedematous, antithrombotic, fibrinolytic and immunomodulatory activities. It also has *in vivo* antitumoral activity. Bromelain can cause allergies in susceptible individuals.

**Pharmacokinetics**
No relevant pharmacokinetic data found.

**Interactions overview**
Although bromelain appears to increase the levels of some antibacterials, the clinical relevance of this is unknown.
**Bromelain + Amoxicillin**

**Clinical evidence**
In a placebo-controlled study, subjects undergoing surgery were given a single 500-mg dose of amoxicillin and a single 80-mg dose of bromelain 3 hours before surgery. When compared with placebo, bromelain appeared to increase intra-operative amoxicillin levels in tissue, serum and skin samples. Amoxicillin levels were still higher in the bromelain group 3 hours after surgery.¹

**Experimental evidence**
No relevant data found.

**Mechanism**
The reason for this interaction is unclear, but it is possible that bromelain increases the uptake of amoxicillin into tissues.

**Importance and management**
The clinical relevance of these increased levels is unclear, but as the increases were only moderate (serum concentration increased by 62%) it seems likely to be small.


---

**Bromelain + Food**

No interactions found.

---

**Bromelain + Herbal medicines**

No interactions found.

---

**Bromelain + Tetracycline**

**Clinical evidence**
In a crossover study, 10 subjects were given tetracycline 500 mg, either alone or with bromelain 80 mg. Bromelain appeared to increase the serum levels of tetracycline by up to about fourfold. Higher serum and urine levels were also found when the study was repeated using multiple doses of the two preparations.¹

**Experimental evidence**
No relevant data found.

**Mechanism**
Unknown.

**Importance and management**
The clinical significance of this interaction is unclear but higher levels of tetracycline may result in an improved outcome, and also an increased risk of adverse effects.

Broom

Cytisus scoparius (L.) Link. (Fabaceae)

**Synonym(s) and related species**
Besom, Broomtops, Hogweed, Irish broom, Scoparium, Scoparius, Scotch broom.

*Sarothagmnus scoparius* (L.) Koch., Sarothamnus vulgaris Wim., *Spartium scoparium* L.

Not to be confused with Butcher’s broom, page 95, which is *Ruscus aculeatus* L.

**Constituents**
The flowering tops contain flavonoids including scoparin (scoparoside), and the quinolizidine alkaloid sparteine. There is also a small amount of volatile oil present.

**Use and indications**
Broom is used traditionally for cardiac disorders including arrhythmias, and may also have diuretic and peripheral vasoconstrictor activity. Sparteine may have strong oxytocic activity.

**Pharmacokinetics**
No relevant pharmacokinetic data found. For information on the pharmacokinetics of individual flavonoids present in broom, see under flavonoids, page 186.

**Interactions overview**
No interactions with broom found. For information on the interactions of individual flavonoids present in broom, see under flavonoids, page 186.
Buchu

*Agathosma betulina* (Bergius) Pillans (Rutaceae)

**Synonym(s) and related species**
Bucco, Diosma, Round buchu, Short buchu.
*Hartogia betulina* Berg.

The use of *Agathosma crenulata* (L.) Pillans (commonly known as Oval buchu), and *Agathosma serratifolia* (Curt.) Spreeth (commonly known as Long buchu), is also allowed. *Agathosma* species were formerly known as *Barosma*.

** Constituents **
Buchu leaf contains a volatile oil composed of diosphenol (buchu camphor), pulegone, isopulegone, 8-mercapto-3-methan-3-one, menthone, isomenthone and others, and the flavonoids diosmin, hesperidin, rutin and others.

**Use and indications**
Buchu preparations are used as diuretics, for bladder and kidney infections, stomachaches, rheumatism, and coughs and colds.

**Pharmacokinetics**
No relevant pharmacokinetic data found. For information on the pharmacokinetics of individual flavonoids present in buchu, see under flavonoids, page 186.

**Interactions overview**
An isolated case of lithium toxicity has been reported in a patient who took a herbal diuretic containing buchu among other ingredients, see under Parsley + Lithium, page 305. For information on the interactions of individual flavonoids present in buchu, see under flavonoids, page 186.
<table>
<thead>
<tr>
<th>Buchu + Food</th>
<th>Buchu + Lithium</th>
</tr>
</thead>
<tbody>
<tr>
<td>No interactions found.</td>
<td>For mention of a case of lithium toxicity in a woman who had been taking a non-prescription herbal diuretic containing corn silk, <em>Equisetum hyemale</em>, juniper, buchu, parsley and bearberry, all of which are believed to have diuretic actions, see under Parsley + Lithium, page 305.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Buchu + Herbal medicines</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>No interactions found.</td>
<td></td>
</tr>
</tbody>
</table>
Synonym(s) and related species
Sweet bugle, Water bugle.

*Lycopus europaeus* (European bugleweed) is known more commonly as Gypsywort, and both species are used interchangeably for medicinal purposes.

Constituents
Neither species has been exhaustively investigated chemically. The main constituents of *Lycopus virginicus* are polyphenolics, such as flavonoids based on apigenin and luteolin. Caffeic, chlorogenic, ellagic and rosmarinic acids, and isopimarane diterpenoids are also present. *Lycopus europaeus* contains similar flavonoids and diterpenoids.

Use and indications
Both species of *Lycopus* are used to treat mild hyperthyroidism and its associated symptoms, and there is some supporting experimental and clinical evidence for this. They are also used as sedatives and cough remedies.

Pharmacokinetics
No relevant pharmacokinetic data found specifically for bugleweed, but see flavonoids, page 186, for more detail on individual flavonoids present in the herb.

Interactions overview
No interactions with bugleweed found, but see flavonoids, page 186, for the interactions of individual flavonoids present in bugleweed.


**Bupleurum**

*Bupleurum falcatum* L. (Apiaceae)

**Synonym(s) and related species**

Chai hui, Hare’s ear, Saiko.

*Bupleurum chinense* DC., *Bupleurum fruticosum* L. and *Bupleurum scorzonerifolium* Wild. are also used medicinally, but *Bupleurum longiradiatum* Turcz. is toxic and should be avoided.

**Constituents**

Bupleurum root contains a range of triterpene saponins, the saikosaponins and saikogenins. There are also polysaccharides known as bupleurans and phytosterols present.

**Use and indications**

Bupleurum is used for chills, fevers, as an anti-inflammatory and general tonic. It is also used for liver disorders and menstrual and uterine problems. Anti-inflammatory and immune-modulatory activities have been demonstrated in laboratory tests. Bupleurum root is an ingredient of a number of traditional Chinese and Japanese herbal medicines such as Sho-saiko-to (Xiao Chai Hu Tang) and Sairei-to, see the table Constituents of some Chinese herbal medicines containing bupleurum opposite. These Chinese medicines are used for similar reasons to bupleurum.

**Pharmacokinetics**

Saikosaponin a, and its monoglycoside and aglycones, were detectable in the plasma of rats when saikosaponin a was given orally. Absorption of other derivatives, structural isomers and their monoglycosides and aglycones, which were formed in the gastrointestinal tract, depended on food intake. The pharmacological effects of saikosaponin a given orally may therefore differ depending on conditions of the gastrointestinal tract.\(^1\)

Saikosaponins a, c and d are metabolised extensively in the mouse gut to at least 27 metabolites in a complex manner. A study in rats to determine which of these metabolites are active, based on their corticosterone-secreting activity, found that saikosaponin a, saikosaponin d and their intestinal metabolites prosaikogenin F and prosaikogenin G showed strong activity. Other compounds and metabolites showed varying degrees of biological activity so the degree to which metabolism occurs is likely to affect pharmacological and clinical effects.\(^2\)

**Interactions overview**

No interactions with bupleurum alone found. Bupleurum is the main constituent of a number of Chinese herbal medicines, such as sho-saiko-to, saiko-ka-ryukotsu-borei-to and sairei-to. Sho-saiko-to slightly inhibits caffeine metabolism. Neither sho-saiko-to nor sairei-to appears to alter the pharmacokinetics of ofloxacin. Sho-saiko-to may modestly affect the absorption of tolbutamide but blood-glucose levels appear to be minimally affected.


---

**Constituents of some Chinese herbal medicines containing bupleurum**

<table>
<thead>
<tr>
<th>Proportion of herbs in the medicines (parts)</th>
<th>Sho-saiko-to(^1)</th>
<th>Sairei-to(^2)</th>
<th>Saiko-ka-ryukotsu-borei-to(^3)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alismatis (rhizome)</td>
<td>4</td>
<td></td>
<td>1.5</td>
</tr>
<tr>
<td>Atractyloides</td>
<td>3</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>Lancea (rhizome)</td>
<td></td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>Bupleuri (root)</td>
<td>7</td>
<td>7</td>
<td>5</td>
</tr>
<tr>
<td>Cinnamomi (cortex), see Cinnamon, page 136</td>
<td>1.5</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>Fossilia Ossis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Massodi</td>
<td></td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>Ginseng (root), see Ginseng, page 219</td>
<td>3</td>
<td>3</td>
<td>2.5</td>
</tr>
<tr>
<td>Glycyrrhizae (root), see Liquorice, page 272</td>
<td>2</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>Hoelen</td>
<td></td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>Ostreae testa</td>
<td></td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>Pinelliae (tuber)</td>
<td>5</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td>Polyporus</td>
<td>3</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>Scutellariae (root), see Baical skullcap, page 51</td>
<td>3</td>
<td>3</td>
<td>2.5</td>
</tr>
<tr>
<td>Zizyphi (fruit)</td>
<td>3</td>
<td>3</td>
<td>2.5</td>
</tr>
<tr>
<td>Zingiberis (rhizome), see Ginger, page 204</td>
<td>1</td>
<td>1</td>
<td></td>
</tr>
</tbody>
</table>
Bupleurum

Sho-saiko-to slightly reduces the metabolism of caffeine, but this is not expected to be clinically important.

**Evidence, mechanism, importance and management**

In a study, 26 healthy subjects were given sho-saiko-to 2.5 g twice daily for 5 days, with a single 150-mg dose of caffeine on days 1 and 5. By assessing the metabolites of caffeine, it was estimated that sho-saiko-to caused a 16% inhibition of the cytochrome P450 isoenzyme CYP1A2.

Note that sho-saiko-to is a Chinese herbal medicine of which bupleurum is one of 7 constituents. Any modest effect is therefore not directly attributable to bupleurum alone. See the table Constituents of some Chinese herbal medicines containing bupleurum, page 89, for a list of the constituents.

The clinical significance of this finding is unclear, but is likely to be small, although further studies would help to clarify this.


---

**Bupleurum + Caffeine**

Any interaction between sho-saiko-to and saiko-ka-ryukotsu-borei-to and carbamazepine is based on experimental evidence only.

**Clinical evidence**

No interactions found.

**Experimental evidence**

A study in rats found that the simultaneous administration of single doses of carbamazepine and sho-saiko-to, of which bupleurum is one of 7 constituents, delayed and lowered (by 45%) the maximum plasma concentrations of carbamazepine. The AUC of carbamazepine-epoxide was also modestly reduced by 32%, but there was no change in elimination rate. In a related study rats were pretreated with sho-saiko-to daily for 2 weeks, and then, 24 hours later, given a single dose of carbamazepine. Although this tended to reduce the maximum carbamazepine level, there was no significant effect on the pharmacokinetics of carbamazepine.

In a further study, rats treated with saiko-ka-ryukotsu-borei-to (of which bupleurum is one of 10 constituents) either as a single dose or as a daily dose for one week, experienced no change in the pharmacokinetics of a single dose of carbamazepine given 3 hours after the Chinese herbal medicine.

**Mechanism**

It was found that sho-saiko-to delayed gastric emptying, and so it could delay absorption of carbamazepine when given at the same time. It is unlikely that sho-saiko-to or saiko-ka-ryukotsu-borei-to affects the metabolism of carbamazepine.

**Importance and management**

While information regarding an interaction between bupleurum and carbamazepine is limited to experimental data using Chinese herbal medicines of which bupleurum is only one constituent, they provide some reassurance that these products are unlikely to affect the metabolism of carbamazepine. The first product, sho-saiko-to, slightly delayed the absorption of carbamazepine, especially when given simultaneously, but, since the extent of absorption was not significantly altered, this is unlikely to be clinically relevant. Other main constituents of the products also seem unlikely to interact. See the table Constituents of some Chinese herbal medicines containing bupleurum, page 89, for a list of the constituents.


---

**Bupleurum + Ofloxacin**

The interaction between sho-saiko-to and toltubamide is based on experimental evidence only.

**Clinical evidence**

No interactions found.

**Experimental evidence**

In a single-dose study in rats, the initial rate of gastrointestinal absorption of toltubamide 50 mg/kg given as a suspension was modestly increased when given simultaneously with sho-saiko-to, of which bupleurum is one of 7 constituents. The maximum toltubamide level was slightly increased, by 21%; however, there was no difference in toltubamide AUC, clearance or elimination half-life. The decrease in plasma glucose levels was greater during the first hour and less in the period 5 to 8 hours after both drugs were given, when compared with toltubamide alone. However, at a maximum, sho-saiko-to increased the blood-glucose-lowering effects of toltubamide by about 11%, which was not statistically significant.

In contrast, in a similar study, the absorption of tolbutamide was delayed when tolbutamide was given 1 hour after the sho-saiko-to.  

**Mechanism**

*In vitro* studies have shown that sho-saiko-to increases the permeability of jejunal epithelial cells to tolbutamide, which could explain the increased absorption in the first study. Conversely, the second study found that sho-saiko-to decreases gastric emptying rate (see also Bupleurum + Carbamazepine, page 90), which could explain the finding of delayed absorption.

**Importance and management**

These preliminary studies provide some evidence that sho-saiko-to might alter the absorption of tolbutamide, but, because of their contrasting findings (one showed an increased rate of absorption and one showed delayed absorption), no conclusions can be drawn. The rate of absorption of tolbutamide is probably unlikely to alter clinical efficacy. This suggestion is supported by the finding of minimal changes in blood-glucose levels in one of the studies. Note that any interaction cannot be directly attributed to bupleurum as sho-saiko-to contains a number of constituents, any one of which may be responsible for the effects seen. See the table Constituents of some Chinese herbal medicines containing bupleurum, page 89, for a list of the constituents.

Burdock

Arctium lappa L. (Asteraceae)

**Synonym(s) and related species**
Bardane, Beggar’s buttons, Great burr, Greater burdock, Lappa, Thorny burr.
Arctium majus Bernh.

**Constituents**
Burdock leaves and root contain lignans including arctiogenin, arctiin and matairesinol, and various sesquiterpenes including arctiol, β-eudesmol, petasitolone, fukinanolide and fukinone, are also found in the leaves. The seeds contain a series of lappaols.

**Use and indications**
Burdock is usually taken for skin conditions and as an anti-inflammatory and antiseptic agent. The lignans have anti-proliferative effects *in vitro* and arctiin has oestrogenic effects.

**Pharmacokinetics**
An *in vitro* study suggests that ethanol extracts of burdock root were only weak inhibitors of the cytochrome P450 isoenzymes CYP3A4 and CYP2C19.1

**Interactions overview**
No interactions with burdock found.

**Burnet**

*Sanguisorba officinalis* L. (Rosaceae)

**Synonym(s) and related species**

Garden burnet, Greater burnet, Sanguisorba.  
*Sanguisorba polygama* F. Nyl.  
Formerly known as *Poterium officinale* A. Gray.  
Not to be confused with Burnet saxifrage (Lesser burnet).

**Pharmacopoeias**

Greater Burnet Root (*BP 2009*).

**Constituents**

The root and rhizome contain the sanguisorbins A–E, which are **triterpene glycosides** based on ursolic acid. Burnet also contains ziyu glycosides I and II and related compounds, and numerous polyphenolics, including a series of ellagittannins known as sanguins H1–H6, and tannins.

**Use and indications**

Burnet has antimicrobial, antihaemorrhagic and astringent properties, which have been demonstrated experimentally but not clinically. Burnet is used to treat infections, ulcerative colitis and diarrhoea, burns and inflammatory conditions, and to stem excessive bleeding.

**Pharmacokinetics**

No relevant pharmacokinetic data found.

**Interactions overview**

Evidence of any interactions with burnet is sparse, but one *animal* study suggests that it may reduce the bioavailability of ciprofloxacin.
Burnet + Food

No interactions found.

Burnet + Herbal medicines

No interactions found.

Burnet + Quinolones

The interaction between burnet and quinolones is based on experimental evidence only.

Clinical evidence
No interactions found.

Experimental evidence
In an animal study, rats were given a burnet powdered extract 2 g/kg and ciprofloxacin, both orally. The maximum levels and AUC of ciprofloxacin were found to be reduced by 94% and 78%, respectively, by the herb.1

Mechanism
It is possible that the metal cations present in the extract may have formed chelates with ciprofloxacin thereby reducing its bioavailability.1

Importance and management
Evidence is limited, but it appears that burnet may reduce the bioavailability of ciprofloxacin. Burnet was given in a clinically relevant dose, and the reduction in levels seen would therefore be expected to result in a clinically relevant reduction in the efficacy of ciprofloxacin. With other chelation interactions with ciprofloxacin, separating administration to reduce the admixture of the two drugs in the gut minimises any interaction. In general, ciprofloxacin should be taken at least 2 hours before, and not less than 4 to 6 hours after, drugs that it may chelate with, such as those containing polyvalent cations; this would appear to include burnet. The majority of the quinolone antibacterials are known to interact with polyvalent cations in the same way as ciprofloxacin, and it would therefore seem prudent to extend this caution to all of them.

Butcher’s broom

*Ruscus aculeatus* L. (Ruscaceae)

**Synonym(s) and related species**
Box holly, Kneeholm, Kneeholy, Pettigree, Sweet broom.
Not to be confused with Broom, page 85, which is *Cystisus scoparius* (L.) Link.

**Pharmacopoeias**
Butcher’s broom (*BP 2009, Ph Eur 6.4*).

**Constituents**
Butcher’s broom contains a range of saponins, including ruscine and ruscoside, which are based on ruscogenin (1-beta-hydroxydiosgenin) and neoruscogenin. The related glycosides aculeosides A and B are present in the root. Extracts are often standardised to contain a minimum of 1% of total sapogenins, expressed as ruscogenins (*BP 2009, Ph Eur 6.4*).

**Use and indications**
Butcher’s broom is used mainly for chronic venous insufficiency, in varicose veins and haemorrhoids, for example. It is also reported to be anti-inflammatory and to reduce vascular permeability. There are a number of studies in support of these uses.

**Pharmacokinetics**
No relevant pharmacokinetic data found.

**Interactions overview**
No interactions with Butcher’s broom found.
Butterbur

*Petasites hybridus* (L.) G.Gaertn., B.Mey. & Scherb. (Asteraceae)

**Synonym(s) and related species**
Blatterdock, Bog rhubarb, Bogshorns, Butterdock, Butterfly dock, Capdockin, Flapperdock, Umbrella plant.

**Constituents**
All parts of the plant contain sesquiterpenes and unsaturated pyrrolizidine alkaloids. During storage, some of the constituents undergo transformation, thus the final composition of herbal preparations may vary depending on storage conditions.

**Use and indications**
Butterbur is used for the prophylaxis of migraines, and as an anti-spasmodic agent for chronic cough or asthma. It has also been used successfully for the prevention of gastric ulcers, and to treat patients with irritable bladder and urinary tract spasms. It has also been used as a diuretic and cardiotonic. The pyrrolizidine alkaloids are hepatotoxic, and have been shown to be carcinogenic and mutagenic in preclinical studies.

**Pharmacokinetics**
No relevant pharmacokinetic data found.

**Interactions overview**
Many theoretical interactions have been proposed, including the suggestion that butterbur may interact through effects on histamine H$_1$-receptors. A post-marketing surveillance study identified over 50 patients taking antihistamines and a butterbur extract (Ze 339), without evidence of either a beneficial or an adverse effect.

Caffeine

The information in this monograph relates specifically to caffeine. A number of herbs contain significant amounts of caffeine, to which many of their pharmacological effects may be attributed. Their caffeine content also means that they have the potential to interact in the same way as caffeine itself, although note that the levels of caffeine are likely to vary widely between different herbal medicines and products. Also, remember that the herbs often contain active constituents other than caffeine, and the reader should refer to the relevant herb for other potential interactions.

Types, sources and related compounds
Caffeine (1,3,7-trimethylxanthine, coffeinum, guaranine, koffein, methyltheobromine, théine) is found in significant quantities, in approximate order of highest to lowest levels: in the seeds of guarana, page 243, the leaves of tea, page 382, the nuts of cola, page 148, the beans of coffee, page 145, the leaves of maté, page 282, and the beans of cocoa, page 139. Cocoa contains significant amounts of the xanthine theobromine. Note that rooibos, page 341, and honeybush, page 249, which are commonly used as a tea-like beverage, do not contain caffeine.

Pharmacopoeias
Caffeine (BP 2009, Ph Eur 6.4, USP 32); Caffeine hydrate (BP 2009); Caffeine monohydrate (Ph Eur 6.4); Caffeine citrate injection (USP 32); Caffeine citrate oral solution (USP 32).

Uses and administration
Extracts of caffeine-containing herbs have been used medicinally for their stimulant and diuretic effects, and may be promoted as slimming aids and for boosting energy. As foods, caffeine and caffeine-containing herbs are very widely consumed as beverages and, on regular consumption, partial tolerance develops to many of the pharmacological effects of caffeine. Caffeine may induce dependence, and stopping intake abruptly can cause withdrawal. Consumption

Conventional drugs that are known inhibitors of the metabolism of caffeine

<table>
<thead>
<tr>
<th>Drug</th>
<th>Reduction in clearance</th>
<th>Prolongation of half-life</th>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Potent inhibitors</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fluvoxamine</td>
<td>80%</td>
<td>5–31 hours</td>
<td>An increase in the stimulant and adverse effects of caffeine (headache, jitteriness, restlessness, insomnia) may be possible in susceptible patients if they continue to consume large amounts of caffeine. They should be warned to reduce their caffeine intake if problems develop.</td>
</tr>
<tr>
<td>Idroclamide</td>
<td>90%</td>
<td>7–59 hours</td>
<td></td>
</tr>
<tr>
<td>Oral psoralens</td>
<td>69%</td>
<td>5.6–57 hours</td>
<td></td>
</tr>
<tr>
<td>Quinolones:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinafloxacin</td>
<td>84%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Enoxacin</td>
<td>78–83%</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Moderate inhibitors</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Artemisinin</td>
<td>35%</td>
<td></td>
<td>Unlikely to be clinically important in most patients, but bear this interaction in mind if the adverse effects of caffeine (insomnia, jitteriness, restlessness, insomnia) become troublesome</td>
</tr>
<tr>
<td>Cimetidine</td>
<td>31–42%</td>
<td>45–96%</td>
<td></td>
</tr>
<tr>
<td>Disulfiram</td>
<td>30–50%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mexiletine</td>
<td>48–57%</td>
<td>4–7 hours</td>
<td></td>
</tr>
<tr>
<td>Quinolones:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ciprofloxacin</td>
<td>33–53%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Norfloxacin</td>
<td>35%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pefloxacin</td>
<td>47%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pipemidic acid</td>
<td>63%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tiabendazole</td>
<td>66%</td>
<td>140%</td>
<td></td>
</tr>
<tr>
<td><strong>Minor inhibitors</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Antifungals:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fluconazole</td>
<td>25%</td>
<td></td>
<td>No action necessary</td>
</tr>
<tr>
<td>Terbinafine</td>
<td>21%</td>
<td>31%</td>
<td>Increases of this magnitude are very unlikely to cause any clinically relevant effects</td>
</tr>
<tr>
<td>Combined oral contraceptives</td>
<td>4–6 hours up to 8–11 hours</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Grapefruit juice (1.2 litres)</td>
<td>23%</td>
<td>31%</td>
<td></td>
</tr>
<tr>
<td>HRT</td>
<td>29%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Verapamil</td>
<td>25%</td>
<td>4.6–5.8 hours</td>
<td></td>
</tr>
</tbody>
</table>
of excess caffeine can cause anxiety, sleeplessness, tremor, palpitations and headache.

Caffeine-containing beverages have been associated with various health benefits in epidemiological studies, which have been attributed to other constituents such as the flavonoids.

**Pharmacokinetics**

Caffeine is predominantly metabolised via N3-demethylation to paraxanthine by the cytochrome P450 isoenzyme CYP1A2, and is often used as a probe substrate to study the effect of medicines and other substances on this isoenzyme. The elimination half-life of caffeine is about 3 to 6 hours in adults, and is about twofold longer in people who do not regularly consume caffeine.

In one study, the pharmacokinetics and subjective effects of caffeine were similar whether consumed as coffee or cola.

(a) **Inhibitors of caffeine metabolism**

There are a number of medicines that are known inhibitors of the cytochrome P450 isoenzyme CYP1A2, by which caffeine is metabolised, and these are listed in the table. Very few of these actually have warnings regarding their use with caffeine-containing beverages, so warnings are unlikely to be needed with concurrent use of caffeine, including that from caffeine-containing herbs. Nevertheless, if an increase in the stimulant and adverse effects of caffeine is seen in patients taking these drugs (most likely with those drugs that are potent inhibitors of caffeine metabolism), then the intake of caffeine should be reduced.

(b) **Inducers of caffeine metabolism**

Barbiturates and phenytoin induce CYP1A2, by which caffeine is metabolised, and they would therefore be expected to reduce the effects of caffeine, including that from caffeine-containing herbs.

**Interactions overview**

Caffeine is a vasopressor and stimulant and it therefore may antagonise the effects of antihypertensive drugs and benzodiazepines. It may also cause serious adverse effects if used with other drugs or herbs with similar effects, such as phenylpropanolamine, bitter orange and ephedra (see page 176). Caffeine may interfere with the dexamethasone suppression test, and the efficacy of adenosine and dipyridamole used during cardiac imaging. Caffeine may raise clozapine levels, and has modest effects on the absorption of some analgesics, but probably does not significantly affect lithium levels.

Note that caffeine is known to have diuretic effects. Therefore caffeine-containing herbs may produce a degree of additive diuresis with other diuretics.

The inhibitory effects of conventional drugs on caffeine metabolism, and management recommendations, are summarised in the table Conventional drugs that are known inhibitors of the metabolism of caffeine, page 97.

Caffeine + Adenosine

Caffeine can inhibit the effects of adenosine infusions used in conjunction with radionuclide myocardial imaging.

Clinical evidence
Studies in healthy subjects, on the way xanthine drugs such as caffeine possibly interact with adenosine, have shown that caffeine reduces the increased heart rate and the changes in blood pressure caused by infusions of adenosine,1,2 and attenuates adenosine-induced vasodilatation.3

Experimental evidence
Because of the quality of the clinical evidence (controlled pharmacokinetic studies), experimental data have not been sought.

Mechanism
Caffeine has an antagonistic effect on adenosine receptors.4 It appears to have opposite effects on the circulatory system; caffeine causes vasoconstriction whereas adenosine infusions generally cause vasodilatation.1 Consequently their concurrent use is likely to result in opposing effects.

Importance and management
Caffeine can inhibit the effects of adenosine infusions used in conjunction with radionuclide myocardial imaging. The manufacturers of adenosine state that xanthine-containing drinks (tea, coffee, chocolate, cola drinks, etc.) should be avoided for at least 12 hours before imaging,2 and this should be taken to include caffeine-containing herbs or supplements. In a recent study in 70 patients, measurable caffeine serum levels were found in 74% of patients after 12 hours of self-reported abstention from caffeine-containing products. Patients with caffeine serum levels of at least 2.9 mg/L had significantly fewer stress symptoms (chest tightness, chest pain, headache, dyspnoea, nausea, dizziness) than those with lower serum levels. The authors suggest that a 12-hour abstention from caffeine-containing products may be insufficient, and could result in false-negative results.5

There appears to be no direct evidence regarding the effects of caffeine on the use of adenosine boluses to reverse supraventricular tachycardias.

Importance and management
Caffeine can inhibit the effects of adenosine infusions used in conjunction with radionuclide myocardial imaging. The manufacturers of adenosine state that xanthine-containing drinks (tea, coffee, chocolate, cola drinks, etc.) should be avoided for at least 12 hours before imaging,2 and this should be taken to include caffeine-containing herbs or supplements. In a recent study in 70 patients, measurable caffeine serum levels were found in 74% of patients after 12 hours of self-reported abstention from caffeine-containing products. Patients with caffeine serum levels of at least 2.9 mg/L had significantly fewer stress symptoms (chest tightness, chest pain, headache, dyspnoea, nausea, dizziness) than those with lower serum levels. The authors suggest that a 12-hour abstention from caffeine-containing products may be insufficient, and could result in false-negative results.5

Caffeine + Aspirin or Diclofenac

Caffeine modestly increases the bioavailability, rate of absorption and plasma levels of aspirin. Adding caffeine to diclofenac may improve its efficacy in the treatment of migraine.

Evidence, mechanism, importance and management
In a study in healthy subjects, caffeine citrate 120 mg given with a single 650-mg dose of aspirin increased the AUC of aspirin by 36%, increased its maximum plasma levels by 15% and increased its rate of absorption by 30%.1 This confirms the results of previous studies.2,3 These studies suggest that caffeine could modestly potentiate the efficacy of aspirin by a pharmacokinetic mechanism. However, a meta-analysis of randomised controlled studies concluded that there was no therapeutic advantage in adding caffeine to analgesic doses of aspirin in patients experiencing postoperative pain.4

In a placebo-controlled study in patients with migraine, there was a non-significant trend towards improved analgesic effect in patients receiving diclofenac softgel capsules 100 mg and caffeine 100 mg, when compared with diclofenac alone, although the sample size was too small to provide meaningful results.5

Caffeine is commonly included in aspirin preparations as an analgesic adjuvant, but its overall value still remains unclear. It seems unlikely that caffeine-containing herbs will have any detrimental effect as a result of their caffeine content if they are given with these analgesics. However, note that if aspirin or diclofenac formulated with caffeine is given there is the potential for caffeine
adverse effects (such as headache, jitteriness, restlessness and insomnia). Caffeine intake should be reduced if this occurs.

Importance and management

This would appear to be an established and clinically important interaction, but unlikely to be a problem if clozapine serum levels are established and well monitored, and if caffeine intake remains fairly stable and moderate. Possible exceptions are if large doses of caffeine are given during ECT treatment or if for some other reason the caffeine intake suddenly increases or decreases markedly. Patients taking clozapine should probably avoid taking large doses of caffeine-containing herbal preparations.


Caffeine + Dexamethasone

The results of the dexamethasone suppression test can be falsified by the acute ingestion of caffeine, but chronic caffeine use does not appear to have an effect.

Evidence, mechanism, importance and management

In one study, 22 healthy subjects and 6 depressed patients were given a single 480-mg dose of caffeine or placebo at 2 pm following a single 1-mg dose of dexamethasone given at 11 pm the previous evening. Caffeine significantly increased the cortisol levels following the dexamethasone dose; cortisol levels taken at 4 pm were about 146 nanomol/L with caffeine, compared with about 64 nanomol/L with placebo. Thus the equivalent of about 4 to 5 cups of coffee may effectively falsify the results of the dexamethasone suppression test. However, in a study in 121 patients with depression, there was no correlation between chronic low to high intake of caffeine (6 mg to 2.3 g daily) and cortisol levels at 8 am, 4 pm or 11 pm on the day after a 1-mg dose of dexamethasone given at 11 pm the previous evening. It was suggested that chronic caffeine intake produces tolerance to the effects of acute caffeine on the hypothalamic–pituitary–adrenal (HPA) axis.

Therefore, it appears that the results of the dexamethasone suppression test can be falsified by the acute ingestion of a high dose of caffeine but that chronic caffeine use does not appear to have an effect. As chronic intake of caffeine does not appear to affect this test, it does not seem necessary to advise patients to stop any regular intake of caffeine-containing herbs. However, bear the potential for an interaction with caffeine-containing herbs in mind should an unexpected response occur.


Caffeine + Dipyridamole

Caffeine may interfere with dipyridamole–thallium-201 myocardial scintigraphy tests.

Clinical evidence

Intravenous caffeine 4 mg/kg (roughly equivalent to 2 to 3 cups of coffee), given before dipyridamole–thallium-201 myocardial scintigraphy, caused a false-negative test result in a patient. A further study in 8 healthy subjects confirmed that caffeine inhibits the haemodynamic response to an infusion of dipyridamole.

Experimental evidence

Because of the quality of the clinical evidence (controlled pharmacokinetic studies), experimental data have not been sought.

Mechanism

It appears that caffeine might antagonise some of the haemodynamic effects of dipyridamole because it acts as a competitive antagonist of adenosine (an endogenous vasodilator involved in the action of dipyridamole).

Importance and management

An interaction between caffeine and intravenous dipyridamole is established. Patients should abstain from caffeine from any source, including caffeine-containing herbal preparations, caffeine-containing beverages (tea, coffee, chocolate, cocoa, cola) and caffeine-containing analgesics for 24 hours before dipyridamole testing. If during the test the haemodynamic response is low (e.g. no increase in heart rate) the presence of caffeine should be suspected. Patients should be specifically prompted to discuss less obvious potential sources such as herbal medicines.


Caffeine + Food: Caffeine-containing

The effects of dietary caffeine and caffeine from herbal medicines will be additive.

Evidence, mechanism, importance and management

The effects of caffeine from herbal medicines will be additive with that from caffeine-containing food (chocolate) and beverages (tea, coffee, cola). People who want to take a caffeine-containing herbal medicine should be aware of the possible increased risk of adverse effects, including headache, jitteriness, restlessness and insomnia. They should be warned to reduce their caffeine intake if problems develop.

Caffeine + Herbal medicines; Bitter orange

The use of caffeine with bitter orange may lead to severe cardiac adverse effects. Bitter orange does not affect the metabolism of caffeine.

Clinical evidence

(a) Cardiovascular effects

Some evidence suggests that the haemodynamic effects of caffeine and bitter orange are synergistic. In a single-dose, crossover study in 10 healthy subjects, a combination product containing, among other ingredients, bitter orange, maté and cocoa (Xenadrine EFX), and a single-ingredient bitter orange product (Advantra Z, containing synephrine 15.6 mg), both increased heart rate (by 16.7 bpm and 11.4 bpm, respectively) when compared with placebo. Xenadrine EFX increased blood pressure (by 9.6/9.1 mmHg), whereas Advantra Z did not. Advantra Z contained eight times the dose of caffeine.
synephrine, a sympathomimetic alkaloid found in bitter orange, than *Xenadrine* (46.9 mg versus 5.5 mg), so it was concluded that caffeine and other stimulants in the *Xenadrine* must be acting synergistically with the synephrine. Although this study did not find that bitter orange alone increased blood pressure, another single-dose study, in 13 healthy subjects, found that bitter orange (*Nature’s Way Bitter Orange*, containing synephrine about 54 mg per capsule) increased systolic blood pressure by 7.3 mmHg and the heart rate by 4.2 bpm, when compared with placebo.

Case reports suggest that this increase in blood pressure might be clinically important. For example, an ischaemic stroke occurred in a 38-year-old man with no relevant past medical history or risk factors for stroke or cardiovascular disease. The stroke occurred one week after he started taking two capsules per day of Stacker 2 *Ephedra Free* weight-loss supplement, which contains bitter orange and cola nut extract, giving synephrine 6 mg and caffeine 200 mg per capsule. Furthermore, from January 1998 to February 2004, Health Canada received 16 reports of serious cardiovascular adverse reactions (including tachycardia, cardiac arrest, ventricular fibrillation, transient collapse and blackout) that were suspected of being associated with bitter orange or supplements containing synephrine. In 15 of these cases, the product also contained caffeine; in 8 of those 15 cases the product also contained ephedra. Note that the use of caffeine with ephedra has been associated with severe cardiac effects, see Ephedra + Caffeine, page 176. From March 2004 to October 2006, Health Canada noted an additional 21 reports, of which 15 were cardiovascular adverse effects. One of these included a report of a myocardial infarction in a patient possibly precipitated by the use of a weight-loss supplement containing bitter orange 300 mg as well as guaranamine and green tea (*Edita’s Skinny Pill*).

**Pharmacokinetics**

In a study in 12 healthy subjects,7 bitter orange 350 mg, standardised to synephrine 4%, was given twice daily for 28 days with a single 100-mg dose of caffeine before and at the end of the treatment with bitter orange. The metabolism of caffeine was not affected by the concurrent use of bitter orange, which suggests that bitter orange is unlikely to affect the metabolism of other drugs that are substrates of the cytochrome P450 isoenzymes CYP1A2.

**Experimental evidence**

Because of the extensive clinical evidence available, experimental data have not been sought.

**Mechanism**

Uncertain. Sympathrine, a sympathomimetic agonist, is one of the main constituents found in bitter orange, although the compounds vary between products. Simple additive hypertensive effects would seem to be part of the explanation. The effects of caffeine may compound the effects of these sympathomimetic drugs on the cardiovascular and central nervous systems by blocking adenosine receptors (causing vasoconstriction) and also augmenting the release of catecholamines.

**Importance and management**

Fairly well-established interactions. These studies and case reports illustrate the potential hazards of using caffeine-containing herbs with bitter orange, even in healthy individuals, so these preparations may pose a serious health risk to some users. The risk may be affected by individual susceptibility, the additive stimulant effects of caffeine, the variability in the contents of alkaloids in non-prescription dietary supplements or pre-existing medical conditions, including compromised cardiac function. *Ephedra* was banned by the FDA in the US in 2004 and, as a result of this, many manufacturers replaced it with bitter orange which contains a similar sympathomimetic alkaloid, synephrine. Evidence shows that these products are no safer than ephedra products when used in a similar way. It would be prudent to avoid using herbal products containing combinations of bitter orange and caffeine or caffeine-containing herbs, especially in patients with risk factors such as heart conditions, diabetes, thyroid disease or hypertension.


**Caffeine + Lithium**

The heavy consumption of caffeine-containing drinks may cause a small-to-moderate reduction in serum lithium levels.

**Clinical evidence**

An early single-dose study found that the intake of xanthines such as caffeine caused an increase in lithium excretion. In contrast, another single-dose study did not find any significant changes in urinary clearance of lithium in 6 subjects given caffeine 200 mg four times daily compared with a caffeine-free control period. However, in a study in 11 psychiatric patients taking lithium 600 mg to 1.2 g daily who were also regular coffee drinkers (4 to 8 cups daily containing 70 to 120 mg of caffeine per cup), serum lithium levels rose by an average of 24% when the coffee was withdrawn, although the levels of 3 patients did not change. These findings are consistent with another report of 2 patients with lithium-induced tremors that were aggravated when they stopped drinking large amounts of coffee. One of the patients had a 50% rise in lithium levels, and required a reduction in lithium dose from 1.5 g daily to 1.2 g daily.

**Experimental evidence**

Because of the quality of the clinical evidence (controlled pharmacokinetic studies), experimental data have not been sought.

**Mechanism**

It is not clear exactly how caffeine affects the excretion of lithium by the renal tubules.

**Importance and management**

The weight of evidence suggests that, although there is no need for patients taking lithium to avoid caffeine (from caffeine-containing herbs, coffee, tea, cola drinks, etc.), they should stick to a moderate intake, and, in cases where a reduction in lithium intake is desirable, it should be withdrawn cautiously. This is particularly important in patients whose serum lithium levels are already high, because of the risk of toxicity. When caffeine is withdrawn it may be necessary to reduce the dose of lithium. In addition, remember that there is a caffeine-withdrawal syndrome (headache and fatigue being the major symptoms) that might worsen some of the major psychiatric disorders (such as affective and schizophrenic disorders), for which lithium is given. Although the evidence is for caffeine and coffee, all caffeine-containing herbal medicines would be expected to have similar effects, and similar caution should be applied to their use.

Caffeine + Nicotine

Caffeine may boost some of the stimulant effects of nicotine, but it only appears to cause a small, if any, rise in nicotine levels.

Clinical evidence
In a study in 21 smokers who regularly drank one to six cups of coffee daily, a 50-mg tablet of caffeine increased self-ratings of ‘stimulated’, ‘alert’ and ‘jittery’ at various doses of nicotine chewing gum (0.25 mg, 0.5 mg and 1 mg) when compared with the nicotine gum alone.1 In a placebo-controlled study, 12 healthy subjects were given nicotine 1 mg or 2 mg with caffeine 50 mg or 100 mg, in a chewing gum. Nicotine alone and caffeine alone increased energy expenditure, but adding caffeine 50 mg to nicotine 1 mg had almost double the effects of simply increasing the nicotine dose from 1 to 2 mg. Similar effects were seen in both smokers and non-smokers. No adverse effects were reported with either nicotine 1 mg alone or combined with caffeine.2 In a similar study by the same authors, caffeine enhanced the appetite-suppressant effects of nicotine.3 In another study in 13 smokers who regularly drank at least one cup of coffee daily, pre-treatment with oral caffeine 2.5 or 5 mg/kg (added to 180 mL of decaffeinated coffee) did not alter the subjects’ ability to discriminate between nasal nicotine and placebo, and did not alter the amount of caffeine that they self-administered during a period of smoking cessation. Caffeine pre-treatment caused a modest dose-related increase in nicotine levels (maximum 21%).4 In a study in 12 smokers, two doses of caffeine 150 mg (given in a decaffeinated cola drink before and during smoking) had no effect on the plasma levels of nicotine achieved by smoking 5 cigarettes.5

Experimental evidence
Because of the quality of the clinical evidence (controlled pharmacokinetic studies), experimental data have not been sought.

Mechanism
Not understood.

Importance and management
A fairly well-studied interaction. Caffeine may boost some of the stimulant effects of nicotine (energy consumption, appetite suppression, but also adverse effects such as jitteriness), but it only appears to cause a small, if any, rise in nicotine levels. Bear the potential for this increase in effects in mind should a patient receiving nicotine replacement therapy and also taking caffeine supplements develop troublesome nicotine-related adverse effects.


Caffeine + Phenylpropanolamine

Phenylpropanolamine can raise blood pressure and in some cases this may be further increased by caffeine. Combined use has resulted in hypertensive crises in a few individuals. An isolated report describes the development of acute psychosis when caffeine was given with phenylpropanolamine. Phenylpropanolamine greatly raises caffeine levels.

Clinical evidence
In a placebo-controlled study, the mean blood pressure of 16 healthy subjects rose by 11/12 mmHg after they took caffeine 400 mg, by 12/13 mmHg after they took phenylpropanolamine 75 mg, and by 12/11 mmHg when both drugs were taken. Phenylpropanolamine 150 mg caused a greater rise of 36/18 mmHg. One of the subjects had a hypertensive crisis after taking phenylpropanolamine 150 mg and again 2 hours after taking caffeine 400 mg. This needed antihypertensive treatment.1 The same group of workers describe a similar study in which the AUC of caffeine 400 mg increased by more than threefold, and the mean peak caffeine concentration increased almost fourfold (from 2.1 to 8 micrograms/mL) after phenylpropanolamine 75 mg was given.2 Additive increases in blood pressure are described in another report.3

A review describes 41 severe adverse reactions to phenylpropanolamine. Of these cases, caffeine was also taken by 15 subjects, with outcomes such as stroke and seizure. However, it should be noted that these effects were similar to those seen in patients who had taken phenylpropanolamine alone.4

Experimental evidence
Because of the quality of the clinical evidence (controlled pharmacokinetic studies), experimental data have not been sought.

Mechanism
Additive pharmacological effects.

Importance and management
Evidence is limited and an adverse effect is not fully established.


Caffeine + Paracetamol

Caffeine has been variously reported to increase, decrease and have no effect on the absorption of paracetamol.

Evidence, mechanism, importance and management
In a study in 10 healthy subjects, caffeine citrate 120 mg increased the AUC of a single 500-mg dose of paracetamol by 29%, increased the maximum plasma levels by 15% and decreased the total body clearance by 32%. The decrease in time to maximum level and increase in absorption rate did not reach statistical significance.1 A randomised, crossover study in 24 healthy subjects found that a single 130-mg dose of caffeine slightly increased the rate of absorption of a single 1-g dose of paracetamol; however, the overall bioavailability was not altered by caffeine. They also noted an increased and prolonged analgesic effects, which correlated with the pharmacokinetic results.2 Similarly, in another study, although caffeine slightly increased the rate of absorption of paracetamol, it had no effect on the extent of absorption.3 In contrast, a third study states that caffeine decreased plasma paracetamol levels and its AUC, and increased paracetamol elimination in healthy men.4

Caffeine is commonly included in paracetamol preparations as an analgesic adjuvant. No serious adverse effects appear to have been reported with this combination; however, its potential benefit and the mechanisms behind its possible effects remain unclear. It seems unlikely that caffeine-containing herbs will have any detrimental effect as a result of their caffeine content if they are given with paracetamol. However, note that if paracetamol formulated with caffeine is given there is the potential for additive caffeine adverse effects (such as headache, jitteriness, restlessness and insomnia). Caffeine intake should be reduced if this occurs.

especially as hypertensive episodes, stroke and seizures have been reported with the use of phenylpropanolamine alone. One possible explanation for the lack of reports could be that these interactions may go unrecognised or be attributed to one drug only, e.g. phenylpropanolamine, whereas caffeine has also been taken in beverages (often not reported). The risk may be affected by individual susceptibility, the additive stimulant effects of caffeine, the variability in the contents of caffeine and other sympathomimetic alkaloids in non-prescription dietary supplements, or pre-existing medical conditions, such as cardiovascular disease. Note that, phenylpropanolamine was available formulated with caffeine. Phenylpropanolamine is no longer available in the US and UK, and its use has been restricted in many other countries.

The authors of one report advised that users of phenylpropanolamine should be warned about the over-use of phenylpropanolamine, and also about taking caffeine at the same time, because of the possible risk of intracranial haemorrhage secondary to severe hypertension. It would therefore seem prudent to also avoid the use of caffeine-containing herbal medicines. If both drugs are given there is the potential for increased caffeine adverse effects (such as headache, jitteriness, restlessness and insomnia). Caffeine intake should be reduced if this occurs.

Caffeine + Theophylline

Caffeine can raise serum theophylline levels.

Clinical evidence
Caffeine can decrease the clearance of theophylline by 18 to 29%, prolong its half-life by up to 44% and increase its average serum levels by as much as 23%. In addition, caffeine plasma levels have been increased about twofold when theophylline was given. In these studies, caffeine was given in the form of tablets or as 2 to 7 cups of instant coffee. In one study, 2 of the subjects who did not normally drink coffee experienced headaches and nausea.

Experimental evidence
Because of the quality of the clinical evidence (controlled pharmacokinetic studies), experimental data have not been sought.

Mechanism
The probable mechanism of the interaction is that the two drugs compete for the same metabolic route resulting in a reduction in their metabolism and accumulation. In addition, when caffeine levels are high, a small percentage of it is converted to theophylline.

Importance and management
There would seem to be no good reason for patients taking theophylline to avoid caffeine (in herbal preparations, beverages such as coffee, tea, cola drinks, or medications, etc.), but if otherwise unexplained adverse effects occur it might be worth considering if caffeine use could be responsible.

Calamus

Acorus calamus L. (Acoraceae)

**Synonym(s) and related species**

Myrtle flag, Sweet flag, Sweet sedge.

*Calamus aromaticus*.

There are various types of calamus, mainly reflecting geographical origin: type I is an American diploid variety, type II is a European triploid, and types III and IV are subtropical tetraploids.

**Constituents**

The main active constituents are found in the volatile oil, but considerable qualitative and quantitative differences are found between different species and varieties. Tetraploid (subtropical, specifically Indian) species contain 96% β-asarone (isosasarone), whereas triploid (European) species contain 5% and diploid (North American) species do not contain any. In addition, α-asarone, acolamone, acoragermacrone, calamenol, calamene, calamone, eugenol, galangin, methyl eugenol and isoacolamone are present in varying amounts.

**Use and indications**

β-Asarone is considered to be toxic (based on the results of animal studies) and it is recommended that oils containing this substance should be avoided. Calamus is traditionally used as a carminative and spasmylytic, in acute and chronic dyspepsia, gastritis and gastric ulcer, intestinal colic and anorexia, and for respiratory disorders.

**Pharmacokinetics**

No relevant pharmacokinetic data found.

**Interactions overview**

No interactions with calamus found.
Calendula

*Calendula officinalis* L. (Asteraceae)

**Synonym(s) and related species**
Gold-bloom, Marigold, Marybud, Pot Marigold. *Caltha officinalis*.

**Pharmacopoeias**
Calendula Flower (*BP 2009, Ph Eur 6.4*).

**Constituents**
Calendula flower extracts contain mainly triterpenes. Also present are oleanolic acid and its saponins calendulosides C–H, sterols, carotenoids and a sesquiterpene glycoside (arvoside A). Flavonoids (specifically flavonol glycosides including isoquercitrin, narcissin, neohesperidoside and rutin) have also been identified.

**Use and indications**
Calendula is often used in externally applied products for the treatment of cuts, bruises, burns and scalds, and topically for conjunctivitis. It has also been used to treat gastric and duodenal ulcers, haemorrhoids and varicose veins.

**Pharmacokinetics**
No relevant pharmacokinetic data found specifically for calendula extracts, but the pharmacokinetics of oleanolic acid have been evaluated. Incubation with rat liver microsomes suggests that oleanolic acid is likely to be extensively metabolised in the liver by hydroxylation, but the exact sites for this were not determined.1 For information on the pharmacokinetics of individual flavonoids present in calendula, see under flavonoids, page 186.

**Interactions overview**
No interactions with calendula found. For information on the interactions of individual flavonoids present in calendula, see under flavonoids, page 186.

Cannabis

Cannabis sativa L. (Cannabaceae)

Synonym(s) and related species
Bhang, Dagga, Ganja, Hashish, Indian hemp, Marihuana, Marijuana.

Cannabis indica Lam.

Constituents
Cannabis herb contains a wide range of cannabinoids, which are the major active compounds. The main psychoactive constituent is Δ⁹-tetrahydrocannabinol (THC; dronabinol), and it is the cause of many of the pharmacological effects elicited by the consumption of cannabis. However, other cannabinoids, which do not possess psychoactive properties, such as cannabidiol, cannabinol (a decomposition product of Δ⁹-tetrahydrocannabinol), cannabigerol and cannabichromene, are increasingly being investigated for their pharmacological and therapeutic properties. Cannabinoids are often found in the plant as their acid metabolites, e.g. 11-nor-9-carboxy-Δ⁹-tetrahydrocannabinol, cannabidiolic acid and others, especially if the plant has been grown in a cooler climate. These decarboxylate to the parent cannabinoid at high temperatures, such as during smoking. Most medicinal cannabis products have been heat treated to ensure that the cannabinoids are present only in the non-acid form.

Use and indications
Cannabis has no current established use in herbal medicine because of its legal position in most parts of the world. However, medicinal cannabis is increasingly being used to treat chronic conditions, as an adjunct, or where other treatments may be inadequate. For example, a buccal spray preparation of cannabis, containing mainly dronabinol (the medicinal name for Δ⁹-tetrahydrocannabinol) with cannabidiol, is available as an adjunctive treatment for the symptomatic relief of neuropathic pain in multiple sclerosis in adults. It is also being investigated for use as an analgesic in other disease states such as diabetic neuropathy and rheumatoid arthritis, and to relieve spasticity in multiple sclerosis and spinal cord injury. Dronabinol and nabilone (a synthetic cannabinol) are used as antiemetics in patients receiving cancer chemotherapy, and dronabinol has been used as an appetite stimulant in AIDS. Cannabis is a widely used illicit drug because of its psychoactive properties, and has a long history of such use, including by those with chronic illnesses.

Varieties of Cannabis sativa that contain very little cannabinoids (often referred to as hemp) have been cultivated for their fibre and seeds, and these, and the oil derived from the seeds, may be found in some herbal products.

Pharmacokinetics
The most important pharmacokinetic effects of cannabis depend on whether the herb (or its extracts) are smoked or taken orally. When smoked, cannabinoid acids are decarboxylated by the high temperature, and reach the lung as active free cannabinoids. Psychotrophic effects start from within seconds to a few minutes, reach a maximum after 20 to 30 minutes, and taper off within 3 to 4 hours. If the same preparation were to be taken orally, however, cannabinoid acid absorption would be lower and much less predictable, with psychotrophic effects starting after a delay of 30 to 90 minutes, reaching their maximum after 2 to 4 hours and lasting for about 6 hours.

The metabolism of cannabis is complex, resulting in both active and inactive compounds. The cannabinoids are extensively metabolised by cytochrome P450, in particular, by the isoenzymes CYP2C9 and CYP3A4. Smoking cannabis may induce CYP1A2, see theophylline, page 113, and also clozapine, page 110. Dronabinol has also been shown to inhibit CYP1A1, despite increasing its expression. Cannabis also induces the expression of CYP2E1 and CYP2D6 in mice.

Research suggests that some constituents of cannabis can affect others. Cannabidiol, an active but non-psychotropic cannabinoid, has been shown to partially inhibit the hydroxylation of dronabinol, probably by CYP2C. There is limited evidence that some cannabinoids might inhibit P-glycoprotein or reduce P-glycoprotein expression.

Interactions overview
Most of the drug interaction data relate to smoking cannabis. Smoking cannabis has been shown to decrease levels of theophylline, chlorpromazine and probably clozapine. Use of transdermal nicotine with cannabis enhances tachycardia, and increases the stimulant effect of cannabis. Tachycardia has also been seen with combined use of tricyclic antidepressants and cannabis. Cannabis might increase the effects of opioids such as morphine. Isolated cases of hypomania have been seen when cannabis was used with disulfiram and with fluoxetine, and a man taking cannabis and sildenafil had a myocardial infarction. Another case report describes a fatal stroke in a young man who received cisplatin and smoked cannabis. Indomethacin might antagonise some of the effects of smoking cannabis. Smoking cannabis does not appear to affect the pharmacokinetics or antiviral efficacy of indinavir or nelfinavir, and oral cannabis does not appear to affect the pharmacokinetics of docetaxel or irinotecan.

2. Watanabe K, Yamaori S, Funahashi T, Kimura T, Yamamoto I. Cytochrome P450

Cannabis + Alcohol

The detrimental effects of drinking alcohol and smoking cannabis may be additive on some aspects of driving performance. However, there is some evidence that regular cannabis use in itself does not potentiate the effects of alcohol. Smoking cannabis may alter the bioavailability of alcohol.

Evidence and mechanism

(a) CNS effects

Simultaneous use of alcohol and oral Δ⁹-tetrahydrocannabinol (THC, the major active ingredient of cannabis) reduced the performance of psychomotor tests, suggesting that those who use both drugs together should expect the deleterious effects to be additive.¹ In a further placebo-controlled study, subjects smoked cannabis containing 100 or 200 micrograms/kg of Δ⁹-tetrahydrocannabinol and drank alcohol (to achieve an initial blood level of 70 mg%, with further drinks taken to maintain levels at 40 mg%) 30 minutes before driving. They found that cannabis, even in low-to-moderate doses, negatively affected driving performance in real traffic situations. Further, the effect of combining moderate doses of both alcohol and cannabis resulted in dramatic performance impairment as great as that observed with blood-alcohol levels of 140 mg% alone.² Similar results (including a suggestion of a synergistic impairment of performance³) have been found in a number of other studies,⁴ including different doses of cannabis and regular cannabis users.⁵

A study in 22 healthy subjects, who occasionally used cannabis cigarettes and drank moderate amounts of alcohol, found that the number of euphoric events in response to a cannabis cigarette was greater after alcohol ingestion, and the duration of euphoric events was longer. The speed of onset of the effects of cannabis was also faster when it was smoked after the ingestion of alcohol.⁶

One study in 14 regular cannabis users (long-term daily use) and 14 infrequent cannabis users found that regular use reduced the disruptive effects of alcohol on some psychomotor skills relevant to driving, whereas infrequent use did not have this effect. In this study, neither group had smoked any cannabis in the 12 hours before the alcohol test.⁷ Another study found that moderate doses of alcohol and cannabis, consumed either alone or in combination, did not produce significant behavioural or subjective impairment the following day.⁸

A study in 12 healthy subjects who regularly used both cannabis and alcohol found that alcohol 0.5 g/kg significantly increased break latency without affecting body sway, whereas cannabis given as a cigarette containing tetrahydrocannabinol 3.33%, increased body sway but did not affect brake latency. There were no significant additive effects on brake latency, body sway or mood when the two drugs were used together.⁹ A population-based study of 2,777 drivers involved in fatal road crashes, who drank alcohol and/or used cannabis, found that, although both cannabis and alcohol increased the risk of being responsible for a fatal crash, no statistically significant interaction was observed between the two drugs.¹⁰

(b) Pharmacokinetic studies

Fifteen healthy subjects given alcohol 0.7 g/kg developed peak plasma alcohol levels of about 78 mg% at 50 minutes, but, if they smoked a cannabis cigarette 30 minutes after the drink, their peak plasma alcohol levels were only 55 mg% and they occurred 55 minutes later. In addition, their subjective experience of the drugs decreased when used together.¹¹ However, another study found that smoking cannabis 10 minutes before alcohol consumption did not affect blood-alcohol levels.¹² A further study found that blood-alcohol levels were not affected by Δ⁹-tetrahydrocannabinol given orally one hour before alcohol.¹³ A study in 22 healthy subjects, who occasionally used cannabis cigarettes and drank moderate amounts of alcohol, found that plasma Δ⁹-tetrahydrocannabinol levels were higher when alcohol was consumed before smoking a cannabis cigarette.¹⁴

Importance and management

Several studies have found that cannabis and alcohol produce additive detrimental effects on driving performance, but other studies have not found any potentiation. This is probably due to the variety of simulated driving tests used and possibly the time lag between the administration of alcohol and cannabis; behavioural impairment after cannabis has been reported to peak within 30 minutes of smoking.⁵ Nevertheless, both drugs have been shown to affect some aspects of driving performance and increase the risk of fatal car accidents. Concurrent use of cannabis and alcohol before driving should therefore be avoided.


Cannabis + Chlorpromazine

Smokers of cannabis may possibly need larger doses of chlorpromazine than non-smokers.

Clinical evidence

A study in 31 patients found that the clearance of chlorpromazine was increased by 38% by tobacco smoking, by 50% by cannabis smoking, and by 107% when both tobacco and cannabis were smoked.¹

Experimental evidence

No relevant data found.

Mechanism

Not established. The probable reason is that some of the components of tobacco smoke act as enzyme inducers, which increase the rate at which the liver metabolises chlorpromazine, thereby reducing its serum levels and clinical effects.

Importance and management

Established interactions but of uncertain clinical importance. Be alert for the need to increase the dosages of chlorpromazine and related antipsychotics in patients who smoke, and reduce the dosages if smoking is stopped.

Cannabis + Ciclosporin

Cannabidiol, an important constituent of cannabis, may increase ciclosporin levels. This interaction is based on experimental evidence only.

Clinical evidence
No interactions found.

Experimental evidence
An in vitro study found that the incubation of human and mouse liver microsomes with cannabidiol, an active but non-psychoactive constituent of cannabis, resulted in inhibition of ciclosporin metabolism. The production of ciclosporin metabolites was reduced by 73 to 83%. Similar results were found in studies in mice.1

Mechanism
Cannabidiol may inhibit the cytochrome P450 subfamily CYP3A, and so increase ciclosporin levels. However, cannabis does not affect the metabolism of other CYP3A4 substrates, see Cannabis + Imatinib, page 111.

Importance and management
These preclinical data suggest that one constituent of cannabis might possibly raise ciclosporin levels. These data require confirmation in humans. Until such data are available, bear in mind the possibility that irregular use of cannabis might be a factor in unstable ciclosporin levels. It might be unwise for patients taking ciclosporin to use cannabis.

Clinical evidence
No relevant data found.

Mechanism
Tobacco smoke contains aromatic hydrocarbons that are potent inducers of the cytochrome P450 isoenzyme CYP1A2, by which ciclosporin is metabolised. The contribution of cannabis smoking to this case is unknown, but cannabis smoking alone is also known to induce CYP1A2, independent of tobacco. See Cannabis + Theophylline, page 113.

Importance and management
It is known that patients who smoke tobacco may experience lower serum ciclosporin levels and, although there is no direct evidence, this may equally apply to cannabis smoking. Irregular smoking of cannabis might cause fluctuations in ciclosporin levels.

Clinical evidence
No relevant data found.

Mechanism
Cannabidiol may inhibit the cytochrome P450 subfamily CYP3A, and so increase ciclosporin levels. However, cannabis does not affect the metabolism of other CYP3A4 substrates, see Cannabis + Imatinib, page 111.

Importance and management
These preclinical data suggest that one constituent of cannabis might possibly raise ciclosporin levels. These data require confirmation in humans. Until such data are available, bear in mind the possibility that irregular use of cannabis might be a factor in unstable ciclosporin levels. It might be unwise for patients taking ciclosporin to use cannabis.

Clinical evidence
No relevant data found.

Mechanism
Tobacco smoke contains aromatic hydrocarbons that are potent inducers of the cytochrome P450 isoenzyme CYP1A2, by which ciclosporin is metabolised. The contribution of cannabis smoking to this case is unknown, but cannabis smoking alone is also known to induce CYP1A2, independent of tobacco. See Cannabis + Theophylline, page 113.

Importance and management
It is known that patients who smoke tobacco may experience lower serum ciclosporin levels and, although there is no direct evidence, this may equally apply to cannabis smoking. Irregular smoking of cannabis might cause fluctuations in ciclosporin levels.

Clinical evidence
No relevant data found.

Mechanism
Tobacco smoke contains aromatic hydrocarbons that are potent inducers of the cytochrome P450 isoenzyme CYP1A2, by which ciclosporin is metabolised. The contribution of cannabis smoking to this case is unknown, but cannabis smoking alone is also known to induce CYP1A2, independent of tobacco. See Cannabis + Theophylline, page 113.

Importance and management
It is known that patients who smoke tobacco may experience lower serum ciclosporin levels and, although there is no direct evidence, this may equally apply to cannabis smoking. Irregular smoking of cannabis might cause fluctuations in ciclosporin levels.

Clinical evidence
No relevant data found.

Mechanism
Tobacco smoke contains aromatic hydrocarbons that are potent inducers of the cytochrome P450 isoenzyme CYP1A2, by which ciclosporin is metabolised. The contribution of cannabis smoking to this case is unknown, but cannabis smoking alone is also known to induce CYP1A2, independent of tobacco. See Cannabis + Theophylline, page 113.

Importance and management
It is known that patients who smoke tobacco may experience lower serum ciclosporin levels and, although there is no direct evidence, this may equally apply to cannabis smoking. Irregular smoking of cannabis might cause fluctuations in ciclosporin levels.

Clinical evidence
No relevant data found.

Mechanism
Tobacco smoke contains aromatic hydrocarbons that are potent inducers of the cytochrome P450 isoenzyme CYP1A2, by which ciclosporin is metabolised. The contribution of cannabis smoking to this case is unknown, but cannabis smoking alone is also known to induce CYP1A2, independent of tobacco. See Cannabis + Theophylline, page 113.

Importance and management
It is known that patients who smoke tobacco may experience lower serum ciclosporin levels and, although there is no direct evidence, this may equally apply to cannabis smoking. Irregular smoking of cannabis might cause fluctuations in ciclosporin levels.

Clinical evidence
No relevant data found.

Mechanism
Tobacco smoke contains aromatic hydrocarbons that are potent inducers of the cytochrome P450 isoenzyme CYP1A2, by which ciclosporin is metabolised. The contribution of cannabis smoking to this case is unknown, but cannabis smoking alone is also known to induce CYP1A2, independent of tobacco. See Cannabis + Theophylline, page 113.

Importance and management
It is known that patients who smoke tobacco may experience lower serum ciclosporin levels and, although there is no direct evidence, this may equally apply to cannabis smoking. Irregular smoking of cannabis might cause fluctuations in ciclosporin levels.

Clinical evidence
No relevant data found.

Mechanism
Tobacco smoke contains aromatic hydrocarbons that are potent inducers of the cytochrome P450 isoenzyme CYP1A2, by which ciclosporin is metabolised. The contribution of cannabis smoking to this case is unknown, but cannabis smoking alone is also known to induce CYP1A2, independent of tobacco. See Cannabis + Theophylline, page 113.

Importance and management
It is known that patients who smoke tobacco may experience lower serum ciclosporin levels and, although there is no direct evidence, this may equally apply to cannabis smoking. Irregular smoking of cannabis might cause fluctuations in ciclosporin levels.

Clinical evidence
No relevant data found.

Mechanism
Tobacco smoke contains aromatic hydrocarbons that are potent inducers of the cytochrome P450 isoenzyme CYP1A2, by which ciclosporin is metabolised. The contribution of cannabis smoking to this case is unknown, but cannabis smoking alone is also known to induce CYP1A2, independent of tobacco. See Cannabis + Theophylline, page 113.

Importance and management
It is known that patients who smoke tobacco may experience lower serum ciclosporin levels and, although there is no direct evidence, this may equally apply to cannabis smoking. Irregular smoking of cannabis might cause fluctuations in ciclosporin levels.

Clinical evidence
No relevant data found.

Mechanism
Tobacco smoke contains aromatic hydrocarbons that are potent inducers of the cytochrome P450 isoenzyme CYP1A2, by which ciclosporin is metabolised. The contribution of cannabis smoking to this case is unknown, but cannabis smoking alone is also known to induce CYP1A2, independent of tobacco. See Cannabis + Theophylline, page 113.

Importance and management
It is known that patients who smoke tobacco may experience lower serum ciclosporin levels and, although there is no direct evidence, this may equally apply to cannabis smoking. Irregular smoking of cannabis might cause fluctuations in ciclosporin levels.

Clinical evidence
No relevant data found.

Mechanism
Tobacco smoke contains aromatic hydrocarbons that are potent inducers of the cytochrome P450 isoenzyme CYP1A2, by which ciclosporin is metabolised. The contribution of cannabis smoking to this case is unknown, but cannabis smoking alone is also known to induce CYP1A2, independent of tobacco. See Cannabis + Theophylline, page 113.

Importance and management
It is known that patients who smoke tobacco may experience lower serum ciclosporin levels and, although there is no direct evidence, this may equally apply to cannabis smoking. Irregular smoking of cannabis might cause fluctuations in ciclosporin levels.

Clinical evidence
No relevant data found.

Mechanism
Tobacco smoke contains aromatic hydrocarbons that are potent inducers of the cytochrome P450 isoenzyme CYP1A2, by which ciclosporin is metabolised. The contribution of cannabis smoking to this case is unknown, but cannabis smoking alone is also known to induce CYP1A2, independent of tobacco. See Cannabis + Theophylline, page 113.

Importance and management
It is known that patients who smoke tobacco may experience lower serum ciclosporin levels and, although there is no direct evidence, this may equally apply to cannabis smoking. Irregular smoking of cannabis might cause fluctuations in ciclosporin levels.

Clinical evidence
No relevant data found.

Mechanism
Tobacco smoke contains aromatic hydrocarbons that are potent inducers of the cytochrome P450 isoenzyme CYP1A2, by which ciclosporin is metabolised. The contribution of cannabis smoking to this case is unknown, but cannabis smoking alone is also known to induce CYP1A2, independent of tobacco. See Cannabis + Theophylline, page 113.

Importance and management
It is known that patients who smoke tobacco may experience lower serum ciclosporin levels and, although there is no direct evidence, this may equally apply to cannabis smoking. Irregular smoking of cannabis might cause fluctuations in ciclosporin levels.

Clinical evidence
No relevant data found.
18% and cannabidiol 0.8%. The clearance and the AUC of docetaxel given on day 12 of the cannabis tea were not significantly altered, when compared with docetaxel given before the cannabis tea. The dose of docetaxel used was 180 mg, reduced to 135 mg in 2 patients who experienced dose-related docetaxel toxicity.1

**Experimental evidence**
No relevant data found.

**Mechanism**
Docetaxel is metabolised by the cytochrome P450 isoenzyme CYP3A4, and this does not appear to be affected by oral cannabis.

**Importance and management**
This study suggests that cannabis taken orally will not affect the pharmacokinetics of docetaxel. No dosage adjustments are likely to be needed if docetaxel is given with cannabis tea.1 It is not known if this applies to other drugs metabolised by CYP3A4, or to other preparations and routes of administration of cannabis, but see also Cannabis + Ciclosporin, page 110, and Cannabis + Irinotecan, below.

---

**Cannabis + Ecstasy**

The information regarding the use of cannabis with ecstasy is based on experimental evidence only.

**Evidence, mechanism, importance and management**
An animal study found that pretreatment with cannabidiol, a major constituent of cannabis, did not affect the levels of ecstasy (MDMA, methylenedioxymethylamphetamine) in the brain of mice.1


---

**Cannabis + Fluooxetine**

An isolated report describes mania when a patient taking fluoxetine smoked cannabis.

**Evidence, mechanism, importance and management**
A 21-year-old woman with a 9-year history of bulimia and depression was taking fluoxetine 20 mg daily. A month later, about 2 days after smoking two ‘joints’ of cannabis (marijuana), she experienced a persistent sense of well-being, increased energy, hypersexuality and pressured speech. These symptoms progressed into grandiose delusions, for which she was hospitalised. Her mania and excitement were controlled with lorazepam and perphenazine, and she largely recovered after about 8 days. The reasons for this reaction are not understood but the authors of the report point out that one of the active components of cannabis, dronabinol (Δ9-tetrahydrocannabinol), is, like fluoxetine, a potent inhibitor of serotonin uptake. Thus a synergistic effect on central serotonergic neurones might have occurred.1 This seems to be the first and only report of an apparent adverse interaction between cannabis and fluoxetine, but it emphasises the risks of concurrent use.


---

**Cannabis + Food**

No interactions found.

---

**Cannabis + Herbal medicines**

No interactions found.

---

**Cannabis + Nicotine**

The effects of transdermal nicotine and cannabis smoking on increasing the heart rate are additive, and nicotine increased the stimulant effect of cannabis. Combined use might increase the addictive potential of both drugs.

**Clinical evidence**
In a study in 20 healthy subjects who smoked either a low-dose or a high-dose cannabis cigarette 4 hours after the application of a placebo or a 21 mg nicotine patch, nicotine enhanced the maximum increase in heart rate seen with cannabis. The increase in heart rate for nicotine alone was between 10 and 15 bpm, for cannabis alone 32 and 42 bpm, for women and men, respectively, and, for the combination, 45 and 58 bpm, respectively. In addition, the duration of tachycardia after smoking the low-dose cannabis was prolonged by 30 minutes by nicotine, but was not changed after the high-dose cannabis. Nicotine increased the subjective stimulant effects of


---

**Cannabis + Herbal medicines**

No interactions found.
cannabis, but the reported duration of effects of cannabis were shortened by nicotine. Plasma levels of nicotine and Δ^9-tetrahydrocannabinol (THC) did not differ on concurrent use. The cannabis cigarettes were standardised to 1.99% THC (low dose) and 3.51% THC (high dose).^1

Experimental evidence
Studies in mice found that nicotine enhanced the effects of Δ^9-tetrahydrocannabinol in terms of hypolocomotion, hyperthermia and antinociceptive responses. Somatic signs of withdrawal from Δ^9-tetrahydrocannabinol were more severe in mice that had received nicotine.^2

Mechanism
Unknown. The additive effect on heart rate may be due to sympathetic activity of both drugs, and might also involve cannabinoïd receptors.\(^ \text{1}\)

Importance and management
Cannabis is often smoked with tobacco. The findings of the clinical study show that transdermal nicotine has additive effects with cannabis on heart rate, and increased the stimulant effect of cannabis. The clinical significance of these findings is uncertain.


Cannabis + Opioids
Low doses of cannabis enhanced the effect of morphine in three patients. Animal studies have shown that cannabinoids may enhance the potency of opioids.

Evidence, mechanism, importance and management
A report of 3 patients with chronic pain (due to multiple sclerosis, HIV-related peripheral neuropathy and lumbar spinal damage) found that small doses of smoked cannabis potentiated the antinociceptive effects of morphine. The patients were able to decrease the dose of opioid by 60 to 100%. Studies in animals have shown that Δ^9-tetrahydrocannabinol, the major psychoactive constituent of cannabis, enhances the potency of opioids such as morphine, codeine, hydromorphone, methadone, oxymorphone and pethidine (meperidine). It has been suggested that low doses of Δ^9-tetrahydrocannabinol given with low doses of morphine may increase opioid potency without increasing adverse effects.\(^ \text{3}\) Cannabis use in methadone-maintained patients did not appear to affect treatment progress, although some psychological difficulties were slightly more prevalent.\(^ \text{4}\) However, other workers have suggested that heavy cannabis use is associated with poorer progress when methadone is given in the treatment of opioid addiction.\(^ \text{5}\)


Cannabis + Phencyclidine
The interaction between cannabis and phencyclidine is based on experimental evidence only.

Clinical evidence
No interactions found.

Experimental evidence
An animal study found that pretreatment with cannabidiol significantly increased the levels of phencyclidine in the brain and blood of mice. Behavioural tests indicated that the increase in brain levels led to an increase in intoxication caused by phencyclidine. When the study was repeated using Δ^9-tetrahydrocannabinol in doses of 120 mg/kg, the brain levels of phencyclidine were increased twofold. Lower doses of Δ^9-tetrahydrocannabinol did not result in such an effect.\(^ \text{1}\)

Mechanism
Unknown.

Cannabis + NSAIDs
Indomethacin appears to antagonise some of the effects of cannabis, and cannabis might antagonise the analgesic efficacy of NSAIDs.

Clinical evidence
Four healthy subjects were given placebo or indomethacin 25 mg three times daily for one day, and then a single-dose 2 hours before smoking cannabis 400 micrograms/kg on the following day. Indomethacin did not alter the pharmacokinetics of Δ^9-tetrahydrocannabinol. Subjective measures of heart rate acceleration and intoxication were modestly attenuated by indomethacin. Subjects also reported that the effects of marihuana on time perception were antagonised by indomethacin.\(^ \text{1}\)

Experimental evidence
In a study rabbits received placebo or 2% indomethacin applied topically to both eyes one hour prior to an intravenous injection of Δ^9-tetrahydrocannabinol. The fall in intraocular pressure caused by Δ^9-tetrahydrocannabinol was inhibited by topical indomethacin.

In an animal model of analgesia, chronic treatment with Δ^9-tetrahydrocannabinol markedly reduced the efficacy of aspirin, celecoxib, indomethacin, ketorolac and naproxen, and reduced the potency of diclofenac and paracetamol (acetaminophen).\(^ \text{2}\)

Mechanism
It is suggested that prostaglandins have some part to play in some of the effects of cannabis, and that these are antagonised by indomethacin, which is a prostaglandin inhibitor.\(^ \text{1,3}\) Similarly, cannabis antagonises the effects of NSAIDs.\(^ \text{2}\)

Importance and management
The effects of indomethacin on the subjective measures and intraocular pressure-lowering effects of Δ^9-tetrahydrocannabinol are probably not of clinical significance. However, the relevance of the finding that chronic use of Δ^9-tetrahydrocannabinol might result in reduced efficacy and potency of NSAIDs requires further study.

Importance and management
This preclinical study provides some evidence that cannabis might increase the abuse potential of phencyclidine.


Cannabis + Phenytoin

There is one in vitro study suggesting that Δ9-tetrahydrocannabinol, a major constituent of cannabis, might induce phenytoin metabolism. Note that, in clinical use dronabinol has induced seizures.

Clinical evidence
No interactions found.

Experimental evidence
In an in vitro study in which human liver microsomes were incubated with phenytoin alone, or phenytoin and Δ9-phenytoin levels, note that there are no reports in the literature of cannabis use affecting confirmation before any recommendations can be made. Note also cytochrome P450 isoenzyme CYP2C9 increased when combined with cannabidiol.2

Mechanism
The in vitro data suggest that Δ9-tetrahydrocannabinol induces the cytochrome P450 isoform CYP2C9.1

Importance and management
This appears to be the only evidence that cannabis might affect phenytoin levels, and is only in vitro data. As such, it requires confirmation before any recommendations can be made. Note also that there are no reports in the literature of cannabis use affecting phenytoin levels. Note that oral dronabinol (Δ9-tetrahydrocannabinol) has caused seizures in clinical use, and the manufacturer recommends caution in those with a seizure disorder.3


Cannabis + Protease inhibitors

The short-term use of cannabis cigarettes or dronabinol (Δ9-tetrahydrocannabinol) did not appear to adversely affect indinavir or nelfinavir levels or viral loads in HIV-positive patients.

Clinical evidence
In 9 HIV-positive patients on a stable regimen containing indinavir (mostly 800 mg every 8 hours), smoking a cannabis cigarette (3.95% tetrahydrocannabinol) three times daily before meals for 14 days resulted in a median 14% decrease in AUC and maximum level and a 34% decrease in minimum indinavir level. However, only the change in maximum level was statistically significant.1 Similarly, dronabinol (Δ9-tetrahydrocannabinol) 2.5 mg three times daily for 14 days had no significant effect on indinavir pharmacokinetics.1

In another 11 patients on a stable regimen containing nelfinavir 750 mg three times daily, there was a non-significant 10% decrease in AUC, 17% decrease in maximum level and 12% decrease in minimum nelfinavir level after 14 days of cannabis cigarettes.1 Similarly, dronabinol 2.5 mg three times daily for 14 days had no significant effect on nelfinavir pharmacokinetics.1

There was no adverse effect on viral load or CD4 count in the patients receiving cannabis cigarettes or dronabinol.2

Experimental evidence
No relevant data found.

Mechanism
No mechanism expected.

Importance and management
Short-term use of cannabis cigarettes or dronabinol does not appear to have any important effect on levels of indinavir or nelfinavir, nor on markers of HIV infection.


Cannabis + Sildenafil

Myocardial infarction occurred in a man who had smoked cannabis and taken a tablet of sildenafil.

Clinical evidence
A 41-year old man with no history of cardiac disease experienced a myocardial infarction after smoking cannabis and recreationally taking a tablet of sildenafil (strength not specified). Later tests showed that he had no evidence of inducible ischaemia.1

Experimental evidence
No relevant data found.

Mechanism
Myocardial infarction is a rare adverse effect of sildenafil alone. It was suggested that the metabolism of sildenafil by cytochrome P450 isoenzyme CYP3A4 might be inhibited by constituents of cannabis such as cannabidiol, thereby increasing the risk of adverse events. However, in clinical studies, oral cannabis did not alter levels of other CYP3A4 substrates. These included Cannabis + Irinotecan, page 111, and Cannabis + Docetaxel, page 110.

Importance and management
The vasodilatory effects of sildenafil necessitate caution in its use in patients with cardiovascular disease; myocardial infarction has rarely been associated with its use. The contribution of an interaction to this case is unclear, but bear the possibility in mind in the event of adverse effects on concurrent use.


Cannabis + Theophylline

Cannabis smokers may need more theophylline than non-smokers to achieve the same therapeutic benefits, because the theophylline is cleared from the body more quickly.

Evidence, mechanism, importance and management
One study found that tobacco or cannabis smoking similarly caused higher total clearances of theophylline (given as oral aminophylline) than in non-smokers (about 74 mL/kg per hour compared with...
52 mL/kg per hour), and that clearance was even higher (93 mL/kg per hour) in those who smoked both. A later analysis by the same authors, of factors affecting theophylline clearance, found that smoking two or more joints of cannabis weekly was associated with a higher total clearance of theophylline than non-use (82.9 mL/kg per hour versus 56.1 mL/kg per hour).

Tobacco and cannabis smoke contain polycyclic hydrocarbons, which act as inducers of the cytochrome P450 isoenzyme CYP1A2, and this results in a more rapid clearance of theophylline from the body.

Little is known about the effects of smoking cannabis on theophylline levels, but be alert for the need to increase the theophylline dosage in regular users. Note that irregular cannabis use might cause fluctuations in theophylline levels.


Cannabis + Tricyclic antidepressants

Tachycardia has been described when patients taking tricyclic antidepressants smoked cannabis.

Evidence, mechanism, importance and management

A 21-year-old woman taking nortriptyline 30 mg daily experienced marked tachycardia (an increase from 90 to 160 bpm) after smoking a cannabis cigarette. It was controlled with propranolol. A 26 year old complained of restlessness, dizziness and tachycardia (120 bpm) after smoking cannabis while taking imipramine 50 mg daily. Four adolescents aged 15 to 18 taking tricyclic antidepressants for attention-deficit hyperactivity disorder had transient cognitive changes, delirium and tachycardia after smoking cannabis.

Increased heart rates are well-documented adverse effects of both the tricyclic antidepressants and cannabis, and what occurred was probably due to the additive beta-adrenergic and antimuscarinic effects of the tricycles, with the beta-adrenergic effect of the cannabis. Direct information is limited but it has been suggested that concurrent use should be avoided.

**Capsicum**

*Capsicum* species (Solanaceae)

**Synonym(s) and related species**
Caspic, Cayenne, Cayenne pepper, Chili pepper, Chilli pepper, Hot pepper, Paprika, Red pepper, Tabasco pepper.


**Pharmacopoeias**

**Constituents**
The pungent principles of capsicum are the capsaicinoids (to which it may be standardised), present in concentrations up to 1.5%, but more usually around 0.1%. The major components are capsaicin, 6,7-dihydrocapsaicin, nordihydrocapsaicin, homodihydrocapsaicin and homocapsaicin. Other constituents include the carotenoid pigments (capsanthin, capsorubin, carotene, lutein), vitamins including A and C, and a small amount of volatile oil.

**Use and indications**
Capsicum possesses stimulant, antispasmodic, carminative and counterirritant effects, which has led to its use in conditions such as colic and flatulent dyspepsia, and to increase peripheral circulation. Topical preparations are used for neuralgia including rheumatic pains and unbroken chilblains.

Capsicum is frequently eaten as part of the diet and, in particular, diets that contain spicy foods. It has been estimated that the average consumption of dietary spice from capsicum fruit is 2.5 g/person per day in India and 5 g/ person per day in Thailand. As the capsaicin content in capsicum fruit is approximately 1%, the daily dietary intake of capsaicin may range from 0.5 to 1 mg/kg per day for a 50 kg person.

**Pharmacokinetics**
*In vitro* study suggests that many of the cytochrome P450 enzymes are involved in the metabolism of capsaicinoids, by dehydrogenation, oxygenation, hydroxylation and O-demethylation. Principal isoenzymes thought to be involved are CYP2C9, CYP2E1 and to some extent CYP3A4.

Some metabolites of the capsaicinoids are thought to inhibit CYP2E1, and a study with phenazone, page 117, a probe drug for hepatic enzyme activity, suggests that capsaicin may inhibit hepatic enzymes, although the lack of interaction seen with theophylline, page 118, a substrate for CYP1A2, suggests that this isoenzyme is not significantly affected. A further *in vitro* study has shown that the acute use of capsaicin inhibits P-glycoprotein whereas long-term exposure induces P-glycoprotein, see digoxin, page 116.

**Interactions overview**
Capsicum has the potential to decrease the absorption of aspirin, increase the absorption of ciprofloxacin and theophylline, and alter the absorption of cefalexin and digoxin. However, the clinical effects of these changes are unknown, not established or not clinically significant. Capsicum may also decrease the metabolism of pentobarbital and phenazone, but it does not alter the metabolism of theophylline or quinine, which suggests that it has selective effects on hepatic enzymes.

Capsicum + Aspirin

The interaction between capsicum and aspirin is based on experimental evidence only.

Clinical evidence
No interactions found.

Experimental evidence
A study in rats given oral aspirin 20 mg/kg found that the acute administration of a standardised extract of Capsicum annuum 100 mg/kg (equivalent to 10 mg/kg capsaicin) reduced the AUC and maximum serum levels of salicylic acid by 44% and 26%, respectively. The effect was dose related, with a 300-mg/kg dose of Capsicum annuum reducing the AUC and maximum serum levels of salicylic acid by 59% and 51%, respectively. Similar, but greater, results were found when aspirin was given to rats that had been treated with Capsicum annuum extract for 4 weeks.

Mechanism
It seems likely that capsaicin alters gastric motility, which reduces aspirin absorption and results in decreased salicylic acid levels.

Importance and management
Evidence is limited, but capsaicin appears to decrease aspirin bioavailability. However, the clinical significance of this effect is unclear, especially as the capsaicin dose used in the study is 10-fold greater than the expected dietary intake in countries where a spicy diet is typically eaten, and many times higher than the expected exposure if capsaicin is given as a cream, or ingested as a medicinal product. More study is needed before any clinical recommendations can be made.


Capsicum + Cefalexin

The interaction between capsicum and cefalexin is based on experimental evidence only.

Clinical evidence
No interactions found.

Experimental evidence
An in vitro study using animal tissue found that high concentrations of capsaicin instilled into rat intestines resulted in a lower rate of absorption of cefalexin.

Mechanism
It was suggested that the capsaicin affected the transport channels in the intestine through which cefalexin is absorbed.

Importance and management
Evidence appears to be limited to this study. Although the rate of cefalexin absorption was decreased the total amount of cefalexin absorbed was not studied, and therefore no conclusions can be drawn on the possible clinical relevance of the findings.


Capsicum + Ciprofloxacin

The interaction between capsicum and ciprofloxacin is based on experimental evidence only.

Clinical evidence
No interactions found.

Experimental evidence
A study in which rats were given oral ciprofloxacin 20 mg/kg with placebo, or capsaicin in concentrations of 0.01%, 0.1%, 0.5% or 1%, found that the maximum levels and AUC of ciprofloxacin increased with increasing concentrations of capsaicin up to 0.5%. The increase in AUC was 49%, 51%, 68% and 15% for capsaicin 0.01%, 0.1%, 0.5% or 1%, respectively.

Mechanism
It is possible that the irritant nature of the capsaicin increased blood flow to the gastrointestinal absorption site or, alternatively, the rate of gastric emptying was increased, so ciprofloxacin reached the duodenum more quickly, where the pH enhances its absorption.

Importance and management
Evidence appears to be limited to this study. The doses of the antibacterial and capsaicin were chosen to reflect those likely to be encountered clinically, and those encountered within dietary levels, respectively. Therefore if these findings are replicated in humans it seems possible that a clinically relevant rise in ciprofloxacin levels could occur; however, given the magnitude of the rise, the effect seems most likely to be beneficial rather than adverse, although more study is needed to establish this.


Capsicum + Digoxin

The interaction between capsicum and digoxin is based on experimental evidence only.

Clinical evidence
No interactions found.

Experimental evidence
In an in vitro study, P-glycoprotein function was assessed by looking at the transport of digoxin, a known substrate of this transporter protein. In the presence of capsaicin the transport of digoxin across cells was enhanced, suggesting that capsaicin induces P-glycoprotein.

Mechanism
Capsaicin may induce P-glycoprotein.

Importance and management
Evidence is limited and difficult to extrapolate to a clinical situation. The study found that the acute use of capsaicin inhibited P-glycoprotein, whereas long-term exposure induced P-glycoprotein. Clinically, P-glycoprotein induction has resulted in reduced digoxin absorption from the intestine and increased biliary excretion, the end result being a reduction in digoxin levels. Whether capsaicin would initially raise then subsequently lower digoxin levels remains to be established, but it may be prudent to consider the possibility of this effect if large doses of capsaicin are given systemically.

Capsicum + Food

No interactions found. Capsicum is widely used as a spice in food.

Capsicum + Herbal medicines

No interactions found.

Capsicum + Iron compounds

Capsicum modestly reduces the absorption of dietary iron.

Clinical evidence
In a randomised, crossover study, 30 healthy women were given a standard Thai meal (fortified with about 4 mg of isotopically labelled ferrous sulfate), with soup, to which 4.2 g of ground Capsicum annuum had been added. Capsicum annuum reduced iron absorption by about 38%.

Experimental evidence
No relevant data found.

Mechanism
Uncertain. It was thought that polyphenols in Capsicum annuum may inhibit iron absorption.

Importance and management
The study suggests that capsicum inhibits the absorption of dietary levels of iron. The levels of capsicum used were high, but they are not unusual in a typical Thai meal. However, the effects of capsicum on iron supplementation (e.g. ferrous sulfate in doses of 200 mg) does not appear to have been studied, so it is difficult to predict the effect of the use of capsicum as a herbal medicine on iron replacement therapy. However, consider this interaction if a patient taking capsicum supplements has a poor response to iron replacement therapy.


Capsicum + Pentobarbital

The interaction between capsicum and pentobarbital is based on experimental evidence only.

Clinical evidence
No interactions found.

Experimental evidence
In a placebo-controlled study, rats were given capsaicin 25 mg/kg daily for 7 days, followed by a single 10-mg intravenous dose of phenazone. It was found that capsaicin increased the half-life of phenazone by 28%, and increased the AUC of phenazone by 43%.

Mechanism
Capsaicin inhibits the metabolism of phenazone by hepatic enzymes.

Importance and management
Evidence is limited to this study in rats. Although rises in phenazone levels of this magnitude may be of clinical relevance, the dose of capsaicin used in the study was very high, so it seems unlikely that these effects would be reproduced with clinical or dietary quantities of capsaicin.


Capsicum + Phenazone (Antipyrine)

The interaction between capsicum and phenazone is based on experimental evidence only.

Clinical evidence
No interactions found.

Experimental evidence
In a placebo-controlled study, rats were given capsaicin 25 mg/kg daily for 7 days, followed by a single 10-mg intravenous dose of phenazone. It was found that capsaicin increased the half-life of phenazone by 28%, and increased the AUC of phenazone by 43%.

Mechanism
Capsaicin inhibits the metabolism of phenazone by hepatic enzymes.

Importance and management
Evidence is limited to this study in rats. Although rises in phenazone levels of this magnitude may be of clinical relevance, the dose of capsaicin used in the study was very high, so it seems unlikely that these effects would be reproduced with clinical or dietary quantities of capsaicin.


Capsicum + Quinine

The information regarding the use of capsicum with quinine is based on experimental evidence only.

Clinical evidence
No interactions found.

Experimental evidence
In a placebo-controlled study, rats were given capsaicin 25 mg/kg daily for 7 days, followed by a single 25-mg/kg intravenous dose of quinine. It was found that capsaicin had no effect on the pharmacokinetics of quinine.

Mechanism
No mechanism expected.

Importance and management
Evidence is limited to this study in rats. If the findings are replicated in humans it seems likely that capsaicin could increase the response to pentobarbital. Therefore if patients taking pentobarbital are given systemic capsaicin it may be prudent to warn them that prolonged drowsiness may occur.

Capsicum + Theophylline

Although capsicum may slightly increase the absorption of theophylline, it does not appear to be clinically relevant.

Clinical evidence
A study in 6 healthy subjects found that the absorption of theophylline 400 to 500 mg was increased after they ate a spicy meal, when compared with a European standard meal: the AUC$_{0-6}$ and AUC$_{0-12}$ were increased by 23% and 15%, respectively.\textsuperscript{1}

Experimental evidence
In a study, rabbits were given a single intravenous 12-mg/kg dose of theophylline either with a single dose of ground capsicum suspension, or after 7 days of treatment with ground capsicum suspension. Capsicum did not affect the pharmacokinetics of theophylline, apart from a 40% increase in the elimination rate constant after the single dose of capsicum.\textsuperscript{2}

A previous study by the same authors found that a ground capsicum fruit suspension, given at the time of the theophylline dose and 11 hours later, increased the AUC of a 20-mg/kg oral dose of theophylline, and increased peak theophylline levels by 33%.\textsuperscript{3}

In contrast, a placebo-controlled study in rats given capsaicin 25 mg/kg daily for 7 days followed by a single 10-mg/kg intravenous dose of theophylline, given as aminophylline, found that capsaicin did not affect the pharmacokinetics of theophylline.\textsuperscript{4}

Mechanism
Capsaicin has been shown in animal studies to increase mesenteric blood flow, which may result in increased absorption of theophylline.\textsuperscript{3}

Importance and management
The evidence suggests that capsaicin has only modest effects on the pharmacokinetics of theophylline. The clinical study found an increase in the theophylline AUC of about 20%, which would not generally be expected to be clinically relevant. It would therefore appear that no specific additional precautions are necessary if patients taking theophylline also take capsaicin.


Cascara
*Rhamnus purshiana* DC. (Rhamnaceae)

**Synonym(s) and related species**
Cascara sagrada, Chittem bark, Rhamnus, Sacred bark. *Frangula purshiana* Cooper.

**Pharmacopoeias**
Cascara (*BP 2009, Ph Eur 6.4*); Standardised Cascara Dry Extract (*BP 2009, Ph Eur 6.4*); Cascara Sagrada (*USP 32*).

**Constituents**
Anthraquinone glycosides are major components of cascara and include cascarosides A, B, C, D, E and F, aloins A and B, and chrysaloins A and B. Aloe-emodin, barbaloin, cryosophanol, emodin, frangulin and physcion are also present in small amounts, as are resins and tannins.

**Use and indications**
Cascara bark is used as a laxative.

**Pharmacokinetics**
For information on the pharmacokinetics of an anthraquinone glycoside present in cascara, see under aloes, page 27.

**Interactions overview**
No interactions with cascara found; however, cascara (by virtue of its anthraquinone content) is expected to share some of the interactions of a number of other anthraquinone-containing laxatives, such as aloes, page 27 and senna, page 349. Of particular relevance are the interactions with corticosteroids, digitalis glycosides and potassium-depleting diuretics.
**Cat’s claw**

*Uncaria tomentosa* DC., *Uncaria guianensis* J.F.Gmel. (Rubiaceae)

**Synonym(s) and related species**
Life-giving vine of Peru, Samento, Savéntaro, Uña de gato.

**Pharmacopoeias**
Cat’s Claw (USP 32); Powdered Cat’s Claw (USP 32); Powdered Cat’s Claw Extract (USP 32); Cat’s Claw Tablets (USP 32); Cat’s Claw Capsules (USP 32).

**Constituents**
The main constituents of both the closely related species of cat’s claw include the tetracyclic oxindole alkaloids, isorhynchophylline and rhynchophylline, and the indole alkaloids, dihydrocorynantheine, hirsutine, and hirsuteine. Quinovic acid glycosides have also been isolated.

Note that there are two chemotypes of *Uncaria tomentosa*, one primarily containing the tetracyclic oxindole alkaloids, isorhynochophylline and rhynchophylline, and one primarily containing the pentacyclic oxindole alkaloids, (iso)pteropodine and (iso)mitraphylline.

**Use and indications**
Cat’s claw roots, bark and leaves have been used for gastric ulcers, arthritis, gonorrhoea, dysentry, herpes zoster, herpes simplex and HIV, and as a contraceptive. In various preclinical studies, antiviral, anti-inflammatory, antirheumatic, immunostimulating, antimutagenic, antitumour and hypotensive properties have been shown. There is some evidence that the tetracyclic oxindole alkaloids antagonise the immunomodulating effects of the pentacyclic oxindole alkaloids, and some preparations for arthritis are standardised to contain little or no tetracyclic oxindole alkaloids. Other preparations are essentially free of oxindole alkaloids.

**Pharmacokinetics**
In two in vitro studies,1,2 alcoholic extracts of *Uncaria tomentosa* were found to be a potent inhibitors of the cytochrome P450 isoenzyme CYP3A4. Inhibitory effects on CYP2D6, CYP2C9 and CYP2C19 were minor (in order of decreasing potency).2 It was suggested that *Uncaria tomentosa* might have the potential to interfere with the metabolism of substrates of CYP3A4,1 but note that St John’s wort was an inhibitor of CYP3A4 in this study, whereas, clinically (multiple dose use), it is an inducer of CYP3A4. This serves as a reminder that in vitro studies cannot be directly extrapolated to the clinical situation, and that the findings need confirmation in a clinical setting.

**Interactions overview**
Cat’s claw has some antiplatelet and antihypertensive effects, which may be additive to those of conventional drugs. Data from a clinical study suggest that cat’s claw may safely be given with sulfasalazine and hydroxychloroquine. An isolated case reports an increase in the levels of atazanavir, ritonavir and saquinavir in a patient also taking cat’s claw.

The interaction between cat’s claw and antihypertensives is based on experimental evidence only.

**Clinical evidence**
No interactions found.

**Experimental evidence**
Isorhynchophylline 10 mg/kg, a tetracyclic oxindole alkaloid from cat’s claw, given intravenously was found to lower systolic arterial blood pressure, diastolic arterial blood pressure and heart rate by about 9%, 21% and 14%, respectively, in normotensive rats and about 9%, 6% and 19%, respectively, in hypertensive rats in an experimental study. The effect appears to be dose dependent because isorhynchophylline 20 mg/kg, given via the duodenum, lowered the systolic pressure by about 25%, diastolic pressure by about 38% and heart rate by about 25% in normotensive rats. A similar effect was seen in dogs.1

**Mechanism**
It is suggested that the hypotensive effect is mainly due to a vasodilating effect and transient reduction in the heart rate and force of cardiac contraction.1 Additive blood pressure-lowering effects with conventional antihypertensives might therefore occur.

**Importance and management**
Evidence appears to be limited to experimental data and an interaction is not established. Uncaria species are commonly used in traditional medicine for hypertension, and the preclinical evidence shows that isorhynchophylline, a tetracyclic oxindole alkaloid from cat’s claw, has antihypertensive activity. However, not all varieties of Uncaria tomentosa contain isorhynchophylline, and some preparations are specifically standardised not to contain this constituent, so not all cat’s claw products will interact. Nevertheless, despite the lack of clinical evidence, there is the potential for an additive blood pressure-lowering effect if cat’s claw containing isorhynchophylline is given with any antihypertensive. Concurrent use need not be avoided, but patients should be made aware of the possibility of increased antihypertensive effects.


### Cat’s claw + Antihypertensives

**Evidence, mechanism, importance and management**
A cat’s claw preparation (without tetracyclic oxindole alkaloids) was used for 52 weeks in a small clinical study in patients taking sulphasalazine or hydroxychloroquine. There were no safety concerns from the use of the combination when compared with placebo, and a modest clinical benefit.1 Although this study does not exclude the possibility of a drug interaction, it provides some evidence that cat’s claw can be combined with these established drugs without a problem.


### Cat’s claw + Antirheumatics

**No additional adverse effects appear to occur when cat’s claw is taken with sulphasalazine or hydroxychloroquine.**

### Cat’s claw + Food

**No interactions found.**

### Cat’s claw + Herbal medicines

**No interactions found.**

### Cat’s claw + Protease inhibitors

**An isolated case report describes raised atazanavir, ritonavir and saquinavir levels following the use of cat’s claw.**

**Clinical evidence**
An HIV-positive woman awaiting liver transplantation, taking atazanavir 300 mg daily, ritonavir 100 mg daily and saquinavir 1 g daily, in combination with abacavir 600 mg daily and lamivudine 300 mg daily, was found to have an increased trough level of all three protease inhibitors. Atazanavir trough levels were 1.22 micrograms/mL (expected range of 0.15 to 0.18 micrograms/mL), ritonavir trough levels were 6.13 micrograms/mL (expected level...
of 2.1 micrograms/mL and saquinavir trough levels were 3.4 micrograms/mL (expected range 0.1 to 0.25 micrograms/mL). On further questioning, the patient reported no change in her compliance with the medication but reported that she been taking a herbal supplement containing cat’s claw for the previous 2 months. No evidence of protease inhibitor-related toxicity was found and the patient reported no adverse effects. The supplement was stopped and by day 15 the levels of all three drugs had returned to within normal limits.1

**Experimental evidence**
No relevant data found.

**Mechanism**
An *in vitro* studies suggested that cat’s claw may inhibit the cytochrome P450 isoenzyme CYP3A4, the main isoenzyme responsible for the metabolism of atazanavir, ritonavir and saquinavir; however, the results of this study are questionable. See under Pharmacokinetics, page 120.

**Importance and management**
Evidence appears to be limited to one case report from which it is difficult to draw general conclusions. What it illustrates is that more research is needed into the use of cat’s claw with protease inhibitors. Patients taking drugs for serious conditions such as HIV infection should carefully consider the risks and benefits of adding herbal medicines to their existing regimen, where the outcome of concurrent use is unknown.

Celery

*Apium graveolens* L. (Apiaceae)

**Synonym(s) and related species**
Apium, Celery fruit, Celery seed, Smallage, Wild celery.
Not to be confused with celery stem, which is commonly eaten as a salad vegetable.

**Constituents**
The fruits of celery (usually referred to as ‘seeds’) contain a volatile oil mainly composed of limonene (about 60%) and selinene. Other important constituents are the flavonoids (notably apigenin and isoquercitrin) and natural coumarins (bergapten, isoimperatorin, osthinsol, umbelliferone and 8-hydroxy-5-methoxypsoralen), some of which may cause photosensitivity; however, celery seed oil has been reported to be non-phototoxic in humans. Note that celery stem contains much lower levels of the phototoxic natural coumarins; even so, cases of phototoxicity have been reported.

**Use and indications**
Celery seed is traditionally used for joint inflammation (including rheumatism), gout and urinary tract inflammation.

**Pharmacokinetics**
No relevant pharmacokinetic data found for celery seed, but see flavonoids, page 186, and natural coumarins, page 297, for information on these constituents present in the herb.

**Interactions overview**
No interactions with celery seed found. For information on the interactions of individual flavonoids present in celery seed, see flavonoids, page 186. Although celery seed contains natural coumarins, the quantity of these constituents is not established, and therefore the propensity of celery seed to interact with other drugs because of their presence is unclear. Consider natural coumarins, page 297, for further discussion of the interactions of coumarin-containing herbs.
Centaury

_Centaurium erythraea_ Rfn. (Gentianaceae)

**Synonym(s) and related species**
Century, Common centaury, Feverwort.


**Pharmacopoeias**
Centaury (BP 2009, Ph Eur 6.4).

**Constituents**
The iridoids (bitters) are considered to be the main active constituents of centaury, and include _gentiopicroside_ (about 2%), with centapicrin, gentioflavoside, sweroside and swertiamarin and _m_-hydroxybenzoylesters of sweroside, and catapicrin. Highly methylated xanthones, including eustomin and 8-demethyleustomin, have been found recently. Alkaloids of the pyridine type, including gentianine, gentianidine, gentioflavine, are also found in trace amounts. The triterpenoids _α_- and _β_-amyrin, erythrodiol, crataegolic acid, oleanolic acid and sitosterol are also present.

**Use and indications**
Centaury is used for disorders of the upper digestive tract, mainly dyspepsia. It is also used in anorexia and has reported anti-inflammatory activity. It should not be taken by patients with peptic ulceration.

**Pharmacokinetics**
No relevant pharmacokinetic data found.

**Interactions overview**
No interactions with centaury found.
Chamomile, German

*Matricaria recutita* L. (Asteraceae)

**Synonym(s) and related species**
Chamomilla, Hungarian chamomile, Matricaria flower, Scented mayweed, Single chamomile, Sweet false chamomile, Wild chamomile.

*Chamomilla recutita* (L.) Rauschert, *Chamomilla vulgaris* SF Gray, *Matricaria chamomilla* L.

**Pharmacopoeias**
Chamomile (*USP 32*).

** Constituents**
The flowerheads of German chamomile contain essential oil composed mainly of (−)-α-bisabolol. Sesquiterpenes and proazulenes (e.g. matricarid and matricin) are also present. Chamazulene (1 to 15%), another volatile oil found in chamomile, is formed from matricin during steam distillation of the oil. Other constituents present in chamomile include flavonoids (apigenin, luteolin, quercetin, rutin), and the natural coumarins umbelliferone and its methyl ether, heniarin.

**Use and indications**
German chamomile is used for dyspepsia, flatulence and travel sickness, especially when the gastrointestinal disturbance is associated with nervous disorders. It is also used for nasal catarrh and restlessness. German chamomile is widely used in babies and children as a mild sedative, and to treat colic and teething pain. It has been used topically for haemorrhoids, mastitis and leg ulcers.

**Pharmacokinetics**
*In vitro* studies have found that a commercial ethanolic extract of *Matricaria chamomilla* and a crude *Matricaria recutita* essential oil extract inhibited the cytochrome P450 isoenzyme CYP3A4. However, the effects were weak when compared with the known potent CYP3A4 inhibitor ketoconazole.

A crude *Matricaria recutita* essential oil extract has also been found to moderately inhibit CYP1A2 *in vitro*. Similarly, a study using liver microsomes from rats pretreated with chamomile tea 2% for 4 weeks (*Vita Fit Nutrition*, made from the dried flower heads of *Matricaria chamomilla* and *Matricaria recutita*) found that CYP1A2 activity was reduced to 39%, when compared with the control group.

A crude *Matricaria recutita* essential oil extract had no significant effect on the cytochrome P450 isoenzymes CYP2C9 and CYP2D6.

For information on the pharmacokinetics of individual flavonoids present in German chamomile, see under flavonoids, page 186.

**Interactions overview**
An isolated case of bleeding in a patient taking warfarin and using chamomile products has been reported. No other relevant drug interactions have been found for German chamomile. For information on the interactions of individual flavonoids present in German chamomile, see under flavonoids, page 186.

Chamomile, German + Food

No interactions found.

Chamomile, German + Herbal medicines

No interactions found.

Chamomile, German + Iron compounds

Chamomile tea (an infusion of *Matricaria chamomilla*) does not appear to affect iron absorption.

Evidence, mechanism, importance and management

A study in 13 healthy subjects found that chamomile tea (an infusion of *Matricaria chamomilla*) sweetened with *panela* (an unrefined cane sugar sweetener containing fructose) did not affect the absorption of iron from an iron-fortified bread, when compared with the absorption of iron from the bread alone.1 The tannin content of the chamomile tea was reported to be 24.5 mg in 100 mL. This is much less than the tannin content of black tea, which is known to reduce iron absorption. See Tea + Iron compounds, page 386. This level of tannins did not appear to affect iron absorption in this particular study and it would therefore appear that chamomile tea may be taken without impairing iron absorption.


Chamomile, German + Warfarin

A single case report describes a woman stabilised on warfarin who developed a marked increase in her INR with bleeding complications 5 days after she started using two chamomile products.

Clinical evidence

A 70-year-old woman stabilised on warfarin with an INR of 3.6 started drinking 4 to 5 cups of chamomile tea (an infusion of *Matricaria chamomilla*) daily for chest congestion, and using a chamomile-based skin lotion 4 to 5 times daily for foot oedema. About 5 days later she developed ecchymoses and was found to have an INR of 7.9, a retroperitoneal haematoma and other internal haemorrhages.1

Experimental evidence

No relevant evidence found.

Mechanism

German chamomile contains the natural coumarin compounds, umbelliferone and heniarin. However, these compounds do not possess the minimum structural requirements (a C-4 hydroxyl substituent and a C-3 non-polar carbon substituent) required for anticoagulant activity. German chamomile essential oil extracts do not appear to significantly affect the cytochrome P450 isoenzyme CYP2C9, the main isoenzyme involved in the metabolism of warfarin, but the effects of chamomile tea do not appear to have been studied.

Importance and management

This appears to be the first report of an interaction between warfarin and German chamomile. There seem to be no reports of German chamomile alone causing anticoagulation, and the natural coumarin constituents of German chamomile do not appear to possess anticoagulant activity, which might suggest that the risk of an additive effect is small. Furthermore, a pharmacokinetic basis for this interaction has not been established. Because of the many other factors influencing anticoagulant control, it is not possible to reliably ascribe a change in INR specifically to a drug interaction in a single case report without other supporting evidence. It may be better to advise patients to discuss the use of any herbal products that they wish to try, and to increase monitoring if this is thought advisable. Cases of uneventful use should be reported, as they are as useful as possible cases of adverse effects.

Chamomile, Roman

*Chamaemelum nobile* (L.) All (Asteraceae)

**Synonym(s) and related species**
Chamomile, Double chamomile, English chamomile, Manzanilla.
*Anthemis nobilis* L.

**Pharmacopoeias**
Chamomile Flowers (*BP 2009*); Chamomile Flower, Roman (*Ph Eur 6.4*).

**Constituents**
The flowerheads contain an essential oil composed mainly of esters of angelic and tiglic acids, with 1,8-cineole, *trans-*pinocarveol, *trans-*pinocarvone, chamazulene, farnesol, nerolidol, various germacranolide-type sesquiterpene lactones, amyl and isobutyl alcohols, and anthemol. The *flavonoids* apigenin, luteolin, quercetin with their glycosides, and the natural coumarin scopoletin-7-glucoside, are also present.

Chamazulene is formed from a natural precursor during steam distillation of the oil.

**Use and indications**
Roman chamomile is used as a carminative, anti-emetic, antispasmodic, and sedative for dyspepsia, nausea and vomiting, anorexia and dysmenorrhoea. It is widely used as a topical preparation for the hair.

**Pharmacokinetics**
No relevant pharmacokinetic data found. For information on the pharmacokinetics of individual flavonoids found in Roman chamomile, see under flavonoids, page 186.

**Interactions overview**
No interactions with Roman chamomile found, but, for information on the interactions of individual flavonoids found in Roman chamomile, see under flavonoids, page 186.
Chaparral

*Larrea tridentata* Coville (Zygophyllaceae)

**Synonym(s) and related species**
Creosote bush.

*Larrea divaricata* Cav. (formerly regarded as the same species as *Larrea tridentata*), *Larrea mexicana* Moric., *Larrea tridentate* var. *glutinosa* Jeps.

**Constituents**
Chaparral contains lignans, the major compound being *nordihydroguaiaretic acid* (NDGA). The herb also contains flavonoids, which include isorhamnetin, kaempferol and quercetin, and their derivatives. There is also a volatile oil present containing calamene, eudesmol, limonene, α- and β-pinene, and 2-rossalene. A cytotoxic naphthoquinone derivative, larreantin, has been isolated from the roots.

**Use and indications**
Chaparral has been used in the treatment of bowel cramps, arthritis, rheumatism and colds. It has also been used to treat other diseases such as cancer, venereal disease and tuberculosis. Its use as a herbal remedy is not recommended due to reports of hepatotoxicity and renal toxicity.

**Pharmacokinetics**
No relevant pharmacokinetic data found. For information on the pharmacokinetics of individual flavonoids present in chaparral, see under flavonoids, page 186.

**Interactions overview**
No interactions with chaparral found. For information on the interactions of individual flavonoids present in chaparral, see under flavonoids, page 186.
Chinese angelica

_Angelica sinensis_ (Oliv.) Diels (Apiaceae)

**Synonym(s) and related species**
Dang Gui (Chinese), Danggui, Dong quai.

_Angelica polymorpha_ var. _sinensis_.

Other species used in oriental medicine include _Angelica dahurica_.

Not to be confused with Angelica, which is _Angelica archangelica_ L.

**Pharmacopoeias**
Angelica Sinensis Root for use in THM (_BP_ 2009); Processed Angelica Sinensis Root for use in THMP (_BP_ 2009).

**Constituents**
The major constituents include natural coumarins (angelicin, archangelicin, bergapten, osthole, psoralen and xanthotoxin) and volatile oils. Other constituents include caffeic and chlorogenic acids, and ferulic acid. _Angelica sinensis_ also contains a series of phthalides (_n_ -butylidenephthalide, ligustilide, _n_ -butylphthalide).

**Use and indications**
One of the most common uses of Chinese angelica root is for the treatment of menopausal symptoms and menstrual disorders. It has also been used for rheumatism, ulcers, anaemia, constipation, psoriasis, the management of hypertension and to relieve allergic conditions.

**Pharmacokinetics**
Evidence is limited to experimental studies, which suggest that the effects of _Angelica dahurica_ and _Angelica sinensis_ may not be equivalent.¹ Most of the evidence relates to _Angelica dahurica_, which may inhibit the cytochrome P450 isoenzymes CYP2C9 (see tolbutamide, page 131), CYP2C19 (see diazepam, page 130) and CYP3A4 (see nifedipine, page 130). If all these effects are found to be clinically relevant then Chinese angelica (where _Angelica dahurica_ is used) has the potential to raise the levels of a wide range of conventional drugs.

**Interactions overview**
_Angelica dahurica_ may raise the levels of diazepam and tolbutamide, thereby increasing their effects. More limited evidence suggests that nifedipine may be similarly affected. Case reports suggest that Chinese angelica may increase the bleeding time in response to warfarin, and may possess oestrogenic effects, which could be of benefit, but which may also, theoretically, oppose the effects of oestrogen antagonists, such as tamoxifen.

**Chinese angelica**

**Chinese angelica + Diazepam**

The interaction between *Angelica dahurica* and diazepam is based on experimental evidence only.

**Clinical evidence**

No interactions found.

**Experimental evidence**

In a study in rats,1 *Angelica dahurica* had little effect on the pharmacokinetics of intravenous diazepam 10 mg/kg. However, when diazepam 5 mg/kg was given orally, the AUC of diazepam was markedly increased from levels below detection to detectable levels, and the maximum plasma level was increased fourfold. In a mobility study, *Angelica dahurica* potentiated the muscle relaxant effects of intravenous diazepam.1

**Mechanism**

In rats, diazepam is principally metabolised in the liver by cytochrome P450 isoenzymes including CYP2C19. It is thought that this isozyme is inhibited by *Angelica dahurica*. It was also suggested by the authors that there was a considerable effect of *Angelica dahurica* on the first-pass metabolism of diazepam.1

**Importance and management**

Although the data are from animal studies, because of the potential for increased levels and effects of diazepam, until more is known it may be prudent to advise caution when giving *Angelica dahurica* with oral diazepam. Warn patients that they may experience increased sedation.

Note that it may not be appropriate to extrapolate from *Angelica dahurica* to other species such as *Angelica sinensis*, since, in one study, *Angelica sinensis* had much less effect on CYP3A4 than *Angelica dahurica*, see under nifedipine, below.


**Chinese angelica + Food**

No interactions found.

**Chinese angelica + Herbal medicines**

No interactions found.

**Chinese angelica + Nifedipine**

The interaction between Chinese angelica and nifedipine is based on experimental evidence only.

**Clinical evidence**

No interactions found.

**Experimental evidence**

In a study, rats were given an extract of *Angelica dahurica*, and then rat liver microsomes were prepared and incubated with nifedipine. *Angelica dahurica* was found to inhibit the activity of nifedipine oxidase 1 to 6 hours after administration, by about 30 to 40%.1

**Mechanism**

Nifedipine oxidation is mediated by the cytochrome P450 isoenzyme CYP3A4.1 This activity of *Angelica dahurica* was shown to be related to furanocoumarin constituents. Other in vitro studies suggest that an alcoholic extract of *Angelica dahurica* more potently inhibited CYP3A4 than an aqueous decoction, whereas extracts of *Angelica sinensis* had no significant effect on CYP3A4.2

**Importance and management**

Evidence is limited to experimental studies, but what is known suggests that any CYP3A4 inhibitory effects of Chinese angelica depend on the species and the type of extract used. The results are difficult to reliably extrapolate to the use of Chinese angelica with nifedipine in humans, but it is possible that alcoholic extracts of *Angelica dahurica* may decrease nifedipine metabolism, and therefore increase its levels and effects. Be aware of this possibility if both substances are given.


**Chinese angelica + Oestrogens or Oestrogen antagonists**

Chinese angelica may contain oestrogenic compounds. This may result in additive effects with oestrogens or it may oppose the effects of oestrogens. Similarly, Chinese angelica may have additive effects with oestrogen antagonists or oppose the effects of oestrogen antagonists (e.g. tamoxifen).

**Clinical evidence**

A letter in the *Medical Journal of Australia*2 draws attention to the fact that some women with breast cancer receiving chemotherapy or hormone antagonists who develop menopausal symptoms have found relief from hot flushes by taking a Chinese herb ‘dong quai’ (or ‘danggui’ root), which has been identified as *Angelica sinensis*. A possible explanation is that this and some other herbs (agnus castus, hops flower, ginseng root and black cohosh) have significant oestrogen-binding activity and physiological oestrogenic actions.3

The oestrogenic potential of Chinese angelica is, however, somewhat unclear. A phytooestrogen preparation containing soy extract 7.5 mg, black cohosh 25 mg and *Angelica polymorpha* (a species related to Chinese angelica) 50 mg taken twice daily reduced the average frequency of menstrually-associated migraine attacks in a 15-week period by 54% in a randomised, placebo-controlled study in 42 women.3 The preparation used in this study was standardised to content of isoflavones from soy, lignistilide from *Angelica polymorpha* and triterpenes from black cohosh. In contrast, in another randomised, placebo-controlled study, *Angelica sinensis* root 4.5 g daily did not produce significant oestrogen-like responses in endometrial thickness or vaginal maturation and did not relieve menopausal symptoms in 71 postmenopausal women.4 The *Angelica sinensis* preparation in this study was standardised to content of ferulic acid.

**Experimental evidence**

In various in vitro and animal studies, Chinese angelica extract has been shown to inhibit the binding of estradiol to the oestrogen receptor and increase uterine growth (oestrogenic effects). However, it also decreased uterine c-myc mRNA levels (which is induced by oestrogens).2

**Mechanism**

If Chinese angelica has oestrogenic actions, which are not
established, then it might directly stimulate breast cancer growth and oppose the actions of competitive oestrogen receptor antagonists such as tamoxifen. See also Isoflavones + Tamoxifen, page 262.

**Importance and management**

One clinical study and the anecdotal cases mentioned in the letter suggest that Chinese angelica, either alone, or with other phytoestrogens, may possess oestrogenic properties. In contrast, in a well-controlled study, Chinese angelica alone did not produce oestrogen-like responses. The concern is that, if Chinese angelica does have oestrogenic effects, it might stimulate breast cancer growth and antagonise the effects of hormone antagonists used to treat cancer. Until more is known, it may be prudent to avoid using herbs with purported oestrogenic effects in women with oestrogen-sensitive cancers. This is more strictly a disease–herb interaction. See also Isoflavones + Tamoxifen, page 262.

**Chinese angelica + Tolbutamide**

The interaction between *Angelica dahurica* and tolbutamide is based on experimental evidence only.

**Clinical evidence**

No interactions found.

**Experimental evidence**

In a study, rats were given an extract of *Angelica dahurica*, and then rat liver microsomes were prepared and incubated with tolbutamide. *Angelica dahurica* was found to inhibit the activity of tolbutamide hydroxylase 1 to 6 hours after administration, by up to about 60%. In further experiments in rats, the AUC of intravenous tolbutamide 10 mg/kg was increased 2.5-fold by *Angelica dahurica* 1 g/kg.1

**Mechanism**

*Angelica dahurica* inhibits the activity of the cytochrome P450 CYP2C subfamily of isoenzymes, which are involved in the metabolism of tolbutamide.1

**Importance and management**

Although there is a lack of clinical evidence, because of the potential for increased levels of tolbutamide, it may be prudent to exercise some caution when using medicines containing *Angelica dahurica* in patients taking tolbutamide. Patients may wish to consider increasing the frequency of blood-glucose monitoring. It may not be appropriate to extrapolate from *Angelica dahurica* to other species such as *Angelica sinensis*, because in one study *Angelica sinensis* did not possess the same enzyme inhibitory properties as *Angelica dahurica*, see nifedipine, page 130.1


**Chinese angelica + Warfarin and related drugs**

Two case reports describe a very marked increase in the anticoagulant effects of warfarin when Chinese angelica was given.

**Clinical evidence**

A 46-year-old African–American woman with atrial fibrillation taking warfarin had a greater than twofold increase in her prothrombin time and INR after taking Chinese angelica for 4 weeks. The prothrombin time and INR had returned to normal 4 weeks after stopping Chinese angelica.1 In another case, a woman who had been taking warfarin for 10 years developed widespread bruising and an INR of 10, a month after starting to take Chinese angelica.2

A further report describes spontaneous subarachnoid haemorrhage in a 53-year-old woman not taking anticoagulants, which was attributed to a herbal supplement containing Chinese angelica root 100 mg and a number of other herbs. See Red clover + Anticoagulants, page 333.

**Experimental evidence**

In a study in rabbits, Chinese angelica aqueous extract 2 g/kg twice daily for 3 days significantly decreased the prothrombin time in response to a single 2-mg/kg dose of warfarin without altering the plasma warfarin concentrations. However, when the study was repeated with warfarin at steady state, prothrombin times tended to be increased after the addition of Chinese angelica, although, as with the single-dose study, warfarin plasma levels were not significantly altered.3 In an in vitro study, Chinese angelica extract alone slightly increased prothrombin time.4

**Mechanism**

The reasons for this interaction are not fully understood but Chinese angelica is known to contain natural coumarin derivatives, which may possibly have anticoagulant properties: these could be additive with those of warfarin. However, note that many coumarins do not have anticoagulant effects, see coumarins, page 297. The data suggest that alteration of warfarin levels is not involved, but other studies suggest that the herb may inhibit the cytochrome P450 isoenzyme CYP2C9, which is the main route of warfarin metabolism. See tolbutamide, above.

**Importance and management**

Clinical evidence for an interaction between Chinese angelica and warfarin appears to be limited to the case reports cited, and an interaction is not fully established. Nevertheless, it would seem prudent to warn patients taking warfarin, and possibly other coumarin anticoagulants, of the potential risks of also taking Chinese angelica. For safety, the use of Chinese angelica should be avoided unless the effects on anticoagulation can be monitored. More study is needed.

Chitosan

Types, sources and related compounds
Poliglusam.

Pharmacopoeias
Chitosan Hydrochloride (BP 2009, Ph Eur 6.4).

Constituents
Chitosan is a polysaccharide composed of polymers of glucosamine and N-acetylglucosamine. It is obtained from the partial deacetylation of chitin obtained from the shells of crustaceans such as shrimps and crabs. It is available in different molecular weights, viscosity grades and degrees of deacetylation.

Use and indications
Chitosan is used as a dietary supplement for obesity and hypercholesterolaemia. Pharmaceutically, chitosan and various derivatives are used, or being investigated, as excipients in drug formulations including oral or nasal dosage forms and gene carrier systems.

Pharmacokinetics
Chitosan is an absorption enhancer and increases the permeability of peptide drugs across intestinal and mucosal epithelia, which has implications for drug delivery systems.\(^1\) A thiolated chitosan derivative is also reported to inhibit the activity of P-glycoprotein, which has possible applications for improving the bioavailability of P-glycoprotein substrates,\(^2\) but note that this derivative does not appear to be used as a dietary supplement.

Interactions overview
Chitosan appears to alter the rate of absorption of water-insoluble drugs such as indometacin and griseofulvin, but it is doubtful whether this is of any clinical significance. A case report suggests that chitosan may increase the effects of warfarin, and possibly other related anticoagulants.

The information regarding the use of chitosan with cefalexin is based on experimental evidence only.

Clinical evidence
No interactions found.

Experimental evidence
There was no significant difference in the AUC and maximum levels of cefalexin 10 mg/kg given alone, and when rats were pretreated with oral chitosan 25 mg/kg.¹

Mechanism
Chitosan does not appear to alter the gastrointestinal absorption of water-soluble drugs such as cefalexin.¹

Importance and management
The evidence is limited to experimental data and the pharmacokinetics of cefalexin were unchanged. Therefore, no action is considered necessary.


Chitosan + Food
No interactions found.

Chitosan + Griseofulvin
The information regarding the use of chitosan with griseofulvin is based on experimental evidence only.

Clinical evidence
No interactions found.

Experimental evidence
The AUC₀–¹₀ and maximum levels of griseofulvin 50 mg/kg were both reduced by about two-thirds when rats were pretreated with oral chitosan 25 mg/kg. The time to reach maximum levels was also prolonged.¹

Mechanism
Little understood. The authors suggest that by binding to bile acids, chitosan inhibits the solubilisation and the gastrointestinal absorption of griseofulvin, which is not water soluble. They suggest that the effect of chitosan is not due to a delay in gastric emptying,¹ because it did not alter the rate of absorption of paracetamol, below.

Importance and management
The evidence is limited to experimental data and the extent of griseofulvin absorption was unchanged. Therefore, no action is considered necessary.


Chitosan + Herbal medicines
No interactions found.

Chitosan + Indometacin
The information regarding the use of chitosan with indometacin is based on experimental evidence only.

Clinical evidence
No interactions found.

Experimental evidence
There was no significant difference in the AUC and maximum levels of indometacin 10 mg/kg when rats were pretreated with oral chitosan 25 mg/kg, although the rate of absorption (time to reach maximum levels) was prolonged.¹

Mechanism
Little understood. The authors suggest that by binding to bile acids, chitosan inhibits the solubilisation and the gastrointestinal absorption of indometacin, which is not water soluble. They suggest that the effect of chitosan is not due to a delay in gastric emptying,¹ because it did not alter the rate of absorption of paracetamol, below.

Importance and management
The evidence is limited to experimental data and the extent of indometacin absorption was unchanged. Therefore, no action is considered necessary.


Chitosan + Paracetamol (Acetaminophen)
The information regarding the use of chitosan with paracetamol is based on experimental evidence only.

Clinical evidence
No interactions found.

Experimental evidence
There was no significant difference in the AUC and maximum levels of paracetamol 30 mg/kg when rats were pretreated with oral chitosan 25 mg/kg.¹

Mechanism
Paracetamol absorption is dependent on the rate of gastric emptying, and it is often used to study this. The findings of this study suggest that chitosan does not alter the gastric emptying rate.¹

Importance and management
The evidence is limited to experimental data and the pharmacokinetics of paracetamol were unchanged. Therefore, no action is considered necessary.

kinetics of paracetamol were unchanged. Therefore, no action is considered necessary.


### Chitosan + Warfarin and related drugs

An isolated report describes an increase in the INR of an elderly man taking warfarin when he also took chitosan.

**Clinical evidence**

A case report describes an 83-year-old man, with type 2 diabetes, who was receiving warfarin (2.5 mg daily for one year, with an INR of between 2 and 3) for atrial fibrillation. At a routine blood test his INR was found to be about 3.7, and, although the dose of warfarin was halved, 3 days later his INR was more than 9. On discussion, it was established that he had recently started taking chitosan 1.2 g twice daily. He was advised to stop this supplement and was subsequently restabilised on warfarin. About one month later, the patient restarted the chitosan, which again resulted in a raised INR.1

**Experimental evidence**

No relevant data found.

**Mechanism**

Chitosan *sulfate* has been reported to have anticoagulant activity, but this has not been found with chitosan. The authors therefore suggest that chitosan impaired the absorption of fat-soluble vitamins, including vitamin K. Warfarin is a vitamin K antagonist and a reduction in vitamin K would be expected to enhance its effects.

**Importance and management**

Evidence is limited to this case, and the mechanism is largely speculative; however, an interaction seems probable. The evidence is too slim to forbid patients taking warfarin from also taking chitosan, but it would seem prudent to discuss the possible outcome and advise an increase in the frequency of anticoagulant monitoring; measuring the INR after a few days of concurrent use seems reasonable. There appears to be no evidence regarding other anticoagulants, but, if the mechanism is correct, all vitamin K antagonists (*coumarins* and *indanediones*) would be expected to be similarly affected.

Chondroitin

Types, sources and related compounds
Chondroitin sulfate sodium.

Pharmacopoeias
Chondroitin sulphate sodium (BP 2009, Ph. Eur. 6.4); Chondroitin sulfate sodium (USP 32).

Use and indications
Chondroitin is an acid mucopolysaccharide and is found naturally in cartilage and connective tissue. Supplemental chondroitin is used for the management of arthritis and is often given with glucosamine, page 226, for osteoarthritis.

Pharmacokinetics
Chondroitin is rapidly adsorbed from the gastrointestinal tract and the absolute bioavailability of an oral dose is about 15%. It is distributed into numerous tissues, with a particular affinity to articular cartilage and synovial fluid.1

Interactions overview
No interactions with chondroitin taken alone found, but chondroitin is often given with glucosamine. For information on these interactions, see under glucosamine, page 226.

Cinnamon

*Cinnamomum cassia* Blume and *Cinnamomum verum* J. Presl. and its varieties (Lauraceae)

**Synonym(s) and related species**

*Cinnamomum cassia*: Cassia, Chinese cinnamon, False cinnamon, *Cassia lignea*, *Cinnamomum aromaticum* Nees, *Cinnamomum pseudomelastoma* auct. non Liao.

*Cinnamomum verum*: Canela, Ceylon cinnamon, *Cinnamomum burmannii* (Nees & T. Nees) Bl. (known as Batavian cinnamon or Panang cinnamon), *Cinnamomum loureiroi* Nees, *Cinnamomum zeylanicum* Nees., *Cinnamomum zeylanicum* Blume.

**Pharmacopoeias**


**Constituents**

The bark of *Cinnamomum cassia* and *Cinnamomum verum* contains volatile oil mainly composed of *trans*-cinnamaldehyde, with cinnamylacetate, phenylpropylacetate, salicylaldehyde and methyleugenol. Diterpenes including cinnassiols, and tannins such as cinnamtannins, are also present.

**Use and indications**

Both varieties of cinnamon are mainly used for digestive disorders such as diarrhoea, and flatulent colic or dyspepsia. Cinnamon has also been used for the common cold, and the oil may have antiseptic activity. It has been used in Chinese medicine for circulatory disorders.

**Pharmacokinetics**

No relevant pharmacokinetic data found.

**Interactions overview**

It has been suggested that cinnamon may interfere with the control of diabetes by conventional antidiabetic drugs, but controlled studies do not appear to support this suggestion. Cinnamon is a constituent of various Chinese herbal medicines, see under bupleurum, page 89, for information.
Although one study suggests that cinnamon may enhance the blood-glucose-lowering effects of conventional antidiabetics, a meta-analysis of controlled studies suggests otherwise.

Clinical evidence
In a placebo-controlled study, patients with type 2 diabetes were given *Cinnamomum cassia* 1 g, 3 g or 6 g daily (total of 30 patients) for a total of 40 days in addition to their normal medications. Blood-glucose levels were decreased by 2.9 mmol/L, 2 mmol/L and 3.8 mmol/L in the 1 g, 3 g and 6 g groups, respectively. Changes in blood-glucose levels were only significant at 20 days in the 6 g group (blood-glucose decreased by 2.8 mmol/L). No particular adverse effects were reported.

Experimental evidence
A literature review found several *animal* studies that suggested that cinnamon may have blood-glucose-lowering properties, but no direct interactions data were found.

Mechanism
Unknown.

Importance and management
Evidence is limited. The study cited above, which was not designed to investigate a potential drug interaction, seems to suggest that cinnamon has the potential to enhance the blood-glucose-lowering effects of conventional antidiabetic medication (unnamed). However, recent meta-analysis of randomised controlled studies, which included the study cited above, found that cinnamon does not appear to improve the control of type 1 or type 2 diabetes (glycosylated haemoglobin, fasting blood glucose and lipids assessed).

In general therefore, cinnamon would not be expected to markedly affect the control of diabetes with conventional antidiabetic drugs. If any effect does occur, it is likely to be picked up by standard blood-glucose monitoring, as high doses of cinnamon only had a significant effect on blood-glucose after 40 days of concurrent use.


Cinnamon + Carbamazepine
For mention that saiko-ka-ryukotsu-borei-to, of which cinnamon (*Cinnamomum cassia*) is one of 10 constituents, did not affect the pharmacokinetics of carbamazepine in an *animal* study, see Bupleurum + Carbamazepine, page 90.

Cinnamon + Food
No interactions found. Cinnamon is commonly used as a flavouring in foods.

Cinnamon + Herbal medicines
No interactions found.

Cinnamon + Ofloxacin
For mention that sairei-to, of which cinnamon (*Cinnamomum cassia*) is one of 12 constituents, did not affect the pharmacokinetics of ofloxacin, see Bupleurum + Ofloxacin, page 90.
Clivers

*Galium aparine* L. (Rubiaceae)

**Synonym(s) and related species**
Cleavers, Galium, Goosegrass.

**Constituents**
Clivers contains the iridoids asperuloside, deacetylasperuloside and monotropein, polyphenolic acids, unspecified tannins based on gallic acid and *flavonoids*. Anthraquinones have been found in the roots, but not the aerial parts.

**Use and indications**
Clivers is traditionally used for dysuria, cystitis, lymphadenitis, psoriasis and as a diuretic.

**Pharmacokinetics**
No relevant pharmacokinetic data found.

**Interactions overview**
No interactions with clivers found.
Cocoa

Theobroma cacao L. (Sterculiaceae)

**Synonym(s) and related species**
Cacao, Chocolate, Chocolate tree, Theobroma.

**Pharmacopoeias**
Chocolate (USP 32); Cocoa Butter (USP 32); Theobroma Oil (BP 2009).

**Constituents**
Cocoa seeds contain xanthine derivatives, principally theobromine (1% to 4%), with small amounts of caffeine (up to about 0.4%) and other alkaloids. They are also rich in flavonoids from the flavanol and procyanidin groups, mainly catechin and epicatechin and their polymers. The nibs (cotyledons) are a rich source of cocoa butter (theobroma oil), which contains oleic, stearic, palmitic and linoleic acids.

**Use and indications**
The seeds roasted and powdered are the source of cocoa, which is mainly used as a food (in chocolate). Medicinal uses include as a stimulant and as a diuretic; effects that can be attributed to the xanthine content. However, note that theobromine is a much weaker xanthine than caffeine. Cocoa butter is used as an emollient and pharmaceutical excipient.

More recently, there has been interest in the possible beneficial effects of cocoa consumption on cardiovascular health, because of its high content of flavonoids.

**Pharmacokinetics**
The pharmacokinetics of caffeine are discussed under caffeine, page 97. In one study, caffeine absorption from chocolate was slower with a lower maximum concentration than from capsules, whereas theobromine absorption was faster with higher maximum concentration than from capsules.¹ For information on the pharmacokinetics of individual flavonoids present in cocoa, see under flavonoids, page 186.

**Interactions overview**
Although the use of cocoa supplements has been cautioned by some in diabetic patients, there seems little evidence to support this. Dark chocolate may slightly decrease blood pressure in hypertensive patients, but caffeine from cocoa may have the opposite effect. Famotidine and foods have no effect, or only modest effects, on the absorption of flavonols from cocoa. Cocoa may reduce the absorption of iron.

Cocoa contains small amounts of caffeine compared with some other caffeine-containing herbs. Although it contains high levels of theobromine, this has weak xanthine effects when compared with caffeine. Nevertheless, when taken in sufficient quantities, cocoa could produce levels of caffeine sufficient to cause interactions, see caffeine, page 97.

For information on the interactions of individual flavonoids present in cocoa, see under flavonoids, page 186. Of particular note are studies showing that cocoa flavanols, might have antiplatelet effects, and that these might be additive with aspirin, see Flavonoids + Anticoagulants or Antiplatelet drugs, page 188.

Cocoa + Anticoagulant or Antiplatelet drugs

For studies showing that cocoa flavanols might have antiplatelet effects, and that these might be additive with aspirin, see Flavonoids + Anticoagulant or Antiplatelet drugs, page 188.

Cocoa + Antidiabetics

Although the use of cocoa supplements has been cautioned by some in diabetic patients, there seems little evidence to support this.

Evidence, mechanism, importance and management

The traditional advice in diabetes is to avoid or limit intake of chocolate. This is principally because of the high calorific value of chocolate, and its high sugar content (particularly milk chocolates).

In one study, an isomalt-based chocolate (about 45% w/w) had a lower glycaemic effect than a sucrose-based chocolate (about 45% w/w), which confirms the concerns regarding the sucrose content.1

Conversely, in animal studies, cocoa extract containing high levels of procyanidins had beneficial effects on blood-glucose levels.2,3 In addition, in one study in patients with untreated essential hypertension, an improvement in glucose and insulin responses was found during an oral glucose tolerance test, and a slightly lower decrease in blood-glucose level was seen, after subjects ate 100 g of dark chocolate daily for 15 days (substituted for food of similar energy and macronutrient composition). This effect was not seen with 90 g of white chocolate daily.4 Taken together, the evidence suggests that cocoa in itself, and cocoa supplements, should not be a problem in diabetics and should not interfere with blood-glucose control.


Cocoa + Antihypertensives

Dark chocolate may slightly decrease blood pressure in hypertensive patients, but caffeine from cocoa may have the opposite effect.

Evidence, mechanism, importance and management

There has been some interest in the possible beneficial effects of cocoa consumption on cardiovascular health, because of its high content of flavonoids. In a meta-analysis of five short-term randomised controlled studies, daily consumption of high doses (46 to 100 g daily) of dark chocolate, or 105 g daily of milk chocolate, all containing high levels of flavonoids, caused a modest 4.7 and 2.8 mmHg reduction in systolic and diastolic blood pressure, respectively.1 Another study with a lower dose (6.3 g daily) showed a smaller effect (2.9/1.9 mmHg reduction).2

These studies show that high doses of dark chocolate 100 g daily modestly decrease blood pressure, an effect attributed to its flavonoid content.1,3 This suggests that blood pressure control is unlikely to be significantly affected by cocoa supplements in patients with hypertension. None of the patients in these studies was taking antihypertensive medication so some caution would still be needed.

Theoretically, the caffeine content of cocoa could result in increases in blood pressure, and therefore large quantities of cocoa supplements could be inadvisable in patients with hypertension, see Caffeine + Antihypertensives, page 99.


Cocoa + Famotidine

Famotidine has no effect on the absorption of flavanols from cocoa.

Evidence, mechanism, importance and management

In a study in 6 healthy subjects, a single 20-mg dose of famotidine given one hour before consumption of sugar-free, flavanol-rich cocoa had no effect on the AUC of flavanols. It was concluded that alteration of gastric pH had no effect on flavanol absorption. No special precautions appear to be necessary.


Cocoa + Food

Food has no effect, or only modest effects, on the absorption of flavanols from cocoa.

Evidence, mechanism, importance and management

In a series of studies in 6 healthy subjects, high-carbohydrate foods (bread or sugar) increased the flavanol AUC by about 40% after consumption of 125 micrograms/kg of sugar-free, flavanol-rich cocoa. Lipid and protein-rich foods (butter or steak) and whole milk had little effect on flavanol absorption. Grapefruit juice had a minor effect (20% increase), which was attributed to its carbohydrate content.1

This study demonstrated that carbohydrates can increase oral flavanol absorption from cocoa. However, the extent is modest, and probably of little clinical relevance.


Cocoa + Herbal medicines

The caffeine content of cocoa suggests that it may interact with other herbal medicines in the same way as caffeine, see Caffeine + Herbal medicines; Bitter orange, page 101, and Ephedra + Caffeine, page 176.

Cocoa + Iron compounds

Cocoa may reduce the absorption of iron.
Clinical evidence
In a study in 10 healthy subjects, a 275 mL serving of cocoa beverage reduced the absorption of radiolabelled iron from a 50 g bread roll by about 70%. In this study, the inhibitory effect of cocoa beverage on iron absorption was only slightly less that of black tea (Assam tea, *Camellia sinensis*). Note that black tea is known to inhibit iron absorption, see Tea + Iron compounds, page 386.

Mechanism
The polyphenols in cocoa may bind to iron in the gastrointestinal tract and reduce its absorption.1

Importance and management
Evidence appears to be limited to this one study, but be aware that some beverages such as cocoa might reduce iron absorption similarly to conventional tea. See Tea + Iron compounds, page 386, for further discussion of the possible impact of this interaction.

Coenzyme Q\textsubscript{10}

Types, sources and related compounds
Ubidecarenone, Ubiquinone.

Pharmacopoeias
Ubidecarenone (BP 2009, Ph Eur 6.4, USP 32); Ubidecarenone Capsules (USP 32); Ubidecarenone Tablets (USP 32).

Use and indications
Coenzyme Q\textsubscript{10} is a naturally occurring enzyme co-factor that has a fundamental role in electron transport in mitochondria, and is also an antioxidant. It is often taken orally as a supplement to aid in the treatment of cardiovascular disorders such as congestive heart failure, angina and hypertension. It has also been used to maintain the levels of endogenous coenzyme Q\textsubscript{10} during treatment with conventional drugs that reduce these, particularly the statins. Coenzyme Q\textsubscript{10} has also been used alongside treatment for breast cancer, Huntington’s disease and Parkinson’s disease, and may help to prevent migraines.

Pharmacokinetics
The absorption of coenzyme Q\textsubscript{10} is relatively slow and is dependent on postprandial lipids in the gastrointestinal tract, see food, page 143.

Interactions overview
Coenzyme Q\textsubscript{10} did not interact with warfarin in a controlled study, but there are a few isolated reports describing either increased or decreased warfarin effects in patients taking coenzyme Q\textsubscript{10}. Coenzyme Q\textsubscript{10} may decrease the effects of aldosterone and alter the levels of the major cytotoxic metabolite of doxorubicin. Pepper (Piper nigrum) may modestly increase the levels of coenzyme Q\textsubscript{10}. 
The interaction between coenzyme Q\textsubscript{10} and doxorubicin is based on experimental evidence only.

**Evidence, mechanism, importance and management**

In experimental studies in rats and dogs, single-dose coenzyme Q\textsubscript{10} increased the sodium reabsorption stimulated by exogenous doxorubicin, but, in contrast, in rats and dogs pretreated for 3 weeks with multiple doses, increasing the dose of coenzyme Q\textsubscript{10} reduced the sodium reabsorption caused by doxorubicin. Potassium excretion remained unaffected throughout.\(^1\)

This study suggests that long-term use of coenzyme Q\textsubscript{10} might have some diuretic activity, and might oppose the effects of doxorubicin. However, the clinical relevance of this is uncertain.


The interaction between coenzyme Q\textsubscript{10} and doxorubicin is based on experimental evidence only.

**Evidence, mechanism, importance and management**

In a study in rats, oral coenzyme Q\textsubscript{10} 20 mg/kg for 6 days had no significant effect on the pharmacokinetics of intravenous doxorubicin 10 mg/kg or its major cytotoxic metabolite doxorubicinol. However, there was a twofold increase in the AUC of the doxorubicinolone metabolite.\(^1\) The findings from this study suggest that coenzyme Q\textsubscript{10} is unlikely to reduce the efficacy of doxorubicin via a pharmacokinetic mechanism. The reason for the significant rise in doxorubicinolone concentration and its impact is unknown. Note that the possible use of coenzyme Q\textsubscript{10} to reduce doxorubicin-induced cardiotoxicity has been investigated.


The interaction between coenzyme Q\textsubscript{10} and food is based on experimental evidence only.

**Clinical evidence**

No interactions found.

**Experimental evidence**

Food increased the maximum serum levels and AUC of oral coenzyme Q\textsubscript{10} 25 mg/kg, given as an emulsion, by about fivefold and twofold respectively in rats. Coenzyme Q\textsubscript{10} given as an emulsion showed greater increases than coenzyme Q\textsubscript{10} given in suspension.\(^1\)

**Mechanism**

Coenzyme Q\textsubscript{10} has a large molecular weight and is relatively hydrophobic, which results in slow absorption in the gastrointestinal tract. Taking the supplement with food and/or as a lipid-based emulsion increases its water solubility and enhances its absorption.

**Importance and management**

Data regarding the effects of food on coenzyme Q\textsubscript{10} absorption appear to be limited. The absorption of coenzyme Q\textsubscript{10} is relatively slow and is dependent on postprandial lipids in the gastrointestinal tract. Coenzyme Q\textsubscript{10} supplements therefore often contain a lipid vehicle and it is recommended that they are taken with fatty meals.\(^2\)


**Coenzyme Q\textsubscript{10} + Herbal medicines; Pepper**

Pepper (Piper nigrum) may modestly increase the levels of coenzyme Q\textsubscript{10}.

**Clinical evidence**

In a single-dose, placebo-controlled study in 12 healthy subjects, there was no change in pharmacokinetics of coenzyme Q\textsubscript{10} (AUC and maximum level or time to maximum level) when piperine 5 mg (Bioperine) from pepper (Piper nigrum) was given with coenzyme Q\textsubscript{10} 90 mg. Similarly, giving piperine 5 mg with coenzyme Q\textsubscript{10} 90 mg daily for 14 days did not alter the AUC of coenzyme Q\textsubscript{10}. However, when piperine 5 mg was given with coenzyme Q\textsubscript{10} 120 mg daily for 21 days, the plasma levels of coenzyme Q\textsubscript{10} were increased by 32% and the AUC was increased by 30%.\(^1\)

**Experimental evidence**

No relevant data found.

**Mechanism**

It was suggested that piperine increased the absorption of coenzyme Q\textsubscript{10} from the gastrointestinal tract, but the exact mechanism is unclear.

**Importance and management**

The modest increase in coenzyme Q\textsubscript{10} levels seen in this study with piperine (an alkaloid derived from black pepper) is unlikely to be clinically important, since coenzyme Q\textsubscript{10} is a ubiquitous compound, generally regarded as safe. Note that a combination product has been marketed.


**Coenzyme Q\textsubscript{10} + Warfarin and related drugs**

Ubidecarenone did not alter the INR or required warfarin dose in a controlled study in patients stabilised on warfarin. However, two reports describe reduced anticoagulant effects of warfarin in four patients taking ubidecarenone. A transient increase in INR has been reported in one patient taking ubidecarenone and warfarin. A 4-month prospective, longitudinal study describes an increased risk of self-reported bleeding events in patients taking coenzyme Q\textsubscript{10} with warfarin.

**Clinical evidence**

In a randomised, crossover study in 21 patients stabilised on warfarin, coenzyme Q\textsubscript{10} 100 mg daily (Bio-Quinone) for 4 weeks did not alter the INR or the required dose of warfarin, when compared with placebo.\(^1\) Similarly, 2 patients taking coenzyme Q\textsubscript{10} to treat alopecia caused by warfarin treatment did not have any notable changes in INR, except that one had a transient INR increase when coenzyme Q\textsubscript{10} was started.\(^2\)

In a 4-month prospective, longitudinal study of 78 patients taking warfarin and a herbal product or dietary supplement, there was a statistically significant increased risk of self-reported bleeding...
events in 14 patients taking warfarin and coenzyme Q₁₀ (57 bleeding events, none major, in a total of 181 weeks of combined use for an odds ratio of 3.7).³ There were 4 elevated INRs (specific values not given) for 55 weeks of combined use, but this was not a statistically significant increase in risk. Note that the coenzyme Q₁₀ products used were not mentioned. The authors acknowledge that their finding might be due to chance and not a true interaction.

In contrast, another report describes 3 patients taking warfarin who had a reduction in their INR while taking coenzyme Q₁₀. In two of these, INR reductions from about 2.5 to 1.4 occurred when they took coenzyme Q₁₀ 30 mg daily for 2 weeks. The INRs rapidly returned to normal when the coenzyme Q₁₀ was stopped.⁴ In two other cases, patients appeared to have a reduced response to warfarin while taking coenzyme Q₁₀, but responded normally when it was stopped.⁵,⁶

**Experimental evidence**

In a study in *rats*, coenzyme Q₁₀ reduced the anticoagulant effect of warfarin and increased the clearance of both enantiomers of warfarin.⁷

**Mechanism**

Not known. Coenzyme Q₁₀ may have some vitamin K-like activity, which would explain the decrease in INR. Explanations for the increase in bleeding or INRs are unknown.

**Importance and management**

The well-controlled study suggests that coenzyme Q₁₀ does not interact with warfarin, and that no warfarin dose adjustment would be expected to be necessary in patients who take this substance. However, the contrasting findings of a decrease in warfarin effect in the case reports, and an increase in bleeding events reported in the epidemiological study, introduce a note of caution. Moreover, the authors of the controlled study recommend close monitoring of the INR if a patient decides to use coenzyme Q₁₀, because the underlying health problem resulting in them choosing to take this substance may alter their response to warfarin.¹ Until more is known it would seem prudent to increase the frequency of INR monitoring in patients taking warfarin if coenzyme Q₁₀ is started.

Coffee

*Coffea* L. species. (Rubiaceae)

**Synonym(s) and related species**
Arabian coffee is from *Coffea arabica*.
Robusta coffee is from *Coffea canephora* (Pierre ex Froehner) also known as *Coffea robusta* (Linden ex De Wild.).
Other species include *Coffea liberica*.

**Constituents**
The kernel of the dried coffee bean contains xanthine derivatives, the main one being caffeine (1 to 2%), with some theobromine and theophylline. It also contains polyphenolic acids such as chlorogenic acids and various diterpenes (e.g. kahweol, cafestrol).

**Use and indications**
Coffee has been used as a stimulant and diuretic. However, when roasted, coffee beans are most commonly used as a beverage.

**Pharmacokinetics**
The pharmacokinetics of caffeine are discussed under caffeine, page 97. Evidence suggests that chlorogenic acid is hydrolysed in the gastrointestinal tract to free caffèic acid, which is then conjugated to form the glucuronate or sulphate.1

**Interactions overview**
Coffee contains significant amounts of caffeine, so the interactions of caffeine, page 97, are relevant to coffee, unless the product is specified as decaffeinated. By virtue of its caffeine content, coffee may also cause serious adverse effects if used with other drugs or herbs with similar effects, such as ephedra, page 176. Evidence is conflicting, but in general the long-term use of coffee does not appear to be detrimental to the control of diabetes; however, coffee may have a small adverse effect on blood pressure control. Coffee may reduce the absorption of iron and the absorption of nicotine from chewing gum, but does not appear to affect the absorption of aspirin or tetracycline. A case report describes mania in a patient who drank coffee and took phenylpropanolamine. For the possible increase in clozapine effects with caffeine, sometimes from coffee, see Caffeine + Clozapine, page 100.

Coffee + Antidiabetics

Evidence is conflicting, but in general the long-term use of coffee does not appear to be detrimental to the control of diabetes.

Evidence, mechanism, importance and management

There is a lot of epidemiological evidence that coffee consumption is associated with a reduced risk of type 2 diabetes (this has been the subject of a review). In addition, a large prospective cohort study in Finland found that coffee drinking was associated with reduced total and cardiovascular disease mortality.

In contrast, some short-term randomised studies have found that coffee consumption had detrimental effects on insulin sensitivity in healthy subjects (high consumption of filtered coffee over 4 weeks) and increased postprandial hyperglycaemia in patients with type 2 diabetes taking unnamed oral antidiabetic drugs (caffeine added to decaffeinated coffee, single dose).

The evidence is not conclusive, which makes it difficult to advise patients taking antidiabetics on use of coffee beverages or supplements. However the Finnish study does provide some reassurance that use of coffee may not be detrimental in the long term, and may even be beneficial.

Coffee + Antihypertensives

Coffee may have a small adverse effect on blood pressure control.

Clinical evidence

Limited data are available on the effect of coffee blood pressure in patients taking antihypertensives. In one study, two 150-mL cups of coffee (made from 24 g of coffee) increased the mean blood pressure of 12 healthy subjects taking propranolol 240 mg, metoprolol 300 mg or a placebo. Mean blood pressure rises were 7%/22% with propranolol, 7%/19% with metoprolol and 4%/16% with placebo. The beta blockers and placebo were given in divided doses over 15 hours before the test. However, there are lots of short-term studies on the effect of coffee on blood pressure in healthy subjects or patients with untreated mild hypertension. In one meta-analysis of 18 randomised studies of coffee consumption, coffee drinking was associated with a very small 1.22/0.49 mmHg increase in blood pressure.

One study found that blood pressure was higher in untreated hypertensives who drank coffee (5 cups daily, each containing approximately 60 mg caffeine) than in untreated hypertensives who did not drink coffee. However, coffee drinking reduced the potentially detrimental post-meal postural drop in systolic blood pressure in patients taking unnamed antihypertensives.

The only long-term studies are of epidemiological type. In one large prospective cohort study in Finland, low-to-moderate daily consumption of coffee (2 to 7 cups daily) was associated with a small (about 24 to 29%) increased risk of requiring antihypertensive drug treatment. In the Nurses Health prospective cohort, coffee consumption was not associated with an increased risk of developing hypertension.

In contrast to some of the data on coffee, chlorogenic acids from coffee have been reported to reduce blood pressure. In one randomised study in patients with mild hypertension not receiving antihypertensives, green coffee bean extract 480 mg (containing 140 mg of chlorogenic acids) daily for 12 weeks was associated with a 10/7 mmHg reduction in blood pressure.

A dose-related decrease in blood pressure with green coffee extract was seen in another study. Note that green coffee is not roasted, and may therefore contain different constituents and have different effects than the usual roasted coffee, although the importance of this remains to be demonstrated.

Experimental evidence

Because of the extensive clinical evidence available, experimental data have not been sought.

Mechanism

Acute intake of caffeine raises blood pressure, but partial tolerance to this effect might possibly develop with regular consumption, see also Caffeine + Antihypertensives, page 99. Polyphenolic compounds in coffee might improve endothelial function, and might therefore lower blood pressure.

Importance and management

The evidence presented here is conflicting; however, most of the studies suggest that coffee might have a small adverse effect on blood pressure. It is possible that this does not extend to green (unroasted) coffee, and therefore supplements containing green coffee extract might not be expected to have a negative effect on blood pressure. Further study is needed.

For discussion of the adverse effect of caffeine on blood pressure, see Caffeine + Antihypertensives, page 99.

Coffee + Aspirin

Coffee does not appear to affect aspirin absorption.

Evidence, mechanism, importance and management

A study in 5 healthy subjects found that 200 mL of coffee had no effect on the rate and extent of absorption of a single 500-mg dose of aspirin, whereas 200 mL of milk reduced the bioavailability and maximum concentration of salicylates from the same dose of aspirin by a modest 30%.

No significant reduction in the bioavailability of aspirin would be expected with black coffee; however the addition of milk, depending on the quantity, may possibly reduce the absorption of aspirin.

Note that caffeine may enhance the analgesic effects of aspirin, see Caffeine + Aspirin or Diclofenac, page 99.

Coffee + Food

No specific interactions found; however, the effects of caffeine from...
coffee or a coffee-containing herbal medicine will be additive to those of other caffeine-containing foods or beverages.

**Coffee + Herbal medicines**

The caffeine content of coffee suggests that it may interact with other herbal medicines in the same way as caffeine, see Caffeine + Herbal medicines; Bitter orange, page 101, and Ephedra + Caffeine, page 176.

**Coffee + Iron compounds**

Coffee may possibly contribute towards the development of iron-deficiency anaemia in pregnant women, and reduce the levels of iron in breast milk. As a result their babies may also be iron deficient.

**Clinical evidence**

In a series of studies in healthy subjects, drinking 200 mL of coffee with various test meals containing radiolabelled iron resulted in a 39% to 83% reduction in the absorption of iron. No decrease was observed if the coffee was drunk one hour before the meal, but when the coffee was given one hour after the meal the reduction was the same as taking it simultaneously with the meal. With one meal, the effect of coffee was about half that of tea.1 In another study, a 275 mL serving of instant coffee reduced the absorption of radiolabelled iron from a 50 g bread roll, and this was not affected by milk.2

A controlled study among pregnant women in Costa Rica found that coffee consumption was associated with reductions in the haemoglobin levels and haematocrits of the mothers during pregnancy, and of their babies shortly after birth, despite the fact that the women were taking ferric sulfate 200 mg and 500 micrograms of folate daily. The babies also had a slightly lower birth weight (3189 g versus 3310 g). Almost a quarter of the mothers were considered to have iron-deficiency anaemia (haemoglobin levels of less than 11 g/dL), compared with none among the control group of non-coffee drinkers. Levels of iron in breast milk were reduced by about one-third. The coffee drinkers drank more than 450 mL of coffee daily, equivalent to more than 10 g of ground coffee.3

In a randomised study in Guatemalan infants, discontinuing coffee intake in those given an iron supplement led to a greater increase in serum ferritin than continuing coffee consumption (median 891 mL weekly). However, discontinuing coffee had no effect on changes in haemoglobin.4

**Experimental evidence**

Because of the extensive clinical evidence available, experimental data have not been sought.

**Mechanism**

It is suggested that polyphenolics in coffee might interfere with the absorption of iron.4

**Importance and management**

The general importance of these findings is uncertain, but be aware that coffee consumption may contribute to iron-deficiency anaemia. Note that coffee is not generally considered to be a suitable drink for babies and children, because of its effects on iron absorption. More study is needed. Consider also Tea + Iron compounds, page 386.


**Coffee + Nicotine**

Coffee drinking may reduce the absorption of nicotine from chewing gum.

**Evidence, mechanism, importance and management**

In a study in 8 otherwise healthy smokers, intermittent mouth rinsing with coffee substantially reduced salivary pH and nicotine absorption from nicotine polacrilex gum.1 Buccal nicotine absorption is best in an alkaline environment, which is provided by the buffering agents in the nicotine gum. Consumption of coffee reduces the pH and therefore nicotine absorption.1 The reduction in the absorption of buccal nicotine would apply only to beverages that affect buccal pH. Drinking coffee beverages during or immediately before nicotine gum use might therefore decrease the efficacy of this form of nicotine replacement therapy. See also Caffeine + Nicotine, page 103.


**Coffee + Phenylpropanolamine**

A case report describes mania in a patient who drank coffee and took phenylpropanolamine.

**Evidence, mechanism, importance and management**

A case report describes mania with psychotic delusions in a healthy woman (who normally drank 7 to 8 cups of coffee daily) within 3 days of her starting to take a phenylpropanolamine-containing decongestant. She recovered within one week of stopping both the coffee and the phenylpropanolamine.1 This appears to be the only case report of an adverse interaction specifically between coffee and phenylpropanolamine. However, case reports have described other severe reactions with caffeine, see Caffeine + Phenylpropanolamine, page 103.


**Coffee + Tetracycline**

Coffee does not appear to affect the absorption of tetracycline.

**Evidence, mechanism, importance and management**

A study in 9 healthy subjects found that 200 mL of coffee (milk content, if any, unstated) did not significantly affect the bioavailability of a single 250-mg dose of tetracycline.1

Milk is well known to decrease the absorption of tetracyclines, and a study in 12 healthy subjects found that 16 mL of evaporated milk added to 200 mL of coffee still significantly reduced tetracycline absorption (by roughly half).2 From the first study, it appears that coffee alone does not affect tetracycline absorption.

Cola

*Cola acuminata* Schott & Endl. or *Cola nitida* Schott & Endl. (Sterculiaceae)

**Synonym(s) and related species**
Guru nut, Kola.
*Garcinia kola* Heckel, *Sterculia acuminata* Beauv.

**Pharmacopoeias**
Cola (*BP 2009, Ph Eur 6.4*).

**Constituents**
Cola seed contains xanthine derivatives, mainly caffeine (1.5 to 3%) to which it may be standardised, with traces of theobromine and theophylline. Other constituents include flavonoids from the flavanol group (such as catechin and epicatechin), amines, an anthocyanin pigment (kola red) and betaine.

**Use and indications**
The main use of cola seed is as a stimulant for depression, tiredness and poor appetite, and as a diuretic. Both uses can be attributed to the caffeine content. Cola is also used as flavouring agent in the manufacture of soft drinks.

**Pharmacokinetics**
For the pharmacokinetics of caffeine, see caffeine, page 97.

For information on the pharmacokinetics of individual flavonoids present in cola, see under flavonoids, page 186.

**Interactions overview**
Cola contains significant amounts of caffeine, therefore the interactions of caffeine, page 97, should be applied to cola, unless the product is specified as decaffeinated. By virtue of its caffeine content cola may also cause serious adverse effects if used with other drugs or herbs with similar effects, such as ephedra, page 176. Cola may reduce the bioavailability of halofantrine and increase the risk of developing hypertension. For information on the interactions of individual flavonoids present in cola, see under flavonoids, page 186.

Carbonated cola beverages are acidic, and they can therefore interact with drugs by altering gastric acidity. The best example of this is that they can increase the absorption of the azole antifungal drugs ketoconazole and itraconazole. However, this mechanism is not going to be applicable to herbal medicines containing cola extracts, and these interactions are not therefore covered here.
Cola + Antihypertensives

Cola appears to modestly increase the risk of developing hypertension.

Evidence, mechanism, importance and management

There is a possibility that the effect of cola on blood pressure might differ from that of pure caffeine. There appear to be very few published studies of the effect of cola on blood pressure; however, in the Nurses Health prospective cohort studies, both sugared cola and diet cola beverages were associated with an increased risk of developing hypertension with increased intake. Whether patients taking antihypertensives should limit their intake of cola is unclear. However, the modest hypertensive effects of the caffeine content of cola may be of importance. See Caffeine + Antihypertensives, page 99, for further discussion of the adverse effect of caffeine on blood pressure.


Cola + Food

No interactions found. Cola is used as a flavouring in carbonated drinks.

Note that the effects of caffeine from cola-containing herbal medicine or supplement will be additive with those of other caffeine-containing foods or beverages.

Cola + Halofantrine

Cola appears to moderately reduce the bioavailability of halofantrine.

Clinical evidence

In a study in 15 healthy subjects, a single 500-mg dose of halofantrine was given alone or with cola 12.5 g. Cola significantly reduced the maximum concentration and AUC of halofantrine by 45% and 31%, respectively. The overall clearance of halofantrine was reduced by 50%. Similar reductions were seen in the major metabolite of halofantrine, \(N\)-desbutylhalofantrine. No adverse effects were reported.

Experimental evidence

No relevant data found.

Mechanism

The authors suggest that caffeine, or other constituents of cola such as catechins or tannins, may have formed a complex with halofantrine to reduce its absorption.

Importance and management

Evidence appears to be limited to this one study, which found a modest reduction in the bioavailability of halofantrine. However, the bioavailability of halofantrine can vary widely between patients. Nevertheless, as there is the potential that this interaction could lead to malaria treatment failure, it may be prudent to advise patients to avoid taking cola during treatment with halofantrine.


Cola + Herbal medicines

The caffeine content of cola suggests that it may interact with other herbal medicines in the same way as caffeine, see Caffeine + Herbal medicines; Bitter orange, page 101, and Ephedra + Caffeine, page 176.
Coltsfoot

*Tussilago farfara* L. (Asteraceae)

**Synonym(s) and related species**
Coughwort, Farfara, Foal’s foot.

**Constituents**
The leaves and flowers of coltsfoot contain mucilage composed of polysaccharides, which include arabinose, fructose, galactose, glucose and xylose, and the carbohydrate inulin. **Flavonoids** (such as rutin, isoquercetin and hyperoside), polyphenolic acids, triterpenes and sterols are present, and sesquiterpenes including bisabolene derivatives and tussilagone may also be found. All parts of the plant may contain the pyrrolizidine alkaloids isotussilagine, senecionine, senkirkine and tussilagine in variable amounts. These are toxic but chemically very labile, and may be absent from some extracts.

**Use and indications**
Coltsfoot is traditionally used in cough and cold preparations as a demulcent and expectorant, and it is used in the treatment of asthma. Extracts have anti-inflammatory and antispasmodic activity and tussilagone alone has been found to be a cardiovascular and respiratory stimulant. The concentration of the most toxic pyrrolizidine alkaloid, senkirkine, is thought to be too low to cause toxicity if used infrequently, and tussilagine is unsaturated and therefore less toxic. However, care should be taken with prolonged use.

**Pharmacokinetics**
No relevant pharmacokinetic data found.

**Interactions overview**
No interactions with coltsfoot found.
Coptis

*Coptis chinensis* Franch (Ranunculaceae)

**Synonym(s) and related species**
Gold thread, Mouth root, Vegetable gold.

**Constituents**
The thread-like rhizomes contain isoquinoline alkaloids, mainly *berberine* and coptisine.

**Use and indications**
Coptis species are used widely in Chinese medicine for infections, especially of the digestive tract, and for similar reasons as bloodroot, page 76 and berberis, page 61.

**Pharmacokinetics**
No relevant pharmacokinetic data found. For information on the pharmacokinetics of the alkaloid constituent, berberine, see under berberine, page 58.

**Interactions overview**
No interactions with coptis found. However, for the interactions of the alkaloid constituent, berberine, see under berberine, page 58.
Cranberry
Vaccinium macrocarpon Aiton (Ericaceae)

**Synonym(s) and related species**
Large cranberry (*Vaccinium macrocarpon*) is the cultivated species.
European cranberry or Mossberry (*Vaccinium oxycoccus*) has also been used.

**Pharmacopoeias**
Cranberry Liquid Preparation (*USP 32*).

** Constituents**
The berries contain anthocyanins and proanthocyanidins (mainly oligomers of epicatechin), and organic acids including malic, citric, quinic and benzoic acids. 
Note that, although salicylic acid does not appear as a constituent of the juice in many cranberry monographs, some studies have shown low levels of salicylates in commercial cranberry juice (e.g. 7 mg/L), which resulted in detectable plasma and urine levels of salicylic acid in women who drank 250 mL of cranberry juice three times daily.1

**Use and indications**
The main use of cranberries and cranberry juice is for the prevention and treatment of urinary tract infections, although they have also been used for blood and digestive disorders. Cranberries are commonly used in food and beverages.

**Pharmacokinetics**
There is high absorption and excretion of cranberry anthocyanins in human urine, as shown by a study where 11 healthy subjects drank 200 mL of cranberry juice containing 651 micrograms of total anthocyanins. The urinary levels of anthocyanins reached a maximum between 3 and 6 hours, and the recovery of total anthocyanins in the urine over 24 hours was estimated to be 5% of the amount consumed.2

Some *in vitro* and *animal* studies have suggested that cranberry may affect the cytochrome P450 isoenzymes CYP2C9 (see flurbiprofen, page 153,) and CYP3A4 (see nifedipine, page 153). However, clinical studies with tizanidine, page 154 (a substrate of CYP1A2), flurbiprofen, page 153 (a substrate of CYP2C9), and midazolam, page 153 (a substrate of CYP3A4) have found no evidence of a significant interaction in humans.

**Interactions overview**
Clinical studies suggest that cranberry juice and/or extracts do not affect the pharmacokinetics of ciclosporin, flurbiprofen, midazolam, tizanidine and warfarin. Despite this, there have been some case reports of raised INRs and significant bleeding with cranberry and warfarin. Cranberry juice is unlikely to affect the pharmacokinetics of nifedipine to a clinically relevant extent.

Occasional consumption of cranberry juice does not appear to affect the bioavailability of ciclosporin. Regular daily consumption has not been studied.

Evidence, mechanism, importance and management
In a well-controlled, single-dose study, 12 healthy fasted subjects were given a 200-mg dose of oral ciclosporin simultaneously with 240 mL of cranberry juice or water. Cranberry juice was found to have no clinically significant effect on the pharmacokinetics of ciclosporin.\(^1\) In this study, the cranberry juice used was reconstituted from frozen concentrate (Ocean Spray).

This study suggests that cranberry juice does not affect the absorption of ciclosporin, and that drinking the occasional glass of cranberry juice with ciclosporin should not affect ciclosporin levels. However, note that a study of regular daily cranberry juice consumption is required to also rule out an interaction affecting ciclosporin elimination, which may have a bearing on the safety of regular (e.g. daily) intake of cranberry juice with ciclosporin.

Limited evidence suggests that cranberry juice does not appear to affect the pharmacokinetics of flurbiprofen.

Clinical evidence
In a study in 14 healthy subjects, 230 mL of cranberry juice taken the night before, and 30 minutes before a single 100-mg dose of flurbiprofen, had no significant effect on the pharmacokinetics of flurbiprofen. Fluconazole, used as a positive control, increased the flurbiprofen AUC by about 80%.\(^1\) In this study, the cranberry juice used was Ocean Spray cranberry juice cocktail from concentrate containing 27% cranberry juice.

Experimental evidence
In an \textit{in vitro} study, cranberry juice inhibited flurbiprofen hydroxylation by about 44%, which was less than that of the positive control sulfaphenazole (79%).\(^1\)

Mechanism
Flurbiprofen is metabolised by the cytochrome P450 isoenzyme CYP2C9, and the clinical study appears to suggest that cranberry has no clinically relevant effect on this particular isoenzyme, despite the fact that it had some weak inhibitory effects \textit{in vitro}.\(^1\)

Importance and management
Both the study in humans and the supporting experimental metabolic data suggest that no pharmacokinetic interaction occurs between flurbiprofen and cranberry juice. Therefore no dosage adjustment appears to be necessary if patients taking flurbiprofen wish to drink cranberry juice.

Flurbiprofen is used as a probe drug for CYP2C9 activity, and therefore these results also suggest that a pharmacokinetic interaction as a result of this mechanism between cranberry juice and other CYP2C9 substrates is unlikely.

No interactions found. Note that cranberry juice is widely used in food and beverages.

Limited evidence suggests that cranberry juice does not appear to affect the pharmacokinetics of midazolam.

Clinical evidence
In a randomised, crossover study in 10 healthy subjects, 200 mL of cranberry juice three times daily for 10 days had no significant effect on the pharmacokinetics of a single 500-microgram oral dose of midazolam taken on day 5. In this study, the cranberry juice used was a concentrate (Kontioehme sokeroitu karpalomehu) diluted 1 to 4 with tap water before use.\(^1\)

Experimental evidence
No relevant data found.

Mechanism
This study suggests that cranberry juice has no clinically relevant effect on CYP3A4 activity.

Importance and management
Although the evidence is limited to this particular study, there appears to be no need for special precautions when taking cranberry juice with midazolam.

Midazolam is used as a probe drug for CYP3A4 activity, and therefore these results also suggest that a pharmacokinetic interaction between cranberry juice and other CYP3A4 substrates is unlikely.

The interaction between cranberry juice and nifedipine is based on experimental evidence only.

Clinical evidence
No interactions found.

Experimental evidence
In a study in human liver microsomes and \textit{rat} intestinal microsomes, cranberry juice slightly decreased the cytochrome P450 isoenzyme CYP3A4-mediated metabolism of nifedipine by around 12% to 18%. Similarly, intraduodenal administration of cranberry juice to \textit{rats} appeared to reduce the apparent clearance and increase the AUC of nifedipine 30 mg/kg by 44% and 60%, respectively, when compared with a control group. However, other pharmacokinetic parameters such as the mean residence time, volume of distribution, and elimination rate constant were not significantly affected.\(^1\)
Mechanism
The experimental evidence suggests that cranberry juice may slightly inhibit the cytochrome P450 isoenzyme CYP3A4 in vitro and in rats. However, note that in a clinical study, cranberry had no effect on a single dose of midazolam, page 153, a well-established probe CYP3A4 substrate.

Importance and management
Evidence appears to be limited to two experimental studies. Taken on its own, this evidence suggests the possibility of a modest interaction, and therefore some caution might be warranted in patients taking nifedipine who drink cranberry juice. However, a clinical study with midazolam, page 153, a sensitive, specific substrate for CYP3A4, found no evidence of an interaction, and this suggests that cranberry juice would be unlikely to affect the pharmacokinetics of nifedipine to a clinically relevant extent.

Clinical evidence
(a) Case reports
In September 2003, the MHRA/CSM in the UK noted that they had received 5 reports suggesting an interaction between warfarin and cranberry juice since 1999 (3 cases of INR increases, one case of unstable INR and one case of a decrease in INR). By October 2004, the MHRA/CSM reported that they had now received 12 reports of a suspected interaction, including 5 additional cases of bleeding episodes and two additional cases of unstable INRs in patients drinking cranberry juice while taking warfarin. The most serious case involved a man taking warfarin whose INR markedly increased (INR greater than 50) 6 weeks after starting to drink cranberry juice. He died from gastrointestinal and pericardial haemorrhages. Further details of this case included that he had recently been treated with cefalexin (not known to interact) for a chest infection, and had been eating virtually nothing for at least 2 weeks, a fact that would have contributed to the increase in anticoagulation.

In a further published case report, a patient stabilised on warfarin was found to have INRs of 10 to 12 in the surgical procedure, although he had no previous record of an INR greater than 4. Vitamin K was given, and heparin was substituted for warfarin. When warfarin was restarted postoperatively, the INR quickly rose to 8 and then to 11 with haematuria, and postoperative bleeding. The patient was drinking almost 2 litres of cranberry juice daily, because of recurrent urinary tract infections, and was advised to stop drinking this. Three days later the INR had stabilised at 3 with no further intervention. Another case of fluctuating INR (between 1 and 10) in a patient taking warfarin has been attributed to cranberry juice.

In the US, a case of major bleeding and a high INR has been reported in a man taking warfarin, which occurred shortly after cranberry juice 710 mL daily was started. Another case describes an increase in the INR of a patient receiving warfarin, from below 3 to 6.45, without bleeding, after the patient drank about 2 litres of cranberry/apple juice over the last week. Of note, the patient was subsequently re-stabilised on a lower dose of warfarin and may have taken an extra dose of warfarin in the week before the raised INR was measured.

(b) Controlled studies
In one controlled crossover study, 7 male patients with atrial fibrillation who were taking stable doses of warfarin drank 250 mL of cranberry juice or placebo [daily] for a week without any significant change in their INR from baseline values. The same finding was reported in another very similar study in patients taking warfarin. However, note that the daily volume of cranberry juice in these studies was lower than the daily volume in the couple of case reports where cranberry juice intake is known. Nevertheless, in another controlled study in 10 healthy subjects, a higher volume of cranberry juice (200 mL three times daily) for 10 days did not alter the effect of a single 10-mg dose of warfarin (given on day 5) on the maximum thromboplastin time or AUC of the thromboplastin time. In addition, cranberry juice had no effect on warfarin pharmacokinetics, except that there was a slight non-significant 7% decrease in the AUC of S-warfarin.

In yet another study in 12 healthy subjects, cranberry juice concentrate 2 capsules three times daily for 21 days (equivalent to 57 g of fruit daily) had no effect on the maximum INR after a single 25-mg dose of warfarin given on day 15 (2.8 versus 2.6). However, the AUC of the INR was slightly increased by 28%, which was statistically significant, but the clinical relevance of this measure is uncertain. The cranberry concentrate had no effect on platelet aggregation, and had no effect on the pharmacokinetics of either R- or S-warfarin.

Experimental evidence
Because of the quality of the clinical evidence (controlled pharmacokinetic studies), experimental data have not been sought.

Mechanism
Not known. It was originally suggested that one or more of the constituents of cranberry juice might inhibit the metabolism of

Clinical evidence
(a) Case reports
In September 2003, the MHRA/CSM in the UK noted that they had received 5 reports suggesting an interaction between warfarin and cranberry juice since 1999 (3 cases of INR increases, one case of unstable INR and one case of a decrease in INR). By October 2004, the MHRA/CSM reported that they had now received 12 reports of a suspected interaction, including 5 additional cases of bleeding episodes and two additional cases of unstable INRs in patients drinking cranberry juice while taking warfarin. The most serious case involved a man taking warfarin whose INR markedly increased (INR greater than 50) 6 weeks after starting to drink cranberry juice. He died from gastrointestinal and pericardial haemorrhages. Further details of this case included that he had recently been treated with cefalexin (not known to interact) for a chest infection, and had been eating virtually nothing for at least 2 weeks, a fact that would have contributed to the increase in anticoagulation.

In a further published case report, a patient stabilised on warfarin was found to have INRs of 10 to 12 in the surgical procedure, although he had no previous record of an INR greater than 4. Vitamin K was given, and heparin was substituted for warfarin. When warfarin was restarted postoperatively, the INR quickly rose to 8 and then to 11 with haematuria, and postoperative bleeding. The patient was drinking almost 2 litres of cranberry juice daily, because of recurrent urinary tract infections, and was advised to stop drinking this. Three days later the INR had stabilised at 3 with no further intervention. Another case of fluctuating INR (between 1 and 10) in a patient taking warfarin has been attributed to cranberry juice.

In the US, a case of major bleeding and a high INR has been reported in a man taking warfarin, which occurred shortly after cranberry juice 710 mL daily was started. Another case describes an increase in the INR of a patient receiving warfarin, from below 3 to 6.45, without bleeding, after the patient drank about 2 litres of cranberry/apple juice over the last week. Of note, the patient was subsequently re-stabilised on a lower dose of warfarin and may have taken an extra dose of warfarin in the week before the raised INR was measured.

(b) Controlled studies
In one controlled crossover study, 7 male patients with atrial fibrillation who were taking stable doses of warfarin drank 250 mL of cranberry juice or placebo [daily] for a week without any significant change in their INR from baseline values. The same finding was reported in another very similar study in patients taking warfarin. However, note that the daily volume of cranberry juice in these studies was lower than the daily volume in the couple of case reports where cranberry juice intake is known. Nevertheless, in another controlled study in 10 healthy subjects, a higher volume of cranberry juice (200 mL three times daily) for 10 days did not alter the effect of a single 10-mg dose of warfarin (given on day 5) on the maximum thromboplastin time or AUC of the thromboplastin time. In addition, cranberry juice had no effect on warfarin pharmacokinetics, except that there was a slight non-significant 7% decrease in the AUC of S-warfarin.

In yet another study in 12 healthy subjects, cranberry juice concentrate 2 capsules three times daily for 21 days (equivalent to 57 g of fruit daily) had no effect on the maximum INR after a single 25-mg dose of warfarin given on day 15 (2.8 versus 2.6). However, the AUC of the INR was slightly increased by 28%, which was statistically significant, but the clinical relevance of this measure is uncertain. The cranberry concentrate had no effect on platelet aggregation, and had no effect on the pharmacokinetics of either R- or S-warfarin.

Experimental evidence
Because of the quality of the clinical evidence (controlled pharmacokinetic studies), experimental data have not been sought.

Mechanism
Not known. It was originally suggested that one or more of the constituents of cranberry juice might inhibit the metabolism of
warfarin by the cytochrome P450 isoenzyme CYP2C9, thereby reducing its clearance from the body and increasing its effects.1 However, four studies have shown that cranberry juice or cranberry extracts do not alter the pharmacokinetics of warfarin, and cranberry juice had no effect on flurbiprofen pharmacokinetics, a drug used as a surrogate index of CYP2C9 activity.12 See also flurbiprofen, page 153. An interaction might therefore be via a pharmacodynamic mechanism. For example, the salicylate constituent of commercial cranberry juice might cause hypoprothrombinaemia.13

Importance and management
An interaction is not established. Controlled studies have not found a pharmacokinetic interaction, and only one of four studies found any evidence for an increase in warfarin effect. Moreover, the clinical relevance of the finding of this study of a 0.2 increase in INR and 28% increase in AUC of the INR is likely to be slight at most, and does not fit with the sometimes marked increase in INR seen in some case reports. This might be explained if the interaction is dose dependent (in one of the cases where cranberry intake was mentioned a quantity of 2 litres daily was being consumed), or if it is product dependent (i.e. due to a constituent present in the cranberry juice that is not standardised for and varies widely). However, it could also be that there is no specific interaction, and that the case reports just represent idiosyncratic reactions in which other unknown factors (e.g. altered diet) were more important.

In 2004, on the basis of the then available case reports and lack of controlled studies, the CSM/MHRA in the UK advised that patients taking warfarin should avoid drinking cranberry juice unless the health benefits are considered to outweigh any risks. They recommended increased INR monitoring for any patient taking warfarin and who has a regular intake of cranberry juice.2 They also advised similar precautions with other cranberry products (such as capsules or concentrates).2 These might still be prudent precautions, although the controlled studies now available do provide some reassurance that, in otherwise healthy individuals, moderate doses of cranberry juice are unlikely to have an important impact on anticoagulation control.

Creatine

N-(Aminoiminomethyl)-N-methylglycine

**Types, sources and related compounds**
Creatine monohydrate. Creatine phosphate is also used.

**Use and indications**
Creatine supplements are taken most often to improve exercise performance and increase muscle mass. They are also used for the treatment of cardiac disorders and have possible uses for motor neurone disease, muscular dystrophies, Huntington’s disease and Parkinson’s disease.

Creatine is found in foods, most abundantly in meat and fish, and is also synthesised endogenously.

Excessive intake of creatine, by the use of supplements, has, very rarely, been reported to cause acute renal impairment.\(^1\)

**Pharmacokinetics**
Creatine is distributed throughout the body, with the majority being found in skeletal muscle. Creatine is degraded to creatinine, and both creatine and creatinine are excreted via the kidneys. Absorption of creatine is likely to be an active process, and may follow nonlinear kinetics with the ingestion of high doses because of saturation of skeletal muscle stores, although this has not been confirmed experimentally. The maximum plasma level of creatine is reached less than 2 hours after the ingestion of doses of under 10 g, but after more than 3 hours for doses over 10 g, and may vary with the ingestion of carbohydrate, see food, page 157. Clearance of creatine would appear to be dependent on both skeletal muscle and renal function.\(^2\)

**Interactions overview**
There are no established interactions with creatine, but there is some evidence that caffeine might counteract its beneficial effects, and a high carbohydrate intake might increase its retention. There is an isolated report of stroke in a patient taking a creatine supplement with caffeine plus ephedra, although the role of creatine in this case is uncertain. There is a possibility that creatine supplements might complicate interpretation of serum creatinine measurement.


Limited evidence suggests that the performance-enhancing effects of creatine may be reduced by caffeine.

**Clinical evidence**

Nine healthy subjects given a creatine supplement 500 mg/kg daily for 6 days, and caffeine capsules 5 mg/kg daily for 3 days beginning on the fourth day, experienced a lack of performance-enhancing effects of creatine during knee extension exercises, when compared with creatine given alone. One subject experienced some gastrointestinal discomfort during concurrent use.1

These findings were replicated in a later study in 9 healthy subjects. Caffeine 5 mg/kg reduced phosphocreatine resynthesis during rest from a period of exercise when given with creatine 25 g daily for 2 or 5 days.2

**Experimental evidence**

No relevant data found.

**Mechanism**

Caffeine appears to inhibit the resynthesis of endogenous phosphocreatine during recovery from a period of strenuous exercise, which, in turn, delays the formation of the energy source, ATP.

**Importance and management**

These studies are preliminary and there seem to be no further reports of an interaction. However, those taking creatine supplements to enhance exercise performance should perhaps reduce caffeine intake from beverages and other sources. Note that caffeine is also present in a number of herbal medicines, consider also caffeine-containing herbs, page 97.


Limited evidence suggests that a high carbohydrate intake may increase creatine retention.

**Clinical evidence**

In a study, 22 healthy male subjects were given 5 g creatine alone, or with 500 mL *Lucozade* (which provided a source of glucose and simple sugars) every 4 to 5 hours, giving a total dose of creatine of 20 g daily for 2 days. Subjects who received creatine alone continued their normal diet, whereas those receiving creatine with *Lucozade* received a high-carbohydrate diet. The peak plasma concentration and AUC of creatine was higher in those who had not received the glucose load (as *Lucozade*), but this group also demonstrated the highest urinary creatine excretion.1 In a similar study, the effect of about 50 g of protein plus 50 g of carbohydrate on the retention of creatine from supplements was similar to that of high carbohydrate (100 g carbohydrate).2

**Experimental evidence**

No relevant data found.

**Mechanism**

The authors suggested that their findings indicate that the ingestion of carbohydrate with creatine led to an increase in insulin secretion, resulting in an increased uptake of creatine by skeletal muscle,1 and that protein/carbohydrate might have a similar effect.2

**Importance and management**

These studies suggest that patients who are taking creatine to improve their muscle creatine stores might experience better results if the creatine is taken at the same time as high amounts of carbohydrates or protein/carbohydrates. However, this requires further study.


There is an isolated report of stroke in a patient taking a creatine supplement with ephedra plus caffeine, although the role of creatine in this case is uncertain.

**Evidence, mechanism, importance and management**

A 33-year-old fit man with no vascular risk factors had a stroke 6 weeks after starting to take two supplements to aid body building. The first contained ephedra alkaloids (from ma huang), caffeine, levocarnitine and chromium, and the second contained creatine, taurine, inosine and coenzyme Q10. His daily consumption was estimated to be 40 to 60 mg of ephedra alkaloids, 400 to 600 mg of caffeine and 6 g of creatine.1 Note that serious adverse events such as stroke have been reported with caffeine and dietary supplements containing ephedra alkaloids, and ephedra is banned in some countries. See Ephedra + Caffeine, page 176. Therefore, this case could be attributed to this supplement alone, and the role of creatine is unclear.

Note that caffeine might counteract some beneficial effects of creatine. Consider caffeine, above.

Damiana

Turnera diffusa Willd. ex Schult. (Turneraceae)

**Synonym(s) and related species**


**Constituents**

Damiana leaves contain flavonoids including trimethoxy-flavone derivatives. The hydroquinone arbutin, a cyanogenetic glycoside tetraphylline B and the phytosterol β-sitosterol have also been reported. The volatile oil contains, among other components, α- and β-pinene, thymol, α-copaene, δ-cadinene and calamene.

**Use and indications**

Damiana is used most often as an aphrodisiac, but, although there are some animal studies, there is no clinical evidence to support this use. It is also reported to be mildly sedative and antidepressant.

**Pharmacokinetics**

No relevant pharmacokinetic data found.

**Interactions overview**

No interactions with damiana found.
Dandelion

*Taraxacum officinale* Weber (Asteraceae)

**Synonym(s) and related species**
Lion’s tooth, *Taraxacum*.

*Leontodon taraxacum* L., *Taraxacum dens-leonis* Desf.,
*Taraxacum palustre* (Lyons) Lam & DC.

*Taraxacum mongolicum* Hand.–Mazz. is used in Chinese medicine.

**Constituents**
The root and leaf of dandelion contain sesquiterpene lactones including: taraxinic acid, dihydrotaraxinic acid, taraxacoside, taraxacolide and others; caffeic, chlorogenic and cichoric acids; the natural coumarins cichorin and aesculin; and flavonoids based on luteolin. The phytosterols sitosterol, stigmas terol, taraxasterol and homotaraxasterol, the triterpenes β-amyrin, taraxol and taraxerol, carotenoids, and vitamin A are also found.

**Use and indications**
Dandelion has been widely used as a diuretic, and also for its purported laxative, anti-inflammatory, choleretic (to increase bile secretion) and blood-glucose-lowering activity. Some of these activities have been demonstrated in some, but not all, animal studies, and no human studies appear to have been published.¹ Dandelion has been used as a foodstuff (the leaf in salads, and the ground root as a coffee substitute). A prebiotic effect has been suggested for the root.

**Pharmacokinetics**
In a study in rats pre-treated for 4 weeks with a dandelion tea solution 2%, the solution inhibited the cytochrome P450 isoenzymes CYP1A2 and CYP2E by 85% and 52%, respectively, when compared with a control group, but did not change CYP2D and CYP3A activity. An increase in UDP-glucuronyl transferase activity of 244% was also reported in the rats given dandelion tea.² The findings of animal studies cannot be directly extrapolated to humans, but positive findings such as these suggest that clinical studies are required. For information on the pharmacokinetics of individual flavonoids present in dandelion, see under flavonoids, page 186.

**Interactions overview**
No interactions specific to dandelion, although there is limited evidence from animals that *Taraxacum mongolicum* (the species used in Chinese medicine) might alter the absorption of ciprofloxacin. For information on the interactions of individual flavonoids present in dandelion, see under flavonoids, page 186.

Dandelion + Ciprofloxacin

The interaction between *Taraxacum mongolicum* and ciprofloxacin is based on experimental evidence only.

**Clinical evidence**
No interactions found.

**Experimental evidence**
In a study in rats, an aqueous extract of *Taraxacum mongolicum* (2 g crude drug/kg) significantly reduced the maximum concentration of a single 20-mg/kg oral dose of ciprofloxacin by 73% when compared with administration of oral ciprofloxacin alone. The overall tissue distribution and half-life were also increased, although the AUC was not different. The *Taraxacum mongolicum* extract used was analysed and found to have a high concentration of magnesium, calcium and iron.1

**Mechanism**
Cations such as magnesium, calcium and iron are known to chelate with ciprofloxacin and modestly reduce its overall absorption. However, in this study, the overall absorption of ciprofloxacin was unchanged. The reason for the reduced maximum level and prolonged elimination half-life is uncertain.

**Importance and management**
The general significance of this animal study is unclear, especially as the overall absorption of ciprofloxacin did not appear to be affected. Further study is required to discover if, and under what circumstances, dandelion might interact with ciprofloxacin in clinical use. Also, study is needed to see whether the effects of the dandelion species used in this study (*Taraxacum mongolicum*) apply to *Taraxacum officinalis*.


Dandelion + Food
No interactions found.

Dandelion + Herbal medicines
No interactions found.
Danshen
Salvia miltiorrhiza Bunge (Lamiaceae)

**Synonym(s) and related species**
Chinese salvia, Dan-Shen, Red root sage, Tan-Shen.

**Constituents**
Danshen products may be standardised according to the content of: tanshinones (diterpene quinones), tanshinone IIA and tanshinone IIB; the polyphenolic acid, salvianolic acid B; and the related compound danshensu (3,4-dihydroxy-phenyllactic acid). Other constituents include fatty-acid (oleoyl) derivatives, lithospermic acid B, and salvinal (a benzofuran) and nitrogen-containing compounds such as salvianen.

**Use and indications**
The dried root of danshen is traditionally used in Chinese medicine for cardiovascular and cerebrovascular diseases, specifically angina pectoris, hyperlipidaemia and acute ischaemic stroke, but also palpitations, hypertension, thrombosis and menstrual problems. It is also used as an anti-inflammatory and for the treatment of cancer and liver disease.

**Pharmacokinetics**
Limited in vitro and animal studies suggest that danshen extracts affect the activities of various cytochrome P450 isoenzymes. However, these effects do not appear to be clinically relevant. In a study in mice, a commercial pharmaceutical extract of danshen induced the activity of the cytochrome P450 isoenzyme CYP1A2 (assessed by 7-methoxyresorufin O-demethylation) by about 60%. An aqueous extract had no effect, whereas an ethyl acetate extract, which is not used in pharmaceutical preparations, had a very marked four- to eightfold increase in CYP1A2 activity. A purified extract of tanshinone IIA had a similar effect in this study, and in one of two mice models in another study. Conversely, in another study using mice and human liver microsomes, tanshinone IIA (extracted in ethyl acetate) inhibited CYP1A2. Any potent effects of danshen extracts on CYP1A2 therefore appear to be limited to ethyl extracts of danshen, which are not used clinically. The more modest effects found with the commercial pharmaceutical extract may not be clinically relevant, as clinical studies with theophylline, page 163, a substrate of CYP1A2 did not find a clinically relevant interaction.

The extracts of danshen that are used pharmaceutically do not appear to have clinically relevant effects on CYP2C9 (see tolbutamide, page 163) or CYP3A4 (see calcium-channel blockers, page 162).

Some extracts of danshen may inhibit P-glycoprotein, see under digoxin, page 162.

**Interactions overview**
Some case reports and animal data indicate that danshen can, rarely, increase the effects of warfarin, resulting in bleeding. The antiplatelet activity of danshen may be partly responsible, and therefore additive antiplatelet effects might occur if danshen is taken with conventional antiplatelet drugs, which may also increase the risk of bleeding. Danshen can falsify the results of serum immunoassay methods for digoxin, and experimental evidence suggests that danshen could raise digoxin levels. Additive blood-pressure-lowering effects could, in theory, occur if danshen is taken with nifedipine, but no clinically relevant pharmacokinetic interaction appears to occur. Clinical evidence suggests that danshen does not affect the pharmacokinetics of theophylline, and experimental evidence suggests that danshen does not affect the pharmacokinetics of alcohol, or tolbutamide.

Danshen + Alcohol

The interaction between danshen and alcohol is based on experimental evidence only.

Clinical evidence
No interactions found.

Experimental evidence
An oral danshen extract 200 mg/kg inhibited the oral absorption of alcohol in rats. Blood-alcohol levels were reduced by up to 60% in comparison to control rats. Danshen had no effect on blood-alcohol levels when ethanol was injected intraperitoneally. The danshen used in this study was standardised to contain 13% tanshinone IIA.1

Mechanism
Unknown.

Importance and management
Evidence for an interaction between alcohol and danshen appears to be limited to one study in rats. Even if these results are replicated in humans, any effect is probably not clinically relevant, and danshen is certainly not proven for use as an aid to reducing alcohol absorption or lowering blood-alcohol levels.


Danshen + Calcium-channel blockers

The interaction between danshen and calcium-channel blockers is based on experimental evidence only.

Clinical evidence
No interactions found.

Experimental evidence
In a study in mice, a commercial pharmaceutical extract and an aqueous extract of danshen had no effect on nifedipine oxidation. In contrast an ethyl acetate extract of danshen (which is not used as a pharmaceutical preparation) caused a threefold increase in nifedipine oxidation.1 Another study found that purified tanshinone IIA, present in ethyl acetate extracts, caused a decrease in nifedipine oxidation in mice,2 whereas a third study reported no change in nifedipine oxidation by tanshinone IIA in human liver microsomes.3 Studies in the rat femoral artery have shown that danshen extracts cause vasorelaxant effects.4

Mechanism
Contradictory findings have been reported on the effect of ethyl acetate danshen extracts on nifedipine oxidation, which is mediated by the cytochrome P450 isoenzyme CYP3A4. This could be increased, decreased or unchanged.

Importance and management
Evidence for an interaction between nifedipine and danshen appears to be limited to experimental studies, which suggest that the type of danshen extract used is important in determining whether or not an interaction may occur. In general an interaction with pharmaceutical extracts seems unlikely. Ethyl acetate extracts may decrease nifedipine metabolism, but as these are not used pharmaceutically, this is of little clinical relevance. A pharmacodynamic interaction may occur, because both nifedipine and danshen have calcium-channel-blocking effects. Until more is known, some caution might be warranted if patients take nifedipine (and possibly any calcium-channel blocker) with danshen, as additive blood pressure-lowering effects could, in theory, occur.


Danshen + Digoxin

The interaction between danshen and digoxin is based on experimental evidence only.

Clinical evidence
No interactions found.

Experimental evidence
Two in vitro studies1,2 have assessed the effects of tanshinone IIA and tanshinone IIB (major constituents of danshen) on the uptake of digoxin by P-glycoprotein. Both extracts exhibited concentration-dependent inhibitor effects on P-glycoprotein. Tanshinone IIA had the greatest effects of the two extracts, inhibiting the P-glycoprotein-mediated transport of digoxin in a similar manner to verapamil, a known clinically relevant P-glycoprotein inhibitor. The effects of tanshinone IIB were modest in comparison.

Mechanism
Tanshinone IIA appears to be a clinically relevant inhibitor of P-glycoprotein, of which digoxin is a substrate.

Importance and management
The available data appear to be from experimental studies in which specific constituents of danshen were used. This makes it difficult to extrapolate the data to the use of the herb in a clinical setting. What is known suggests that danshen may inhibit the transport of digoxin by P-glycoprotein, which could lead to raised digoxin levels. Therefore if danshen is taken by a patient receiving digoxin it may be prudent to be alert for symptoms of raised digoxin levels, such as bradycardia, and consider monitoring levels, should this occur. However, note that danshen may interfere with some of the tests used to assess digoxin levels, see also laboratory tests, page 163.


Danshen + Food

No interactions found.

Danshen + Herbal medicines

No interactions found.
### Daneshen + Laboratory tests

Daneshen can falsify the results of serum immunoassay methods for digoxin.

**Evidence, mechanism, importance and management**

Daneshen can falsify some laboratory measurements of digoxin because it contains digoxin-like immunoreactive components. A study found that a fluorescent polarisation immunoassay method (Abbott Laboratories) for digoxin gave falsely high readings in the presence of daneshen, whereas a microparticle enzyme immunoassay (Abbott Laboratories) gave falsely low readings. These, or similar findings, have been reported elsewhere.1 These false readings could be eliminated by monitoring the free (i.e. unbound) digoxin concentrations2 or by choosing assay systems that are unaffected by the presence of daneshen (said to be the Roche and Beckman systems3 or an enzyme-linked chemiluminescent immunosorbent digoxin assay by Bayer HealthCare4). Similarly, when assaying serum from patients taking digoxin, to which a variety of daneshen extracts were added, the use of a fluorescent polarisation immunoassay gave variable results, whereas the results were more consistent with a chemiluminescent assay, the EMIT 2000 digoxin assay and the Randox digoxin assay.5 It would therefore seem prudent, wherever possible, to use a chemiluminescent assay for digoxin in patients also taking daneshen.


### Daneshen + Salicylates

The interaction between daneshen and salicylates is based on experimental evidence only.

**Clinical evidence**

No interactions found.

**Experimental evidence**

**(a) Protein binding**

*In vitro* experiments show that daneshen can increase free salicylate concentration by displacing salicylate from binding to albumin proteins. In contrast, unexpectedly, salicylate significantly decreased free daneshen concentrations at full anti-inflammatory concentrations of salicylate (150 micrograms/mL and above). However, no significant change in free daneshen concentrations was observed when salicylate concentrations were less than this (up to 100 micrograms/mL).1

**(b) Pharmacodynamic**

An active component of daneshen (765-3) has been shown to inhibit human platelet aggregation via its effects on platelet calcium.2

**Mechanism**

*In vitro* many conventional drugs are capable of being displaced by others, but in the body the effects seem almost always to be buffered so effectively that the outcome is not normally clinically important. It would therefore seem that the importance of this interaction mechanism has been grossly over-emphasised. It is difficult to find an example of a clinically important interaction (with conventional drugs) due to this mechanism alone.

**Additive antiplatelet effects might occur, which might increase the risk of bleeding.**

**Importance and management**

*In vitro* evidence suggests that daneshen displaces salicylate from protein-binding sites at high doses, but the clinical relevance of this seems minimal. There may be a more clinically significant interaction with low-dose aspirin, as both it and daneshen have antiplatelet activity. Concurrent use may therefore result in additive antiplatelet effects. Bear this possibility in mind if unexpected signs of bleeding, such as bruising, occur.


### Daneshen + Theophylline

Daneshen does not appear to affect the pharmacokinetics of theophylline.

**Clinical evidence**

In a crossover study, 12 healthy subjects were given a single 100-mg dose of theophylline alone and, after taking four tablets, each containing an extract of daneshen 1 g, three times daily, for 14 days. Daneshen slightly decreased the time to maximum theophylline levels, but this was not expected to be clinically relevant, and no other pharmacokinetic parameters were altered.1

**Experimental evidence**

No relevant data found.

**Mechanism**

Alcoholic extracts of daneshen may have effects on cytochrome P450 CYP1A2, the isoenzyme by which theophylline is metabolised. See Pharmacokinetics, page 161.

**Importance and management**

The available evidence is limited, but seems to suggest that the dose of theophylline will not need to be altered in patients also taking daneshen extracts tablets.


### Daneshen + Tolbutamide

The information regarding the use of daneshen with tolbutamide is based on experimental evidence only.

**Clinical evidence**

No interactions found.

**Experimental evidence**

In a study in mice, a commercial pharmaceutical extract of daneshen had no effect on tolbutamide hydroxylation. Similarly, an aqueous extract had no effect, whereas the ethyl acetate extract (which is not used as a pharmaceutical preparation, and contained the greatest amount of tanshinone IIA) caused a twofold increase in tolbutamide hydroxylation.3
However, in vitro, tanshinone IIA did not affect the oxidation of tolbutamide in mouse or human liver microsomes.2

Mechanism
Tolbutamide is a substrate of the cytochrome P450 isoenzyme CYP2C9, and is also used as a probe substrate to assess the effects of other substances on this isoenzyme. The evidence suggests that the usual extracts of danshen do not affect tolbutamide metabolism, and therefore would not be expected to have clinically relevant effects on other substrates of CYP2C9.

Importance and management
Evidence appears to be limited to two experimental studies. However, they provide reasonably strong evidence to suggest that danshen will not affect the metabolism of tolbutamide. Therefore no dosage adjustments are expected to be needed if danshen is given to patients also taking tolbutamide. This study also suggests that danshen is unlikely to affect the metabolism of other drugs that are substrates of this isoenzyme.


Danshen + Warfarin and related drugs

Three case reports and some animal data indicate that danshen can increase the effects of warfarin, resulting in bleeding.

Clinical evidence
A woman taking warfarin, furosemide and digoxin, who began to take danshen on alternate days, was hospitalised a month later with anaemia and bleeding (prothrombin time greater than 60 seconds, INR greater than 5.62). The anaemia was attributed to occult gastrointestinal bleeding and the over-anticoagulation to an interaction with the danshen. She was later restabilised on warfarin in the absence of the danshen with an INR of 2.5, and within 4 months her haemoglobin levels were normal.1

A man taking warfarin, digoxin, captopril and furosemide, with an INR of about 3, developed chest pain and breathlessness about 2 weeks after starting to take danshen. He was found to have a massive pleural effusion, and an INR of more than 8.4. He was later discharged on his usual dose of warfarin with an INR stable at 3, in the absence of the danshen.2

Over-anticoagulation was investigated in Chinese patients admitted to a medical unit during a 9-month period in 1994/1995. An interaction with warfarin was reported in a patient using a medicated oil product that contained methyl salicylate 15%, and an ‘analgesic balm’ that contained danshen, methyl salicylate 50% and diclofenac.3

Experimental evidence
In a study in rats, danshen aqueous extract 5 g/kg twice daily given intraperitoneally for 3 days prolonged the prothrombin time and increased the steady-state levels of both isomers of warfarin.4 Similar findings were reported in another earlier study by the same group.5 In contrast, in a study in mice, a commercial pharmaceutical extract of danshen had no effect on warfarin 7-hydroxylation (mediated by the cytochrome P450 isoenzyme CYP2C9). Similarly, an aqueous extract had no effect, but an ethyl acetate extract (which is not used as a pharmaceutical preparation, and contained the greatest amount of tanshinone IIA) increased warfarin 7-hydroxylation threefold, which would be expected to lead to a decrease in its anticoagulant effects.6

A study in animals found that high doses of Kangen-Karyu (a mixture of peony root, cnidium rhizome, safflower, cyperus rhizome, saussurea root and the root of danshen) 2 g/kg twice daily inhibited the metabolism and elimination of single doses of warfarin, and prolonged bleeding time. There was no interaction at a lower dose of 500 mg/kg, which suggests that a clinical interaction is unlikely at the recommended dose of 90 mg/kg of Kangen-Karyu daily.7

Mechanism
Danshen has antiplatelet actions, which may be additive to the anticoagulant effect of warfarin. The mechanism for the increase in warfarin levels is unknown, because the studies suggest that the usual extracts of danshen do not inhibit the cytochrome P450 isoenzyme CYP2C9, the main route of warfarin metabolism. Consider also tolbutamide, page 163, and for more information on the antiplatelet effects of danshen, see salicylates, page 163.

Importance and management
Evidence appears to be limited to three case studies, which alone would be insufficient to establish an interaction. The pharmacokinetic effects of the usual extracts of danshen seem to suggest that an interaction resulting in raised warfarin levels is unlikely in most patients. However, because danshen may have antiplatelet effects, an interaction between warfarin and danshen, resulting in increased bleeding, is possible. Clinically the use of an antiplatelet drug with an anticoagulant should generally be avoided in the absence of a specific indication. It may therefore be prudent to advise against concurrent use. However, if concurrent use is felt desirable it would seem sensible to warn patients to be alert for any signs of bruising or bleeding, and report these immediately, should they occur.

**Devil’s claw**

*Harpagophytum procumbens* (Burch.) DC. (Pedaliaceae)

**Synonym(s) and related species**
Grapple plant, Harpagophytum, Wood spider.  
*Harpagophytum burchelli* Decne.

**Pharmacopoeias**
Devil’s Claw (*BP 2009*); Devil’s Claw Dry Extract (*BP 2009, Ph Eur 6.4*); Devil’s Claw Root (*Ph Eur 6.4*).

**Constituents**
Devil’s claw is usually standardised to the content of the iridoid glycoside, *harpagoside*. Other iridoid glycosides include harpagide and procumbide, and other constituents include diterpenes, the phenolic glycosides 6-acetylacteoside and 2,6-diacetylacteoside, flavonoids (including kaempferol), triterpenes and harpagoquinone.

**Use and indications**
The dried secondary root tuber is used as a stomachic and bitter tonic, and for inflammatory disorders including arthritis, gout, myalgia, fibrositis, lumbago and rheumatic disease.

**Pharmacokinetics**
*In vitro*, a Devil’s claw extract moderately inhibited the activity of the cytochrome P450 isoenzymes, CYP2C8, CYP2C9, CYP2C19, and CYP3A4.¹ Devil’s claw had the greatest effect on CYP2C9, but this was still, at best, a modest effect. For information on the pharmacokinetics of individual flavonoids present in Devil’s claw, see under flavonoids, page 186.

**Interactions overview**
Limited evidence is available. Devil’s claw does not appear to affect blood pressure, and its theoretical interaction with drugs with antiplatelet effects seems unlikely to be of practical relevance; however, it may increase the anticoagulant effects of drugs such as warfarin.

For information on the interactions of individual flavonoids present in Devil’s claw, see under flavonoids, page 186.

Devil’s claw + Antiplatelet drugs and NSAIDs

The interaction between Devil’s claw and antiplatelet drugs and NSAIDs is based on a prediction only.

Evidence, mechanism, importance and management

One licensed preparation for Devil’s claw suggests that there is a theoretical increased risk of bleeding if Devil’s claw is given with drugs that inhibit platelet aggregation, such as antiplatelet drugs and NSAIDs.1 The exact basis for this recommendation is unclear and another subsequently licensed preparation does not carry this warning.2 A case report suggests that Devil’s claw may interact with warfarin, see below, but this seems most likely to be due to a metabolic effect rather than intrinsic antiplatelet properties. Devil’s

claw appears to be contraindicated in peptic ulceration, and this could be taken to suggest that any antiplatelet effects that it may have could increase the risks of bleeding from an ulcer. However, some sources suggest that this contraindication is because of the bitter properties of Devil’s claw (implying that it may stimulate gastric secretions), and there are no documented cases of bleeding or ulceration with the use of Devil’s claw. This warning with antiplatelet drugs and NSAIDs therefore appears to represent tremendous caution and it seems unlikely that the theoretical prediction will be of clinical importance.

1. Shaw D, Leon C, Kolev S, Murray V. Traditional remedies and food supplements. A 5-year toxicological study 1 describes the development of purpura in a patient following the concurrent use of Devil’s claw and warfarin.

Devil’s claw + Warfarin and related drugs

Devil’s claw may increase the effects of warfarin, and possibly other coumarins.

Clinical evidence

A case report from a 5-year toxicological study1 describes the development of purpura in a patient following the concurrent use of Devil’s claw and warfarin.

Experimental evidence

In an in vitro study, a Devil’s claw extract modestly inhibited the activity of the cytochrome P450 isoenzyme CYP2C9.2

Mechanism

Limited in vitro evidence suggests that Devil’s claw may inhibit the cytochrome P450 isoenzyme CYP2C9. Although the metabolism of warfarin is complex, CYP2C9 plays a significant role. Therefore it is possible that Devil’s claw could inhibit the metabolism of warfarin, raising its levels and increasing its effect.

Importance and management

Evidence is limited to a case study, which reports minor adverse effects, and experimental data. An interaction seems possible, but it has not been conclusively demonstrated. Although only warfarin has been studied, all coumarins are metabolised by CYP2C9 to some extent, and therefore they also have the potential to be affected. The evidence is too sparse to make any firm recommendations, but it may be prudent to consider a possible interaction if a patient taking a coumarin develops otherwise unexplained bruising.

Echinacea

Echinacea species (Asteraceae)

Synonym(s) and related species
Black sampson, Brauneria, Coneflower, Purple coneflower, Rudbeckia.

Echinacea angustifolia (DC) Heller, Echinacea pallida (Nutt.) Britt., Echinacea purpurea (L.) Moensch. Other names that have been used include Brauneria pallida (Nutt.) Britton, Echinacea intermedia Lindl., Rudbeckia hispida Hoffm, Rudbeckia pallida Nutt. Rudbeckia purpurea L. and Rudbeckia serotina (Nutt) Sweet.

Pharmacopoeias
Echinacea angustifolia: Powder and Powdered extract (USP 32); Root (BP 2009).
Echinacea pallida: Powder and Powdered extract (USP 32); Root (BP 2009).
Echinacea purpurea: Aerial Parts (USP 32); Herb (BP 2009); Powder and Powdered extract (USP 32); Root (BP 2009, USP 32).

Constituents
The constituents of the various species are slightly different and this leads to confusion as to the potential for drug interactions.

(a) Echinacea angustifolia
The root contains alkamides, mainly 2-monoene isobutylamides, and similar caffeic acid esters and glycosides to Echinacea purpurea, including the major component, echinacoside, and cynarin. Alkylketones, and the saturated pyrrolizidine alkaloids, tussilagine and isotussilagine, are also present (these are not the unsaturated hepatotoxic type).

(b) Echinacea pallida
The root contains similar caffeic acid esters and glycosides to Echinacea purpurea, including the major component, echinacoside. Polyenes and polyacetylenes, including a range of ketoalkenes and ketopolyacetylenes, have been reported and polysaccharides and glycoproteins are also present.

(c) Echinacea purpurea
The root contains alkamides, mainly 2,4-dienoic isobutylamides of straight-chain fatty acids, caffeic acid derivatives including the major component, cichoric acid, with echinacoside, verbascoside, caffeoylchinasocide, chlorogenic acid, isochlorogenic acid and caftaric acid. The saturated pyrrolizidine alkaloids tussilagine and isotussilagine are present.

The herb contains similar alkamides, and cichoric acid is the major caffeic acid derivative present. Polysaccharides PS1 (a methylglucuronomannosyran), PS2 (an acidic rhamnoarabinogalactan), a xyloglucan and glycoproteins have been reported.

The pressed juice (from the aerial parts) contains heterogeneous polysaccharides, inulin-type compounds, arabinogalactan polysaccharides and glycoproteins.

Use and indications
Echinacea is mainly used for its immunostimulant (immunomodulatory) effects, particularly in the treatment and prevention of the common cold, influenza and other upper respiratory tract infections. It has a long history of medicinal use for infections, both bacterial and viral, especially in skin conditions such as acne and boils, and also in mild septicaemia.

Pharmacokinetics
Most work has been carried out using Echinacea purpurea, although other Echinacea species have been studied on selected isoenzymes. In vitro studies using non-drug probe substrates1,2 suggest that Echinacea purpurea extracts (Echinacare and Echinagard) do not have any significant effects on the cytochrome P450 isoenzyme CYP2D6: a finding supported by in vitro and clinical studies using drugs as probe substrates, see dextromethorphan, page 169. Similarly, in vitro studies1,3 suggest that Echinacea purpurea extracts (Echinacare, Echinagard and Echinaforce) either do not inhibit, or only weakly inhibit, CYP1A2, CYP2C9, and CYP2C19. These in vitro findings for CYP2C9 and CYP1A2 would be expected to be replicated in most patients, as suggested by clinical studies with the probe substrates tolbutamide, page 170, and caffeine, page 169, respectively.

The effects of echinacea on CYP3A4 are less clear. Some extracts of Echinacea angustifolia, Echinacea pallida and Echinacea purpurea (Echinaforce) weakly2,3 or moderately4 inhibited CYP3A4, whereas one extract of Echinacea purpurea (Echinacare) caused both weak inhibition and induction of CYP3A4.1 However, in one study2 the inhibitory properties varied greatly (150-fold). This seemed to be related to the alkamide content of the extract, although Echinacea pallida contains only low concentrations of alkamides, so other constituents may also have a role in CYP3A4 inhibition. Indeed, one study found that the caffeic acid derivatives echinacoside and cichoric acid caused moderate and very weak CYP3A4 inhibition, respectively.4 The findings of a clinical study using midazolam (a probe substrate for CYP3A4) were also somewhat complex (see midazolam, page 170), but appears to suggest only a clinically modest effect of echinacea on CYP3A4.


Interactions overview

Theoretically, echinacea may antagonise the effects of immunosuppressants. The use of echinacea has been studied with a number of drugs that are used as probe substrates for cytochrome P450 activity or P-glycoprotein. With the possible exceptions of midazolam and caffeine, no clinically relevant interactions have been identified. Echinacea seems to present a low risk for interactions occurring as a result of these mechanisms.

Echinacea appears to have a variable effect on the pharmacokinetics of caffeine. In most patients, echinacea is unlikely to raise caffeine levels.

Clinical evidence
In a pharmacokinetic study, 12 healthy subjects were given an 8-day course of *Echinacea purpurea* root 400 mg four times daily, with a single 200-mg oral dose of caffeine on day 6. The maximum serum concentration and AUC of caffeine were increased by about 30%.[1] There was a large variation between subjects, with some having a 50% increase in caffeine clearance, and some a 90% decrease. However, the paraxanthine-to-caffeine ratio (a measure of CYP1A2 activity) was reduced by just 10%.[1] In another study in 12 healthy subjects given *Echinacea purpurea* 800 mg twice daily for 28 days, the paraxanthine-to-caffeine ratio was not significantly affected when a single 100-mg dose of caffeine was given at the end of the treatment with *Echinacea purpurea*.[2]

Experimental evidence
No relevant data found.

Mechanism
Echinacea is an inhibitor of the cytochrome P450 isoenzyme CYP1A2, which is involved in caffeine metabolism. Echinacea was therefore expected to raise caffeine levels. Although the studies found that caffeine levels were modestly raised by caffeine this did not appear to be due to an effect of echinacea on CYP1A2 (effects found were mild).

Importance and management
Evidence appears to be limited to the two studies cited, which suggest that in most patients echinacea is unlikely to raise caffeine levels by inhibiting CYP1A2. However, some patients did experience a decrease in caffeine clearance, which suggests that, rarely, caffeine levels may be raised. Some patients may therefore experience some increase in the adverse effects of caffeine, such as headache, tremor and restlessness, particularly if they have a high caffeine intake. Should this occur, advise the patient to either stop taking echinacea and/or reduce their caffeine intake.

Caffeine is used as a probe drug for CYP1A2 activity, and therefore these results also suggest that a pharmacokinetic interaction between echinacea and other CYP1A2 substrates is unlikely.

---


---

Echinacea + Digoxin

Echinacea does not appear to have a clinically relevant effect on the pharmacokinetics of digoxin.

Clinical evidence
In a study, 18 healthy subjects were given an extract containing *Echinacea purpurea* 195 mg and *Echinacea angustifolia* 72 mg three times daily for 14 days with a single 250-microgram dose of digoxin before and after the course of echinacea. No significant effects on the pharmacokinetics of digoxin were reported for echinacea, suggesting that echinacea does not have any significant effects on P-glycoprotein. No adverse effects were reported when digoxin was given with echinacea.[1]

---

affect the pharmacokinetics of digoxin, and therefore no digoxin dosage adjustments appear necessary if echinacea is also taken. Digoxin is used as a probe substrate for P-glycoprotein, and therefore these results also suggest that a clinically relevant pharmacokinetic interaction between echinacea and other P-glycoprotein substrates is unlikely.


**Echinacea + Food**

No interactions found.

**Echinacea + Herbal medicines**

No interactions found.

**Echinacea + Immunosuppressants**

The interaction between echinacea and immunosuppressants is based on a prediction only.

**Evidence, mechanism and importance and management**

Echinacea has immunostimulating effects. Theoretically therefore, echinacea may antagonise the effects of immunosuppressant drugs. The manufacturers of three echinacea products licensed by the MHRA in the UK advise against concurrent use with immunosuppressants and specifically name etizolam and methotrexate.1–3

There do not appear to be any clinical reports of an interaction, but, until more is known, it may be prudent to follow this advice.


**Echinacea + Tolbutamide**

Echinacea does not appear to have a clinically relevant effect on the pharmacokinetics of tolbutamide.

**Clinical evidence**

In a pharmacokinetic study, 12 healthy subjects were given *Echinacea purpurea* root 400 mg four times daily for 8 days with a single 500-mg dose of tolbutamide on day 6. The AUC of tolbutamide was increased by 14%, and the time to maximum levels was increased from 4 to 6 hours.1 The oral clearance was decreased by a mean of 11%, although 2 subjects had a 25% or greater reduction.

**Experimental evidence**

No relevant data found.

**Mechanism**

Midazolam is predominantly metabolised by the cytochrome P450 isoenzyme CYP3A4. It was suggested the echinacea may have exerted opposing effects on the cytochrome P450 isoenzyme CYP3A in the liver and the intestine, which resulted in this difference in its effects on oral and intravenous midazolam.2

**Importance and management**

Direct evidence about an interaction between midazolam and echinacea appears to be limited to these two clinical studies. Their findings suggest that echinacea is unlikely to interact with oral midazolam, as even though the oral bioavailability was increased this did not affect the maximum levels or AUC. The interaction of echinacea with intravenous midazolam is, at best, modest. As the dose of intravenous midazolam is usually tapered to the individual’s response, the potential for a reduced effect should be accommodated. The authors of one of the studies2 suggest that the effect of echinacea on CYP3A4 substrates may depend on whether they have high oral bioavailability and the degree of hepatic extraction, and is not easily predicted. More study is needed to establish if echinacea has any clinically relevant effects on a range of CYP3A4 substrates. See the table Drugs and herbs affecting or metabolised by the cytochrome P450 activity in vivo. *Clin Pharmacol Ther* (2004) 75, 89–100.


**Echinacea + Midazolam**

Echinacea does not appear to alter the AUC and clearance of oral midazolam, although the bioavailability may be increased. Clearance of intravenous midazolam may be modestly increased in patients taking echinacea.

**Clinical evidence**

In a pharmacokinetic study, 12 healthy subjects were given *Echinacea purpurea* root (Nature’s Bounty, USA) 400 mg four times daily for 28 days, with a single 50-microgram/kg intravenous dose of midazolam on day 6 and, 24 hours later, a single 5-mg oral dose of midazolam. The clearance of intravenous midazolam was increased by 42%, and its AUC was reduced by 23%. In contrast, the clearance and AUC of oral midazolam were not significantly altered; however, the oral bioavailability of midazolam was increased by 50% but the oral bioavailability was still relatively low. In another study in 12 healthy subjects given *Echinacea purpurea* 800 mg twice daily for 28 days with a single 8-mg oral dose of midazolam, there was no difference in the ratio of midazolam to its 1-hydroxy metabolite.1

**Experimental evidence**

No relevant data found.

**Mechanism**

Midazolam is predominantly metabolised by the cytochrome P450 isoenzyme CYP3A4. It was suggested the echinacea may have exerted opposing effects on the cytochrome P450 isoenzyme CYP3A in the liver and the intestine, which resulted in this difference in its effects on oral and intravenous midazolam.2

**Importance and management**

This one study suggests that echinacea does not significantly affect the pharmacokinetics of tolbutamide, and therefore no tolbutamide dosage adjustments appear necessary if echinacea is also taken.

Tolbutamide is used as a probe substrate for CYP2C9, and therefore these results also suggest that a clinically relevant pharmacokinetic interaction between echinacea and other CYP2C9 substrates is unlikely.

Eclipta

_Eclipta alba_ Hassk (Asteraceae)

**Synonym(s) and related species**

Trailing eclipta.

_Eclipta prostrata_ (L.).

**Constituents**

Eclipta contains terthienyl derivatives, including \( \alpha \)-formyl-terthienyl and a number of esterified 5-hydroxyterthienyl derivatives. The leaves and stem contain the **flavonoids** apigenin and luteolin, and the **isoflavone** orobol; wedelolactone and desmethyldwedelolactone, as well as their glucosides, are present throughout the herb. Oleanane-type triterpenoids known as the ecliptasaponins, eclalbatin and the eclalbasaponins (based on echinocystic acid), and several steroidal alkaloids based on verazine and ecliptalbine, are also found in eclipta.

**Use and indications**

Eclipta is traditionally used for blood-related diseases, including liver diseases such as hepatitis and jaundice. Pharmacological studies support these uses to some extent, but clinical data are lacking. It has also been used for alopecia, as an antiseptic and as an analgesic; its analgesic effects have been attributed to the alkaloid content.

**Pharmacokinetics**

No relevant pharmacokinetic data found. For information on the pharmacokinetics of individual flavonoids and isoflavones present in eclipta, see under flavonoids, page 186 and isoflavones, page 258, respectively.

**Interactions overview**

No interactions with eclipta found. For information on the interactions of individual flavonoids and isoflavones present in eclipta, see under flavonoids, page 186 and isoflavones, page 258, respectively.
Elder

*Sambucus nigra* L. (Caprifoliaceae)

**Synonym(s) and related species**
Black elder, European elder, *Sambucus*. Not to be confused with American elder, which is *Sambucus canadensis* L.

**Pharmacopoeias**
Elder Flower *(BP 2009, Ph Eur 6.4).*

**Constituents**
The flowers and berries of elder are most often used medicinally. The flowers contain: triterpenes based on oleanolic and ursolic acids; the *flavonoids* rutin, quercetin, hyperoside, kaempferol, nicotoflorin and others; and linolenic and linoleic acids. The berries contain: anthocyanins cyanidin-3-sambubioside and cyanidin-3-glucoside; the *flavonoids* quercetin and rutin; cyanogenic glycosides including sambunigrin; and vitamins. The unripe berries of elder contain toxic constituents, but these are lost on drying and/or heating, and are not present in the medicinal product. Elder extracts may be standardised to contain 0.8% *flavonoids* based on isoquercitrinoside *(BP 2009, Ph Eur 6.4).*

**Use and indications**
Elder extracts are used mainly to treat colds and flu. Several *in vitro* studies have shown that elder berry constituents have antidiabetic, antiviral and immune-modulating effects, enhance cytokine production and activate phagocytes, but clinical data are lacking.

**Pharmacokinetics**
No relevant pharmacokinetic data found. For information on the pharmacokinetics of individual flavonoids found in elder, see under flavonoids, page 186.

**Interactions overview**
There is some very weak experimental evidence to suggest that elder extracts may have additive effects with antidiabetic drugs and phenobarbital, and may antagonise the effects of morphine. For information on the interactions of individual flavonoids found in elder, see under flavonoids, page 186.
Elder + Antidiabetics

The interaction between elder and antidiabetics is based on experimental evidence only.

Clinical evidence
No interactions found.

Experimental evidence
In an in vitro study, it was found that an aqueous elder flower extract enhanced glucose uptake by 70%, but had no additional effect on glucose uptake when insulin was also given. The extract also stimulated insulin secretion and glycogen synthesis.\(^1\)

Mechanism
Elder is thought to enhance insulin secretion in a similar manner to the sulphonylureas. This study supports this suggestion as it found that diazoxide inhibited the effects of elder.

Importance and management
The in vitro study provides limited evidence of a possible blood-glucose-lowering effect of an aqueous elder flower extract. Because of the nature of the evidence, applying these results in a clinical setting is extremely difficult, and the effect of elder flower extracts given with conventional antidiabetic medication is unknown. However, if patients taking antidiabetic drugs want to take elder it may be prudent to discuss the potential for additive effects, and advise an increase in blood-glucose monitoring, should an interaction be suspected.


---

Elder + Food

No interactions found.

Elder + Herbal medicines

No interactions found.

Elder + Morphine

The interaction between elder and morphine is based on experimental evidence only.

Clinical evidence
No interactions found.

Experimental evidence
In a study in rats aqueous extracts of elder flower and elder berry were found to modestly decrease the analgesic effects of morphine 90 minutes after dosing. The elder extracts had no effect on the analgesic response to morphine at a subsequent time point (150 minutes), and had tended to increase the effects of morphine 10 minutes after dosing. The berry and flower extracts had no analgesic effect when given alone.\(^1\)

Mechanism
Unknown.

Importance and management
Evidence for an interaction between extracts of elder flower and elder berry and morphine appears to be limited to this study in rats, which found only a modest decrease in analgesic effects at just one time point. It is unknown if this effect would occur in humans, but, even if it does, it seems unlikely to be of much clinical relevance.


---

Elder + Phenobarbital

The interaction between elder and phenobarbital is based on experimental evidence only.

Clinical evidence
No interactions found.

Experimental evidence
In a study in rats aqueous extracts of elder flower and elder berry were found to approximately halve the time to the onset of sleep and increase the sleeping time in response to phenobarbital (from about 190 minutes to 200 minutes).\(^1\)

Mechanism
Unknown.

Importance and management
Evidence for an interaction between extracts of elder flower and elder berry and phenobarbital appears to be limited to this study in rats, which found only a very modest increase in sleeping time. It is unknown if this effect would occur in humans, but, even if it does, it seems unlikely to be clinically relevant.

Elecampane

*Inula helenium* L. (Asteraceae)

**Synonym(s) and related species**
Alant, Helenio, Horseheal, Inula, Scabwort, Yellow starwort.
*Aster helenium* (L.) Scop., *Aster officinalis* All., *Helenium grandiflorum* Gilib.

**Constituents**
The root contains sesquiterpene lactones, mainly helenalin (alantolactone or elecampane camphor), iso-helenalin, dihydroalantolactone, alantic acid, azulene and a large amount of inulin. Phytosterols including β- and γ-sitosterols, stigmasterol and friedelin are also present.

**Use and indications**
Elecampane is used as an expectorant, antitussive and antiseptic, especially for catarrh and dry irritating cough in children.

**Pharmacokinetics**
No relevant pharmacokinetic data found.

**Interactions overview**
No interactions with elecampane found.
Ephedra

*Ephedra sinica* Stapf., *Ephedra gerardiana* Wall., *Ephedra equisetina* Bunge (Ephedraceae)

**Synonym(s) and related species**
Ma huang.

**Constituents**
The main active components of ephedra are the amines (sometimes referred to as alkaloids, or more properly pseudoalkaloids) ephedrine, pseudoephedrine, norephedrine, norpseudoephedrine, *N*-methylephedrine, ephedroxe, maokonine, a series of ephedradines and others. Other constituents include the diterpenes ephedrannin A and mahuannin, catechins, and a trace of volatile oil containing terpinen-4-ol, α-terpineol, linalool and other monoterpenes.

**Use and indications**
Ephedra is used traditionally for asthma, bronchitis, hayfever and colds, but recently the herb has become liable to abuse as a stimulant and slimming aid. For this reason the herb has been banned by the FDA in the US. Its main active constituents are ephedrine and pseudoephedrine; however, ephedra herb is claimed to have many more effects than those ascribed to ephedrine and its derivatives. It is these compounds that also give rise to the toxic effects of ephedra.

**Pharmacokinetics**
No relevant pharmacokinetic data found.

**Interactions overview**
Ephedra herb contains ephedrine and pseudoephedrine, and therefore has the potential to interact in the same manner as conventional medicines containing these substances. The most notable of these interactions is the potential for hypertensive crises with MAOIs; it would therefore seem unwise to take ephedra during, or for 2 weeks after, the use of an MAOI. There do not seem to be any reports of drug interactions for ephedra itself, with the exception of caffeine.
Ephedra + Caffeine

Ephedrine can raise blood pressure and in some cases this may be further increased by caffeine. Combined use has resulted in hypertensive crises in a few individuals. Isolated reports describe the development of acute psychosis when caffeine was given with ephedra.

Clinical evidence
A review of reports from the FDA in the US revealed that several patients have experienced severe adverse effects (subarachnoid haemorrhage, cardiac arrest, hypertension, tachycardia and neurosis) after taking dietary supplements containing ephedrine or ephedra alkaloids with caffeine. However, it is not possible to definitively say that these effects were the result of an interaction because none of the patients took either drug separately. Similarly, a meta-analysis assessing the safety of ephedra or ephedrine and caffeine found a two- to threefold increase in the risk of adverse events (including psychiatric symptoms and palpitations) with ephedra or ephedrine, but concluded that it was not possible to assess the contribution of caffeine to these events.

Two episodes of acute psychosis occurred in a 32-year-old man after he took Vigueur fit tablets (containing ephedra alkaloids and caffeine), Red Bull (containing caffeine) and alcohol. He had no previous record of aberrant behaviour despite regularly taking 6 to 9 tablets of Vigueur fit daily (about twice the recommended dose). However, on this occasion, over a 10-hour period, he consumed 3 or 4 bottles of Red Bull (containing about 95 mg of caffeine per 250-mL bottle) and enough alcohol to reach a blood-alcohol level of about 335 mg%. No more episodes occurred after he stopped taking the Vigueur fit tablets. Ephedra alkaloids (ephedrine and pseudoephedrine) may cause psychosis and it appears that their effects may be exaggerated by an interaction with caffeine and alcohol. In another case report, an ischaemic stroke that occurred in a 33-year-old man was thought to be due to taking a supplement called Thermadrene, (now reformulated, but which at the time contained ephedrine, guarana, caffeine, cayenne pepper and willow bark). The use of bupropion may have been a contributory factor. A similar case of stroke is reported in a man who took a creatine supplement with ephedra plus caffeine. In this case, the interaction was attributed to creatine. See Creatine + Herbal medicines; Ephedra with Caffeine, page 157.

Experimental evidence
In a study, rats were given an oral solution of ephedra (containing up to 50 mg/kg ephedrine) with, and without, caffeine. Ephedra with caffeine increased the clinical signs of toxicity (salivation, hyperactivity, ataxia, lethargy, failure to respond to stimuli) in the treated rats, when compared with ephedrine alone. Histological analysis for cardiotoxicity showed some evidence of haemorrhage, necrosis, and tissue degeneration within 2 to 4 hours of treatment. No statistical difference in the occurrence of cardiotoxic lesions was found when animals treated with ephedrine were compared with those treated with ephedra, indicating that the cardiotoxic effects of ephedra are due to ephedrine.

Another study also reported that cardiac toxicity was observed in 7- and 14-week-old male rats administered ephedrine (25 mg/kg) in combination with caffeine (30 mg/kg) for one or two days. The ephedrine and caffeine dosage was approximately 12-fold and 1.4-fold, respectively, above average human exposure. Five of the seven treated 14-week-old rats died or were sacrificed 4 to 5 hours after the first dose, and massive interstitial haemorrhage was reported.

Mechanism
Ephedrine and caffeine may cause catecholamine release and an increase in intracellular calcium release which leads to vasoconstriction. Myocardial ischaemia may occur as a result of this vasoconstriction (in the coronary artery), and this may result in myocardial necrosis and cell death.

Importance and management
The interaction between ephedra alkaloids and caffeine is fairly well established. However, it has to be said that there seem to be few reports of adverse interactions specifically with ephedra alkaloids. One possible explanation for this could be that these interactions may go unrecognised or be attributed to one drug only, whereas caffeine may also have been taken either as part of the preparation or in beverages or foods (often not reported). Nevertheless, a number of serious adverse events have been reported and these preparations may pose a serious health risk to some users. The risk may be affected by individual susceptibility, the additive stimulant effects of caffeine, the variability in the contents of alkaloids or pre-existing medical conditions. Note that the FDA has banned combinations of caffeine and herbal products containing ephedra. It would seem prudent to avoid concurrent use.


Ephedra + Food
No interactions found.

Ephedra + Herbal medicines
No interactions found.
Epimedium

Epimedium brevicomum Maxim. (Berberidaceae)

Synonym(s) and related species
Barrenwort, Horny goat weed, Yin Yang Huo.

There is some taxonomic confusion within the species, and most of the commercially available material has not been properly characterised. In Chinese medicine, a mixture of species (referred to as Herba Epimedii) is often used and includes the following species (some of which may be synonyms): *Epimedium koreanum* Nakai, *Epimedium pubescens* Maxim., *Epimedium sagittatum* (Sieb. Et Zucc) Maxim and *Epimedium wushanense* T.S.Ying.

Constituents
The major constituents of all species of epimedium are prenylated flavonoids and isoflavones: the most important are icariin, epimedin A, B and C, and 6-prenylchrysin. Apigenin, luteolin, kaempferol and quercetin are also present. A multitude of other constituents, for which the pharmacological relevance is unclear, have been identified.

Use and indications
Epimedium is used traditionally as an antirheumatic, tonic and to enhance bone health and treat osteoporosis. The isoflavones and prenylated flavones have oestrogenic activity.

The herb is also used to enhance sexual function. Legend has it that this use was discovered after a goat herd in China found that his animals became much more sexually active after eating the herb, hence the name horny goat weed. It has therefore been widely advertised as a ‘herbal Viagra’.

Pharmacokinetics
In vitro, freeze-dried aqueous extracts of Herba Epimedii have been found to have some inhibitory effect on the cytochrome P450 isoenzyme CYP1A2, an effect thought to be related to the quercetin content of the herb. Extracts of Herba Epimedii may also inhibit (in decreasing order of potency) CYP2C19, CYP2E1, CYP2C9, CYP3A4, and CYP2D6, but the clinical relevance of this has not been established. See flavonoids, page 186, for information on the pharmacokinetics of individual flavonoids present in epimedium.

Interactions overview
Little is known. Epimedium may have additive effects with other medicines used for erectile dysfunction. For information on the interactions of the individual flavonoids present in epimedium, see flavonoids, page 186.

Epimedium + Food

No interactions found.

Epimedium + Herbal medicines

No interactions found.

Epimedium + Phosphodiesterase type-5 inhibitors

The interaction between epimedium and phosphodiesterase type-5 inhibitors is based on experimental evidence only.

**Clinical evidence**

No interactions found.

**Experimental evidence**

An *in vitro* study using rabbit corpus cavernosum tissue found that an aqueous extract of *Epimedium brevicornum* relaxed the smooth muscle of the corpus cavernosum. The extract also enhanced the relaxation caused by sildenafil, tadalafil and vardenafil.¹

**Mechanism**

Epimedium appears to have a similar mode of action to the phosphodiesterase type-5 inhibitors. *In vitro*, an extract of *Epimedium brevicornum* and one of its constituents, icariin, have been found to inhibit phosphodiesterase type-5, although both had weaker effects than sildenafil.²

**Importance and management**

Evidence is limited to experimental studies, but what is known suggests that epimedium may potentiate the effects of the phosphodiesterase type-5 inhibitors, sildenafil, tadalafil and vardenafil. The results of *in vitro* studies are difficult to reliably extrapolate to humans. Nevertheless, the concurrent use of epimedium and a phosphodiesterase type-5 inhibitor could potentially lead to additive effects, which may be beneficial, but which could in theory also lead to adverse effects, such as priapism. It would therefore seem prudent to discuss concurrent use with patients, and warn them of the potential risks. Note that it is generally recommended that other agents for erectile dysfunction should be avoided in those taking sildenafil, tadalafil or vardenafil.

Evening primrose oil
Oenothera biennis L. (Onagraceae)

Synonym(s) and related species
Common evening primrose, King’s cureall, Sun drop, Tree primrose.
Oenothera lamarkiana, Onagra biennis (L.) Scop.

Pharmacopoeias
Evening primrose oil (BP 2009, Ph Eur 6.4).

Constituents
The oil from evening primrose seeds contains the essential fatty acids of the omega-6 series, linoleic acid (about 65 to 85%) and gamolenic acid (gamma-linolenic acid, about 7 to 14%). Other fatty acids include oleic acid, alpha-linolenic acid, palmitic acid and stearic acid.

Use and indications
Evening primrose oil is used as a food supplement to provide essential fatty acids. It is also used for atopic eczema and mastalgia; however, in the UK licences for two prescription products containing gamolenic acid derived from evening primrose oil were withdrawn in 2002, due to lack of evidence in support of efficacy.

Other conditions for which it is used include rheumatoid arthritis, premenstrual syndrome, menopausal symptoms, chronic fatigue syndrome and attention deficit hyperactivity disorder. Evening primrose oil has also been used topically as a cream, for the relief of dry or inflamed skin. Traditionally it has been used for asthma, whooping cough, gastrointestinal disorders, and as a sedative painkiller.

In manufacturing, evening primrose oil is used in soaps and cosmetics. The root of evening primrose has been used as a vegetable.

Pharmacokinetics
In in vitro experiments,\(^1\) cis-linoleic acid, was found to be a modest inhibitor of the cytochrome P450 isoenzyme CYP2C9 (but this is not expected to result in clinically relevant effects on drug metabolism, see warfarin and related drugs, page 181), and a modest to minor inhibitor of, in order of potency, CYP1A2, CYP2C19, CYP3A4 and CYP2D6.

Interactions overview
Evening primrose oil has been predicted to interact with antiplatelet and anticoagulant drugs, but data supporting this prediction are limited. Although seizures have occurred in a few schizophrenics taking phenothiazines and evening primrose oil, no adverse effects were seen in others, and there appears to be no firm evidence that evening primrose oil should be avoided by epileptic patients.

Evening primrose oil + Antiplatelet drugs

Evening primrose oil can inhibit platelet aggregation and increase bleeding time. It has therefore been suggested that it may have additive effects with other antiplatelet drugs, but evidence of this is generally lacking.

Clinical evidence

In 12 patients with hyperlipidaemia given evening primrose oil 3 g daily for 4 months, platelet aggregation decreased and bleeding time increased by 40%. The evening primrose oil was given in the form of six 500-mg soft-gel capsules and the daily dose contained linoleic acid 2.2 g and gamolenic acid 240 mg.

Experimental evidence

Similar findings to the clinical study above have been reported in animals given evening primrose oil or gamolenic acid.

Mechanism

Prostaglandin E₁ (which has antiplatelet properties) and thromboxane (which promotes platelet aggregation) are formed from gamolenic acid. Supplementing the diet with gamolenic acid has been shown to augment the production of prostaglandin E₁ and, because prostaglandin E₁ is also preferentially formed (the conversion of gamolenic acid to thromboxane is slower), evening primrose oil could inhibit platelet aggregation. This effect could be additive with the effects of other antiplatelet drugs.

Importance and management

Information is limited to one clinical study, in which patients were not taking conventional antiplatelet drugs, and experimental data. Based on the potential antiplatelet effects of evening primrose oil, some authors suggest that patients taking antiplatelet drugs should use evening primrose oil cautiously or not at all. This seems overly cautious because evening primrose oil is a widely used herbal product, and was formerly used as a prescription product in the UK, and clinical reports of an interaction have yet to come to light. Furthermore, the concurrent use of two conventional antiplatelet drugs is not uncommon.

Evidence, mechanism, importance and management

Gamolenic acid, a major constituent of evening primrose oil, is a precursor of prostaglandin E₁, which inhibits the synthesis of tumour necrosis factor-α (which has an important effect in the inflammatory processes of rheumatoid arthritis). Supplementing the diet with gamolenic acid has been shown to augment the production of prostaglandin E₁, which has a rate-limiting step mediated by cyclooxygenase-2. Theoretically, the production of prostaglandin E₁, and therefore the anti-inflammatory effects of gamolenic acid, could be opposed by the concurrent use of NSAIDs because both selective and non-selective NSAIDs inhibit cyclooxygenase-2. However, evening primrose oil is often used alongside conventional treatments for arthritis and two clinical studies found that high doses of gamolenic acid reduced pain and swelling of the joints of arthritic patients when given with usual doses of NSAIDs. This theoretical interaction therefore appears to be of little clinical importance.


Evening primrose oil + Food

No interactions found.

Evening primrose oil + Herbal medicines

No interactions found.

Evening primrose oil + NSAIDs

The interaction between evening primrose oil and NSAIDs is based on a prediction only.

Evening primrose oil + Phenothiazines

Although seizures have occurred in a few schizophrenics taking phenothiazines and evening primrose oil, no adverse effects were seen in others, and there appears to be no firm evidence that evening primrose oil should be avoided by epileptic patients.

Clinical evidence

Twenty-three patients were enrolled in a placebo-controlled study of evening primrose oil in schizophrenia. During the treatment phase, patients were given 8 capsules of Efamol in addition to their normal medication. Seizures developed in 3 patients, one during treatment with placebo. The other two patients were taking evening primrose oil: one was receiving fluphenazine decanoate 50 mg once every 2 weeks and the other fluphenazine decanoate 25 mg once every 2 weeks with thioridazine, which was later changed to chlorpromazine. In another study, 3 long-stay hospitalised schizophrenics were taking evening primrose oil. Their schizophrenia became much worse and all 3 patients showed EEG evidence of temporal lobe epilepsy.

In contrast, no seizures or epileptiform events were reported in a crossover study in 48 patients (most of them schizophrenics) taking phenothiazines when they were given evening primrose oil for 4 months. Concurrent use was also apparently uneventful in another study in schizophrenic patients.

Experimental evidence

No relevant data found.

Mechanism

Not understood. One suggestion is that evening primrose oil possibly increases the well-recognised epileptogenic effects of the phenothiazines, rather than having an epileptogenic action of its own. Another idea is that it might unmask temporal lobe epilepsy.

Importance and management

The interaction between phenothiazines and evening primrose oil is not well established, nor is its incidence known, but clearly some caution is appropriate during concurrent use, because seizures may develop in a few individuals. There seems to be no way of identifying the patients at particular risk. The extent to which the underlying disease condition might affect what happens is also unclear.

No interaction between antiepileptics and evening primrose oil has been established and the reports cited above appear to be the
sole basis for the suggestion that evening primrose oil should be avoided by epileptics. No seizures appear to have been reported in patients taking evening primrose oil in the absence of phenothiazines. One review,5 analysing these two reports, goes as far as suggesting that formularies should now remove seizures or epilepsy as an adverse effect of evening primrose oil because the evidence for the seizures clearly point to the phenothiazines taken. Moreover, the manufacturers of Epogam, an evening primrose oil preparation, claim that it is known to have improved the control of epilepsy in patients previously uncontrolled with conventional antiepileptic drugs, and other patients are said to have had no problems during concurrent treatment.6


Evening primrose oil + Warfarin and related drugs

The information regarding the use of evening primrose oil with warfarin is based on experimental evidence only.

Clinical evidence
No interactions found.

Experimental evidence
In vitro, cis-linoleic acid was found to be a moderate inhibitor of the cytochrome P450 isoenzyme CYP2C9, which is the main isoenzyme involved in the metabolism of warfarin. However, it was 26-fold less potent than sulfaphenazole,1 a drug known to have clinically relevant inhibitory effects on CYP2C9 in vivo.

Mechanism
Prostaglandin E1 (which has antiplatelet properties) and thromboxane (which promotes platelet aggregation) are formed from gamolenic acid. Supplementing the diet with gamolenic acid has been shown to augment the production of prostaglandin E1 and, because prostaglandin E1 is also preferentially formed (the conversion of gamolenic acid to thromboxane is slower), evening primrose oil could inhibit platelet aggregation. This effect could slightly increase the risk of bleeding with anticoagulants.

Importance and management
Evening primrose oil seems unlikely to alter the pharmacokinetics of warfarin. Other coumarins are metabolised by a similar route to warfarin, and are therefore also unlikely to be affected. However, based on the potential antiplatelet effects of evening primrose oil, some authors2 suggest that patients taking anticoagulants should use evening primrose oil cautiously or not at all. This seems overly cautious because evening primrose oil is a widely used herbal product, and was formerly used as a prescription product in the UK, and clinical reports of an interaction have yet to come to light.

Fenugreek  
Trigonella foenum-graecum L. (Fabaceae)

**Synonym(s) and related species**
Bird’s foot, Bockshornsame, Foenugreek, Greek hay.
Not to be confused with Bird’s foot trefoil, which is *Lotus corniculatus*.

**Pharmacopoeias**
Fenugreek (*Ph Eur 6.4*).

**Constituents**
Fenugreek seeds are about 25% protein (particularly lysine and tryptophan) and about 50% mucilaginous fibre. The seeds also contain flavonoids (luteolin, quercetin and vitexin). Saponins, natural coumarins and vitamins (nicotinic acid) are also present.

**Use and indications**
The seeds of fenugreek have been used as an appetite stimulant and for digestive disorders (including constipation, dyspepsia and gastritis). It has also been used in respiratory disorders and is said to be an expectorant. Topically, fenugreek has been used for wounds and leg ulcers, and as an emollient. It has been reported to have hypocholesterolaemic and hypoglycaemic activity.

**Pharmacokinetics**
No relevant pharmacokinetic data found. For information on the pharmacokinetics of individual flavonoids present in fenugreek, see under flavonoids, page 186.

**Interactions overview**
Fenugreek saponins may modestly enhance the antidiabetic effects of the sulfonylureas. For a case report describing a raised INR in a patient taking a herbal medicine containing boldo and fenugreek, see Boldo + Warfarin and related drugs, page 79. For information on the interactions of individual flavonoids present in fenugreek, see under flavonoids, page 186.
In one study, fenugreek saponins had modest additional antidiabetic effects when they were added to established treatment with sulfonylureas.

Clinical evidence
Fenugreek seed appears to have been widely studied for its blood-glucose-lowering properties; however, studies on its effects in combination with conventional treatments for diabetes appear limited. In one randomised study, 46 patients taking sulfonylureas (not named), with fasting blood-glucose levels of 7 to 13 mmol/L, were given fenugreek saponins 2.1 g three times daily after meals for 12 weeks. When compared with 23 similar patients given placebo it was found that fenugreek saponins decreased fasting blood-glucose levels by 23% (8.38 mmol/L versus 6.79 mmol/L). Diabetic control was also improved: glycosylated haemoglobin levels were about 20% lower in the treatment group (8.2% versus 6.56%). The fenugreek saponin preparation was an extract of total saponins of fenugreek given as capsules containing 0.35 mg per capsule, equivalent to 5.6 g of crude fenugreek.

Experimental evidence
The blood-glucose-lowering activity of fenugreek and its extracts has been well studied in animal models; however, there appear to be no data directly relating to interactions.

Mechanism
It is suggested that fenugreek decreases blood-glucose levels by affecting an insulin signalling pathway.

Importance and management
Evidence on the use of fenugreek with conventional antidiabetic medicines appears to be limited to this one study, which suggests that fenugreek may have some modest additional blood-glucose-lowering effects to those of the sulfonylureas. As these modest effects were apparent over a period of 12 weeks it seems unlikely that a dramatic hypoglycaemic effect will occur.

Fenugreek + Antidiabetics
Fenugreek + Food
No interactions found. Fenugreek is often used as a flavouring in foodstuffs.

Fenugreek + Herbal medicines
No interactions found.

Fenugreek + Warfarin and related drugs
For a case report describing a raised INR in a patient taking a herbal medicine containing boldo and fenugreek, see Boldo + Warfarin and related drugs, page 79.

Feverfew

*Tanacetum parthenium* Sch.Bip. (Asteraceae)

**Synonym(s) and related species**
Altamisa, Featherfew, Featherfoil, Midsummer daisy.

*Chrysanthemum parthenium* (L.) Bernh., *Leucanthemum parthenium* (L.) Gren & Godron, *Pyrethrum parthenium* (L.) Sm.

**Pharmacopoeias**
Feverfew (*BP 2009*, *Ph Eur 6.4*, *USP 32*); Powdered Feverfew (*USP 32*).

**Constituents**
The leaf and aerial parts contain sesquiterpene lactones, especially *parthenolide*, its esters and other derivatives, santamarin, reynosin, artemorin, partholide, chrysanthemolin and others. The volatile oil is composed mainly of α-pinene, bornyl acetate, bornyl angelate, costic acid, camphor and spirotekal ethers.

**Use and indications**
Feverfew is mainly used for the prophylactic treatment of migraine and tension headache, but it has antiplatelet and anti-inflammatory activity, and has been used for coughs, colds and rheumatic conditions. It can cause allergic and cytotoxic reactions due to the presence of sesquiterpene lactones with an α-methylene butyrolactone ring, as in parthenolide.

**Pharmacokinetics**
In a study investigating the *in vitro* inhibitory potency of an extract of feverfew using a commercially available mixture of cytochrome P450 isoenzymes, and established substrates of these isoenzymes, the feverfew extract modestly inhibited the activity of CYP1A2, CYP2C8, CYP2C9, CYP2C19 and CYP3A4.¹ The findings of *in vitro* studies cannot be directly extrapolated to humans, but positive findings such as these suggest that further study is required.

In an *in vitro* study, the transport of parthenolide, a constituent of feverfew, was not affected by the presence of MK-571, an inhibitor of P-glycoprotein.²

**Interactions overview**
Feverfew inhibits platelet aggregation *in vitro* and, theoretically, might increase the risk of bleeding in patients taking other drugs that increase bleeding such as aspirin or anticoagulants.

**Feverfew + Anticoagulants**

The interaction between feverfew and anticoagulants is based on a prediction only.

**Evidence, mechanism, importance and management**

The manufacturer¹ advises that feverfew as a herbal medicine may theoretically interact with warfarin and increase the risk of bleeding on the basis of its *in vitro* antiplatelet effects (see Feverfew + Antiplatelet drugs, below). However, they note that the clinical relevance of this *in vivo* is unknown.² Some reviews also note this potential for an interaction and suggest that concurrent use should be avoided.³ Clinically the use of an antiplatelet drug with an anticoagulant should generally be avoided in the absence of a specific indication. It may therefore be prudent to advise against concurrent use. However, if concurrent use is felt desirable, the risks and benefits of treatment should be considered. It would seem sensible to warn patients to be alert for any signs of bruising or bleeding, and report these immediately, should they occur.


---

**Feverfew + Antiplatelet drugs**  

Feverfew inhibits platelet aggregation *in vitro* and, theoretically, might have additive effects with conventional antiplatelet drugs.

**Clinical evidence**

A letter briefly describes a study in which platelet aggregation was assessed in samples taken from 10 patients who had taken feverfew for at least 3.5 years. The platelets aggregated normally in response to thrombin and ADP; however, the response to serotonin and U46619 (a thromboxane mimic) was attenuated, and occurred only at higher doses.¹

**Experimental evidence**

In a number of early *in vitro* studies, mostly by the same research group, feverfew was found to inhibit platelet aggregation.²–⁴ In these studies, feverfew extracts inhibited ADP, thrombin and collagen-induced platelet aggregation,⁵–⁷ and inhibited the uptake⁸ and release of arachidonic acid.⁹,¹⁰ Parthenolide, a constituent of feverfew, has also been shown to inhibit platelet aggregation *in vitro.*¹¹

**Mechanism**

Unclear. It was suggested that the mechanism of platelet inhibition is neutralisation of sulfhydryl groups within the platelets, although the exact sulfhydryl groups involved still need to be defined.¹²

**Importance and management**

There appears to be only one clinical study, which does not wholly substantiate the *in vitro* findings that feverfew inhibits platelet aggregation in response to certain chemical stimuli. However, the study does support the finding of somewhat reduced platelet responsiveness. It could be argued that any interaction should have come to light by now, since feverfew has been in fairly widespread use for the management of migraines, and, in this setting, it is likely to have been taken with aspirin and NSAIDs. On the other hand, the small increased risk of bleeding with low-dose aspirin has required very large retrospective comparisons to establish. Concurrent use need not be avoided (indeed combinations of antiplatelet drugs are often prescribed together) but it may be prudent to be aware of the potential for increased bleeding if feverfew is given with other antiplatelet drugs such as aspirin and clopidogrel. Patients should discuss any episode of prolonged bleeding with a healthcare professional.


---

**Feverfew + Food**

No interactions found.

---

**Feverfew + Herbal medicines**

No interactions found.
The flavonoids are a large complex group of related compounds, which are widely available in the form of dietary supplements, as well as in the herbs or foods that they are originally derived from. They are the subject of intensive investigations and new information is constantly being published.

You may have come to this monograph via a herb that contains flavonoids. Note that the information in this general monograph relates to the individual flavonoids, and the reader is referred back to the herb (and vice versa) where appropriate. It is very difficult to confidently predict whether a herb that contains one of the flavonoids mentioned will interact in the same way. The levels of the flavonoid in the particular herb can vary a great deal between specimens, related species, extracts and brands, and it is important to take this into account when viewing the interactions described below.

Types, sources and related compounds

Flavonoids are a very large family of polyphenolic compounds synthesised by plants that are common and widely distributed. With the exception of the flavonols (e.g. catechins) and their polymers, the proanthocyanidins, they usually occur naturally bound to one or more sugar molecules (flavonoid glycosides) rather than as the free aglycones. The sub-groups of flavonoids, their main representatives, and their principal sources are as follows:

- **Flavones:** e.g. apigenin, luteolin; found in celery, page 123, and parsley, page 304. The rind of citrus fruits is rich in the polymethoxylated flavones, tangeretin (from tangerine), nobiletin and sinensetin.

- **Flavanols:** e.g. quercetin, kaempferol, myricetin,isorhamnetin; widely distributed in berries, teas, broccoli, apples and onions. **Rutin** (sophorin), also known as quercetin-3-rutinoside, is a common glycoside of quercetin; other glycosides include querctin, baicalin and hyperin. **Morin** is a flavonol found in *Morus* species.

- **Flavanones:** e.g. hesperetin (from oranges), naringenin (from grapefruit), eriodictyol (from lemons); and their glycosides, hesperidin, **naringin** and eriocitrin. They are most concentrated in the membranes separating the fruit segments and the white spongy part of the peel. Flavanone glycosides are often present in supplements as **citrus bioflavonoids**.

- **Flavanols (Flavan-3-ols):** monomers, e.g. catechins and gallic acid esters of catechins, epicatechins and gallic acid esters of epicatechins; found in teas, page 382, (particularly green and white), cocoa, page 139, grapes, berries, and apples. **Dimers,** e.g. theaflavins and gallic acid esters of theaflavins, and thearubigins also found in teas, page 382 (particularly black and oolong). **Proanthocyanidins** are polymers of flavanols, also known as condensed tannins, the most frequent being **procyanidins** (polymers of catechin and epicatechin). Found widely in cocoa, page 139, some berries and nuts, hops, page 251 and grapeseed, page 239.

- **Anthocyanins:** e.g. cyanidin, delphinidin, malvidin, pelargonidin, peonidin and petunidin; found widely in chocolate, apples, red, blue and purple berries, red and purple grapes, and red wine.

- **Isoflavones (Isoflavonoids):** are a distinct group of flavonoids with phytoestrogenic effects and are considered elsewhere, see isoflavones, page 258.

Use and indications

Some prospective cohort studies show that a high dietary intake of flavonoid-rich foods is associated with a reduced risk of coronary heart disease, but they do not all show this effect. Other cohort and case–control studies show a reduced risk of some cancers. However, there do not appear to be any studies to show whether isolated flavonoid supplements confer similar benefits to flavonoid-rich foods.

Many beneficial properties have been identified for flavonoids, one of the most popularly cited being their antioxidant activity. Other actions that are proposed to contribute to their biological effects include chelating metal ions, stimulating phase II detoxifying enzyme activity, inhibiting proliferation and inducing apoptosis, reducing inflammation, decreasing vascular cell adhesion molecule expression, increasing endothelial nitric oxide synthase (eNOS) activity and inhibiting platelet aggregation.

Pharmacokinetics

The bioavailability of flavonoids is relatively low due to limited absorption and rapid elimination, and they are generally rapidly and extensively metabolised. Flavonoid esters, glycosides or polymers require hydrolysis to the free aglycone before absorption, and this occurs by intestinal enzymes (e.g. beta-glucosidases) and colonic bacteria. During absorption, the aglycone is then conjugated by sulfation, glucuronidation or methylation. These conjugates are excreted back into the intestine by efflux pumps. Those absorbed are eventually excreted in the urine and bile, and may undergo enterohepatic recycling. It appears that metabolism of flavonoids by cytochrome P450 isoenzymes is probably minor compared with conjugation reactions for flavonoids.

The potential for flavonoids to alter drug metabolism by cytochrome P450 isoenzymes, in particular, and also
intestinal and hepatic drug transporters, such as P-glycoprotein, has been extensively investigated in vitro. There are also some animal studies, but few human clinical pharmacokinetic studies, and those that are available have generally used very high doses of the flavonoids.

There is at present no reason to avoid flavonoids in the diet, or in the form of herbal medicines (most of which contain significant amounts of flavonoids naturally), and many positive reasons for including them. However, very high doses (such as the use of specific flavonoid supplements) could potentially alter the metabolism of other drugs that are substrates for CYP3A4 and/or P-glycoprotein, and increase the bioavailability of some drugs; for instance the statins, page 194, such as lovastatin and simvastatin; ciclosporin, page 190; benzodiazepines, page 189, such as midazolam; and digoxin, page 191.

**Interactions overview**

The interactions covered in this monograph relate to individual flavonoids. It may be possible to directly extrapolate some of these interactions to some flavonoid supplements, especially those regarding quercetin; however, caution must be taken when applying these interactions to herbs or foods known to contain the flavonoid in question. This is because the amount of the flavonoid found in the herb or food must be considered (this can be highly variable, and might not be known) and the other constituents present in the herb or food might affect the bioavailability or activity of the flavonoid (information that is usually unknown). Therefore, although data on isolated flavonoids are useful, it is no substitute for direct studies of the herb, food or dietary supplement in question.

Flavonoids + Aciclovir

The interaction between quercetin and aciclovir is based on experimental evidence only.

Evidence, mechanism, importance and management

Findings from an in vitro study suggest that quercetin might modestly increase the absorption of oral aciclovir by inhibiting intestinal P-glycoprotein. The effect of high-dose quercetin (80 mg/L) was equivalent to that of verapamil 10 mg/L, which is an established, clinically relevant inhibitor of P-glycoprotein. However, because aciclovir has a wide therapeutic index, even if this change is seen in practice, it is unlikely to be clinically important.


Flavonoids + Antibacterials

The interaction between flavonoids and antibacterials is based on experimental evidence only.

Evidence, mechanism, importance and management

**(a) Aminoglycosides**

In a study, rats were given either the aglycone baicalein or the parent flavone baicalin orally. The bioavailability of baicalin from the parent flavone was reduced from 28% to about 8% in rats given neomycin and streptomycin, when compared with rats not given these antibacterials, but the antibacterials did not affect the bioavailability of administered baicalein.

These antibacterials decimate colonic bacteria, which are involved in the hydrolysis of baicalin to baicalein. This study used the combination of neomycin and streptomycin because previous research had shown that this combination was most effective in reducing intestinal microflora, and that a single aminoglycoside did not have this effect.

These findings are likely to have little clinical relevance, because individuals are rarely given combinations of aminoglycosides with such potent effects on colonic microflora. It would be of use to know the effect of standard broad-spectrum antibacterials in general clinical use. However, even these are only given for short courses, so any reduction in the effect of the flavonoid would be short-lived.

**(b) Nitrofurantoin**

In a study in rats, oral administration of high-dose chrysin 200 mg/kg increased the AUC of nitrofurantoin by about 76%, and decreased its clearance by 42%, whereas low-dose chrysin 50 mg/kg had no effect on the pharmacokinetics of nitrofurantoin.

Available evidence suggests that chrysin increases the AUC of nitrofurantoin by inhibition of the transporter protein BCRP.

The doses used in this study were much greater than those likely to be encountered clinically, and therefore these data suggest that even high doses of chrysin used as dietary supplements (e.g. 3 g daily) are unlikely to have a clinically important effect on nitrofurantoin pharmacokinetics.


Flavonoids + Anticoagulant or Antiplatelet drugs

The interaction between flavonoids and anticoagulant or antiplatelet drugs is based on a prediction only.

Clinical evidence

There are few clinical studies investigating whether the in vitro antiplatelet effect of flavonoids occurs in humans, and whether this effect could be clinically relevant, and findings are not consistent. Some studies are cited in the following section as examples to illustrate the differences.

**Antiplatelet effects**

In one randomised controlled study, a cocoa supplement (234 mg of cocoa flavanols and procyanidins daily) given for 28 days decreased collagen- and ATP-induced platelet aggregation when compared with placebo.

Similarly, onion soup high in quercetin (one ‘dose’ of about 69 mg) inhibited collagen-stimulated platelet aggregation.

However, in another study, neither dietary supplementation with onions 220 g daily (providing quercetin 114 mg daily) nor supplementation with parsley 4.9 g daily (providing apigenin 84 mg daily) for 7 days affected platelet aggregation or other haemostatic variables.

Similarly, a supplement containing quercetin 1 g daily and other flavonoids did not affect platelet aggregation in a placebo-controlled study in healthy subjects.

In a single-dose study in healthy subjects, a flavanol-rich cocoa beverage (897 mg total flavonoids in 300 mL) had a similar, but less marked, effect than aspirin 81 mg on adrenaline-stimulated platelet activation and function. The effect of the cocoa beverage and aspirin appeared to be additive.

**Experimental evidence**

Numerous in vitro studies show that many flavonoids, and flavanols and procyanidins in particular, inhibit platelet aggregation, and this has been suggested as a mechanism to explain why some epidemiological studies show that a diet high in flavonoids is associated with a reduced risk of cardiovascular disease.

**Mechanism**

Flavonoids might have antiplatelet effects, which, if confirmed, could be additive with other antiplatelet drugs. In addition, they might increase the risk of bleeding when used with anticoagulants.

**Importance and management**

There is a large amount of information regarding an interaction between flavonoids and antiplatelet drugs, but an interaction is not established. There is a well-established small increased risk of bleeding when aspirin at antiplatelet doses is combined with the anticoagulant drug warfarin. Theoretically, very high intakes of flavonoids (e.g. from supplements) might have similar clinically important antiplatelet effects, and could therefore increase the risk of bleeding when taken with any anticoagulant drug, and have additive effects with antiplatelet drugs. However, available evidence is conflicting, with some studies showing that a number of flavonoids have antiplatelet effects and others finding no antiplatelet effects. Until more is known, some caution might be appropriate with high doses of flavonoid supplements. In practice this would mean being aware of an increased risk of bleeding, and patients being alert for symptoms of bleeding, such as petechiae and bruising. Modest doses of flavonoids are unlikely to cause any problems.


---

### Flavonoids + Benzodiazepines

In a study, tangerine juice, containing tangeretin, did not affect the pharmacokinetics of midazolam. However, grapefruit juice, which contains different flavonoids, does increase levels of some benzodiazepines.

**Clinical evidence**

In a crossover study in 8 healthy subjects, tangerine juice (which contains the flavone tangeretin) 100 mL, given 15 minutes before and with a single 15-mg dose of oral midazolam, had no effect on the AUC and elimination of midazolam. The only change was a slight delay in midazolam absorption.

Note that grapefruit juice (a rich source of flavonoids) has a well-established inhibitory effect on the metabolism of some benzodiazepines, resulting in increased production (1.5- to 3.5-fold increase in AUC).

**Experimental evidence**

**(a) Anxiolytic effect**

In various animal models, the anxiolytic effects were additive for diazepam and baicalin, and synergistic for diazepam and hesperidin.

**(b) Pharmacokinetics**

*In vitro*, tangeretin (a flavone from tangerine) stimulated the hydroxylation of midazolam in human liver microsomes. Conversely, in another study, quercetin was found to be an inhibitor of the metabolism of midazolam, with kaempferol and naringenin also having some effect.

**Mechanism**

Theoretically, flavonoids might inhibit the metabolism of some benzodiazepines by the cytochrome P450 isoenzyme CYP3A4 (note that not all benzodiazepines are metabolised by this route). Some flavonoids have anxiolytic properties in animal models.

**Importance and management**

Contrary to what was predicted from *in vitro* studies using tangeretin, a single dose of tangerine juice did not appear to alter the pharmacokinetics of midazolam. In contrast, grapefruit juice, which contains different flavonoids, does increase levels of some benzodiazepines. However, grapefruit juice also affects the levels of some calcium-channel blockers, but studies with the flavonoid naringin have found no interaction, suggesting that naringin is not the primary active constituent of grapefruit juice (see calcium-channel blockers, below). Therefore individual flavonoids might not be anticipated to increase benzodiazepine levels. Furthermore, although evidence is preliminary, it is possible that high doses of some individual flavonoids such as hesperidin and baicalin might have additive anxiolytic effects with benzodiazepines, suggesting a possible pharmacodynamic interaction.

This suggests that, until more is known, some caution might be appropriate if citrus bioflavonoids are used with benzodiazepines, bearing in mind the possibility of increased benzodiazepine effects.

---

### Flavonoids + Calcium-channel blockers

Supplements of specific citrus bioflavonoids do not appear to affect the pharmacokinetics of calcium-channel blockers to a clinically relevant extent.

**Clinical evidence**

**(a) Felodipine**

In a crossover study in 9 healthy subjects, 200 mL of an aqueous solution of naringin 450 micrograms/mL had no effect on the mean AUC of a single 5-mg dose of felodipine. This contrasted with the effect of 200 mL of grapefruit juice (determined to have the same naringin level), which doubled the AUC of felodipine. In another study, in 12 healthy subjects, the liquid fraction (after centrifugation and filtration) of grapefruit juice, which contained naringin 148 mg, had less effect on the AUC of felodipine than the particulate fraction (the sediment after centrifugation, which contained 7 mg of naringin; 20-fold less). The AUC of felodipine increased by about
Flavonoids

50% with the liquid fraction and by about 100% with the particulate fraction.2

(b) Nifedipine
In a crossover study in 8 healthy subjects, high-dose quercetin 200 mg given the night before, 100 mg given on waking and 100 mg given with nifedipine 10 mg had no effect on the AUC of nifedipine. This contrasted with the effect of 200 mL of double-strength grapefruit juice (a rich source of flavonoids), which increased the AUC of nifedipine by about 50%.3

(c) Nisoldipine
In a crossover study in 12 healthy subjects, the AUC of a single 20-mg dose of nisoldipine was not altered by naringin 185 mg (given simultaneously), but was increased by 75% by 250 mL of grapefruit juice (a rich source of flavonoids).4

Experimental evidence
One research group has extensively investigated the effects of various flavonoids on the pharmacokinetics of various oral calcium-channel blockers in rats and rabbits.5-10 In these studies, the flavonoids tested (morin, naringin, quercetin) caused dose-dependent increases in the AUC of diltiazem (30 to 120%).5,8 nimodipine (47 to 77%)9 and verapamil (27 to 72%).5,10 No effect was seen on the elimination half-life. An interaction occurred when the flavonoid was given 30 minutes before the calcium-channel blocker, but not when it was given simultaneously.7,10

Mechanism
The increased bioavailability of calcium-channel blockers in animals pretreated with morin, naringin or quercetin may result from inhibition of P-glycoprotein and the cytochrome P450 isoenzyme CYP3A4. However, no individual flavonoid has had any effect on the bioavailability of calcium-channel blockers in humans. It is probable that furanocoumarins are more important for the grapefruit interaction in humans,11 see also Natural coumarins + Feloipidine, page 300.

Importance and management
Experimental evidence for an interaction is extensive, but less is known about any interaction between flavonoids and calcium-channel blockers in humans. In contrast to the effect of grapefruit juice, no individual flavonoid has had any effect on the pharmacokinetics of a calcium-channel blocker in clinical studies (naringin with felodipine, quercetin with nimodipine, naringin with nisoldipine). Although, high doses of these flavonoids have increased levels of several calcium-channel blockers in animals, the clinical data seem to suggest that this is not applicable to humans. Supplements of specific citrus bioflavonoids are therefore unlikely to interact with calcium-channel blockers; however, an interaction might occur with extracts of grapefruit if these contain constituents other than just the flavonoids (e.g. furanocoumarins such as bergamottin). Consider also Grapefruit + Calcium-channel blockers, page 237.

Flavonoids + Ciclosporin

A study found that quercetin increased the bioavailability of ciclosporin.

Clinical evidence
In a study in 8 healthy subjects, a single 300-mg dose of ciclosporin was given four times: alone, with oral quercetin 5 mg/kg, 30 minutes after oral quercetin 5 mg/kg or after a 3-day course of quercetin 5 mg/kg twice daily. It was found that the AUC of ciclosporin was increased by 16% when given with a single dose of quercetin, by 36% when given after single-dose quercetin and by 46% when given after multiple-dose quercetin.1

Experimental evidence
(a) Nephrotoxicity
There are some data suggesting that flavonoids might reduce the renal toxicity of ciclosporin. For example, in one study in rats, quercetin given with ciclosporin for 21 days attenuated the renal impairment and morphological changes (such as interstitial fibrosis), when compared with ciclosporin alone.2

(b) Pharmacokinetics
In contrast to the clinical evidence above, in an animal study, giving single doses of oral ciclosporin with quercetin 50 mg/kg resulted in a 43% and 42% decrease in the AUC of ciclosporin in rats and pigs, respectively (note, this did not reach statistical significance in pigs).3 In a further study in rats, onion (which is a rich source of quercetin) caused a 68% reduction in the levels of ciclosporin given orally, but had no effect on the AUC of ciclosporin given intravenously.4 Similarly, in another study, morin decreased levels of ciclosporin in blood by a modest 33%, and also decreased levels in other tissues (by 17% to 45%). However, despite this reduction, the ciclosporin-suppressed Th1 immune response was not reduced by morin.5

In yet another study, the individual flavonoids baicalin and baicalein markedly increased ciclosporin levels in rats, whereas the root of baical skullcap, which contains these flavonoids, decreased the AUC of ciclosporin by up to 82%.6 In rats, ciclosporin halved the AUC of baicalin in blood, and increased its levels in bile by about 60%.7

Mechanism
Flavonoids might affect ciclosporin levels by their effects on P-glycoprotein or the cytochrome P450 isoenzyme CYP3A4. In animal studies both increased and decreased levels have been seen.1-6

Importance and management
Evidence for an interaction between flavonoids and ciclosporin is largely limited to experimental data. In the one clinical study, high-dose quercetin modestly increased ciclosporin levels. The interaction is not sufficiently severe to suggest that concurrent use should be avoided; however, it may make ciclosporin levels less stable as the quercetin content of different herbs and preparations is likely to vary. Concurrent use may therefore be undesirable. If concurrent use of ciclosporin and a quercetin-containing product is undertaken it should be monitored well.

In animal studies, both increases and decreases in ciclosporin levels have been seen with individual flavonoids. Until more is known, it may be prudent to be cautious with any flavonoid supplement and ciclosporin, especially those containing high doses. Although the reduced nephrotoxicity is interesting, this has to be
viewed in the context of possible adverse pharmacokinetic interactions.


### Flavonoids + Digoxin

The interaction between flavonoids and digoxin is based on experimental evidence only.

#### Clinical evidence

No interactions found.

#### Experimental evidence

In a study in pigs, three animals were given digoxin 20 micrograms/kg with quercetin 50 mg/kg, and three animals were given digoxin alone. Unexpectedly, two of the pigs receiving the combination died suddenly within 30 minutes. At 20 minutes, the serum digoxin levels of the animals receiving the combination were 2.6-fold higher than those in the animals given digoxin alone (6.73 nanograms/mL versus 2.54 nanograms/mL). In a further crossover study in 4 pigs, quercetin at a slightly lower dose of 40 mg/kg increased the maximum level of digoxin fivefold and the AUC 2.7-fold. The authors state that they specifically chose pigs for this study, as a preliminary study suggested that the pharmacokinetics of digoxin in pigs were similar to that in humans.

#### Mechanism

Quercetin is suspected to increase the oral absorption of digoxin by inhibiting intestinal P-glycoprotein. A study investigating the effects of *kaempferol* derivatives isolated from *Zingiber zerumbet*, a species related to ginger, found that some of these derivatives inhibited P-glycoprotein, with a potency similar to verapamil, a known clinically relevant P-glycoprotein inhibitor. *Kaempferol* may therefore also raise digoxin levels.

#### Importance and management

Although there is just one animal study of quercetin, its findings of markedly increased levels of digoxin and toxicity suggest that caution would be appropriate with supplements containing quercetin in patients taking digoxin until further data become available. Monitor for digoxin adverse effects, such as bradycardia, and consider measuring digoxin levels if this occurs.

Note that there is currently no evidence of any clinically important interactions between digoxin and food, even for foods known to be rich sources of quercetin such as onions (about 7 to 34 mg/100 g), which suggests that any interaction might require very high doses. The only possible evidence identified was one early pharmacokinetic paper, which reported a modest 43% increase in the peak level of digoxin after administration of acetyldigoxin with carob seed flour, which is also a rich source of quercetin (about 39 mg/100 g).

### Flavonoids + Enalapril

The interaction between flavonoids and enalapril is based on experimental evidence only.

#### Clinical evidence

No interactions found.

#### Experimental evidence

In rats, oral *kaempferol* 2 mg/kg and 10 mg/kg given with enalapril increased the AUC of enalaprilat (the active metabolite of enalapril) by 60% and 109%, respectively, but only the effect with 10 mg/kg was statistically significant. *Naringenin* 2 mg/kg and 10 mg/kg caused only a minor 18 to 38% increase in AUC of enalaprilat, which was not statistically significant.

#### Mechanism

In vitro, both *kaempferol* and *naringenin* were shown to be potent esterase inhibitors. Esterases hydrolyse enalapril in the gut: esterase inhibition by these flavonoids may be expected to increase the stability of enalapril, increasing its absorption.

#### Importance and management

Evidence appears to be limited to this experimental study. The effect of *kaempferol* would not be expected to be clinically important because enalapril has a wide therapeutic range. *Naringenin* does not appear to interact. No dosage adjustments would therefore be expected to be needed if either of these flavonoids is given with enalapril.


### Flavonoids + Etoposide

The interaction between flavonoids and etoposide is based on experimental evidence only.

#### Clinical evidence

No interactions found.

#### Experimental evidence

In an in vitro study using rat gut sacs, pre-treatment with *quercetin* or a natural diet (assumed to contain flavonoids) for 30 minutes increased etoposide absorption when compared with a flavonoid-free diet. However, there was no difference in etoposide absorption when rats were pretreated for one week with a natural diet (assumed to contain flavonoids) compared with a flavonoid-free diet.

In another animal study, oral *morin* given 30 minutes before etoposide increased the AUC of oral etoposide by about 46% but had no effect on the AUC of intravenous etoposide.

#### Mechanism

It is suggested that flavonoids might inhibit P-glycoprotein or the cytochrome P450 isoenzyme CYP3A4 in the gut, and thereby increase the absorption of etoposide, which is a substrate of CYP3A4 and/or P-glycoprotein.

#### Importance and management

A finding of a 50% increase in the AUC of etoposide might be clinically relevant in humans. However, these are animal data, and therefore some caution is required in extrapolating their findings. Also, the data suggest that the effect of continued use over one week
might have little effect. Further study is needed before any specific recommendations can be made.


### Flavonoids + Fexofenadine

Naringin and hesperidin may slightly reduce fexofenadine bioavailability.

**Clinical evidence**
In a crossover study in 12 healthy subjects, fexofenadine 120 mg was given with either 300 mL of grapefruit juice, an aqueous solution of naringin at roughly the same concentration found in the juice (1210 micromol), or water. The AUC of fexofenadine with grapefruit juice and naringin solution was reduced by 45% and 25%, respectively, when compared with water.

In another study in 12 healthy subjects, fexofenadine was given with grapefruit juice, or water, at the same time, or 2 hours before, an aqueous suspension of the particulate fraction of grapefruit juice. The particulate fraction (i.e., the solid matter after centrifugation of the juice) is known to be rich in furanocoumarins, which are clinical inhibitors of intestinal CYP3A4, but relatively low in naringin (34 micromol). The AUC of fexofenadine was reduced by 43% by grapefruit juice, but was not affected by the particulate fraction (when compared with water).

**Experimental evidence**
An in vitro study found that the flavonoids in grapefruit (naringin) and orange (hesperidin) were potent inhibitors of intestinal OATP transport.

**Mechanism**
The authors suggested that naringin directly inhibited enteric OATP1A2 to decrease oral fexofenadine bioavailability, and that inactivation of enteric CYP3A4 was probably not involved.

**Importance and management**
The small 25% reduction in AUC of fexofenadine with a high concentration of naringin is unlikely to be clinically important. No interaction would therefore be expected with naringin supplements. However, note that grapefruit juice and other fruit juices might cause clinically relevant reductions in fexofenadine levels in some individuals. See the table Summary of established drug interactions of grapefruit juice, page 236. Therefore an interaction with other extracts from these juices cannot be ruled out.


### Flavonoids + Paclitaxel

The interaction between morin, naringin or quercetin and paclitaxel is based on experimental evidence only.

**Clinical evidence**
No interactions found.

**Experimental evidence**
(a) Morin
The pharmacokinetics of paclitaxel were determined in rats after oral or intravenous administration of paclitaxel with or without morin (3.3 and 10 mg/kg). Compared with paclitaxel alone, morin, given 30 minutes before oral paclitaxel, increased the maximum levels and AUC of paclitaxel by 70 to 90% and 30 to 70%, respectively, without any change in the time to reach maximum levels, or elimination half-life. In contrast, the pharmacokinetics of intravenous paclitaxel (3.3 mg/kg) were not altered significantly by morin.

(b) Naringin
A study to investigate the effects of oral naringin on the pharmacokinetics of intravenous paclitaxel in rats found that oral

---

### Flavonoids + Food; Milk

The addition of milk to tea did not alter the absorption of quercetin or kaemperol, or catechins, see Tea + Food, page 385.

### Flavonoids + Herbal medicines

No interactions found. Flavonoids are a very large family of polyphenolic compounds synthesised by plants that are common and widely distributed.
naringin (3.3 and 10 mg/kg), when given to rats 30 minutes before intravenous administration of paclitaxel (3 mg/kg), produced a significantly higher AUC for paclitaxel (about 41% and 49% for naringin doses of 3.3 and 10 mg/kg, respectively). Clearance was also delayed (29% and 33% decrease, respectively) when compared with the controls.2 In a similar study using oral paclitaxel, oral naringin increased the AUC of paclitaxel by up to threefold, and increased the elimination half-life. The oral bioavailability of paclitaxel increased from 2.2% up to 6.8%.3

Mechanism
Paclitaxel is a substrate of P-glycoprotein and the hepatic cytochrome P450 subfamily CYP3A and isoenzyme CYP2C8. The flavonoids might inhibit the metabolism of paclitaxel by CYP3A and the transport of paclitaxel via intestinal P-glycoprotein, thereby increasing the AUC of paclitaxel. Note that there is evidence that quercetin does not inhibit CYP2C8, because it did not alter the metabolism of rosiglitazone, below, a specific substrate for CYP2C8.

Importance and management
The finding of increased oral absorption of paclitaxel with morin, naringin and quercetin is of little clinical relevance because paclitaxel is not used orally (it is poorly absorbed, even in the presence of the flavonoids).

Flavonoids is predicted to interact with quinine and quinidine via effects on cytochrome P450 450 isoenzymes or P-glycoprotein.

Flavonoids + Quinine or Quinidine

The interaction between flavonoids and quinine or quinidine is based on experimental evidence only.

Clinical evidence
No interactions found.

Experimental evidence
In rats, naringin 25 mg/kg daily for 7 days increased the oral bioavailability of a single 25-mg/kg oral dose of quinine from 17% to 42%, but did not affect the pharmacokinetics of intravenous quinine.1 In an in vitro study, quercetin and naringenin were modest inhibitors of quinine metabolism.2

In another in vitro study, quercetin was an inhibitor of quinidine metabolism, with kaempferol and naringenin also having an effect,3 and, in rats, quinidine approximately halved the AUC of baicalin in blood, and increased its levels in bile by 47%.4

Mechanism
Flavonoids are predicted to interact with quinine and quinidine via effects on cytochrome P450 450 isoenzymes or P-glycoprotein.

**Flavonoids + Rosiglitazone**

Quercetin does not appear to affect the pharmacokinetics of rosiglitazone.

Clinical evidence
In a crossover study in 10 healthy subjects, quercetin 500 mg daily for 3 weeks had no effect on the pharmacokinetics of a single 4-mg dose of rosiglitazone, or its principal metabolite N-desmethylrosiglitazone.1

Experimental evidence
No relevant data found.

Mechanism
Rosiglitazone is a specific substrate for the cytochrome P450 isoenzyme CYP2C8, and it therefore appears that multiple-dose quercetin has no clinically relevant effect on this isoenzyme. The rationale that it might was because, in vitro, quercetin inhibits the CYP2C8-mediated metabolism of a number of substrates including paclitaxel, page 192. However, in the case of paclitaxel (and possibly the other substrates), P-glycoprotein inhibition and CYP3A4 might also be important.

Importance and management
Although evidence appears to be limited to this one study, it is supported by in vitro data that suggest the absence of an interaction. No clinically important pharmacokinetic interaction would be expected with long-term use of quercetin supplements in patients taking rosiglitazone, and therefore no dosage adjustments would be expected to be needed.

Flavonoids + Saquinavir

Quercetin does not appear to affect the pharmacokinetics of saquinavir.

Clinical evidence
In a study in 10 healthy subjects, the pharmacokinetics of saquinavir 1.2 g three times daily (Fortovase; soft capsules) were not affected by the concurrent use of quercetin 500 mg three times daily for 8 days. Concurrent use of both products was well tolerated.1
Experimental evidence
No relevant data found.

Mechanism
Based on other data for quercetin, it was suggested that this flavonoid might increase saquinavir levels by inhibiting P-glycoprotein, or by effects on the cytochrome P450 isoenzyme CYP3A4.

Importance and management
Although the study appears to be the only published data, the absence of an interaction is fairly well established. Quercetin is unlikely to have a detrimental (or beneficial) pharmacokinetic effect when used with saquinavir, and therefore no dosage adjustments would be expected to be necessary on concurrent use.


Flavonoids + Statins
The interaction between flavonoids and statins is based on experimental evidence only.

Clinical evidence
No interactions found.

Experimental evidence
In rats, oral kaempferol and naringenin, given with lovastatin, markedly increased the AUC of lovastatin acid. Increases were 2.7-fold and 3.5-fold with kaempferol 2 mg/kg and 10 mg/kg, respectively, and 2.6-fold and 3.9-fold with naringenin 2 mg/kg and 10 mg/kg, respectively. Other in vitro studies have shown that naringenin inhibits simvastatin metabolism.

Mechanism
Kaempferol and naringenin may be esterase inhibitors. In addition, naringenin may inhibit the cytochrome P450 isoenzyme CYP3A4, the main route of metabolism of simvastatin and lovastatin. Esterases hydrolyse lovastatin in the gut toLovastatin acid which is poorly absorbed; esterase inhibition by these flavonoids may be expected to increase the stability oflovastatin, increasing its absorption. Subsequent metabolism then leads to greater levels oflovastatin acid than would have occurred in the absence of the flavonoids.

Importance and management
There appears to be no clinical evidence to support these experimental findings of an interaction between kaempferol or naringenin and simvastatin or Lovastatin. However, the marked increase in lovastatin levels that occurred with these flavonoids in the animal study, and the known important interaction ofgrapefruit juice (which is a rich source of flavonoids) withlovastatin and simvastatin (leading to rhabdomyolysis and myopathy), suggest that kaempferol and naringenin supplements should generally be avoided in patients taking these statins. This advice should be extended to citrus bioflavonoid supplements.


Flavonoids + Tamoxifen
The interaction between flavonoids and tamoxifen is based on experimental evidence only.

Clinical evidence
No interactions found.

Experimental evidence
(a) Antagonistic effects
Various flavonoids have been investigated in vitro for their ability to reduce the proliferation of cancer cells, and in vivo some studies have shown synergistic cytotoxicity with tamoxifen (e.g. with catechins).

In contrast, and of concern, it has been reported that tangeretin abolished the growth inhibitory effects of tamoxifen in mice, and shortened the survival time of tamoxifen-treated tumour-bearing mice compared with those receiving tamoxifen alone. This finding was not explained by changes in tamoxifen pharmacokinetics, see below.

(b) Pharmacokinetics
In a study, mice receiving tangeretin and tamoxifen had higher tamoxifen levels than those receiving tamoxifen alone. In addition, tangeretin did not alter the ratio between tamoxifen and its N-desmethyl metabolite.

In a study in rats, oral quercetin modestly increased the AUC of oral tamoxifen given concurrently. The effect was not dose dependent; there was a 35% increase with quercetin 2.5 mg/kg, a 60% increase with quercetin 7.5 mg/kg and a smaller 20% increase with quercetin 15 mg/kg. There was also a minor 8 to 29% increase in the AUC of the active 4-hydroxytamoxifen metabolite. When compared with intravenous tamoxifen, quercetin 7.5 mg/kg increased the absolute oral bioavailability of tamoxifen by 60% (from 15% to 24%).

Mechanism
These findings suggest that quercetin inhibits both drug transporter proteins and possibly the cytochrome P450 isoenzyme CYP3A4, which decreases the first-pass metabolism of tamoxifen. The authors suggested that the antagonistic effect of tangeretin against tamoxifen was because tangeretin is an inhibitor of natural killer cell activity.

Importance and management
There do not appear to be any clinical data investigating the possible interactions between flavonoids and tamoxifen, and extrapolating the available animal findings to the clinical situation is difficult. Nevertheless, some caution is required if patients taking tamoxifen also take products containing tangeretin, because the effect of tamoxifen was abolished in one study, despite an increase in its levels. Studies are clearly needed that assess both efficacy and pharmacokinetic effects of the concurrent use of tangeretin and tamoxifen. The authors of the study with tangeretin suggested that the level of tangeretin used (human equivalent of about 280 mg daily) could not be obtained by eating citrus fruits or drinking juices. However, they advise caution with the use of products containing large amounts of citrus peel oil, and dietary supplements containing large amounts of citrus bioflavonoids as these could provide sufficient amounts of tangeretin to interact. Given the severity of the possible outcome, until more is known this seems prudent.

Flaxseed

Linum usitatissimum L. (Linaceae)

Synonym(s) and related species
Flax, Linseed.

Constituents
The seeds contain a fixed oil, composed of glycerides of linoleic and linolenic acid. The seeds also contain: mucilage; the lignans secoisolariciresinol and its diglucoside; and the cyanogenic glycosides linamarin and lotaustralin.

Use and indications
Flaxseed was formerly used as a demulcent and soothing emollient agent for bronchitis and coughs, and applied externally to burns. More recently, flaxseed oil has been used to lower blood-cholesterol levels, and flaxseed extract is being taken as a form of hormone replacement therapy due to its phytoestrogenic effects, thought to be due to the lignans (although note that the information available on phytoestrogenic lignans is limited).

Pharmacokinetics
Ingested lignans such as secoisolariciresinol have been shown to undergo bacterial hydrolysis and metabolism to produce the mammalian lignans enterolactone and enterodiol, which have oestrogenic effects.

Interactions overview
Flaxseed lignan supplementation appears to have no significant effect on blood-glucose levels in type 2 diabetic patients also taking oral antidiabetic drugs (not named). Limited evidence suggests that flaxseed oil may increase bleeding times and therefore some caution might therefore be appropriate with aspirin and anticoagulants.
**Flaxseed + Anticoagulant or Antiplatelet drugs**

Limited evidence suggests that flaxseed oil may have some antiplatelet effects, which could be additive with those of conventional antiplatelet drugs, and increase the risk of bleeding with anticoagulants.

**Clinical evidence**

Two case reports briefly describe increased bleeding (haematuria and nosebleeds) in patients taking aspirin and flaxseed oil, one of whom was taking low-dose aspirin.1 Some studies have investigated the effect of flaxseed oil alone on bleeding time, and one, in 10 healthy subjects, found that a flaxseed oil rich diet (20.5 g daily of α-linolenic acid) for 56 days had no significant effect on bleeding times, prothrombin times or partial thromboplastin times.2 However, another study in 11 patients with rheumatoid arthritis reported that flaxseed oil 30 g daily for 3 months (9.6 g daily of α-linolenic acid) increased the bleeding time by about one minute when compared with baseline, although this result was not statistically significant.3

**Experimental evidence**

No relevant data found.

**Mechanism**

Omega-3 fatty acids such as linolenic acid are thought to have some antiplatelet effects and might therefore prolong bleeding time. Theoretically, this effect might be additive to that of other antiplatelet drugs, and increase the risk of bleeding with anticoagulants.

**Importance and management**

The general significance of these reports is unclear and no interaction has been established. Nevertheless, a large epidemiological study would be needed to quantify any excess risk in the order of that seen with antiplatelet doses of aspirin taken with warfarin. As with high doses of fish oils (marine omega-3 fatty acids), it may be prudent to use some caution with the concurrent use of high doses of flaxseed supplements in patients also taking aspirin or anticoagulants.


**Flaxseed + Antidiabetics**

Flaxseed lignan supplementation appears to have no significant effect on blood-glucose levels in type 2 diabetic patients also taking oral antidiabetic drugs.

**Clinical evidence**

In a randomised, crossover study in 68 patients with type 2 diabetes and mild hypercholesterolaemia, taking a supplement containing a total of 360 mg of flaxseed lignan daily for 12 weeks had no significant effect on blood-lipid profile, insulin resistance, fasting glucose and insulin concentrations. A minor reduction of glycosylated haemoglobin (HbA1c) of about 0.1% occurred, although the clinical significance of this reduction is likely to be minimal. In this particular study, patients continued to take their usual medication, which included oral antidiabetics and lipid-lowering medications, none of which was specifically named in the study. Patients were excluded from the study if they were using insulin.1 Similarly, in another study, flaxseed oil (60 mg/kg α-linolenic acid daily) had no significant effect on blood-glucose control in type 2 diabetics. Patients taking insulin were also excluded from this study; however, information on other concurrent medication was not reported.2 In another study in 25 menopausal women with hypercholesterolaemia, there was a slight 5.3% reduction in blood-glucose levels (0.1 mmol/L) with crushed flaxseed, and this was less than that seen with conventional HRT,3 which is not considered to have blood-glucose-lowering effects.

**Experimental evidence**

No relevant data found.

**Mechanism**

No mechanism expected.

**Importance and management**

It appears from these studies that flaxseed oil or lignans have minimal effects on glycaemic control in type 2 diabetes, and in one study the lignans had no additive blood-glucose-lowering effects with oral antidiabetic drugs (not named). Flaxseed is therefore unlikely to affect the blood-glucose-lowering efficacy of concurrent antidiabetic medication. However, more detailed information on specific antidiabetic drugs is unavailable.


**Flaxseed + Food**

No interactions found.

**Flaxseed + Herbal medicines**

No interactions found.
Frangula

*Rhamnus frangula* L. (Rhamnaceae)

**Synonym(s) and related species**
Alder buckthorn.


**Pharmacopoeias**
Frangula Bark (*BP 2009, Ph Eur 6.4*); Standardised Frangula Bark Dry Extract (*BP 2009, Ph Eur 6.4*).

**Constituents**
The major constituents of frangula are the anthraquinone glycosides. The frangulosides are the main components, which include frangulin A and B, emodin derivatives, chrysophanol and physcion glycosides, and free aglycones. Frangula also contains flavonoids and tannins.

**Use and indications**
Frangula bark is used as a laxative.

**Pharmacokinetics**
For information on the pharmacokinetics of an anthraquinone glycoside present in frangula, see under aloes, page 27.

**Interactions overview**
No interactions with frangula found; however, frangula (by virtue of its anthraquinone content) is expected to share some of the interactions of a number of other anthraquinone-containing laxatives, such as aloes, page 27 and senna, page 349. Of particular relevance are the interactions with corticosteroids, digitalis glycosides and potassium-depleting diuretics.
Garlic

Allium sativum L. (Alliaceae)

Synonym(s) and related species
Ajo, Allium.

Pharmacopoeias
Garlic (USP 32); Garlic Delayed Release Tablets (USP 32); Garlic Fluid Extract (USP 32); Garlic for Homeopathic Preparations (BP 2009, Ph Eur 6.4); Garlic Powder (Ph Eur 6.4, BP 2009); Powdered Garlic (USP 32); Powdered Garlic Extract (USP 32).

Constituents
Garlic products are produced from the bulbs (cloves) of garlic and are usually standardised according to the content of the sulphur-containing compounds, alliin, allicin (produced by the action of the enzyme alliinase on alliin) and/or γ-glutamyl-(S)-allyl-L-cysteine.

Other sulphur compounds such as allylmethyltrisulfide, allylpropyldisulfide, diallyldisulfide, diallyltrisulfide, ajoene and vinylthiones, and mercaptan are also present. Garlic also contains various glycosides, monoterpenoids, enzymes, vitamins, minerals and flavonoids based on kaempferol and quercetin.

Use and indications
Garlic has been used to treat respiratory infections (such as colds, flu, chronic bronchitis, and nasal and throat catarrh) and cardiovascular disorders. It is believed to possess antihypertensive, antithrombotic, fibrinolytic, antimicrobial, and/or antiplatelet effects. Garlic has been suggested that any antiplatelet effects of garlic may be additive with conventional antiplatelet drugs and NSAIDs, and studies suggest that garlic may reduce isoniazid levels. However, no interaction has been proven with any of these drugs.

In general, garlic seems to have no effect, or have only clinically irrelevant effects when it is given with alcohol, benzodiazepines (such as midazolam), caffeine, chlorozoxazone, dextromethorphan, docetaxel, gentamicin, paracetamol (acetaminophen), rifampicin (rifampin) or ritonavir. Any interaction between garlic and fish oils may be beneficial.

One study suggested that a high-fat diet did not affect the absorption of some of the active constituents of garlic oil.

Interactions overview
Case reports suggest that garlic may have additive blood pressure-lowering effects with lisinopril, and may cause bleeding in those taking warfarin or fluindione. It has also been suggested that any antiplatelet effects of garlic may be additive with conventional antiplatelet drugs and NSAIDs, and studies suggest that garlic may reduce isoniazid levels. However, no interaction has been proven with any of these drugs.

Clindamycin (Clyndamycin) and studies suggest that any antiplatelet effects of garlic may be additive with conventional antiplatelet drugs and NSAIDs, and studies suggest that garlic may reduce isoniazid levels. However, no interaction has been proven with any of these drugs.

One study suggested that a high-fat diet did not affect the absorption of some of the active constituents of garlic oil.

For information on the interactions of individual flavonoids present in garlic, see under flavonoids, page 186.

Garlic + ACE inhibitors

In a single report, a patient taking lisinopril developed marked hypotension and became faint after taking garlic capsules.

Evidence, mechanism, importance and management

A man whose blood pressure was 135/90 mmHg while taking lisinopril 15 mg daily began to take garlic 4 mg daily (Boots odourless garlic oil capsules). After 3 days he became faint on standing and was found to have a blood pressure of 90/60 mmHg. Stopping the garlic restored his blood pressure to 135/90 mmHg within a week. The garlic on its own did not lower his blood pressure. The reasons for this interaction are not known, although garlic has been reported to cause vasodilation and blood pressure reduction. This seems to be the first and only report of this reaction, so its general importance is small. There seems to be nothing documented about garlic and any of the other ACE inhibitors.


Garlic + Alcohol

The interaction between garlic and alcohol is based on experimental evidence only.

Evidence, mechanism, importance and management

Garlic juice, from fresh garlic bulbs, inhibited the metabolism of alcohol in mice. Garlic is a common ingredient in food and so it is very unlikely that this interaction is clinically relevant.


Garlic + Antiplatelet drugs

Garlic may have antiplatelet properties. It might therefore be expected to increase the risk of bleeding with conventional antiplatelet drugs and other drugs that have antiplatelet adverse effects.

Clinical evidence

In a study in 23 healthy subjects, liquid aged garlic extract 5 mL (Kyolic), given daily for 13 weeks, inhibited both the rate of platelet aggregation and total platelet aggregation. Similar effects were found in another study in 28 healthy subjects given aged garlic extract capsules 2.4 g, 4.8 g and 7.2 g. Each dose was given daily for a 6-week period.

Experimental evidence

Ajoene, a sulphur compound derived from garlic with antiplatelet and antithrombotic properties, was found to synergistically potentiate the antiplatelet actions of dipyridamole, epoprostenol and indometacin in vitro.

Mechanism

Uncertain. The authors of an experimental study suggest that ajoene inhibits the binding of fibrinogen to the fibrinogen receptor, which occurs in the final step of the platelet aggregation pathway. Ajoene would therefore be expected to interact synergistically with antiplatelet drugs that act at an earlier step in the pathway.

Importance and management

There is a reasonable body of evidence, which suggests that aged garlic herbal products may have antiplatelet properties. If they do, and they are similarly active to low-dose aspirin, they might therefore be expected to increase the risk of bleeding with conventional antiplatelet drugs and other drugs that have antiplatelet adverse effects, such as indometacin. However, considering the widespread use of garlic and garlic products, and the limited information available, it seems unlikely that garlic has any generally important interaction with antiplatelet drugs. Nevertheless, bear the possibility in mind in the event of an unexpected response to treatment.

Garlic does not appear to affect the pharmacokinetics of caffeine.

Clinical evidence
Garlic oil 500 mg three times daily for 28 days did not affect the metabolism of a single 100-mg dose of caffeine in young or elderly healthy subjects.

Experimental evidence
No relevant data found.

Mechanism
Garlic does not have a clinically relevant effect on the cytochrome P450 isoenzyme CYP1A2 activity using caffeine as a probe substrate.

Importance and management
Evidence for an interaction between garlic and caffeine appears to come from two well-designed studies in humans. These studies suggest that garlic does not affect the metabolism of caffeine, and therefore an increase in caffeine adverse effects would not be expected in those who also take garlic supplements. Caffeine is used as a probe drug for CYP1A2 activity, and therefore these results also suggest that a pharmacokinetic interaction between garlic and other CYP1A2 substrates is unlikely.

Garlic does not appear to affect the pharmacokinetics of dextromethorphan or debrisoquine.

Clinical evidence
A study in 14 healthy subjects found that Kwai garlic tablets 600 mg twice daily for 14 days did not affect the pharmacokinetics of a single 30-mg dose of dextromethorphan. Garlic oil 500 mg three times daily for 28 days did not affect the metabolism of debrisoquine 5 mg in young or elderly healthy subjects.

Experimental evidence
The effect of garlic constituents; alliin, cyclooalliiin, methyl-L-cysteine, S-methyl-L-cysteine, S-allyl-L-cysteine, N-acetyl-S-allyl-L-cysteine, S-allomercapto-L-cysteine, and γ-glutamyl-S-allyl-L-cysteine, on the activity of the CYP2D6 probe substrate, dextromethorphan, was investigated using human liver microsomes. No significant inhibition was apparent.

Mechanism
Garlic does not appear to affect the cytochrome P450 isoenzyme CYP2D6.

Importance and management
There appear to be two clinical studies investigating the potential for an interaction between garlic and dextromethorphan, both of which found that the pharmacokinetics of dextromethorphan were unaffected by garlic and its constituents. Therefore the dosage of dextromethorphan would not need adjusting if patients also wish to take garlic supplements. Dextromethorphan and debrisoquine are used as probe drugs for CYP2D6 activity, and therefore these results also suggest that a pharmacokinetic interaction between garlic and other CYP2D6 substrates is unlikely.

Garlic + Caffeine

Garlic + Dextromethorphan

Garlic + Chlorzoxazone

The metabolism of chlorzoxazone is modestly inhibited by garlic but this effect is probably not clinically relevant.

Clinical evidence
Garlic oil 500 mg, given to 12 healthy subjects three times daily for 28 days, reduced the conversion of a single 500-mg dose of chlorzoxazone to 6-hydroxychlorzoxazone by about 40%. In a later similar study by the same authors, in 12 elderly healthy subjects, a smaller reduction of 22% was seen. Another study in 8 healthy subjects found that a high dose of the garlic constituent diallyl sulfide 200 micrograms/kg (equivalent to 15 cloves of fresh garlic, containing 1 mg/g diallyl sulfide), reduced the conversion of chlorzoxazone to 6-hydroxychlorzoxazone by about 30%.

Experimental evidence
A garlic constituent, diallyl sulfide 50 mg/kg and 200 mg/kg, was given to rats 12 hours before an intravenous dose of chlorzoxazone 150 micrograms/kg. Diallyl sulfide increased the AUC of chlorzoxazone by threefold and fivefold, respectively.

Mechanism
Garlic appears to inhibit the activity of the cytochrome P450 isoenzyme CYP2E1, which metabolises chlorzoxazone to 6-hydroxychlorzoxazone.

Importance and management
There appear to be several clinical studies into the potential for an interaction between garlic and chlorzoxazone. Although these studies suggest that metabolism of chlorzoxazone is modestly inhibited by garlic in healthy subjects, this effect is probably not clinically relevant.

Chlorzoxazone is used as a probe drug for CYP1E2 activity, and therefore these results also suggest that a pharmacokinetic interaction between garlic and other CYP1E2 substrates is unlikely.


Garlic appears to inhibit the activity of the cytochrome P450 isoenzyme CYP2E1, which metabolises chlorzoxazone to 6-hydroxychlorzoxazone.

Garlic does not appear to affect the pharmacokinetics of intravenous docetaxel.

Clinical evidence
In a pharmacokinetic study, 10 patients with metastatic, or incurable localised, breast cancer were given 1-hour intravenous infusions of docetaxel 30 mg/m² weekly for 3 weeks (days 1, 8 and 15). Five days after the first infusion, garlic tablets 600 mg were taken twice daily for 13 days (days 5 to 17). The garlic tablets used were *GarlicPure Maximum Allicin Formula*, Natrol, containing 3.6 mg of allicin per tablet. Patients were also given a premedication regimen of oral dexamethasone 8 mg 12 hours before each docetaxel infusion and then every 12 hours for two more doses, and ondansetron 8 mg, ranitidine 150 mg and diphenhydramine 25 mg half an hour before each infusion of docetaxel. Garlic tablets had no effect on the pharmacokinetics of docetaxel on the second or third week, when compared with the first week (i.e. after 4 and 12 days’ use of garlic).1

Experimental evidence
No relevant data found.

Mechanism
Docetaxel is metabolised, in part, by the cytochrome P450 isoenzyme CYP3A4. This study suggests that garlic is unlikely to alter the activity of this isoenzyme. See also benzodiazepines, page 199.

Importance and management
Evidence appears to be limited to this one study, but it is supported by the findings of other studies that suggest that garlic does not alter the effects of CYP3A4, the main route of docetaxel metabolism. Therefore what is known suggests that no pharmacokinetic interaction would be expected in patients taking garlic supplements with intravenous docetaxel.


Garlic supplements and fish oils may have beneficial effects on blood lipids.

Clinical evidence
In a placebo-controlled study in 46 subjects with moderate, untreated hypercholesterolaemia, combined use of garlic pills 300 mg three times daily (*Kovari*) and fish oil capsules 4 g three times daily for 12 weeks was compared with either garlic or fish oil alone. Garlic modestly reduced total cholesterol, and fish oil did not alter this effect. Fish oil reduced triacylglycerol levels, and garlic did not alter this effect. Garlic alone reduced low-density-lipoprotein cholesterol, and combined use with fish oil reversed the increase of low-density-lipoprotein cholesterol seen with fish oil alone and produced a reduction similar to that seen with garlic alone. Slight reductions in blood pressure were also reported with all treatments.1 The fish oil used was 1-g capsules (*Nupulse*) each containing eicosapentaenoic acid 180 mg and docosahexaenoic acid 120 mg.

Experimental evidence
Garlic oil has been found to enhance the antioxidant effects of fish oils in *rats*.2

Mechanism
Unclear. In the experimental study, garlic oil synergistically increased the induction of the antioxidant superoxide dismutase by fish oils, and the combination additively increased the protein levels of CYP1A1, CYP2E1 and CYP3A1.

Importance and management
The available clinical evidence appears to come from one study, which suggests that the combined use of garlic supplements and fish oils may have beneficial effects on blood lipids, which are known to be risk factors in coronary artery disease and atherosclerosis. While the clinical importance is inconclusive, any interaction is not expected to be harmful as far as blood lipids are concerned. Further study is needed to establish the benefits of combined use.


Evidence, mechanism, importance and management
Aged garlic extract or garlic powder extract did not affect the *in vitro* antibacterial activity of gentamicin.2 The bactericidal effect of gentamicin against *E. coli*, measured by optical density, was increased by S-allylcysteine, diallyl sulfide, and diallyl disulfide, at concentrations of 0.25 mg/mL, 0.5 mg/mL and 1 mg/mL but the significance of this is unclear. However, no clinically significant interaction is expected as far as antibacterial activity is concerned.1


Garlic did not interact with caffeine, page 200, and is therefore unlikely to interact with caffeine-containing herbs, as a result of this constituent.

Garlic + Herbal medicines; Caffeine-containing

**Garlic + Herbal medicines; Fish oil**

The information regarding the use of garlic with food is based on experimental evidence only.

Evidence, mechanism, importance and management
In a study in *rats* that were fed a high-fat or low-fat diet, and also given garlic oil or its constituents diallyl sulfide and diallyl disulfide, there were no biochemical changes between the groups attributable to an interaction between the garlic oil and dietary fat.2 No clinical interaction is expected; note that garlic is extensively used as a food ingredient.

For the lack of pharmacokinetic interaction of garlic with caffeine, see caffeine, page 200.


Garlic + Food

The information regarding the use of garlic with food is based on experimental evidence only.

Garlic + Gentamicin

The information regarding the use of garlic with gentamicin is based on experimental evidence only.
Garlic + Isoniazid

The interaction between garlic and isoniazid is based on experimental evidence only.

Clinical evidence
No interactions found.

Experimental evidence
In a study in rabbits, a garlic extract, produced from blended garlic cloves (exact dosage unknown) and given orally over 14 days, reduced the AUC and maximum serum levels of a single 30-mg/kg dose of isoniazid by about 55% and 65%, respectively, when compared with the levels attained after a single 30-mg/kg dose of isoniazid given 7 days before the garlic extract.1

Mechanism
Unclear. It was anticipated that garlic might increase isoniazid levels by inhibiting the cytochrome P450 isoenzyme CYP2E1, but decreased levels were seen. While the authors speculate that garlic extract may induce enzymes in the intestinal mucosa, which interferes with the absorption of isoniazid, they suggest that the findings cannot be explained solely on this basis.

Importance and management
The evidence is limited to this one study, and because the mechanism is unknown, a crude garlic extract was used, and the data are from rabbits, it is difficult to apply these findings to a clinical setting. However, if the reduction was shown to be replicated in humans then isoniazid efficacy might be reduced, so further study is warranted. Until more is known, a conservative approach would be to suggest some caution with the use of garlic supplements in patients taking isoniazid.


Garlic + Paracetamol (Acetaminophen)

Studies in healthy subjects found that garlic did not affect the pharmacokinetics of single-dose paracetamol to a clinically relevant extent.

Clinical evidence
A study in 16 healthy subjects found that the use of an aged garlic extract (approximately equivalent to 6 to 7 cloves of garlic daily) for 3 months had little effect on the metabolism of a single 1-g oral dose of paracetamol.2

Experimental evidence
Diallyl sulfide, a constituent of garlic, and, to a greater extent, its metabolite diallyl sulfone, protected mice from paracetamol-induced hepatotoxicity when given immediately after a toxic dose of paracetamol (200 mg/kg). The effect of diallyl sulfone 25 mg/kg was equivalent to that of the known antidote, acetylcysteine.3

Mechanism
There was a very slight increase in glucuronidation of a therapeutic dose of paracetamol after the long-term use of garlic in the clinical study, and some evidence that sulfate conjugation was enhanced, but no effect on oxidative metabolism.

It was suggested that diallyl sulfone protected against the hepatotoxicity of paracetamol after a toxic dose in mice because it irreversibly inhibited the cytochrome P450 isoenzyme CYP2E1. This isoenzyme is thought to be responsible for the production of a minor but highly reactive paracetamol metabolite, N-acetyl-p-benzoquinoneimine (NABQI).4

Importance and management
The evidence regarding an interaction between paracetamol and garlic is limited, but what is known suggests that no clinically significant interaction would be expected if paracetamol is taken with garlic. The animal data suggest that it is possible that some garlic constituents, or substances derived from them, might prove to protect against the hepatotoxicity from higher than therapeutic doses of paracetamol, but this requires further study.


Garlic + Protease inhibitors

A garlic supplement reduced the plasma levels of saquinavir in one study, but had little effect in another. Another garlic supplement did not significantly affect the pharmacokinetics of a single dose of ritonavir.

Clinical evidence
In a study in 9 healthy subjects garlic reduced the AUC and maximum and minimum plasma levels of saquinavir by about 50%. The garlic was taken in the form of a dietary supplement (GarliPure, Maximum Allicin Formula caplets) twice daily for 20 days. Saquinavir 1.2 g three times daily was given for 4-day periods before, during and after the garlic supplement. Fourteen days after the garlic supplement was stopped the saquinavir pharmacokinetics had still not returned to baseline values. Of the 9 subjects, 6 had a substantial drop in the AUC of saquinavir while taking garlic, then a rise when garlic was stopped. The remaining 3 had no change in the AUC of saquinavir while taking garlic, but had a drop when garlic was stopped.4 However, in another study, garlic extract (GarliPure) 1.2 g daily for 3 weeks had no significant effect on the pharmacokinetics of a single 1.2-g dose of saquinavir (a slight decrease in AUC in 7 subjects and a slight increase in 3).2

In a study in 10 healthy subjects the use of a garlic extract (10 mg, equivalent to 1 g of fresh garlic) twice daily for 4 days did not significantly affect the pharmacokinetics of a single 400-mg dose of ritonavir. There was a non-significant 17% decrease in the AUC of ritonavir. The garlic was given in the form of capsules (Natural Source Odourless Garlic Life Brand).3 Gastrointestinal toxicity was noted in 2 patients taking garlic or garlic supplements when they started to take ritonavir-containing regimens.4

Experimental evidence
In an experimental study using cell lines, allicin, a major active constituent of garlic, significantly decreased the clearance (efflux) of ritonavir from the cells in a dose-dependent manner.5

Mechanism
The mechanism of this interaction is uncertain, but it is thought that garlic reduced the bioavailability of saquinavir by increasing its metabolism in the intestine.6 Why there was a disparity in the effect of garlic on saquinavir between patients is unclear.

Allicin is thought to have inhibited the activity of P-glycoprotein in vitro, which caused the build-up of ritonavir within the cell.5

Importance and management
Although information is limited, a reduction in saquinavir plasma levels of the magnitude seen in the first study could diminish its antiviral efficacy. All garlic supplements should probably be avoided in those taking saquinavir as the sole protease inhibitor, but note that this is no longer generally recommended. The effect of garlic on saquinavir levels in the presence of ritonavir (as a pharmacokinetic enhancer) does not appear to have been studied. The pharmacoki-
kinetic effect on single-dose ritonavir was not clinically important, but this requires confirmation in a multiple-dose study.


Garlic + Rifampicin (Rifampin)

The information regarding the use of garlic with rifampicin is based on experimental evidence only.

Clinical evidence
No interactions found.

Experimental evidence
In a study in rabbits, a garlic extract, produced from blended garlic cloves (exact dosage unknown) and given orally over 14 days, did not alter the AUC and maximum serum levels of a single 24-mg/kg dose of rifampicin, when compared with the levels attained after a single 24-mg/kg dose of rifampicin given 7 days before the garlic extract.1

Mechanism
No mechanism expected.

Importance and management
Evidence appears to be limited to this one study in animals. Nevertheless, what is known suggests that no changes in the dose of rifampicin are likely to be needed if it is also taken with garlic.


Garlic + Warfarin and related drugs

An isolated report described increases in the anticoagulant effects of warfarin in two patients taking garlic supplements. Another report described a decrease in anticoagulant effects of fludione in a patient taking garlic tablets. Garlic supplements alone have also rarely been associated with bleeding. However, in one study, aged garlic extract did not increase the INR or risk of bleeding in patients taking warfarin.

Clinical evidence

(a) Fludione

In an 82-year-old man stabilised on fludione 5 mg (dosage frequency not stated) for chronic atrial fibrillation, the INR dropped to below its usual range (2 to 3) when garlic tablets 600 mg daily were taken, and remained below 2 for 12 consecutive days despite an increase in fludione dosage to 10 mg. The INR returned to normal, with an associated reduction in fludione dose, when the garlic tablets were stopped. He was also taking enalapril 20 mg, furosemide 40 mg and pravastatin 20 mg (dosage frequency not stated).1

(b) Warfarin

The INR of a patient stabilised on warfarin more than doubled and haematuria occurred 8 weeks after the patient started to take three Höfels garlic pearles daily. The situation resolved when the garlic was stopped. The INR rose on a later occasion while the patient was taking two Kwai garlic tablets daily. The INR of another patient was also more than doubled by six Kwai garlic tablets daily.2

In contrast, in a placebo-controlled study in 48 patients stabilised on warfarin, there was no change in INR or evidence of increased bleeding in those receiving 5 mL of aged garlic extract (Kyolic) twice daily for 12 weeks.3 Similarly, in a preliminary report of the use of alternative and complementary medicines in 156 patients taking warfarin, there was no apparent increased risk or bleeding or raised INRs in 57 patients taking potentially interacting complementary medicines (garlic in 10%), compared with 84 who did not.4

Experimental evidence
No relevant data found.

Mechanism
Garlic has been associated with decreased platelet aggregation. See antiplatelet drugs, page 199 for possible mechanisms. This effect on platelet aggregation has, on at least two documented occasions, led to spontaneous bleeding in the absence of an anticoagulant.6,7 These effects might therefore increase the risk of bleeding with anticoagulants. However, this would not cause an increase in INR, and the mechanism for this effect in the cases seen is unknown.

Importance and management
Information about an adverse interaction between coumarin anticoagulants and garlic seems to be limited to these two reports, with warfarin and fludione. Bearing in mind the wide-spread use of garlic and garlic products, the limited information from the review5 about the use of alternative and complementary medicines and the study with aged garlic extract,4 it seems most unlikely that garlic usually has any generally important interaction with anticoagulants. Nevertheless, bear the possibility in mind in the event of an unexpected response to treatment.

In addition, garlic may have some antiplatelet effects and, although there appear to be no clinical reports of an adverse interaction between garlic and antiplatelet drugs, it may be prudent to consider the potential for an increase in the severity of bleeding if garlic is given with anticoagulants. See Garlic + Antiplatelet drugs, page 199.
**Ginger**

*Zingiber officinale* Roscoe (Zingiberaceae)

---

**Synonym(s) and related species**

Gan Jiang, Zingiber.

Not to be confused with the wild gingers, which are *Asarum canadense* L. and *Asarum europaeum* L.

---

**Pharmacopoeias**

Ginger (*BP 2009, Ph Eur 6.4, USP 32*); Ginger Capsules (*USP 32*); Ginger Tincture (*USP 32*); Powdered Ginger (*USP 32*).

---

**Constituents**

The constituents of ginger vary depending on whether fresh or dried forms are used. Generally, ginger rhizomes contain volatile oils of which *zingiberene* and *bisabolene* are major components: zingerone, zingiberol, zingiberenol, curcumene, camphene and linalool are minor components.

The rhizomes also contain *gingerols* and their derivatives, ginerdiols, gingerdiones and dihydrogingerdiones. *Shogaols* are formed from *gingerols* during drying, and together these make up the pungent principles of ginger.

Ginger extracts have been standardised to contain a minimum of 15 mL/kg of essential oil with reference to the dried drug.

---

**Use and indications**

Ginger is thought to possess carminative, anti-emetic, anti-inflammatory, antispasmodic and antiplatelet properties. Both fresh and dried ginger are mainly used to settle the stomach, to alleviate the symptoms of motion sickness and to relieve morning sickness. Ginger has also been used in the treatment of osteoarthritis and rheumatoid arthritis, and for migraines.

Ginger is also an important culinary spice and the pungent properties of ginger have also been exploited for use in cosmetics and soaps.

Ginger is a constituent of *Trikatu*, a medicine used in Ayurvedic medicine in a ratio of 1:1:1 with *Piper nigrum* and *Piper longum*, see pepper, page 313.

---

**Pharmacokinetics**

Detailed information on the pharmacokinetics of ginger in humans is scarce but what has been found, in *animals*, is that gingerol, a major constituent of ginger, is rapidly cleared from plasma and elimination by the liver is involved. Gingerol is also a substrate of several UDP-glucuronosyl-transferases, which are major phase 2 metabolic enzymes responsible for the metabolism of several drugs. Gut flora also play a part in the metabolism of gingerol.1

---

**Interactions overview**

There are isolated cases of ginger increasing the response to anticoagulant treatment with warfarin and related drugs, but a controlled study did not confirm an interaction. A small study showed antiplatelet effects for ginger that were synergistic with those of nifedipine, but any effect needs confirming.

For the interactions of ginger as a constituent of *Trikatu*, a medicine used in Ayurvedic medicine, see Pepper + Isoniazid, page 316, Pepper + NSAIDs, page 316, and Pepper + Rifampicin (Rifampin), page 318. For the interactions of ginger as a constituent of Chinese herbal medicines, see under bupleurum, page 89.

---

Evidence from pharmacological studies suggests that ginger does not increase the anticoagulant effect of warfarin, nor does it alter coagulation or platelet aggregation on its own. However, two case reports describe markedly raised INRs with phenprocoumon and warfarin, which were associated with eating dried ginger and drinking ginger tea. A prospective, longitudinal study also reports an increased risk of self-reported bleeding events in patients taking warfarin and ginger.

Clinical evidence
In a randomised, crossover study in 12 healthy subjects, 3 ginger capsules taken three times daily for 2 weeks did not affect either the pharmacokinetics or pharmacodynamics (INR) of a single 25-mg dose of warfarin taken on day 7. The brand of ginger used was Blackmores Travel Calm Ginger, each capsule containing an extract equivalent to 400 mg of ginger rhizome powder. Moreover, ginger alone did not affect the INR or platelet aggregation.

However, a case report describes a rise in INR to greater than 10, with epistaxis, in a woman stabilised on phenprocoumon several weeks after she started to eat ginger regularly in the form of pieces of dried ginger and tea from ginger powder. She was eventually re-stabilised on the original dose of phenprocoumon, and was advised to stop taking ginger. Another very similar case has been described in a woman taking warfarin.

Moreover, in a prospective, longitudinal study of patients taking warfarin and a herbal product or dietary supplement, there was a statistically significant increased risk of self-reported bleeding events in patients taking warfarin and ginger (7 bleeds in 25 weeks, none of which was major; odds ratio 3.2). No elevated INRs were reported for the combination. Note that the number of patients taking ginger was not reported, except to say it was less than 5% of 171 patients – so it was less than 8 patients. Also, the ginger products used were not mentioned and some patients were taking more than one potentially interacting supplement.

Experimental evidence
See under Mechanism below.

Mechanism
Ginger (Zingiber officinale) has sometimes been listed as a herb that interacts with warfarin on the basis that in vitro it inhibits platelet aggregation. However, this antiplatelet effect has generally not been demonstrated in controlled clinical studies (three of which have been reviewed) although in one other study ginger had antiplatelet effects that were synergistic with those of nifedipine, see nifedipine, below.

Importance and management
Evidence from a controlled study suggests that ginger does not increase the anticoagulant effect of warfarin. Despite it being cited as a herb that inhibits platelet aggregation, there is limited evidence that it increases bleeding when given alone or with warfarin, and there are just two case reports of markedly raised INRs with phenprocoumon and warfarin, which were associated with ginger root and ginger tea. Because of the many other factors influencing anticoagulant control, it is not possible to reliably ascribe a change in INR specifically to a drug interaction in a single case report without other supporting evidence. It may be better to advise patients to discuss the use of any herbal products that they wish to try, and to increase monitoring if this is thought advisable. Cases of uneventful bleeding events and supratherapeutic international normalized ratios associated with complementary and alternative medicine: a longitudinal analysis. Pharmacotherapy (2007) 27, 1237–47.


For mention that sho-saiko-to (of which ginger is one of 7 constituents) only slightly reduced the metabolism of caffeine in one study, see Bupleurum + Caffeine, page 90.

For mention that saiko-ka-ryukotsu-borei-to and sho-saiko-to (of which ginger is one of a number of constituents) did not affect the pharmacokinetics of carbamazepine in animal studies, see Bupleurum + Carbamazepine, page 90.

No interactions found. Ginger is extensively used as a food ingredient.

No interactions found.

For details of an animal study to investigate a possible interaction between isoniazid and Trikatu, an Ayurvedic medicine containing ginger, black pepper and long pepper, see Pepper + Isoniazid, page 316.

A small study found that antiplatelet effects for ginger were synergistic with those of nifedipine, but any effect needs confirmation.

Evidence, mechanism, importance and management
In a small study in 10 hypertensive patients and another in 10 healthy subjects, ginger 1 g daily for 7 days given with nifedipine 10 mg twice daily for 7 days inhibited platelet aggregation by up to three times more than nifedipine alone. In these studies, ginger alone had similar antiplatelet effects to aspirin 75 mg (used as a control), either alone, or given with nifedipine. Nifedipine alone also had antiplatelet effects, but these were not as great as aspirin 75 mg...
alone. The ginger used in this study was dried, but no other details about the preparation were given.

Calcium-channel blockers are not generally viewed as antiplatelet drugs, and the finding of synergistic antiplatelet effects between nifedipine and aspirin in this report and its clinical relevance needs further study. Furthermore, this study suggests that ginger alone may have similar antiplatelet effects to low-dose aspirin alone; however, this antiplatelet effect has generally not been demonstrated in other controlled clinical studies of ginger (three of which have been reviewed). Therefore, it is difficult to make any clinical recommendations on the basis of this one small study. Further study is clearly needed.


**Ginger + NSAIDs**

For details of an animal study to investigate a possible interaction between diclofenac and Trikatu, an Ayurvedic medicine containing ginger, black pepper and long pepper, see Pepper + NSAIDs, page 316.

**Ginger + Ofloxacin**

For mention that sairei-to and sho-saiko-to (of which ginger is one of a number of constituents) do not affect the pharmacokinetics of ofloxacin, see Bupleurum + Ofloxacin, page 90.

**Ginger + Rifampicin (Rifampin)**

For details of an interaction between rifampicin and Trikatu, an Ayurvedic medicine containing ginger, black pepper and long pepper, see Pepper + Rifampicin (Rifampin), page 318.

**Ginger + Tolbutamide**

For conflicting evidence from animal studies that sho-saiko-to (of which ginger is one of 7 constituents) might increase or decrease the rate of absorption of tolbutamide, see Bupleurum + Tolbutamide, page 90.
Ginkgo
Ginkgo biloba L. (Ginkgoaceae)

Synonym(s) and related species
Fossil tree, Kew tree, Maidenhair tree.
Salisburia adiantifolia Sm., Salisburia biloba Hoffmanns.

Pharmacopoeias
Ginkgo (USP 32); Ginkgo capsules (USP 32); Ginkgo dry extract, refined and quantified (BP 2009, Ph Eur 6.4); Ginkgo leaf (BP 2009, Ph Eur 6.4); Ginkgo tablets (USP 32); Powdered ginkgo extract (USP 32).

Constituents
Ginkgo leaves contain numerous flavonoids including the biflavone glycosides such as ginkgetin, isoginkgetin, bilobetin, sciadopitysin, and also some quercetin and kaempferol derivatives. Terpene lactones are the other major component, and these include ginkgolides A, B and C, and bilobalide. Ginkgo extracts may be standardised to contain between 22 and 27% flavonoids (flavone glycosides) and between 5 and 12% terpene lactones, both on the dried basis. The leaves contain only minor amounts of ginkgolic acids, and some pharmacopoeias specify a limit for these. The seeds contain ginkgotoxin (4-O-methylpyridoxine) and ginkgolic acids.

Use and indications
The leaves of ginkgo are the part usually used. Ginkgo is often used to improve cognitive function in cases of dementia and memory loss, and it has been investigated for use in the treatment of Alzheimer’s disease. The ginkgolides are thought to possess antiplatelet and anti-inflammatory properties and it has been used for cerebrovascular and peripheral vascular disorders, tinnitus, asthma and to relieve the symptoms of altitude sickness.

Ginkgo seeds contain some toxic constituents; nevertheless, they are used in China and Japan, including as a food.

Pharmacokinetics
The two main active components of ginkgo are flavonoids and terpene lactones. For information on the pharmacokinetics of individual flavonoids present in ginkgo, see under flavonoids, page 186. In contrast to the flavonoids, the bioavailability of ginkgolide A and B (but not C) and bilobalide is relatively high and a large proportion of the dose is excreted unchanged in the urine.1

The effects of ginkgo on cytochrome P450 isoenzymes appear to have been relatively well studied. It appears that the flavonoid fraction of ginkgo has more of an effect on the cytochrome P450 isoenzymes than the terpene lactones,2,3 and the effect on these enzymes can be halted relatively quickly when ginkgo is stopped.4

In vitro and rat studies2–5 have found that ginkgo may have some modest effects on CYP1A2 (see also theophylline, page 216). However, evidence from clinical studies using the specific probe substrate caffeine suggests that this is not clinically relevant with therapeutic doses of ginkgo. See Ginkgo + Caffeine, page 211.

Similarly, in vitro and rat studies2–4,6–8 have suggested that ginkgo affects CYP2C9, CYP2D6 and CYP1E2, but clinical studies using the specific probe substrates tolbutamide, page 217, for CYP2C9, dextromethorphan, page 213, for CYP2D6, and chlorzoxazone, page 212, for CYP1E2 have found no clinically relevant effect.

In contrast, in vitro findings suggesting that ginkgo may affect CYP3A42–4,6–9 and induce CYP2C92–4,6–8 are supported by clinical studies with midazolam, page 210 and omeprazole, page 216, respectively. However, the effect of ginkgo on CYP3A4 is unclear (induction and inhibition reported), but any effect appears modest at best.

In vitro and rat studies4,6–7 also suggest that ginkgo may affect CYP2B6 and CYP2C8, but the clinical relevance of this needs investigation.

Ginkgo is unlikely to affect the activity of P-glycoprotein to a clinically relevant extent (see digoxin, page 213).

Interactions overview
Ginkgo appears to decrease the levels of omeprazole; it seems likely that most other proton pump inhibitors will be similarly affected. Some evidence suggests that diltiazem and nifedipine levels may be raised by ginkgo, whereas nicardipine levels may be reduced.

Isolated cases of bleeding have been seen when ginkgo has been taken with conventional antiplatelet drugs, anticoagulants and NSAIDs, and some cases have occurred with ginkgo alone, although a clinically relevant antiplatelet effect for ginkgo alone is not established. Isolated case reports also suggest that ginkgo may cause seizures in patients taking phenytoin and/or valproate and one case had decreased phenytoin and valproate levels. Phenobarbital levels do not appear to be significantly affected, although this is based on experimental data only. Isolated cases also describe coma in a patient taking trazodone with ginkgo, priapism in a patient taking ginkgo with risperidone, and CNS depression in a patient taking ginkgo with valerian, although this case is confused by alcohol consumption.

There are some animal data suggesting that ciclosporin levels might be reduced by ginkgo, and it has been suggested that the extrapyramidal adverse effects of haloperidol and the ototoxic effects of amikacin may be enhanced by ginkgo.

Ginkgo does not appear to affect the pharmacokinetics/metabolism of alprazolam, caffeine, chlorzoxazone, dextromethorphan, diclofenac, digoxin, donepezil, fexofenadine,
flurbiprofen, lopinavir/ritonavir, midazolam, propranolol, theophylline, or tolbutamide to a clinically relevant extent.

For a case of anxiety and memory deficits in a woman taking several drugs and herbal medicines, including ginkgo, see St John’s wort + Buspirone, page 365.

For information on the interactions of individual flavonoids present in ginkgo, see under flavonoids, page 186.

The interaction between ginkgo and amikacin is based on experimental evidence only.

Clinical evidence
No interactions found.

Experimental evidence
Ginkgo 100 mg/kg (EGb 761) daily for 20 days and amikacin 600 mg/kg daily for the first 14 days were given to rats. Amikacin-induced ototoxicity developed earlier and to a greater level than that caused by amikacin given alone. Ginkgo alone did not induce ototoxicity.1

Mechanism
Unknown.

Importance and management
Ginkgo appears to accelerate the appearance of amikacin-induced ototoxicity and to increase its ototoxic effects in rats. Because the development of ototoxicity is cumulative, if ginkgo accelerates this process, there is potential for ototoxicity to develop at a lower cumulative dose. The available evidence is weak, but until more is known it may be prudent to carefully consider the risks and benefits of continuing ginkgo during treatment with drugs such as the aminoglycosides.1


Ginkgo + Antiepileptics
Case reports describe seizures in three patients taking valproate, or valproate and phenytoin, when ginkgo was also taken.

Clinical evidence
A 55-year-old man taking valproate and phenytoin for a seizure disorder that developed following coronary artery bypass surgery suffered a fatal breakthrough seizure while swimming a year later. Analysis of his medical history showed that he had unexplained subtherapeutic serum levels of valproate and phenytoin on three occasions over the previous year. It was later found that the patient had also been taking numerous vitamins, supplements and herbal medicines without the knowledge of his physician, of which a ginkgo extract was stated to be the most common ingredient.1 The only other herbal medicines named in the report were ginseng and saw palmetto.

In another case, a 78-year-old man, whose epileptic seizures had been well controlled by valproate 1.2 g daily for 7 years, suffered a cluster of seizures after taking a ginkgo extract 120 mg daily for 2 weeks for the management of mild cognitive impairment. The ginkgo was stopped and the patient was reportedly seizure free 8 months later. All other medications taken by the patient remained unchanged.1

An 84-year-old epileptic woman with severe dementia taking valproate 1.2 g daily had been seizure free for 2 years. After taking a ginkgo extract 120 mg daily for 12 days prescribed by her psychiatrist, she suffered a cluster of seizures, which were treated with intravenous diazepam in the accident and emergency department. The ginkgo extract was stopped on admission and the patient remained free of seizures 4 months later. All other medications taken by the patient were unchanged.2

Experimental evidence
No relevant data found.

Mechanism
Unknown. Ginkgo seeds (nuts) contain the neurotoxin 4-O-methoxypryridoxine (ginkgotoxin), which indirectly inhibits the activity of glutamate decarboxylase, which in turn results in seizure induction by lowering the levels of γ-aminobutyric acid (GABA). A large quantity of ginkgo nuts (about 70 to 80) alone have been reported to be the cause of seizures in a healthy 36-year-old woman.3 However, leaf extracts would not generally be expected to contain sufficient levels of this neurotoxin to be a problem.

Another possible mechanism is induction of the cytochrome P450 isoenzyme CYP2C19 by ginkgo. Phenytoin is a substrate of CYP2C19 and therefore, in theory, ginkgo may increase the metabolism of phenytoin and thereby reduce its levels. Ginkgo has been seen to induce CYP2C19 in clinical studies. See Ginkgo + Proton pump inhibitors, page 216.

Importance and management
Evidence for an interaction between ginkgo and valproate and phenytoin appears to be limited to case reports. The only case that measured serum levels of these antiepileptics is complicated by the use of numerous other supplements. An interaction is therefore by no means established. Nevertheless, it may be prudent to consider the possibility of reduced effects if a patient taking phenytoin and/or valproate wishes also to take ginkgo.

For details of a possible interaction between ginkgo and phenobarbital in animals see Ginkgo + Phenobarbital, page 215.


Ginkgo + Antiplatelet drugs
Ginkgo biloba has been associated with platelet, bleeding and clotting disorders, and there are isolated reports of serious adverse reactions after its concurrent use with antiplatelet drugs such as aspirin, clopidogrel and ticlopidine.

Clinical evidence
A study in 10 healthy subjects found no significant increase in the antiplatelet effects of single doses of clopidogrel 75 mg or cilostazol 100 mg when a single dose of ginkgo 120 mg was added. However, the bleeding time was significantly increased when cilostazol was combined with ginkgo, although none of the subjects developed any significant adverse effects.4 Another study in 8 healthy subjects found that ginkgo 40 mg three times daily had no significant effect on the pharmacokinetics of a single 250-mg dose of ticlopidine taken on day 4.

A randomised, double-blind study in 55 patients with established peripheral artery disease (PAD), or with risk factors for developing PAD, found that the addition of ginkgo 300 mg (standardised extract EGb 761) in divided doses to aspirin 325 mg daily did not have a significant effect on platelet aggregation. Five of the patients taking combined therapy reported nosebleeds or minor bleeding; however, 4 patients from the aspirin-only group also reported minor bleeding.5 Similarly, a study in 41 healthy subjects found that 120-mg ginkgo-coated tablets (EGb 761) twice daily had no effect on the antiplatelet activity of aspirin 500 mg daily given for 7 days. Minor bleeding was seen in a few subjects but this was attributed to the use of aspirin.6 In an analysis of supplement use, 23% of 123 patients were currently taking supplements, and 4 patients were found to be taking ginkgo and aspirin. However, no problems from this use were found on review of the patients’ notes.5

Nevertheless, a number of cases of clinically significant bleeding have been reported. A 70-year-old man developed spontaneous bleeding from the iris into the anterior chamber of his eye within one week of starting to take a ginkgo supplement (Ginkoba) tablet.
twice daily. He experienced recurrent episodes of blurred vision in one eye lasting about 1.5 minutes, during which he could see a red discolouration through his cornea. Each tablet contained 40 mg of concentrated (50:1) extract of ginkgo. He was also taking aspirin 325 mg daily, which he had taken uneventfully for 3 years since having coronary bypass surgery. He stopped taking the ginkgo but continued with the aspirin, and 3 months later had experienced no recurrence of the bleeding. Another case reports persistent postoperative bleeding from a hip arthroplasty wound, which continued despite stopping aspirin. On closer questioning, the patient had continued to take ginkgo extract 120 mg daily postoperatively. The oozing from the wound gradually reduced when the ginkgo was stopped.

### Experimental evidence

Ginkgo (EGb 761) 40 mg/kg daily had no effect on the antiplatelet activity of ticlopidine 50 mg/kg daily when given to rats for 3 days. However, when both were given for 5 days, the inhibition of platelet aggregation was double that of ticlopidine given alone and the bleeding time was increased by about 60%. Also, when given for 9 days, the combination was twice as effective at inhibiting thrombus formation when compared with the same dose of ticlopidine alone.8

#### Mechanism

The reason for the bleeding is not known, but ginkgo extract contains ginkgolide B, which is a potent inhibitor of platelet-activating factor in vitro; this is needed for arachidonate-independent platelet aggregation. However, in one controlled study in healthy subjects, taking a ginkgo preparation alone for 2 weeks had no effect on platelet function.9 Nevertheless, there are case reports of ginkgo supplements, on their own, being associated with prolonged bleeding times,10–12 left and bilateral subdural haematomas,10,13 a right parietal haematoma,14 a retrobulbar haemorrhage,15 post-laparoscopic cholecystectomy bleeding16 and subarachnoid haemorrhage.17 It seems that the effects of ginkgo and conventional antiplatelet drugs can be additive, leading to bleeding complications on rare occasions.

#### Importance and management

The evidence from these case reports is too slim to advise patients taking aspirin, clopidogrel or ticlopidine to avoid ginkgo, but some do recommend caution,17 which seems prudent, especially as this is generally advised with most combinations of conventional antiplatelet drugs. There may also be a theoretical risk of increased bleeding if ginkgo is taken with other antiplatelet drugs and anticoagulants; interactions have been reported with NSAIDs, some of which have antiplatelet effects, and warfarin.

Consider also Ginkgo + NSAIDs, page 214 and Ginkgo + Warfarin and related drugs, page 217.

### Clinical evidence

#### (a) Alprazolam

Ginkgo leaf extract 120 mg twice daily for 16 days was given to 12 healthy subjects before and with a single 2-mg dose of alprazolam on day 14. The ginkgo preparation (Ginkgold) was standardised to ginkgo flavonol glycosides 24% and terpene lactones 6%. The alprazolam AUC was reduced by 17%, and the maximum concentration was not significantly affected.3

#### (b) Midazolam

In 12 healthy subjects, ginkgo 60 mg four times daily for 28 days did not affect the metabolism of midazolam 8 mg. The ginkgo preparation was stated to contain 24% flavonol glycosides and 6% terpene lactones.2 These findings were repeated in a later study using the same criteria in 12 elderly healthy subjects.3 In contrast, in another similar study, ginkgo 120 mg twice daily modestly reduced the AUC and maximum serum levels of a single 8-mg dose of midazolam by about one-third. The ginkgo preparation was assayed, and contained 29% flavonol glycosides and 5% terpene lactones.4 Furthermore, in yet another study in 10 healthy subjects, ginkgo 360 mg daily for 28 days increased the AUC of a single 8-mg dose of oral midazolam by about one-quarter. The ginkgo preparation used was Ginkgold, which was stated to contain 24% flavone glycosides and 6% terpene lactones.5

### Experimental evidence

In an experimental study, unfamiliar pairs of rats were placed together in a novel arena for 10 minutes to determine the effects of combined administration of ginkgo and diazepam on social behaviour. Social contact between rats given ginkgo 96 mg/kg (EGb 761) daily for 8 days and then a single injection of diazepam 1 mg/kg 30 minutes before testing, was significantly higher than those given ginkgo or diazepam alone.6

#### Mechanism

Alprazolam and midazolam are probe substrates for the cytochrome P450 isoenzyme CYP3A4. The studies here show that ginkgo has minimal effects on this isoenzyme, the maximum effect on midazolam being about a 33% reduction in AUC. However, it is unusual for studies to show opposite effects (one of the studies found a minor increase in midazolam AUC), and the reasons for this are unclear, but may be to do with the methodology (use of midazolam metabolic ratios rather than midazolam exposure, and length of sampling time, and the fact that in one study the subjects had previously received lopinavir/ritonavir for 30 days, concurrently with the ginkgo for 2 weeks, just 2 weeks before the midazolam).
The reasons for the experimental findings are not understood but ginkgo may interact with dextromethorphan through its effects on the \( \gamma \)-aminobutyric acid (GABA) receptor.

**Importance and management**

The pharmacokinetic evidence here shows that alprazolam and midazolam levels are not significantly affected by ginkgo, and no clinically relevant interaction would be expected. The conflicting midazolam levels are not significantly affected by ginkgo, and no pharmacokinetic interaction as a result of this mechanism between ginkgo and other CYP3A4 substrates is unlikely.

The clinical relevance of the possible interaction of ginkgo with diazepam in rats is unknown.

**Clinical evidence**

No interactions found.

**Experimental evidence**

Ginkgo 20 mg/kg approximately doubled the AUC and maximum serum levels of oral diltiazem 30 mg/kg when given to rats 1 hour before diltiazem. Ginkgo 20 mg/kg had no significant effect on the levels of intravenous diltiazem 3 mg/kg.\(^1\)

**Mechanism**

The authors suggest that ginkgo may inhibit the activity of the cytochrome P450 isoenzyme CYP3A4 or P-glycoprotein, both of which would raise diltiazem levels by inhibiting its metabolism or increasing its absorption, respectively.\(^1\) However, in clinical studies, ginkgo had no clinically relevant effect on the P-glycoprotein substrate digoxin, page 213, or on the conventional CYP3A4 probe substrate, midazolam, page 210.

**Importance and management**

An interaction between ginkgo and diltiazem has only been demonstrated in one study in rats, and ginkgo does not appear to have clinically relevant effects on the activity of P-glycoprotein or on the metabolism of other CYP3A4 substrates such as the benzodiazepines. Because the findings of animal studies cannot be directly extrapolated to humans, further study is needed before any specific recommendations can be made. Until more is known, bear the possibility of an interaction in mind in the event of an unexpected response to treatment.


---

**Ginkgo + Calcium-channel blockers; Diltiazem**

The interaction between ginkgo and diltiazem is based on experimental evidence only.

**Clinical evidence**

No interactions found.

**Experimental evidence**

Ginkgo 20 mg/kg approximately doubled the AUC and maximum serum levels of oral diltiazem 30 mg/kg when given to rats 1 hour before diltiazem. Ginkgo 20 mg/kg had no significant effect on the levels of intravenous diltiazem 3 mg/kg.\(^1\)

**Mechanism**

The authors suggest that ginkgo may inhibit the activity of the cytochrome P450 isoenzyme CYP3A4 or P-glycoprotein, both of which would raise diltiazem levels by inhibiting its metabolism or increasing its absorption, respectively.\(^1\) However, in clinical studies, ginkgo had no clinically relevant effect on the P-glycoprotein substrate digoxin, page 213, or on the conventional CYP3A4 probe substrate, midazolam, page 210.

**Importance and management**

An interaction between ginkgo and diltiazem has only been demonstrated in one study in rats, and ginkgo does not appear to have clinically relevant effects on the activity of P-glycoprotein or on the metabolism of other CYP3A4 substrates such as the benzodiazepines. Because the findings of animal studies cannot be directly extrapolated to humans, further study is needed before any specific recommendations can be made. Until more is known, bear the possibility of an interaction in mind in the event of an unexpected response to treatment.


---

**Ginkgo + Calcium-channel blockers; Nicardipine**

The interaction between ginkgo and nicardipine is based on experimental evidence only.

**Clinical evidence**

No interactions found.

**Experimental evidence**

In an experimental study in rats, ginkgo extract 0.5% daily for 4 weeks significantly reduced the hypotensive effects of both oral nicardipine 30 mg/kg and intravenous nicardipine 30 micrograms/kg.\(^1\) These findings were repeated in a later study in rats: ginkgo extract 0.5% daily for 2 weeks reduced the maximum serum levels and AUC of oral nicardipine 30 mg/kg by about 65%.\(^2\)

---

**Ginkgo + Buspirone**

For a case of anxiety, with episodes of over-sleeping and memory deficits in a woman taking fluoxetine and buspirone with St John’s wort, ginkgo and melatonin, see St John’s wort + Buspirone, page 365.

**Ginkgo + Caffeine**

Ginkgo does not appear to affect the pharmacokinetics of caffeine.

**Clinical evidence**

In 12 healthy subjects, ginkgo 60 mg four times daily for 28 days did not affect the metabolism of caffeine 100 mg. The ginkgo preparation used was standardised to 24% flavone glycosides and 6% terpene lactones.\(^3\) These findings were repeated in a later study using the same criteria in 12 elderly healthy subjects.\(^2\)

**Experimental evidence**

No relevant data found.

**Mechanism**

This study shows that ginkgo has no clinically relevant effect on the cytochrome P450 isoform CYP1A2.

**Importance and management**

Evidence from studies in healthy subjects suggests that ginkgo does not affect the metabolism of caffeine and is therefore unlikely to increase its adverse effects. Caffeine is used as a probe drug for CYP1A2 activity, and therefore these results also suggest that a pharmacokinetic interaction as a result of this mechanism between ginkgo and other CYP1A2 substrates is unlikely.

extract contained 24% flavonoids (12% quercetin) and 9% terpene lactones.

**Mechanism**

The authors suggested that ginkgo may induce the cytochrome P450 subfamily CYP3A, which would increase the metabolism of nicardipine, a CYP3A4 substrate, and reduce its levels. However, in contrast, studies with diltiazem, page 211 and nifedipine, below have shown inhibition of CYP3A4 and increased levels. Moreover, note also that clinically relevant CYP3A4 inhibition has not been seen with the conventional CYP3A4 probe substrate, midazolam, page 210.

**Importance and management**

These experiments in rats suggest that ginkgo can significantly reduce the levels of nicardipine by inducing CYP3A, but note that there is experimental evidence of ginkgo increasing nifedipine and diltiazem levels. Moreover, clinical studies with CYP3A4 substrates such as the benzodiazepines, page 210, have not shown any clinically relevant pharmacokinetic interaction. Because of this, and because the doses used were higher than those used in humans, the animal data here are unlikely to be of general clinical importance.

---

**Ginkgo + Calcium-channel blockers; Nifedipine**

Ginkgo may increase the levels and some of the effects of nifedipine.

**Clinical evidence**

In the preliminary report of a clinical study, 22 healthy subjects were given ginkgo 120 mg daily for 18 days before a single 10-mg oral dose of nifedipine. Ginkgo increased the levels of nifedipine by about 50%.1

In another study, a single 240-mg dose of ginkgo extract did not significantly affect the pharmacokinetics of a single 10-mg oral dose of nifedipine when they were given at the same time to 8 healthy subjects. However, the maximum level tended to increase (30% increase), and two subjects experienced a doubling of nifedipine maximum serum levels. In addition, the incidence and severity of headaches, hot flushes and dizziness tended to be higher with the combination when compared with nifedipine alone. Subjects also experienced increased heart rate with the combination although the decrease in blood pressure was unaffected.2 The ginkgo extract used in this study contained 24% flavonoids and 6% terpene lactones.

**Experimental evidence**

In a study in rats, ginkgo extract 20 mg/kg increased the maximum serum levels and AUC of an oral dose of nifedipine 5 mg/kg by about 60% when they were given at the same time.3 Ginkgo extract had no effect on the pharmacokinetics of intravenous nifedipine.

**Mechanism**

Experimental data1 have found that ginkgo has no significant effect on the pharmacokinetics of intravenous nifedipine, suggesting that ginkgo reduces the first-pass metabolism of nifedipine. Ginkgo may therefore inhibit the cytochrome P450 isoenzyme CYP3A4, which would reduce the pre-systemic metabolism of nifedipine, a CYP3A4 substrate, and increase its levels. Note that simultaneous administration of single doses is probably insufficient to completely evaluate CYP3A4 inhibition. Note also that clinically relevant CYP3A4 inhibition has not been seen with the conventional CYP3A4 probe substrates such as midazolam. See Ginkgo + Benzodiazepines, page 210.

**Importance and management**

Limited clinical data suggest that ginkgo may raise the levels of nifedipine and increase its effects. Until more is known, some caution might be warranted when they are used together. Monitor for signs of nifedipine adverse effects such as headaches, hot flushes, dizziness and palpitations. If they become apparent, advise the patient to stop taking ginkgo.


---

**Ginkgo + Chlorzoxazone**

Ginkgo does not appear to affect the pharmacokinetics of chlorzoxazone.

**Evidence, mechanism, importance and management**

In a study in 12 healthy subjects, ginkgo 60 mg four times daily for 28 days did not significantly affect the metabolism of chlorzoxazone 500 mg. The ginkgo preparation used was standardised to 24% flavone glycosides and 6% terpene lactones.1 These findings were repeated in a later study using the same criteria in 12 elderly healthy subjects.2

Chlorzoxazone is used a probe substrate for the cytochrome P450 isoenzyme CYP2E1, and this study shows that ginkgo has no clinically relevant effect on this isoenzyme. No action is necessary with combined use, and no pharmacokinetic interaction would be expected with other substrates of CYP2E1.


---

**Ginkgo + Ciclosporin**

The interaction between ginkgo and ciclosporin is based on experimental evidence only.

**Clinical evidence**

No interactions found.

**Experimental evidence**

In a study in rats, ginkgo extract 8 mL/kg (containing the flavonoid quercetin 775 nanomol/kg) reduced the maximum serum levels and AUC of oral ciclosporin by about 60% and 50% respectively, but had no effect on the pharmacokinetics of intravenous ciclosporin.3

**Mechanism**

The authors suggest that the flavonoid component of ginkgo, quercetin, might affect ciclosporin levels via its effects on P-glycoprotein or cytochrome P450 isoenzyme CYP3A4. However, in clinical studies, ginkgo had no clinically relevant effect on the P-glycoprotein substrate digoxin, page 213, or on midazolam, page 210, a CYP3A4 substrate.
**Importance and management**

The evidence for an interaction between ginkgo and ciclosporin is limited to one study in rats. However, ginkgo contains flavonoids, and of these quercetin has been implicated in modest interactions with ciclosporin in other studies (see Flavonoids + Ciclosporin, page 190 for more information). On this basis, while there is insufficient evidence to suggest that concurrent use should be avoided, there is the possibility that ginkgo may make ciclosporin levels less stable as the quercetin content of different preparations is likely to vary. Some caution might therefore be prudent on concurrent use.


**Ginkgo + Dextromethorphan**

Ginkgo does not appear to affect the metabolism of dextromethorphan.

**Clinical evidence**

Ginkgo leaf extract 120 mg twice daily for 16 days was given to 12 healthy subjects with a single 30-mg dose of dextromethorphan on day 14. The ginkgo preparation (Ginkgold) contained ginkgo flavonol glycosides 24% and terpene lactones 6%. There was no change in the metabolism of dextromethorphan when it was taken after the ginkgo.1

In 12 healthy subjects, ginkgo 60 mg four times daily for 28 days did not significantly affect the metabolism of debrisoquine 5 mg. The ginkgo preparation used was standardised to 24% flavone glycosides and 6% terpene lactones.2 These findings were repeated in a later study using the same criteria in 12 elderly healthy subjects.3

**Experimental evidence**

In *in vitro* experiments, low-dose and high-dose ginkgo modestly decreased and increased the metabolism of dextromethorphan, respectively.4,5

**Mechanism**

Dextromethorphan is used as a probe substrate for the cytochrome P450 isoenzyme CYP2D6, and the study shows that ginkgo has no clinically relevant effect on this isoenzyme. Studies with debrisoquine, another CYP2D6 substrate, also suggest that ginkgo does not affect CYP2D6.

**Importance and management**

The available evidence seems to reliably suggest that ginkgo does not affect the pharmacokinetics of dextromethorphan. No action is therefore needed on concurrent use.

Dextromethorphan is used as a probe drug for CYP2D6 activity, and therefore these results (along with those for debrisoquine) also suggest that a clinically relevant pharmacokinetic interaction between ginkgo and other CYP2D6 substrates is unlikely.


**Ginkgo + Digoxin**

Ginkgo does not appear to affect the pharmacokinetics of digoxin.

**Clinical evidence**

A study in 8 healthy subjects found that ginkgo leaf extract 80 mg three times daily had no significant effects on the pharmacokinetics of a single 500-microgram dose of digoxin.1

**Experimental evidence**

In *in vitro* experiments, ginkgo modestly inhibited the cellular transport of digoxin resulting in the intracellular accumulation of digoxin.2

**Mechanism**

Digoxin is a P-glycoprotein substrate and *in vitro* studies3 suggest that ginkgo may inhibit the activity of this drug transporter protein, which could lead to increased digoxin levels. However, this effect was not seen clinically.

**Importance and management**

The clinical study suggests that ginkgo is unlikely to alter digoxin levels in clinical use. Therefore no dosage adjustment would be expected to be necessary if patients taking digoxin also wish to take ginkgo. As digoxin is used as a probe substrate for P-glycoprotein, this study also suggests that ginkgo is unlikely to interact with other drugs that are substrates of P-glycoprotein. No action is necessary with combined use.


**Ginkgo + Donepezil**

Ginkgo does not appear to alter the pharmacokinetics or effects of donepezil.

**Evidence, mechanism, importance and management**

In a pharmacokinetic study, 14 elderly patients with Alzheimer’s disease were given donepezil 5 mg daily for at least 20 weeks, after which ginkgo extract 90 mg daily was also given for a further 30 days. Concurrent use did not affect the pharmacokinetics or cholinesterase activity of donepezil, and cognitive function appeared to be unchanged.1 Therefore, over the course of 30 days, concurrent use appears neither beneficial nor detrimental. No action is necessary with combined use.


**Ginkgo + Fexofenadine**

Ginkgo does not appear to affect the pharmacokinetics of fexofenadine.

**Evidence, mechanism, importance and management**

In a clinical study, 13 healthy subjects took a single oral dose of fexofenadine 120 mg after 4 weeks of twice-daily doses of ginkgo 120 mg containing 29% flavonol glycosides and 5% terpene lactones. The pharmacokinetics of fexofenadine were not significantly affected.1
Fexofenadine is a P-glycoprotein substrate and the findings of this study therefore suggest that ginkgo does not affect P-glycoprotein activity. No action is necessary with combined use.


Experimental evidence
No relevant data found.

Ginkgo + Food
No interactions found.

Ginkgo + Haloperidol

Animal studies suggest that ginkgo may increase extrapyramidal effects in response to haloperidol, but clinical studies do not appear to have reported this effect.

Clinical evidence
Ginkgo has been tried in schizophrenia as an addition to standard antipsychotics such as haloperidol. For example, in one clinical study, an improvement in positive symptoms was seen in 43 schizophrenic patients given ginkgo extract 360 mg daily with haloperidol 250 micrograms/kg daily for 12 weeks.¹ This study did not report any adverse events.

Experimental evidence
High-dose ginkgo extract (EGb 761, Tebonin®), 80 mg/kg daily for 5 days, significantly potentiated the cataleptic adverse effects of haloperidol 2 mg/kg given to rats on the first and last day.² The cataleptic response to haloperidol is used as an animal model of extrapyramidal adverse effects.

Mechanism
Unknown. Haloperidol is a dopamine D₂-receptor antagonist. It is thought that ginkgo may interfere with dopamine neurotransmission by scavenging nitric oxide, which in turn reduces locomotor activity.

Importance and management
The authors of the experimental study caution that there is a possibility of an increase in extrapyramidal effects when ginkgo is used with haloperidol.² However, their study in rats used high doses, and there are clinical studies investigating the addition of ginkgo to haloperidol that do not mention this adverse effect. Nevertheless, a clinical study specifically of extrapyramidal effects would be required to investigate this further. It may be prudent to be aware of this possible interaction in case there is an unexpected outcome in patients taking haloperidol and ginkgo.


Ginkgo + Herbal medicines; Valerian

A case report describes psychotic symptoms in a woman who took ginkgo with valerian, but an interaction was not established as the cause.

Clinical evidence
A 51-year-old woman taking valerian 1 to 2 g daily and an unknown amount of ginkgo daily, and who regularly consumed over 1 L of wine daily, was admitted to hospital after a fainting episode and changes in mental status. Over the next couple of days she exhibited a variety of psychotic symptoms including paranoid delusions, disorganised behaviour, anxiety and auditory hallucinations. Her blood-alcohol level was zero on admission and there was no evidence of alcohol withdrawal during her stay in hospital.¹

Experimental evidence
No relevant data found.

Ginkgo + NSAIDs
An isolated case describes fatal intracerebral bleeding in a patient taking ginkgo with ibuprofen, and another case describes prolonged bleeding and subdural haematomas in another patient taking ginkgo and rofecoxib. Studies with diclofenac and flurbiprofen showed that ginkgo had no effect on the pharmacokinetics of these drugs.

Clinical evidence
A case of fatal intracerebral bleeding has been reported in a 71-year-old patient taking a ginkgo supplement (Gingium) 4 weeks after he started to take ibuprofen 600 mg daily.¹ A 69-year-old man taking a ginkgo supplement and rofecoxib had a subdural haematoma after a head injury, then recurrent small spontaneous haematomas. He was subsequently found to have a prolonged bleeding time, which returned to normal 1 week after stopping the ginkgo supplement and rofecoxib, and remained normal after restarting low-dose rofecoxib.²

A placebo-controlled study in 11 healthy subjects who were given ginkgo leaf (Ginkgold) 120 mg twice daily for three doses, followed by a single 100-mg dose of flurbiprofen, found that the pharmacokinetics of flurbiprofen were unchanged.³

A study in 12 healthy subjects who were given diclofenac 50 mg daily for 14 days, with ginkgo extract (Ginkgold) 120 mg twice daily on days 8 to 15, found no alteration in the AUC or oral clearance of diclofenac.⁴

Experimental evidence
See Mechanism, below.

Mechanism
The reason for the bleeding is not known, but ginkgo extract contains ginkgolide B, which is a potent inhibitor of platelet-activating factor in vitro, which is needed for arachidonate-independent platelet aggregation. However, in one controlled study in healthy subjects, taking a ginkgo preparation alone for 2 weeks had no effect on platelet function.⁵ Nevertheless, there are case reports of ginkgo supplements, on their own, being associated with prolonged bleeding times,⁶,⁷ left and bilateral subdural haematomas,⁸,⁹ a right parietal haematoma, a retrolobular haemorrhage, post-laparoscopic cholecystectomy bleeding,¹⁰ and subarachnoid haemorrhage.¹¹ Ibuprofen is an inhibitor of platelet aggregation, but
selective inhibitors of COX-2 such as rofecoxib have no effect on platelets and would not be expected to potentiate any bleeding effect of ginkgo.

The pharmacokinetic studies involving diclofenac and flurbiprofen were designed to identify whether ginkgo exerted an inhibitory effect on cytochrome P450 isoenzyme CYP2C9, and confirm that ginkgo has no effect on this isoenzyme.

**Importance and management**

The evidence from these reports is too slim to forbid patients to take NSAIDs and ginkgo concurrently, but some do recommend caution. Medical professionals should be aware of the possibility of increased bleeding tendency with ginkgo, and report any suspected cases.

For other reports of bleeding events with ginkgo see Ginkgo + Antiplatelet drugs, page 209, and Ginkgo + Warfarin and related drugs, page 217.


**Ginkgo + Phenobarbital**

The interaction between ginkgo and phenobarbital is based on experimental evidence only.

**Clinical evidence**

No interactions found.

**Experimental evidence**

In an experimental study in rats, ginkgo extract 0.5% daily (equating to about 1.3 g/kg) for 2 weeks modestly reduced the maximum serum levels of a single 90-mg/kg dose of phenobarbital by about 35%, and reduced the AUC by about 18% (not statistically significant). Conversely, the phenobarbital-induced sleeping time was reduced markedly from about 8 hours to about 3 hours. The ginkgo extract used was standardised to 24% flavonoids and 9% terpenes.1

**Mechanism**

Ginkgo may induce the cytochrome P450 isoenzyme CYP2B subfamily, which would increase the metabolism of phenobarbital, a CYP2B6 substrate, and reduce its levels. However, the modest reduction in levels seen with high-dose ginkgo does not explain the marked reduction in sleeping time.

**Importance and management**

The evidence for this interaction is limited to an animal study and the doses used are far higher than those used in humans. It is therefore difficult to assess the clinical relevance of this interaction. If anything, it would appear that the interaction may be beneficial (reduced sedation), but this is far from established.

For details of possible interactions with other antiepileptics, see Ginkgo + Antiepileptics, page 209.


**Ginkgo + Propranolol**

The interaction between ginkgo and propranolol is based on experimental evidence only.

**Clinical evidence**

No interactions found.

**Experimental evidence**

The maximum serum levels and AUC of propranolol 10 mg/kg given to rats, pretreated with ginkgo extract 100 mg/kg (EGb 761) for 10 days, were reduced by about 40% and 45% respectively when compared with propranolol alone. The serum levels and AUC of its metabolite, N-desisopropyipropranolol, were increased by about 70% and 55%. Ginkgo extract 10 mg/kg had no effect.1

**Mechanism**

The authors suggested that ginkgo may induce the activity of the cytochrome P450 isoenzyme CYP1A2, which is one of the major enzymes involved in the metabolism of propranolol. Ginkgo would therefore reduce the levels of propranolol by inducing its metabolism. However, compare caffeine, page 211.

**Importance and management**

This experiment in rats suggests that high-dose ginkgo might significantly reduce the levels of propranolol by inducing CYP1A2. However, a human study using caffeine as a CYP1A2 probe substrate found that ginkgo does not affect CYP1A2 to a clinically relevant extent (see Ginkgo + Caffeine, page 211). Therefore an interaction with propranolol based on this mechanism is unlikely to be clinically important.


**Ginkgo + Protease inhibitors**

Ginkgo does not appear to affect the pharmacokinetics of lopinavir/ritonavir.

**Clinical evidence**

In a study in 14 healthy subjects, ginkgo 120 mg twice daily for 2 weeks had no significant effect on the pharmacokinetics of lopinavir/ritonavir 400 mg/100 mg twice daily (given for 2 weeks alone before adding the ginkgo). The ginkgo extract was assayed and contained 29% flavonol glycosides and 5% terpene lactones.1

**Experimental evidence**

No relevant data found.

**Mechanism**

The authors suggest that, without ritonavir, the levels of lopinavir would have been reduced by ginkgo because they also found that ginkgo modestly reduced the levels of midazolam, probably by inducing the cytochrome P450 isoenzyme CYP3A4. As ritonavir is an inhibitor of CYP3A4, they suggest that it attenuates the action of ginkgo on lopinavir metabolism. However, note that all protease inhibitors are inhibitors of CYP3A4 to varying extents, and note also that, in other studies with midazolam, ginkgo had no effect on
Importance and management

The study here shows that ginkgo does not alter the pharmacokinetics of lopinavir/ritonavir, and no special precautions are required on concurrent use. This would apply to all other ritonavir-boosted protease inhibitors. As regards protease inhibitors that are not boosted by ritonavir, the authors of this study recommend avoiding ginkgo.1 This seems an over-cautious approach, given that the sum of studies available shows that ginkgo does not have a clinically relevant effect on the probe CYP3A4 substrate midazolam.

Clinical evidence

In one study, 18 healthy Chinese subjects were given a single 40-mg dose of omeprazole before and after a 12-day course of a standardised extract of ginkgo 140 mg twice daily. The subjects were divided into three groups: homozygous extensive CYP2C19 metabolisers (6 subjects), heterozygous extensive CYP2C19 metabolisers (5) and poor CYP2C19 metabolisers (7). The AUC of omeprazole was modestly decreased by 42%, 27% and 40%, respectively, and the plasma levels of the inactive metabolite, hydroxymeprazole, were increased by 38%, 100% and 232% in the three groups, respectively. Renal clearance of hydroxymeprazole was also reduced by ginkgo.2

Experimental evidence

No relevant data found.

Mechanism

It was concluded that ginkgo increases the metabolism (hydroxylation) of omeprazole by inducing the cytochrome P450 isozyme CYP2C19.

Importance and management

This appears to be the only study examining the effects of ginkgo on proton pump inhibitors. However, the reduction seen in the AUC of omeprazole (about 40%) suggests that there is a possibility that omeprazole will be less effective in patients taking ginkgo. As all PPIs are metabolised by CYP2C19 to varying extents, it is likely that the effects of ginkgo seen in these studies will be similar with other PPIs, although note that rabeprazole is much less dependent on this route of metabolism than other PPIs.

There is insufficient evidence to generally recommend that ginkgo should be avoided in patients taking PPIs. However, the potential reduction in the efficacy of the PPI should be borne in mind, particular where the consequences may be serious, such as in patients with healing ulcers.


Ginkgo + Proton pump inhibitors

Ginkgo induces the metabolism of omeprazole. Most other proton pump inhibitors are likely to be similarly affected.

Clinical evidence

Ginkgo + Theophylline

The interaction between ginkgo and theophylline is based on experimental evidence only.

Clinical evidence

No interactions found.

Experimental evidence

In an experimental study in rats pretreated with oral ginkgo extract 100 mg/kg daily for 5 days, the serum levels and AUC of a single 10 mg/kg oral dose of theophylline given on day 6 were reduced by about 20% and 40%, respectively. The clearance was increased by 70%. A less marked effect was seen with ginkgo 10 mg/kg (30% increase in clearance). Similar results were seen with intravenous theophylline 10 mg/kg.1

Mechanism

This interaction is thought to be due to the induction of the cytochrome P450 isozyme CYP1A2 by ginkgo. Theophylline is a substrate of CYP1A2 and by inducing the activity of this isozyme, theophylline is more readily metabolised and cleared from the body. However, ginkgo had no relevant effect on another CYP2D6 substrate. See Ginkgo + Dextromethorphan, page 213.

Importance and management

The use of ginkgo is widespread and this appears to be the only report in the literature of an interaction with risperidone. Its general relevance is therefore unclear. Bear it in mind in the event of an unexpected response to treatment.


Ginkgo + Risperidone

An isolated case describes priapism in a patient taking risperidone and ginkgo.

Clinical evidence

A 26-year-old paranoid schizophrenic who had been taking risperidone 3 mg daily for the past 3 years developed priapism that had lasted for 4 hours 2 weeks after starting ginkgo 160 mg daily for occasional tinnitus. The priapism required treatment, and both ginkgo and risperidone were stopped. Risperidone was then restarted and the patient reported no further episodes of priapism at follow-up 6 months later.1

Experimental evidence

No relevant data found.

Mechanism

Unclear. Risperidone alone does rarely cause priapism, probably because of its alpha-adrenergic properties, and ginkgo might have vascular effects that could be additive. Ginkgo is unlikely to inhibit the metabolism of risperidone by inhibiting the cytochrome P450 isozyme CYP2D6 because it has no clinical effect on other CYP2D6 substrates. See Ginkgo + Dextromethorphan, page 213.

Importance and management

The use of ginkgo is widespread and this appears to be the only report in the literature of an interaction with risperidone. Its general relevance is therefore unclear. Bear it in mind in the event of an unexpected response to treatment.


Ginkgo + Benzodiazepines

No interactions found.


Midazolam levels, or even caused a minor increase in levels, which suggests that ginkgo does not have a clinically relevant effect on CYP3A4 activity. Consider also Ginkgo + Benzodiazepines, page 210.

Ginkgo does not appear to have a clinically relevant effect on the metabolism or blood-glucose-lowering effects of tolbutamide.

**Clinical evidence**

In healthy subjects, ginkgo extract (Ginkgold) 120 mg twice daily for 7 days had no effect on the urinary metabolic ratio of tolbutamide.1 In another study in 10 healthy subjects, ginkgo 360 mg daily for 28 days slightly reduced the AUC of a single 125-mg oral dose of tolbutamide by about 16%, with no significant changes in other pharmacokinetic parameters. The ginkgo product used was Ginkgold, which contained 24% flavone glycosides and 6% terpene lactones. The pharmacodynamics of tolbutamide were not significantly altered although there was a tendency towards the attenuation of its hypoglycaemic effects by ginkgo (14% reduction).2

**Experimental evidence**

In an experimental study, ginkgo 32 mg/kg given daily for 5 days before a single 40-mg/kg dose of tolbutamide significantly reduced its blood-glucose-lowering effects in aged rats. However, when a single 100-mg/kg dose of ginkgo was given with a single 40-mg/kg dose of tolbutamide, the blood-glucose levels were significantly lower, when compared with tolbutamide alone, suggesting that ginkgo potentiated the blood-glucose-lowering effects of tolbutamide.3

**Mechanism**

It was suggested that ginkgo might induce the cytochrome P450 isoenzyme CYP2C9, by which tolbutamide is metabolised. However, the clinical study shows that ginkgo has little or no clinically relevant effect on CYP2C9. The disparate effects between single and multiple dose administration in the animal study are not understood.

**Importance and management**

From the clinical evidence, it is clear that ginkgo has little, if any, effect on the metabolism and blood-glucose-lowering effects of tolbutamide. A clinically relevant interaction therefore seems unlikely.

Tolbutamide is used as a probe drug for CYP2C9 activity, and therefore these results also suggest that a clinically relevant pharmacokinetic interaction between ginkgo and other CYP2C9 substrates is unlikely.

---

**Ginkgo + Warfarin and related drugs**

Evidence from pharmacological studies in animals and in healthy subjects suggests that ginkgo does not usually interact with warfarin. However, an isolated report describes intracerebral haemorrhage associated with the use of ginkgo and warfarin, and there are a few reports of bleeding associated with the use of ginkgo alone.

**Clinical evidence**

In a randomised, crossover study in 21 patients stabilised on warfarin, ginkgo extract 100 mg daily (Bio-Biloba) for 4 weeks did not alter the INR or the required dose of warfarin, when compared with placebo.1 Similarly, in another study in healthy subjects,2 Tavonin (containing standardised dry extract Egb 761 of ginkgo equivalent to 2 g of leaf) two tablets three times daily for 2 weeks did not affect either the pharmacokinetics or pharmacodynamics (INR) of a single dose of warfarin given on day 7. Moreover, a retrospective review of 21 clinical cases involving the concurrent use of ginkgo and warfarin also found no evidence of altered INRs.3 Conversely, a report describes an intracerebral haemorrhage, which occurred in an elderly woman within 2 months of her starting to take ginkgo. Her prothrombin time was found to be 16.9 seconds and her partial thromboplastin time was 35.5 seconds. She had been taking warfarin uneventfully for 5 years.4 The author of the report speculated that ginkgo may have contributed towards the haemorrhage.

**Experimental evidence**

In animal studies it was found that the AUC of warfarin was decreased by 23.4% when the ginkgo extract Egb 761 was given, and the prothrombin time was also reduced by EGB 761, which would suggest that ginkgo should reduce the effects of warfarin.3

**Mechanism**

Uncertain. Isolated cases of bleeding have been reported with ginkgo alone (which have been the subject of a review).5 In pharmacological studies, ginkgo extract alone did not alter coagulation parameters or platelet aggregation,2,4 Moreover, the experimental study suggests that ginkgo might reduce the effects of warfarin. Ginkgo extracts and ginkgo. The patient woke immediately after being given flumazenil 1 mg intravenously.1

---

**Ginkgo + Trazodone**

Coma developed in an elderly patient with Alzheimer’s disease after she took trazodone and ginkgo.

**Clinical evidence**

An 80-year-old woman with Alzheimer’s disease became comatose a few days after starting to take low-dose trazodone 20 mg twice daily and ginkgo. The patient woke immediately after being given flumazenil 1 mg intravenously.1

**Mechanism**

No relevant data found.

---


also do not appear to affect the metabolism of a number of substrates of the cytochrome P450 isoenzyme CYP2C9, suggesting that a pharmacokinetic interaction with warfarin, which is metabolised by this route, is unlikely. Consider also Ginkgo + NSAIDs, page 214, and Ginkgo + Tolbutamide, page 217.

**Importance and management**

There is good evidence from pharmacological studies in patients and healthy subjects that ginkgo extract would not be expected to interact with warfarin. However, there is one case report of over-anticoagulation, and a few reports of bleeding with ginkgo alone. This is insufficient evidence to justify advising patients taking warfarin to avoid ginkgo, but they should be warned to monitor for early signs of bruising or bleeding and seek informed professional advice if any bleeding problems arise.

Consider also Ginkgo + Antiplatelet drugs, page 209, and Ginkgo + NSAIDs, page 214 for other reports of bleeding events.

Ginseng

Panax ginseng C.A.Mey (Araliaceae)

Synonym(s) and related species

Many species and varieties of ginseng are used. Panax ginseng C.A.Mey is also known as Asian ginseng, Chinese ginseng, Korean ginseng, Oriental ginseng, Renshen.

Panax quinquefolius L. is also known as American ginseng.

Other species used include: Panax notoginseng (Burkill) F.H.Chen ex C.Y.Wu & K.M.Feng known as Sanchi Renshen.

Chinese ginseng, Korean ginseng, Oriental ginseng, Panax quinquefolius (American ginseng), Eleutherococcus senticosus (Siberian ginseng) and the

Use and indications

Ginseng is used to enhance the body’s resistance to stress and to improve mental and physical performance. It has also been used for diabetes, insomnia, sexual inadequacy, for degenerative conditions associated with ageing, to improve healing and as a stimulant.

Pharmacokinetics

In vitro studies of various extracts and individual ginsenosides from Panax ginseng (Asian ginseng) and Panax quinquefolius (American ginseng) have generally found little to suggest that they interfere with the activity of cytochrome P450 isoenzymes.1-5 This also seems to be the case for Eleutherococcus senticosus (Siberian ginseng) and the eleutherosides.3,5

The ginsenosides have been reported to inhibit CYP1A2 to some extent,6 and various ginsenoside metabolites have been found to exert an inhibitory effect on CYP3A4.1-4 However, the clinical relevance of these in vitro findings appears to be small, as clinical studies have found that Panax ginseng and Eleutherococcus senticosus do not affect CYP3A4 (see benzodiazepines, page 222) or CYP2D6 (see dextromethorphan, page 223), and Panax ginseng also does not affect CYP1A2 (see caffeine, page 222) or CYP2E1 (see chlorzoxazone, page 222).

Some ginsenosides have been shown to be substrates for P-glycoprotein in vitro, and may actually inhibit its activity.4,5 Whether this is clinically relevant is uncertain.

Interactions overview

Panax ginseng (Asian ginseng), Panax quinquefolius (American ginseng) and Eleutherococcus senticosus (Siberian ginseng) appear to modestly lower blood-glucose levels and may therefore potentiate the blood-glucose-lowering effects of conventional oral antidiabetics, although this was not demonstrated in one study. Panax ginseng and Panax quinquefolius may reduce the effects of warfarin. As both ginsengs also contain antiplatelet components, excessive bleeding cannot be ruled out. Panax ginseng, Panax quinquefolius and Eleutherococcus senticosus may also interfere with digoxin assays and, although the evidence is limited, the psychoactive effects of ginseng may be additive with those of MAOIs. Preliminary study suggests that Panax ginseng may increase the clearance of alendazole and alcohol, but the clinical significance of this is not clear. Panax ginseng is a constituent of some Chinese herbal medicines. For interactions relating to these products, see under bupleurum, page 89.


The interaction between *Panax ginseng* (Asian ginseng) and albendazole is based on experimental evidence only.

**Clinical evidence**
No interactions found.

**Experimental evidence**
*Panax ginseng* (Asian ginseng) 10 mg/kg given intravenously to rats, increased the intestinal clearance of intravenous albendazole sulfoxide 10 mg/kg, the active metabolite of albendazole, by about 25%. The AUC was not significantly affected.1

**Mechanism**
Uncertain. *Panax ginseng* may interfere with the metabolism of albendazole.

**Importance and management**
The findings of this study using intravenous *Panax ginseng* (Asian ginseng) may not apply to oral use, as is used clinically. However, even if replicated in humans, the minor changes seen in the clearance of albendazole would be unlikely to be clinically relevant. Based on this study, no action is needed if patients taking albendazole also wish to take *Panax ginseng*.


---

The interaction between *Panax ginseng* (Asian ginseng) and alcohol comes from a clinical study, which confirms the initial findings of some experimental studies.2,3 What the reduction in blood-alcohol levels means in practical terms is not clear but the authors of the clinical report suggest the possibility of using *Panax ginseng* to treat alcoholic patients and those with acute alcohol intoxication;4 however, this suggestion needs confirmation in further clinical studies. The available data do, however, suggest that the concurrent use of alcohol and *Panax ginseng* is unlikely to be detrimental.


---

**In patients with diabetes taking various oral antidiabetics,** *Panax quinquefolius* (American ginseng) and *Panax ginseng* (Asian ginseng) have both shown modest reductions in postprandial glucose levels after a glucose tolerance test, but *Panax ginseng* did not result in any improvement in diabetes control when given for 12 weeks.

**Clinical evidence**
In a placebo-controlled crossover study, 19 patients with well-controlled type 2 diabetes were treated with oral *Panax ginseng* (Asian ginseng) 2 g three times daily 40 minutes before meals in addition to their usual treatment (antidiabetics and/or diet) for 12 weeks. The ginseng had no effect on glycosylated blood-glucose, which remained at about 6.5%, but it did slightly decrease the blood-glucose levels after a 75 g oral glucose tolerance test. All patients in the study were diet controlled: 5 patients received no additional treatment; 3 patients were taking a sulfonylurea; 3 patients were taking metformin; 5 patients were taking a sulfonylurea with metformin; 1 patient was taking a sulfonylurea with rosiglitazone; 1 patient was taking a sulfonylurea and rosiglitazone; and 1 patient was taking acarbose.1

In earlier studies by the same research group, single dose *Panax quinquefolius* (American ginseng) 3 to 9 g slightly reduced the postprandial blood-glucose concentrations by about 20 to 24% in patients with type 2 diabetes when given 40 minutes before or at the same time as a 25 g oral glucose challenge. These patients were being treated with diet alone, sulfonylureas, or sulfonylureas plus metformin.2,3 When comparing the effect between those receiving antidiabetes and those not, there was no difference, suggesting no specific drug interaction.4

**Experimental evidence**
The blood-glucose-lowering effects of *Panax quinquefolius* (American ginseng) and *Panax ginseng* (Asian ginseng) has been demonstrated in various animal models, and is not covered here because there is adequate clinical information. In an experimental study, *Eleutherococcus senticosus* (Siberian ginseng) also showed significant blood-glucose-lowering activity in mice.5

**Mechanism**
Additive blood-glucose-lowering effects are theoretically possible when ginseng is given with antidiabetics. However, very limited data suggest no specific interactions with conventional antidiabetics.

**Importance and management**
These studies show that *Panax ginseng* (Asian ginseng) and *Panax quinquefolius* (American ginseng) might possess blood-glucose-lowering activity, but the multiple-dose study showed that this was not clinically relevant in patients with well-controlled diabetes. The available data suggest that it is very unlikely that a dramatic hypoglycaemic effect will occur in patients with diabetes.


### Ginseng + Benzodiazepines

*Eleutherococcus senticosus* (Siberian ginseng) did not alter the pharmacokinetics of alprazolam, and *Panax ginseng* (Asian ginseng) did not alter midazolam metabolism.

#### Clinical evidence

A study in 12 healthy subjects found that *Eleutherococcus senticosus* (Siberian ginseng), 485 mg twice daily for 15 days, did not significantly affect the pharmacokinetics of a single 2-mg dose of alprazolam given with the morning dose on day 14.1 Similarly, in 12 healthy subjects, *Panax ginseng* (Asian ginseng), 500 mg three times daily for 28 days, did not significantly affect the metabolism of oral midazolam 8 mg. The ginseng preparation used was standardised to 5% ginsenosides.2 These findings were repeated in a later study using the same criteria in 12 elderly healthy subjects.3

#### Experimental evidence

No relevant data found.

#### Mechanism

These studies showed that neither *Eleutherococcus senticosus* nor *Panax ginseng* had any effect on the cytochrome P450 isoenzyme CYP3A4, by which alprazolam and midazolam are metabolised.

#### Importance and management

These studies suggest that both *Panax ginseng* (Asian ginseng) and *Eleutherococcus senticosus* (Siberian ginseng) are unlikely to affect the metabolism of alprazolam and midazolam. Therefore no dosage adjustments would appear necessary on concurrent use.

Alprazolam and midazolam are used as probe drugs for CYP3A4 activity, and therefore these results also suggest that an interaction between *Panax ginseng* or *Eleutherococcus senticosus* and these benzodiazepines as a result of this mechanism is unlikely.


### Ginseng + Carbamazepine

Panax ginseng (Asian ginseng) did not alter chlorzoxazone metabolism in one study.

#### Clinical evidence

In a study in 12 healthy subjects, *Panax ginseng* (Asian ginseng) 500 mg three times daily for 28 days did not significantly affect the pharmacokinetics of chlorzoxazone 500 mg. The ginseng preparation used was standardised to 5% ginsenosides.1 These findings were repeated in a later study using the same criteria in 12 elderly healthy subjects.2

#### Experimental evidence

No relevant data found.

#### Mechanism

These studies show that *Panax ginseng* does not have a clinically significant effect on the cytochrome P450 isoenzyme CYP1A2 by which caffeine is metabolised.

### Ginseng + Chlorzoxazone

Panax ginseng (Asian ginseng) did not alter chlorzoxazone metabolism in one study.

#### Clinical evidence

In a study in 12 healthy subjects, *Panax ginseng* (Asian ginseng) 500 mg three times daily for 28 days did not significantly affect the pharmacokinetics of chlorzoxazone 500 mg. The ginseng preparation used was standardised to 5% ginsenosides. These findings were repeated in a later study using the same criteria in 12 elderly healthy subjects.3

#### Experimental evidence

No relevant data found.

#### Mechanism

These studies show that *Panax ginseng* does not have a clinically significant effect on the cytochrome P450 isoenzyme CYP2E1 by which chlorzoxazone is metabolised.

### Importance and management

These studies suggest that *Panax ginseng* (Asian ginseng) is unlikely to affect the metabolism of caffeine. Therefore it would not be expected to reduce the effects or increase the adverse effects of caffeine. Nevertheless, ginseng is considered to be a stimulant, and it is possible that additive stimulant effects might occur with caffeine, although there do not appear to be many data on this. However, if both substances are given, bear the possibility of increased stimulant effects in mind.

Caffeine is used as a probe substrate for CYP1A2 activity, and therefore these results also suggest that a pharmacokinetic interaction as a result of this mechanism between *Panax ginseng* and other CYP1A2 substrates is unlikely.

For information on one study where the stimulant effects of a caffeine-containing herb appeared to be additive to those of *Panax ginseng*, see Ginseng + Herbal medicines; Guarana, page 223.


used as a probe drug for CYP2E1 activity, and therefore these results also suggest that a pharmacokinetic interaction as a result of this mechanism between Panax ginseng and other CYP2E1 substrates is unlikely.


**Ginseng + Dextromethorphan**

*Eleutherococcus senticosus* (Siberian ginseng) does not appear to affect the metabolism of dextromethorphan.

**Clinical evidence**

A study in 12 healthy subjects found that *Eleutherococcus senticosus* (Siberian ginseng), 485 mg twice daily for 14 days, did not significantly affect the metabolism of a single 30-mg dose of dextromethorphan.¹

**Experimental evidence**

No relevant data found.

**Mechanism**

This study shows that *Eleutherococcus senticosus* does not have a clinically significant effect on the cytochrome P450 isoenzyme CYP2D6 by which dextromethorphan is metabolised. Note also that *Panax ginseng* (Asian ginseng) had no effect on the metabolism of debrisoquine, another CYP2D6 probe substrate, in clinical pharmacokinetic interaction studies.²

**Importance and management**

This study suggests that *Eleutherococcus senticosus* (Siberian ginseng) is unlikely to interact with dextromethorphan. Dextromethorphan and debrisoquine are used as probe drugs for CYP2D6 activity, and therefore these results also suggest that a pharmacokinetic interaction as a result of this mechanism between *Panax ginseng* (Asian ginseng) or *Eleutherococcus senticosus* and other CYP2D6 substrates is unlikely.


**Ginseng + Laboratory tests**

*Panax ginseng* (Asian ginseng), *Panax quinquefolius* (American ginseng) and *Eleutherococcus senticosus* (Siberian ginseng) may interfere with the results of digoxin assays.

**Clinical evidence**

A 74-year-old man who had been taking digoxin for many years (serum levels normally in the range 0.9 to 2.2 nanograms/mL) was found, during a routine check, to have digoxin levels of 5.2 nanograms/mL, but without evidence of toxicity or bradycardia or any other ECG changes.¹ The levels remained high even when the digoxin was stopped. It turned out he had also been taking *Eleutherococcus senticosus* (Siberian ginseng) capsules. When the ginseng was stopped, the digoxin levels returned to the usual range, and digoxin was resumed. Later rechallenge with the ginseng caused a rise in his serum digoxin levels. No digoxin or digitoxin contamination was found in the capsules, and the authors of the report also rejected the idea that the eleutherosides (chemically related to cardiac glycosides) in ginseng might have been converted in vivo into digoxin, or that the renal elimination of digoxin might have been impaired, since the patient showed no signs of toxicity.¹

**Experimental evidence**

*Panax ginseng* (Asian ginseng), *Panax quinquefolius* (American ginseng) and *Eleutherococcus senticosus* (Siberian ginseng) have been found to interfere with some digoxin assays including
Ginseng

fluorescence polarisation immunoassay (FPIA, Abbott Laboratories) 2,4 and microparticle enzyme immunoassay (MEIA, Abbott Laboratories).2,3 The more specific monoclonal antibody-based digoxin immunoassay, Tina-quant (Roche), was unaffected by all the ginsengs,3,4 and the Beckman (Synchron LX system) monoclonal assay was unaffected by Panax ginseng (Asian ginseng).4

Mechanism
Uncertain. One possible explanation is that the ginsengs affected the accuracy of the digoxin assays so that they gave false results.

Importance and management
The interference in the digoxin measurements described in the assays was not as high as that reported in the elderly patient and there is some doubt as to whether the herbal medicine taken by the patient was actually Eleutherococcus senticosus (Siberian ginseng).5 So, whether this is clinically important, and measurement of serum digoxin levels is actually affected, is uncertain. Nevertheless it may be sensible to ask about ginseng use when interpreting unexpected digoxin levels and consider using a more specific monoclonal immunoassay.


Ginseng + MAOIs

Case reports describe headache, insomnia and tremulousness, which was attributed to the concurrent use of ginseng and phenelzine.

Clinical evidence
A 64-year-old woman taking phenelzine [60 mg daily] developed headache, insomnia and tremulousness after taking Natrol High, a product containing ginseng.1,2 probably Eleutherococcus senticosus (Siberian ginseng). She had the same symptoms on another occasion after drinking a ginseng tea (type not stated), which she had used without problem before starting phenelzine.1 Three years later, while taking phenelzine 45 mg daily, she experienced the same symptoms and an increase in depression 72 hours after starting to take ginseng capsules (type not stated) and a herbal tea.2

Another depressed woman taking ginseng (type not stated) and bee pollen experienced relief of her depression and became active and extremely optimistic when she started to take phenelzine 45 mg daily, but this was accompanied by insomnia, irritability, headaches and vague visual hallucinations. When the phenelzine was stopped and then re-started in the absence of the ginseng and bee pollen, her depression was not relieved.3

Experimental evidence
No relevant data found.

Mechanism
Uncertain. It seems unlikely that the bee pollen had any part to play. Note that the ginsengs have stimulant effects, and adverse effects include insomnia, nervousness, hypertension and euphoria.

Importance and management
Evidence is limited to three case reports, and the general importance of these poorly documented early cases is unclear. It may be that these cases could just represent idiosyncratic reactions, and not be due to an interaction. The data are therefore too limited to suggest any particular caution. Nevertheless, consider the possibility of an interaction in case of an unexpected response to treatment with phenelzine (or potentially any MAOI) in a patient taking any type of ginseng.


Ginseng + Ofloxacin

For mention that sairei-to and sho-saiko-to (of which ginseng is one of a number of constituents) do not affect the pharmacokinetics of ofloxacin, see Bupleurum + Ofloxacin, page 90.

Ginseng + Tamoxifen and other oestrogen antagonists?

Ginseng may contain oestrogenic compounds that might directly stimulate breast cancer growth and oppose the actions of competitive oestrogen receptor antagonists such as tamoxifen. However, there is some evidence that ginseng use before diagnosis might not adversely affect breast cancer survival.

Evidence, mechanism, importance and management
In one report ginseng root was listed as an example of a herbal medicine with oestrogenic activity that might directly stimulate breast cancer growth and oppose the actions of competitive oestrogen receptor antagonists such as tamoxifen, see Chinese angelica + Oestrogens or Oestrogen antagonists, page 130.

However, there is some evidence that ginseng use before diagnosis might not adversely affect breast cancer survival. In the Shanghai breast cancer study, 398 women who regularly used ginseng before diagnosis actually had better disease-free and overall survival over 5 years than 1057 women who had never used ginseng. Data on ginseng use had been obtained within 66 days of diagnosis of breast cancer. Most of the ginseng used was Panax quinquefolius (American ginseng) or white Panax ginseng (Asian ginseng), the average daily dose was 1.3 g of ginseng root, and the average cumulative duration of use was 4.3 months per year. It should be noted that ginseng users were of higher educational achievement and were more likely to have used tamoxifen (69% versus 61%), both factors that might contribute to increased survival. Although ginseng use post-diagnosis was assessed at follow-up interview, it was not possible to examine the effect of this on survival since there were no data on post-diagnosis use of ginseng in patients who had already died.1 While not conclusive, this study does provide some reassurance about the use of ginseng in breast cancer. However, a prospective randomised study is required to fully ascertain this.

Ginseng + Tolbutamide

For conflicting evidence that sho-saiko-to (of which ginseng is one of 7 constituents) might increase or decrease the rate of absorption of tolbutamide in animal studies, see Bupleurum + Tolbutamide, page 90.

Ginseng + Warfarin and related drugs

One pharmacological study found that Panax quinquefolius (American ginseng) modestly decreased the effect of warfarin, whereas another study found that Panax ginseng (Asian ginseng) did not alter the effect of warfarin. Two case reports describe decreased warfarin effects, one with thrombosis, attributed to the use of ginseng (probably Panax ginseng).

Clinical evidence

In a placebo-controlled study, 20 healthy subjects were given warfarin 5 mg daily for 3 days alone then again on days 15 to 17 of a 3-week course of Panax quinquefolius (American ginseng) 1 g twice daily. In the 12 subjects given ginseng, the peak INR was modestly reduced by 0.16, compared with a non-significant reduction of 0.02 in the 8 subjects given placebo. There was also a modest reduction in the AUC of warfarin. In this study, Panax quinquefolius root was ground and capsulated.1

Evidence from two earlier case reports supports a reduction in warfarin effect. A man taking warfarin long term, and also diltiazem, glyceryl trinitrate and salbutamol, had a fall in his INR from 3.1 to 1.5 within 2 weeks of starting to take ginseng capsules (Ginsana) three times daily. This preparation contains 100 mg of standardised concentrated ginseng [probably Panax ginseng (Asian ginseng)] in each capsule. Within 2 weeks of stopping the ginseng his INR had risen again to 3.3.2 Another patient taking warfarin was found to have thrombosis of a prosthetic aortic valve, with a subtherapeutic INR of 1.4. Three months prior to this episode his INR had become persistently subtherapeutic, requiring a progressive increment in his warfarin dose. It was suggested that this might have been because he had begun using a ginseng product (not identified).3

In contrast, in a randomised, crossover study in 12 healthy subjects, ginseng capsules 1 g three times daily for 2 weeks did not affect either the pharmacokinetics or pharmacodynamics (INR) of a single 25-mg dose of warfarin taken on day 7. The brand of ginseng used was Golden Glow, each capsule containing an extract equivalent to 0.5 g of Panax ginseng (Asian ginseng).4

Experimental evidence

A study in rats failed to find any evidence of an interaction between warfarin and an extract from Panax ginseng (Asian ginseng).5 See also Andrographis + Anticoagulants, page 31, for details of a lack of an interaction between Kan Jang, a standardised fixed combination of extracts from Andrographis paniculata and Eleutherococcus senticosus (Siberian ginseng), and warfarin.

Mechanism

It is unclear why ginseng might reduce the efficacy of warfarin, particularly as no pharmacokinetic interaction occurs. In vitro experiments have found that Panax ginseng contains antiplatelet components that inhibit platelet aggregation and thromboxane formation, although antiplatelet activity was not demonstrated in a study in healthy subjects.6 If an antiplatelet effect were confirmed, this might suggest the possibility of an increased risk of bleeding with the combination of ginseng and warfarin. There are a few reports of vaginal bleeding in women using ginseng preparations (unspecified) in the absence of an anticoagulant,7–10 but these are probably due to a possible hormonal effect of ginseng.

Importance and management

The available evidence suggests that ginseng might decrease the effect of warfarin. It is possible that the effect is greater with, or specific to, Panax quinquefolius (American ginseng), since this interacted in one study whereas Panax ginseng (Asian ginseng) did not. Although the ginseng dose was higher in the Panax ginseng study, the treatment duration was not as long, which may have obscured an effect. Moreover, the two case reports of decreased warfarin effects attributed to the use of ginseng were probably Panax ginseng.

Until further information becomes available it would seem prudent to be alert for decreased effects of warfarin and related drugs in patients using ginseng, particularly Panax quinquefolius. However, the possibility of an increased risk of bleeding due to the antiplatelet component of Panax ginseng cannot entirely be ruled out, although the clinical study suggests that this is unlikely.

Glucosamine
2-Amino-2-deoxy-β-D-glucopyranose

Types, sources and related compounds
Chitosamine, Glucosamine hydrochloride, Glucosamine sulfate potassium chloride, Glucosamine sulfate sodium chloride.

Pharmacopoeias
Glucosamine Hydrochloride (USP 32); Glucosamine Sulfate Potassium Chloride (USP 32); Glucosamine Sulfate Sodium Chloride (USP 32); Glucosamine Tablets (USP 32).

Use and indications
Glucosamine is a natural substance found in chitin, mucoproteins and mucopolysaccharides. It can be made by the body, and is found in relatively high concentrations in cartilage, tendons and ligaments. The primary use of supplemental glucosamine is for the treatment of osteoarthritis and other joint disorders. It is sometimes given with chondroitin, page 135. Glucosamine in supplements may be prepared synthetically, or extracted from chitin.

Pharmacokinetics
The oral bioavailability of glucosamine has been estimated to be about 25 to 50%, probably due to first-pass metabolism in the liver. Glucosamine is rapidly absorbed and distributed into numerous tissues, with a particular affinity for articular cartilage.1,2

Interactions overview
Glucosamine supplements have modestly increased the INR in a few patients taking warfarin. Increased blood-glucose has been recorded in patients with diabetes, but no interaction was found in a controlled study. Glucosamine might modestly increase tetracycline or oxytetacycline levels, and very limited evidence suggests that glucosamine may possibly decrease the efficacy of paracetamol and some cytotoxic antineoplastics. Unnamed diuretics may slightly reduce the efficacy of glucosamine.

In a controlled study, glucosamine supplements with chondroitin had no effect on glycaemic control in patients taking oral antidiabetic drugs but one report notes that unexpected increases in blood-glucose levels have occurred.

**Evidence, mechanism, importance and management**

In 2000, the Canadian Adverse Drug Reaction Monitoring Programme (CADRMP) briefly reported that unexpected increases in blood-glucose levels had occurred in diabetic patients taking glucosamine sulfate, or glucosamine with chondroitin. However, in a well-controlled study, Cosamin DS glucosamine hydrochloride 1.5 g daily with chondroitin sulfate sodium 1.2 g daily for 90 days had no effect on the control of diabetes (glycosylated haemoglobin) in 22 patients with type 2 diabetes, 4 who were diet controlled and 18 who were receiving oral antidiabetics (specific drugs not named). Endogenous glucosamine has a role in glucose metabolism, and may increase insulin resistance. In one case, glucosamine also reduced hypoglycaemic episodes in a patient with metastatic insulinoma.

The interaction is not established, and the results of the controlled study suggest that glucosamine supplements are generally unlikely to affect the control of diabetes. However, it has been suggested that the results of this study may not be applicable to patients in the later stages of diabetes (i.e. those with type 2 diabetes who require, or are expected to require, insulin). Therefore it may be prudent to increase monitoring of blood-glucose in these patients if glucosamine supplements are taken. Also, if glucose control unexpectedly deteriorates, bear the possibility of self-medication with supplements such as glucosamine in mind.


**Glucosamine + Antidiabetics**

The interaction between glucosamine and antidiabetics is based on experimental evidence only.

**Clinical evidence**

No interactions found

**Experimental evidence**

An *in vitro* study found that colon and ovary cancer cell lines showed resistance to doxorubicin and etoposide after exposure to glucosamine at a concentration of 10 mmol. Only a weak effect of glucosamine was found in the responsiveness of breast cancer cell lines to etoposide.

**Mechanism**

It is suggested that the expression of topoisomerase II was reduced by the presence of glucosamine. Topoisomerase II is required for doxorubicin and etoposide to exert their antineoplastic effects; therefore decreasing the levels of this enzyme increased the resistance to these antineoplastics.

**Importance and management**

This possible interaction appears not to have been studied *in vivo* and, until more data are available, the clinical significance of the findings is unclear. However, the implication is that glucosamine could reduce the efficacy of these antineoplastics. Bear this possibility in mind should an unexpected response to treatment with topoisomerase inhibitors occur.


**Glucosamine + Diuretics**

Limited evidence from a large open study suggests that unnamed diuretics may slightly reduce the efficacy of glucosamine.

**Clinical evidence**

In a large open study, 1183 evaluable patients with osteoarthritis were given glucosamine 1.5 g taken daily for an average of 50 days. The overall assessment of efficacy was ‘good’ in about 59% of patients and ‘sufficient’ in 36%. When response was analysed by concurrent treatment, in the 64 patients also taking diuretics (none specifically named), there was a slightly lower incidence of good efficacy (44%) and a slightly higher incidence of sufficient efficacy (52%), which reached statistical significance. However, note that this study was non-randomised, and other patient factors might therefore have accounted for these differences.

**Experimental evidence**

No relevant data found.

**Mechanism**

Unknown.

**Importance and management**

The concurrent use of glucosamine and diuretics is probably quite common, and the fact that this old study appears to be the only report in the literature of a possible interaction, and in itself inconclusive, suggests that any interaction is, in the main, unlikely to be clinically important.


**Glucosamine + Food**

No interactions found.

**Glucosamine + Herbal medicines**

No interactions found.

**Glucosamine + Paracetamol**

Limited evidence suggests that glucosamine may reduce the efficacy of paracetamol (acetaminophen).
Evidence, mechanism, importance and management
In a survey of herbal medicine use in 122 patients from 6 outpatient clinics, 2 patients with osteoarthritis (a 66-year-old man and a 74-year-old woman), had complained of reduced paracetamol (acetaminophen) efficacy when starting glucosamine. The salt of glucosamine used was not mentioned.1

It has been suggested that increased serum sulfate levels arising from glucosamine sulfate might lead to increased metabolism of paracetamol by sulfate conjugation.2 However, there are no studies assessing this. Note that this would only occur with glucosamine sulfate salts and would not occur with glucosamine hydrochloride.

The combined use of glucosamine and paracetamol to alleviate the symptoms of osteoarthritis is common, and the limited evidence here does not provide any reason to suggest any changes to this practice.


Glucosamine + Tetracyclines

Glucosamine modestly increases tetracycline levels.

Clinical evidence
A single-dose study in healthy subjects given tetracycline 250 mg alone or with glucosamine 250 mg found that the serum tetracycline levels were 105%, 50% and 25% higher at 2, 3 and 6 hours after administration, respectively, in those patients who had received the combined treatment. Similar results were found when oxytetracycline was given with glucosamine, with the corresponding increases being 36%, 44% and 30% at 2, 3 and 6 hours after administration, respectively.1 The AUC of the antibacterials was not reported.

In contrast, in another single-dose study in 12 healthy subjects given tetracycline 250 mg alone, and then with glucosamine 125 mg and 250 mg at 1-week intervals, the addition of glucosamine slightly increased serum tetracycline levels at 2, 3, 6 and 8 hours, but this was not statistically significant.2

Experimental evidence
A study in dogs and mice found that giving glucosamine hydrochloride with radioactive oxytetracycline increased the serum radioactivity, suggesting an increase in serum oxytetracycline levels. In the dogs, the increase in radioactivity was over twofold at 30 minutes, 1 hour and 24 hours after drug administration, whereas in the mice the increase was only greater than twofold at 15 minutes after drug administration.3

Mechanism
Unknown.

Importance and management
These very early studies from the 1950s suggest that glucosamine might cause a modest increase in tetracycline levels. As a result of these studies, it appears that a preparation of oxytetracycline formulated with glucosamine was tried. A modest increase in tetracycline or oxytetracycline levels is unlikely to have adverse consequences, and, if anything, might be slightly beneficial.


Glucosamine + Warfarin and related drugs

A few reports suggest that glucosamine with or without chondroitin may increase the INR in patients taking warfarin. In contrast, one case of a decreased INR has been reported when glucosamine was given with acencoumarol.

Clinical evidence
The first indication of a possible interaction was in 2001, when the Canadian Adverse Drug Reaction Monitoring Program briefly reported that an increase in INR had been noted when glucosamine was given to patients taking warfarin, and that INR values decreased when glucosamine was stopped.1 In 2004, a full case report was published. In this case, a 69-year-old man stabilised on warfarin 47.5 mg weekly had an increase in his INR from 2.58 to 4.52 4 weeks after starting to take 6 capsules of Cosamin DS (glucosamine hydrochloride 500 mg, sodium chondroitin sulfate 400 mg, manganese ascorbate per capsule) daily. His warfarin dose was reduced to 40 mg weekly, and his INR returned to the target range of 2 to 3 (INR 2.15) with continued Cosamin DS therapy.2 A comment on this report noted that this is twice the usual dose of glucosamine.3 Since then, one other similar case of a modest rise in INR has been published. A man taking warfarin and glucosamine hydrochloride 500 mg with chondroitin sulfate 400 mg twice daily had a gradual increase in his INR (from 2.3 to 4.7 over 5 weeks) when he trebled the dose of the glucosamine supplement.4

Analysis of regulatory authority data has revealed other unpublished reports. In 2006 the CHM in the UK reported that they had received 7 reports of an increase in INR in patients taking warfarin after they started taking glucosamine supplements.5 In 2007, a search of the FDA database identified 20 possible cases,6 and a search of the WHO database identified 22 possible case reports of an increase in warfarin effect with glucosamine, which originated from Australia, Canada, Denmark, Sweden, the UK and the USA.7 In two of the WHO cases, chondroitin was used, but the other cases were with glucosamine alone. Of 15 reports giving details of time to onset, the increased INR was noted within 3 days (in a 99 year old) and up to 6 months; mostly commonly the interaction took several weeks to manifest.8

In contrast, a 71-year-old man stabilised on acencoumarol 15 mg weekly had a decrease in his INR to 1.6 after taking glucosamine sulfate (Xicil) 1.5 g daily for 10 days. The glucosamine was stopped and the INR reached 2.1. When the glucosamine was restarted, with an increase in acencoumarol dose to 17 mg weekly, the INR only reached 1.9. The glucosamine was eventually stopped.9 Similarly, the WHO database contained one report of a decreased effect of warfarin with glucosamine.10 The Australian Adverse Drug Reactions Advisory Committee have also identified 12 cases of alterations in INR in patients taking warfarin. Nine of these cases are included in the WHO report.8

There do not appear to have been any controlled studies of the effects of glucosamine supplements on the pharmacodynamics or pharmacokinetics of oral anticoagulants.

Experimental evidence
No relevant data found.

Mechanism
Unknown.

Importance and management
Glucosamine is a widely used supplement, particularly in the middle-aged and elderly, who are also the group most likely to be using warfarin or similar anticoagulants. Despite this, there are just three published reports of a possible interaction, two describing moderate rises in INR and one a decrease. Even taking into account the possible cases reported to regulatory authorities, the interaction would seem to be quite rare. Nevertheless, the cases described suggest that it would be prudent to monitor the INR more closely if...
glucosamine is started or stopped. Also, if a patient shows an unexpected change in INR, bear in mind the possibility of self-medication with supplements such as glucosamine.

Note that in 2006 the CHM in the UK recommend that patients taking warfarin do not take glucosamine, but the subsequent 2007 UK-approved labelling for the prescription-only glucosamine product Alateris recommends close monitoring when a patient taking a coumarin anticoagulant starts or stops glucosamine.

Goldenseal

*Hydrastis canadensis* L. (Ranunculaceae)

**Synonym(s) and related species**
Hidrastis, Hydrastis, Orange root, Yellow root.
*Xanthorrhiza simplicissima* Marsh.

**Pharmacopoeias**
Goldenseal (*USP 32*); Goldenseal Rhizome (*Ph Eur 6.4*); Goldenseal Root (*BP 2009*); Powdered Goldenseal (*USP 32*); Powdered Goldenseal Extract (*USP 32*).

**Constituents**
The rhizome of goldenseal contains the isoquinoline alkaloids *hydrastine* and *berberine*, to which it may be standardised, and also berberastine, hydrastinine, canadine (tetrahydroberberine), canalidine and others.

**Use and indications**
Used for inflammatory and infective conditions, such as amoebic dysentery and diarrhoea; gastric and liver disease. The alkaloids are antibacterial, amoebicidal and fungicidal. For details on the uses of berberine, a major constituent of goldenseal, see berberine, page 58.

**Pharmacokinetics**
In several *in vitro* studies, goldenseal root has been identified as a potent inhibitor of the cytochrome P450 isoenzyme CYP3A4,
1–4 but more modest inhibitory effects were seen clinically with the CYP3A4 probe substrate, midazolam, page 231. Two studies in healthy subjects, found that goldenseal, given for 14 to 28 days, reduced the metabolism or urinary clearance of debrisoquine, a probe substrate of CYP2D6, by 36% and 47%, respectively.
3, 6 *In vitro* studies using another CYP2D6 probe, dextromethorphan also found that goldenseal inhibits CYP2D6, and suggested that this may be, at least in part, due to berberine; hydrastine had no effects on CYP2D6.4

Goldenseal has also been reported to possibly have some inhibitory effect on CYP2C8* (see paclitaxel, page 232) and CYP2C9* (see diclofenac, page 231). Another study suggested that goldenseal had no significant effect on CYP2E1 (see chlorzoxazone, page 231), CYP1A2 (see caffeine, page 231) or CYP2C19. In addition, there is some *in vitro* evidence of P-glycoprotein inhibition, but no effect was seen on the levels of digoxin, page 232, which is used as a probe substrate of this transporter.

For information on the pharmacokinetics of the constituent berberine, see under berberine, page 58.

**Interactions overview**
Goldenseal appears to modestly decrease the metabolism of midazolam, but has no significant effects on the pharmacokinetics of indinavir or digoxin.

Goldenseal does not appear to affect the metabolism of caffeine or chlorzoxazone. The interaction between goldenseal and diclofenac, paclitaxel or tolbutamide is based on experimental evidence only.

For a possible interaction with ciclosporin, occurring as a result of the constituent berberine, see Berberine + Ciclosporin, page 59.

Goldenseal appears to modestly decrease the metabolism of midazolam.

Clinical evidence
A study in 12 healthy subjects investigated the effects of goldenseal 900 mg three times daily taken for 28 days on a single 8-mg dose of oral midazolam. Goldenseal reduced the metabolism of midazolam to hydroxymidazolam by about 40%. The supplement used had no standardisation information.1 Similarly, in a study in 16 healthy subjects given a single 8-mg dose of midazolam after goldenseal 1323 mg three times daily for 14 days, there was a significant increase in the maximum concentration and AUC of midazolam of 41% and 62%, respectively, and a reduction in the clearance of about 36%. These increases were considered moderate when compared with the effects of clarithromycin and rifampicin in the study, which produced a 448% increase and 93% decrease in the AUC of midazolam, respectively. The goldenseal product used gave an estimated daily dose of berberine of about 77 mg and of hydrastine of 132 mg.2

Experimental evidence
Goldenseal appears to be a potent inhibitor of the cytochrome P450 isoenzyme CYP3A4 in vitro. See Pharmacokinetics, page 230.

Mechanism
A standardised goldenseal extract appears to modestly inhibit the cytochrome P450 isoenzyme CYP3A4, which is the major route of midazolam metabolism. Concurrent use therefore raises midazolam levels.

Importance and management
Evidence for an interaction between goldenseal and midazolam is based on clinical studies in healthy subjects. They suggest that some caution might be appropriate if patients taking goldenseal supplements are given oral midazolam; however, the effects were modest. Nevertheless, the clinical effects of this interaction do not appear to have been studied and so it may be prudent to be aware of the small possibility of increased sedation if midazolam is given to patients taking goldenseal supplements. Any interaction is unlikely to be significant in patients given a single dose of intravenous or oral midazolam pre-operatively.

Midazolam is used as a probe drug for CYP3A4 activity, and therefore these results also suggest that a modest pharmacokinetic interaction between goldenseal and other CYP3A4 substrates is possible. See the table Drugs and herbs affecting or metabolised by the cytochrome P450 isoenzyme CYP3A4, page 8, for a list of known CYP3A4 substrates.

For mention of an animal study of the possible anxiolytic effect of high-dose berberine and its interaction with diazepam, see Berberine + Anxiolytics, page 59.

Goldenseal did not affect chlorzoxazone metabolism in one study.

Clinical evidence
In a study in 12 healthy subjects, a goldenseal supplement 900 mg three times daily taken for 28 days had no significant effects on the metabolism of a single 100-mg oral dose of chlorzoxazone.1 The supplement used had no standardisation information.

Mechanism
A standardised goldenseal extract did not inhibit CYP1A2 in vitro,2 nor did goldenseal have a clinically relevant effect on the cytochrome P450 isoenzyme CYP1A2 activity using caffeine as a probe substrate.

Importance and management
This study suggests that goldenseal does not have any clinically relevant effect on caffeine metabolism in healthy subjects.

Caffeine is used as a probe substrate for CYP1A2 activity, and therefore these results also suggest that a pharmacokinetic interaction as a result of this mechanism between goldenseal and other CYP1A2 substrates is unlikely.

Goldenseal did not affect caffeine metabolism in one study.

Clinical evidence
A study in 12 healthy subjects found that a goldenseal supplement 900 mg three times daily taken for 28 days had no significant effects on the metabolism of a single 100-mg oral dose of caffeine.1 The supplement used had no standardisation information.

Mechanism
A standardised goldenseal extract did not inhibit CYP1A2 in vitro;2 nor did goldenseal have a clinically relevant effect on the cytochrome P450 isoenzyme CYP1A2 activity using caffeine as a probe substrate.

Importance and management
This study suggests that goldenseal does not have any clinically relevant effect on caffeine metabolism in healthy subjects.

Caffeine is used as a probe substrate for CYP1A2 activity, and therefore these results also suggest that a pharmacokinetic interaction as a result of this mechanism between goldenseal and other CYP1A2 substrates is unlikely.

Goldenseal + Caffeine

Goldenseal did not affect caffeine metabolism in one study.

Clinical evidence
A study in 12 healthy subjects found that a goldenseal supplement 900 mg three times daily taken for 28 days had no significant effects on the metabolism of a single 100-mg oral dose of caffeine.1 The supplement used had no standardisation information.

Mechanism
A standardised goldenseal extract did not inhibit CYP1A2 in vitro;2 nor did goldenseal have a clinically relevant effect on the cytochrome P450 isoenzyme CYP1A2 activity using caffeine as a probe substrate.

Importance and management
This study suggests that goldenseal does not have any clinically relevant effect on caffeine metabolism in healthy subjects.

Caffeine is used as a probe substrate for CYP1A2 activity, and therefore these results also suggest that a pharmacokinetic interaction as a result of this mechanism between goldenseal and other CYP1A2 substrates is unlikely.

Goldenseal + Diclofenac

The interaction between goldenseal and diclofenac is based on experimental evidence only.
Evidence, mechanism, importance and management

An *in vitro* study investigated the effects of a goldenseal extract, (containing equal amounts of the active constituents hydrastine and berberine) on the activity of the cytochrome P450 isoenzyme CYP2C9 in human liver microsomes, using diclofenac as a probe drug. Goldenseal 0.98% inhibited the hydroxylation of diclofenac by about 50%. When berberine and hydrastine were tested separately, hydrastine inhibited CYP2C9 to a greater extent than berberine. However, note that another *in vitro* study found that goldenseal had little effect on the metabolism of tolbutamide, page 233, another probe drug for CYP2C9 activity.

The general relevance of this is unknown as there are no clinical studies reporting the effects of goldenseal on CYP2C9. However, note that in the study cited here, goldenseal was about five times more potent as an inhibitor of CYP3A4 than CYP2C9, and clinically, goldenseal has only a modest effect on the CYP3A4 substrate midazolam, page 231. This provides some indication that CYP2C9 inhibition by goldenseal might not be clinically relevant. However, a clinical study is needed to confirm this.


Goldenseal + Digoxin

Goldenseal has only very small effects on the pharmacokinetics of digoxin.

Clinical evidence

A study in 20 healthy subjects given a single 500-microgram dose of digoxin before and on the last day of treatment with standardised goldenseal root extract 1070 mg three times daily for 14 days, found a 14% increase in the maximum digoxin plasma levels, but no other changes in the pharmacokinetics of digoxin. The product gave an estimated daily dose of berberine of about 77 mg and of hydrastine of about 132 mg.

Experimental evidence

See under Mechanism, below.

Mechanism

It was suggested that constituents of goldenseal may alter digoxin pharmacokinetics by affecting P-glycoprotein, since goldenseal alkaloids are modulators of P-glycoprotein *in vitro*. However, the clinical study showed that goldenseal does not cause clinically relevant changes in digoxin pharmacokinetics.

Importance and management

Evidence from the clinical study suggests that goldenseal has only very modest effects on the pharmacokinetics of digoxin, which would not be expected to be clinically relevant. No dosage adjustment would be expected to be necessary if patients taking digoxin also wish to take goldenseal.

Digoxin is used as a probe substrate for P-glycoprotein activity and therefore this study also suggests that goldenseal is unlikely to have a clinically relevant effect on the transport of other drugs by P-glycoprotein.


Goldenseal + Paclitaxel

The interaction between goldenseal and paclitaxel is based on experimental evidence only.

Evidence, mechanism, importance and management

In an *in vitro* study using human liver microsomes, an aqueous and ethanolic goldenseal extract inhibited CYP2C8 activity by about 50 to 60% when used at a concentration of 20 micromol alkaloids (sum of hydrastine and berberine), and had a lesser effect at 1 micromol (40%). However, because of wide confidence intervals, only the 60% decrease with the ethanolic extract was statistically significant. Paclitaxel was used as a probe cytochrome P450 isoenzyme...
CYP2C8 substrate, and therefore this study also suggests that goldenseal has the potential to inhibit the metabolism of other CYP2C8 substrates. When studied individually, both berberine and hydrastine had some CYP2C8 inhibitory activity (also not statistically significant).\(^1\)

The general relevance of the effect of goldenseal on paclitaxel metabolism is unknown as there are no clinical studies reporting the effects of goldenseal on CYP2C8 substrates. Note that high-dose berberine blocked the anticancer effects of paclitaxel in one in vitro study, see Berberine + Paclitaxel, page 60, and therefore, until more data are available, some caution may be prudent.


---

**Goldenseal + Tolbutamide**

The interaction between goldenseal and tolbutamide is based on experimental evidence only.

---

**Evidence, mechanism, importance and management**

An in vitro study investigated the effects of aqueous and alcoholic extracts of goldenseal on the cytochrome P450 isoenzyme CYP2C9 as measured by the activity of tolbutamide hydroxylase. The activity of CYP2C9 was increased by about 35% when incubated with the extract with an alkaloid concentration of 1 micromol, but this was only statistically significant for the ethanol extract. Moreover, the higher alkaloid concentration of 20 micromol had no effect.\(^1\) Note that another in vitro study found that goldenseal inhibited the metabolism of diclofenac, page 231, a probe drug for CYP2C9.

The clinical relevance of these results is unknown, and the disparate findings of goldenseal on CYP2C9 are not easily explained, but any effect was modest. Therefore goldenseal would be expected to have only modest, if any, effects on the response to tolbutamide. Further study is needed to assess these effects.

Gotu kola

Centella asiatica (L.) Urb. (Apiaceae)

Synonym(s) and related species
Asiatic pennywort, Centella, Gota kola, Gotu cola, Hydrocotyle, Indian pennywort, Indian water navelwort.

Hydrocotyle asiatica L., Hydrocotyle lurida Hance.

Pharmacopoeias
Centella (BP 2009, Ph Eur 6.4).

Constituents
Gotu kola contains a wide range of triterpene saponin glycosides such as asiaticoside (to which it may be standardised), centelloside, madecassoside, brahmoside, brahminoside and others. Free asiatic, centelic, centoic betulinic and madecassic acids are also present and these are considered to be the main active constituents. Flavonoids based on quercetin and kaempferol, and a small amount of volatile oil containing farnesene, germacrene-D, elemene and other terpenes are also present.

Use and indications
Gotu kola is widely used, mainly for inflammatory dermatological disorders and to aid the healing of ulcers and wounds. It is applied externally and taken internally for venous insufficiency and as an immunomodulator and antioxidant, and for many other conditions including memory enhancement, circulatory disorders and anxiety. A number of pharmacological and clinical studies support some of these activities.

Pharmacokinetics
No relevant pharmacokinetic data found. For information on the pharmacokinetics of the individual flavonoids present in gotu kola, see under flavonoids, page 186.

Interactions overview
No interactions with gotu kola found. For information on the interactions of the individual flavonoids present in gotu kola, see under flavonoids, page 186.
Grapefruit
Citrus paradisi Macfad. (Rutaceae)

Synonym(s) and related species
Citrus paradisi Macfad.

Grapefruit is a hybrid of the Pummelo or Pomelo (Citrus maxima (Burm.) Merr) with the sweet orange (Citrus sinensis (L.) Osbeck).

Constituents
Grapefruit contains furanocoumarins including bergamottin, 6',7'-dihydroxybergamottin, bergapten, bergaptol, geranilyl-coumarin and paradisin A. flavonoid glycosides such as naringin and flavonoid aglycones galangin, kaempferol, morin, naringenin, quercetin and others.

The peel contains a volatile oil, mostly composed of limonene.

Note that some grapefruit seed extracts have been found to contain preservatives such as benzethonium chloride, triclosan and methyl-p-hydroxybenzoate, which might be present because of the methods of production.

Use and indications
Grapefruit is used as a source of flavonoids (citrus bioflavonoids), which are widely used for their supposed antioxidant effects, and are covered under flavonoids, page 186.

Grapefruit seed extracts are used for their antimicrobial properties, but there is some controversy that this might be due to preservative content rather than natural constituents. Grapefruit and grapefruit juice are commonly ingested as part of the diet, and the oil is used as a fragrance.

Pharmacokinetics
Most of the data on the pharmacokinetics of grapefruit relate to the juice, which are summarised below. Note that it should not be directly extrapolated to herbal medicines containing grapefruit, because some differences in interaction potential have been seen. For information on the pharmacokinetics of the flavonoid constituents of grapefruit, see under flavonoids, page 186, and for information on the furanocoumarin constituents of grapefruit, see under natural coumarins, page 297.

(a) Cytochrome P450 isoenzymes
Grapefruit juice has been found to irreversibly inhibit the cytochrome P450 isoenzyme CYP3A4, and to cause drug interactions in quantities as low as 200 mL. Several compounds present are known to have inhibitory effects on CYP3A4, CYP2D6 and CYP2C9 in vitro, with the most potent thought to be the furanocoumarins, particularly dihydroxybergamottin, and the flavonoids naringenin and quercetin. However, the exact constituents that are responsible for the well-established clinical interactions of grapefruit juice are still uncertain. Naringin is present in grapefruit, but absent from other citrus fruits which led to the suggestion that naringin is the active principle, but this was later refuted. Quercetin has been reported to inhibit CYP3A4 in vitro; however, a clinical study found that, unlike grapefruit juice, quercetin alone, given at a concentration 40 times that found in the grapefruit juice, had no significant effect on the metabolism of nifedipine by CYP3A4. Furano-coumarins may also contribute to the interactions of grapefruit juice, because furanocoumarin-free grapefruit juice did not interact with felodipine, page 237, in one study. Nevertheless, none of the furanocoumarins individually appears to have much effect, and it appears that the net effect of all the furanocoumarins present determines the clinical effect. The effect of grapefruit juice on CYP3A is thought to be mainly exerted on intestinal CYP3A rather than hepatic CYP3A, because drugs given intravenously tend to be affected only to a small extent.

(b) P-glycoprotein
Based on the results of in vitro and interaction studies, it is thought that some component of grapefruit juice inhibits the activity of P-glycoprotein. However, note that there is no significant interaction with digoxin, a substrate of P-glycoprotein.

(c) Organic anion-transporting polypeptide (OATP)
In vitro, grapefruit juice has been shown to inhibit the organic anion-transporting protein (OATP), as have the individual ingredients bergamottin, 6',7'-dihydroxybergamottin, quercetin, naringin, naringenin and tangeretin. The inhibitory effect of naringin on OATP1A2 has also been confirmed in another in vitro study. Inhibition of this transporter protein results in a modest reduction in the bioavailability of drugs that are substrates for this transporter, such as fexofenadine, page 237.

Interactions overview
The vast majority of known drug interactions of grapefruit have been reported with grapefruit juice, which is not used as a medicine or dietary supplement. For this reason, these interactions are not included here in detail, but they are summarised in the table Summary of established drug interactions of grapefruit juice, page 236. While most clinically important interactions of grapefruit juice result in an increase in drug exposure, note that modest decreased exposure occurs with the beta blockers celiprolol and talinolol, and with the antihistamine, fexofenadine.

The interactions of grapefruit juice are probably also applicable to the consumption of the fresh fruit, as reported with carbamazepine and some calcium-channel blockers,
such as felodipine. An interaction has also been reported with grapefruit marmalade and tacrolimus. However, grapefruit juice interactions cannot be directly extrapolated to other grapefruit products such as the citrus bioflavonoids. In general, bioflavonoids are unlikely to interact to the same extent as grapefruit juice, because usually the furanocoumarins are required for a significant interaction to occur. However, there is evidence that citrus bioflavonoids alone might have an important interaction with lovastatin and simvastatin. For interactions of individual bioflavonoids present in grapefruit supplements, see under flavonoids, page 186, and for the interaction of individual furanocoumarins, see under natural coumarins, page 297.

There is one report of grapefruit seed extract interacting with warfarin; however, this was shown be due to the preservative content rather than the grapefruit extract.

### Summary of established drug interactions of grapefruit juice

<table>
<thead>
<tr>
<th>Drug</th>
<th>Effect on AUC</th>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Avoid grapefruit juice with these drugs</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ciclosporin</td>
<td>Increase of 23 to 85% (trough level)</td>
<td>Because of the likely adverse consequences of these interactions, it is probably best to avoid concurrent grapefruit juice altogether</td>
</tr>
<tr>
<td>Felodipine*</td>
<td>Increase of two- to threefold</td>
<td></td>
</tr>
<tr>
<td>Halofantrine</td>
<td>2.8-fold increase</td>
<td></td>
</tr>
<tr>
<td>Lovastatin, simvastatin</td>
<td>1.6 to 16-fold increase</td>
<td></td>
</tr>
<tr>
<td>Primaquine</td>
<td>Up to twofold increase</td>
<td></td>
</tr>
<tr>
<td>Tacrolimus**</td>
<td>Increase of 300% (trough level)</td>
<td></td>
</tr>
<tr>
<td><strong>Drugs requiring caution with grapefruit juice intake</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Amiodarone</td>
<td>Increase of 50%</td>
<td>Monitor the effects of concurrent use. Consider advising limiting the intake of grapefruit juice and/or reducing the dose of the drug. Bear in mind that variability in the constituents of grapefruit juice and variability in timing and amount of the juice consumed complicate management of these interactions</td>
</tr>
<tr>
<td>Atorvastatin</td>
<td>2.5-fold increase</td>
<td></td>
</tr>
<tr>
<td>Buspirone</td>
<td>9-fold increase</td>
<td></td>
</tr>
<tr>
<td>Carbamazepine*</td>
<td>Increase of 40%</td>
<td></td>
</tr>
<tr>
<td>Celiprolor</td>
<td>Decrease of 87%</td>
<td></td>
</tr>
<tr>
<td>Dextromethorphan</td>
<td>Fivelfold increase</td>
<td></td>
</tr>
<tr>
<td>Ibavradine</td>
<td>Twofold increase</td>
<td></td>
</tr>
<tr>
<td>Nicardipine, nifedipine,* nimodipine, nisoldipine*</td>
<td>Up to twofold increase</td>
<td></td>
</tr>
<tr>
<td>Verapamil†</td>
<td>Increase of 40%</td>
<td></td>
</tr>
<tr>
<td><strong>Drugs for which the interaction with grapefruit juice is usually of little practical importance</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Benzodiazepines:</td>
<td></td>
<td>These interactions are generally unlikely to be clinically relevant. Bear them in mind in the event of an unexpected response to treatment</td>
</tr>
<tr>
<td>Diazepam</td>
<td>3.2-fold increase</td>
<td></td>
</tr>
<tr>
<td>Oral Midazolam</td>
<td>Increase of 52%</td>
<td></td>
</tr>
<tr>
<td>Triazolam</td>
<td>Increase of 50 to 150%</td>
<td></td>
</tr>
<tr>
<td>Digoxin</td>
<td>Increase of 10%</td>
<td></td>
</tr>
<tr>
<td>Erythromycin</td>
<td>Increase of 49%</td>
<td></td>
</tr>
<tr>
<td>Fexofenadine</td>
<td>Decrease of up to 67%</td>
<td></td>
</tr>
<tr>
<td>Fluoxetine</td>
<td>Increase of 60%</td>
<td></td>
</tr>
<tr>
<td>Methylprednisolone</td>
<td>Increase of 75%</td>
<td></td>
</tr>
<tr>
<td>Praziqantel</td>
<td>Increase of 90%</td>
<td></td>
</tr>
<tr>
<td>Saquinavir</td>
<td>Increase of 50%</td>
<td></td>
</tr>
<tr>
<td>Sertraline</td>
<td>Increase of 50% (trough level)</td>
<td></td>
</tr>
<tr>
<td>Sildenafil†</td>
<td>Increase of 25%</td>
<td></td>
</tr>
<tr>
<td>Talinolol</td>
<td>Decrease of 44%</td>
<td></td>
</tr>
</tbody>
</table>

1. Compiled from Stockley’s Drug Interactions, 8th edition. Karen Baxter, Ed. Pharmaceutical Press, 2008. This table does not include drugs that are predicted to interact, and for which there is no evidence, or drugs for which no interaction occurs.
2. Effect also seen with the fruit (grapefruit segments or grapefruit pulp).
3. Effect also seen with excessive consumption of grapefruit marmalade.
4. Manufacturer actually advises avoidance of grapefruit juice with these drugs.
Grapefruit + Caffeine

For mention that grapefruit *juice* and one of its constituents naringin, a grapefruit flavonoid, had no effect on the metabolism of caffeine, see Flavonoids + Caffeine, page 189.

Grapefruit + Calcium-channel blockers

Grapefruit segments increase the exposure to nifedipine, nisoldipine and felodipine.

Clinical evidence

In a single-dose pharmacokinetic study in 12 healthy subjects, homogenised grapefruit segments or an extract from the segment-free parts increased the AUC of *felodipine* by 3.2-fold and 3.6-fold, respectively. This increase was the same or slightly greater than the increase seen with 250 mL of grapefruit juice. In another single-dose study in 8 healthy subjects, grapefruit pulp from one grapefruit increased the AUC of both *nifedipine* and *nisoldipine* by about 30%, and increased the maximum concentration of *nifedipine* and *nisoldipine* by about 40% and 50%, respectively, when the grapefruit was eaten 1 hour before taking the calcium-channel blocker. The authors noted that these increases were smaller than those previously seen with grapefruit juice.

Experimental evidence

Because these interactions are established, experimental data have not been sought.

Mechanism

Grapefruit appears to inhibit the activity of the cytochrome P450 isoenzymes CYP3A subfamily in the intestinal wall so that the first-pass metabolism of these calcium-channel blockers is reduced, thereby increasing their bioavailability and therefore their effects. Grapefruit juice is well established to have this effect.

One small clinical study suggests that quercetin is not involved in the interaction between grapefruit juice and nifedipine. Three interactions are established, experimental data have not been sought.

Importance and management

These interactions are established. It has been suggested that whole grapefruit should be avoided in patients taking felodipine. Given the data here, this would appear to be prudent advice. It has also been suggested that other products made from whole grapefruit such as marmalade should be avoided, although there is no published evidence that grapefruit marmalade may interact with calcium-channel blockers. However, an isolated case describes raised tacrolimus levels and toxicity associated with the excessive consumption of grapefruit marmalade. See Grapefruit + Tacrolimus, below.

For mention that furanocoumarin-free grapefruit juice had no consistent effect on felodipine pharmacokinetics, but also that no individual furanocoumarin tested had an effect as great as grapefruit juice, see Natural coumarins + Felodipine, page 300.

Some caution would also be appropriate with nifedipine and nisoldipine. There appears to be no specific information on a potential interaction between whole grapefruit and other calcium-channel blockers. However, it may be worth considering an interaction with grapefruit in any patient who complains of an otherwise unexplained increase in adverse effects with any of the calcium-channel blockers.


Grapefruit + Carbamazepine

A case of possible carbamazepine toxicity has been seen when a man taking carbamazepine started to eat grapefruit.

Clinical evidence

A 58-year-old man, taking carbamazepine 1 g daily for epilepsy developed visual disturbances with diplopia, and was found to have a carbamazepine level of 11 micrograms/mL (therapeutic range 4 to 10 micrograms/mL). Previous levels had not exceeded 5.4 micrograms/mL. The patient said that one month previously he had started to eat one whole grapefruit each day. The levels restabilised at 5.1 micrograms/mL after the carbamazepine dose was reduced to 800 mg daily.

Experimental evidence

No relevant data found.

Mechanism

The cytochrome P450 isoenzyme CYP3A4 is the main isoenzyme involved in the metabolism of carbamazepine. Components of grapefruit juice are known to inhibit CYP3A4, which in this case would lead to a reduction in the metabolism of carbamazepine, and therefore an increase in levels.

Importance and management

Evidence for an interaction between grapefruit and carbamazepine appears to be limited to one isolated case. In this report, the patient continued to eat grapefruit, and this was successfully managed by a reduction in the carbamazepine dose. However, it should be noted that intake of a set amount of grapefruit would need to be maintained for this approach to work, and carbamazepine dosage adjustment and monitoring of levels should be undertaken as appropriate. If monitoring is not practical, or regular intake of grapefruit is not desired, it may be prudent to avoid grapefruit.


Grapefruit + Fexofenadine

For mention that grapefruit *juice* and, to a lesser extent, naringin, a grapefruit flavonoid, modestly decrease the AUC of fexofenadine, see Flavonoids + Fexofenadine, page 192.

Grapefruit + Food

No interactions found. For mention that grapefruit *juice* and one of its constituents naringin, a grapefruit flavonoid, had no effect on the metabolism of caffeine, see Flavonoids + Caffeine, page 189.

Grapefruit + Herbal medicines

No interactions found. Note that naringin, a grapefruit flavonoid, and grapefruit juice do not alter the metabolism of caffeine, see Flavonoids + Caffeine, page 189.
Flavonoids + Caffeine, page 97, and so would be unlikely to interact with caffeine in caffeine-containing herbs, page 97.

Grapefruit + Tacrolimus

A case of tacrolimus toxicity has been seen when a man ate more than 1.5 kg of grapefruit marmalade during one week.

Clinical evidence
A 52-year-old man with a liver transplant, stabilised on tacrolimus 3 mg twice daily, began to feel anxious and febrile with continued trembling and blurred vision. Within 5 days he deteriorated and developed severe left chest pain. His tacrolimus whole blood level was found to be markedly raised to 55.4 micrograms/L from a previous therapeutic level (between 8 and 13 micrograms/L), and he had renal impairment (serum creatinine of 174 micromols/L). It transpired that during the week preceding the onset of symptoms he had eaten more than 1.5 kg of a home-made marmalade, which was made with more than 50% grapefruit.1

Experimental evidence
No relevant data found.

Mechanism
It is well established that grapefruit juice increases levels of tacrolimus, and this case appears to show that this can occur with grapefruit marmalade. The process of making marmalade uses the whole fruit, and it appears that, whatever the active interacting constituents are, these are not destroyed by the long boiling.1

Importance and management
This is the first case to show that a drug interaction can occur with grapefruit marmalade. As such, it requires confirmation by further study. Note that, in this case, the patient consumed an unusually large amount of marmalade (estimated 14 dessert spoonfuls (15 g) daily). More modest consumption (a spoonful of about 15 g daily) would appear unlikely to interact. Note that grapefruit juice is well established to interact with tacrolimus and combined use should be avoided.


Grapefruit + Warfarin

A rise in INR occurred in a couple taking warfarin who took a grapefruit seed extract product containing considerable amounts of the preservative benzethonium chloride for 3 days. One of them developed a minor haematoma.

Clinical evidence
A couple, both well stabilised on warfarin, took some drops of a grapefruit seed extract product (Estratto di Semillas di Pomelo, Lakshmi, Italy) for 3 days. No more was taken, but after a further 3 days the woman developed a minor subcutaneous haematoma, and her INR was found to be 7.9. The man was found to have an INR of 5.1, with no evidence of bleeding.1

Experimental evidence
See under Mechanism, below.

Mechanism
The product used was stated to contain grapefruit seed extract, glycerol and water. However, chemical analysis of this product revealed that it also contained considerable amounts (77 mg/mL) of the preservative, benzethonium chloride, and did not contain any significant amount of natural substances from grapefruit seeds. The constituents of two other commercial grapefruit seed products were similar on analysis (Citroseed and Citricidal).

Further, in vitro analysis showed that benzethonium chloride, and the three products, were potent inhibitors of the cytochrome P450 isoenzyme CYP2C9, suggesting that they could inhibit the metabolism of warfarin.

Importance and management
Data presented in this report, and other papers (one of which is cited as an example2), suggest that the primary constituent of many grapefruit seed extract products appears to be the preservative benzethonium chloride. The evidence from the two cases, backed by in vitro data, suggests that this has the potential to interact with warfarin. On this basis, it would probably be prudent for patients taking warfarin to avoid grapefruit seed extract products, or for concurrent use to be monitored closely. Some caution might also be appropriate with other pharmaceutical preparations containing benzethonium chloride.

Synonym(s) and related species

*Vitis vinifera* is the Grape vine, of which there are many cultivars.

Constituents

Grapeseed extract contains flavonoids, which include gallic acid, catechin, (−)-epicatechin, and their galloylated derivatives, and proanthocyanidins. Resveratrol, a polyphenolic stilbene derivative, and tocopherols and tocotrienols are also present.

Use and indications

Grapeseed extract is promoted as an antioxidant supplement for preventing degenerative disorders in particular, in the same way as other flavonoid-containing products. The *in vitro* antioxidant properties are well documented and there is some clinical evidence to suggest that it can promote general cardiovascular health.

Pharmacokinetics

An *in vitro* study found that grapeseed extract potently inhibits CYP3A4, but only when the catechin content is high. In contrast, another *in vitro* study found that grapeseed extract is a weak inducer of the cytochrome P450 isoenzyme CYP3A4. The author suggests that grapeseed therefore has the potential to cause interactions. However, the effect of grapeseed extract was less than that of omeprazole, which does not commonly interact by this mechanism, suggesting that any effect is unlikely to be clinically relevant. Furthermore, a study in rats suggests that grapeseed extract does not significantly alter the pharmacokinetics of midazolam, page 240, a probe substrate for CYP3A4.

Another *in vitro* study found that grapeseed extract does not affect the activity of CYP1A2, CYP2C8, CYP2C19 and CYP2E1, and only moderately inhibits CYP2C9 and CYP2D6 at high concentrations of catechins. In addition, it has no significant effect on P-glycoprotein.

Grapeseed extracts appear to moderately inhibit the transporter protein OATP-B, but the clinical implications of this have not been established.

See under flavonoids, page 186, for information on the individual flavonoids present in grapeseed, and see under resveratrol, page 335, for the pharmacokinetics of resveratrol.

Interactions overview

Contrary to expectation, the concurrent use of grapeseed extracts and ascorbic acid may have detrimental cardiovascular effects. Evidence for other clinically relevant interactions appears to be generally lacking. For information on the interactions of flavonoids, see under flavonoids, page 186, and for the interactions of resveratrol, see under resveratrol, page 335.

Grapeseed + Ascorbic acid (Vitamin C)

The concurrent use of grapeseed and ascorbic acid (vitamin C) appears to increase systolic and diastolic blood pressure.

Clinical evidence
A placebo-controlled study in 69 hypertensive patients taking one or more antihypertensive medications investigated the effects on cardiovascular parameters of vitamin C 250 mg twice daily, grapeseed polyphenols 500 mg twice daily, or a combination of the two, for 6 weeks. There was a 3-week washout period between treatments. Vitamin C alone reduced systolic blood pressure by about 1.8 mmHg, but the grapeseed polyphenols had no effect on blood pressure. However, treatment with the combination of vitamin C and polyphenols increased systolic blood pressure by 4.8 and 6.6 mmHg and diastolic blood pressure by between 1.5 and 3.2 mmHg. Endothelium-dependent and -independent vasodilation, and markers of oxidative damage were not significantly altered.1

Experimental evidence
No relevant data found.

Mechanism
Unknown.

Importance and management
Evidence is limited to one study, with no supporting mechanism to explain the effects seen, and so an interaction between vitamin C and grapeseed extract is not established. The authors of this study suggest that caution should be used when advising patients with hypertension on taking a combination of vitamin C and grapeseed. However, the general importance of any interaction is difficult to assess as the effect of taking these two supplements together is likely to vary depending on the patient and the degree to which their hypertension is controlled. It may be prudent to question a patient with poorly controlled blood pressure to establish if they are taking supplements containing both vitamin C and grapeseed, and discuss the option of stopping them to see if this improves their blood pressure control.


Grapeseed + Food
No interactions found.

Grapeseed + Herbal medicines
No interactions found.

Grapeseed + Midazolam
The interaction between grapeseed and midazolam is based on experimental evidence only.

Clinical evidence
No interactions found.

Experimental evidence
In a study in rats, a single dose of an aqueous grapeseed extract had no significant effects on the pharmacokinetics of midazolam. However, after one week of treatment, grapeseed extract increased the elimination rate of midazolam by about 30%, and reduced its half-life by 28%. However, these effects were modest, and the AUC of midazolam was not significantly altered.1

Mechanism
The study in rats suggests that grapeseed weakly induces the cytochrome P450 isoenzyme CYP3A4, the main route of midazolam metabolism. Some in vitro studies support this suggestion, although stronger effects may occur if the catechin content is high, see Pharmacokinetics, page 239.

Importance and management
Clinical evidence regarding an interaction between grapeseed and midazolam appears to be lacking. However, evidence from rat studies suggests that a clinically relevant interaction is unlikely and therefore no dose adjustments of midazolam are likely to be needed if grapeseed extract is also taken.

Greater celandine

Chelidonium majus L. (Papaveraceae)

Synonym(s) and related species
Celandine, Common celandine, Garden celandine, Swallow wort.
Not to be confused with lesser celandine (Ranunculus ficaria L.).

Pharmacopoeias
Greater Celandine (BP 2009, Ph Eur 6.4).

Constituents
All parts of the plant contain benzylisoquinoline alkaloids, including berberine, chelerythrine, chelidonine, coptisine, cryptopine, protopine and sanguinarine.

Use and indications
Greater celandine has been traditionally used in the treatment of jaundice, gallbladder and biliary diseases, and eczema and other skin disorders. In Chinese medicine it has been used as an antitussive, anti-inflammatory and detoxicant. However, information on the safety and toxicity of greater celandine is limited: hepatotoxic effects, including severe hepatitis, severe cholestasis and fibrosis, have been reported with long-term use (one month or more).

Pharmacokinetics
No relevant pharmacokinetic data for greater celandine found, but see berberine, page 58, for details on this constituent of greater celandine.

Interactions overview
No interactions with greater celandine found. However, for the interactions of one of its constituents, berberine, see under berberine, page 58.
Ground ivy  
*Glechoma hederacea* L. (Lamiaceae)

**Synonym(s) and related species**
Ale-hoof, Gundelrebe, Gundermann.  
*Nepeta glechoma* Benth., *Nepeta hederacea* (L.) Trevis.

**Constituents**
Ground ivy contains flavonoids including isoquercitrin, luteolin diglucoside and rutin, and other polyphenolic compounds such as glycosides of icariol, cistanoside E and rosmarinic acid. Other compounds present include β-sitosterol, the triterpenes oleanolic acid, and α- and β-ursolic acids, and a volatile oil containing the monoterpenes *p*-cymene, linalool, limonene and terpineol, among others. The sesquiterpene glechomafuran and the diterpene marrubiin are also present. Two alkaloids, hederacine A and B, which may have cytotoxic activity, have been found in very small amounts in the plant.

**Use and indications**
Ground ivy is used as a mild expectorant for chronic bronchial catarrh. It is also said to be astringent, and therefore used for wound healing, haemorrhoids, gastritis and diarrhoea.

**Pharmacokinetics**
No relevant pharmacokinetic data found. For information on the pharmacokinetics of individual flavonoids present in ground ivy, see under flavonoids, page 186.

**Interactions overview**
No interactions with ground ivy found. For information on the interactions of individual flavonoids present in ground ivy, see under flavonoids, page 186.
Guarana
Paullinia cupana Kunth (Sapindaceae)

**Synonym(s) and related species**
Brazilian cocoa.
*Paullinia sorbilis*.

**Constituents**
Guarana seeds contain xanthine derivatives; principally caffeine (also known as guaranine, up to 7%), with theobromine, theophylline and others, and small amounts of flavonoids, from the flavanol group, such as catechin. Other constituents include saponins and an essential oil containing estragole and anethole.

**Use and indications**
The main use is as a tonic or stimulant for tiredness and to promote alertness, which can be attributed to the caffeine content.

**Pharmacokinetics**
The pharmacokinetics of caffeine are discussed under caffeine, page 97.

**Interactions overview**
Guarana contains significant amounts of caffeine, therefore the interactions of caffeine, page 97, are relevant to guarana. Two case reports describe muscular disorders, which were related to the use of guarana-containing herbal supplements. For mention of a study in which a herbal supplement containing guarana and black tea, among other ingredients, slightly increased blood pressure, see Tea + Antihypertensives, page 383.
Guarana + Antihypertensives

For mention of a study in which a herbal supplement containing guarana and black tea, among other ingredients, slightly increased blood pressure, see Tea + Antihypertensives, page 383.

Guarana + Food

No interactions found; however, the effects of caffeine from herbal medicines or supplements containing guarana and caffeine-containing foods or beverages will be additive.

Guarana + Herbal medicines

Two case reports describe muscular disorders in patients who took supplements containing guarana and ephedra, and guarana and kava.

Evidence, mechanism, importance and management

A case report describes a 54-year-old woman, with no significant medical history, who developed rhabdomyolysis after she started to take guarana 190 mg and ephedra 150 mg (containing ephedrine 12 mg), with other dietary supplements. The creatine kinase elevations resolved within 3 weeks of stopping the herbal weight-loss supplement. The authors of this report suggest that, as guarana contains caffeine alkaloids, this and the combination of ephedrine effects may have contributed to the myopathy.1 Another case describes myoglobinuria in a patient taking a supplement containing guarana, ginkgo and kava.2 Again, this was thought to be related to the combined effects of guarana and other herbal medicines, in this case, kava.

The general importance of these cases is unclear, and many patients taking drugs that are known to cause muscle damage such as the statins, frequently take caffeine, which is found in guarana, food or beverages.

The caffeine content of guarana suggests that it may interact with other herbal medicines in the same way as caffeine, see Caffeine + Herbal medicines; Bitter orange, page 101, and Ephedra + Caffeine, page 176.

Guggul

Commiphora wightii (Arn.) Bhandari (Burseraceae)

**Synonym(s) and related species**
Mukul myrrh.

*Commiphora mukul* Engl., *Balsamodendrum wightii*.

**Constituents**
The resinous sap, harvested from the tree bark by tapping, is extracted to produce guggul. *Gugulipid* is the purified standardised extract of crude gum guggul, and contains the active *guggulsterone* components Z-*guggulsterone* and E-*guggulsterone*, with cembranoids, myrrhanone and myrrhanol derivatives.

**Use and indications**
Guggul is used mainly in Ayurvedic medicine and has been traditionally used to treat hypertension, osteoporosis, epilepsy, ulcers, cancer, obesity and rheumatoid arthritis. It is now often used for hyperlipidaemia, but clinical studies have found conflicting results for its lipid-lowering effects.

**Pharmacokinetics**
An *in vitro* study reported that gugulipid extract and purified guggulsterones may induce the expression of the cytochrome P450 isoenzyme CYP3A4. However, the clinical significance of this is unclear and further study is needed.1

**Interactions overview**
In healthy subjects, the absorption of diltiazem and propranolol was modestly reduced by gugulipid. If the mechanism is confirmed, guggul might interact with a wide range of other drugs. A case of rhabdomyolysis has been attributed to the use of guggul alone, which should be borne in mind if it is combined with the statins, which also, rarely, cause this adverse effect.

Guggul

**Guggul + Diltiazem**

Limited evidence suggests that guggul modestly reduces the absorption of single-dose diltiazem.

**Clinical evidence**

A crossover study in 7 fasting healthy subjects found that a single 1-g dose of gugulipid reduced the AUC and maximum concentration of a single 60-mg dose of diltiazem by 35% and 41%, respectively. This single dose of diltiazem did not have any effect on blood pressure or heart rate in these particular subjects, so it was not possible to assess the effect of the reduction in levels of diltiazem on its pharmacological effects. No details were given of the gugulipid or diltiazem preparations used.

**Experimental evidence**

No relevant data found.

**Mechanism**

Gugulipid is an oleoresin extracted from guggul. The authors of this study suggest that it might bind with drugs in the gut and reduce their absorption in a similar way to colestyramine and colestipol.

**Importance and management**

Gugulipid modestly reduced the absorption of diltiazem in this study, and this degree of reduction is probably unlikely to be clinically relevant. However, the formulation of diltiazem given was not stated and the effects of multiple dosing, or of larger doses of diltiazem, is unknown. Further study is needed. Bear in mind the potential for an interaction should a patient taking guggul have a reduced response to diltiazem.


**Guggul + Propranolol**

Limited evidence suggests that guggul modestly reduces the absorption of single-dose propranolol.

**Clinical evidence**

A crossover study in 10 fasting healthy subjects found that a single 1-g dose of gugulipid reduced the AUC and maximum concentration of a single 40-mg dose of propranolol by 34% and 43%, respectively. This single dose of propranolol did not have any effect on blood pressure or heart rate in these particular subjects, so it was not possible to assess the effect of the reduction in levels of propranolol on its pharmacological effects. No details were given of the gugulipid or propranolol preparations used.

**Experimental evidence**

No relevant data found.

**Mechanism**

Gugulipid is an oleoresin extracted from guggul. The authors of this study suggest that it might bind with drugs in the gut and reduce their absorption in a similar way to colestyramine and colestipol.

**Importance and management**

Gugulipid modestly reduced the absorption of propranolol in this study. The clinical relevance of this reduction is not certain, but it is likely to be minor. Bear in mind the potential for an interaction should a patient taking guggul have a reduced response to propranolol.


**Guggul + Statins**

An isolated case suggests that guggul alone can cause rhabdomyolysis. If statins are also taken, the risk could be additive.

**Clinical evidence**

A case of rhabdomyolysis has been reported in a patient, 2 weeks after an extract of guggul 300 mg three times daily was started. The rhabdomyolysis resolved when the guggul preparation was stopped. The patient was not reported to be taking any other medication known to cause rhabdomyolysis and simvastatin had been stopped one year previously because of an increase in creatine kinase. The herbal product used was prepared by a local chemist using a standardised drug extract of the oleo gum resin without excipients.

**Experimental evidence**

No relevant data found.

**Mechanism**

Not known. The possibility that the resin used was adulterated was not investigated.

**Importance and management**

This appears to be the only case report of rhabdomyolysis occurring with a guggul-containing preparation. Guggul is widely used for cholesterol lowering, and the most commonly used conventional drugs for this condition are the statins, which are well recognised, rarely, to cause rhabdomyolysis. It is quite likely that guggul and statins are being used together, and the concern generated by this case report is that, if guggul alone can cause rhabdomyolysis, then combined use might increase the risk of rhabdomyolysis. However, this is only one case, and the mechanism (which could include adulteration) is uncertain. Bear the possibility of an additive effect in mind if myositis occurs with concurrent use. All patients taking statins should be warned about the symptoms of myopathy and told to report muscle pain or weakness. It would be prudent to reinforce this advice if they are known to be taking guggul.


**Guggul + Food**

No interactions found.

**Guggul + Herbal medicines**

No interactions found.

**Guggul + Propranolol**

Limited evidence suggests that guggul modestly reduces the absorption of single-dose propranolol.

**Clinical evidence**

A crossover study in 10 fasting healthy subjects found that a single 1-g dose of gugulipid reduced the AUC and maximum concentration of a single 40-mg dose of propranolol by 34% and 43%, respectively. This single dose of propranolol did not have any effect on blood pressure or heart rate in these particular subjects, so it was not possible to assess the effect of the reduction in levels of propranolol on its pharmacological effects. No details were given of the gugulipid or propranolol preparations used.

**Experimental evidence**

No relevant data found.

**Mechanism**

Gugulipid is an oleoresin extracted from guggul. The authors of this study suggest that it might bind with drugs in the gut and reduce their absorption in a similar way to colestyramine and colestipol.

**Importance and management**

Gugulipid modestly reduced the absorption of propranolol in this study. The clinical relevance of this reduction is not certain, but it is likely to be minor. Bear in mind the potential for an interaction should a patient taking guggul have a reduced response to propranolol.

Hawthorn

Crataegus laevigata (Poir.) DC., Crataegus monogyna Jacq. (Rosaceae)

Synonym(s) and related species
Crataegus, Haw, May, Weissdorn, Whitethorn.

Crataegus oxyacantha auct., Crataegus oxyacanthoides Thuill.

Pharmacopoeias
Hawthorn Berries (BP 2009, Ph Eur 6.4); Hawthorn Leaf and Flower (BP 2009, Ph Eur 6.4); Hawthorn Leaf and Flower Dry Extract (BP 2009, Ph Eur 6.4); Hawthorn Leaf with Flower (USP 32); Quantified Hawthorn Leaf and Flower Liquid Extract (BP 2009, Ph Eur 6.4).

Constituents
The leaves and flowers of hawthorn are usually standardised to their flavonoid content, and the berries may be standardised to their procyanidin content. Other flavonoids present include quercetin, isoquercetin and their glycosides, and rutin. Other constituents include catechins and epicatechin dimers, polyphenolic acid derivatives including chlorogenic and caffeic acids, phenethylamine, dopamine, and ursolic and oleanolic acid triterpenenoid derivatives.

Use and indications
Hawthorn extracts are used as a cardiotonic, mild antihypertensive and antisclerotic.

Pharmacokinetics
No relevant pharmacokinetic data found. For information on the pharmacokinetics of individual flavonoids present in hawthorn, see under flavonoids, page 186.

Interactions overview
The safety of hawthorn extracts was investigated in a comprehensive systematic review,¹ which included data up to January 2005 from the WHO, relevant medical journals and conference proceedings. The investigators found that 166 adverse events were reported in 5577 patients from 24 clinical studies, and 18 cases of adverse events were reported via the WHO spontaneous reporting scheme. None of these involved drug interactions. In the clinical studies assessed, the daily dose and duration of treatment with hawthorn preparations ranged from 160 to 1800 mg and from 3 to 24 weeks, and the extracts most used contained leaves and flowers and were WS 1442 (standardised to 18.75% oligomeric procyanidins) and LI 132 (standardised to 2.25% flavonoids). Other studies do not appear to have identified any clinically significant drug interactions.

For information on the interactions of individual flavonoids present in hawthorn, see under flavonoids, page 186.

Hawthorn + Antidiabetics

Hawthorn does not appear to affect the glycaemic control in patients taking conventional antidiabetic drugs.

Clinical evidence
In a randomised study, 80 patients with type 2 diabetes taking antidiabetics (including metformin, gliclazide and/or low-dose insulin) with or without antihypertensives were given hawthorn extract 600 mg twice daily, or placebo, for 16 weeks. There was no difference between the two groups in measures of glycaemic control (fasting glucose, glycosylated haemoglobin and fructosamine) at 16 weeks. The hawthorn extract used in this study, LI 132, contained dried flowering tops and was standardised to 2.2% flavonoids.1

Experimental evidence
No relevant data found.

Mechanism
No mechanism expected.

Importance and management
Evidence is limited to this one study. However, as no alteration in glycaemic control was reported, no interventions are deemed necessary in patients taking antidiabetics and hawthorn extract.


Hawthorn + Antihypertensives

Limited evidence suggests that there may be additive blood pressure-lowering effects if hawthorn is taken with conventional antihypertensives, but the effects are small.

Clinical evidence
In a randomised study, 80 patients with type 2 diabetes, of whom 71% were taking antihypertensives (including ACE inhibitors, calcium-channel blockers, beta blockers and/or diuretics), were given hawthorn extract 600 mg twice daily or placebo for 16 weeks. The group given hawthorn extract (39 of 40 patients assessed) had a small additional 2.6 mmHg reduction in diastolic blood pressure compared with no change in the placebo group. The 3.6 mmHg decline in systolic blood pressure in the hawthorn group was not statistically significant. The hawthorn extract used in this study, LI 132, contained dried flowering tops and was standardised to 2.2% flavonoids.1

Experimental evidence
No relevant data found.

Mechanism
Little known. Additive blood pressure-lowering effects might occur.

Importance and management
Evidence appears to be limited to this one clinical study. Although hawthorn extract caused a reduction in diastolic blood pressure in patients, many of whom were taking antihypertensives, the effect was small. As such, it is unlikely that clinically important hypotension would occur if hawthorn is added to existing antihypertensive treatment.


Hawthorn + Digoxin

Hawthorn does not appear to affect digoxin levels.

Clinical evidence
In a randomised, crossover study, 8 healthy subjects were given hawthorn extract 450 mg twice daily with digoxin 250 micrograms daily for 21 days, or digoxin 250 micrograms alone daily for 10 days. While digoxin levels tended to be lower when hawthorn was given (the biggest difference being a 23% reduction in the trough level), these reductions were not statistically significant. There was no change in ECG effects or heart rate, and the combination was well tolerated. The hawthorn extract used in this study, WS 1442, contained an extract of leaves with flowers standardised to 84.3 mg of oligomeric procyanidines.1

Experimental evidence
No relevant data found.

Mechanism
Little known. It was thought that flavonoids in hawthorn might have an effect on P-glycoprotein, of which digoxin is a substrate. In addition, it is possible that the cardioactive constituents of hawthorn might increase the effect of digoxin on cardiac contractility.1

Importance and management
This study appears to be the only evidence reported. It suggests that, despite theoretical concerns that hawthorn may affect treatment with digoxin, in practice there appears to be no clinically relevant alteration in digoxin levels or effects. It therefore appears that hawthorn can be given to patients taking digoxin without the need for further monitoring.


Hawthorn + Food

No interactions found.

Hawthorn + Herbal medicines

No interactions found.
Honeybush

*Cyclopi* species (Fabaceae)

**Synonym(s) and related species**
Bergtee, Boertee, Bossiestee, Bush tea, Heuingbos, Heuningtee.

*Cyclopia intermedia* E. Mey, *Cyclopia genistoides* (L.) Vent, *Cyclopia subternata* Vogel and other species are all referred to as Honeybush.

**Constituents**
The leaves of honeybush contain the xanthones mangiferin and isomangiferin, and flavonoids including hesperidin, hesperitin, isokuranetin and kaempferols. The leaves also contain isoflavones such as formononetin and afrormosin, and coumestans such as medicagol. The quantity of flavonoids is reduced when honeybush is fermented; however, the non-flavonoid components increase. Honeybush does not contain caffeine.¹

**Use and indications**
Honeybush has been traditionally used in South Africa for a variety of ailments including digestive problems and skin problems, and to promote lactation.¹ Honeybush is principally used to produce a tea-like beverage. There is experimental evidence of various activities including antioxidant, chemopreventative, antidiabetic and immunomodulating effects.¹

**Pharmacokinetics**
No relevant pharmacokinetic data found. For the pharmacokinetics of individual flavonoids and isoflavones present in honeybush, see flavonoids, page 186, and isoflavones, page 258.

**Interactions overview**
No interactions with honeybush found. For information on the interactions of individual flavonoids and isoflavones present in honeybush, see under flavonoids, page 186, and isoflavones, page 258.

Hoodia

_Hoodia gordonii_ (Masson) Sweet ex Decne. (Asclepiadaceae)

**Synonym(s) and related species**


Other species of _Hoodia_ are also used, but are less well investigated.

**Constituents**

The succulent flesh of hoodia contains a large number of oxypregnane glycosides known as the hoodigosides, and steroidal glycosides, the gordonosides. The active constituent (an oxypregnane glycoside of hoodigogenin) is often referred to as P57AS3 or, more commonly, P57.

**Use and indications**

Hoodia is used to suppress appetite and thirst. The active constituent, P57, is reported to have a CNS effects.

**Pharmacokinetics**

An _in vitro_ study has shown that P57, an active constituent isolated from _Hoodia gordonii_, weakly inhibited the action of the cytochrome P450 isoenzyme CYP3A4 in a dose-dependent manner. CYP1A2, CYP2C9 and CYP2D6 were unaffected by P57. These results suggest that pharmacokinetic interactions with substrates of these isoenzymes are unlikely. This study also indicated that P57 may be a substrate of P-glycoprotein.

**Interactions overview**

No interactions with hoodia found.

---

Hops

*Humulus lupulus* L. (Cannabaceae)

**Synonym(s) and related species**
Humulus, Lupulus.

**Pharmacopoeias**
Hop Strobile (*BP 2009, Eur Ph 6.4*).

**Constituents**
The flowers (strobiles) of hops contain a volatile oil composed mainly of humulene (alpha-caryophyllene), with beta-caryophyllene, myrcene, farnesene and others. There is also an oleo-resin fraction composed of bitter acids. Flavonoids present include glycosides of kaempferol and quercetin, and a series of prenylated flavonoids (including 6-prenylnaringenin) and prenylated chalcones. A number of hop proanthocyanidins, based on gallicatechin, azelechin and epicatechin derivatives, and the *trans* isomer of the stilbenoid resveratrol and its glucoside, piceid, have also been isolated. Note that a large variety of hops genotypes exist, and the relative content of these constituents may vary between genotype.

**Use and indications**
Hops are used mainly as a sedative, anxiolytic, hypnotic and tranquilliser. These properties have been demonstrated pharmacologically but there is little clinical evidence to date. Hops also contain a number of compounds with oestrogenic activity such as 6-prenylnaringenin. Many products include hops as one of several ingredients rather than as a single extract. There are also many varieties of hops, normally produced for their flavour and other characteristics useful for beer production. The variety used medicinally is usually not stated.

**Pharmacokinetics**
Most of the investigations carried out into the metabolism of hops have concerned the metabolism of isoxanthohumol to the more potent phytoestrogen 8-prenylnaringenin by human liver microsomes,1 and by intestinal microflora, particularly in the colon.2,3 These studies suggest that the levels of active constituents vary between individuals, and may be altered by antibacterial treatment, which suggests that the activity (particularly the oestrogenic activity*) of hops, and its potential to interact, is also likely to vary between individuals. The cytochrome P450 isoenzymes CYP1A2, CYP2C19 and CYP2C8 may be involved,4 but information is too sparse to be able to comment further on the potential for conventional drugs to diminish the effects of hops.

See under flavonoids, page 186, for information on the individual flavonoids present in hops, and see under resveratrol, page 335, for the pharmacokinetics of resveratrol.

**Interactions overview**
Animal studies suggest that hops extracts potentiate the analgesic effects of paracetamol, suppress the stimulant effects of cocaine, suppress the effects of diazepam and potentially alter the sedative effects of pentobarbital. For information on the interactions of flavonoids, see under flavonoids, page 186, and for the interactions of resveratrol, see under resveratrol, page 335.

Hops + Cocaine

The interaction between hops and cocaine is based on experimental evidence only.

Clinical evidence
No interactions found.

Experimental evidence
In a study of the interactions of various genotypes of hops, *mice* were given cocaine 25 mg/kg after they had received four intraperitoneal doses of a 0.5% alcoholic extract of hops. Three hops genotypes were used: Aroma, Magnum and wild hops. The study found that the Magnum hops extracts almost completely suppressed the excitatory effects of cocaine (measured by spontaneous motility), when compared with controls. Extracts of the wild genotype also decreased the excitatory effects of cocaine, but to a lesser extent than the Magnum genotype, whereas the Aroma genotype did not alter the effects of cocaine.1

Mechanism
It has been suggested that hops may alter the effects of cocaine on the central nervous system, but it is not known how this occurs.

Importance and management
Evidence appears to be limited to this one study in *mice*, the clinical relevance of which is unclear. What is known suggests that any interaction may be advantageous or, more likely, not clinically important. Of more interest is the variability in the interaction between the different hops genotypes, which suggests that the exact source of the hops used in any preparation is likely to be of importance in establishing their potential for interactions.


Hops + Paracetamol (Acetaminophen)

The interaction between hops and paracetamol is based on experimental evidence only.

Clinical evidence
No interactions found.

Experimental evidence
In a study of the interactions of various genotypes of hops, *mice* were given paracetamol 80 mg/kg after they had received four intraperitoneal doses of a 0.5% alcoholic extract of hops. Three hops genotypes were used: Aroma, Magnum and wild hops. The study found that the hops extracts alone did not possess an analgesic effect, but each of the extracts increased the analgesic effect of paracetamol 80 mg/kg, with the most pronounced effect occurring with the extracts of Aroma and wild genotypes hops.1

Mechanism
Unknown.

Importance and management
Evidence appears to be limited to this one study in *mice*, the clinical relevance of which is unclear. What is known suggests that any interaction may be advantageous. Of more interest is the variability in the interaction between the different hops genotypes, which suggests that the exact source of the hops used in any preparation is likely to be of importance in establishing their potential for interactions.


Hops + Herbal medicines

No interactions found.

Hops + Oestrogens or Oestrogen antagonists

Hops contains oestrogenic compounds. This may result in additive effects with oestrogens or it may oppose the effects of oestrogens. Similarly, hops may have additive effects with oestrogen antagonists or oppose the effects of oestrogen antagonists (e.g. tamoxifen). See Chinese angelica + Oestrogens or Oestrogen antagonists, page 130 for more information.

Hops + Food

No interactions found.
The interaction between hops and pentobarbital is based on experimental evidence only.

Clinical evidence
No interactions found.

Experimental evidence
In a study of the interactions of various genotypes of hops, *mice* were given pentobarbital 40 mg/kg after they had received four intraperitoneal doses of 0.5% alcoholic extract of hops. Three hops genotypes were used: Aroma, Magnum and wild hops. The study found that the hops extracts suppressed the hypnotic effects of pentobarbital (measured by a decrease in the sleeping time of the *mice*). The most pronounced effect occurred with the extracts of Magnum and Aroma genotypes whereas the wild genotype had no significant effect. However, the effects varied greatly between individual *mice*, with some sleeping for a longer time.1

Mechanism
It has been suggested that hops may alter the effects of phenobarbital on the central nervous system, but it is not known how this occurs.

Importance and management
Evidence appears to be limited to this one study in *mice*, the clinical relevance of which is unclear. What is known suggests that hops may slightly decrease the sedative effects of pentobarbital in some individuals, or increase them in others. It is difficult to extrapolate these findings to humans, but there appears to be no good reason to avoid concurrent use, although patients should be aware that there is a possibility that they may be more or less sedated than with either medicine alone. Of more interest is the variability in the interaction between the different hops genotypes, which suggests that the exact source of the hops used in any preparation is likely to be of importance in establishing their potential for interactions.

Horse chestnut
*Aesculus hippocastanum* L. (Hippocastanaceae)

**Synonym(s) and related species**
*Aesculus.*

*Hippocastanum vulgare* Gaertn.

**Pharmacopoeias**
Horse Chestnut (*USP 32*); Powdered Horse Chestnut (*USP 32*); Powdered Horse Chestnut Extract (*USP 32*).

**Constituents**
Horse chestnut seeds contain more than 30 saponins, a complex mixture known as ‘aescin’ or ‘escin’ (to which it may be standardised), based on the aglycones protoescigenin and barringtogenol-C. Other compounds including sterols and triterpenes, such as friedelin, taraxerol and spinasterol, and flavonoids, based on quercetin and kaempferol, are also present. The natural coumarins found in horse chestnut (such as aesculin (esculin) and fraxin) do not possess the minimum structural requirements for anticoagulant activity.

**Use and indications**
Horse chestnut extracts (aescin) are used to treat vascular insufficiency, especially varicose veins, venous ulcers, haemorrhoids and inflammation. They are usually applied as topical preparations, particularly gel formulations, but a licensed oral dosage form is also available.⁴ There is a considerable body of clinical and pharmacological evidence to support their use.

**Pharmacokinetics**
An isolated *in vitro* study suggests that horse chestnut may inhibit P-glycoprotein-mediated transport, assessed using digoxin, page 255 as a substrate. In this study, horse chestnut did not inhibit cytochrome P450 isoenzyme CYP3A4.² Similarly, in a previous study, the authors briefly noted that, *in vitro*, horse chestnut had little inhibitory effect on CYP1A2, CYP2D6 and CYP3A4.³ For information on the pharmacokinetics of individual flavonoids present in horse chestnut, see under flavonoids, page 186.

**Interactions overview**
One *in vitro* study suggests that horse chestnut may affect P-glycoprotein, and could therefore affect the pharmacokinetics of drugs such as digoxin, although the clinical significance of this is unknown. Some have suggested that horse chestnut may interact with anticoagulants, presumably based on its natural coumarin content, but the coumarins present are not known to possess the structural requirements necessary for anticoagulant activity. For more information, see Natural coumarins + Warfarin and related drugs, page 301. For information on the interactions of individual flavonoids present in horse chestnut, see under flavonoids, page 186.

The interaction between horse chestnut and digoxin is based on experimental evidence only.

Evidence, mechanism, importance and management

An in vitro study to investigate the effects of a horse chestnut product (Venostat) on P-glycoprotein transport found that the extract inhibited the transport of digoxin by P-glycoprotein to a minor extent. Nevertheless, the authors predicted that inhibitory levels might easily be reached in the small intestine with usual therapeutic doses of horse chestnut.1

Since this appears to be the only available study, this inhibition of digoxin transport needs confirming, and then an in vivo clinical study would be required to assess whether horse chestnut does alter digoxin absorption on concurrent use, and whether any changes are clinically relevant. No specific recommendations can be made on the basis of this single in vitro study.


Horse chestnut + Food

No relevant interactions found.

Horse chestnut + Herbal medicines

No interactions found.
Horsetail

_Equisetum arvense_ L. (Equisetaceae)

**Synonym(s) and related species**

Equisetum. The related species _Equisetum hyemale_ L. has also been used, but note that standardised pharmacopoeial preparations of horsetail should contain no more than 5% of other _Equisetum_ species.

**Pharmacopoeias**

Equisetum Stem (_Ph Eur 6.04_); Horsetail (_BP 2009_).

**Constituents**

Horsetail contains high concentrations of *silicic acid*, up to 8%, and is sometimes used as an organic source of silicon. It also contains *flavonoids* such as apigenin, kaempferol, luteolin and quercetin and their derivatives, and may be standardised to the total *flavonoid* content expressed as *isoquercitrin*. Other polyphenolic compounds such as caffeic acid derivatives, and trace amounts of the alkaloid nicotine, and sterols including cholesterol, isofucosterol and campesterol, are also present. Horsetail also contains thiaminase (an enzyme that breaks down thiamine), and this is inactivated in some supplements.

**Use and indications**

Horsetail is used mainly as an astringent, haemostatic and anti-inflammatory agent, and for urinary tract complaints such as cystitis, prostatitis, urethritis and enuresis. There is little pharmacological, and no clinical, evidence to support the main uses.

**Pharmacokinetics**

An _in vitro_ study using alcoholic extracts of horsetail found that it had only weak inhibitory effects on the cytochrome P450 isoenzyme CYP3A4. For information on the pharmacokinetics of individual flavonoids present in horsetail, see under flavonoids, page 186.

**Interactions overview**

An isolated case of lithium toxicity has been reported in a patient who took a herbal diuretic containing horsetail among other ingredients, see under Parsley + Lithium, page 305. For information on the interactions of individual flavonoids present in horsetail, see under flavonoids, page 186.

**Horsetail + Food**

No interactions found.

**Horsetail + Herbal medicines**

No interactions found.

**Horsetail + Lithium**

For mention of a case of lithium toxicity in a woman who had been taking a non-prescription herbal diuretic containing corn silk, *Equisetum hyemale*, juniper, buchu, parsley and bearberry, all of which are believed to have diuretic actions, see under Parsley + Lithium, page 305. Note that this case was with *Equisetum hyemale*, which is not the species more commonly used (*Equisetum arvense*).
Isoflavones

Isoflavonoids

This is a large group of related compounds with similar structures and biological properties in common, which are widely available as additives in dietary supplements as well as the herbs or foods that they were originally derived from. Isoflavones are the subject of intensive investigations and new information is constantly being published.

You may have come to this monograph via a herb that contains isoflavones. The information in this monograph relates to the individual isoflavones, and the reader is referred back to the herb (and vice versa) where appropriate. It is very difficult to confidently predict whether a herb that contains one of the isoflavones mentioned will interact in the same way. The levels of the isoflavone in the particular herb can vary a great deal between specimens, related species, extracts and brands, and it is important to take this into account when viewing the interactions described below.

Types, sources and related compounds

Isoflavones are plant-derived polyphenolic compounds that are a distinct group of flavonoids, page 186. They can exert oestrogen-like effects, and therefore belong to the family of ‘phytooestrogens’. Most occur as simple isoflavones, but there are other derivatives such as the coumestans, the pterocarps and the rotenoids, some of which also have oestrogenic properties.

The isoflavones are found in small amounts in many legumes, seeds, grains and vegetables, but soya, page 356, is by far the most concentrated dietary source; it contains principally genistein and daidzein. There are various other isoflavone-rich supplements, including those derived from alfalfa, page 21 and red clover, page 332 (both of which are rich in biochanin A and formononetin), and kudzu, page 267, which contains puerarin. In addition, some popular herbal medicines, such as astragalus, page 46 and shatavari, page 353 contain isoflavones as well as other types of active constituents.

In plants, isoflavones are usually found in the glycoside form, i.e. bound to a sugar molecule, but digestion results in the release of the sugar molecule leaving the aglycone. The most important isoflavones are: genistein and daidzein, which are hydrolysed from their glycosides genistin, daidzin and puerarin (daidzein 8-C-glucoside); glycetin and its glycoside glycetin; formononetin, biochanin A, isoformononetin, prunetin, calycosin, ononin, orobol; and others.

Use and indications

Epidemiological studies show that a high dietary intake of isoflavones from foods such as soya, page 356 might be protective against certain cancers (breast, endometrium, prostate) and degenerative diseases, in the same way as the flavonoids, page 186. Although isoflavone supplements are used for these possible benefits, it remains to be seen whether they are effective. Many of their biological effects, as with the flavonoids, appear to be related to their ability to modulate cell signalling pathways, and genistein in particular has been widely investigated for its tyrosine kinase-inhibiting properties, and it is now also considered by some to be a SERM (selective oestrogen receptor modulator). Some biologically active constituents of genistein have given cause for concern, as it can be genotoxic and cause cell damage, and it is a topoisomerase II inhibitor.

Isoflavones have weak oestrogenic effects, but under certain conditions (for example, in premenopausal women) they can also act as oestrogen antagonists by preventing the more potent natural compounds, such as oestriol, from binding to receptor sites. In some cases the activities are tissue selective. Isoflavones also inhibit the synthesis and activity of enzymes involved in oestrogen and testosterone metabolism, such as aromatase.

Because of their oestrogenic effects, isoflavone supplements have been investigated for treating menopausal symptoms such as hot flushes (hot flashes) and for prevention of menopausal osteoporosis, with generally modest to no benefits when compared with placebo in randomised controlled studies. Isoflavones have also been extensively studied for lipid lowering, and there are a few studies on other cardiovascular benefits, and effects on cognitive function. In a 2006 analysis, the American Heart Advisory Committee concluded that the efficacy and safety of soya isoflavones were not established for any indication and, for this reason, they recommended against the use of isoflavone supplements in food or pills.

Pharmacokinetics

The uptake, metabolism and disposition of the isoflavones are highly complex and have not yet been fully elucidated. Isoflavone glycosides are probably hydrolysed in the gut wall by intestinal beta-glucosidases to release the aglycones (genistein, daidzein, etc.), which can then be absorbed. Intestinal bacteria may also hydrolyse the glycosides, and, in some people, they metabolise daidzein to the more active oestrogen equol. After absorption, the aglycones are conjugated, predominantly to glucuronic acid. Gut bacteria also extensively metabolise isoflavones: for example, daidzein may be metabolised to equol, a metabolite with greater oestrogenic activity than daidzein, but also to other compounds that are less oestrogenic. Because of differences in gut flora, there are individual differences in the metabolism of isoflavones, which might have important implications for their effects: for example, studies measuring urinary equol excretion after soya consumption indicate that only
about one-third of Western individuals metabolise daidzein to equol.8

In a study in 9 healthy subjects the isoflavone puerarin, given orally, was rapidly absorbed and reached peak levels at 2 hours, and had a half-life of about 4.5 hours. The elimination half-life was not significantly altered after repeated administration. The authors concluded that three times a day dosing is recommended, as accumulation will not occur, and plasma levels remain at levels that are biologically active, even 8 hours after the last steady-state dose.9 For mention that colonic bacteria hydrolyse puerarin to the more active aglycone daidzein, see Isoflavones + Antibacterials, page 260.

In an in vitro study in human liver microsomes, fluvoxamine was a potent inhibitor of genistein and tangeretin metabolism.10 This finding suggests that these isoflavones are principally metabolised by CYP1A2, of which fluvoxamine is a potent inhibitor. The relevance of this to the activity of these isoflavones is unknown, since the relative activity of the metabolites to the parent isoflavone is unknown.

The isoflavones genistein and equol were found to inhibit the cytochrome P450 isoenzymes CYP2E1 and CYP1A2,11 see also theophylline, page 263, but note also that infant formulas, including soya-based formulas, appear to induce the cytochrome P450 isoenzymes CYP2C9.13 However, in one of these studies,12 St John and digoxin, page 261.

In vitro, the soya isoflavones daidzein and genistein and a hydrolysed soya extract inhibited CYP3A412,13 and CYP2C9.13 However, in one of these studies,12 St John's wort also inhibited CYP3A4, but clinically this herb is known to be an inducer of CYP3A4. This highlights the problems of extrapolating the findings of in vitro studies to the clinical situation.13

Genistein and biochanin A inhibit P-glycoprotein-mediated drug transport, for example, see paclitaxel, page 261 and digoxin, page 261.

**Interactions overview**

The interactions covered in the following sections relate to individual isoflavones. Some of these may be directly applicable to isoflavone supplements; however, caution must be taken when extrapolating these interactions to herbs or foods known to contain the isoflavone in question. This is because the amount of the isoflavone found in the herb or food can be highly variable, and might not be known, and other constituents present in the herb or food might affect the bioavailability or activity of the isoflavone. Therefore, although data on isolated isoflavones are useful, it is no substitute for direct studies of the herb or food in question.

Isoflavones + Antibacterials

The interaction between isoflavones and antibiotics is based on a prediction only.

Clinical evidence
No interactions found.

Experimental evidence
It is well known that colonic bacteria are involved in the metabolism of isoflavones. For example, it has been shown that equol is exclusively formed from daidzin by colonic bacteria, but that only about one-third of people are equol producers.1 In another study, the isoflavone glycosides puerarin and daidzin were incubated with human intestinal bacteria. All bacteria hydrolysed daidzin to the aglycone daidzein, and a few bacteria also transformed puerarin to daidzein. Human faecal specimens hydrolysed puerarin and daidzin to daidzein, but their hydrolysing activities varied between individual specimens. When the oestrogenic effects of the glycosides puerarin and daidzin were compared with those of the aglycone daidzein, the aglycone metabolite was more potent.2 Intestinal bacteria have also been reported to metabolise daidzein to the more active oestrogen equol.3 However, it is also now established that beta-glucosidases in the intestinal wall are also important for the hydrolysis of glycosides to form the aglycones (see Pharmacokinetics, page 258).

Mechanism
Colonic bacteria appear to play an important role in the metabolism of soya isoflavones; therefore, it is possible that antibacterials that decimate colonic bacteria could alter isoflavone metabolism and biological activity.

Importance and management
Evidence is limited to experimental studies that were not designed to study drug interactions; however, it is known that suggests that the concurrent use of antibacterials active against gut flora might theoretically alter or reduce the efficacy of some isoflavones. However, no evidence is available to support this supposition and, in any case, the effect is likely to be temporary. No action is therefore needed.


Isoflavones + Benzodiazepines

The interaction between isoflavones and benzodiazepines is based on experimental evidence only.

Evidence, mechanism, importance and management
In two experimental studies,1,2 the isoflavone puerarin has been shown to be a weak benzodiazepine antagonist. It is therefore theoretically possible that puerarin might reduce the effects of benzodiazepines if given concurrently. However, there is no clinical evidence to support this supposition. The fact that the information relates to an isolated isoflavone, and the effect was only weak, suggests that a clinically important interaction between isoflavones and benzodiazepines is unlikely.


Isoflavones + Cardiovascular drugs; Miscellaneous

The interaction between isoflavones and miscellaneous cardiovascular drugs is based on experimental evidence only.

Evidence, mechanism, importance and management
Some experimental studies have shown that isoflavones from kudzu, page 267, may inhibit of platelet aggregation.1 In one small study in patients with angina,2 treatment with the isoflavone puerarin reduced the activation of platelet surface activity protein. Some have interpreted these studies to indicate that, theoretically, kudzu might increase the risk of bleeding when used with anticoagulants, and that caution is warranted on concurrent use. Given the nature of the evidence, and the fact that it relates to isolated isoflavone constituents, this appears to be a very cautious approach. Note that puerarin injection is used in China to treat angina and cardiovascular disease. Clinical studies comparing standard Western treatment (nitrates, beta blockers, calcium-channel blockers, aspirin, anticoagulants, etc.) with or without puerarin injection have been reviewed. It was concluded that, although adverse events were inadequately reported, treatment including the injection tended to result in more adverse effects.3


Isoflavones + Antidiabetics

The interaction between isoflavones and antidiabetics is based on experimental evidence only.

Evidence, mechanism, importance and management
In various studies in animal models of diabetes, a couple of which are cited for information,1,2 puerarin, an isoflavone found in kudzu, page 267, has demonstrated blood glucose-lowering effects. Some have interpreted these studies to indicate that kudzu might have additive effects with antidiabetic drugs, and that the dose of antidiabetic medications might need to be adjusted. Given the nature of the evidence, and the fact that it relates to isolated isoflavone constituents, this appears to be a very cautious approach.

**Isoflavones + Digoxin**

The interaction between isoflavones and digoxin is based on experimental evidence only.

**Clinical evidence**
No interactions found.

**Experimental evidence**
In a study in rats, biochanin A 100 mg/kg increased the AUC and maximum serum levels of an oral 20-mg/kg dose of digoxin by 75% and 71%, respectively. No significant changes in mean residence time and terminal half-life of digoxin were observed, suggesting a negligible effect of biochanin A on renal elimination.

**Mechanism**
Digoxin is a substrate for P-glycoprotein. Biochanin A may modestly inhibit P-glycoprotein, resulting in a moderate increase in oral bioavailability of digoxin.

**Importance and management**
There appears to be no clinical data regarding an interaction between biochanin A and digoxin, and the clinical relevance of the experimental data needs to be determined. However, until more is known, because of the narrow therapeutic index of digoxin, it may be prudent to be cautious if patients taking digoxin also wish to take supplements containing high doses of biochanin A. Patients should be alert for any evidence of adverse effects, such as bradycardia, and if these occur it may be prudent to monitor digoxin levels.


**Isoflavones + Food**

No interactions found

**Isoflavones + Herbal medicines**

No interactions found. Isoflavones are regularly ingested as part of the diet.

**Isoflavones + Nicotine**

Soya isoflavones slightly decrease the metabolism of nicotine.

**Clinical evidence**
The effects of soya isoflavones on nicotine metabolism were investigated in a study in 7 healthy Japanese subjects who were non-smokers. Taking an isoflavone tablet (containing daidzein 4.2 mg, genistein 5.2 mg and glycitein 600 micrograms) six times daily for 5 days, in addition to their usual diet, slightly reduced nicotine metabolism by about 24% (measured 2 hours after chewing a piece of nicotine gum). This was when compared with nicotine metabolism after abstaining from soya foods for one week.1

**Experimental evidence**
*In vitro*, these isoflavones decreased nicotine metabolism, by inhibiting the cytochrome P450 isoenzyme CYP2A6.1

**Mechanism**
Isoflavones slightly decrease the metabolism of nicotine by the inhibition of CYP2A6.

**Importance and management**
Although evidence is limited to one study, it is a well-designed clinical study. The minor change in nicotine metabolism when the subjects were taking isoflavones suggests that isoflavone supplements are unlikely to have a clinically relevant effect on the efficacy of nicotine replacement therapy. No action is therefore needed.


**Isoflavones + Paclitaxel**

The interaction between isoflavones and paclitaxel is based on experimental evidence only.

**Clinical evidence**
No interactions found.

**Experimental evidence**
In a study in rats, genistein 10 mg/kg given orally 30 minutes before a single dose of oral or intravenous paclitaxel modestly increased the AUC of paclitaxel by 55% and 43%, respectively. The increase in AUC with a lower dose of genistein 3.3 mg/kg was not significant, although it did increase the peak concentration of paclitaxel by 67%.1

In another similar study, biochanin A 100 mg/kg caused a marked 3.8-fold increase in the oral bioavailability of paclitaxel 20 mg/kg.2

Mechanism
It seems that these isoflavones increase the systemic exposure of oral paclitaxel by inhibiting P-glycoprotein. In addition, isoflavones might reduce paclitaxel drug resistance via their effects on P-glycoprotein.

Importance and management
The available evidence for an interaction between isoflavones and paclitaxel is from experimental studies, the clinical relevance of which needs to be determined. Furthermore, paclitaxel is given intravenously, and the effect of biochanin A has only been assessed with oral paclitaxel. However, genistein modestly increased the AUC of intravenous paclitaxel, and therefore, until more is known, some caution might be appropriate with high doses of these individual isoflavones, in view of the possibility of increased exposure and increased toxicity of paclitaxel.

Evidence and mechanism
(a) Breast cancer
In various animal studies, soya isoflavones have either inhibited or enhanced the preventative effect of tamoxifen on the development of breast cancer. Note that the body of evidence is vast, and only a selection of representative papers has therefore been cited. For example, in a study in rats given tamoxifen, a diet supplemented with daidzein increased protection against chemically induced breast cancer, whereas a diet supplemented with genistein reduced protection, when compared with tamoxifen alone. In another study, a ‘low-dose’ isoflavone-enriched diet (genistein plus daidzein) halved the protective effect of tamoxifen against the development of breast tumours, whereas a soy meal or ‘high-dose’ isoflavones did not have any effect. In yet another study, genistein and tamoxifen had a synergistic effect on delaying the growth of oestrogen-dependent breast tumours in mice, especially at lower levels of tamoxifen.

Note that disparate findings (both prevention and stimulation) have been found for genistein alone on induction of mammary tumours in animals. It has been suggested that the effect might depend on age, with a preventative effect seen at a young age, and a stimulatory effect seen when oestrogen levels are low, as occurs postmenopausally. Note also that there is a large body of epidemiological data on the effect of dietary soya products on the risk of breast cancer, which suggest a possible increase in risk.

Some animal studies have clearly shown that genistein can antagonise the inhibitory effect of tamoxifen on growth of oestrogen-dependent human breast cancer. In an in vitro study, this effect was shown to be biphasic, with low levels of genistein simulating cancer cell growth, and high levels of genistein inhibiting cancer cell growth. Similarly, in vitro studies have shown that genistein has a synergistic or additive inhibitory effect on the growth of breast cancer cells exposed to tamoxifen, or antagonises the response of breast cancer cells to tamoxifen.

Note that, in one study in 17 women with biopsy-confirmed breast cancer, supplementation with soya isoflavones 200 mg daily for 2 weeks did not increase tumour growth over the 2 to 6 weeks before surgery. There was a trend towards cancer growth inhibition in the isoflavone treatment group, manifested as an increase in the apoptosis/mitosis ratio, when compared with those from a historical control group, although this was not statistically significant. However, in another study in women requiring surgery for a benign or malignant breast tumour, supplementation with dietary soy, containing isoflavones 45 mg daily for 2 weeks, increased proliferation markers in a healthy zone of the breast. Similarly, another study of dietary supplementation with soya protein (providing 37.4 mg of genistein daily) for 6 months found an increase in breast secretion (an assessment of breast gland function) in premenopausal women, but a small or lack of an increase, in postmenopausal women and epithelial hyperplasia in about one-third of the women, which was suggestive of oestrogenic breast tissue stimulation in response to genistein.

(b) Menopausal symptoms
In a placebo-controlled crossover study in 149 women with a history of breast cancer, about two-thirds of whom were taking tamoxifen, soya isoflavones (genistein, daidzein and glycitein) 50 mg three times daily for 4 weeks had no effect on the incidence of hot flushes. Another similar study also reported a lack of efficacy for hot flushes in 157 women breast cancer survivors given a soya beverage (90 mg isoflavones daily) or placebo beverage for 12 weeks, of whom about one-third were taking tamoxifen. Vaginal spotting was reported by 4 women who drank the soya beverage and one woman who drank the placebo beverage, but this was not thought to be due to the soya. In a third study, in 72 women with breast cancer, 78% of whom were taking tamoxifen, a soya supplement (35 mg of isoflavones twice daily; Phytosoya) for 12 weeks had no effect on menopausal symptoms when compared with placebo.

These studies are probably too short, and too small, to detect any possible effect of the isoflavones on the efficacy of tamoxifen. Nevertheless, they show that isoflavones are probably no more effective than placebo for one of the most common reasons for which they are used in this patient group.

(c) Tamoxifen metabolism
In a cross-sectional study in 380 Asian–American women (including Chinese and Japanese Americans) with breast cancer the serum levels of tamoxifen and its major metabolites were unrelated to serum levels of isoflavones (genistein, daidzein, equol) or reported dietary soya intake.

In an in vitro study using female rat liver microsomes, genistein inhibited α-hydroxylation of tamoxifen (a minor metabolic route), but did not affect 4-hydroxylation, N-demethylation or N-oxidation (major metabolic routes). A combination of three to five isoflavones (genistein, daidzein and glycitein, or these three isoflavones plus biochanin A and formononetin) inhibited tamoxifen α-hydroxylation to a greater extent, but did not decrease the formation of other metabolites. Studies using selective chemical inhibitors showed that tamoxifen α-hydroxylation was mainly mediated by CYP1A2 and CYP3A1/2 in rats. Although α-hydroxytamoxifen is a minor metabolite of tamoxifen, it is thought to be responsible for DNA adduct formation and increased risk of endometrial cancer with tamoxifen. The authors concluded that using genistein and its isoflavone analogues with tamoxifen might potentially be beneficial because of the inhibition of the formation of α-hydroxytamoxifen. However, this requires confirmation in humans. Also, note that isoflavones themselves may not be free of endometrial adverse effects, for example, in one study, long-term clinical use of isoflavones (genistein, daidzein, glycitein) induced endometrial hyperplasia in some women.

Importance and management
The available evidence on the effect of isoflavone supplements on the efficacy of tamoxifen in breast cancer is inconclusive, and the effect of isoflavones on breast tissue appears to be complex. It is possible that whether the effect is beneficial or antagonistic might be related to the dose of isoflavones used, and also the oestrogen status of the patient (pre- or postmenopausal). Because of differences in
gut flora, there are individual differences in the metabolism of isoflavones, which might have important implications for their effects. For example, studies indicate that urinary equol (which has more potent oestrogenic effects than daidzein) excretion after soya consumption indicates that only about one-third of Western individuals metabolise daidzein to equol.17

Most authorities recommend that patients taking oestrogen antagonists (that is, drugs such as tamoxifen and the aromatase inhibitors) for breast cancer should avoid isoflavone supplements. Given the available evidence, this seems a sensible precaution, particularly because there is no clear clinical evidence that isoflavones are beneficial for menopausal symptoms in these women. The advice to avoid isoflavone supplements is not usually extended to soya foods, although some have argued that available data do not appear to warrant making this distinction.18 Further study is needed.


### Isoflavones + Theophylline

**High doses of isoflavones might modestly increase theophylline levels.**

**Clinical evidence**

In a placebo-controlled study in 20 healthy non-smoking subjects, pre-treatment with daidzein 200 mg twice daily for 10 days increased the AUC and maximum level of a single 100-mg dose of theophylline by about 34% and 24%, respectively, and increased the elimination half-life from about 9 hours to about 12 hours.1

**Experimental evidence**

The isoflavones genistein and equol were found to inhibit the cytochrome P450 isoenzyme CYP1A2.2 Conversely, note that soya-based infant formula *induced* CYP1A2 *in vitro*, see Soya + Caffeine, page 357.

**Mechanism**

Daidzein, and some other isoflavones, appear to be moderate inhibitors of cytochrome P450 isoenzyme CYP1A2, of which theophylline is a substrate.

**Importance and management**

The dose of daidzein used in this study was higher than that usually taken in isoflavone supplements, or as part of the diet, and the effects on theophylline pharmacokinetics were modest. Nevertheless, bear in mind that high doses of isoflavones might modestly increase theophylline levels and that this could be clinically important in patients with theophylline levels already at the higher end of the therapeutic range. Note that an increase in theophylline levels has been seen in a patient given the synthetic isoflavone, ipriflavone.3 Amidophylline would be expected to interact similarly.

Note also that, conversely, there is evidence that infants receiving formula feeds, (which may include soya-based formula) require higher doses of caffeine (which, like theophylline, is a substrate of CYP1A2) than those that are breastfed, see Soya + Caffeine, page 357.


---

No interactions have been included for herbal medicines or dietary supplements beginning with the letter J
Kelp

*Fucus vesiculosus* L. and other species (Fucaceae)

**Synonym(s) and related species**
Black tang, Bladder fucus, Bladderwrack, Cutweed, Kelpware, Rockweed, Seawrack.

*Fucus serratus* L., (known as Toothed wrack). *Ascophyllum nodosum* (L.) Le Jolis (known as Knotted wrack) is also used in a similar way to *Fucus* species.

Technically, kelps are species of *Laminaria* and *Macrocystis*.

**Pharmacopoeias**
Kelp (*BP 2009*, *Ph Eur 6.4*).

**Constituents**
The thallus of kelp contains polysaccharides including alginic acid (the major component), fucoidan and laminarin (sulfated polysaccharide esters), free phloroglucinol and its high-molecular-weight polymers the phlorotannins and fucols and galactolipids. The iodine content can be high, and kelp may be standardised to the total iodine content. Kelp also contains vitamins and minerals, particularly ascorbic acid (vitamin C), and it is a moderate source of vitamin K₁ (phytomenadione). Kelp may be contaminated with various heavy metals such as arsenic, and it may be standardised to a maximum limit of these.

**Use and indications**
Traditionally kelp has been used as a source of minerals such as iodine for thyroid deficiency. It has also been used as a slimming supplement. Note that the iodine content in kelp may precipitate hyperthyroidism, and prolonged or excessive intake is inadvisable.

**Pharmacokinetics**
No relevant pharmacokinetic data found.

**Interactions overview**
Kelp is probably unlikely to interact with warfarin, because, although it is a moderate source of vitamin K₁, and therefore has the potential to reduce the effect of warfarin and related anticoagulants, sufficient vitamin K is very unlikely to be attained with usual doses of kelp supplements. Note also that anticoagulant fucoidans in kelp are unlikely to be orally active.
### Kelp + Anticoagulants

Unintentional and unwanted antagonism of warfarin occurred in one patient when she ate seaweed sushi. It has been suggested that kelp contains substances with anticoagulant activity, but the evidence for this is theoretical.

#### Clinical evidence

An isolated report describes a patient taking warfarin who had, on two occasions, reduced INRs of 1.6 and 1.8 (usual range 2 to 3) within 24 hours of eating sushi with seaweed (asakusa-nori). It was estimated that she had consumed only about 45 micrograms of vitamin K$_1$, which would not usually be sufficient to interact. However, if her vitamin K stores were low, this amount could have accounted for a large percentage of her vitamin K intake or stores, and might therefore have interacted. Note that kelp is a moderate source of vitamin K, having about 66 micrograms per 100 g. However, this means that supplements containing 1 g of kelp will contain very little vitamin K (0.66 micrograms). Also, when the kelp is used to prepare an infusion, it would be unlikely to contain much vitamin K$_1$, because the vitamin is not water soluble.

#### Experimental evidence

In experimental studies, fucoidans from brown seaweeds including kelp have demonstrated anticoagulant activity. For example, in one in vitro study, the fucoidan from Fucus serratus had anticoagulant activity, as measured by activated partial thromboplastin time; this was roughly equivalent to 19 units of heparin per mg. The fucoidin inhibited thrombin-induced human platelet activation. The fucoidans from Fucus vesiculosus and Ascophyllum nodosum had a smaller effect (roughly equivalent to 9 and 13 units of heparin per mg, respectively).

#### Mechanism

Kelp is a moderate source of vitamin K, and therefore, if eaten in sufficient quantities, would antagonise the effects of coumarins and indanediones, because these anticoagulants act as vitamin K antagonists. Fucoidans from kelp may act like heparin and inhibit thrombin activity, and therefore have some anticoagulant effects. However, they are large polysaccharides, and are therefore unlikely to be orally active.

### Importance and management

The interaction of warfarin with vitamin K from foods is a very well-established, well-documented and clinically important drug–food interaction, expected to occur with every coumarin or indanedione anticoagulant because they have a common mode of action. However, the evidence suggests that, in patients with normal vitamin K$_1$ status, in general, clinically relevant changes in coagulation status require large continued changes in intake of vitamin K$_1$ from foods, which would be highly unlikely to be attained from usual doses of kelp supplements. This interaction would therefore be more applicable to kelp eaten as a food.

Fucoids in kelp are very unlikely to be orally active, so kelp supplements would be unlikely to have any anticoagulant activity. Taking the evidence together, there appears to be no reason why patients taking warfarin should particularly avoid taking kelp supplements.


### Kelp + Food

No interactions found.

### Kelp + Herbal medicines

No interactions found.
Kudzu

Pueraria montana (Lour.) Merr. (Fabaceae)

**Synonym(s) and related species**

Ge Gen.


Other species used include *Pueraria mirifica* Airy Shaw & Suvatbandhu (Thai kudzu, Kwao Kreu Kao) and *Pueraria phaseoloides* (Roxb.) Benth. (Puero, Tropical kudzu).

** Constituents**

The major isoflavone constituent of the root of *Pueraria lobata* is **puerarin**, which is the 8-C-glucoside of daidzein, but there are many others, such as puerarin hydroxy- and methoxy- derivatives and their glycosides, daidzein and its O-glycoside daidzin, biochanin A, genistein and formononetin derivatives. Pterocarpans are also present, including medicarpin glycinol and tuberosin. The flowers contain the phytoestrogens kakkalide and tectoridin.

*Pueraria mirifica* root contains similar constituents to *Pueraria lobata*, the major difference being lower amounts of daidzein.

Much of the research carried out on kudzu has been on the effects of isolated **puerarin**.

**Use and indications**

Kudzu contains isoflavones and is used as a phytoestrogen for menopausal symptoms, with a particular emphasis on bone metabolism for use in postmenopausal osteoporosis. It also has a popular reputation for being able to lower alcohol consumption and to treat symptoms of alcohol intoxication. This effect has not been reported for other isoflavone-containing herbs and the possible mechanism of action is unknown. Kudzu has also been used for migraine and hypertension, pain and stiffness, and angina. The phytoestrogenic properties are well known, and puerarin is thought to be the major component with this effect, which has been well documented in animals. For further details about the general and specific effects of isoflavones, see isoflavones, page 258.

**Pharmacokinetics**

No relevant pharmacokinetic data for kudzu found. For information on the pharmacokinetics of its main isoflavone constituent puerarin, see isoflavones, page 258.

**Interactions overview**

Kudzu + Antibacterials

No data for kudzu found. For the theoretical possibility that broad-spectrum antibacterials might reduce the metabolism of the isoflavone constituents of kudzu, such as puerarin and daidzin, by colonic bacteria, and so alter their efficacy, see Isoflavones + Antibacterials, page 260.

Kudzu + Antidiabetics

No data for kudzu found. For comment on the blood-glucose-lowering effects of puerarin, a major isoflavone constituent of kudzu, see Isoflavones + Antidiabetics, page 260.

Kudzu + Benzodiazepines

No data for kudzu found. Puerarin, a major isoflavone constituent of kudzu, has been reported to be a weak benzodiazepine antagonist, see Isoflavones + Benzodiazepines, page 260.

Kudzu + Cardiovascular drugs; Miscellaneous

No data for kudzu found. For a discussion of the evidence that puerarin, an isoflavone present in kudzu, might inhibit platelet aggregation, see Isoflavones + Cardiovascular drugs; Miscellaneous, page 260.

Kudzu + Digoxin

No data for kudzu found. For the possibility that high-dose biochanin A, an isoflavone present in kudzu, might increase digoxin levels, see Isoflavones + Digoxin, page 261.

Kudzu + Fexofenadine

For the possibility that high-dose biochanin A, an isoflavone in kudzu, may slightly decrease fexofenadine levels in rats, see Isoflavones + Fexofenadine, page 261.

Kudzu + Food

No interactions found.

Kudzu + Herbal medicines

No interactions found.

Kudzu + Methotrexate

The interaction between kudzu and methotrexate is based on experimental evidence only.

Clinical evidence

No interactions found.

Experimental evidence

In a pharmacokinetic study in rats, the use of a kudzu root decoction significantly decreased the elimination and resulted in markedly increased exposure to methotrexate. Animals were given methotrexate, orally or intravenously, alone or with the decoction. Giving the decoction at a dose of 4 g/kg and 2 g/kg significantly increased the AUC of oral methotrexate by about 3-fold and 2.3-fold, respectively. This resulted in high mortality rates (57.1% and 14.3%). With intravenous methotrexate, the concurrent use of the kudzu decoction at 4 g/kg increased the half-life by 54% and decreased the clearance by 48%.

Mechanism

Kudzu markedly reduces the elimination of methotrexate. This might occur because of competition for renal or biliary excretion, possibly via organic anion transporter (OAT).1

Importance and management

Evidence is limited to data in rats, and the doses of kudzu used in this study are very high. Nevertheless, the findings suggest that kudzu might markedly increase the effects of methotrexate. Until more is known, caution might be appropriate on concurrent use. The risks are likely to be greatest with high-dose methotrexate (for neoplastic diseases) and in patients with impaired renal function, but less in those given low doses (5 to 25 mg weekly) for psoriasis or rheumatoid arthritis and with normal kidney function. Note that the use of methotrexate requires routine monitoring (e.g. of LFTs), and patients should be advised to report any sign or symptom suggestive of infection, particularly sore throat (which might possibly indicate that white cell counts have fallen) or dyspnoea or cough (suggestive of pulmonary toxicity).


Kudzu + Nicotine

For discussion of a study showing that daidzein and genistein present in kudzu caused a minor decrease in the metabolism of nicotine, see Isoflavones + Nicotine, page 261.

Kudzu + Oestrogens or Oestrogen antagonists

Kudzu contains oestrogenic compounds. This may result in additive effects to oestrogens or it may oppose the effects of oestrogens. Similarly, kudzu may have additive effects to oestrogen antagonists or oppose the effects of oestrogen antagonists (e.g. tamoxifen).

Evidence, mechanism, importance and management

Kudzu has a long history of use for menopausal symptoms, and is known to contain isoflavones (plant oestrogens). Numerous in vitro and animal studies have demonstrated oestrogenic effects for the herb (too many to cite here). However, few clinical studies have
been conducted. In one study,1 *Pueraria mirifica* alleviated menopausal symptoms in perimenopausal women, but in another study in postmenopausal women,2 *Pueraria lobata* did not alter menopausal symptoms or lipids or hormone levels, and was less effective than conventional HRT.

Theoretically, the isoflavones from kudzu might have oestrogen antagonistic effects when they are given with potent oestrogenic drugs, as their oestrogenic effects are weaker and they might competitively inhibit the conventional oestrogenic drugs. Conversely, because of their oestrogenic effects it is possible that they might reduce the efficacy of potent oestrogen antagonists.

Although many studies have been carried out, clinical information on the potential interaction of kudzu with oestrogens or oestrogen antagonists is sparse. On the basis of the postulated oestrogenic effects of kudzu and the theoretical mechanisms of antagonism, some have recommended caution if kudzu is given with other oestrogens including hormonal contraceptives, or with oestrogen antagonists such as tamoxifen. However, isoflavones from plants are widely consumed as part of the traditional diet in many parts of the world, and there is no clear evidence that this affects response to hormonal contraceptives or oestrogen antagonists such as tamoxifen. For further information on the oestrogenic effects of isoflavone supplements, see Isoflavones + Tamoxifen, page 262.


---

**Kudzu + Paclitaxel**

No data for kudzu found. For the possibility that the isoflavones biochanin A and genistein present in kudzu might increase paclitaxel levels, see Isoflavones + Paclitaxel, page 261. Note that paclitaxel is used intravenously, and the effect of biochanin A on intravenous paclitaxel does not appear to have been evaluated.

**Kudzu + Theophylline**

No data for kudzu found. For the possibility that high doses of daidzein present in kudzu might modestly increase theophylline levels, see Isoflavones + Theophylline, page 263.
Lapacho

*Tabebuia avellanedae* Lorentz ex Griseb. (Bignoniaceae)

**Synonym(s) and related species**
Pau D’arco, Taheebo.


**Constituents**
Naphthoquinones are the major active constituents of the inner bark, the most important of which is lapachol, with deoxylapachol and α- and β-lapachone and others. Flavonoids and natural coumarins are also present.

Other constituents that may contribute to the pharmacological activity of lapacho include: iridoid glycosides such as ajugol; lignans based on secoisolariciresinol and cycloolivil; isocoumarin glycosides based on 6-hydroxymellein; phenolic glycosides of methoxyphenol derivatives and vanillyl 4-hydroxybenzoate; various aldehydes; and volatile constituents such as 4-methoxybenzaldehyde, elemicin, trans-anethole and 4-methoxybenzyl alcohol.

**Use and indications**
Lapacho is used traditionally for infectious diseases of bacterial, protozoal, fungal and viral origin, to enhance the immune system, and as an anti-inflammatory agent. It is also used as an anticancer therapy, especially in South America, and, although there is experimental evidence to support some of these uses, good clinical evidence is not available. Lapachol is toxic in high doses.

**Pharmacokinetics**
No relevant pharmacokinetic data found.

**Interactions overview**
Lapachol is reported to have anticoagulant properties, which may be additive with those of conventional anticoagulants.
# Lapacho + Anticoagulants

Lapacho may have anticoagulant effects and therefore, theoretically, concurrent use of conventional anticoagulants may be additive.

## Clinical evidence

No interactions data found. However, it has been stated that lapacho (the main active constituent of lapacho) was originally withdrawn from clinical study because of its anticoagulant adverse effects, but the original data do not appear to be available.

## Experimental evidence

An *in vitro* study in rat liver microsomes found that lapachol is a potent inhibitor of vitamin K epoxide reductase. These effects were said to be similar to those of warfarin.

## Mechanism

Anticoagulants such as warfarin exert their effects by antagonising the effects of vitamin K, which is necessary to produce some clotting factors. They do this by inhibiting vitamin K epoxide reductase, which reduces the synthesis of vitamin K. This action appears to be shared by lapachol, and therefore the concurrent use of lapacho and anticoagulants may be additive.

## Importance and management

Evidence is extremely limited, but the fact that lapachol was withdrawn from clinical studies due to its anticoagulant effects adds weight to the theoretical mechanism. Until more is known it would seem prudent to discuss the possible increase in anticoagulant effects with any patient taking an anticoagulant, who also wishes to take lapacho. If concurrent use is considered desirable it may be prudent to refer the patient to have their INR, or other suitable clotting parameters, checked.


### Lapacho + Food

No interactions found.

### Lapacho + Herbal medicines

No interactions found.
**Liquorice**

*Glycyrrhiza glabra* L. (Fabaceae)

**Synonym(s) and related species**

Licorice.
- Spanish and Italian liquorice is *Glycyrrhiza glabra* var *typica* Reg. et Herd.
- Persian or Turkish liquorice is *Glycyrrhiza glabra* var *violacea* Boiss.
- Russian liquorice is *Glycyrrhiza glabra* L var *glandulifera*.
- Chinese liquorice is the closely related *Glycyrrhiza uralensis* Fisch., also known as Gancao.

**Pharmacopoeias**


**Constituents**

Liquorice has a great number of active compounds of different classes that act in different ways. The most important constituents are usually considered to be the oleanane-type triterpenes, mainly *glycyr rhizin* (glycyrrhizic or *glycyr rhizinic acid*), to which it is usually standardised, and its aglycone glycyrrhetinic acid. There are also numerous phenolics and flavonoids of the chalcone and isoflavone type, and many natural coumarins such as licoumarin, umbelliferone, gabrocoumarones A and B, herniarin and glycin. It also contains polysaccharides such as glycyrrhizan GA, and a small amount of volatile oil.

**Use and indications**

The dried root and stolons of liquorice are used as an expectorant, antispasmodic and anti-inflammatory, and to treat peptic and duodenal ulcers. Liquorice is widely used in traditional oriental systems of medicine, and as a flavouring ingredient in food. It has mineralocorticoid and oestrogenic activity in large doses, as a result of glycyrrhetinic acid, and has many other reputed pharmacological effects.

**Pharmacokinetics**

Prolonged intake of high doses of liquorice extract, or its constituent glycyrrhizin, on probe cytochrome P450 isoenzyme substrates was investigated in *mice*.\(^1\) With repeated treatment, both liquorice extract and glycyrrhizin significantly induced hepatic CYP3A and to a lesser extent, CYP1A2.

In a single-dose study in 2 healthy subjects, plasma levels of glycyrrhetic acid were much lower after administration of aqueous liquorice root extract 21 g (containing 1600 mg glycyrrhizin) than after the same 1600-mg dose of pure glycyrrhizin. This suggests that the biological activity of a given dose of glycyrrhizin might be greater if taken as the pure form than as liquorice. This confirmed data from a study in *rats*.\(^2\) Note that much of the evidence relating to possible interactions is for pure constituents. These findings therefore suggest that the effect of liquorice might be less than that of pure glycyrrhizin at the same dose.

**Interactions overview**

Liquorice appears to diminish the effects of antihypertensives and may have additive effects on potassium depletion if given in large quantities with laxatives and corticosteroids. Iron absorption may be decreased by liquorice, whereas antibacterials may diminish the effects of liquorice. A case report describes raised digoxin levels and toxicity in a patient taking liquorice. Although it has been suggested that liquorice may enhance the effects of warfarin, there appears to be no evidence to support this. Note that liquorice is a constituent of a number of Chinese herbal medicines. See under bupleurum, page 89, for possible interactions of liquorice given as part of these preparations.

Liquorice may cause fluid retention and therefore reduce the effects of antihypertensives. Additive hypokalaemia may also occur with loop and thiazide diuretics.

**Clinical evidence**

In 11 patients with treated hypertension, liquorice 100 g daily for 4 weeks (equivalent to glycyrrhetinic acid 150 mg daily) increased mean blood pressure by 15.3/9.3 mmHg. Smaller rises (3.5/3.6 mmHg) were seen in 25 normotensive subjects taking the same dose of liquorice.1 In another study in healthy subjects liquorice 50 to 200 mg daily for 2 to 4 weeks (equivalent to glycyrrhetic acid 75 to 540 mg daily) increased systolic blood pressure by 3.1 to 14.4 mmHg. The group taking the largest quantity of liquorice experienced the greatest rise in systolic blood pressure, and was the only group to have a statistically significant rise in diastolic blood pressure.3

There are many published case reports of serious hypertension occurring in people consuming, often, but not always, excessive doses of liquorice from various sources (confectionery, alcoholic drinks, flavoured chewing tobacco, herbal teas, herbal medicines).

**Experimental evidence**

Because of the quality of the clinical evidence, experimental data have not been cited. There is an extensive literature, which has been the subject of a review.3

**Mechanism**

Ingestion of liquorice inhibits 11β-hydroxysteroid dehydrogenase type 2, thereby preventing the inactivation of cortisol to cortisone.3,4 This results in mineralocorticoid effects including sodium and water retention (leading to hypertension) and hypokalaemia.5 This effect would oppose the effects of drugs used to lower blood pressure. In addition, the potassium-depleting effect of liquorice would be expected to be additive with loop and thiazide diuretics. The mineralocorticoid effect of liquorice is due to the content of glycyrrhetic acid (a metabolite of glycyrrhizic acid), and therefore deglycyrrhizinated liquorice would not have this effect.

**Importance and management**

The ability of liquorice to increase blood pressure is well established. The dose required to produce this effect might vary between individuals, and the evidence from the study cited suggests that patients with hypertension might be more sensitive to its effect. It is probably not appropriate for patients taking antihypertensive drugs to be treated with liquorice, especially if their hypertension is not well controlled. Although liquorice-containing confectionery and other foodstuffs have also been implicated in this interaction it is usually when it has been consumed to excess. It seems unlikely that the occasional consumption of small amounts of these products will cause a notable effect. Nevertheless, in patients with poorly controlled blood pressure it may be prudent to ask about liquorice consumption to establish whether this could be a factor.

Note also that the potassium-depleting effect of liquorice would be additive with that of potassium-depleting diuretics such as loop diuretics and thiazides. Deglycyrrhizinated liquorice would not be expected to have these effects.

Liquorice

enzyme system depends on its chemical structure. Therefore, it cannot be assumed that liquorice will inhibit the inactivation of all corticosteroids.

Dexamethasone appears to attenuate the mineralocorticoid effects of glycyrrhizin because it suppresses endogenous cortisol secretion (causes adrenal suppression). Other corticosteroids would be expected to interact similarly if given in adrenal-suppressing doses. Deglycyrrhizinated liquorice would not have these effects.

**Importance and management**

The clinical importance of these observations is uncertain. Doses of corticosteroids sufficient to cause adrenal suppression would be expected to reduce the mineralocorticoid activity of liquorice, but mineralocorticoid activity might still occur. Glycyrrhizin (an active constituent of liquorice) and its metabolite glycyrrhetinic acid slightly increased the plasma levels of hydrocortisone and prednisolone and markedly potentiated the cutaneous effects of hydrocortisone. This suggests that liquorice will slightly potentiate the effects of these steroids. However, this might not apply to other corticosteroids (see Mechanism, above). Nevertheless, it might be prudent to monitor the concurrent use of liquorice and corticosteroids, especially if liquorice ingestion is prolonged or if large doses are taken, as additive effects on water and sodium retention and potassium depletion may occur.


An isolated case of digoxin toxicity has been reported in an elderly patient attributed to the use of a herbal laxative containing kanzo (liquorice).

**Clinical evidence**

An 84-year-old man taking digoxin 125 micrograms daily and furosemide 80 mg daily complained of loss of appetite, fatigue and oedema of the lower extremities 5 days after starting to take a Chinese herbal laxative containing liquorice (kanzo) 400 mg and rhubarb (daio) 1.6 g three times daily. He was found to have a raised digoxin level of 2.9 nanograms/mL (previous level 1 nanogram/mL) with a pulse rate of 30 bpm, and a slightly low potassium level (2.9 mmol/L).

**Experimental evidence**

No relevant data found.

**Mechanism**

The reason for the increase in digoxin levels is unclear. Digoxin inhibits the sodium–potassium ATPase pump, which is concerned with the transport of sodium and potassium ions across the membranes of the myocardial cells. Potassium loss caused by a combination of the liquorice, rhubarb and diuretics exacerbated the potassium loss from the myocardial cells, thereby enhancing the bradycardia, already caused by an elevated digoxin level. Hypokalaemia also promotes the binding of digoxin to myocardial cells. The patient’s pre-existing cardiovascular disease may have also predisposed the patient to enhanced digoxin effects.

**Importance and management**

Evidence appears to be limited to one case. It is likely that the effects of the elevated digoxin levels were exacerbated by the hypokalaemia possibly caused by the herbal laxative. The theoretical basis for an interaction between liquorice and digoxin is well established, but there are few actual cases. Any herbal preparation that can reduce potassium levels would be expected to increase the risk of digoxin toxicity. This is likely to be additive with other concurrent medications that a patient may also be taking that can cause hypokalaemia, such as loop diuretics. It would be prudent to exercise caution in patients who are taking digitals glycosides and who regularly use/abuse laxatives including liquorice and/or anthraquinone-containing substances such as rhubarb. However, note that, if these laxatives are used as recommended (at a dose producing a comfortable soft-formed motion), then this interaction is probably unlikely to be important.


**Liquorice + Digitalis glycosides**

No interactions found. Note that liquorice is consumed as part of the diet.

**Liquorice + Food**

See under Liquorice + Laxatives, page 275.

**Liquorice + Iron compounds**

The interaction between liquorice and iron compounds is based on experimental evidence only.

**Clinical evidence**

No interactions found.

**Experimental evidence**

Liquorice extract 5 g/100 mL slightly enhanced the absorption index of iron by about 44% in rats.

**Mechanism**

Unknown. It may be related to the content of iron and vitamin C (which promotes iron absorption) in the liquorice extract.

**Importance and management**

The experimental evidence suggests that liquorice might slightly enhance the bioavailability of medicinal iron, but further study is needed to assess the clinical relevance of this. At present, no action is considered necessary.

Liquorice + Laxatives

Liquorice may cause additive hypokalaemia if given in large quantities with laxatives.

Evidence and mechanism

(a) Additive potassium depletion

Liquorice root may cause water retention and potassium depletion. Chronic diarrhoea caused by the long-term use or abuse of stimulant laxatives such as aloe and senna may lead to excessive loss of water and potassium, and can also lead to potassium deficiency. Theoretically, concurrent use of these herbs might have additive effects on potassium loss. Although the increased potential for potassium deficiency on combined use is mentioned in some reviews,1 there appear to be few clinical reports of this having occurred. Moreover, laxatives containing both senna and liquorice are available in some countries. One report describes four cases of pseudohyperaldosteronism (hypertension, hypokalaemia and suppression of the renin-aldosterone axis) in patients taking liquorice-containing laxatives for chronic constipation. In three of the patients, the preparation had been prepared by a herbalist and the fourth patient was taking a proprietary preparation containing senna and liquorice (Midro). The liquorice doses were high, varying from 0.5 to 8 g daily. Patients had the liquorice laxative withdrawn and replaced by glycerine suppositories or lactulose, and received spironolactone 200 mg daily for 2 weeks to correct blood pressure and potassium. Two months later, the patients had no signs or symptoms of hyperaldosteronism.2 It is not possible to say what contribution senna made to these cases, as the effects seen could be attributed to liquorice alone. Note that a similar combination laxative of liquorice with rhubarb caused mild hypokalaemia and digoxin toxicity, see Liquorice + Digoxin, page 274.

(b) Reduced absorption of liquorice

The introduction to an animal study briefly reported that, in a study in healthy subjects, the AUC and maximum levels of glycyrrhetic acid were much lower after oral administration of Onpito, a Kampo medicine composed of five herbs including liquorice and rhubarb, than after other Kampo medicines containing liquorice and not containing rhubarb.3 In a series of experiments in rats, the AUC of glycyrrhetic acid, a major component of liquorice, was reduced by up to about 70% by sennoside A, an anthraquinone derivative found in rhubarb.4 The authors propose that competitive inhibition of the anaerobic glycoside glycyrrhizin to its active metabolite glycyrrhetic acid.5 It was suggested that sodium picosulfate could reduce the metabolism of the glycoside glycyrrhizin to its active metabolite glycyrrhetic acid.4 Note that shaoyao-gancao-tang is a traditional Chinese medicine containing liquorice (gancao), of which glycyrrhizin is a major constituent.

Importance and management

The possible additive potassium depletion in patients given liquorice and anthraquinone-containing laxatives (such as senna and rhubarb) is a theoretical interaction, but bear it in mind in patients who are taking liquorice and who are regular users/abusers of anthraquinone-containing substances. However, note that, if anthraquinone laxatives are used as recommended (at a dose producing a comfortable soft-formed motion), this interaction is unlikely to be important.

It is unclear if sodium picosulfate affects the efficacy of liquorice as a laxative, and combination products are common.


Liquorice + Ofloxacin

For mention that sho-saiko-to and sairei-to (of which liquorice is one of the constituents) did not affect the metabolism of ofloxacin, see Bupleurum + Ofloxacin, page 90.

Liquorice + Tolbutamide

For conflicting evidence from animal studies that sho-saiko-to (of which liquorice is one of 7 constituents) might increase or decrease the rate of absorption of tolbutamide, see Bupleurum + Tolbutamide, page 90.

Liquorice + Ulcer-healing drugs

The interaction between liquorice and ulcer-healing drugs is based on experimental evidence only.

Clinical evidence

No interactions found.

Experimental evidence

In a study in rats, a single oral dose of shaoyao-gancao-tang was given alone and on the last day of a number of different drugs given twice daily for 7 doses. Pretreatment with amoxicillin or clarithromycin with metronidazole or clarithromycin with metronidazole markedly reduced the AUC of glycyrrhetic acid by about 90%. Hyoscine or omeprazole had no effect on the AUC of glycyrrhetic acid. Cimetidine decreased the AUC of glycyrrhetic acid by 42%, but this was not statistically significant.1 However, in a further study, it was found that the reduction in glycyrrhetic acid levels seen with the antibacterials could be markedly attenuated by the repetitive administration of shao-yao-gancao-tang.2

Mechanism

It was suggested that amoxicillin, clarithromycin and metronidazole decimate intestinal bacteria and so reduce the hydrolysis of the glycoside glycyrrhizin to glycyrrhetic acid, which is the form absorbed.1 Note that shaoyao-gancao-tang is a traditional Chinese medicine containing liquorice (gancao), of which glycyrrhizin is a major constituent.

Importance and management

There appear to be no clinical data regarding an interaction between liquorice and ulcer-healing drugs. The findings of the single-dose experimental study suggested that the clinical efficacy of shaoyao-gancao-tang in peptic ulcer disease might be reduced by the concurrent use of antibacterials used to eliminate Helicobacter pylori infection. However, the multiple-dose study suggests that, with repeated doses of the herbal medicine, the interaction might not be clinically relevant.

2. He J-X, Akao T, Tani T. Repetitive administration of Shaoyao-Gancao-tang to rats...

Liquorice + Warfarin

The interaction between liquorice and warfarin is based on experimental evidence only.

Clinical evidence
No interactions found.

Experimental evidence
In a study in rats, pretreatment with gancao aqueous extract 900 mg/kg daily by gastric lavage for 6 days reduced the AUC of a single 2-mg/kg dose of intravenous warfarin by about 38% and increased its clearance by 57%.

Mechanism
The authors of the study in rats suggest that gancao increases the metabolism of warfarin by the activation of the pregnane X receptor (PXR), which increases the expression of cytochrome P450 subfamily CYP3A, and isoenzyme CYP2C9.

Importance and management
Evidence appears to be limited to one experimental study in rats. It has been hypothesised that liquorice (gancao) might increase the effect of warfarin because of its natural coumarin content, but the coumarin constituents of liquorice are not known to be anticoagulants, and there is no evidence of liquorice acting as an anticoagulant. Furthermore, liquorice is not known as a food substance that reduces the activity of warfarin anticoagulation, nor is it known to induce the metabolism of other drugs; however, the experimental study introduces the possibility that it might. The evidence presented is too slim to make any specific recommendations regarding concurrent use.


Lycium

*Lycium barbarum* L. (Solanaceae)

**Synonym(s) and related species**
Chinese wolfberry, Goji berries, Matrimony vine, Wolfberry. *Lycium chinense*.

**Constituents**
Lycium fruit contains carotenoids such as betacarotene and zeaxanthin, beta-sitosterol, linoleic acid, betaine and various polysaccharides, vitamins and amino acids. The root bark contains beta-sitosterol and betaine among other constituents.

**Use and indications**
Lycium (dried berries or root bark) has been used to treat diabetes, ophthalmic disorders, hypertension and erectile dysfunction, and is thought to possess anti-inflammatory, antioxidant and anticancer properties. The dried berries are also used as a foodstuff.

**Pharmacokinetics**
*In vitro* studies suggest that lycium may be a weak inhibitor of the cytochrome P450 isoenzyme CYP2C9, although this is considered insufficient to cause a drug interaction, see warfarin, page 278.

**Interactions overview**
Lycium has antidiabetic effects, which may be additive to conventional antidiabetics, although evidence for this is largely experimental. A case report suggests that lycium may enhance the effects of warfarin, but this does not appear to be as a result of inhibiting CYP2C9, as has been suggested by some sources.

Lycium + Antidiabetics

The interaction between lycium and antidiabetics is based on experimental evidence only.

Clinical evidence
No interactions found.

Experimental evidence
In an experimental study in rats with streptozotocin-induced type 2 diabetes, lycium decreased insulin resistance, and reduced fasting insulin and postprandial glucose levels. In another study, a fruit extract of Lycium barbarum 10 mg/kg twice daily for 10 days significantly reduced blood-glucose levels in diabetic rabbits but did not reduce blood-glucose levels in healthy mice.

Mechanism
Lycium appears to improve glucose transport and increase insulin signalling thereby reducing blood-glucose levels. In theory, these effects may be additive with conventional antidiabetics.

Importance and management
The evidence is limited and purely experimental but what there is suggests that lycium may have antidiabetic properties. This is supported by the traditional use of lycium, in diabetes. Therefore, until more is known, it would be unwise to advise anything other than general caution.


Lycium + Food

No interactions found. Note that lycium berries are used as a foodstuff.

Lycium + Herbal medicines

No interactions found.

Lycium + Warfarin

A case report suggests that lycium may enhance the effects of warfarin.

Clinical evidence
A 61-year-old Chinese woman stabilised on warfarin (INR normally 2 to 3) had an unexpected rise in her INR to 4.1, which was identified during a routine monthly check. No bleeding was seen. She was also taking atenolol, benazepril, digoxin and fluvastatin. It was found that 4 days before visiting the clinic she had started to take one glass (about 170 mL) 3 or 4 times daily of a Chinese herbal tea made from the fruits of lycium to treat blurred vision caused by a sore eye. When the herbal treatment was stopped, her INRs rapidly returned to normal.

Experimental evidence
See under Mechanism, below.

Mechanism
Warfarin is metabolised by a number of isoenzymes, the most important being CYP2C9. Inhibition of this isoenzyme may therefore lead to increased warfarin levels and effects. The authors also carried out an in vitro study and concluded that, although lycium is a weak inhibitor of the cytochrome P450 isoenzyme CYP2C9, this is insufficient to cause an interaction. However, they note that other mechanisms cannot be ruled out.

Importance and management
Although the authors suggest avoiding the concurrent use of lycium and warfarin, because of the many other factors influencing anticoagulant control, it is not possible to reliably ascribe a change in INR specifically to a drug interaction in a single case report without other supporting evidence. It may be better to advise patients to discuss the use of any herbal products that they wish to try, and to increase monitoring if this is thought advisable. Cases of uneventful use should be reported, as they are as useful as possible cases of adverse effects. It should be noted that lycium berries are also used as an ingredient in Chinese foods.

Lycopene

Types, sources and related compounds
E160(d).

Pharmacopoeias
Lycopene (USP 32); Lycopene preparation (USP 32); Tomato extract containing lycopene (USP 32).

Use and indications
Lycopene is a carotenoid – a natural red pigment found in plants including some fruit and vegetables (such as tomatoes) – and is therefore eaten as part of a healthy diet, and is also used as a food colouring. It has been used for age-related macular degeneration and its antioxidant properties have been investigated for possible use in cardiovascular disease and cancer prevention, especially prostate cancer.

Pharmacokinetics
Lycopene is similar to betacarotene, the most widely studied carotenoid, but, unlike betacarotene, it is not a precursor to vitamin A. A study in 25 healthy men found that the amount of lycopene absorbed from a single dose of up to 120 mg was less than 6 mg in 80% of subjects, regardless of dose.1

Interactions overview
There is very little information on the interactions of lycopene supplements, but there is some information on dietary lycopene. Combined use with sucrose polyesters, colestyramine, probucol or betacarotene modestly reduces dietary lycopene absorption. Lycopene does not appear to affect the absorption of betacarotene. A low-fat diet does not alter dietary lycopene absorption when dietary intake is high. Colchicine and orlistat modestly reduce the absorption of the related carotenoid, betacarotene, probably because of their effects on fat absorption. If the mechanism is correct, lycopene levels could also be affected, see Betacarotene + Colchicine, page 63 and Betacarotene + Orlistat, page 64.

Lycopene + Colchicine

Colchicine modestly reduces the absorption of the related carotenoid, betacarotene, potentially because of its effects on fat absorption. Because lycopene levels tended to be lower in those taking low-fat diets (see food, below), if the mechanism is correct, lycopene levels may also be affected by colchicine, see Betacarotene + Colchicine, page 63.

Lycopene + Food

A low-fat diet is unlikely to alter the absorption of lycopene when the dietary intake of lycopene is high.

Clinical evidence

There do not appear to be any studies on the effect of food on the absorption of lycopene from supplements; however, there are studies on the effect of foods on absorption of dietary lycopene. In one crossover study in 13 healthy men eating a diet with a controlled carotenoid content and high in lycopene, there was no significant difference in the serum levels of lycopene between a high-fat monounsaturated-fat-enriched diet, or a high-carbohydrate low-fat diet. Lycopene was consumed as 300 g tomato soup and 60 g of tomato paste every day for 14 days. Similarly, no change in serum lycopene levels or betacarotene levels were found in a 12-month study in women randomised to a control diet or a low-fat diet, although plasma lycopene levels tended to be lower in those on the low-fat diet.

Experimental evidence

In an experimental study in rats fed a diet including lycopene 250 mg/kg for 3 weeks, food restriction of 20% significantly increased the accumulation of lycopene in the liver by about 70% and reduced the serum lycopene levels by about 90%.

Mechanism

Carotenoids are transported in plasma in lipoprotein cholesterol. The study in humans indicates that in situations of abundant lycopene intake, the fat content of the diet does not affect absorption. In a situation of food restriction, the distribution of carotenoids is also restricted because the circulating total lipid concentrations are reduced, thus resulting in a reduction in the serum levels and accumulation in the liver.

Importance and management

The available data suggest that diet, especially dietary fat, is unlikely to alter the absorption of lycopene when the dietary intake of lycopene is high. This might therefore apply to lycopene supplements, but further study is needed to confirm the absence of an effect of food on their absorption.

Clinical evidence

In a study in 10 healthy subjects, a single 60-mg dose of betacarotene given with a single 60-mg dose of lycopene appeared to significantly increase the AUC of lycopene by about fourfold when compared with lycopene given alone. Betacarotene levels remained the same when given alone and when given with lycopene. However, it was unclear whether absorption was complete by the 24-hour time point, and there was large variation in the absorption of the carotenoids between subjects in this study.

In contrast, in a study in 5 healthy subjects (not taking any lycopene supplements), very high-dose betacarotene 300 mg daily for 21 days decreased the levels of endogenous lycopene by about 30%.

Experimental evidence

In a study in ferrets, although the serum levels of betacarotene following a single 10-mg/kg dose were reduced by a single 10-mg/kg dose of lycopene, the average reduction was not significant.

Mechanism

Unclear. There is some debate as to whether these two carotenoids share the same biochemical pathways and compete for absorption, or whether the chemical nature of the preparations in which the supplements are taken affects absorption kinetics.

Importance and management

The evidence is limited, but it suggests that absorption of betacarotene from supplements is affected only modestly, if at all, by lycopene supplements, whereas betacarotene supplements might increase absorption of lycopene supplements taken at the same time. However, the clinical relevance of this, if any, is uncertain. Note that the doses of betacarotene used in the studies are much higher than the maximum daily dose of supplements of 7 mg recommended by the Food Standards Agency in the UK.


Lycopene + Lipid regulating drugs

Colestyramine and probucol reduce the serum levels of lycopene eaten as part of a normal diet.

Clinical evidence

There do not appear to be any studies on the effect of lipid regulating drugs on the absorption of lycopene from supplements; however, one 3-year study of 303 hypercholesterolaemic subjects given colestyramine in doses of 8 g to 16 g daily, according to tolerance, found that the serum levels of dietary-derived lycopene were reduced by about 30% after 2 months. When probucol 500 mg twice daily was then added, the serum levels of lycopene were reduced by another 30% after a further 2 months. After the initial 6-month period, patients were randomised to receive probucol or placebo, and all continued to take colestyramine. In those patients randomised to the placebo group, it took about 1 year for the lycopene levels to return to the pre-probucol level and, in those randomised to probucol, lycopene levels remained at the same low level and did not drop further.

Experimental evidence

No relevant data found.
**Mechanism**

Colestyramine and probucol are lipid regulating drugs that reduce the levels of low-density-lipoprotein-cholesterol and high-density-lipoprotein-cholesterol respectively. Colestyramine also reduces the intestinal absorption of lipids and the authors suggest that probucol may also displace lycopene from very-low-density-lipoprotein-cholesterol in the liver. All these factors may contribute to the reduction of lycopene serum levels because lycopene is fat soluble and therefore its absorption and distribution are dependent on the presence of lipoproteins.

**Importance and management**

This long-term study suggests that colestyramine and probucol reduce the serum levels of lycopene eaten as part of a normal diet. Supplemental lycopene does not appear to have been studied, but be aware that its desired effect may be reduced by colestyramine and probucol.


---

**Clinical evidence**

There do not appear to be any studies on the effect of sucrose polyesters on the absorption of lycopene from supplements; however, in one study in 194 healthy subjects, the serum levels of *dietary* lycopene were reduced by up to about 30% by *Olestra* 18 g daily. *Olestra* is a sucrose polyester that is a non-absorbable, non-calorific fat ingredient in snack foods.

**Experimental evidence**

No relevant data found.

**Mechanism**

*Olestra* is thought to reduce the absorption of fat-soluble vitamins when present at the same time in the gastrointestinal tract.

**Importance and management**

Evidence is limited to data on dietary lycopene and it is not known whether *Olestra* or other sucrose polyesters will reduce the absorption of supplemental lycopene; however, it has been found that the baseline levels of *vitamin A* have been maintained when subjects take *vitamin A* supplements with *Olestra*, and theoretically, at least, this may also be the case with lycopene. The manufacturers of *Olestra* state that, because snacking is just a part of the normal balanced diet and because there is a lack of scientific agreement on the health benefits of carotenoids, it is not necessary to take carotenoid supplements with *Olestra*. It should also be pointed out that the intake of *Olestra* in this study is far higher than the average daily intake from snack foods. Nevertheless, separating the intake of lycopene and sucrose polyesters should be enough to avoid any possible interaction.

Maté

*Ilex paraguariensis* A. St.-Hil. (Aquifoliaceae)

**Synonym(s) and related species**
Ilex, Jesuit’s Brazil tea, Paraguay tea, St Bartholomew’s tea, Yerba maté.

**Constituents**
Maté leaves contain xanthine derivatives, mainly *caffeine* (0.2 to 2%) and theobromine, with minor amounts of theophylline. They also contain various *flavonoids* of the flavonol subclass (quercetin, kaempferol and rutin), and polyphenolics, tannins and caffeic acid derivatives. Others include triterpenoid saponins and volatile oil.

**Use and indications**
Maté leaves are used as a stimulant, diuretic and analgesic, effects that can be attributed to the caffeine content. Maté is used to make a tea-like beverage in South America. High consumption of this tea appears to be associated with a high incidence of cancers of the oropharynx and oesophagus.

**Pharmacokinetics**
For the pharmacokinetics of caffeine, see caffeine, page 97. For information on the pharmacokinetics of individual flavonoids present in maté, see under flavonoids, page 186.

**Interactions overview**
The interactions of maté are mainly due to its caffeine content, see caffeine, page 97. For information on the interactions of individual flavonoids found in maté, see under flavonoids, page 186.
Meadowsweet
*Filipendula ulmaria* (L.) Maxim. (Rosaceae)

**Synonym(s) and related species**
Bridewort, Queen of the meadow.
*Spiraea ulmaria* L.

**Pharmacopoeias**
Meadowsweet (*BP 2009, Ph Eur 6.4*).

**Constituents**
Meadowsweet contains the phenolic glycosides spiraein, monotropin and gaultherin, and the essential oil is composed of up to 75% salicylaldehyde, with methylsalicylate and other salicylates. It also contains flavonoids, tannins, traces of natural coumarin and ascorbic acid. It may be standardised to a minimum content of steam volatile substances.

**Use and indications**
Meadowsweet is used as an anti-inflammatory and antacid. Surprisingly for a herb containing salicylates, meadowsweet is used traditionally to treat stomach complaints, and anti-ulcer activity has been demonstrated in some animal studies. Extracts from the flowers have been reported to have bacteriostatic activity *in vitro*.

**Pharmacokinetics**
No relevant pharmacokinetic data found.

**Interactions overview**
No interactions with meadowsweet have been found. Note, however, that it contains salicylates, although it is unknown whether the salicylates are at sufficient levels to have antiplatelet effects and thereby interact with warfarin. For more information about salicylate-containing herbs, see willow, page 399.
**Meadowsweet + Anticoagulant or Antiplatelet drugs**

The information regarding the use of meadowsweet with anticoagulants and antiplatelet drugs is based on a prediction only.

**Evidence, mechanism, importance and management**

No evidence found. However, note that meadowsweet contains salicylates, and conventional salicylate drugs increase the risk of bleeding with anticoagulants such as **warfarin**, and may have additive effects with antiplatelet drugs, because of their antiplatelet effects.

Whether there are sufficient salicylates in meadowsweet to have an equivalent antiplatelet effect to low-dose aspirin is unknown. Further study of the *in vitro* antiplatelet potential of meadowsweet is required, using aspirin as a control. See also Interactions overview, under willow, page 399.

**Meadowsweet + Food**

No interactions found.

**Meadowsweet + Herbal medicines**

No interactions found.
Melatonin

N-[2-(5-Methoxyindol-3-yl)ethyl]acetamide

**Types, sources and related compounds**

N-Acetyl-5-methoxytryptamine.

**Use and indications**

Melatonin is a hormone that is produced in the pineal gland of the brain and influences the circadian rhythm. Supplements are therefore principally used for treating sleep disturbances and disorders such as jet lag, insomnia, sleep walking, and shift-work sleep disorder. It is also believed to have anticancer and antihypertensive properties, and has been used to treat cluster headaches. Melatonin has also been detected in a large number of plant species, including those used as foods. Concentrations detected have been very variable, the reasons for which are currently uncertain. In addition, the importance of dietary melatonin is unclear.

**Pharmacokinetics**

When an oral melatonin supplement 3 mg was given to 17 healthy subjects the AUC and maximum serum levels of melatonin were about 18-fold and 100-fold greater, respectively, than overnight endogenous melatonin secretion, although there was a wide variation between individuals. The oral bioavailability was approximately 15% after oral doses of 2 or 4 mg, possibly due to significant first-pass metabolism. The half-life has been found to be about 1 hour. The oral bioavailability was approximately 15% after oral doses of 2 or 4 mg, possibly due to significant first-pass metabolism. The half-life has been found to be about 1 hour. The oral bioavailability was approximately 15% after oral doses of 2 or 4 mg, possibly due to significant first-pass metabolism. The half-life has been found to be about 1 hour. The oral bioavailability was approximately 15% after oral doses of 2 or 4 mg, possibly due to significant first-pass metabolism. The half-life has been found to be about 1 hour.

Melatonin has been found to be extensively metabolised by the cytochrome P450 isoenzymes CYP1A1 and CYP1A2 in vitro. This has been supported by in vivo studies, see fluvoxamine, page 288 and caffeine, page 286. In vitro, melatonin had no inhibitory effect on CYP3A4, CYP2D6, CYP2C9 and CYP2C19 and a modest inhibitory effect on CYP1A2.

**Interactions overview**

Fluvoxamine markedly increases melatonin levels and increases its effects (drowsiness). Similarly, combined oral contraceptives modestly increase melatonin levels, and other oestrogens are predicted to interact similarly. Other drugs that inhibit CYP1A2 are predicted to similarly interact with melatonin. These include some quinolone antibacterials such as ciprofloxacin, the oral psoralens and, to a lesser extent, cimetidine. Caffeine also modestly increases melatonin levels. Increased cognitive impairment or similar has been seen when melatonin was used with zolpidem, imipramine and thioridazine, and might be expected with any CNS depressant drug. Alcohol is expected to decrease the efficacy of melatonin on sleep. Tobacco smoking reduces melatonin levels, and carbamazepine might be expected to have the same effect, but melatonin had no effect on carbamazepine levels. A few cases of increased or decreased effects of warfarin have been noted, but the relevance of this is uncertain. Melatonin slightly increased mean 24-hour blood pressure when given to patients taking nifedipine.

Melatonin + Alcohol

Alcohol may reduce the effects of melatonin on sleep.

Evidence, mechanism, importance and management

The manufacturer briefly notes that alcohol reduces the effectiveness of melatonin on sleep, and that it should not be taken with melatonin. Given the known effects of alcohol on sleep, if melatonin is being taken to improve quality of sleep then this is sensible advice.


Melatonin + Benzodiazepines and related drugs

The CNS effects of benzodiazepines and related hypnotics, such as zolpidem, may be additive to those of melatonin.

Clinical evidence

In a well-controlled single-dose study in 16 healthy subjects aged 55 years and older, giving prolonged-release melatonin 2 mg with zolpidem 10 mg at bedtime enhanced the impairment of cognitive function seen with zolpidem alone at 1 hour and 4 hours post-dose, but not the next morning. Melatonin alone had no effect on cognitive function. No pharmacokinetic interaction was found.

Mechanism

The activity of melatonin is thought to involve similar interactions at the GABA (γ-aminobutyric acid) receptors in the brain to benzodiazepines. It may therefore enhance the activity of benzodiazepines and related drugs. Flumazenil is a benzodiazepine antagonist and may have blocked the direct effect of the melatonin, thus causing the GABA activity to fall below the level required to have the effects seen in the experimental study.

Importance and management

The evidence available suggests that melatonin might enhance the sedative properties of benzodiazepines and related hypnotics such as zolpidem. Although in the study of zolpidem, the enhanced effect was not apparent the morning after dosing, it would be wise to be aware that increased drowsiness is a possibility if melatonin is also given, especially with longer-acting hypnotics.


Melatonin + Caffeine

Caffeine may moderately raise melatonin levels.

Clinical evidence

A crossover study in 12 healthy subjects found that a single 200-mg dose of caffeine (equivalent to one large or two small cups of coffee), taken 1 hour before and 1 and 3 hours after a single 6-mg oral dose of melatonin, increased the average AUC and maximum levels of melatonin by 120% and 137%, respectively, although the half-life of melatonin was not significantly affected. The interaction was less pronounced in smokers (6 subjects) than in non-smokers (6 subjects). In a similar study, taking caffeine 12 or 24 hours before melatonin did not affect the melatonin levels, although 2 subjects had raised melatonin levels when caffeine was taken 12 hours, but not 24 hours, before melatonin.

In 12 healthy subjects given a single 200-mg dose of caffeine, taken in the evening, endogenous, nocturnal melatonin levels were found to be increased, and the AUC of melatonin was increased by 32%.

Experimental evidence

No relevant data found.

Mechanism

Caffeine is thought to reduce the metabolism of melatonin by competing for metabolism by the cytochrome P450 isoenzyme CYPIA2.

Importance and management

It appears that caffeine significantly increases the levels of single doses of supplementary melatonin; however, the long-term effects of caffeine and concurrent multiple dosing of melatonin do not appear to have been studied. Melatonin can cause drowsiness when taken on its own, so patients who take melatonin should be advised that this effect may be increased (because of increased melatonin levels) if they also take caffeine, including that from beverages. This increased drowsiness may oppose the stimulating effect of caffeine, or alternatively caffeine may diminish the sedating effects of melatonin; the outcome of concurrent use does not appear to have been studied.


Melatonin + Carbamazepine

Carbamazepine levels are not affected by melatonin. Melatonin levels are predicted to be reduced by carbamazepine.

Evidence, mechanism, importance and management

In a placebo-controlled study on the effects of melatonin on antioxidant enzymes, melatonin 6 to 9 mg/kg daily for 14 days was given to children with epilepsy taking carbamazepine monotherapy. Serum levels of carbamazepine and its metabolite carbamazepine-10,11-epoxide were not affected by melatonin. Melatonin appeared


Melatonin + Buspirone

For a case report describing anxiety, with episodes of over-sleeping and memory deficits in a woman taking fluoxetine and buspirone with St John’s wort, ginkgo and melatonin, see St John’s wort + Buspirone, page 365.
to antagonise the accumulation of reactive oxygen species caused by carbamazepine.\
One manufacturer predicts that carbamazepine may increase the metabolism of melatonin (by induction of the cytochrome P450 isoenzyme CYP1A2), decreasing its levels (magnitude unknown). However, note that carbamazepine is not a particularly potent inducer of this isoenzyme.

It appears that carbamazepine dose adjustments are unlikely to be needed when melatonin is taken. Nevertheless, be aware that melatonin may be less effective.


Melatonin + Cimetidine

Cimetidine slightly increases melatonin levels.

Evidence, mechanism, importance and management

In a single-dose controlled study, cimetidine 800 mg increased the plasma concentration of melatonin after a 2-mg oral dose (magnitude not stated), whereas the plasma levels of cimetidine were unaffected. The pharmacodynamics of melatonin were not affected.\(^1\)\(^2\) Cimetidine is a weak inhibitor of the cytochrome P450 isoenzyme CYP1A2 by which melatonin is principally metabolised. The pharmacokinetic interaction would be unlikely to be clinically relevant. Nevertheless, the manufacturer recommends caution.\(^1\) Be aware of a possible interaction if there is an increase in adverse effects of melatonin (e.g. irritability, dry mouth, dizziness) on concurrent use. Other H\(_2\)-receptor antagonists are unlikely to interact as they are not known to have enzyme-inhibiting effects.


Melatonin + Food

No interactions found, but caffeine-containing beverages might increase melatonin levels, see Melatonin + Caffeine, page 286.

Melatonin + Herbal medicines

No interactions found, but note that caffeine from caffeine-containing herbs might increase melatonin levels, see Melatonin + Caffeine, page 286.

Melatonin + Imipramine

The concurrent use of imipramine and melatonin may lead to increased CNS effects.

Evidence, mechanism, importance and management

In a single-dose controlled study, there was no pharmacokinetic interaction between melatonin 2 mg and imipramine 75 mg. However, there was a possible pharmacodynamic interaction, with increased feelings of tranquillity and difficulty in performing tasks (undefined) when compared with imipramine alone.\(^1\)\(^2\) Patients should be warned of a possible additive effect.


Melatonin + Nifedipine

Melatonin may have some modest effects on blood pressure in patients taking nifedipine.

Clinical evidence

Forty-seven subjects with mild-to-moderate hypertension well controlled on nifedipine GITS 30 mg or 60 mg daily for the past 3 months were given melatonin immediate-release capsules 5 mg each morning for 4 weeks. At the end of the 4 weeks, there was a modest increase in mean 24-hour systolic and diastolic blood pressure of 6.5 mmHg and 4.9 mmHg, respectively, and an increase in heart rate of 3.9 bpm. However, there was no difference in single-time point ‘clinical’ blood pressure (116/85 mmHg versus 138/87 mmHg) and heart rate. While taking melatonin, there was a greater incidence of drowsiness, during the morning, and weakness. One subject dropped out of the study complaining of marked weakness.\(^1\)

Experimental evidence

No relevant data found.

Mechanism

Unknown. Melatonin has been reported to possess blood pressure-lowering properties when used alone and was expected to have additive effects to nifedipine.\(^1\)

Importance and management

Chronic use of melatonin appears to modestly impair the hypotensive effects of nifedipine and increase the blood pressure and heart rates of patients. However, this was only detected on 24-hour blood pressure monitoring, and was not apparent with single measurements of blood pressure at the clinic. Therefore, the clinical relevance of the effect is probably minor. The mechanism is not clear and, until more is known, bear in mind the possibility of an interaction if patients taking calcium-channel blockers have increased blood pressure while also taking melatonin supplements.


Melatonin + Oestrogens

Oestrogens, from combined hormonal contraceptives, appear to increase melatonin levels.

Clinical evidence

In a clinical study, the AUC and maximum level of a single 6-mg dose of melatonin was about 4 times higher in subjects taking a combined oral contraceptive than those not. Melatonin alone did not significantly affect alertness in this study, and no reduced alertness was noted in those taking oral contraceptives. Oral contraceptives being used by the women included ethinylestradiol with cyproterone acetate, desogestrel, drospirenone or gestodene. There did not appear to be any obvious differences between these contraceptives, but the numbers of women taking each were too small for this to be conclusive.\(^1\)
Experimental evidence
No relevant data found.

Mechanism
Ethinylenestradiol is a moderate inhibitor of the cytochrome P450 isoenzyme CYP1A2, by which melatonin is principally metabolised.

Importance and management
Women taking combined oral contraceptives may have higher levels of melatonin after using supplements. Although in the study cited this did not decrease alertness, it would be prudent to be aware of the possibility of increased drowsiness. One UK manufacturer extends this caution to hormone replacement therapy, although it is unclear whether the oestrogens used for HRT will have the same effect as ethinylenestradiol.


### Melatonin + Propofol

Melatonin slightly reduces the dose of propofol needed for the induction of anaesthesia.

**Clinical evidence**
A study in 45 adult patients found that the induction dose of intravenous propofol, as measured by bispectral index and loss of eyelash reflex, was 15% lower in patients who had received a single 3–5 mg oral dose of melatonin 100 minutes preoperatively, compared with patients who had received placebo. The time to recover from the anaesthetic was not affected by premedication with melatonin. Propofol was given in an incremental dose fashion in this study so that any difference could be assessed, but is usually given as a bolus dose.

**Experimental evidence**
No relevant data found.

**Mechanism**
Melatonin appears to have anxiolytic and sedative effects, which might reduce the required induction dose of propofol.

**Importance and management**
This study was conducted to assess the clinical value of using melatonin premedication, which is not an established use. The reduction in required dose of propofol was small and, on the basis of these data, it is unlikely that any untoward effects would be seen in the situation where a patient who had recently taken a melatonin supplement was anaesthetised with propofol.


### Melatonin + Psoralens

Psoralens are predicted to increase melatonin levels.

**Evidence, mechanism, importance and management**
The manufacturer briefly notes that methoxsalen and 5-methoxypsoralen inhibit the metabolism of melatonin and increase its levels (magnitude not stated). Note that 5-methoxypsoralen has been shown to increase *endogenous* melatonin levels (one study is cited as an example).

Psoralens are potent inhibitors of the cytochrome P450 isoenzyme CYP1A2 by which melatonin is principally metabolised, and the manufacturer recommends caution on concurrent use, which seems prudent as the adverse effects of melatonin may be increased. Any interaction would apply only to these psoralens used orally, and not when they are used topically. Be aware of a possible interaction if there is an increase in adverse effects of melatonin (e.g. irritability, dry mouth, dizziness) in patients also taking psoralens.


### Melatonin + SSRI s

Fluvoxamine raises melatonin levels. Limited evidence suggests that citalopram does not affect melatonin levels, and no effect would be expected with other SSRIs.

**Clinical evidence**

**a) Citalopram**
In a study in 7 healthy subjects, citalopram 40 mg had no effect on the levels of *endogenous* melatonin or its excretion from the body. Extrapolating these findings to an instance where melatonin is given exogenously as a supplement is difficult, but they suggest that citalopram does not inhibit melatonin metabolism.

**b) Fluvoxamine**
In a study in 5 healthy subjects, a single 50-mg dose of fluvoxamine taken 3 hours before a single 5 mg oral dose of melatonin markedly increased the AUC and maximum levels of melatonin by 17-fold and 12-fold respectively, although the half-life of melatonin was not significantly affected. The interaction was more pronounced in the one subject who was of a CYP2D6-poor metaboliser phenotype (meaning that this patient was lacking or deficient in this isoenzyme). All subjects reported marked drowsiness after melatonin intake, and this was even more pronounced after fluvoxamine was also given.

Similarly, fluvoxamine 75 mg raised the levels of oral melatonin 5 mg by about 20-fold and significantly improved the sleep behaviour of a 51-year-old insomniac.

In another study in 7 healthy subjects, fluvoxamine 50 mg doubled the maximum serum levels and excretion of *endogenous* melatonin and increased the AUC by about threefold.

**Experimental evidence**
No relevant data found.

**Mechanism**
Fluvoxamine is a potent inhibitor of the cytochrome P450 isoenzyme CYP1A2, which is the principal isoenzyme involved in the metabolism of melatonin.

**Importance and management**
Fluvoxamine markedly increases the bioavailability of endogenous melatonin and melatonin given as a supplement. However, the long-term effects of fluvoxamine and concurrent multiple dosing of melatonin do not appear to have been studied. Be aware that excessive drowsiness and related adverse effects may occur on concurrent use. Note that one UK manufacturer advises that the combination should be avoided. Other inhibitors of CYP1A2 may interact similarly (although to a lesser extent as fluvoxamine is currently the most potent CYP1A2 inhibitor in clinical use). The UK manufacturer specifically mentions the quinolones. Of the quinolones in common usage, ciprofloxacin is an example of a clinically important CYP1A2 inhibitor.

Note that this effect would not be expected with other SSRIs, as these are not CYP1A2 inhibitors, and the study looking at the effects
of citalopram on endogenous melatonin somewhat supports this suggestion.

For a case report describing anxiety, with episodes of oversleeping and memory deficits in a woman taking fluoxetine and buspirone with St John’s wort, ginkgo and melatonin, see St John’s wort + Buspirone, page 365.


### Melatonin + Thioridazine

The concurrent use of thioridazine and melatonin may lead to increased CNS effects.

**Evidence, mechanism, importance and management**

In a single-dose controlled study, there was no pharmacokinetic interaction between thioridazine 50 mg and melatonin 2 mg. However, there was a possible pharmacodynamic interaction, with increased feelings of ‘muzzy-headedness’ when compared with thioridazine alone.1,2 Patients should be warned of a possible additive effect.


### Melatonin + Tobacco

Tobacco smoking reduces melatonin levels.

**Evidence, mechanism, importance and management**

In a study in 8 tobacco smokers, the AUC of a single 25-mg dose of melatonin was almost threefold higher when the melatonin was taken after 7 days of smoking abstinence than when taken while smoking.1

Constituents of tobacco smoke are minor to moderate inducers of the cytochrome P450 isoenzyme CYP1A2, by which melatonin is principally metabolised. The finding of this study suggests that melatonin might not be as effective in smokers. Be aware of this possibility, and consider trying an increased melatonin dose if it is not effective in a smoker.


### Melatonin + Warfarin

Case reports suggest that melatonin may raise or lower the INR in response to warfarin.

**Clinical evidence**

Six case reports of a suspected interaction between melatonin and warfarin have been documented by the WHO Uppsala Monitoring Centre, and have been briefly summarised in a review of melatonin.1 In three cases, the prothrombin time was increased, with bleeding events in two (nosebleed, eye haemorrhage, bruising) occurring up to 8 days after starting to take melatonin. The other three cases reports describe a prothrombin time decrease.1

**Experimental evidence**

See Mechanism, below.

**Mechanism**

Unknown. Melatonin did not inhibit the cytochrome P450 isoenzyme CYP2C9 *in vitro*,2 and would not therefore be expected to alter warfarin metabolism via this mechanism.

**Importance and management**

These appear to be the only reports in the literature of a possible interaction between melatonin and warfarin. They are difficult to interpret, since they include both increased and decreased warfarin effects, and it is possible that they are just idiosyncratic cases. Because of these cases, a study designed to exclude a pharmacokinetic/pharmacodynamic interaction would be useful. Until more is known, bear these cases in mind in the event of an unexpected change in coagulation status in patients also taking melatonin supplements.

Melilot

Melilotus officinalis (L.) Pall. (Fabaceae)

Synonym(s) and related species
King’s clover, Sweet clover, Ribbed melilot, Yellow melilot, Yellow sweet clover.

Melilotus arvensis Wallr.

Pharmacopoeias
Melilot (BP 2009, Ph Eur 6.4).

Constituents
The main active constituents of melilot are natural coumarin and its derivatives, melilotin, melilotol, dihydrocoumarin, umbelliferone and scopoletin, which are formed on drying from the glycoside melilotoside. If spoilage and subsequent fermentation occur, some coumarin derivatives can be transformed into the potent anticoagulant dicoumarol (bishydroxycoumarin). Other constituents present are flavonoids (including quercetin) and a number of saponins.

Use and indications
Melilot is used mainly to treat inflammation, oedema and capillary fragility.

Pharmacokinetics
No relevant pharmacokinetic data for melilot found. For information on the pharmacokinetics of individual flavonoids present in melilot, see under flavonoids, page 186.

Interactions overview
Two cases describe bleeding and a raised INR in patients taking a tea and using a topical cream containing melilot, but an interaction has not been established. For information on the interactions of individual flavonoids present in melilot, see under flavonoids, page 186.
Melilot + Food

No interactions found.

Melilot + Herbal medicines

No interactions found.

Melilot + Warfarin and related drugs

The INR of a patient taking acenocoumarol was increased after she used a melilot-containing topical cream, and a woman who had been drinking large quantities of a herbal tea containing melilot developed a prolonged prothrombin time.

Clinical evidence

A 66 year old taking acenocoumarol, levothyroxine and prazepam had an increase in her INR after massaging a proprietary topical cream (Cyclo 3) containing melilot and butcher’s broom on her legs three times daily. On the first occasion her INR rose from about 2 to 5.8 after 7 days of use, and on a later occasion it rose to 4.6 after 10 days of use.1 In another report, a woman with unexplained abnormal menstrual bleeding was found to have a prothrombin time of 53 seconds, and laboratory tests showed that her blood clotting factors were abnormally low. When given parenteral vitamin K her prothrombin time rapidly returned to normal (suggesting that she was taking a vitamin K antagonist of some kind). She strongly denied taking any anticoagulant drugs, but it was eventually discovered that she had been drinking large quantities of a herbal tea containing among other ingredients tonka beans, melilot and sweet woodruff, all of which might contain natural coumarins.2

Experimental evidence

No relevant data found.

Mechanism

Unknown. Melilot is known to contain natural coumarins, although these do not possess the minimum structural requirements required for anticoagulant activity. See Natural coumarins + Warfarin and related drugs, page 301. It seems that fermentation and spoilage of the melilot by mould are necessary for anticoagulant effects to occur.

Importance and management

Evidence appears to be limited to these isolated cases, which are not established. Many factors influence anticoagulant control, and therefore it is not possible to reliably ascribe a change in INR specifically to a drug interaction in a single case report without other supporting evidence. It may be better to advise patients to discuss the use of any herbal products that they wish to try, and to increase monitoring if this is thought advisable. Cases of uneventful use should be reported, as they are as useful as possible cases of adverse effects.

Milk thistle

*Silybum marianum* (L.) Gaertn. (Asteraceae)

**Synonym(s) and related species**
Lady’s thistle, Marian thistle, Mediterranean milk thistle, St Mary’s thistle.

*Carduus marianus, Mariana lactea* Hill.

**Pharmacopoeias**

**Constituents**
The mature fruit (seed) of milk thistle contains *silymarin*, which is a mixture of the flavonolignans silibinin (silybin), silicristin (silychristin), silidianin (silydianin), isosilibinin and others. It may be standardised to contain not less than 1.5% (*Ph Eur 6.4*), or not less than 2% (*USP 32*) of *silymarin*, expressed as silibinin (dried drug). Standardised extracts, containing high levels of *silymarin*, are often used. Milk thistle fruit also contains various other flavonoids, page 186, such as quercetin, and various sterols.

Note that milk thistle leaves do not contain *silymarin*, and contain the flavonoids, page 186, apigenin and luteolin, and the triterpene, beta-sitosterol.

**Use and indications**
Milk thistle is reported to have hepatoprotective properties and is mainly used for liver diseases and jaundice. Traditionally milk thistle was used by nursing mothers for stimulating milk production, as a bitter tonic, demulcent, as an antidepressant and for dyspeptic complaints. Both the fruit and leaves are used as a herbal medicine, but currently the fruit is the main target of investigation because it contains the pharmacologically active silymarin component. Standardised extracts of silymarin are also commonly used. A water-soluble salt of the individual flavonolignan silibinin is used intravenously for preventing hepatotoxicity after poisoning with the death cap mushroom *Amanita phalloides*.

**Pharmacokinetics**
Several studies have investigated the effect of milk thistle extracts on cytochrome P450 isoenzymes and drug transporters. In some *in vitro* studies1–7 milk thistle or its flavonolignan constituents inhibited CYP3A4. Although some clinical pharmacokinetic studies suggest that milk thistle may raise the levels of some CYP3A4 substrates, several other studies have found no effect on CYP3A4 substrates, see midazolam, page 294, and protease inhibitors, page 295. These conflicting findings may be due, in part, to the dose of milk thistle used. Indeed, some *in vitro* studies found that the effect of milk thistle on CYP3A4 was sometimes minor or seen only at higher concentrations.2,4–7

Other *in vitro* studies have found that milk thistle or its flavonolignan constituents were minor or moderate inhibitors of CYP2C9,3,4,7 CYP2C194 and CYP2C8,5 but the clinical relevance of this seems likely to be limited. It has been suggested that, while *in vitro* levels of silymarin may cause moderate inhibition of several cytochrome P450 isoenzymes, *in vivo* levels do not reach inhibitory concentrations and so milk thistle would not be expected to exhibit inhibition at pharmacologically effective concentrations.5,6,8

Other *in vivo* and *in vitro* studies, have found that milk thistle is unlikely to affect the metabolism of drugs that are substrates of CYP1A24,5,9 (see caffeine, page 294), CYP2E15,9 (see chlorzoxazone, page 294) or CYP2D6.4,5,9

*In vitro* studies have suggested that silymarin may affect P-glycoprotein substrate binding. However, there is no evidence from human pharmacokinetic studies that milk thistle has a clinically important effect on the levels of drugs that are P-glycoprotein substrates, see digoxin, page 294.

Silymarin has also been found to inhibit several UDP-glucuronosyltransferases *in vitro*.1,3 These enzymes are involved in phase II glucuronidation, a process that affects the metabolism of several drugs (such as irinotecan, paracetamol and zidovudine), and reduced activity could theoretically lead to raised drug levels, although the clinical implications of this are, as yet, unclear.

Silibinin dihemisuccinate has also been found to inhibit several of the organic anion-transporting polypeptide (OATP) family *in vitro*, which could theoretically lead to reduced cellular uptake, and therefore raised levels, of drugs that are OATP substrates.10 For information on the pharmacokinetics of individual flavonoids present in milk thistle, see under flavonoids, page 186.

**Interactions overview**
*In vitro* studies have suggested that milk thistle may interact with a number of drugs by inhibiting their metabolism by various cytochrome P450 isoenzymes or affecting their transport by P-glycoprotein. However, *in vivo* studies suggest that any such inhibition is unlikely to be clinically relevant. Milk thistle may raise the levels of a hepatotoxic metabolite of pyrazinamide. For information on the interactions of individual flavonoids present in milk thistle, see under flavonoids, page 186.


Milk thistle does not appear to affect the pharmacokinetics of midazolam.

Evidence, mechanism, importance and management
In a study 19 healthy subjects were given milk thistle 300 mg three times daily for 14 days (standardised to silymarin 80%) with a single 8-mg oral dose of midazolam on the last day. There was no change in the pharmacokinetics of midazolam, and milk thistle had no effect on the duration of midazolam-induced sleep.1 Similarly, in another study in 12 healthy subjects, milk thistle 175 mg (standardised to silymarins 80%) given twice daily for 28 days had no significant effects on the metabolism of a single 8-mg dose of midazolam.2 These studies show that the pharmacokinetics of midazolam are not affected by the concurrent use of milk thistle. As midazolam is used as a probe substrate for the cytochrome P450 3A4 isoenzyme, this study also suggests that milk thistle is unlikely to affect the metabolism of other drugs that are substrates of this isoenzyme. This suggestion is supported by the finding that the metabolism of other known CYP3A4 substrates is not affected by isoenzyme. This suggestion is supported by the finding that the metabolism of other known CYP3A4 substrates is not affected by milk thistle.

See also Milk thistle + Protease inhibitors, page 295.

Milk thistle does not appear to affect the pharmacokinetics of caffeine.

Evidence, mechanism, importance and management
In a study in 12 healthy subjects, milk thistle 175 mg (standardised to silymarins 80%) given twice daily for 28 days had no significant effects on the metabolism of a single 100-mg dose of caffeine.1 This study suggests that the pharmacokinetics of caffeine are not affected by the concurrent use of milk thistle. As caffeine is used as a probe substrate for the cytochrome P450 1A2 isoenzyme, this study also suggests that milk thistle is unlikely to affect the metabolism of other drugs that are substrates of this isoenzyme. This suggestion is supported by the finding that the metabolism of other known CYP1A2 substrates is not affected by milk thistle.

See Mechanism, below.

Milk thistle does not appear to affect the pharmacokinetics of chlorzoxazone.

Evidence, mechanism, importance and management
In a study in 12 healthy subjects, milk thistle 175 mg (standardised to silymarins 80%) given twice daily for 28 days had no significant effects on the metabolism of a single 250-mg dose of chlorzoxazone.1 This study suggests that the pharmacokinetics of chlorzoxazone are not affected by the concurrent use of milk thistle. As chlorzoxazone is used as a probe substrate for the cytochrome P450 2E1 isoenzyme, this study also suggests that milk thistle is unlikely to affect the metabolism of other drugs that are substrates of this isoenzyme.


Milk thistle does not appear to affect the pharmacokinetics of digoxin.

Clinical evidence
In a study, 16 healthy subjects were given a single 400-microgram dose of digoxin before and on the last day of a 14-day course of a milk thistle extract (standardised to 80% silymarin) 300 mg three times daily. No statistically significant changes in the pharmacokinetics of digoxin were found, although there was a trend towards a minor 10% reduction in the AUC of digoxin.1

Experimental evidence
See Mechanism, below.

Mechanism
In vitro,2 P-glycoprotein ATPase activity, which is the energy source for the active transport of drugs across cell membranes by P-glycoprotein, was inhibited by silymarin, suggesting a direct interaction with P-glycoprotein substrate binding. Digoxin is a P-glycoprotein substrate, and it had been suggested that milk thistle would therefore affect digoxin pharmacokinetics.

Importance and management
Direct evidence appears to be limited to one clinical study, which showed that milk thistle does not cause clinically relevant changes in digoxin pharmacokinetics. It would therefore appear that the dose of digoxin would not need to be adjusted in patients also given milk thistle. As digoxin is used as a probe substrate for P-glycoprotein this study also suggests that milk thistle is unlikely to affect the metabolism of other drugs that are substrates of this transporter protein.


Milk thistle does not appear to affect the pharmacokinetics of irinotecan.


No interactions found.

Milk thistle + Food
No interactions found.

Milk thistle + Herbal medicines
No interactions found.

Milk thistle + Irinotecan
Milk thistle does not appear to affect the pharmacokinetics of irinotecan.
Evidence, mechanism, importance and management
A pharmacokinetic study was undertaken in 6 patients who were being treated with intravenous irinotecan 125 mg/m² once weekly for 4 weeks, followed by a 2-week rest period. Four days before the second dose of irinotecan, a 14-day course of 200 mg milk thistle seed extract (containing silymarin 80%) three times daily was started. The pharmacokinetics of irinotecan and its metabolites did not differ from week 1 (no milk thistle), week 2 (4 days of milk thistle) to week 3 (12 days of milk thistle).1 No dosage alterations would therefore be expected to be needed if milk thistle (standardised to silymarin 80%) is given with irinotecan.


Milk thistle + Metronidazole

Silymarin (the active constituent of milk thistle) modestly reduces metronidazole levels.

Evidence, mechanism, importance and management
Silymarin (Silybon) 140 mg daily was given to 12 healthy subjects for 9 days, with metronidazole 400 mg three times daily on days 7 to 10. Silymarin reduced the AUC of metronidazole and hydroxy-metronidazole (a major active metabolite) by 28% and the maximum serum levels by 29% and 20%, respectively.

The authors suggest that silymarin causes these pharmacokinetic changes by inducing P-glycoprotein and the cytochrome P450 isoenzyme CYP3A4, which are involved in the transport and metabolism of metronidazole.1 But evidence from other interactions suggests that a clinically relevant effect on P-glycoprotein and CYP3A4 is unlikely. See Milk thistle + Benzodiazepines, page 294, and Milk thistle + Protease inhibitors, below. The general importance of this interaction is unclear, but a 28% reduction in the AUC of metronidazole would not be expected to be of much clinical significance.


Milk thistle + Nifedipine

Milk thistle does not appear to alter the haemodynamic effects of nifedipine.

Clinical evidence
In a study in 16 healthy subjects, silymarin 280 mg was given 10 hours, and 90 minutes, before a 10-mg dose of nifedipine. Silymarin increased the AUC of nifedipine by about 10% and reduced its maximum serum levels by about 30%, but these effects varied greatly between subjects. Silymarin did not alter the haemodynamic effects of nifedipine.2 One capsule of the product used in this study (Legalon) contains 173 to 186 mg dry extract from milk thistle fruits, equivalent to silymarin 140 mg calculated as silibinin.

Experimental evidence
Two in vitro studies found that silymarin flavonolignans moderately inhibited the oxidation of nifedipine1 and denironitifedipine,3 a closely related nifedipine derivative, as marker substrates for CYP3A4 activity.

Mechanism
The maximum serum levels of nifedipine were reduced slightly but the AUC was not, suggesting a delay in nifedipine absorption. This could be due to irregular gastric emptying in the presence of silymarin, or an interaction with drug transporters such as OATP. While the experimental evidence suggests an inhibitory effect on CYP3A4, this has not been found to be clinically significant (see under benzodiazepines, page 294).

Importance and management
Evidence appears to be limited to these three studies. The clinical study found that milk thistle may modestly delay the absorption of nifedipine with an apparent high intra-individual variability. However, as there was no considerable change in the pharmacokinetics or pharmacodynamic effects of nifedipine (blood pressure and heart rate), this is probably not clinically relevant. It would appear that the modest effects found in vitro do not translate in to a clinically relevant effect.


Milk thistle + Protease inhibitors

Although some studies have found that milk thistle slightly lowers indinavir levels, it appears that this is a time-dependent effect rather than a drug interaction, since it also occurred in a control group in one study. The balance of evidence suggests that no important pharmacokinetic interaction occurs.

In vitro studies suggest that silibinin does not affect the pharmacokinetics of ritonavir.

Clinical evidence
Milk thistle 175 mg three times daily (Thisilym; Nature’s Way; standardised for 80% silymarin content) for 3 weeks caused a 9% reduction in the AUC of indinavir and a 25% reduction in its trough plasma level after four doses of indinavir 800 mg every 8 hours, but only the value for the trough level reached statistical significance.4 The authors suggested that the effect on the trough level could represent a time-dependent effect of indinavir pharmacokinetics, as the plasma levels without milk thistle were found to be similarly lowered after a washout phase.1 In another similar study, in 10 healthy subjects, milk thistle standardised for silymarin 160 mg (General Nutrition Corp.) three times daily for 13 days and then with indinavir 800 mg every 8 hours for 4 doses did not cause any statistically significant changes in the indinavir pharmacokinetics (6% reduction in AUC and 32% reduction in minimum level).5 In yet another similar study, in 8 healthy subjects, milk thistle capsules (standardised for silymarins 456 mg; Kare and Hope Ltd.) three times daily for 28 days, had no effect on the pharmacokinetics of indinavir 800 mg every 8 hours for four doses when compared with 6 subjects in a control group not receiving milk thistle extract. Both the control and indinavir group had a lower indinavir AUC after the second and third time of administration compared with the first, and this decline was greater in the control group.6 A meta-analysis of these 3 studies showed no effect of milk thistle on indinavir levels.3

Experimental evidence
In a series of experiments on human cell lines and rat hepatocytes, silibinin, the major active constituent of the silymarin flavonolignan mixture found in milk thistle, was found not to affect the pharmacokinetics of ritonavir.4

Mechanism
Based on animal data, milk thistle might be expected to increase indinavir levels by inhibiting its metabolism;1 or transport by P-glycoprotein.2 However, silibinin was found not to have a significant effect on P-glycoprotein or cytochrome P450 isoenzyme.
CYP3A4 activity when given with ritonavir. The clinical studies found only a minor reduction in indinavir levels, which was attributed to a time-dependent effect.

Importance and management

The currently available data suggest that milk thistle extract does not have an effect on the pharmacokinetics of indinavir (and possibly ritonavir), although this is not totally conclusive. The reduction in indinavir levels appears to be just a time-dependent effect rather than an effect of the milk thistle, but further study is needed with longer exposure to indinavir than just four doses. Evidence appears to be too slim to prohibit concurrent use, but until more is known it may be prudent to give milk thistle cautiously to patients taking indinavir.


**Milk thistle + Pyrazinamide**

The interaction between milk thistle and pyrazinamide is based on experimental evidence only.

**Clinical evidence**

No interactions found.

**Experimental evidence**

In a study in rats, pyrazinamide and its active metabolite, pyrazinoic acid, were given after either long-term or short-term exposure to siliibinin, the major active constituent of the silymarin flavonolignan mixture found in milk thistle. The first group of rats received intravenous siliibinin 100 mg/kg for 3 days before an intravenous dose of pyrazinamide 50 mg/kg or pyrazinoic acid 30 mg/kg concurrently on the fourth day. The second group received intravenous siliibinin 30 mg/kg 10 minutes before an intravenous dose of pyrazinamide 50 mg/kg or pyrazinoic acid 30 mg/kg. Siliibinin had no effect on the pharmacokinetics of pyrazinamide, but increased the AUC of pyrazinoic acid by 3.5-fold in the long-term exposure group and 4-fold in the short-term exposure group. The maximum serum levels of pyrazinoic acid were increased by about 60% and 70% respectively.

**Mechanism**

It is thought that siliibinin may inhibit xanthine oxidase, which is involved in pyrazinamide and pyrazinoic acid hydroxylation. Siliibinin may also decrease the hepatobiliary excretion of pyrazinoic acid.

**Importance and management**

Evidence appears to be limited to experimental data. While no pharmacokinetic changes were seen when milk thistle was given with pyrazinamide, milk thistle appears to increase the levels of the active metabolite, pyrazinoic acid. So far, this has only been shown in rats so determining the clinical relevance of this interaction is difficult. Nevertheless, because of the dose-related hepatotoxic adverse effects associated with pyrazinamide, it would be prudent to bear this possible interaction in mind in case of an unexpected response to treatment.


**Milk thistle + Rosuvastatin**

Siliibinin, a major constituent of milk thistle, does not appear to affect the pharmacokinetics of single-dose rosuvastatin.

**Clinical evidence**

In a randomised study, 8 healthy subjects were given silymarin (Legalon) 140 mg three times daily for 7 days did not significantly affect the pharmacokinetics of a single 150-mg dose of ranitidine. No particular precautions would appear to be necessary if patients take milk thistle and ranitidine together.


**Milk thistle + Ranitidine**

Siliibinin, a major constituent of milk thistle, does not appear to affect the pharmacokinetics of single-dose ranitidine.

**Evidence, mechanism, importance and management**

In a study in 12 healthy subjects, silymarin capsules (Sylvar) 140 mg three times daily for 7 days did not significantly affect the pharmacokinetics of single-dose ranitidine. No particular precautions would appear to be necessary if patients take milk thistle and ranitidine together.

Natural coumarins

Natural coumarins are widespread in herbal medicines and vegetables. There is a misconception that if a plant contains natural coumarins it will have anticoagulant properties, but very specific structural requirements are necessary for this – namely there must be a non-polar carbon substituent at the 3-position of 4-hydroxycoumarin. Moreover, at present, there are no established interactions between warfarin and herbal medicines that have been attributed to the natural coumarin content of the herb. Even in the classic case of haemorrhagic death of livestock that led to the discovery of dicoumarol, it was the action of the mould on the natural coumarin in the sweet clover (melilot, page 290) that led to the production of the anticoagulant, so consumption of a spoiled product would seem to be necessary for this specific interaction to occur. This suggests that the occurrence of natural coumarins in dietary supplements or herbal medicines should not trigger immediate concern as regards interactions with anticoagulants.

The information in this family monograph relates to the individual natural coumarins, and the reader is referred back to the herb (and vice versa) where appropriate. Note that, to avoid confusion with the synthetic anticoagulant coumarins, such as warfarin, the term ‘natural coumarins’ has been used to describe those that are of plant origin.

Types, sources and related compounds

Natural coumarins are aromatic lactones and phenylpropa-

noids based on 1,2-benzopyrone (coumarin). They usually

occur naturally bound to one or more sugar molecules as

glycosides rather than as the free aglycone. There are three

major classes of natural coumarins based on the structure of

the aglycone:

- Hydroxycoumarins: such as umbelliferone, aesculetin (esculetin), herniarin, scopoletin and osthol occur in many plants. Some are further derivatised or prenylated, and coumarins in this class are generally harmless. However, some of the substituted 4-hydroxyderivatives have potent anticoagulant properties. The classic example that occurs naturally is dicoumarol (bishydroxycoumarin), which can occur in mouldy forage crops when coumarin itself is transformed into dicoumarol by microbial action. This compound has been used therapeutically as an anticoagulant, and is also the causative agent of haemor-
hagic sweet clover disease (caused by ingestion of mouldy Melilotus officinalis) in cattle. See melilot, page 290. Note that the coumarin anticoagulants used clinically (acenocoumarol, phenprocoumon, warfarin) are all synthetic 4-hydroxycoumarins.

- Furanocoumarins (furocoumarins): have an additional furan ring attached, and this group can be further divided into linear compounds including psoralen, 5-methoxy-

psoralen (bergapten) and methoxsalen (xanthotoxin or 8-methoxypsoralen), and angular compounds such as angelicin (isopsoralen) and pimpinellin (5,6-dimethox-
yangelicin). Some furanocoumarins may have additional prenyl substitution (e.g. bergamottin, alloimperatorin) and some occur as dimers, for example the paradisins, which are found in grapefruit juice. Others are more complex, such as the highly toxic aflatoxin B1, which is produced by microbial contamination of food crops with Aspergillus niger. Furanocoumarins are commonly found in food items. They are mainly present in the two large plant families Rutaceae and Apiaceae, but occur in others. The Rutaceae family includes grapefruit, page 235, and prickly ash, page 326. The Apiaceae family includes aniseed, page 33, asafoetida, page 39, celery, page 123, Chinese angelica, page 129, carrot, parsnip, and many other herbs and spices. Note that the furanocoumarins are thought to be principally responsible for the main drug interactions of grapefruit juice, page 235.

- Pyranocoumarins: have a fused pyran ring attached, and can be divided into linear or angular.1

There is also a minor class of coumarins, the 4-phenylcoumarins such as mammeisin, which can also be classified as neoflavonoids.

Isocoumarins (1,4-benzopyrones) are more commonly known as chromones; the most important of these is khellin, a compound found in Ammi visnaga which was the basis for the development of the anti-allergic drug cromoglicate and the class III antiarrhythmic amiodarone. Apart from khellin, which is a smooth muscle relaxant with bronchodilatory and vasodilatory effects, little is known of their activities or toxicities.

Coumarin (1,2-benzopyrone) itself was initially isolated from the tonka bean, and is found in other herbs such as melilot, page 290, and in many vegetables, fruits, and spices. It has a sweet scent, recognisable as the odour of new-mown hay.

Use and indications

Natural coumarins have a wide spectrum of activity ranging from the beneficial to the highly toxic. Generally, the furanocoumarins are more biologically active than the other types. Unlike the flavonoids, page 186, and isoflavones, page 258, it is not possible to generalise about their group actions, and this also applies to their toxic and drug interaction effects. In addition, coumarin supplements are not marketed or taken in the way that isoflavone or flavonoid (bioflavonoid) products are. Therefore only the most notable
actions of the natural coumarin derivatives will be outlined here.

(a) Anticoagulant activity

The anticoagulant activity possessed by some natural coumarins is not universal and should not be attributed to all of them. In order to have anticoagulant activity, there must be a nonpolar carbon substituent at the 3-position of 4-hydroxycoumarin.2,3 The best known natural example is dicoumarol (bishydroxycoumarin), which is formed by the action of moulds on coumarin in sweet clover, see melilot, page 290. It functions as a vitamin K antagonist and has been used therapeutically as an anticoagulant, but the anticoagulant coumarins commonly used clinically are all fully synthetic compounds (e.g. acenocoumarol, phenprocoumon, warfarin).

(b) Photosensitisation and PUVA

Many furanocoumarins cause phototoxicity by sensitising the skin to UV light. This can cause hyperpigmentation of the skin, and extracts of plants containing these compounds have been used in traditional medicine to treat vitiligo. This property is also responsible for the allergenicity that is characteristic of some plants in the Apiaceae and Rutaceae families, particularly giant hogweed (Heracleum mantegazzianum) and rue (Ruta graveolens).

Photochemotherapy or PUVA (psoralen plus UVA) is a recognised conventional treatment for certain skin disorders such as cutaneous T-cell lymphoma, chronic graft-versus-host disease and psoriasis. UVA irradiation can help these conditions and the effect is enhanced by oral treatment with psoralen and other furanocoumarin derivatives (including methoxsalen), which cause photosensitisation. The doses of psoralens used for these treatments (up to 1.2 mg/kg) are very unlikely to be achieved with herbs containing methoxsalen, and therefore interactions involving the oral psoralens are probably unlikely to occur with herbs containing these substances.

(c) Antioxidant effects

The phenolic structure of the natural coumarins means that most will have free radical scavenging and therefore antioxidant effects.4,5 Many natural coumarins are potent metal-chelating agents and powerful chain-breaking antioxidants.4 However, these properties have, as yet, only been studied experimentally.

(d) Anti-inflammatory activity

There is experimental evidence from in vitro and animal studies to suggest that various natural coumarins have anti-inflammatory activity. Esculetin, herniarin, scopoletin and scoponolin have been used in Spanish traditional medicine against inflammation,4 and scopoletin has been shown to be pharmacologically active,6 as has esculin, extracted from the stem bark of Fraxinus ornus.7

Coumarin itself is an anti-inflammatory agent. This has been demonstrated in animal studies where a coumarin-containing extract of Melilotus officinalis was found to have similar anti-inflammatory action to that of hydrocortisone.8 Coumarin has also been used in the treatment of lymphoedema.9

(e) Chemopreventive and cytotoxic effects

Experimental work has suggested that natural coumarins may prevent carcinogenesis, or have cytotoxic effects. Further work is required to confirm whether this is a potential therapeutic use of these substances.10,11

(f) Miscellaneous effects

Insecticidal, antidiabetic, antifungal and larvicidal, activities have all been described for natural coumarin derivatives. It has also been suggested that some of the natural coumarins may be reverse transcriptase, protease or integrase inhibitors, and may warrant further investigation for possible use in the management of HIV infection.12

Coumarin has also been used in perfumery, and as a flavour. However, it has been banned as a food additive in numerous countries, or limits have been set on its use, because it is moderately toxic to the liver and kidneys.

Pharmacokinetics

(a) Coumarin

Coumarin is completely absorbed after oral administration, and in humans subject to extensive first-pass hepatic metabolism, by the cytochrome P450 isoenzyme CYP2A6, to 7-hydroxycoumarin (umbelliferone), which is less toxic and also occurs widely in plants. However, in some people, coumarin is much more hepatotoxic than in others, and this is thought to be due to reduced metabolism of coumarin by CYP2A6, and greater dependence on metabolism by CYP3A4 to form the more toxic 3-hydroxycoumarin and intermediates.9,13

(b) Bergamottin and related products

Bergamottin is metabolised in vivo to 6’,7’-dihydroxybergamottin. In a study in 12 healthy subjects given single 6-mg or 12-mg doses of bergamottin, 8 subjects had measurable levels of bergamottin and 3 had detectable levels of 6’,7’-dihydroxybergamottin.14

(c) Effect on cytochrome P450 isoenzymes

Furanocoumarins are now recognised as major cytochrome P450 enzyme inhibitors. They are mainly responsible for the complex drug interaction profile of grapefruit products, as shown by a study using furanocoumarin-free grapefruit juice (see Natural coumarins + Felodipine, page 300), although other constituents contribute to the effect (see pharmacokinetics, under grapefruit, page 235). The furanocoumarins, bergamottin, bergapten, dihydroxybergamottin, geranlycoumarin and paradisin A, have been shown to have inhibitory effects on CYP3A4, CYP2D6 and CYP2C9 in vitro,15 and paradisin B has also been found to be a potent inhibitor of human CYP3A4.16 Methoxsalen and 5-methoxypsoralen (bergapten) are inhibitors of CYP1A2. In clinical pharmacokinetic drug interaction studies oral methoxsalen 1.2 mg/kg has been shown to markedly inhibit CYP1A2 using caffeine and theophylline as probe substrates.17,18 In another study, oral methoxsalen slightly increased ciclosporin levels.19 It is very unlikely that these doses of methoxsalen would be achieved using herbs containing psoralens including methoxsalen. However, the findings are presented for information.
(d) **Effect on P-glycoprotein**

*In vitro* data\(^{20}\) suggest that some of the furanocoumarins present in grapefruit juice, such as 6',7'-dihydroxybergamottin and 6',7'-epoxybergamottin, are able to inhibit P-glycoprotein activity, raising the possibility of interactions between drugs that are substrates of this transporter protein and furanocoumarins, see talinolol, page 301. However, another *in vitro* study has suggested that 6',7'-dihydroxybergamottin does not affect the function of P-glycoprotein.\(^ {21}\)

**Interactions overview**

None of the individual natural coumarins is used as a dietary supplement or herbal medicine on its own, but rather as the herbs that contain it. Any interactions of the herbal medicines containing natural coumarins are covered under the specific herb.

Coumarin itself and the psoralens such as methoxsalen are used in conventional medicine. The doses used for these treatments are very unlikely to be achieved by taking herbal medicines containing these substances, and therefore the interactions of drugs such as methoxsalen are not covered here.

The drug interaction potential of some of the furanocoumarins is well established, and has been identified by investigating the mechanism of the interactions involving grapefruit juice, page 235.

This monograph does not contain any of the interactions of the synthetic 4-hydroxycoumarin derivatives that are used as anticoagulants, such as warfarin, because these are not natural coumarins.

Natural coumarins + Ciclosporin

A citrus soft drink containing furanocoumarins increased the bioavailability of ciclosporin in an isolated case.

Clinical evidence
A lung transplant recipient taking ciclosporin had large variations in his ciclosporin levels, which ranged between 319 and 761 nanograms/mL, on discharge from hospital, which were unexplained by changes in his current medication or ciclosporin dose changes. It was found that, on the days when the ciclosporin levels were increased, the patient had drunk a citrus soft drink (Sun Drop) at breakfast. These fluctuations resolved when he stopped drinking the soft drink. However, a subsequent pharmacokinetic study in healthy subjects were tested, and found to contain the furanocoumarin bergamottin 0.078 and 6.5 mg/L, respectively, (note that grapefruit, which is known to interact with ciclosporin, contains about 5.6 mg/L). The authors note that factors such as genetic and disease-related variability in ciclosporin metabolism, as well as changes in the bergamottin content between batches of the drinks, may account for the contrasting results.

Experimental evidence
No relevant data found.

Mechanism
The authors of the report of an interaction with a citrus soda drink confirmed with the manufacturers that it contained furanocoumarins, such as bergamottin, which are thought to inhibit the cytochrome P450 isoform CYP3A4, which is the major isoform involved in the metabolism of ciclosporin.

Importance and management
The isolated report of an interaction between a citrus soft drink (containing furanocoumarins) and ciclosporin was not confirmed by a subsequent single-dose pharmacokinetic study in healthy subjects and therefore its significance is unclear. The case does highlight the influence that diet can have on ciclosporin levels and it should be borne in mind should any unexpected changes in ciclosporin levels occur.


Natural coumarins + Felodipine

Clinical studies demonstrate that bergamottin and other furanocoumarins may cause a clinically relevant increase in the levels of felodipine, but that other active constituents also present in grapefruit juice may interact by additive or synergistic mechanisms.

Clinical evidence
In a single-dose study in healthy subjects, the maximum plasma level of felodipine was increased by 33%, 35% and 40% by bergamottin, 2, 6 and 12 mg, respectively, and by 86% by grapefruit juice 250 mL containing about 1.7 mg of bergamottin. The AUC0–12 of felodipine was increased by 37% by bergamottin 12 mg, and by 48% by the grapefruit juice. There was, however, a wide variation between individuals. In another study, one-quarter strength lime juice, which contained the same concentration of bergamottin as grapefruit juice, had much less effect on the AUC of felodipine than grapefruit juice (20% increase versus 80% increase).

A further study in 18 healthy subjects found that furanocoumarin-free grapefruit juice had no consistent effect on the pharmacokinetics of felodipine relative to orange juice, with AUC changes ranging between a decrease of 46% and an increase of 44%. The median increase in the AUC of felodipine was 104% (range 6% to 230%) in those subjects given grapefruit juice with furanocoumarins present. Furanocoumarins identified in the grapefruit juice included 6′-dihydroxybergamottin, bergamottin, bergamottin-like substances and spiro-esters.

A study in 12 healthy subjects, which investigated the effects of grapefruit juice and fractions of grapefruit juice on the pharmacokinetics of felodipine, found that 6′-dihydroxybergamottin was not one of the main active ingredients. The fraction with the greatest 6′ dihydroxybergamottin concentration caused a smaller increase in the AUC of felodipine than the fraction with one-third the amount of 6′-dihydroxybergamottin.

Experimental evidence
No relevant data found.

Mechanism
The furanocoumarins inhibit the activity of the cytochrome P450 isoform CYP3A4, which is the major isoform involved in the metabolism of felodipine.

Importance and management
These studies demonstrate that bergamottin and other furanocoumarins may cause a clinically relevant increase in the levels of felodipine, but that other active constituents are also present in grapefruit juice, which may interact by additive or synergistic mechanisms.

Note that the interaction of grapefruit juice and felodipine, page 237 is established and the manufacturers of felodipine say that it should not be taken with grapefruit juice.

Because any interaction between furanocoumarins and felodipine appears to depend upon interactions between the individual furanocoumarin constituents present, it is difficult to predict what the effects of individual herbs may be. The effects of the individual furanocoumarins appear to be modest.


Natural coumarins + Food

No interactions found.

Natural coumarins + Herbal medicines

No interactions found.
Natural coumarins + Saquinavir

The interaction between natural coumarins and saquinavir is based on experimental evidence only.

Evidence, mechanism, importance and management
In an in vitro study in which human liver microsomes were incubated with **bergamottin** and with **6'-dihydroxybergamottin** (furanocoumarins), the metabolism of saquinavir by the cytochrome P450 isoenzyme CYP3A4 was inhibited by both compounds to a similar extent to ketoconazole, a known CYP3A4 inhibitor. The transport of saquinavir by P-glycoprotein was also, to an extent, inhibited by **6'-dihydroxybergamottin**.1

Note that grapefruit juice, of which these furanocoumarins are a principal constituent, is known to modestly increase saquinavir levels.

It is difficult to extrapolate these findings to the clinical situation, but, if the effect of these furanocoumarins is similar to that of grapefruit juice, any interaction with herbal medicines containing these constituents would be expected to be mild, and of limited clinical relevance.


Natural coumarins + Warfarin and related drugs

The interaction between natural coumarins and warfarin and related drugs is based on a prediction only.

Evidence, mechanism, importance and management
It has been suggested that herbal medicines containing naturally occurring coumarins might interact with warfarin and other anticoagulants by causing additive anticoagulant effects. On this basis, some authors have produced lists of plants that might increase the effect of warfarin solely because they contain natural coumarins.

It is known that, to have anticoagulant activity, a coumarin needs to be a 4-hydroxycoumarin with a nonpolar carbon substituent at the 3-position.2,3 Natural coumarins differ widely in their structures, as discussed under Types, sources and related compounds, page 297, and many do not meet this structural requirement. Moreover, even if anticoagulant activity for a natural coumarin was likely to be based on its structure, it would need to be determined whether it could occur in sufficiently high enough levels in a plant to be expected to be active.4 Also, it would need to be demonstrated that it is absorbed when given orally.4

There are no established interactions between warfarin and herbal medicines that have been shown to be due to the natural coumarin content of the herb. Even in the classic case of haemorrhagic death of livestock after eating mouldy hay that led to the discovery of dicoumarol, it was the action of the mould on the natural coumarin of the sweet clover (melilot, page 290) that led to the production of the anticoagulant, so consumption of a spoiled product would seem to be necessary for this interaction to occur.

On this basis, the occurrence of natural coumarins in herbal medicines should not cause immediate concern.4

Nettle

*Urtica dioica* L. (Urticaceae)

**Synonym(s) and related species**
Stinging nettle, *Urtica*.

Note that *Urtica urens* L. has been referred to as Dwarf nettle.

**Pharmacopoeias**
Nettle Leaf (*BP 2009, Ph Eur 6.4*); Stinging Nettle (*USP 32*).

**Constituents**
Nettle root contains sterols including beta-sitosterol, and lignans, such as pinoresinol, secoisolariciresinol, dehydroconiferyl alcohol and neo-olivil. The triterpenes, oleanolic acid and ursolic acid, and their derivatives, and a lectin mixture known as *Urtica dioica* agglutinin (UDA) are also present. Root extracts may be standardised to its content of beta-sitosterol, scopoletin and amino acids (*USP 32*).

The leaves contain flavonoids, mainly kaempferol, isorhamnetin and quercetin glycosides, and caffeic acid derivatives. Extracts may be standardised to caffeoylmalic acid and chlorogenic acid expressed as chlorogenic acid (*BP 2009, Ph Eur 6.4*). Note that histamine, formic acid, acetylcholine, acetic acid and 5-hydroxytryptamine, which form the ‘sting’ when the fresh leaf is touched, are denatured during drying and processing.

**Use and indications**
The root is used mainly to treat benign prostatic hyperplasia in men, and difficulties in passing urine. There is some pharmacological evidence to support this use, but clinical evidence is equivocal and further trials are required. Leaf extracts have been used for treating allergies. Whole nettle extracts have been shown to have anti-inflammatory activity and may improve symptoms of osteoarthritis.

**Pharmacokinetics**
No relevant pharmacokinetic data found. For information on the pharmacokinetics of individual flavonoids present in nettle, see under flavonoids, page 186.

**Interactions overview**
No interactions with nettle found. For information on the interactions of individual flavonoids present in nettle, see under flavonoids, page 186.
Oregon grape

*Mahonia aquifolium* (Pursh) Nutt. (Berberidaceae)

**Synonym(s) and related species**
Holly-leaved berberis, Mountain grape.

*Berberis aquifolium* (Pursh), *Mahonia aquifolium* Nutt.

**Constituents**
The root, rhizome and stem bark contain the isoquinoline alkaloids berberine, berbamine, columbamine, jatrorrhizine, oxyacanthine, oxyberberine and others.

**Use and indications**
Used for many conditions, particularly diarrhoea, gastritis and skin diseases such as psoriasis.

**Pharmacokinetics**
No relevant pharmacokinetic data found for Oregon grape, but see berberine, page 58, for details on this constituent of Oregon grape.

**Interactions overview**
No interactions with Oregon grape found. However, for the interactions of one of its constituents, berberine, see under berberine, page 58.
**Parsley**

*Petroselinum crispum* (Mill.) A.W.Hill (Apiaceae)

**Synonym(s) and related species**


**Constituents**

All parts of the parsley plant contain similar compounds but possibly in different proportions. The most important constituents are the natural coumarins (furanocoumarins including bergapten, psoralen, 8- and 5-methoxypsoralen), and the phthalides Z-ligustilide, cnidilide, neocnidilide and senkyunolide. Flavonoids present include apigenin, luteolin and others. There is also a small amount of volatile oil present, in all parts but especially the seed, containing apiole, myristicin, eugenol, osthole, carotol and others.

**Use and indications**

Parsley root and seed are traditionally used as a diuretic, carminative and for arthritis, rheumatism and other inflammatory disorders. The leaves are used as a culinary herb in foods.

**Pharmacokinetics**

A small study in *mice* reported that a parsley root extract reduced the liver content of cytochrome P450 when compared with control animals. The general significance of this is unclear and further study is needed.\(^1\) For information on the pharmacokinetics of individual flavonoids present in parsley, see under flavonoids, page 186.

**Interactions overview**

A single case reports lithium toxicity in a patient who took a herbal diuretic containing parsley, among many other ingredients. A patient taking warfarin had an increase in his INR when he stopped taking a regular supplement containing various vitamin K-containing plants, including parsley. For information on the interactions of individual flavonoids present in parsley, see under flavonoids, page 186.

Parsley + Aminophenazone

The interaction between parsley and aminophenazone is based on experimental evidence only.

Evidence, mechanism, importance and management
A study in mice found that parsley (extracted from the rhizome and mixed with water and olive oil in a ratio of 4:3:3), given 2 hours before a single 60-mg/kg dose of aminophenazone, potentiated and prolonged the analgesic action of aminophenazone.\(^1\)

The authors of this study suggest that it is possible that the parsley extract reduced the metabolism of aminophenazone by cytochrome P450, as the overall content of cytochrome P450 in the livers of the mice given parsley was significantly reduced, when compared with the control group.

The clinical relevance of this small preliminary study is unclear and further study is needed, particularly as parsley is commonly used in food.


Parsley + Food

No interactions found. Parsley is commonly used in food.

Parsley + Herbal medicines

No interactions found.

Parsley + Lithium

A woman developed lithium toxicity after taking a herbal diuretic.

Evidence, mechanism, importance and management
A 26-year-old woman who had been taking lithium 900 mg twice daily for 5 months, with hydroxyzine, lorazepam, propranolol, risperidone and sertraline, came to an emergency clinic complaining of nausea, diarrhoea, unsteady gait, tremor, nystagmus and drowsiness, (all symptoms of lithium toxicity). Her lithium level, which had previously been stable at 1.1 mmol/L, was found to be 4.43 mmol/L. For the past 2 to 3 weeks she had been taking a non-prescription herbal diuretic containing corn silk, *Equisetum hyemale*, juniper, ovate buchu, parsley and bearberry, all of which are believed to have diuretic actions. The other ingredients were bromelain, paprika, potassium and vitamin B\(_6\).\(^1\)

The most likely explanation is that the herbal diuretic caused the lithium toxicity. It is impossible to know which herb or combination of herbs actually caused the toxicity, or how, but this case once again emphasises that herbal remedies are not risk free just because they are natural. It also underscores the need for patients to avoid self-medication without first seeking informed advice and monitoring if they are taking potentially hazardous drugs like lithium.


Parsley + Pentobarbital

The interaction between parsley and pentobarbital is based on experimental evidence only.

Experimental evidence, mechanism, importance and management
A study in mice found that parsley (extracted from the rhizome and mixed with water and olive oil in a ratio of 4:3:3), given 2 hours before a single 40-mg/kg dose of pentobarbital significantly extended the sleeping time, when compared with a control group of animals who received pentobarbital alone. This effect was not seen when the same parsley extract was given 30 minutes before pentobarbital.\(^1\)

The authors suggest that it is possible that the parsley extract reduced the metabolism of pentobarbital by cytochrome P450, as the overall content of cytochrome P450 in the livers of the mice given parsley was significantly reduced compared with the control group.\(^1\)

The clinical relevance of this small preliminary study is unclear and further study is needed, particularly as parsley is commonly used in food.


Parsley + Paracetamol

The interaction between parsley and paracetamol (acetaminophen) is based on experimental evidence only.

Parsley + Warfarin and related drugs

A man had a rise in his INR after stopping taking a herbal nutritional supplement (*Nature’s Life Greens*), which contained a number of plants including parsley.

Clinical evidence
A 72-year-old man stabilised on warfarin was found to have an INR of 4.43 at a routine clinic visit, which was increased from 3.07 six weeks previously. The patient had stopped taking a herbal product *Nature’s Life Greens* that month because he did not have enough money to buy it. He had been taking it for the past 7 years as a
vitamin supplement because he had previously been instructed to limit his intake of green leafy vegetables. He was eventually restabilised on warfarin and the same nutritional product.

**Experimental evidence**
No relevant data found.

**Mechanism**
The product label listed 25 vegetables without stating the amounts or concentrations, but at least 5 of the listed ingredients are known to contain high levels of vitamin $K_1$ including parsley, green tea leaves, spinach, broccoli, and cabbage. It is therefore likely that the supplement contained sufficient vitamin to antagonise the effect of the warfarin so that when it was stopped warfarin requirements fell and, without an appropriate adjustment in dose, this resulted in an increased INR.

**Importance and management**
The interaction of vitamin $K_1$ from vegetables with warfarin is well established. However, the evidence suggests that, in patients with normal vitamin $K_1$ status, in general, clinically relevant changes in coagulation status require large continued changes in intake of vitamin $K_1$ from foods. It is unlikely that the parsley alone caused this effect, and there appear to be no other published cases of parsley reducing the efficacy of warfarin and related anticoagulants. Because of the many other factors influencing anticoagulant control, it is not possible to reliably ascribe a change in INR specifically to a drug interaction in a single case report without other supporting evidence. It may be better to advise patients to discuss the use of any herbal products that they wish to try, and to increase monitoring if this is thought advisable. Cases of uneventful use should be reported, as they are as useful as possible cases of adverse effects.

Nevertheless, some consider that increased INR monitoring is required in any patient wanting to stop or start any herbal medicine or nutritional supplement.

Synonym(s) and related species
Apricot vine, Maypop, Passion flower, Passion vine.

Note that Passiflora edulis Sims is the source of the edible passion fruit.

Pharmacopoeias
Passion Flower (BP 2009, Ph Eur 6.4); Passion Flower Dry Extract (BP 2009, Ph Eur 6.4).

Constituents
The major constituents of passiflora leaf and flower are C-glycosides of flavonoids based on apigenin and luteolin, to which it may be standardised. Other flavonoids present include chrysin (5,7-hydroxyflavone), quercetin and kaempferol. The indole alkaloids of the β-carboline type (e.g. harman, harmol and others) are minor constituents or may not even be detectable. Other minor constituents include a cyanogenic glycoside gynocardin, γ-benzopyrones maltol and ethylmaltol, a polyacetylene passicol and an essential oil.

Use and indications
Passiflora is used as a sedative, hypnotic and anxiolytic and has been reported to have antiepileptic and anti-inflammatory effects. Some clinical studies in patients appear to support the anxiolytic and sedative effects of passiflora, and animal data suggest that some of the flavonoid constituents, chrysin and apigenin, may be responsible for these effects.

Pharmacokinetics
No relevant pharmacokinetic data found. For information on the pharmacokinetics of individual flavonoids present in passiflora, see under flavonoids, page 186.

Interactions overview
Passiflora is used for its sedative effects; additive sedation is therefore a theoretical possibility with other drugs with sedative properties, whereas the effects of stimulant drugs may be reduced. For information on the interactions of individual flavonoids present in passiflora, see under flavonoids, page 186.
Passiflora + Amfetamines

The interaction between passiflora and amfetamines is based on experimental evidence only.

Evidence, mechanism, importance and management

A study in rats reported that a passiflora extract 250 mg/kg reduced the hyperactivity induced by subcutaneous amfetamine by 39%, when compared with a control group who received amfetamine alone. This effect was reduced by 83% when a Piper methysticum (kava) extract 100 mg/kg was also given.1

Although this was a high-dose study in animals, these results appear to be in line with the known sedative effects of passiflora. Bear in mind the possibility of antagonistic effects when passiflora is given with stimulants.


Passiflora + Anxiolytics and Hypnotics

The interaction between passiflora and phenobarbital is based on experimental evidence only.

Evidence, mechanism, importance and management

A study in rats found an additive sedative effect when a passiflora extract 250 mg/kg was given with phenobarbital. This was reported as a 53% increase in sleep duration. This effect was greater (92%) when Piper methysticum (kava) extract 100 mg/kg was also given.1

Although this was a high-dose study in animals, these results appear to be in line with the known sedative effects of passiflora. Bear in mind the possibility of additive sedative effects when passiflora is taken with other known sedative drugs.


Passiflora + Food

No interactions found.

Passiflora + Herbal medicines; Kava

The effects of passiflora extract and Piper methysticum (kava) extract were synergistic in one animal study, see Passiflora + Amfetamines, above, and Passiflora + Anxiolytics and Hypnotics, above.
**Pelargonium**

*Pelargonium sidoides* DC. and *Pelargonium reniforme* Curt. (Geraniaceae)

**Synonym(s) and related species**
Geranium, South African geranium.

**Pharmacopoeias**
Pelargonium Root (*BP 2009, Ph Eur 6.4*).

**Constituents**
The active constituents of pelargonium root are not conclusively known, although they are thought to be proanthocyanidin oligomers based on epigallo- and galloatechin. A unique series of O-galloyl-C-glucosylflavones, and novel ellagitannins with a (1)C(4) glucopyranose core (trivially named pelargoniins), have been found in *Pelargonium reniforme*. There are also oxygenated benzopyranones such as 6,7,8-trihydroxycoumarin and 8-hydroxy-5,6,7-trimethoxycoumarin, predominantly as sulphated derivatives. The **natural coumarins** found in *Pelargonium sidoides* do not possess the structure required for anticoagulant activity.

**Use and indications**
Pelargonium is used in the treatment of acute bronchitis, tonsillitis and upper respiratory tract infections.

**Pharmacokinetics**
No relevant pharmacokinetic data found.

**Interactions overview**
Pelargonium does not appear to affect either the pharmacokinetics or the anticoagulant response to warfarin.
Pelargonium + Food
No interactions found.

Pelargonium + Herbal medicines
No interactions found.

Pelargonium + Warfarin and related drugs
The interaction between pelargonium and warfarin is based on experimental evidence only.

Clinical evidence
No interactions found.

Experimental evidence
In a study in rats,1 pelargonium 500 mg/kg (alcoholic extract of *Pelargonium sidoides* root, *Umckaloabo*) given for 14 days had no significant effect on the pharmacokinetics of a single 0.2-mg/kg dose of warfarin given on day 15. In a separate study, the coagulation parameters (thromboplastin time, partial thromboplastin time and thrombin time) of rats remained unchanged when they were given pelargonium up to 500 mg/kg daily for 2 weeks. Furthermore, coagulation parameters in response to warfarin 0.05 mg/kg did not differ when pelargonium 500 mg/kg was also given.1

Mechanism
It has been suggested that the natural coumarins present in pelargonium may affect the anticoagulant response to warfarin.

Importance and management
Evidence is limited to this one study in rats, but the coumarin constituents of pelargonium have not been found to possess anticoagulant activity (consider also coumarins, page 297). The manufacturers of a UK product containing *Pelargonium sidoides* (*Kaloba*) state that it may theoretically have an effect on coagulation and therefore interact with anticoagulants.2 However, the natural coumarins found in *Pelargonium sidoides* do not possess the structure required for anticoagulant activity,1,3 and the evidence above supports the conclusion that an interaction is unlikely. Therefore, the dose of warfarin does not need adjusting if *Pelargonium sidoides* extracts are also given.

Pennyroyal

*Mentha pulegium* L. or *Hedeoma pulegioides* Pers. (Lamiaceae)

**Synonym(s) and related species**

*Hedeoma pulegioides* Pers.: American pennyroyal, Squaw mint.

*Melissa pulegioides* L.

**Constituents**
The main constituent of pennyroyal is the toxic volatile oil *pulegone*. Other components include menthone, isomenthone, piperitone, neomenthol, 2-octanol, camphene and limonene. Pennyroyal also contains polyphenolic acids and flavonoids.

**Use and indications**
Traditionally, pennyroyal has been used for dyspepsia, colds, skin eruptions and delayed menstruation, and it is reported to be an effective antibacterial and antifungal. It is also believed to be carminative, abortifacient and diaphoretic and it has been used as an insect repellent. The oil from pennyroyal (*pulegium oil*) is toxic to the liver, kidneys and nerves, and its use is generally considered unsafe.

**Pharmacokinetics**
The toxic effects of pennyroyal are thought to be principally due to metabolites of pulegone such as menthofuran. The metabolism to toxic metabolites and then inactivation has been shown to be subject to cytochrome P450 isoenzyme-mediated metabolism. Preclinical experiments are inconclusive as to which isoenzyme is principally involved. One study using human isoenzymes found that CYP2E1 is the main metaboliser of pulegone and its metabolite menthofuran, with CYP1A2, CYP2C19 and CYP2A6 also contributing to some extent. In contrast, a study in mice found that CYP1A2 is the major metabolising enzyme with CYP2E1 playing a lesser role.

Note that peppermint, page 320, contains only small amounts of pulegone.

**Interactions overview**
Pennyroyal may reduce the absorption of iron compounds.

Pennyroyal + Food
No interactions found.

Pennyroyal + Herbal medicines
No interactions found.

Pennyroyal + Iron compounds

Pennyroyal tea reduces iron absorption similarly to conventional tea.

Clinical evidence
In a study in 9 healthy subjects, a 275 mL serving of pennyroyal tea reduced the absorption of iron in a 50 g bread roll by about 70%. The tea was prepared by adding 300 mL of boiling water to 3 g of the herbal tea, then infusing for 10 minutes before straining and serving. In this study, the inhibitory effect of pennyroyal tea on iron absorption was modestly less than that of black tea (Assam tea, *Camellia sinensis* L.), which is known to inhibit iron absorption.\(^1\) Consider also, Tea + Iron compounds, page 386.

Experimental evidence
No relevant data found.

Mechanism
The polyphenols in pennyroyal may bind to iron in the intestine and influence its absorption.

Importance and management
The clinical impact of this interaction is not fully known, but be aware that some herbal teas such as pennyroyal reduce iron absorption similarly to conventional tea, which is not generally considered to be a suitable drink for babies and children, because of its effects on iron absorption. Furthermore, the safety of pennyroyal tea is not established, and there are concerns about the toxicity of its major volatile oil, pulegone.

Pepper
Piper nigrum L. (Piperaceae)

Synonym(s) and related species
Black and white pepper are derived from the fruits of the same species, *Piper nigrum* L. Black pepper is the unripe fruit which has been immersed in hot water and dried in the sun, during which the outer pericarp shrinks and darkens into a thin, wrinkled black layer. White pepper consists of the seed only, prepared by soaking the fully ripe berries, removing the pericarp and drying the naked seed.

Long pepper, *Piper longum* L., is a closely related species where the fruits are smaller and occur embedded in flower ‘spikes’, which form the seed heads.

Constituents
Alkaloids and alkylamides, the most important being piperine, with piperanine, piperetidine, piperlongumine, pipernonaline, lignans and minor constituents such as the pipereineis, have been isolated from the fruits of both species of pepper. Black pepper and long pepper also contain a volatile oil which may differ in constitution, but is composed of bisabolene, sabine and many others; white pepper contains very little. The pungent taste of pepper is principally due to piperine, which acts at the vanilloid receptor.

Use and indications
Pepper is one of the most popular spices in the world, and it is also used as a folk medicine in many countries. It is used as a stimulant and carminative, and is reputed to have anti-asthmatic, anti-oxidant, antimicrobial, hepatoprotective and hypcholesterolaemic effects. Most of the pharmacological effects reported to date are attributed to piperine. A black pepper extract containing 95% piperine is used in a number of herbal supplements.

Both long pepper and black pepper are important ingredients of many Ayurvedic herbal medicines where they are intended to enhance absorption of other medicines, for example in the traditional formula known as Trikatu, which contains *Piper nigrum*, *Piper longum* and *Zingiber officinale* (ginger, page 204) in a ratio of 1:1:1. There is increasing evidence to support this rationale as well as some of the other traditional uses, but it should be noted that the actions of Trikatu are not always the same as for pepper extracts or pure piperine, and Trikatu has been implicated in reducing rather than enhancing bioavailability of some drugs. Trikatu is also used as a digestive aid.

Pharmacokinetics
Piperine, given to mice has been shown to delay gastrointestinal transit in a dose-dependent manner. A non-significant trend towards a delay in gastrointestinal transit has also been seen in a study in 14 healthy fasting subjects given 1.5 g black pepper. This has been suggested as one way that piperine might increase the absorption of drugs, but its clinical significance is unclear, as pepper is normally ingested as part of a meal.

It has been known for some time that pepper, and piperine in particular, inhibit cytochrome P450, but it is only recently that activity against specific human isoenzymes has been tested. Piperine has been found to inhibit the cytochrome P450 isozyme CYP3A4, see verapamil, page 319, *in vitro*. The bisalkaloids, di-piperamides D and E have also been shown *in vitro* to inhibit this isozyme using nifedipine as a probe substrate. Similarly, methanolic and ethanolic extracts of *Piper nigrum* fruit inhibited CYP3A4 and CYP2D6 *in vitro* using erythromycin and dextromethorphan as probe substrates, although only the activity of the methanolic extract against CYP3A4 had a low IC50 value. These findings have also been published elsewhere. Piperine did not alter CYP2C, see verapamil, page 319.

*In vitro* studies suggest that piperine may inhibit P-glycoprotein, see digoxin, page 315, and ciclosporin, page 315.

It has also been suggested, using data from *in vitro* studies using guinea-pig cell cultures, and *in vivo* studies in rats that piperine may inhibit glucuronidation via the UDP-glucuronyltransferase enzyme system, which is involved in the metabolism of a number of drugs.

Interactions overview
Piperine, the active alkaloidal constituent of pepper, markedly increased the AUC of a single dose of nevirapine and of theophylline when given at a dose that might easily be achieved with piperine-containing supplements. Some caution might be appropriate with these combinations. The AUC of a single dose of propranolol was similarly increased, but this is less likely to be clinically important. Increases in phenytoin levels have also been demonstrated, and high-dose piperine also increased the AUC of rifampicin.

Various *animal* studies have shown increased levels of amoxicillin, barbiturates, NSAIDs and oxytetracycline with piperine, but little effect on cefadroxil. Piperine also had an antithyroid effect in *animals*. In other *animal* studies, Trikatu decreased diclofenac and isoniazid levels.

5. Atal CK, Dubey RK, Singh J. Biochemical basis of enhanced drug bioavailability of


Pepper + Barbiturates

The interaction between piperine and pentobarbital or phenobarbital is based on experimental evidence only.

Clinical evidence
No interactions found.

Experimental evidence
In a single-dose study in rats, pre-treatment with increasing doses of oral piperine from 10 to 50 mg/kg increased the pentobarbital sleeping time (up to twofold). Blood levels of pentobarbital were raised (by 38% at 45 minutes). Piperine at a lower dose of 5 mg/kg had no significant effect on the pentobarbital sleeping time. When the study was repeated after pre-treatment with phenobarbital 100 mg/kg for 7 days, the pentobarbital sleeping time was still prolonged after administration of piperine, but the length of sleeping time was much less than without barbiturate pretreatment.1

Mechanism
It was suggested that the increase in sleeping time induced by pentobarbital and phenobarbital was a result of inhibition of drug metabolising enzymes by piperine.1

Importance and management
This preclinical study provides some limited evidence that piperine, the main active constituent of pepper, might increase exposure to some antibacterials. While it is not possible to directly apply these data to the clinical situation, the level of increases seen would not be expected to be clinically important. It should be noted that the doses used are probably unlikely to be ingested from pepper itself, or from piperine-containing supplements.


Pepper + Beta-lactam antibiotics

The interaction or lack of interaction between piperine and amoxicillin, cefadroxil or cefotaxime is based on experimental evidence only.

Clinical evidence
No interactions found.

Experimental evidence
(a) Amoxicillin
In a single-dose study in rats, giving piperine 10 mg/kg or 20 mg/kg followed 30 minutes later by oral amoxicillin 100 mg/kg significantly increased the maximum amoxicillin plasma concentration by 90% and 124%, respectively, and the AUC by 66% and 107%, respectively. The time to reach maximum levels was reduced, and the half-life increased.1

(b) Cefadroxil
In a single-dose study in rats, giving piperine 10 mg/kg or 20 mg/kg followed 30 minutes later by oral cefadroxil 100 mg/kg had no effect on the pharmacokinetics of cefadroxil.1

(c) Cefotaxime
In a single-dose study in rats, giving piperine 10 mg/kg or 20 mg/kg followed 30 minutes later by intraperitoneal cefotaxime 10 mg/kg significantly increased the maximum cefotaxime plasma concentration by 51% and 71%, respectively, the AUC by 71% and 118%, respectively, and the half-life by 44% and 65%, respectively.1

Mechanism
Unknown. The increase in elimination half-life of amoxicillin and cefotaxime suggests a mechanism affecting drug clearance, and not a mechanism of increased gastrointestinal absorption. Although the authors suggest that an effect on drug metabolising enzymes cannot be ruled out, this is unlikely as none of these antibacterials undergoes significant metabolism by this route.

Importance and management
Unclear. It is difficult to apply this finding to human intake of pepper. The authors of one of the studies suggest that an inhibitory concentration of piperine could potentially be achieved in vivo after ingestion of soup containing 1 g black pepper.1 This amount could have the effect of increasing plasma digoxin levels. However, a clinical study is needed to assess whether ingestion of pepper or piperine-containing supplements actually alters ciclosporin levels. Until more is known, bear this finding in mind in the event of unexpected outcomes in patients taking ciclosporin and piperine-containing supplements.


Pepper + Ciclosporin

The interaction between piperine and ciclosporin is based on experimental evidence only.

Evidence, mechanism, importance and management
In an in vitro study, the transport of ciclosporin by P-glycoprotein was modestly inhibited in the presence of piperine, in a concentration-dependent manner.1 It is difficult to apply the findings of one experimental study to human intake of pepper and a clinical study is needed to assess whether ingestion of pepper or piperine-containing supplements actually alters ciclosporin levels. Until more is known, bear this finding in mind in the event of unexpected outcomes in patients taking ciclosporin and piperine-containing supplements.


Pepper + Digoxin

The interaction between piperine and digoxin is based on experimental evidence only.

Clinical evidence
No interactions found.

Experimental evidence and mechanism
In two in vitro studies, piperine inhibited the transport of digoxin by P-glycoprotein in a concentration-dependent manner.1 In one of these studies, piperine 50 micromol had an effect comparable to verapamil 100 micromol, a known P-glycoprotein inhibitor.2

Importance and management
Unclear. It is difficult to apply this finding to human intake of pepper. The authors of one of the studies suggest that an inhibitory concentration of piperine could potentially be achieved in vivo after ingestion of soup containing 1 g black pepper.1 This amount could have the effect of increasing plasma digoxin levels. However, a clinical study is needed to assess whether ingestion of pepper or piperine-containing supplements actually alters digoxin levels. Until more is known, bear this finding in mind in the event of unexpected outcomes in patients taking digoxin and piperine-containing supplements.


outcomes in patients taking digoxin and piperine-containing supplements.


Pepper + Food

No interactions found between pepper and food. Note that pepper is an ingredient in many foods. For mention that piperine increased the absorption of one green tea catechin, see Tea + Herbal medicines, page 386.

Pepper + Herbal medicines; Coenzyme Q10

For a study showing that piperine modestly increased the AUC of one dose of coenzyme Q10, see Coenzyme Q10 + Herbal medicines; Pepper, page 143.

Pepper + Herbal medicines; Rhodiola

For mention that piperine might reduce the antidepressant activity of rhodiola, see Rhodiola + Herbal medicines; Pepper, page 339.

Pepper + Herbal medicines; Turmeric

For mention that piperine increased the bioavailability of curcumin, see Turmeric + Herbal medicines; Pepper, page 391.

Pepper + Isoniazid

The interaction between piperine and isoniazid is based on experimental evidence only.

Clinical evidence

No interactions found.

Experimental evidence

In a single-dose study,1 rabbits were given isoniazid 14 mg/kg alone or with Trikatu 500 mg, which contained 10 mg of the active principle piperine. Trikatu was found to significantly reduce the maximum plasma levels and AUC of isoniazid by 35% and 39%, respectively. Trikatu is an Ayurvedic medicine which contains ginger, black pepper and long pepper in a 1:1:1 ratio.

Mechanism

It has been suggested that Trikatu delays gastric motility, causing retention of the isoniazid in the stomach. Since isoniazid is largely absorbed from the intestine, this might explain the decrease in plasma isoniazid concentrations.

Importance and management

If the findings of the study in animals were also replicated in humans, it would seem possible that ingestion of Trikatu with isoniazid may reduce isoniazid levels to below the required minimum inhibitory concentration. However, the widespread use of pepper in cooking and lack of reports of treatment failure with isoniazid provide some reassurance that an interaction is unlikely. Nevertheless, bear in mind the possibility of an interaction if there is any indication of a lack of isoniazid efficacy in a patient taking Trikatu.


Pepper + Nevirapine

Piperine markedly increases the AUC of a single dose of nevirapine in healthy subjects.

Clinical evidence

In a well-controlled study in 8 healthy subjects who received piperine 20 mg daily for 7 days, with a single 200-mg dose of nevirapine at the same time as the piperine on day 7, the maximum plasma concentration and AUC of nevirapine were markedly increased by about twofold and 2.6-fold, respectively. The estimated elimination half-life of nevirapine was not significantly altered. In this single-dose study there was no difference in the incidence of adverse events.1

Experimental evidence

No relevant data found.

Mechanism

Uncertain. It was suggested that piperine inhibited the cytochrome P450 isoenzyme CYP3A4, which is involved in the metabolism of nevirapine.1 However, since the elimination half-life of nevirapine was unaltered, it is unlikely that hepatic CYP3A4 was affected. Also, inhibition of gastrointestinal CYP3A4 would not explain the marked increase in nevirapine levels seen, because nevirapine is already over 90% bioavailable. On repeated dosing nevirapine induces its own metabolism (hence the need to increase the dose after 2 weeks), but in this study nevirapine was given as a single dose, so autoinduction would not have played any part. Subjects in this study were fasting, but food does not affect nevirapine pharmacokinetics.

Importance and management

This study appears to show that piperine markedly increases the exposure to single-dose nevirapine that might easily be achieved with piperine-containing supplements or even from consuming black pepper. However, at present there is no clear explanation for the finding, and further investigation is clearly warranted. Furthermore, how the findings relate to the use of multiple-dose nevirapine is unknown, especially as nevirapine induces its own metabolism. Although no adverse effects were seen in this small single-dose study in healthy subjects, nevirapine is known to cause a dose-related rash, and to be hepatotoxic. Until more is known, it would be prudent to be cautious with the use of piperine-containing supplements in patients taking nevirapine.


Pepper + NSAIDs

The interaction between piperine and diclofenac, indometacin and oxyphenbutazone is based on experimental evidence only.
Clinical evidence
No interactions found.

Experimental evidence

(1) Diclofenac
In a single-dose study in rabbits, the AUC of diclofenac 25 mg/kg was markedly reduced by about 80% when given with Trikatu 500 mg/kg. In this study, a suspension of a combination of diclofenac and Trikatu was used. The anti-inflammatory effects of diclofenac 25 mg/kg were also reduced by Trikatu 500 mg/kg when the combination was given to rats. Trikatu is an Ayurvedic medicine that contains ginger, black pepper and long pepper in a 1:1:1 ratio.

(2) Indometacin
In a single-dose study in rabbits, Trikatu 500 mg/kg modestly increased the maximum plasma levels of indometacin 7 mg/kg by 29%, without affecting the AUC or other pharmacokinetic parameters. Trikatu is an Ayurvedic medicine that contains ginger, black pepper and long pepper in a 1:1:1 ratio.

(3) Oxphenbutazone
A single-dose study in rats and mice found that giving piperine 10 mg/kg at the same time as oxphenbutazone 50 mg/kg modestly increased the AUC and maximum plasma levels of oxphenbutazone by 28% and 36%, respectively. The anti-inflammatory activity of oxphenbutazone in an animal model was increased.

Mechanism
Unknown. It was expected that Trikatu might increase the bioavailability of diclofenac and indometacin. It is possible that there was an incompatibility between diclofenac and a constituent of Trikatu in the single suspension that resulted in the decreased absorption. The increased bioavailability of oxphenbutazone with piperine was attributed to increased gastric absorption and inhibition of hepatic metabolism of oxphenbutazone.

Importance and management
The relevance of these disparate findings in animal studies to humans is unclear. Both ginger and pepper, which make up the Trikatu herbal formulation, are used extensively as food ingredients, and as there appear to be no reports of an interaction in humans, the clinical impact of the diclofenac and indometacin findings is probably minor. Similarly, while the modestly increased exposure to oxphenbutazone with piperine cannot be directly extrapolated to humans, increased levels of oxphenbutazone in this magnitude are unlikely to be of much clinical relevance.


Pepper + Phenytoin

Piperine appears to increase the maximum levels and AUC of phenytoin, although the effect may be less in patients receiving long-term phenytoin.

Clinical evidence
Piper or its active alkaloid piperine have been reported to enhance the oral bioavailability of phenytoin in three clinical studies. In one crossover study, 6 healthy subjects received a single 300-mg dose of phenytoin 30 minutes after a soup with or without black pepper, 1 g per 200 mL. The presence of pepper increased the AUC0–48h, AUC0–∞ and maximum plasma concentration of phenytoin by 49%, 133% and 13%, respectively, and the elimination half-life was increased from 22.48 to 49.71 hours. The pepper was added to the soup after preparation, and the piperine content of the soup was analysed and found to be 44 mg per 200 mL.

In another crossover study, 5 healthy subjects received a single 300-mg dose of phenytoin orally alone, or after pretreatment with piperine 20 mg daily for 7 days. Piperine increased the AUC and maximum plasma level of phenytoin by 50% and 27%, respectively. The rate of absorption of phenytoin was higher when given after piperine.

In a study in patients with epilepsy taking phenytoin 150 mg twice daily (10 patients) or 200 mg twice daily (10 patients), there was a minor increase in the AUC and maximum plasma concentrations of phenytoin when they were given a single 20-mg dose of piperine with their morning dose of phenytoin. The increase in AUC and maximum plasma concentrations of phenytoin were about 9% in the 150-mg phenytoin group, and 17% and 22%, respectively, in the 200-mg phenytoin group, and the elimination half-life was unchanged.

Experimental evidence
A study in mice found that the rate and extent of absorption of a single 10-mg oral dose of phenytoin were increased by the concurrent administration of oral piperine 0.6 mg, and the rate of elimination was reduced. Similarly oral piperine reduced the rate of elimination of phenytoin after an intravenous dose.

Mechanism
The increase in bioavailability of phenytoin caused by piperine may be the result of increased gastrointestinal absorption and decreased elimination. The effects of piperine in patients already taking phenytoin were far less marked than those in the healthy subjects given single doses of phenytoin. This might be because a single dose of piperine was given simultaneously with the phenytoin in the study in patients, rather than prior to the phenytoin. Alternatively, it could be that, after long-term use of phenytoin, piperine has little effect on the elimination of phenytoin.

Pepper + Oxytetracycline

The interaction between long pepper and oxytetracycline is based on experimental evidence only.

Clinical evidence
No interactions found.

Experimental evidence
In a study in hens, giving long pepper, equivalent to piperine 15 mg/kg, for 7 days, increased the AUC of a single 10-mg/kg oral dose of oxytetracycline given on day 8 by 27%. The elimination half-life was also increased by 29%. The rate of absorption of oxytetracycline was not affected by the pepper. Note that oxytetracycline levels were determined by microbial assay.

Mechanism
The authors of the study attributed the increased bioavailability to inhibition of microsomal metabolising enzymes by piperine in the long pepper.

Importance and management
This animal study provides some evidence that pepper might increase exposure to oxytetracycline. While it is not possible to directly apply these data to the clinical situation, the level of increases seen would not be expected to be clinically important.

**Pepper + Propranolol**

Piperine pretreatment increased the AUC of a single dose of propranolol by twofold in a study in healthy subjects.

**Clinical evidence**
In a study in 6 healthy subjects who received a single 40-mg dose of propranolol alone, and after taking piperine 20 mg daily for 7 days, the bioavailability of propranolol was significantly increased, with a twofold increase in both the AUC and maximum plasma concentration. However, the rate of elimination of propranolol was unaffected by piperine.

**Experimental evidence**
No relevant data found.

**Mechanism**
Piperine is known to increase the absorption of some substances from the gastrointestinal tract, but the exact mechanism is unclear.

**Importance and management**
The effect of piperine on propranolol in this study was fairly large, but increases of this level are not usually considered clinically relevant with drugs such as propranolol that have marked variation in levels between individuals, and are titrated to effect. Also, this dose of piperine is easily achievable by the consumption of black pepper in the diet, and there do not appear to be any reports of interactions. Moreover, because it involved only a single dose of propranolol, its findings might not be replicated in the clinical situation. Nevertheless, bear the possibility of an interaction in mind if a patient who starts taking piperine-containing supplements presents with an unexpectedly high propranolol levels.


**Pepper + Theophylline**

Piperine almost doubled the AUC of a single dose of theophylline.

**Clinical evidence**
In a study in 6 healthy subjects who received a single 150-mg dose of theophylline alone, and after taking piperine 20 mg daily for 7 days, the bioavailability of theophylline was significantly increased, with an increase in the AUC and maximum plasma concentration of 96% and 61%, respectively. Although not specifically stated, it is assumed that this study used a standard-release theophylline preparation.

**Experimental evidence**
No relevant data found.

**Mechanism**
Piperine is known to increase the absorption of some substances from the gastrointestinal tract, but the exact mechanism is unclear. However, theophylline already has high oral bioavailability. The finding of an increased elimination half-life suggests a mechanism of...
reduced metabolism or clearance. Piperine is known to inhibit some of the cytochrome P450 isoenzymes, although there do not appear to be any data specifically on CYP1A2, which is mainly involved in the metabolism of theophylline.

**Importance and management**

This study appears to show a marked increase in exposure to single-dose theophylline when given with a dose of piperine that might easily be achieved with piperine-containing supplements or even from consuming black pepper. How the findings relate to the use of multiple-dose theophylline or sustained-release formulations is also unknown. The widespread use of pepper in cooking and lack of reports of interactions with theophylline gives some reassurance that any interaction is unlikely to be clinically important. Nevertheless, until more is known, it would be prudent to be cautious with the use of piperine-containing supplements in patients taking theophylline.


---

**Pepper + Thyroid and Antithyroid drugs**

The interaction between piperine and thyroid drugs, such as levothyroxine, or antithyroid drugs, such as carbimazole, is based on experimental evidence only.

**Clinical evidence**

No interactions found.

**Experimental evidence**

Piperine was evaluated for its thyroid-hormone and glucose-regulatory effects in a study in mice. Oral piperine 2.5 mg/kg daily for 15 days lowered the serum levels of the thyroid hormones thyroxine (T4) and triiodothyronine (T3) as well as glucose concentrations. The decreases were comparable to that of the antithyroid drug, propylthiouracil. A 10-fold lower dose of piperine (0.25 mg/kg) had little effect.


---

**Pepper + Verapamil**

The interaction between piperine and verapamil is based on experimental evidence only.

**Evidence, mechanism, importance and management**

In an in vitro study, the CYP3A4-mediated metabolism of verapamil to norverapamil was inhibited by the presence of piperine, but the CYP2C-mediated metabolism of verapamil was not significantly altered by piperine. It is difficult to apply this finding to human intake of pepper. However, a clinical study is needed to assess whether ingestion of pepper or piperine-containing supplements actually alters verapamil levels. Until more is known, bear this finding in mind in the event of unexpected outcomes in patients taking verapamil and piperine-containing supplements.

Peppermint
*Mentha piperita* L. (Lamiaceae)

**Synonym(s) and related species**
Black mint (*Mentha piperita* Sole), White mint (*Mentha piperita* Sole).
Note that *Mentha × piperita* L. is a hybrid between *Mentha spicata* L. and *Mentha viridis* L.

**Pharmacopoeias**

** Constituents**
Essential oils, including *menthol*, menthone, methyl acetate as the main components, and cineole, isomenthone, neomenthol, piperitone, pulegone and limonene. A maximum level of pulegone is permitted, since this is toxic, see pennyroyal, page 311. Peppermint also contains flavonoids such as rutin, menthoside, luteolin and phenolic acids, and lactones.

**Use and indications**
Peppermint leaf and distilled oil have carminative, antispasmodic, diaphoretic and antiseptic properties, and are mainly used to relieve symptoms of indigestion. Peppermint is commonly used as a flavouring ingredient in food, cosmetics and medicines.

**Pharmacokinetics**
Peppermint tea was found to inhibit the activity of the cytochrome P450 subfamily CYP2E by up to 40% in a study in rats pretreated for 4 weeks with the tea. In an in vitro study, peppermint oil 20 to 500 micrograms/mL was found to moderately inhibit the activity of the cytochrome P450 isoenzymes CYP2C8, CYP2C9, CYP2C19 and CYP2D6. Both these studies found that there was no significant inhibition of CYP3A4 by peppermint, but see also calcium-channel blockers, page 321 and ciclosporin, page 321. Peppermint oil does not appear to have any clinically relevant effects on the cytochrome P450 iso-enzyme CYP1A2, see caffeine, page 321. For information on the pharmacokinetics of individual flavonoids present in peppermint, see under flavonoids, page 186.

**Interactions overview**
Food and antacids may compromise the enteric coating of some commercially available peppermint oil capsules. Peppermint oil appears to increase ciclosporin and felodipine levels and topically, in high doses, it may also enhance the skin penetration of some topical medicines. Peppermint tea contains digoxin-like constituents, but the clinical relevance of this is unclear. It may also impair iron absorption, and is unlikely to have a significant effect on the pharmacokinetics of caffeine.

For information on the interactions of individual flavonoids present in peppermint, see under flavonoids, page 186.

Peppermint oil does not appear to affect the metabolism of caffeine but might slightly delay its absorption.

**Clinical evidence**
In a crossover study in 11 healthy women, a single 100-mg capsule of menthol (a major constituent of peppermint oil) taken with decaffeinated coffee, to which 200 mg of caffeine had been added, had no effect on caffeine pharmacokinetics except for an increase in time to maximum caffeine concentration of about 30 minutes. The maximum decrease in heart rate seen with caffeine was less in the presence of menthol (about 4 bpm difference), but menthol had no effect on the small changes in blood pressure seen with caffeine.1

**Experimental evidence**
One *in vitro* study and one *animal* study found that peppermint oil or tea inhibited the cytochrome P450 isoenzyme CYP1A2.2

**Mechanism**
Experimental evidence2,3 suggests that peppermint might inhibit cytochrome P450 isoenzyme CYP1A2, for which caffeine is a probe substrate; the clinical evidence with menthol (a major constituent of peppermint oil) found that caffeine metabolism was not altered. Menthol slightly delayed the absorption of caffeine.

**Importance and management**
The clinical evidence suggests that peppermint oil might not have clinically relevant effects on the metabolism of substrates of CYP1A2, which would be in keeping with the fact that no such interactions appear to have been reported. Peppermint oil might slightly delay the absorption of caffeine, and presumably other drugs, but the delay of 30 minutes suggests that this is usually unlikely to be clinically relevant.

---

Peppermint oil capsules appear to increase the bioavailability of felodipine, and therefore may increase the incidence of adverse effects such as headache, light-headedness and flushing. In *in vitro* experiments suggest that peppermint oil is a moderate inhibitor of nifedipine metabolism.

**Clinical evidence**
In a randomised, single-dose study in 12 healthy subjects,1 peppermint oil capsules 600 mg increased the AUC and maximum serum levels of extended-release felodipine 10 mg by about 55% and 40%, respectively, without affecting the half-life. The AUC and maximum serum levels of dehydrofelodipine, the metabolite of felodipine, were increased by 37% and 25%, respectively.1

**Experimental evidence**
Peppermint oil and two of its components, menthol and menthyl acetate, were found to be moderate reversible inhibitors of nifedipine metabolism in *in vitro* investigations in human liver microsomes.1

**Mechanism**
It is thought that menthol may account for a substantial portion of the interactions reported for peppermint oil. Felodipine undergoes at least two sequential metabolic steps mediated by CYP3A4 and the authors of the clinical study suggest that peppermint may selectively inhibit the secondary step as opposed to the primary step but further study is needed.1 In contrast, two other *in vitro* studies found that peppermint did not affect CYP3A4, see Pharmacokinetics, page 320.

**Importance and management**
The clinical study suggests that peppermint oil may modestly increase the bioavailability of felodipine, which might therefore increase the incidence of adverse effects such as headache, light-headedness and flushing. Further study is needed, but, until then, it would be prudent to be aware of this possibility in any patient taking felodipine if they are given oral peppermint oil. It is possible that not all calcium-channel blockers will be affected, since some, unlike felodipine, are highly bioavailable. This interaction is similar to that of grapefruit juice, which affects felodipine and nisoldipine (low oral bioavailability), but only minimally affects amlopidine and diltiazem (high oral bioavailability).

The data would be expected to have relevance only to therapeutic doses of oils, and not to herbal teas, or small amounts in foods, where no clinically relevant interaction is anticipated.


---

Peppermint + Calcium-channel blockers

Peppermint oil capsules appear to increase the bioavailability of felodipine, and therefore may increase the incidence of adverse effects such as headache, light-headedness and flushing. In *in vitro* experiments suggest that peppermint oil is a moderate inhibitor of nifedipine metabolism.

**Clinical evidence**
In a randomised, single-dose study in 12 healthy subjects,1 peppermint oil capsules 600 mg increased the AUC and maximum serum levels of extended-release felodipine 10 mg by about 55% and 40%, respectively, without affecting the half-life. The AUC and maximum serum levels of dehydrofelodipine, the metabolite of felodipine, were increased by 37% and 25%, respectively.1

**Experimental evidence**
Peppermint oil and two of its components, menthol and menthyl acetate, were found to be moderate reversible inhibitors of nifedipine metabolism in *in vitro* investigations in human liver microsomes.1

**Mechanism**
It is thought that menthol may account for a substantial portion of the interactions reported for peppermint oil. Felodipine undergoes at least two sequential metabolic steps mediated by CYP3A4 and the authors of the clinical study suggest that peppermint may selectively inhibit the secondary step as opposed to the primary step but further study is needed.1 In contrast, two other *in vitro* studies found that peppermint did not affect CYP3A4, see Pharmacokinetics, page 320.

**Importance and management**
The clinical study suggests that peppermint oil may modestly increase the bioavailability of felodipine, which might therefore increase the incidence of adverse effects such as headache, light-headedness and flushing. Further study is needed, but, until then, it would be prudent to be aware of this possibility in any patient taking felodipine if they are given oral peppermint oil. It is possible that not all calcium-channel blockers will be affected, since some, unlike felodipine, are highly bioavailable. This interaction is similar to that of grapefruit juice, which affects felodipine and nisoldipine (low oral bioavailability), but only minimally affects amlopidine and diltiazem (high oral bioavailability).

The data would be expected to have relevance only to therapeutic doses of oils, and not to herbal teas, or small amounts in foods, where no clinically relevant interaction is anticipated.

mode of action. They say that inhibition of the cytochrome P450 subfamily CYP3A may have a role, and enhanced gastrointestinal permeability may also be a factor.

**Importance and management**
Although clinical data are lacking, the experimental study demonstrates that peppermint oil significantly enhances the oral bioavailability of ciclosporin in rats. Further study is needed to see if a similar effect occurs in humans. Until then, it may be prudent to be aware of the possibility that peppermint oil might increase ciclosporin levels. If patients taking ciclosporin are given peppermint oil it may be prudent to monitor ciclosporin levels within a few weeks of starting concurrent use, if this is not already planned.

The data would have relevance only to therapeutic doses of oils, and not to herbal teas, or small amounts in foods, which would not be expected to interact to a clinically relevant extent.

---

**Peppermint + Digitalis glycosides**

Many herbal medicines contain cardiac glycosides, which could in theory have additive effects with digoxin or digitoxin, or interfere with their assays. However, there appear to be few such interactions reported.

**Evidence, mechanism, importance and management**

In an *in vitro* study, 46 commercially packaged herb teas and 78 teas prepared from herbs were assayed for digoxin-like factors by their cross-reactivity with digoxin antibody, and these values were used to give approximate equivalent daily doses of digoxin. Peppermint was found to contain greater than 30 micrograms of digoxin equivalents per cup and was suggested that this would provide a therapeutic daily dose of digoxin if 5 cups of peppermint tea a day were drunk.1,2 However, note that some common teas sampled in this study (e.g. English Breakfast, Earl Grey) contained over 20 micrograms of digoxin equivalents per cup. Given that these teas are commonly consumed in the UK and an interaction with digoxin has not been reported, the interpretation of the findings of this study is unclear.

Theoretical interactions with herbal medicines are not always translated into practice. On the basis of this one study, no special precautions would be expected to be necessary in patients taking digoxin who drink peppermint tea.

---

**Peppermint + Food**

Food may compromise the enteric coating of some commercially available peppermint oil capsules.

**Evidence, mechanism, importance and management**

The manufacturers of some enteric-coated peppermint oil preparations advise that they should not be taken immediately after food.1,2 This is presumably because presence of food in the stomach will delay gastric emptying and might cause premature dissolution of the enteric coating and release of the peppermint oil before it reaches the intestine. This may result in adverse effects, such as indigestion.

---

**Peppermint + Herbal medicines**

No interactions found.

**Peppermint + Iron compounds**

Peppermint tea appears to reduce iron absorption similarly to conventional tea.

**Clinical evidence**

In a study in 9 healthy subjects a 275-mL serving of peppermint tea reduced the absorption of iron from a 50-g bread roll by about 85%. The tea was prepared by adding 300 mL of boiling water to 3 g of the herb tea, then infusing for 10 minutes before straining and serving. In this study, the inhibitory effect of peppermint tea on iron absorption was equivalent to that of black tea (Assam tea, *Camellia sinensis* L.), which is known to inhibit iron absorption, see Tea + Iron compounds, page 386.1

**Mechanism**
The polyphenols in peppermint tea may bind to iron in the gastrointestinal tract and reduce its absorption.

**Importance and management**
The clinical impact of this interaction between peppermint tea and iron is not fully known, but be aware that some herbal teas such as peppermint reduce iron absorption similarly to conventional tea. See Tea + Iron compounds, page 386. Note that tea and coffee are not generally considered to be suitable drinks for babies and children, because of their effects on iron absorption.

---

**Peppermint + Miscellaneous**

The information regarding the use of topical peppermint oil preparations is based on experimental evidence only.

**Evidence, mechanism, importance and management**

Preliminary *in vitro* experiments using human skin samples1 have found that low-dose peppermint oil (0.1% and 1%) on the skin surface can significantly reduce the amount of topical benzoin acid penetrating the dermal barrier. Conversely, at higher concentrations (5%), peppermint oil decreased the integrity of the dermal barrier.1 In another study, peppermint oil enhanced the fluorouracil permeation across rat skin.2

These experimental studies suggest that topical peppermint oil might increase the absorption of other topical drugs; however, there is currently insufficient evidence to make any clinical recommendations.

---


---

Policosanol

Types, sources and related compounds
Octacosanol.

Constituents
Policosanol consists of a mixture of alcohols with octacosanol being the major component. Triacontanol and hexacosanol are also present but in lesser amounts.

Use and indications
Policosanol is isolated from sugar cane wax and, because of its lipid-lowering and antiplatelet properties, is mainly used for cardiovascular disorders. It is also being investigated for possible use in the treatment of Parkinson’s disease, and for enhancing athletic performance.

Pharmacokinetics
Policosanol did not alter the metabolism of phenazine (antipyrine) in dogs.¹ Phenazine is used as a probe drug to assess the effects of other drugs on hepatic enzyme induction and inhibition. This finding therefore suggests that policosanol is unlikely to induce or inhibit the metabolism of other drugs that are substrates of hepatic enzymes.

Interactions overview
Policosanol has antiplatelet effects, which may be additive with other antiplatelet drugs, and could theoretically increase the risk of bleeding in patients taking anticoagulants. Policosanol may also enhance the blood pressure-lowering effects of some antihypertensives.

The interaction between policosanol and anticoagulants is based on a prediction only.

Clinical evidence
No interactions found.

Experimental evidence
Policosanol 200 mg/kg did not prolong the bleeding time of warfarin 200 micrograms/kg given for 3 days in rats.\(^1\)

Mechanism, importance and management
Although policosanol did not enhance the prolongation of the bleeding time induced by warfarin in rats, policosanol has antiplatelet properties and increased bleeding has been reported when it was given with aspirin, see below, so bear this in mind if excessive bleeding is seen.


Policosanol appears to increase the blood pressure-lowering effects of beta blockers.

Clinical evidence
In a randomised study in patients (aged 60 to 80 years) taking beta blockers, the addition of policosanol 5 mg tablets daily (titrated to a dose of 2 to 4 tablets) found that the average blood pressure was reduced from about 141/83 mmHg to 131/81 mmHg after one year, and 126/79 mmHg after 3 years. The efficacy of policosanol was not reduced and adverse effects were actually slightly lower in the policosanol group.\(^1\)

Mechanism
Policosanol is thought to reduce vascular resistance.

Importance and management
Policosanol increased the blood pressure-lowering effects of beta blockers and the clinical study suggests that the effect is gradual and beneficial. Furthermore, adverse effects related to hypotension were not reported. It therefore appears that, as with other conventional antihypertensives, policosanol may increase the effects of the beta blockers and so some caution is warranted, but no adverse effects such as first-dose hypotension would be expected.


Policosanol + Anticoagulants

Policosanol has antiplatelet effects, which may be additive with those of other antiplatelet drugs.

Clinical evidence
In a randomised study, four groups, each containing 10 or 11 subjects, were given placebo, policosanol 20 mg daily, aspirin 100 mg daily or both drugs together, for 7 days. Adrenaline-induced platelet aggregation was reduced in the group given aspirin and policosanol by about 35% more than in the group given aspirin alone: the effects of aspirin and policosanol were approximately additive. Furthermore, collagen-induced platelet aggregation was reduced in the group given aspirin and policosanol by about 10% more than in the group given aspirin alone. One patient taking both drugs suffered from bleeding gums. There was no significant effect on coagulation time.\(^1\) A 3-year study, primarily designed to assess the safety and efficacy of policosanol in patients taking beta blockers, included 32 patients taking antiplatelet drugs (mainly aspirin). No adverse effects related to bleeding were reported.\(^2\)

Experimental evidence
No relevant data found.

Mechanism
Additive antiplatelet effects.

Importance and management
The concurrent use of two conventional antiplatelet drugs is not uncommon, and so concurrent use of policosanol and aspirin need not be avoided. However, because platelet aggregation was reduced significantly, and a bleeding event was experienced, caution is perhaps warranted when taking policosanol supplements with aspirin or any other antiplatelet drug.


Policosanol + Beta blockers

Policosanol appears to increase the blood pressure-lowering effects of beta blockers.

Clinical evidence
In a study in hypertensive rats, a single 200-mg/kg oral dose of policosanol enhanced the blood pressure-lowering effects of intravenous and oral propranolol without increasing the reduction in heart rate induced by propranolol.\(^2\)

Mechanism
Policosanol is thought to reduce vascular resistance.

Importance and management
Policosanol increased the blood pressure-lowering effects of beta blockers and the clinical study suggests that the effect is gradual and beneficial. Furthermore, adverse effects related to hypotension were not reported. It therefore appears that, as with other conventional antihypertensives, policosanol may increase the effects of the beta blockers and so some caution is warranted, but no adverse effects such as first-dose hypotension would be expected.


Policosanol + Food

No interactions found.

Policosanol + Herbal medicines

No interactions found.

Policosanol + Nifedipine

Policosanol does not appear to affect the blood pressure-lowering effects of nifedipine.

Clinical evidence
A 3-year study, primarily designed to assess the safety and efficacy of policosanol in patients taking beta blockers, included 28 patients taking calcium-channel blockers (unnamed). No adverse effects related to hypotension were reported.\(^1\)

Experimental evidence
In a study in hypertensive rats, a single 200-mg/kg oral dose of policosanol did not affect the blood pressure-lowering effects of intravenous nifedipine 300 micrograms/kg given 2 hours later.\(^2\)
Mechanism
Policosanol is thought to reduce vascular resistance.

Importance and management
There appears to be no reason to avoid taking policosanol supplements with nifedipine. However, additive blood pressure-lowering effects seem possible, see beta blockers, page 324.


Policosanol + Phenazone (Antipyrine)

The information regarding the use of policosanol with phenazone (antipyrine) is based on experimental evidence only.

Clinical evidence
No interactions found.

Experimental evidence
A study in dogs found that the pharmacokinetics of an intravenous dose of phenazone 10 mg/kg were not affected by oral treatment with policosanol, 25 mg/kg daily for 21 days.1

Mechanism
No mechanism expected.

Importance and management
On the basis of the results from this animal study, there appears to be no reason to avoid taking policosanol supplements with phenazone.


Policosanol + Sodium nitroprusside

The interaction between policosanol and sodium nitroprusside is based on experimental evidence only.

Clinical evidence
No interactions found.

Experimental evidence
A study found that the antiplatelet and hypotensive effect of sodium nitroprusside was greater in rats that had been pre-treated with a single 200-mg/kg oral dose of policosanol, than in animals that had not received policosanol.1

Mechanism
Both policosanol and sodium nitroprusside have antiplatelet effects. These appear to be additive. Policosanol reduces vascular resistance and has been shown to enhance the blood pressure-lowering effects of other antihypertensives.

Importance and management
The clinical significance of this finding is unclear, but bear it in mind in case of an unexpected response to treatment.

Prickly ash

*Zanthoxylum americanum* Mill., *Zanthoxylum clava-herculis* L. (Rutaceae)

**Synonym(s) and related species**
Toothache tree, Xanthoxylum, Yellow wood, Zanthoxylum.

**Constituents**
The main constituents of prickly ash bark include the isoquinoline alkaloids magnoflorine, laurifoline, nitidine, chelerythrine, tambetarine and candidine. Various natural coumarins, tannins, lignans, including sesamin and asarinin, resins and volatile oil are also present.

**Use and indications**
Prickly ash is traditionally used for cramps and Raynaud’s syndrome. The bark is mainly used as an antirheumatic, analgesic and carminative, and is believed to possess cardioprotective effects. It is also used to treat toothache and fevers, and is used as a flavouring agent in food and drink. It is also used as a fish poison. Because of doubts about the toxicity of the alkaloids that it contains (which are said to have hypotensive, anti-inflammatory and neuromuscular blocking activity), some sources do not recommend its use.

**Pharmacokinetics**
No relevant pharmacokinetic data found.

**Interactions overview**
No interactions with prickly ash found.
Pumpkin

*Cucurbita pepo* L. (Cucurbitaceae)

**Synonym(s) and related species**
Cucurbita, Gourd, Melon pumpkin seeds, Squash.
*Cucurbita maxima* Duchesne and other *Cucurbita* species.

**Constituents**
Pumpkin seeds contain a fixed oil, the predominant fatty acids of which are linoleic, oleic, palmitic and stearic. There is a high sterol content with cholestanol and lathostanol derivatives present, and vitamin E, particularly gamma-tocopherol. The seeds also contain a number of cucurbitacins such as cucurbitin, the type and concentration depending on growth and variety.

**Use and indications**
Pumpkin seeds are widely used as a foodstuff. Traditionally, they were used to treat tapeworm infection (cucurbitin has anthelmintic effects), but more recently they have begun to be more widely used to treat benign prostatic hyperplasia.

**Pharmacokinetics**
No relevant pharmacokinetic data found.

**Interactions overview**
No interactions with pumpkin seed found. Note that pumpkin seeds are widely used as a foodstuff.
Pycnogenol

Pinus pinaster Aiton (Pinaceae)

**Synonym(s) and related species**

French maritime pine.

*Pinus maritima* Lam.

Note that Pycnogenol is a trademark for the extract from the bark of the French maritime pine which grows in the southern coastal area of France.

** Constituents **

Pycnogenol is a standardised water extract of the bark of French maritime pine, containing a range of flavonoid polyphenols and procyanidins, including catechin, and, to a lesser degree, epicatechin. Other constituents are polyphenolic monomers, which include taxifolin, ferulic acid, benzoic acid and cinnamic acid, and their glycosides.

** Use and indications **

Pycnogenol is used for a wide variety of disease states and is promoted for its antioxidant effects. Clinical studies indicate that it can be effective in the treatment of chronic venous insufficiency, cardiovascular disorders, asthma, vascular retinopathies and inflammatory conditions such as systemic lupus erythematosus.

** Pharmacokinetics **

No relevant pharmacokinetic data found. For information on the pharmacokinetics of individual flavonoids present in pycnogenol, see under flavonoids, page 186.

** Interactions overview **

Pycnogenol only modestly increases the antiplatelet effects of aspirin. For information on the interactions of individual flavonoids present in pycnogenol, see under flavonoids, page 186.
The interaction between pycnogenol and antiplatelet drugs is based on experimental evidence only.

Clinical evidence
No interactions found.

Experimental evidence
An *in vitro* study using blood samples from 38 healthy subjects found that pycnogenol dissolved in alcohol-inhibited, ADP-stimulated platelet aggregation, but only slightly enhanced the platelet inhibition caused by aspirin. Pycnogenol dissolved in water did not affect platelet inhibition caused by aspirin.1

Mechanism
Pycnogenol inhibits both COX-1 and COX-2, which, it is suggested, may account for its antiplatelet effects.2

Importance and management
Evidence is limited to one experimental study, which suggests that pycnogenol may inhibit platelet aggregation; however, it does not appear to particularly enhance the effects of aspirin. Therefore concurrent use seems likely to be safe, although this needs confirmation in clinical studies. The use of pycnogenol with other antiplatelet drugs does not appear to have been studied.


Pycnogenol + Food
No interactions found.

Pycnogenol + Herbal medicines
No interactions found.
Pygeum

Prunus africana (Hook.f.) Kalkman (Rosaceae)

Synonym(s) and related species
African prune.
Pygeum africanum (Gaert).

Pharmacopoeias
Pygeum (USP 32); Pygeum Africanum Bark (Ph Eur 6.4); Pygeum Bark (BP 2009).

Constituents
Pygeum bark contains phytosterols including beta-sitosterol and beta-sitostenone, pentacyclic triterpenes based on oleanolic and ursolic acids, and ferulic esters.

Use and indications
Pygeum bark is used to treat benign prostatic hyperplasia. Several clinical and pharmacological studies suggest that it may be effective.

Pharmacokinetics
No relevant pharmacokinetic data found.

Interactions overview
No interactions with pygeum found.
No interactions have been included for herbal medicines or dietary supplements beginning with the letter Q
Synonym(s) and related species
Cow clover, Meadow clover, Purple clover, Trefoil.  
Not to be confused with melilot, page 290, which is known as sweet clover.

Pharmacopoeias
Powdered Red Clover (*USP 32*); Powdered Red Clover extract (*USP 32*); Red Clover (*USP 32*); Red Clover Tablets (*USP 32*).

Constituents
Red clover flowers contain *isoflavones*, to which they may be standardised. The major isoflavones are *biochanin A* and *formononetin*, with small amounts of genistein and daidzein and others, and their glycoside conjugates. Other constituents include clovamides, coumestrol, and the natural coumarins medicagol and coumarin.

Use and indications
Red clover was traditionally used for skin conditions, such as eczema and psoriasis. However, the isoflavone fraction is now more commonly used as a form of HRT in women to reduce the symptoms of the menopause, although randomised controlled studies show only a slight benefit at best.¹,² It is also used for mastalgia, premenstrual syndrome and cancer prevention.

Pharmacokinetics
In an *in vitro* study, an extract of red clover reduced the activity of CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6 and CYP3A4. The effects on CYP2C8 and CYP2C9 were the most significant.³ Biochanin A, a major component of red clover, can inhibit P-glycoprotein and OATP, see *Isoflavones + Digoxin*, page 261 and *Isoflavones + Paclitaxel*, page 261.

For further information on the pharmacokinetics of the specific isoflavones genistin, daidzein and biochanin A, see isoflavones, page 258. Note that biochanin A is metabolised to genistein and formononetin to daidzein.⁴

Interactions overview
It has been suggested that red clover may interact with anticoagulants, but evidence for this is largely lacking. Potential interactions of isoflavone constituents of red clover are covered under isoflavones; see antibacterials, page 260, digoxin, page 260, fexofenadine, page 261, paclitaxel, page 261 and tamoxifen, page 262.

Red clover + Antibacterials

No data for red clover found. For the theoretical possibility that broad-spectrum antibacterials might reduce the metabolism of the isoflavone constituents of red clover, such as daidzin, by colonic bacteria, and so alter their efficacy, see Isoflavones + Antibacterials, page 260.

Red clover + Anticoagulants

The interaction between red clover and anticoagulants is based on a prediction only.

Evidence, mechanism, importance and management
Some reviews list red clover as having the potential to increase the risk of bleeding or potentiate the effects of warfarin,1 based on the fact that red clover contains natural coumarins. Although red clover contains coumarin, it is not itself an active anticoagulant. With melilot, page 290, which has a high content of coumarin, the action of moulds on the herb can result in the formation of an active anticoagulant, dicoumarol, from the coumarin, and bleeding disorders have occurred in animals fed spoiled hay containing melilot. There appears to be no published evidence of haemorrhagic disorders in animals fed red clover silage or hay. It might be that the coumarin content of red clover is too low to be a problem. Note that mouldy red clover hay has caused poisoning in animals, but this is because of mycotoxins such as slaframine. However, there is one case report of spontaneous subarachnoid haemorrhage in a 53-year-old woman, which was attributed to a herbal supplement containing red clover, and also wild yam, black cohosh, Chinese angelica, raspberry leaf, agnus castus, Siberian ginseng, partridge berry and nettle leaf, which she had been taking for 4 months.2 With case reports, it is not possible to say, conclusively, which, if any, of these constituents might have contributed to the adverse effect. However, of the constituents in this preparation, Chinese angelica has been associated with bleeding events, see Chinese angelica + Warfarin and related drugs, page 131.

Taken together, the evidence suggests that no special precautions are likely to be required when red clover supplements are used with anticoagulants.


Red clover + Digoxin

No data for red clover found. For the possibility that high-dose biochanin A, an isoflavone present in red clover, might increase digoxin levels, see Isoflavones + Digoxin, page 261.

Red clover + Fexofenadine

No data for red clover found. For the possibility that high-dose biochanin A, a major isoflavone in red clover, has been shown to slightly decrease fexofenadine levels in rats, see Isoflavones + Fexofenadine, page 261.

Red clover + Food

No interactions found.

Red clover + Herbal medicines

No interactions found.

Red clover + Paclitaxel

No data for red clover found. For the possibility that biochanin A and genistein present in red clover might markedly increase paclitaxel levels, see Isoflavones + Paclitaxel, page 261. Note that paclitaxel is used intravenously, and the effect of biochanin A on intravenous paclitaxel does not appear to have been evaluated.

Red clover + Tamoxifen

No data for red clover found. Data relating to the use of the isoflavone constituents of red clover, such as biochanin A, daidzein and genistein, with tamoxifen are covered under Isoflavones + Tamoxifen, page 262.
Red vine leaf

*Vitis vinifera* L. (Vitaceae)

**Synonym(s) and related species**

*Vitis vinifera* is the Grape vine, of which there are many cultivars. Red vine leaf is a cultivar with red leaves.

**Constituents**

Red vine leaf contains a range of polyphenolics, mainly flavonoids, proanthocyanins and anthocyanins. The major flavonoids in the extract are quercetin and isoquercitrin. Catechins present include galloallocatechin and epigallocatechin and their polymers. The red colour is due to the anthocyanins, which are mainly glucosides of malvidin, but also of delphinidin, cyanidin and pertunidin. Hydroxycinnamic acids (e.g. caffeic acid) and resveratrol are also present.

**Use and indications**

Red vine leaf extract is used both internally and externally to improve blood circulation, particularly in the legs for varicose veins. There is some clinical evidence to support its use in venous insufficiency.

**Pharmacokinetics**

No relevant pharmacokinetic data found. See under flavonoids, page 186, for information on the individual flavonoids present in red vine leaf, and see under resveratrol, page 335, for the pharmacokinetics of resveratrol.

**Interactions overview**

No interactions with red vine leaf found. For information on the interactions of flavonoids, see under flavonoids, page 186, and for the interactions of resveratrol, see under resveratrol, page 335.
Resveratrol

Types, sources and related compounds
Resveratrol is a polyphenol present in most grape and wine products and is the compound largely credited with providing the health benefits of red wine. However, the concentration is very variable between foods and supplements, so it is difficult to evaluate the clinical relevance of the available information.

Use and indications
Resveratrol is used for its reputed anti-ageing effects. It is said to have antioxidant properties and antiplatelet effects, and is therefore promoted as having benefits in a variety of cardiovascular diseases, including atherosclerosis. It also has some oestrogenic and anti-inflammatory activity, and is under investigation in the prevention and treatment of cancer, because it appears to reduce cell proliferation.

Pharmacokinetics
An in vitro study reported that resveratrol inhibited the cytochrome P450 isoenzyme CYP3A4, but was much less potent than erythromycin,1 a known, clinically relevant, moderate CYP3A4 inhibitor. Similar results were found in other studies.2,3 Interestingly, red wine also inhibited CYP3A4, but this effect did not correlate with the resveratrol content.1,4

In other studies resveratrol had only very weak inhibitory effects on CYP1A2, which are unlikely to be of any clinical relevance.3,5,6 Similarly, one study3 suggests that resveratrol and its primary metabolite do not inhibit CYP2C9 (see Resveratrol + Diclofenac, page 336) and CYP2D6, and resveratrol only weakly inhibits CYP2C19 (see Resveratrol + Mephenytoin, page 336).

Interactions overview
Resveratrol may have clinically significant antiplatelet effects which may be additive with antiplatelets and anticoagulant drugs as well as other drugs that may cause bleeding such as NSAIDs. An in vitro study reports that resveratrol had no significant effect on the metabolism of diclofenac and only weakly inhibited the metabolism of (S)-mephenytoin. Therefore clinically relevant pharmacokinetic interactions between resveratrol and substrates of CYP2C9 and CYP2C19, respectively, would not be expected. An in vitro study also found that resveratrol moderately inhibited the metabolism of paclitaxel; however, the clinical relevance of this is unclear.

Resveratrol + Anticoagulant or Antiplatelet drugs

The interaction between resveratrol and anticoagulants or antiplatelet drugs is based on experimental evidence only.

Clinical evidence
No interactions found.

Experimental evidence
An ex vivo study using samples of platelet-rich plasma from 50 high-risk cardiac patients taking aspirin found that resveratrol significantly reduced platelet aggregation in response to collagen and adrenaline (epinephrine) in the samples taken from aspirin-resistant patients, but only had a minimal effect in those taken from aspirin-sensitive patients. Resveratrol had minimal effects on ADP-induced platelet aggregation in both groups of patients. Another in vitro study found that a low concentration of resveratrol (2 or 5 micromoles) increased the inhibitory effect of prostaglandins E2 and I2 on platelet aggregation in response to collagen, although it did not itself affect collagen-induced platelet aggregation. This subject has been extensively studied and is the subject of a number of review articles.

Mechanism
Resveratrol appears to enhance the inhibitory response to platelet aggregation. This effect may be additive to the effects of other drugs with antiplatelet effects.

Importance and management
Although there appears to be a plethora of in vitro studies to support the antiplatelet role of resveratrol, there is a lack of clinical data in humans. Therefore it is difficult to confirm if a clinically significant enhancement of antiplatelet effects would occur in patients taking resveratrol with antiplatelet drugs. Concurrent use need not be avoided (indeed combinations of antiplatelet drugs are often prescribed together), but it may be prudent to be aware of the potential for increased bleeding if resveratrol is given with other antiplatelet drugs such as aspirin and clopidogrel. Patients should discuss any episode of prolonged bleeding with a healthcare professional.

Drugs that enhance antiplatelet effects may also increase the risk of bleeding in patients receiving anticoagulants such as warfarin. Clinically, the use of an antiplatelet drug with an anticoagulant should generally be avoided in the absence of a specific indication. However, if concurrent use is felt desirable it would seem sensible to warn patients to be alert for any signs of bruising or bleeding, and report these immediately, should they occur.

No interactions found.

Resveratrol + Food

No interactions found.

Resveratrol + Herbal medicines

No interactions found.

Resveratrol + Mephénytoïn

The information regarding the use of resveratrol with mephénytoïn is based on experimental evidence only.

Clinical evidence
No interactions found.

Experimental evidence
An in vitro study using human liver microsomes found that resveratrol only weakly inhibited the metabolism of (S)-mephénytoïn.

Mechanism
Nothing expected. Mephénytoïn can be used as a probe substrate for cytochrome P450 isoenzyme CYP2C9 activity.

Importance and management
Evidence is limited to this one in vitro study. Although there are no in vivo data available, it seems unlikely that resveratrol will affect the metabolism of mephénytoïn and therefore no dosage adjustments are likely to be needed if they are given together. Note that resveratrol may have some antiplatelet effects, which may be additive with those of NSAIDs such as diclofenac, consider also resveratrol + Anticoagulant or Antiplatelet drugs, above. Diclofenac can be used as a probe drug for CYP2C9 activity, and therefore these results also suggest that a pharmacokinetic interaction between resveratrol and other CYP2C9 substrates is unlikely.


Resveratrol + Diclofenac

The information regarding the use of resveratrol with diclofenac is based on experimental evidence only.

Clinical evidence
No interactions found.

Experimental evidence
An in vitro study using human liver microsomes found that resveratrol had no significant effect on the metabolism of diclofenac.

Mechanism
Nothing expected. Diclofenac can be used as a probe substrate for cytochrome P450 isoenzyme CYP2C9 activity.

Importance and management
Evidence is limited to this one in vitro study. Although there are no in vivo data available, it seems unlikely that resveratrol will affect the metabolism of diclofenac and therefore no dosage adjustments are likely to be needed if they are given together. Note that resveratrol may have some antiplatelet effects, which may be additive with those of NSAIDs such as diclofenac, consider also resveratrol + Anticoagulant or Antiplatelet drugs, above. Diclofenac can be used as a probe drug for CYP2C9 activity, and therefore these results also suggest that a pharmacokinetic interaction between resveratrol and other CYP2C9 substrates is unlikely.

The interaction between resveratrol and paclitaxel is based on experimental evidence only.

**Clinical evidence**
No interactions found.

**Experimental evidence**
An *in vitro* study in human liver microsomes investigated the effects of resveratrol on the metabolism of paclitaxel. In both rat and human liver microsomes, resveratrol moderately inhibited paclitaxel metabolism.\(^1\)

**Mechanism**
Paclitaxel is metabolised by the cytochrome P450 isoenzyme CYP2C8 and, to a lesser extent, CYP3A4. In this study resveratrol appeared to moderately inhibit these isoenzymes.

**Importance and management**
The clinical relevance of this study is unknown. Further study is needed to confirm if this inhibition produces a clinically relevant increase in paclitaxel levels, which could also potentially increase the adverse effects of paclitaxel. However, the authors also suggested that, as the metabolites of paclitaxel are less active than paclitaxel itself, inhibiting its metabolism may be beneficial. There is currently insufficient evidence on which to base any clinical recommendations.

**Rhodiola**

*Rhodiola rosea* L. (Crassulaceae)

**Synonym(s) and related species**
Arctic root, Golden root, Rodiola, Rose root.
*Sedum rosea* (L.) Scop., *Sedum roseum* (L.) Scop.
Other *Rhodiola* species may also be used, particularly in Chinese medicine.

**Constituents**
The main active constituents of rhodiola rhizome and root are thought to be the rosavins (a complex series of monoterpene alcohol and phenylpropanoid glycosides such as rosin, rosarin and rosavin), rosinidin and tyrosol. Rhodiola also contains flavonoids such as kaempferol and its glycoside derivatives, sterols (β-sitosterol), tannins, and rhodiolo-sides or salidrosides (a series of hydroxylated, methoxylated and methylated octadienyl and octenyl glucosides). There is also a small amount of essential oil (about 0.05%).

**Use and indications**
Rhodiola is widely used throughout the world, and the different species are used for similar purposes. It is considered to be an adaptogen, used for coping with stress, improving mood and alleviating depression. There is a large amount of pharmacological evidence available in support of its use and studies have shown that it can improve both physical and mental performance, reduce fatigue and prevent altitude sickness. However, the evidence is of variable quality and the clinical efficacy of rhodiola remains to be conclusively demonstrated.

**Pharmacokinetics**
An *in vitro* study found that an extract of rhodiola root inhibited the cytochrome P450 isoenzyme CYP3A4; the extent of the inhibition increased with increasing concentrations of rosarin.1 The manufacturer2 of a licensed rhodiola product reports that in an *in vitro* study, a rhodiola extract 10 micrograms/mL inhibited CYP2C9 and CYP2C19. However, in another study, an extract of rhodiola did not affect the metabolism of warfarin, page 339, which is a substrate of CYP2C9. Rhodiola did not affect the metabolism of theophylline, page 339, and therefore seems unlikely to affect the metabolism of other drugs that are substrates of CYP1A2. For information on the pharmacokinetics of individual flavonoids present in rhodiola, see under flavonoids, page 186.

**Interactions overview**
Rhodiola does not appear to affect the pharmacokinetics of theophylline or warfarin. The concurrent use of pepper may diminish the antidepressant effects of rhodiola. For information on the interactions of individual flavonoids present in rhodiola, see under flavonoids, page 186.

2. Vitano Film-coated Tablets (Dry extract of Rhodiola rosea roots and rhizomes). Schwabe Pharma (UK) Ltd. UK Summary of product characteristics, July 2008.
### Rhodiola + Food

No interactions found.

### Rhodiola + Herbal medicines; Pepper

The interaction between rhodiola and warfarin is based on experimental evidence only.

#### Clinical evidence

No interactions found.

#### Experimental evidence

In a study, rats were given a standardised rhodiola extract (SHR-5, containing rhodioloside 2.7%, rosavin 6% and tyrosol 0.8%) twice daily for 3 days with a single dose of **aminophylline**, given one hour after the last dose of rhodiola extract. The pharmacokinetics of theophylline were only slightly affected by the rhodiola extract (less than 15% decrease in AUC and maximum levels).

#### Mechanism

Unknown.

#### Importance and management

Information appears to be limited to this one study in rats, which may not necessarily extrapolate directly to humans. However, what is known suggests that rhodiola extract is unlikely to have a clinically significant effect on the pharmacokinetics of theophylline.


### Rhodiola + Theophylline

The interaction between rhodiola and theophylline is based on experimental evidence only.

#### Clinical evidence

No interactions found.

#### Experimental evidence

In a study, rats were given a standardised rhodiola extract (SHR-5, containing rhodioloside 2.7%, rosavin 6% and tyrosol 0.8%) twice daily for 3 days with a single dose of **aminophylline**, given one hour after the last dose of rhodiola extract. The pharmacokinetics of theophylline were only slightly affected by the rhodiola extract (less than 15% decrease in AUC and maximum levels).

#### Mechanism

Unknown.

#### Importance and management

Information appears to be limited to this one study in rats, which may not necessarily extrapolate directly to humans. However, what is known suggests that rhodiola extract is unlikely to have a clinically significant effect on the pharmacokinetics of theophylline.

Rhubarb

*Rheum officinale* Baill., *Rheum palmatum* L. (Polygonaceae)

**Synonym(s) and related species**
Chinese rhubarb.
*Rheum tanguticum* Maxim.
Note that Indian rhubarb (Himalayan rhubarb) consists of the dried root of *Rheum emodi* Wall. or some other related species of *Rheum*.
Note also that the root of *Rheum rhaponticum* Willd (English rhubarb, Garden rhubarb) sometimes occurs as an adulterant in rhubarb and pharmacopoeias specify a test for its absence.

**Pharmacopoeias**
Compound Rhubarb Tincture (*BP 2009*); Rhubarb (*BP 2009*, *Ph Eur 6.4*).

**Constituents**
*Anthraquinone glycosides* are major components of rhubarb. It contains chrysophanol, emodin, rhein, aloe-emodin, physcion and sennosides A to E. Various tannins, stilbene glycosides, resins, starch and trace amounts of volatile oil are also present.
Indian rhubarb contains similar anthraquinones, but English rhubarb contains only chrysophanol and some of its glycosides.

**Use and indications**
Rhubarb rhizome and root is used as a laxative, but at low doses it is also used to treat diarrhoea, because of the tannin content. It is also used as a flavouring in food.

**Pharmacokinetics**
For information on the pharmacokinetics of an anthraquinone glycoside present in rhubarb, see under aloes, page 27.

**Interactions overview**
A case report describes raised digoxin levels and toxicity in a patient taking a Chinese herbal laxative containing rhubarb (daio), see Liquorice + Digitalis glycosides, page 274 for further details.
No further interactions with rhubarb found; however, rhubarb (by virtue of its anthraquinone content) is expected to share some of the interactions of a number of other anthraquinone-containing laxatives, such as aloes, page 27 and senna, page 349. Of particular relevance are the interactions with corticosteroids and potassium-depleting diuretics.
Rooibos

Aspalathus linearis (Burm.f.) R.Dahlgren (Fabaceae)

**Synonym(s) and related species**
Red bush tea, Green red bush, Kaffree tea.

**Constituents**
The needle-like leaves and stems of rooibos contain polyphenolic flavonoids. The unfermented product remains green in colour and contains aspalathin, a dihydrochalcone, whereas the fermented product is red in colour due to oxidation of the constituent polyphenols. Oxidation of aspalathin produces dihydro-iso-orientin. Other flavonoids present in both green and red rooibos include rutin, isoquercetin, hyperoside and quercetin. Rooibos also contains volatile oils and minerals, but does not contain caffeine. Rooibos tea is principally used to produce a tea-like beverage. In experimental studies, it has shown some antioxidant, chemopreventive and immunomodulating effects.

**Pharmacokinetics**
Rooibos appears to induce the cytochrome P450 isoenzyme CYP3A4, see midazolam, page 342. For information on the pharmacokinetics of individual flavonoids present in rooibos, see under flavonoids, page 186.

**Interactions overview**
Midazolam levels are reduced by rooibos tea *in vitro* and in rats, but clinical evidence for an interaction is lacking. Rooibos tea does not appear to affect iron absorption. For information on the interactions of individual flavonoids present in rooibos, see under flavonoids, page 186.

### Rooibos + Food

No interactions found.

### Rooibos + Herbal medicines

No interactions found.

### Rooibos + Iron compounds

Rooibos tea does not appear to significantly reduce the absorption of iron.

**Clinical evidence**

In a parallel group study in healthy subjects, mean iron absorption after ingestion of radiolabelled iron 16 mg with a beverage was 7.25% with rooibos tea, 1.7% with tea and 9.34% with water.\(^1\) Note that tea is known inhibit iron absorption, see Tea + Iron compounds, page 386.

**Experimental evidence**

No relevant data found.

**Mechanism**

Rooibos does not appear to reduce the absorption of iron. It contains some polyphenolic flavonoids which might bind iron in the gut; however, these differ from the polyphenols found in tea, such as the catechins, which have reported to affect iron absorption. Tannins found in tea are also thought to reduce iron absorption, but rooibos tea has less than 5% tannins.

**Importance and management**

The evidence suggests that rooibos does not reduce the absorption of iron. No special precautions are likely to be required.

---


### Rooibos + Midazolam

The interaction between rooibos tea and midazolam is based on experimental evidence only.

**Clinical evidence**

No interactions found.

**Experimental evidence**

An *in vitro* study investigating the effects of rooibos tea on midazolam pharmacokinetics found that a 10% solution of rooibos tea 4 g/L brewed for 5 minutes reduced the levels of the 4-hydroxy metabolite of midazolam to undetectable levels.\(^1\) A subsequent study in rats found that an unrestricted amount of rooibos tea given for 2 weeks reduced the AUC and maximum concentration of a single 20-mg/kg oral dose of midazolam by 70% and 64%, respectively. Intestinal metabolism appeared to be more affected than hepatic metabolism.\(^2\)

**Mechanism**

Midazolam is a substrate of the cytochrome P450 isoenzyme CYP3A4. These studies suggest that rooibos tea induces CYP3A4, mainly in the intestine, thereby increasing midazolam metabolism and decreasing its levels.

**Importance and management**

Although the data are limited and there appear to be no clinical studies, it would seem that rooibos tea may have the potential to significantly reduce the levels of midazolam, and therefore reduce its efficacy. However, the amount of rooibos tea required to significantly inhibit CYP3A4 in humans, and produce a clinically important reduction in drug levels, is unknown. Nevertheless, until more is known, it would seem prudent to monitor the outcome of concurrent use, being alert for a decrease in the efficacy of midazolam.

Midazolam is used as a probe drug for CYP3A4 activity, and therefore these results also suggest that a pharmacokinetic interaction between rooibos and other CYP3A4 substrates is possible. See the table Drugs and herbs affecting or metabolised by the cytochrome P450 isoenzyme CYP3A4, page 8 for a list of known CYP3A4 substrates.

---


Sage

_Salvia officinalis_ L. (Lamiaceae)

**Synonym(s) and related species**

Dalmatian sage, Garden sage, Red sage, Salvia, True sage.

There are many related species, which include _Salvia lavandulifolia_ Vahl. (Spanish sage) and _Salvia triloba_ L. (Greek sage).

**Pharmacopoeias**

Sage Leaf (BP 2009, Ph Eur 6.4); Sage Oil (BP 2009); Sage Tincture (BP 2009, Ph Eur 6.4); Spanish Sage Oil (BP 2009, Ph Eur 6.4); Three-lobed Sage Leaf (BP 2009, Ph Eur 6.4).

**Constituents**

The major constituents of sage are flavonoids including luteolin and derivatives, caffeic acid derivatives, diterpenes and triterpenes.

The essential oil components vary according to species and origin. _Salvia officinalis_ contains the monoterpenoid hydrocarbons α- and β-thujones as the major components, together with 1,8-cineole, camphor and borneol, and others. _Salvia lavandulifolia_ does not contain thujones, and _Salvia triloba_ only small amounts, making these oils less toxic.

**Use and indications**

Sage is used traditionally to reduce ‘hot flushes’ and hyperhidrosis associated with the menopause. It has antiseptic and spasmolytic properties, and a tea infusion is used as a gargle for sore throats. Extracts are also strongly antioxidant. Sage (_Salvia lavandulifolia_ in particular because of the absence of thujones) has recently generated interest as a cognition enhancer due to its anticholinesterase properties. The oil may be applied topically as an antiseptic and rubefacient but it should not be taken internally, applied externally in large amounts or used by pregnant women. Note that sage is widely used as a flavouring in foods.

**Pharmacokinetics**

An _in vitro_ study\(^1\) found that sage does not have a clinically significant inductive effect on the cytochrome P450 isoenzymes CYP1A2, CYP2D6 and CYP3A4. Other _in vitro_ studies\(^2,3\) have found that sage does not inhibit CYP2D6, hepatic CYP3A4 or P-glycoprotein to a clinically relevant extent, although it may have some potentially clinically relevant effects on intestinal CYP3A4. In contrast, a further _in vitro_ study\(^4\) found that sage had inhibitory effects on CYP2C9, CYP2C19, CYP2D6 and CYP3A4, but these findings should be interpreted with caution, as the study also found St John’s wort to be a CYP3A4 inhibitor, whereas, clinically, it is a CYP3A4 inducer. Therefore sage appears to have a low potential for causing interactions by these mechanisms, although the potential for a clinically relevant effect on intestinal CYP3A4 warrants further study.

For information on the pharmacokinetics of individual flavonoids present in sage, see under flavonoids, page 186.

**Use and indications**

Sage is used traditionally to reduce ‘hot flushes’ and hyperhidrosis associated with the menopause. It has antiseptic and spasmolytic properties, and a tea infusion is used as a gargle for sore throats. Extracts are also strongly antioxidant. Sage (_Salvia lavandulifolia_ in particular because of the absence of thujones) has recently generated interest as a cognition enhancer due to its anticholinesterase properties. The oil may be applied topically as an antiseptic and rubefacient but it should not be taken internally, applied externally in large amounts or used by pregnant women. Note that sage is widely used as a flavouring in foods.

**Interactions overview**

No interactions with sage found. Sage is commonly used as a flavouring in foods. For information on the interactions of individual flavonoids present in sage, see under flavonoids, page 186.

---

Saw palmetto

Serenoa repens (Bartram) J.K. Small (Arecaceae)

Synonym(s) and related species
American dwarf palm, Sabal, Serenoa.  

Pharmacopoeias
Powdered Saw Palmetto (*USP 32*); Saw Palmetto (*USP 32*); Saw Palmetto Capsules (*USP 32*); Saw Palmetto Fruit (*BP 2009, Ph Eur 6.4*).

Constituents
The fruit of saw palmetto contains about 25% fatty acids (extracts are often standardised to a minimum of 11% total fatty acids) consisting of capric, caprylic, lauric, palmitic, oleic, linoleic and linolenic acids in the form of fixed oils. Sterols including campesterol, stig masterol and β-sitosterol are also present, as are long-chain alcohols, carotenoids, various polysaccharides and some flavonoids, including rutin, isoquercetin and kaempferol.

Use and indications
The main contemporary use of saw palmetto fruit is to treat the urological symptoms of benign prostatic hyperplasia. It has also been used as a diuretic, a sedative, an endocrine agent, an antiseptic and for treating disorders involving the sex hormones.

Pharmacokinetics
Saw palmetto (*ProstaPro* 160 mg berry extract containing 85 to 95% fatty acids and sterols) was found to inhibit the cytochrome P450 isoenzymes CYP2D6, CYP2C9 and CYP3A4 *in vitro*. However, a clinical study in patients given debrisoquine, a probe substrate for CYP2D6, found that saw palmetto had no effect on this isoenzyme, and other clinical studies suggest that the *in vitro* effects reported for CYP3A4 and CYP2D6 may not be clinically relevant, see benzodiazepines, page 345, and dextromethorphan, page 346, for further information. Clinical studies with chlorzoxazone, page 345, and caffeine, page 345, also suggest that saw palmetto has no clinically relevant effect on CYP1E2 or CYP1A2, respectively. For information on the pharmacokinetics of individual flavonoids present in saw palmetto, see under flavonoids, page 186.

Interactions overview
There may be an increased response to anticoagulant treatment in patients who also take saw palmetto. Saw palmetto does not appear to have a clinically relevant effect on the majority of cytochrome P450 isoenzymes and no other interactions with saw palmetto have been found. For information on the interactions of individual flavonoids present in saw palmetto, see under flavonoids, page 186.

---

Saw palmetto does not appear to affect the pharmacokinetics of caffeine.

Clinical evidence
In a randomised study, 12 healthy subjects were given saw palmetto 160 mg twice daily for 28 days, with a single 100-mg dose of caffeine at the end of treatment with saw palmetto. The pharmacokinetics of caffeine were unchanged by saw palmetto.1

Experimental evidence
No relevant data found.

Mechanism
Caffeine is metabolised by the cytochrome P450 isoenzyme CYP1A2. Saw palmetto does not appear to inhibit this route of metabolism.

Importance and management
Evidence appears to be limited to the study cited, which suggests that in most patients saw palmetto is unlikely to raise caffeine levels. Caffeine is used as a probe drug for CYP1A2 activity, and therefore these results also suggest that a pharmacokinetic interaction between saw palmetto and other CYP1A2 substrates is unlikely.


Saw palmetto + Anticoagulants

The INR of one patient taking warfarin modestly increased after he took Curbicin (saw palmetto, cucurbita and vitamin E). This product has also been associated with an increased INR in a patient not taking anticoagulants. Excessive bleeding during surgery has been reported in another patient who had been taking saw palmetto.

Clinical evidence
A 61-year-old man taking warfarin and simvastatin, with a stable INR of around 2.4, had an increase in his INR to 3.4 within 6 days of starting to take 5 tablets of Curbicin daily. Within a week of stopping the Curbicin, his INR had fallen to its previous value. Another elderly man who was not taking any anticoagulants and was taking 3 tablets of Curbicin daily was found to have an INR of 2.1 (normal 0.9 to 1.2). His INR decreased (to between 1.3 and 1.4) when he was given vitamin K, but did not normalise until a week after the Curbicin was stopped. Curbicin is a herbal remedy used for micturition problems, and contains extracts from the fruit of saw palmetto and the seed of Cucurbita pepo.1

In addition, saw palmetto has been attributed to excessive bleeding in a 53-year-old man undergoing a surgical procedure to remove a brain tumour. An estimated 2 litres of blood were lost during surgery and bleeding time did not return to normal for 5 days. The patient denied taking NSAIDs pre-operatively but admitted to taking saw palmetto for benign prostate hypertrophy.2

Experimental evidence
Saw palmetto may inhibit the cytochrome P450 isoenzyme CYP2C9 in vitro (see Pharmacokinetics, page 344), but it is not known if this is clinically relevant.

Mechanism
The authors of the first report suggest that what happened was possibly due to the presence of vitamin E in the Curbicin preparation (each tablet contains 10 mg), but vitamin E does not normally affect INRs. Experimental evidence suggests that saw palmetto may inhibit the cytochrome P450 isoenzyme CYP2C9, which is an important route of warfarin metabolism.

Importance and management
Evidence appears to be limited to case reports and an experimental study of unknown clinical relevance. Because of the many other factors influencing anticoagulant control, it is not possible to reliably ascribe a change in INR specifically to a drug interaction in a single case report without other supporting evidence. It may be better to advise patients to discuss the use of any herbal products that they wish to try, and to increase monitoring if this is thought advisable. Cases of uneventful use should be reported, as they are as useful as possible cases of adverse effects.


Saw palmetto + Benzodiazepines

No pharmacokinetic interaction appears to occur between saw palmetto and alprazolam or midazolam.

Clinical evidence
In a study in 12 healthy subjects, saw palmetto 320 mg daily for 16 days did not affect the pharmacokinetics of a single 2-mg dose of alprazolam given on day 14. In another study in 12 healthy subjects saw palmetto 160 mg twice daily for 28 days did not affect the metabolism of a single 8-mg dose of midazolam.2

Experimental evidence
Experimental studies have suggested that saw palmetto may inhibit the cytochrome P450 isoenzyme CYP3A4, see Pharmacokinetics, page 344.

Mechanism
Midazolam is metabolised by the cytochrome P450 isoenzyme CYP3A4. In vitro study suggested that saw palmetto inhibited this route or metabolism, but this does not appear to be clinically relevant.

Importance and management
The findings of these studies suggest that saw palmetto does not alter the metabolism of alprazolam or midazolam, and therefore no dosage adjustments of these benzodiazepines would be expected to be needed on concurrent use.

Midazolam is used as a probe drug for CYP3A4 activity, and therefore these results also suggest that a pharmacokinetic interaction between saw palmetto and other CYP3A4 substrates is unlikely.


Saw palmetto + Chlorzoxazone

Saw palmetto does not appear to affect the pharmacokinetics of chlorzoxazone.

Clinical evidence
In a study in 12 healthy subjects the metabolism of a single 250-mg
A dose of chlorzoxazone was not affected by saw palmetto 160 mg twice daily for 28 days.1

**Experimental evidence**
No relevant data found.

**Mechanism**
Chlorzoxazone is used as a probe substrate of the cytochrome P450 isoenzyme CYP2E1. Saw palmetto does not appear to inhibit this route of metabolism.

**Importance and management**
Evidence appears to be limited to the study cited, which suggests that saw palmetto is unlikely to raise chlorzoxazone levels.

Chlorzoxazone is used as a probe drug for CYP2E1 activity, and therefore these results also suggest that a pharmacokinetic interaction between saw palmetto and other CYP2E1 substrates is unlikely.


---

**Saw palmetto + Dextromethorphan**

Saw palmetto does not appear to affect the metabolism of dextromethorphan.

**Clinical evidence**
In a study in 12 healthy subjects, saw palmetto 320 mg daily for 16 days did not affect the metabolism of a single 30-mg dose of dextromethorphan given on day 14.1

**Experimental evidence**
No relevant data found.

**Mechanism**
Dextromethorphan is used as a probe substrate of the cytochrome P450 isoenzyme CYP2D6. Saw palmetto does not appear to inhibit this route of metabolism.

**Importance and management**
Evidence appears to be limited to the study cited, which suggests that saw palmetto is unlikely to raise dextromethorphan levels.

Dextromethorphan is used as a probe drug for CYP2D6 activity, and therefore these results also suggest that a pharmacokinetic interaction between saw palmetto and other CYP2D6 substrates is unlikely.

This finding is confirmed by a study using debrisoquine, see Pharmacokinetics, page 344.


---

**Saw palmetto + Food**

No interactions found.

**Saw palmetto + Herbal medicines**

No interactions found.
**Schisandra**

*Schisandra chinensis* K.Koch (Schisandraceae)

**Synonym(s) and related species**

Gomishi (Japanese), Magnolia vine, Wu-Wei-Zi (Chinese).

*Kadsura chinensis* Turcz.

*Schisandra sphenanthera* Rehder & EH Wilson is often used with, or substituted for, *Schisandra chinensis*. Other species of *Schisandra* are also used medicinally in China.

**Constituents**

The major active components of the fruits of *Schisandra chinensis* are dibenzocyclooctene lignans. The identity and nomenclature are confusing, because, when originally isolated by different researchers, the same compounds were given different names. The main groups of compounds are the *schisandrins* (schizandrin) and the *gomisins* (some of which were originally called wuweizu esters) and their derivatives. Schisandrin is also referred to in the literature as schisandrin A, gomisin A as schisandrin B, deoxyschisandrin as schisandrin A or wuweizu A, and schisantherin B as gomisin B or wuweizu B, for example. An essential oil contains borneol, 1,8-cineole, citral, sesquicarene and other gomisin B or wuweizu B, for example. An essential oil contains borneol, 1,8-cineole, citral, sesquicarene and other gomisins B, C, G and N, and *γ*-schisandrin have all demonstrated inhibition of CYP3A4 in *vitro*. Gomisin C was the most potent and competitive inhibitor and was even stronger than that of ketoconazole. It has also been suggested that gomisin C irreversibly inactivates CYP3A4. In contrast, schisandrol B [gomisin A], schisandrin A and schisandrin B [gomisin B] induced CYP3A4 in another *in vitro* study. The conflicting effects found with gomisin B are unclear, but it has been suggested that, due to confusion over the naming and identification of these compounds, studies may have been carried out with constituents with the same names but different structures. Furthermore, the clinical effects of these extracts on CYP3A4 are unclear, as *in vitro* inhibition has not been replicated in rats, see nifedipine, page 348.

*Schisandra* may also induce the cytochrome P450 isoenzyme CYP2C9, see warfarin, page 348.

*In vitro* studies using schisandrin A and B, schisandrols A and B [gomisin A] and schisantherin A [gomisin C], suggest that these constituents are inhibitors of P-glycoprotein, although schisandrol A and B [gomisin A] had only weak effects in one study.

It has also been demonstrated that schisandrin A and B, schisandrols A and B [gomisin A] and schisantherin A [gomisin C] are inhibitors of MDR1, which is a multidrug resistance-associated protein.

A study in rats given schisandrin, an aqueous extract of *Schisandra chinensis*, or Sheng-Mai-San (a traditional Chinese medicine containing Radix ginseng, Radix ophiopogonis and Fructus schisandrae) found that schisandrin was detectable in the plasma after each preparation, but after the aqueous extract or Sheng-Mai-San was given, the half-life and AUC of schisandrin were greater than when schisandrin alone was given. It is therefore possible that components of these products could alter the metabolism of schisandrin. This may be important when extrapolating the effects of multi-constituent herbal preparations to the use of schisandrin.

**Use and indications**

Schisandra is a very important herb in Chinese medicine. It is used as a tonic and restorative and considered to have liver-protecting, cardiotonic, hypotensive, immunomodulating, expectorant, hypnotic and sedative effects. It is used in the treatment of asthma, hyperproliferative and inflammatory skin diseases, night sweats, urinary disorders, chronic diarrhoea, insomnia and many other conditions.

**Pharmacokinetics**

The effects of extracts of schisandra on cytochrome P450 isoenzymes are reasonably well studied. The gomisins B, C, G and N, and *γ*-schisandrin have all demonstrated inhibition of CYP3A4 in *vitro*. Gomisin C was the most potent and competitive inhibitor and was even stronger than that of ketoconazole. It has also been suggested that gomisin C irreversibly inactivates CYP3A4. In contrast, schisandrol B [gomisin A], schisandrin A and schisandrin B [gomisin B] induced CYP3A4 in another *in vitro* study. The conflicting effects found with gomisin B are unclear, but it has been suggested that, due to confusion over the naming and identification of these compounds, studies may have been carried out with constituents with the same names but different structures. Furthermore, the clinical effects of these extracts on CYP3A4 are unclear, as *in vitro* inhibition has not been replicated in rats, see nifedipine, page 348.

*Schisandra* may also induce the cytochrome P450 isoenzyme CYP2C9, see warfarin, page 348.

*In vitro* studies using schisandrin A and B, schisandrols A and B [gomisin A] and schisantherin A [gomisin C], suggest that these constituents are inhibitors of P-glycoprotein, although schisandrol A and B [gomisin A] had only weak effects in one study.

It has also been demonstrated that schisandrin A and B, schisandrols A and B [gomisin A] and schisantherin A [gomisin C] are inhibitors of MDR1, which is a multidrug resistance-associated protein.

A study in rats given schisandrin, an aqueous extract of *Schisandra chinensis*, or Sheng-Mai-San (a traditional Chinese medicine containing Radix ginseng, Radix ophiopogonis and Fructus schisandrae) found that schisandrin was detectable in the plasma after each preparation, but after the aqueous extract or Sheng-Mai-San was given, the half-life and AUC of schisandrin were greater than when schisandrin alone was given. It is therefore possible that components of these products could alter the metabolism of schisandrin. This may be important when extrapolating the effects of multi-constituent herbal preparations to the use of schisandrin.

**Interactions overview**

Schisandra may modestly induce the metabolism of warfarin and greatly increase the absorption of tacrolimus, but it appears to have little effect on the metabolism of nifedipine.

Schisandra + Food
No interactions found.

Schisandra + Herbal medicines
No interactions found.

Schisandra + Nifedipine
The interaction between schisandra and nifedipine is based on experimental evidence only.

Clinical evidence
No interactions found.

Experimental evidence
In a single-dose study, rats were given nifedipine 2 mg/kg 30 minutes after a 50-mg/kg dose of Shoseiryuto. The effects of Shoseiryuto were also studied in vitro in rats. Although the in vitro study found that Shoseiryuto inhibited CYP3A4, the study in rats found that the pharmacokinetics of nifedipine were not affected by the preparation. Shoseiryuto contains schisandra fruit, ephedra herb, cinnamon bark, peony root, processed ginger, asiasarum root, pinellia tuber and glycyrrhiza.1

Mechanism
Schisandra has been shown in vitro to have an inhibitory effect on the cytochrome P450 isoenzyme CYP3A4, which is involved in the metabolism of nifedipine. This animal study does not support the in vitro findings.

Importance and management
Evidence appears to be restricted to experimental studies involving rats, and the findings, which cannot be directly extrapolated to humans, suggest that the in vitro effects do not seem to be clinically relevant in vivo. Because of the nature of the evidence, it is difficult to make recommendations on the concurrent use of nifedipine and Shoseiryuto until human studies are conducted; however, a clinically relevant interaction appears unlikely.

Schisandra + Tacrolimus
Schisandra greatly increases tacrolimus levels and its adverse effects.

Clinical evidence
In a pharmacokinetic study, 12 healthy subjects were given an extract of Schisandra sphenanthera (containing 33.75 mg schizandrin) twice daily for 14 days, with a single 2-mg oral dose of tacrolimus on day 14. The extract of Schisandra sphenanthera increased the AUC and maximum plasma concentrations of tacrolimus by 164% and 227%, but did not alter its half-life. Six of the 12 subjects experienced indigestion, and burning hands and feet, one hour after both medicines were given. These symptoms resolved over 10 hours.1

Experimental evidence
No relevant data found.

Schisandra + Warfarin and related drugs
The interaction between schisandra and warfarin is based on experimental evidence only.

Clinical evidence
No interactions found.

Experimental evidence
In a study in rats, pretreatment with schisandra aqueous extract 500 mg/kg daily by gastric lavage for 6 days reduced the AUC of a single 2-mg/kg dose of intravenous warfarin by 29%, and increased warfarin clearance by 37%. The half-life of warfarin was also reduced from 13.1 hours to 11.6 hours.1

Mechanism
The authors of the study suggest that schisandra increases the metabolism of warfarin by inducing the cytochrome P450 isoenzyme CYP2C9, the most important isoenzyme involved in the metabolism of warfarin.1

Importance and management
Evidence is limited to this one experimental study in rats, which suggests that schisandra extracts may modestly increase the metabolism of warfarin. If similar effects occur in humans there may be a slight decrease in the anticoagulant effects of warfarin, although note that a decrease in the AUC of 29% is fairly modest and only small effects would be expected. If schisandra extracts are given to any patient taking warfarin, it may be prudent to consider monitoring the INR within the first week of treatment, if this is not already planned. All coumarin anticoagulants are metabolised by CYP2C9 to a greater or lesser extent, and therefore they may interact similarly. It would seem prudent to use similar precautions if these drugs are given with schisandra.

Senna

*Cassia senna* L., *Cassia angustifolia* Vahl. (Fabaceae)

**Synonym(s) and related species**

Indian senna.

*Cassia acutifolia* Delile, *Senna alexandrina* Mill.

Senna obtained from *Cassia senna* is also known as Alexandrian senna or Khartoum senna, and senna obtained from *Cassia angustifolia* is also known as Tinnevelly senna.

**Pharmacopoeias**


**Constituents**

*Anthraquinone glycosides* are major components of senna. In the leaf the anthraquinones include sennosides A, B, C and D, and palmidin A, rhein antherone and aloe-emodin glycosides. The fruit contains sennosides A and B and a closely related glycoside, sennoside A1. Senna is usually standardised to the content of sennosides, generally calculated as sennoside B.

Senna also contains naphthalene glycosides in the leaves and pods, mucilage (arabinose, galactose, galacturonic acid) and various other constituents such as *flavonoids*, volatile oil and resins.

**Use and indications**

Senna leaf or fruit is used as a laxative.

**Pharmacokinetics**

For information on the pharmacokinetics of an anthraquinone glycoside present in senna, see under aloes, page 27.

**Interactions overview**

Although senna has been predicted to interact with a number of drugs that lower potassium (such as the corticosteroids and potassium-depleting diuretics), or drugs where the effects become potentially harmful when potassium is lowered (such as digoxin), there appears to be little or no direct evidence that this occurs in practice. Senna may slightly reduce quinidine levels.
**Senna + Corticosteroids**

Theoretically, the risk of hypokalaemia might be increased in patients taking corticosteroids, who also regularly use, or abuse, anthraquinone-containing substances such as senna.

**Clinical evidence**

Chronic diarrhea as a result of long-term use, or abuse, of stimulant laxatives such as senna can cause excessive water and potassium loss; one paper (cited as an example) describes a number of cases of this. Systemic corticosteroids with mineralocorticoid effects can cause water retention and potassium loss. The effect of senna over-use combined with systemic corticosteroids is not known, but, theoretically at least, the risk of hypokalaemia might be increased. Although this is mentioned in some reviews on herbal interactions there do not appear to be any case reports of such an interaction.

It has also been suggested that senna, by increasing gastrointestinal transit times, might theoretically reduce the absorption of oral corticosteroids. However, there appears to be no published clinical data suggesting that that the absorption of corticosteroids is affected by senna or other drugs that alter gastrointestinal transit time, such as metoclopramide or loperamide.

**Experimental evidence**

No relevant data found.

**Mechanism**

In theory the additive loss of potassium caused by anthraquinone-containing substances and systemic corticosteroids may result in hypokalaemia.

**Importance and management**

The interaction between senna and corticosteroids is theoretical, but be aware of the potential in patients who regularly use, or abuse, anthraquinone-containing substances such as senna. However, note that, if anthraquinone laxatives are used as recommended (at a dose producing a comfortable soft-formed motion), then this interaction would not be expected to be clinically relevant.


---

**Senna + Digitalis glycosides**

Theoretically, digitalis toxicity could develop if patients regularly use, or abuse, anthraquinone-containing substances such as senna.

**Clinical evidence**

For the risk of digitalis toxicity including cardiac arrhythmias because of hypokalaemia induced by abuse of anthraquinone laxatives, see Aloes + Digitalis glycosides, page 28. For mention of a case of digoxin toxicity and mild hypokalaemia in a patient taking digoxin and furosemide, who started to take a laxative containing rhubarb and liquorice, see Liquorice + Digitalis glycosides, page 274.

**Experimental evidence**

The effects of anthraquinones found in senna (rhein, danthron, sennidins A and B, sennosides A and B), and senna leaf infusion (senna tea), on the absorption of furosemide 100 micromoles, were examined in human cell lines. Rhein and danthron increased the absorptive permeability of furosemide by about 3.6- and 3-fold, respectively. Furosemide permeability was reduced by more than a third by the sennidins and sennosides, but senna leaf infusion had little effect.

**Mechanism**

Little understood. The changes in furosemide absorptive permeability may be caused by interference with P-glycoprotein or other transporter proteins.


---

**Senna + Diuretics; Potassium-depleting**

Theoretically, patients taking potassium-depleting diuretics could experience excessive potassium loss if they also regularly use, or abuse, anthraquinone-containing substances such as senna.

**Clinical evidence**

For information on the additive risk of hypokalaemia with the use of potassium-depleting diuretics and abuse of anthraquinone-containing laxatives. See Aloes + Diuretics; Potassium-depleting, page 28.

**Experimental evidence**

The effects of the anthraquinones found in senna (rhein, danthron, sennidins A and B, sennosides A and B), and senna leaf infusion (senna tea), on the absorption of furosemide 100 micromoles, a poorly permeable drug, was examined in human cell lines. Rhein and danthron increased the absorptive permeability of furosemide by about 3.6- and 3-fold, respectively. Furosemide permeability was reduced by more than a third by the sennidins and sennosides, but senna leaf infusion had little effect.

**Mechanism**

Little understood. The changes in furosemide absorptive permeability may be caused by interference with P-glycoprotein or other transporter proteins.


---

**Senna + Estradiol**

Senna does not appear to affect the pharmacokinetics of estradiol.

**Clinical evidence**

In a clinical study in 19 women, the maximum daily tolerated dose of senna tablets (Senokot) was taken for 10 to 12 days with a single 1.5-mg dose of estradiol glucuronide given 4 days before the end of the assessment period. Senna had no significant effect on the median AUC of estradiol or estrone.

Experimental evidence

No relevant data found.

Mechanism

It was thought that reducing intestinal transit time with senna might lead to reduced blood levels of estradiol.

Importance and management

Limited evidence suggests that there is unlikely to be a clinically relevant pharmacokinetic interaction between anthraquinone-containing laxatives and estradiol.


Senna + Food

No interactions found.

Senna + Herbal medicines; Liquorice

Consider Liquorice + Laxatives, page 275, for the potential additive effects of anthraquinone-containing laxatives and liquorice.

Senna + Ketoprofen

The interaction between senna and ketoprofen is based on experimental evidence only.

Clinical evidence

No interactions found.

Experimental evidence

The effects of the anthraquinones found in senna (rhein, danthron, sennidins A and B, sennosides A and B), and senna leaf infusion (senna tea), on the absorption of ketoprofen 100 micromoles was examined in human cell lines.1 Danthron reduced the absorptive permeability of ketoprofen by almost 30% and the senna leaf infusion enhanced ketoprofen permeability by about 1.5-fold.

Mechanism

Little understood. The reduction in absorptive permeability of ketoprofen caused by danthron may be due to reduced ATP production in the cells. The enhanced permeability caused by senna leaf infusion is more difficult to explain because of the many different active compounds contained within the extract.1

Importance and management

Evidence is sparse, but what is known suggests that the use of anthraquinone-containing laxatives is unlikely to affect the intestinal permeability of ketoprofen.


Senna + Propranolol

The information regarding the use of senna with propranolol is based on experimental evidence only.

Clinical evidence

No interactions found.

Experimental evidence

The effects of the anthraquinones found in senna (rhein, danthron, sennidins A and B, sennosides A and B), and senna leaf infusion (senna tea), on the absorption of propranolol 100 micromoles, was examined in human cell lines.1 The in vitro absorption of highly permeable drugs such as propranolol was not significantly altered.

Mechanism

No mechanism expected.

Importance and management

Evidence is sparse, but what is known suggests that the use of anthraquinone-containing laxatives seems unlikely to affect the intestinal permeability of propranolol.


Senna + Quinidine

Quinidine plasma levels can be reduced by the anthraquinone-containing laxative senna.

Clinical evidence

In a study in 7 patients with cardiac arrhythmias taking sustained-release quinidine bisulfate 500mg every 12 hours, senna reduced plasma quinidine levels, measured 12 hours after the last dose of quinidine, by about 25%.1

Experimental evidence

No relevant data found.

Mechanism

Not understood.
Importance and management

The modest reduction in quinidine levels might be of clinical importance in patients whose plasma levels are barely adequate to control their arrhythmia.


Senna + Verapamil

The information regarding the use of senna with verapamil is based on experimental evidence only.

Clinical evidence

No interactions found.

Experimental evidence

The effects of the anthraquinones found in senna (rhein, danthron, sennidins A and B, sennosides A and B), and senna leaf infusion (senna tea), on the absorption of verapamil 100 micromoles was examined in human cell lines. The in vitro absorption of highly permeable drugs such as verapamil was not significantly altered.

Mechanism

No mechanism expected.

Importance and management

Evidence is sparse, but what is known suggests that the use of anthraquinone-containing laxatives seems unlikely to affect the intestinal permeability of verapamil.

**Shatavari**

*Asparagus racemosus* Willd. (Asparagaceae)

**Synonym(s) and related species**
Wild asparagus. Not to be confused with asparagus, page 44, which is *Asparagus officinalis*, the species used as a food.

**Constituents**
The root and rhizome of shatavari contain a series of steroidal saponins, the shatavarins and others, based on sarsapogenin, diosgenin and arasapogenin. The polycyclic alkaloid asparagamine A, benzofurans such as racemofuran and racemosol, and the *isoflavone* 8-methoxy-5,6,4′-tri-hydroxyisoflavone 7-O-β-D-glucopyranoside are also present.

**Use and indications**
Shatavari is widely used in Ayurvedic medicine for dealing with problems related to women’s fertility, loss of libido, threatened miscarriage and menopausal problems, and to increase the flow of breast milk. It is also reported to be antispasmodic, aphrodisiac, demulcent, diuretic, anti-diarrhoeal, antirheumatic and antidiabetic. Some of these indications are supported by pharmacological (but little clinical) evidence.

**Pharmacokinetics**
No relevant pharmacokinetic data found.

**Interactions overview**
Shatavari may have additive effects with conventional antidiabetic drugs, and may alter the absorption of a number of drugs by delaying gastric emptying. Shatavari contains phytoestrogens and therefore has the potential to be antagonistic or synergistic with oestrogens or oestrogen antagonists.
The interaction between shatavari and antidiabetics is based on experimental evidence only.

**Evidence, mechanism, importance and management**
In pharmacological studies, shatavari extracts have been shown to lower blood-glucose and stimulate insulin secretion. In one *in vitro* study, the insulin stimulatory effect of various extracts and partition fractions of shatavari was potentiated by tolbutamide. This suggests that shatavari might have some antidiabetic effects; this is in line with one of its traditional uses as an antidiabetic. The evidence is too slim to say whether a clinically important effect is likely for usual preparations of the herb, but an additive antidiabetic effect with conventional medicines for diabetes seems possible. Bear this information in mind in the event of an unexpected response to treatment.


No interactions found.

**Shatavari + Herbal medicines**
No interactions found.

**Shatavari + Miscellaneous**
Limited evidence suggests that shatavari increases the gastric emptying rate similarly to metoclopramide, which is known to decrease the absorption of atovaquone, digoxin and ketoprofen, and increase the absorption of ciclosporin, dantrolene, morphine and paracetamol (acetaminophen). Shatavari has the potential to interact similarly.

**Evidence, mechanism, importance and management**
In a crossover study in 8 healthy subjects, powdered root of shatavari 2 g reduced the gastric emptying half-life from a mean baseline of about 160 minutes to 101 minutes after two radio-labelled jam sandwiches were eaten. This was similar to the effect of a single 10-mg dose of oral metoclopramide (85 minutes). If shatavari increases the gastric emptying rate, it has the potential to increase or decrease the absorption of other drugs that are taken concurrently. Metoclopramide is known to have this effect and modestly decreases the absorption of atovaquone, digoxin and ketoprofen, and increases the absorption of ciclosporin, dantrolene, morphine and paracetamol (acetaminophen). Based on the limited evidence presented, it is possible that shatavari might interact similarly. Until more is known, some caution might be appropriate; however, note that, with the exception of atovaquone, in most cases the interactions of metoclopramide with these drugs are of limited clinical importance.


No interactions found.

**Shatavari + Oestrogens or Oestrogen antagonists**
The interaction between shatavari and oestrogens or oestrogen antagonists is based on a prediction only.

**Evidence, mechanism, importance and management**
Shatavari contains phytoestrogens and has been investigated in a variety of pharmacological and clinical studies for its effect on lactation, dysfunctional uterine bleeding, premenstrual syndrome and menopausal symptoms; this has been the subject of a review. Based on these studies, a cautious approach would be to recommend care when combining shatavari with conventional oestrogenic drugs or oestrogen antagonists such as tamoxifen, because it is unknown whether the effects might be antagonistic or synergistic (or, indeed, not clinically relevant). For further discussion of this subject, see Isoflavones + Tamoxifen, page 262.

Skullcap

*Scutellaria lateriflora* L. (Lamiaceae)

**Synonym(s) and related species**
Helmet flower, Hoodwort, Quaker bonnet, Scullcap, Scutellaria.

**Constituents**
The major active components of skullcap are the flavonoids scutellarin, scutellarein, baicalein, baicalin (the glucuronide of baicalein), dihydrobaicalin, apigenin, luteolin and other methoxyflavones. The iridoid catalpol, and γ-amino-benzoic acid (GABA) have also been found and there is a small amount of essential oil present composed of monoterpenes and sesquiterpenes.

**Use and indications**
Skullcap has been used traditionally as a sedative and to treat nervous disorders. Previous reports about its possible toxicity have been found to be because of contamination with *Teucrium* species; skullcap itself is now considered to be safe to use.

**Pharmacokinetics**
No relevant pharmacokinetic data found for skullcap, but see flavonoids, page 186, for information on individual flavonoids present in the herb.

**Interactions overview**
No interactions with skullcap found, but for information on the interactions of individual flavonoids present in skullcap, see under flavonoids, page 186.
Soya

Glycine max (L.Merr.) (Fabaceae)

Synonym(s) and related species
Soy.  
Glycine soja Siebold and Zucc.

Pharmacopoeias
Hydrogenated Soya Oil (BP 2009); Hydrogenated Soybean Oil (Ph Eur 6.4, USP 32); Powdered Soy Isoflavones Extract (USP 32); Refined Soya Oil (BP 2009); Soybean Oil (USP 32); Soybean Oil, Refined (Ph Eur 6.4).

Constituents
The isoflavones in soya beans consist mainly of genistein and daidzein, with smaller amounts of isoformononetin, ononin, glyce tin, desmethyltexasin and others. They are present mainly as glycosides, and the amount varies between the different soya products. Soya beans also contain coumestans (mainly in the sprouts) and phytosterols. The fixed oil from soya beans contains linoleic and linolenic acids.

Fermented soya products contain variable amounts of tyramine.

Use and indications
Soya is a widely used food, particularly in Japanese and Chinese cuisine. Flour and protein from the beans are used as tofu and as a substitute for meat. Fermented products include soy sauce, natto and miso, and these can contain high concentrations of the isoflavones. Soya milk is used as a substitute for individuals who are allergic to cows’ milk, including in infant formula. Edamame beans are soya beans eaten while still green.

There are numerous purported benefits of soya protein, the most well studied being possible reductions in hyperlipidemia, menopausal symptoms and osteoporosis, and prevention of some cancers. Epidemiological studies suggest that a diet with a high intake of soya might protect against breast cancer.1 Numerous randomised clinical studies show a small benefit for soya protein on blood lipids (which is probably independent of isoflavone content),2,3 and there is also evidence of a modest benefit in patients with diabetes.4 Soya protein and the isoflavone fraction have also shown some benefits for menopausal symptoms5 and postmenopausal osteoporosis6 in some studies. One paper notes that many of the demonstrable actions of isoflavones in soya are attributed to the aglycones genistein and daidzein; however, these occur in negligible amounts unless the product has been fermented.7 For further information on the individual isoflavones present in soya, see isoflavones, page 258. Despite numerous studies and meta-analyses, the health benefits of soya have not been conclusively proven and remain controversial. In a 2006 analysis, the American Heart Advisory Committee concluded that the main benefit of a soya-based diet probably relates to its high content of polyunsaturated fats and fibre and low content of saturated fat.8

Pharmacokinetics
In healthy subjects, a soya extract did not induce the cytochrome P450 isoenzyme CYP3A4.9 In vitro, soya bean products and a hydrolysed soya extract, as well as the soya isoflavones daidzein and genistein, inhibited CYP3A4,10 and CYP2C9.9 However, in one of these studies,10 St John’s wort also inhibited CYP3A4, but clinically this herb is known to be an inducer of CYP3A4. This highlights the problems of extrapolating the findings of in vitro studies to clinical situations.9 Soya-based infant formulas (as well as cow-milk infant formulas) induced CYP1A2 in vitro see caffeine, page 357).

The pharmacokinetics of the isoflavone constituents of soya are further discussed under isoflavones, page 258.

Interactions overview
Soya products may increase the metabolism of caffeine and reduce the absorption of levothyroxine. Fermented soya bean products contain high levels of tyramine and vitamin K and may therefore cause hypertensive reactions with MAOIs, and decrease the activity of warfarin and related anticoagulants.

Potential interactions of isoflavone constituents of soya are covered under isoflavones; see antibiotics, page 260, nicotine, page 261, paclitaxel, page 261, tamoxifen, page 262, and theophylline, page 263.

Soya + Antibacterials

No data for soya found. For the theoretical possibility that broad-spectrum antibacterials might reduce the metabolism of the isoflavone constituents of soya, such as daidzein, by colonic bacteria, and so alter their efficacy, see Isoflavones + Antibacterials, page 260.

Soya + Caffeine

Soya products may increase the metabolism of caffeine.

Clinical evidence

Caffeine elimination is low in neonates, but increases faster in those receiving formula feeds (type not specified), than in breast-fed infants. In another study of caffeine for apnoea, formula-fed (type not specified) infants required higher caffeine doses than breast-fed infants (4.4 mg/kg compared with 8.3 mg/kg), but still had lower trough caffeine levels.

Experimental evidence

Both soya-based and cow milk-based infant formulas induced the cytochrome P450 isoenzyme CYP1A2, by which caffeine metabolism matures in the first year of life. Infant formula appears to induce the cytochrome P450 isoenzyme CYP1A2, by which caffeine is metabolised. This property is common to both cows’ milk and soya, so must be due to a common constituent of both, or the lack of a constituent present in breast milk. The fact that soya isoflavones have some CYP1A2 inhibitory activity does not appear to counteract this effect.

Importance and management

Clinical evidence in support of an interaction between soya and caffeine is limited, because the two studies do not state the formula feeds used, although it seems likely that soya feeds are implicated; this suggestion is supported by experimental evidence. In infants, caffeine is dosed individually, but be aware that required doses are likely to increase in those receiving formula feeds, including soya-based formula.

Note that, conversely, in high doses, soya isoflavone supplements might reduce the required dose of CYP1A2 substrates such as isoflavones + Theophylline, page 263.


Soya + Food

No interactions found.

Soya + Herbal medicines

No interactions found.

Soya + Levothyroxine and related drugs

Soya products or soya isoflavones might increase the dose required of thyroid hormone replacement therapy.

Clinical evidence

A 45-year-old woman who had hypothyroidism after a near-total thyroideectomy and radioactive iodine ablative therapy for papillary carcinoma of the thyroid required unusually high oral doses of levothyroxine (300 micrograms daily) to achieve clinically effective levels of free thyroxine (T4); suppression of thyroid-stimulating hormone (TSH) was unsatisfactory, even at this dose. She had routinely been taking a ‘soya cocktail’ protein supplement immediately after her levothyroxine. Taking the soya protein cocktail in the morning and the levothyroxine in the evening avoided this effect.

A newborn infant with primary hypothyroidism failed to respond to a usual dose of levothyroxine until his soya formula was replaced with cows’ milk formula. In another report, three infants with primary hypothyroidism fed soya formula required 18 to 25% decreases in their levothyroxine dose after soya formula was discontinued. In a retrospective study of primary hypothyroidism, TSH values took longer to normalise in 8 infants fed soya formula than in 70 other infants not given soya.

Historical data (from before the 1960s) show that soya formula without iodine supplementation caused goitre, which could be reversed by iodine supplementation. However, soya isoflavones do not appear to cause thyroid hormone abnormalities in euthyroid individuals (also reviewed). However, similar precautions would seem prudent if patients receiving levothyroxine wish to take soya supplements; however, remember that the intake of soya supplementation will need to remain relatively constant.

Mechanism

Soya isoflavones clearly inhibit thyroid peroxidase; however, hypothyroidism does not usually occur unless iodine deficiency is also present. Soya formula or other similar products might decrease levothyroxine absorption in some individuals.

Importance and management

There is a good body of evidence, which suggests that soya products or soya isoflavones might increase the dose required of thyroid hormone replacement therapy. It would seem prudent to closely monitor the resolution of primary hypothyroidism in infants receiving soya formula, and expect to use higher dose of levothyroxine than anticipated in these individuals. Monitor thyroxine levels, and either discontinue the soya formula or further increase the dose if necessary. Similar precautions would seem prudent if patients receiving levothyroxine wish to take soya supplements; however, remember that the intake of soya supplementation will need to remain relatively constant.

A potentially fatal hypertensive reaction can occur between the non-selective MAOIs and tyramine-rich foods. Significant amounts of tyramine may be present in fermented or preserved soya products such as soy sauce and tofu, and it may be prudent to avoid these while taking an MAOI. Effects may last for up to two weeks after discontinuation of the MAOI. However, other soya products such as dried textured soya protein and fresh soya beans are unlikely to contain important amounts of tyramine. The risk of a serious hypertensive reaction with moclobemide (or other RIMAs) is very much reduced. Most patients therefore do not need to follow the special dietary restrictions required with the non-selective MAOIs.

Clinical evidence
A 33-year-old woman taking tranylcypromine 10 mg four times daily presented to an emergency department with global headache and stiffness of the neck and was found to have a blood pressure of 230/140 mmHg and bradycardia of 55 bpm. Twenty minutes earlier she had eaten chicken teriyaki containing aged soy sauce. She was successfully treated with intravenous labetolol.1

Experimental evidence
The tyramine content of a variety of soya products showed marked variability, including clinically significant tyramine levels in tofu when stored for one week and high tyramine content in one of 5 soy sauces (a tyramine level of 6 mg or less was considered safe).2 In another analysis, high tyramine levels were found in two soy sauces, fermented soya beans, fermented soya bean paste and a soya bean curd condiment.3 Other non-fermented soya products (tofu, soya bean soup, bean flour, dried bean curd, soya bean drink) had low levels of tyramine, as did one fermented soya bean soup product (miso soup).3

Mechanism
Potentiation of the pressor effect of tyramine.2 Tyramine is formed in foods by the bacterial degradation of proteins, firstly to tyrosine and other amino acids, and the subsequent decarboxylation of the tyrosine to tyramine. This interaction is therefore not associated with fresh foods, but with those that have been allowed to over-ripen or ‘mature’ in some way,4 or if spoilage occurs. Tyramine is an indirectly acting sympathomimetic amine, one of its actions being to release noradrenaline (norepinephrine) from the adrenergic neurones of the large amounts of noradrenaline that reaches the general circulation. However, if the activity of the enzyme monoamine oxidase in the gut wall and liver before it accumulates there during inhibition of MAO,4 RIMAs such as moclobemide and toloxatone selectively inhibit MAO-A, which leaves MAO-B still available to metabolise tyramine. This means that they have less effect on the tyramine pressor response than non-selective MAOIs.

Importance and management
A potentially fatal hypertensive reaction can occur between the non-selective MAOIs and tyramine-rich foods. Significant amounts of tyramine may be present in fermented or preserved soya products such as soy sauce and tofu, and it may be prudent to avoid these while taking an MAOI. Effects may last for up to two weeks after discontinuation of the MAOI. However, other soya products such as dried textured soya protein and fresh soya beans are unlikely to contain important amounts of tyramine.

Moclobemide is safer (in the context of interactions with tyramine-rich foods and drinks) than the non-selective MAOIs, because it is more readily reversible and selective. Therefore the risk of a serious hypertensive reaction with moclobemide (or other RIMAs) is very much reduced. Most patients therefore do not need to follow the special dietary restrictions required with the non-selective MAOIs.

For discussion of a study showing that soya isoflavones (daidzein and genistein) caused a minor decrease in the metabolism of nicotine, see Isoflavones + Nicotine, page 261.

No data for soya found. For the possibility that genistein, an isoflavone present in soya, might markedly increase paclitaxel levels, see Isoflavones + Paclitaxel, page 261.

The data relating to the use of soya products and isoflavone supplements (containing the isoflavones daidzein and genistein, among others) with tamoxifen are covered under Isoflavones + Tamoxifen, page 262.

No data for soya found. For the possibility that high doses of daidzein present in soya might modestly increase theophylline levels, see Isoflavones + Theophylline, page 263.

Soya + Warfarin and related drugs
Natto, a Japanese food made from fermented soya bean, can markedly reduce the effects of warfarin and acenocoumarol, because of the high levels of vitamin K1 substance produced in the fermentation process. In one study, soya bean protein also modestly reduced the effects of warfarin, and a similar case has been reported with soy milk. Two cases of “warfarin resistance” have been seen in patients given intravenous soya oil emulsions.
Clinical evidence

(a) Fermented soya bean products (natto)
In a controlled study in 12 healthy subjects stabilised on acenocoumarol, a single meal containing 100 g of natto decreased the mean INR from 2.1 to 1.5 after 24 hours, and the INR had still not returned to the original level after 7 days (INR 1.75 one week later). The effect was considered clinically important in 6 of the 12 subjects. Similarly, in an earlier retrospective study of 10 patients taking warfarin, eating natto caused the thrombostest values to rise from a range of 12 to 29% up to a range of 33 to 100%. The extent of the rise appeared to be related to the amount of natto eaten. The thrombostest values fell again when the natto was stopped. A healthy subject taking warfarin, with a thrombostest value of 40%, ate 100 g of natto. Five hours later the thrombostest value was unchanged, but 24 hours later it was 86%, and after 48 hours it was 90% (suggesting that the anticoagulant effect was decreased).2

(b) Soya milk
In a 70-year-old man stabilised on warfarin 3 mg daily, consumption of soya milk 480 mL daily (240 mL of both Sun Soy and 8th Continent mixed together) decreased the INR from 2.5 to 1.6 after about 4 weeks.3 One week after stopping the soya milk, his INR was 1.9, and 4 weeks after it was 2.5.

(c) Soya oil
Soya oil is an important source of dietary vitamin K. Two cases of ‘warfarin resistance’ have been seen in patients given intravenous soya oil emulsions.4,5

(d) Soya protein
In a study in 10 patients with hypercholesterolaemia who were stabilised on warfarin, substitution of all animal protein for textured soya protein for 4 weeks caused a marked reduction (Quick value approximately doubled) in the anticoagulant effects of warfarin by the second week.6

Experimental evidence
Experiments in animals to investigate the clinical observations for natto found that natto strongly antagonised the effects of warfarin.2 In one in vitro metabolism study in human liver microsomes,7 hydrolysed soya extract inhibited all of the cytochrome P450 isoenzymes tested, particularly CYP2C9 and CYP3A4 (which are responsible for the metabolism of warfarin). This suggests that an increased warfarin effect might have been expected, but the authors point out there is a lack of concordance between in vitro and in vivo findings.

Mechanism
Soya beans are a moderate source of vitamin K1 (19 micrograms per 100 g),8 and soya oil and products derived from it are an important dietary source of vitamin K. However, the soya milk brand taken in the case report did not contain vitamin K,9 and another reference source lists soya milk as containing just 7.5 micrograms vitamin K per 250 mL,10 which would not be expected to cause an interaction. Why this product decreased the effect of warfarin is therefore open to speculation.

The vitamin K content of textured soya protein is unknown. Note that soy sauce made from soya and wheat is reported to contain no vitamin K, and soft tofu made from the curds by coagulating soya milk contains only low levels (2 micrograms per 100 g).8

In contrast, fermented soya bean products such as natto contain very high levels of a particular vitamin K2 substance (MK-7),7 because of the fermentation process with Bacillus natto. In addition, the bacteria might continue to act in the gut to increase the synthesis and subsequent absorption of vitamin K2.2 Although the role of vitamin K2 in anticoagulation is less well established than vitamin K1, it appears that this also opposes the actions of coumarins and indanediones, which are vitamin K antagonists.

Importance and management
The interaction between warfarin and fermented soya bean products is established, marked and likely to be clinically relevant in all patients. Patients taking coumarins and probably indanedione anticoagulants should be advised to avoid natto, unless they want to consume a regular, constant amount.

Although information is limited, it appears that soya protein might also modestly reduce the effect of warfarin. In particular, complete substitution of animal protein for soya protein appears to reduce the effect of warfarin. Case reports suggest that soya milk and soya oil may also interact, and therefore some caution would be prudent with these products. On the basis of known vitamin K content, whole soya beans could potentially reduce the effect of warfarin, whereas soy sauce should not.8 Note that patients taking coumarins and indanediones are advised to have their INR checked if they markedly change their diet. This would seem particularly important if they decide to change their intake of soya-related products.

**St John’s wort**

*Hypericum perforatum* L. (Clusiaceae)

**Synonym(s) and related species**

Hypericum, Millepertuis.

*Hypericum noeanum* Boiss., *Hypericum veronense* Schrank.

**Pharmacopoeias**

St John’s Wort (*BP 2009, Ph Eur 6.4, USP 32*); St John’s Wort Dry Extract, Quantified (*BP 2009, Ph Eur 6.4*).

**Constituents**

The main groups of active constituents of St John’s wort are thought to be the anthraquinones, including hypericin, isohypericin, pseudohypericin, protohypericin, protopseudo-hypericin and cyclopropahypericin, and the prenylated phloroglucinols, including hyperforin and adhyperforin. Flavonoids, which include kaempferol, quercetin, luteolin, hyperoside, isorhamnetin, quercitin and rutin; biflavonoids, which include biapigenin and amentoflavone, and catechins are also present. Other polyphenolic constituents include caffeic and chlorogenic acids, and a volatile oil containing methyl-2-octane.

Most St John’s wort products are standardised at least for their hypericin content (*BP 2009*), even though hyperforin is known to be a more relevant therapeutic constituent, and some preparations are now standardised for both (*USP 32*). It is important to note that there will be some natural variation, and as both hypericin and hyperforin are sensitive to light, they are relatively unstable, so processes used during extraction and formulation, as well as storage conditions, can affect composition of the final product. Therefore different preparations of St John’s wort have different chemical profiles and they may not be equivalent in effect.

**Use and indications**

St John’s wort is widely used to treat mild-to-moderate depression, seasonal affective disorder, low mood, anxiety and insomnia, particularly if associated with menopause. It has also been used topically for its astringent properties.

**Pharmacokinetics**

St John’s wort has been implicated in numerous clinical interactions with conventional drugs and has therefore been extensively studied. Alongside the extensive clinical studies and case reports, there is also a plethora of *in vitro* and *animal* experimental data regarding its interactions and pharmacokinetics. This monograph will discuss the clinical evidence in preference to experimental data, where extensive literature is available and the clinical data are conclusive.

The main constituent found to be responsible for the activity of St John’s wort is hyperforin, but other constituents are considered to contribute to its antidepressant activity, such as hypericin and pseudohypericin, the flavonoid quercetin and its glycosides, and rutin. Bioavailability from varying formulations and extracts appears to be low, giving variable steady-state plasma concentrations. For information on the pharmacokinetics of individual flavonoids present in St John’s wort, see under flavonoids, page 186.

(a) Cytochrome P450 isoenzymes

St John’s wort is known to affect several cytochrome P450 isoenzymes and this accounts for the wide range of drugs with which St John’s wort has been reported to interact. It is thought to exert a biphasic effect on these isoenzymes, with inhibition occurring in *in vitro* studies with the initial exposure, and induction following long-term use. Therefore, predicting the overall effect from *in vitro* and *animal* experiments may not always be reliable.

The following is a list of cytochrome P450 isoenzymes that have been assessed with St John’s wort in a clinical setting:

- **CYP3A4**: the main clinically relevant effect of St John’s wort on cytochrome P450 is the induction of CYP3A4. This has been shown to be related to the constituent, hyperforin. Products vary in their hyperforin content; preparations with a high-hyperforin content, given for a long period of time, will induce CYP3A4 activity, and therefore decrease the levels of drugs metabolised by CYP3A4, by a greater extent than preparations containing low-hyperforin levels taken for a shorter period of time.

Conventional drugs are often used as probe substrates in order to establish the activity of another drug on specific isoenzyme systems. For CYP3A4 the preferred probe drug is midazolam, because it has no effects of its own on CYP3A4, and is metabolised almost exclusively by CYP3A4, with no known interference from other metabolic processes, such as transport proteins. See St John’s wort + Benzodiazepines, page 364, for an example of the effects of St John’s wort on CYP3A4.

Studies have assessed the duration of the effects of St John’s wort on CYP3A4. One study found that CYP3A4 activity returned to baseline in about one week after St John’s wort was taken for 14 days. This may provide an indication of how long to leave between using St John’s wort and starting another drug, and therefore avoiding clinically important interactions. However, another study found that the effects of St John’s wort lasted for more than 2 weeks in some patients. See the table Drugs and herbs affecting or metabolised by the cytochrome P450 isoenzyme CYP3A4, page 8 for a list of known CYP3A4 substrates.
(b) P-glycoprotein

St John’s wort is known to affect P-glycoprotein activity, especially intestinal P-glycoprotein, and it is generally thought that inhibition takes place initially, and briefly, but is followed by a more potent and longer-acting induction. It is the induction that leads to the clinically relevant drug interactions of St John’s wort that occur as a result of this mechanism. Hyperforin is implicated as the main constituent responsible for the effect, see St John’s wort + Digoxin, page 368.

(c) Serotonin syndrome

St John’s wort inhibits the reuptake of 5-hydroxytryptamine (5-HT, serotonin) and this has resulted in a pharmacodynamic interaction, namely the development of serotonin syndrome (see under Pharmacodynamics, page 10) with conventional drugs that also have serotonergic properties. These include bupropion, page 364, SSRIs, page 375, SSRIs, page 376, and triptans, page 379.

Interactions overview

St John’s wort is known to interact with many conventional drugs because of its ability to induce the activity of CYP3A4 and P-glycoprotein, which are involved in the metabolism and distribution of the majority of drugs. CYP2C19, CYP2C8 and CYP2E1 may also be induced by St John’s wort, although the evidence is not conclusive and further study is needed. In general, CYP2C9 and CYP1A2 do not appear to be significantly affected by St John’s wort; however, isolated reports of an interaction have still occurred. Hyperforin is the active constituent believed to be central to the inducing effects of St John’s wort. As St John’s wort preparations and dose regimens are varied, the amount of hyperforin exposure will also vary a great deal, which makes predicting whether an interaction will occur, and to what extent, difficult. For more information concerning the pharmacokinetic and pharmacodynamic properties of St John’s wort that are relevant to drug interactions, see under Pharmacokinetics, and for detail on the interactions of St John’s wort, see the sections that follow page 361. For information on the interactions of individual flavonoids present in St John’s wort, see under flavonoids, page 186.

St John’s wort + 5-Aminolevulinic acid

An isolated case report describes a severe phototoxic reaction attributed to a synergistic effect of 5-aminolevulinic acid and St John’s wort.

Clinical evidence
A 47-year-old woman who was taking St John’s wort (Hyperforce, dose not stated), experienced a phototoxic reaction on skin areas exposed to light 6 hours after receiving 5-aminolevulinic acid 40 mg/kg. She developed a burning erythematous rash and severe swelling of the face, neck and hands. Treatment with oral corticosteroids resulted in complete resolution after skin desquamation.

Experimental evidence
An in vitro study using human cell lines found that the combination of 5-aminolevulinic acid and an extract of St John’s wort (Hyperforce) increased light-induced toxicity by up to 15%.

Mechanism
It was suggested that there was a synergistic photosensitivity reaction between the two drugs.

Importance and management
This appears to be the only report of such an effect, but bear it in mind in the event of an unexpected adverse reaction to 5-aminolevulinic acid.

St John’s wort + Anaesthetics, general

It has been predicted that St John’s wort may prolong the effects of anaesthetics, which is supported by an isolated case. A case of profound hypotension during anaesthesia following the long-term use of St John’s wort has also been reported. The American Society of Anesthesiologists recommends that all herbal medicines should be stopped two weeks prior to elective surgery.

Clinical evidence
Prolonged anaesthesia has been reported in a 21-year-old woman who had been taking St John’s wort 1 g three times daily for 3 months before general anaesthetics were given for the surgical removal of an abscess. Anaesthesia was induced by intravenous fentanyl citrate 1 microgram/kg and propofol 3 mg/kg, and maintained throughout the procedure by sevoflurane and nitrous oxide using a facemask.

Another case report describes a healthy 23-year-old woman, who had been taking St John’s wort on a daily basis for 6 months, who developed severe hypotension (BP 60/20 mmHg) during general anaesthesia, which responded poorly to ephedrine and phenylephrine (BP increased to 70/40 mmHg).

Experimental evidence
No relevant data found.

Mechanism
It was suggested that St John’s wort may prolong anaesthesia, but there are no reports of this occurring. This appears to have been based on the possibility that St John’s wort acts as an MAOI (although this has been disputed), and the limited evidence that MAOIs may cause hepatic enzyme inhibition and potentiate the effects of barbiturates.

However, there is now increasing evidence that St John’s wort induces hepatic enzymes, and might therefore increase the metabolism of barbiturates, which suggests that it could increase requirements for thiopental anaesthesia. The possible MAOI activity of St John’s wort has led to the recommendation that the same considerations apply as for other MAOIs and general anaesthetics.

The authors of the second case report suggest that St John’s wort might have caused adrenergic desensitisation with decreased responsiveness to the vasopressors.

St John’s wort + Antidiabetics

St John’s wort modestly decreases the AUC of gliclazide and rosiglitazone. Pioglitazone and repaglinide are similarly metabolised and may therefore be expected to interact similarly. St John’s wort does not affect the metabolism of tolbutamide.

Clinical evidence
(a) Gliclazide
In a study in 21 healthy subjects, a 300-mg dose of a St John’s wort preparation with a high hyperforin content (LI 160, Lichtwer Pharma) was given 3 times daily for 15 days. On the last day of treatment, a single 80-mg dose of gliclazide was given, followed 30 minutes later by glucose 75 g. St John’s wort reduced the maximum levels and AUC of gliclazide by 22% and 35%, respectively. The clearance was increased by 47%. No statistically significant changes were found in the AUCg-0.4 or blood levels of glucose or insulin.

(b) Rosiglitazone
A preliminary report of a pharmacokinetic study states that St John’s wort 900 mg daily decreased the AUC of a single dose of rosiglitazone by 26% and increased its clearance by 35%.

(c) Tolbutamide
In a study using tolbutamide as a probe drug for CYP2C9 activity, St John’s wort 900 mg had no effect on the metabolism of a single dose of tolbutamide either after one day or after 2 weeks of use. The St John’s wort product used was from Sundown Herbs and provided about 33 mg of hyperforin daily. Similarly, in another study, a St John’s wort preparation with low hyperforin content (Esbericum) at a dose of 240 mg daily (which provided about 3.5 mg of hyperforin daily) had no effect on tolbutamide metabolism.
St John’s wort + Antiepileptics

St John’s wort modestly increased the clearance of single-dose carbamazepine, but had no effect on multiple-dose carbamazepine pharmacokinetics. Carbamazepine does not appear to significantly affect the pharmacokinetics of hypericin or pseudohypericin (constituents of St John’s wort). St John’s wort increased the clearance of mephenytoin by about 3-fold and is predicted to reduce the blood levels of phenytoin and phenobarbital, but this awaits clinical confirmation.

Clinical evidence
In a multiple-dose study in 8 healthy subjects, St John’s wort had no effect on the pharmacokinetics of carbamazepine or its metabolite (carbamazepine-10,11-epoxide). In this study, subjects took carbamazepine 200 mg increased to 400 mg daily alone for 20 days, then with St John’s wort 300 mg (standardised to hypericin 0.3%) three times daily for a further 14 days. In contrast, the AUC of a single 400-mg dose of carbamazepine was reduced by 21% after St John’s wort 300 mg was given three times daily for 14 days, and the AUC of the 10,11-epoxide metabolite was increased by 26%.

A double-blind, placebo-controlled study in healthy subjects found that, apart from a modest 29% decrease in the AUC of pseudohypericin, carbamazepine did not significantly affect the pharmacokinetics of either hypericin or pseudohypericin, which are both constituents of St John’s wort.

In another placebo-controlled study in 6 extensive metabolisers of CYP2C19, St John’s wort 300 mg three times daily for 14 days increased the clearance of a single oral dose of mephenytoin 100 mg given on day 15, by about 3-fold. There were no significant effects when mephenytoin was given to 6 poor metabolisers of CYP2C19. Each St John’s wort tablet contained 0.3% hypericin and 4% hyperforin.

Note that St John’s wort does not appear to interfere with laboratory assays for carbamazepine, mephenytoin, phenobarbital or valproate. See St John’s wort + Laboratory tests, page 372.
St John’s wort + Benzodiazepines

Long-term use of St John’s wort decreases the plasma levels of alprazolam, midazolam and quazepam. St John’s wort preparations taken as a single dose, or containing low-hyperforin levels, appear to have less of an effect.

Clinical evidence

(a) Alprazolam

In a study in 12 healthy subjects, St John’s wort (LI 160, Lichtwer Pharma, 0.12 to 0.3% hypericin) 300 mg three times daily for 16 days with a single 2-mg dose of alprazolam on day 14. The AUC of alprazolam was halved by St John’s wort and the clearance was increased by about twofold.1

In another study, alprazolam 1 or 2 mg was given to 7 healthy subjects on the third day of a 3-day treatment period with St John’s wort (Solaray; hypericin content standardised at 0.3%) 300 mg three times daily. The pharmacokinetics of alprazolam were unchanged by St John’s wort, but the authors note that 3 days may have been an insufficient time for St John’s wort to fully induce cytochrome P450 isoenzymes.2 In another study, 16 healthy subjects were given St John’s wort extract 120 mg (Esbericum capsules; corresponding to 0.5 mg total hypericins and 1.76 mg hyperforin) twice daily for 10 days. A single 1-mg dose of alprazolam was given on the day before treatment with St John’s wort and on the last day of treatment. St John’s wort extract at this low dosage and low hyperforin content had no clinically relevant effects on the pharmacokinetics of alprazolam, when compared with 12 subjects given placebo.3

(b) Midazolam

An open-label study in 12 healthy subjects found that a single 900-mg dose of St John’s wort had no significant effect on the pharmacokinetics of single doses of either oral midazolam 5 mg or intravenous midazolam 0.05 mg/kg, although there was a trend for increased oral clearance. However, St John’s wort 300 mg three times daily for 14 or 15 days decreased the AUC and maximum plasma concentration of oral midazolam by about 50% and 40%, respectively. Intravenous midazolam was not significantly affected. Similar results were found in another six studies.4–9 In one of the studies, although no serious adverse events occurred, 3 subjects reported that the sedative effects of midazolam were less noticeable when St John’s wort was taken at the same time.6

(c) Quazepam

In a placebo-controlled study, 13 healthy subjects were given St John’s wort (TranNature; hypericin content standardised at 0.3%) 300 mg three times daily for 14 days with a single 15-mg dose of quazepam on day 14. St John’s wort modestly decreased the AUC and maximum plasma levels of quazepam by 26% and 29%, respectively, but the pharmacodynamic effects of quazepam were not affected.10

Experimental evidence

No relevant data found.

Mechanism

Alprazolam, midazolam and quazepam are substrates of the cytochrome P450 isoenzyme CYP3A4. St John’s wort appears to induce CYP3A4, thus increasing the metabolism of oral midazolam,5,6,11 alprazolam1 and quazepam,10 and reducing the bioavailability of these benzodiazepines.

Hyperforin appears to be the main active constituent that induces CYP3A4, because high-hyperforin extracts have more of an inducing effect than low-hyperforin extracts.6–9

Importance and management

Although not all the studies found an interaction between St John’s wort and alprazolam or midazolam, those that did found a reduction in levels, which is in line with the known CYP3A4-inducing effects of St John’s wort. The variable findings reported in the studies (some found no interaction) could be due to the preparation of St John’s wort used and the duration of treatment.2–8 Until more is known about the interacting constituents of St John’s wort, and the amount necessary to provoke an interaction, it would seem prudent to monitor patients receiving alprazolam and oral midazolam concurrently for any signs of reduced efficacy. Single doses of intravenous midazolam do not appear to be significantly affected. Note that triazolam is also a substrate of CYP3A4 and is likely to be affected in the same way as alprazolam and midazolam.

The modest reduction in quazepam levels did not reduce its efficacy; however, it may be prudent to bear the potential for an interaction in mind should a patient taking St John’s wort have a reduced response to quazepam.

These benzodiazepines that undergo glucuronidation, such as lorazepam, oxazepam and temazepam, would not be expected to be affected by St John’s wort, and may be useful alternatives.

St John’s wort + Bupropion

Two cases describe symptoms indicative of serotonin syndrome when bupropion was taken with long-term St John’s wort.

Clinical evidence

A 58-year-old woman who had been taking St John’s wort 300 mg daily for several years and receiving HRT (estradiol and medroxyprogesterone) developed acute facial dystonia affecting the right side of her face, neck and right arm when she started taking bupropion 150 mg daily for 4 days. The episodic spasms were completely resolved after 5 months of treatment with oral chlophendramine, procyclidine, diazepam and carbamazepine.1

A brief report describes the development of mania in one patient, which was associated with the concurrent use of St John’s wort and bupropion.2

Experimental evidence

No relevant data found.

Mechanism

A pharmacodynamic interaction may occur between St John’s wort and bupropion because they can both inhibit the reuptake of 5-hydroxytryptamine (serotonin). Serotonin syndrome has been seen

with St John’s wort alone, and so additive serotonergic effects appear to be the explanation for what occurred in the cases described here.

**Importance and management**

Information appears to be limited to these two reports, one of which is lacking detail. Nevertheless because of the potential severity of the reactions it would seem prudent to monitor concurrent use closely for an increased incidence of adverse reactions.


### St John’s wort + Buspirone

Two patients taking buspirone developed marked CNS effects after starting to take herbal medicines including St John’s wort.

**Clinical evidence**

A 27-year-old woman who had been taking buspirone 30 mg daily for over one month started to take St John’s wort (Hypericum 2000 Plus, Herb Valley, Australia) three tablets daily. After 2 months she complained of nervousness, aggression, hyperactivity, insomnia, confusion and disorientation, which was attributed to serotonin syndrome. The St John’s wort was stopped, the buspirone was increased to 50 mg daily and her symptoms resolved over a week. A 42-year-old woman who was taking fluoxetine 20 mg twice daily and buspirone 15 mg twice daily started to develop symptoms of anxiety, with episodes of over-sleeping and memory deficits. It was discovered that she had been self-medicating with St John’s wort, ginkgo biloba and melatonin. She was asked to stop the non-prescribed medication and her symptoms resolved.

**Experimental evidence**

No relevant data found.

**Mechanism**

The exact mechanism of these interactions is not clear, but it seems most likely they were due to the additive effects of the buspirone and the herbal medicines, either through their effects on elevating mood or through excess effects on serotonin. Fluoxetine may have had a part to play in one of the cases. See St John’s wort + SSRIs, page 376.

### St John’s wort + Caffeine

Two studies suggest that St John’s wort increases the metabolism of caffeine. However, four other studies using preparations of varying hyperforin content suggest that the metabolism of caffeine is not affected by St John’s wort.

**Clinical evidence**

A study in 16 healthy subjects given a single 200-mg dose of caffeine before and after St John’s wort 300 mg (containing 900 micrograms of hypericin) three times daily for 14 days found no overall change in the pharmacokinetics of caffeine. However, when the subset of 8 female patients was considered, it was found that there was an induction of CYP1A2 in this group of patients resulting in an increase in the production of caffeine metabolites.

In another study, St John’s wort 300 mg given to 12 healthy subjects three times daily for 28 days, modestly increased the metabolism of caffeine 100 mg (a CYP1A2 probe substrate) to paraxanthine by about 26%, although no serious adverse events occurred. The St John’s wort preparation used was standardised to 0.3% hypericin and provided each subject with about 12.2 mg of hyperforin daily. However, a later study using the same criteria in 12 elderly healthy subjects found that St John’s wort 300 mg three times daily for 28 days (standardised to hypericin 0.3%) generally had no statistically significant effect on the metabolism of a single 100-mg dose of caffeine to paraxanthine taken on day 28, although some individuals showed moderate changes.

Similarly, another study in 28 healthy subjects found no significant change in caffeine pharmacokinetics when a low-hyperforin (about 3.5 mg daily) St John’s wort extract (Ershericum) 120 mg was given twice daily for 11 days to patients who had received a single caffeine dose of 100 mg before St John’s wort was started, and on the last day of the study. These findings were also reported in two other studies using caffeine as a probe drug for CYP1A2 activity and a St John’s wort regimen that provided a high-hyperforin dose. One study gave hyperforin 33 mg and hypericin 2.5 mg daily, and the other gave a minimum of hyperforin 36 mg and hypericin 2.7 mg daily.

**Experimental evidence**

No relevant data found.

**Mechanism**

These studies investigated whether St John’s wort had any effect on the cytochrome P450 isoenzyme CYP1A2 by which caffeine is metabolised.

### St John’s wort + Calcium-channel blockers

St John’s wort significantly reduces the bioavailability of...
nifedipine and verapamil. Other calcium-channel blockers would be expected to interact similarly.

Clinical evidence

(a) Nifedipine
In a study in 10 healthy subjects, St John’s wort 900 mg daily for 14 days decreased the maximum levels and AUC of a single oral dose of nifedipine 10 mg by about 38% and 45%, respectively. The maximum levels and AUC of the active metabolite of nifedipine, dehydronifedipine, were raised by about 45% and 26%, respectively. The St John’s wort preparation used was standardised to contain hypericin 0.3% and hyperforin 5%.1

(b) Verapamil
In a study in 8 healthy subjects, verapamil 24 mg was given as a jejunal perfusion over 100 minutes both before and after treatment with St John’s wort tablets (Movina; containing 3 to 6% hyperforin) 300 mg three times daily for 14 days. St John’s wort did not affect jejunal permeability or the absorption of either R- or S-verapamil. The AUCs of R- and S-verapamil were decreased by 78% and 80%, respectively, and the peak plasma levels were decreased by 76% and 78%, respectively. The terminal half-life was not changed significantly. The AUC for R-verapamil was sixfold higher than that of S-verapamil and St John’s wort did not change this ratio.2

Experimental evidence

No relevant data found.

Mechanism
It appears that St John’s wort decreased the bioavailability of both nifedipine and verapamil by inducing their metabolism by the cytochrome P450 isoenzyme CYP3A4 in the gut. An effect on P-glycoprotein-mediated transport is not likely, as intestinal permeability to cytochrome P450 isoenzyme CYP3A4, to a greater or lesser extent, it would seem prudent to monitor concurrent use carefully.

Importance and management
The general importance of this interaction is unclear, as neither study reported on the clinical outcome of these reductions in calcium-channel blocker levels. Patients taking St John’s wort with nifedipine or verapamil should have their blood pressure and heart rate monitored to ensure that they are still effective, and the dose should be adjusted if needed. There appears to be no information about other calcium-channel blockers, but as they are all metabolised by CYP3A4, to a greater or lesser extent, it would seem prudent to monitor concurrent use carefully.


St John’s wort + Ciclosporin

Marked reductions in ciclosporin blood levels and transplant rejection can occur within a few weeks of starting St John’s wort.

Clinical evidence
A marked drop in ciclosporin blood levels was identified in one kidney transplant recipient as being due to the addition of St John’s wort extract 300 mg three times daily. When the St John’s wort was stopped the ciclosporin levels rose. The authors of this report identified another 35 kidney and 10 liver transplant recipients whose ciclosporin levels had dropped by an average of 49% (range 30 to 64%) after starting St John’s wort. Two of them had rejection episodes.12 In addition, subtherapeutic ciclosporin levels in 7 kidney transplant recipients,3–7 one liver transplant recipient,4 and 6 heart transplant recipients5–11 have been attributed to self-medication with St John’s wort. Acute graft rejection episodes occurred in 7 cases,3,5,7,10,11 and one recipient subsequently developed chronic rejection, requiring a return to dialysis.5 Another case of subtherapeutic ciclosporin levels occurred in a kidney transplant recipient during the concurrent use of a herbal tea containing St John’s wort. The recipient’s levels remained subtherapeutic despite a ciclosporin dose increase from 150 to 250 mg daily. The levels recovered within 5 days of stopping the herbal tea and the ciclosporin dose was reduced to 175 mg daily.12

These case reports are supported by a small study in which 11 renal transplant recipients, with stable dose requirements for ciclosporin, were given St John’s wort extract (Jarsin 300) 600 mg daily for 14 days. Pharmacokinetic changes were noted 3 days after the St John’s wort was added. By day 10 the ciclosporin dose had to be increased from an average of 2.7 to 4.2 mg/kg daily in an attempt to keep ciclosporin levels within the therapeutic range. Two weeks after the St John’s wort was stopped, only 3 patients had been.
successfully re-stabilised on their baseline ciclosporin dose. Additionally, the pharmacokinetics of various ciclosporin metabolites were substantially altered.

Another study in 10 kidney transplant recipients stable taking ciclosporin found that the content of hyperforin in the St John’s wort affected the extent of the interaction with ciclosporin. In patients taking St John’s wort with a high hyperforin content (hyperforin 7 mg, hypericin 0.45 mg) the reduction in the AUC of ciclosporin was 45% greater than that in patients taking St John’s wort with a low hyperforin content (hyperforin 0.1 mg, hypericin 0.45 mg). The maximum blood ciclosporin level and the trough ciclosporin level were also reduced by 36% and 45%, respectively, in the patients taking the higher hyperforin-containing St John’s wort preparation, when compared with the patients taking the preparation with a lower hyperforin content. The patients taking the high-hyperforin preparation required a mean ciclosporin dose increase of 65% whereas the patients taking the low-hyperforin preparation did not require any ciclosporin dose alterations.14

Experimental evidence
Because of the extensive clinical evidence available, experimental data have not been sought.

Mechanism
St John’s wort is a known inducer of the cytochrome P450 isoenzyme CYP3A4 by which ciclosporin is metabolised. Concurrent use therefore reduces ciclosporin levels. It has also been suggested that St John’s wort affects ciclosporin reabsorption by inducing the drug transporter protein, P-glycoprotein, in the intestine.9,13

Importance and management
An established and clinically important interaction. The incidence is not known, but all patients taking ciclosporin should avoid St John’s wort because of the potential severity of this interaction. Transplant rejection can develop within 3 to 4 weeks. It is possible to accommodate this interaction by increasing the ciclosporin dosage11 (possibly about doubled) but this raises the costs of an already expensive drug. Also, the varying content of natural products would make this hard to monitor. The advice of the CSM in the UK is that patients receiving ciclosporin should avoid or stop taking St John’s wort. In the latter situation, the ciclosporin blood levels should be well monitored and the dosage adjusted as necessary.15 The study described above suggests that increased monitoring will be needed for at least 2 weeks after the St John’s wort is stopped.13

Note that St John’s wort does not appear to interfere with laboratory assays for ciclosporin, see St John’s wort + Laboratory tests, page 372.


St John’s wort + Cimetidine

Cimetidine does not significantly alter the metabolism of the constituents of St John’s wort, hypericin and pseudohypericin.

Clinical evidence
A placebo-controlled study in healthy subjects taking St John’s wort (LI160, Lichtwer Pharma) 300 mg three times daily found that, apart from a modest 25% increase in the AUC of pseudohypericin, cimetidine 1 g daily (in divided doses) did not significantly affect the pharmacokinetics of either the hypericin or the pseudohypericin constituents of St John’s wort.1

Experimental evidence
No relevant data found.

Mechanism
Cimetidine is an inhibitor of the cytochrome P450 isoenzymes CYP3A4, CYP1A2 and CYP2D6. This study suggests that St John’s wort is not significantly metabolised by these isoenzymes.

Importance and management
The available evidence suggests that cimetidine is unlikely to affect the dose requirements of St John’s wort.


St John’s wort + Dextromethorphan

St John’s wort does not affect the pharmacokinetics of dextromethorphan or debrisoquine.

Clinical evidence
In a study in 12 healthy subjects, St John’s wort (LI160, Lichtwer Pharma, 0.12 to 0.3% hypericin) 300 mg three times daily was taken for 16 days with a single 30-mg dose of dextromethorphan on day 14. There was no consistent change in the urinary dextromethorphan to dextrophan metabolic ratio: 6 subjects had an increase in the production of dextrophan while the other 6 subjects had a reduction in dextromethorphan production. This finding was within the normal inter-patient variation in dextromethorphan metabolism.1 Similar findings were reported in another study in 16 healthy subjects given a single 25-mg dose of dextromethorphan on the last day of a 14-day course of St John’s wort (Jarsin; 900 micrograms of hypericin) 300 mg three times daily.2 Similarly, the metabolism of dextromethorphan was not significantly affected by St John’s wort when 12 healthy subjects were given a single 30-mg dose of dextromethorphan after 14 days of St John’s wort (Jarsin, Lichtwer Pharma) 300 mg three times daily.3 In yet another study in 12 healthy subjects, St John’s wort 300 mg three times daily for 14 days had no significant effect on the urinary excretion of a single 30-mg oral dose of dextromethorphan either after one day or after 2 weeks of use. The St John’s wort product used was from Sundown Herbs and provided about 33 mg of hyperforin daily.4 Three further studies found that St John’s wort 300 mg three times daily (containing up to 24 mg of hyperforin) for 14 or 28 days had no
clinically relevant effect on the pharmacokinetics of a single 5-mg dose of debrisoquine.2,3

**Experimental evidence**

An *in vitro* study4 found that a St John’s wort extract (*Hypericum Stada*) inhibited the metabolism of dextromethorphan when used as a probe substrate for cytochrome P450 isozyme CYP2D6.

**Mechanism**

St John’s wort taken as a multiple-dose regimen does not appear to have a clinically relevant effect on the metabolism of dextromethorphan or debrisoquine, both of which are used as substrates to assess the activity of the cytochrome P450 isozyme CYP2D6. Inhibition of CYP3A4, seen in the single dose *in vitro* study, is therefore not expected to be clinically relevant.

**Importance and management**

St John’s wort is unlikely to interact with dextromethorphan to a clinically relevant extent. Dextromethorphan and debrisoquine are used as a probe drugs for CYP2D6 activity, and therefore these results also suggest that a pharmacokinetic interaction as a result of this mechanism between St John’s wort and other CYP2D6 substrates is unlikely.

### References


### St John’s wort + Digoxin

**Clinical evidence**

An 80-year-old man taking long-term digoxin and St John’s wort herbal tea (2 litres daily) developed symptoms of digoxin toxicity (nodal bradycardia of 36 bpm and bigeminy) when he stopped taking the herbal tea.1

In a study 13 healthy subjects were given digoxin for 5 days until steady state had been achieved, and then St John’s wort extract (*LI 160*, Lichtwer Pharma) 300 mg three times daily for a further 10 days. The AUC and trough level of digoxin decreased by 28% and 18%, respectively. When compared with a parallel group of 12 subjects taking digoxin and placebo, the St John’s wort group had 26.3% lower maximum plasma digoxin levels, 33.3% lower trough plasma levels by about 18%, 21% and 13%, respectively. Comparable results were found with hypericum powder containing similar amounts of hyperforin (about 21 mg daily), while hypericum powder with half the hyperforin content (about 10 mg daily) reduced the AUC, peak and trough plasma levels by about 18%, 21% and 13%, respectively.

**Mechanism**

In a study using human cell lines, St John’s wort and hyperforin, a major active constituent, were found to induce *P*-glycoprotein transport of digoxin out of the cells in a reversible manner, which was comparable to rifampicin, a known inducer of *P*-glycoprotein. When treated with hypericin, another active constituent of St John’s wort, the transport of digoxin out of the cells was not increased.2

**Importance and management**

Information seems to be limited to these reports, but the interaction would appear to be established. The extent of the interaction may depend on the St John’s wort preparation involved and dose used and seems to be correlated with the dose of hyperforin.2,3 Reductions in serum digoxin levels of the size seen with *LI 160* could diminish the control of arrhythmias or heart failure. Digoxin serum levels should therefore be closely monitored if St John’s wort is either started or stopped, and appropriate dosage adjustments made if necessary. The recommendation of the CSM in the UK is that St John’s wort should not be used by patients taking digoxin.8

Note that St John’s wort does not appear to interfere with various immunoassays used for therapeutic drug monitoring of digoxin, see St John’s wort + Laboratory tests, page 372.

St John’s wort slightly decreases the AUC of eplerenone.

Clinical evidence
St John’s wort caused a small 30% decrease in the AUC of a single 100-mg dose of eplerenone.1,2

Experimental evidence
No relevant data found.

Mechanism
Eplerenone is metabolised by the cytochrome P450 isoenzyme CYP3A4, and therefore inducers of this isoenzyme, such as St John’s wort, would be expected to decrease its levels.

Importance and management
Because of the possibility of decreased efficacy of eplerenone, the UK manufacturers do not recommend the concurrent use of potent CYP3A4 inducers with eplerenone and they specifically name St John’s wort.1 However, it is unlikely that the decrease seen with St John’s wort is clinically relevant. Further study is needed to demonstrate the clinical significance.

Clinical relevance
Importance and management
Because of the possibility of decreased efficacy of eplerenone, the UK manufacturers do not recommend the concurrent use of potent CYP3A4 inducers with eplerenone and they specifically name St John’s wort.1 However, it is unlikely that the decrease seen with St John’s wort is clinically relevant. Further study is needed to demonstrate the clinical significance.

St John’s wort + Etoposide

The interaction between St John’s wort and etoposide is based on experimental evidence only.

Clinical evidence
No interactions found.

Experimental evidence
In vitro studies suggest that hypericin, a component of St John’s wort, may antagonise the effects of etoposide. It may also stimulate the hepatic metabolism of etoposide by the cytochrome P450 isoenzyme CYP3A4.1

Mechanism
Etoposide is metabolised by the cytochrome P450 isoenzyme CYP3A4, and therefore inducers of this isoenzyme, such as St John’s wort, would be expected to decrease its levels.

Importance and management
Information is very limited but it seems that it would be prudent to avoid St John’s wort in patients taking etoposide or related drugs. More study is needed.

St John’s wort + Fexofenadine

Pretreatment with St John’s wort had no clinically relevant effect on the plasma levels of single-dose fexofenadine in one study, but markedly reduced fexofenadine levels in two others.

Clinical evidence
In a study in 12 healthy subjects, a single 900-mg dose of St John’s wort (Hypericum perforatum) increased the maximum plasma level and AUC of a single 60-mg dose of fexofenadine by 45% and 31%, respectively.

Conversely, St John’s wort 300 mg three times daily for 14 days caused a slight 5 to 10% decrease in the maximum level and AUC of a single dose of fexofenadine 60 mg in the same subjects.1

In contrast, in another study, 12 days of pretreatment with St John’s wort increased the oral clearance of a single dose of fexofenadine by about 1.6-fold in healthy subjects.2 Similarly, a study in 30 healthy subjects found that 10 days of pretreatment with St John’s wort 300 mg three times daily almost doubled the oral clearance of a single 60-mg dose of fexofenadine.3

Experimental evidence
No relevant data found.

Mechanism
In these studies St John’s wort was thought to be interacting via its effects on P-glycoprotein.

Importance and management
The findings from these multiple-dose studies suggest that St John’s wort either has no clinically relevant effect on fexofenadine, or a decrease occurs that is possibly clinically important. It may be prudent to monitor closely for signs of reduced fexofenadine efficacy in a patient taking regular St John’s wort and, if this is the case, consider St John’s wort as a possible cause. Further study is needed.


St John’s wort + Food; Tyramine-rich

An isolated report describes a patient taking St John’s wort who experienced a hypertensive crisis after consuming tyramine-rich food and drink.

Clinical evidence
A man who had taken a St John’s wort supplement for 7 days (preparation and dose not stated) was admitted to hospital with confusion and disorientation. He was unable to recall events after eating aged cheeses and pouring a glass of red wine 8 hours earlier. On examination he had a pulse rate of 115 bpm, a respiratory rate of 16 breaths per minute and his blood pressure was 210/140 mmHg. On examination he had a pulse rate of 115 bpm, a respiratory rate of 16 breaths per minute and his blood pressure was 210/140 mmHg. He was treated with intravenous phen tolamine and oral labetalol and his blood pressure decreased to 160/100 mmHg after 2 hours and the delirium also resolved. Extensive laboratory investigations did not find any cause for the hypertension and delirium.1

Experimental evidence
No relevant data found.

Mechanism
It was suggested that the time scale of starting to regularly take St John’s wort and the onset of delirium and hypertension after the consumption of tyramine-rich food and drink was suggestive of hypertension associated with MAOIs. Normally any ingested tyramine is rapidly metabolised by the enzyme monoamine oxidase in the gut wall and liver before it reaches the general circulation. However, if the activity of the enzyme at these sites is inhibited (by the presence of an MAOI), any tyramine passes freely into the brain and increases the blood pressure. The patient had been taking St John’s wort regularly and the onset of delirium and hypertension was consistent with this time scale.
circulation, causing not just a rise in blood pressure, but a highly exaggerated rise due to the release from the adrenergic neurones of the large amounts of noradrenaline that accumulate there during inhibition of MAO. Although St John’s wort is a potent inhibitor of MAO, this effect has not been demonstrated at recommended doses. It was concluded that the hypertensive crisis in this patient may have been mediated by MAO inhibition, but there was also a possibility of another, as yet unknown, pharmacological action of St John’s wort being involved.1

Importance and management
Given the widespread use of St John’s wort, this case would seem to be unusual, and there is currently little grounds for suggesting any dietary restriction in those taking St John’s wort.


St John’s wort + Herbal medicines
For a case report describing delirium following the use of St John’s wort, valerian and loperamide, see under St John’s wort + Loperamide, page 373.

St John’s wort + Hormonal contraceptives
St John’s wort may affect the pharmacokinetics of desogestrel, ethinylestradiol and norethisterone. Both breakthrough bleeding and, more rarely, combined oral contraceptive failure have been reported in women taking St John’s wort. Two cases describe the failure of emergency hormonal contraception, which was attributed to the use of St John’s wort.

Clinical evidence
(a) Combined hormonal contraceptives
A study in 17 healthy women taking ethinylestradiol/desogestrel 20/150 micrograms daily found that St John’s wort (300 mg twice or three times daily) did not affect the AUC or maximum levels of ethinylestradiol. However, the AUC and maximum levels of the active metabolite of desogestrel were significantly decreased by about 40% and 20%, respectively. There was no evidence that ovulation occurred. However, the frequency of breakthrough bleeding increased significantly from 35% to around 80%, which may affect compliance.1 Another study in 12 healthy women taking ethinylestradiol/norethisterone 35 micrograms/1 mg (Ortho-Novum) found that St John’s wort 300 mg three times daily for 8 weeks increased the oral clearance of norethisterone and reduced the half-life of ethinylestradiol, but the serum levels of LH, FSH and progesterone were unaffected. However, of more importance, was the increase in breakthrough bleeding, which the authors state as a major cause of patients stopping hormonal contraceptives.2 A further study in 16 subjects also found reductions in the levels of low-dose ethinylestradiol/norethisterone 20 micrograms/1 mg. Furthermore, they found increased progesterone levels of more than 3 nanograms/mL (an indication that ovulation occurred) in 3 patients who also took St John’s wort compared with one subject who took placebo. Breakthrough bleeding was also increased.3 In a secondary analysis of this study,4 the anti-androgenic effects of ethinylestradiol/norethisterone, utilised in the treatment of hirsutism and acne, were not significantly affected by St John’s wort.

The Adverse Drug Reactions Database of the Swedish Medical Products Agency has on record 2 cases of pregnancy due to the failure of a combined oral contraceptive, which was attributed to the use of products containing St John’s wort (Esbericium and Kira). One woman was taking ethinylestradiol and norethisterone and the other was taking ethinylestradiol and levonorgestrel.5 This follows an earlier report from the Swedish Medical Products Agency of 8 cases of breakthrough bleeding in women aged 23 to 31 taking long-term oral contraceptives and St John’s wort. Breakthrough bleeding occurred within about a week of starting St John’s wort in 5 of the cases, and was known to have resolved in 3 cases when the St John’s wort was stopped.6 The CSM in the UK has on record a further 7 cases of pregnancy in women taking St John’s wort and oral contraceptives in the two-year period from February 2000 to February 2002.7 Another earlier brief report describes 3 women taking a combined oral contraceptive (ethinylestradiol/desogestrel 30/150 micrograms) who developed breakthrough bleeding one-week (2 cases) and 3 months (1 case) after starting to take St John’s wort.8 A single case of pregnancy has also been reported in a patient taking St John’s wort with ethinylestradiol/dienogest (Valette).9 The German Federal Institute for Drugs and Medical Devices has received a total of 8 case reports of ineffective contraception with St John’s wort.10

In contrast, in a study, 16 healthy women took ethinylestradiol/desogestrel 20/150 micrograms daily on days 1 to 21 of a 28-day cycle, and an extract of St John’s wort with a low hyperforin content of 650 micrograms, (Ze117, standardised to 0.2% hypericin), 250 mg twice daily on days 7 to 21. The plasma levels of ethinylestradiol and the active metabolite of desogestrel were not significantly altered by St John’s wort. None of the women experienced any breakthrough bleeding or spotting, and measurements of plasma hormone levels indicated that the contraceptive efficacy was unchanged.11

(b) Emergency hormonal contraceptives
The CSM in the UK has received reports of 2 women taking St John’s wort who became pregnant despite taking emergency hormonal contraception. One of them was also taking an oral contraceptive.7

Experimental evidence
No relevant data found.

Mechanism
It is believed that St John’s wort can induce the metabolism of the contraceptive steroids by the cytochrome P450 isoenzyme CYP3A4, thereby reducing their serum levels and their effects.6,8,12 This can lead to breakthrough bleeding and, in some cases, contraceptive failure. This is consistent with the way that St John’s wort appears to lower the serum levels of some other drugs. Note that, although hyperforin is the most likely constituent responsible for enzyme induction (supported by the study that found no interaction with a low-hyperforin preparation), others may contribute and the levels of individual constituents can vary between different preparations of the herb.

Importance and management
Information appears to be limited to these reports but the interaction between hormonal contraceptives and St John’s wort appears to be established. Its incidence is not known but the evidence so far suggests that breakthrough bleeding may be a problem, although pregnancy resulting from this interaction appears to be uncommon. Only two cases of emergency hormonal contraceptive failure attributed to an interaction with St John’s wort have so far been reported, but the effects of any interaction here would be very difficult to assess. Since it is not known who is particularly likely to be at risk, the recommendation of the CSM/MCA and the Faculty of Family Planning and Reproductive Health Care (FFPRHC) in the UK12,13 is that women taking oral contraceptives (both combined and progesterone-only pills) should either avoid St John’s wort or they should use an additional form of contraception. The FFPRHC Clinical Effectiveness Unit is in agreement with the CSM advice but recommends that, if St John’s wort must be continued, the following...
The effectiveness of both combined oral contraceptives should use an ethinylestradiol dose of at least 50 micrograms daily. The dose may be increased further above 50 micrograms if breakthrough bleeding occurs. Omitting or reducing the pill-free interval has not been shown to reduce the risk of ovulation with liver enzyme inducers. Additional non-hormonal methods of contraception, such as condoms, should also be used by patients using combined hormonal contraceptives, both when taking the liver enzyme inducers and for at least 4 weeks after stopping the drug. Alternatives to all forms of combined hormonal contraceptives should be considered with long-term use of liver enzyme inducers.

The combined contraceptive patch may be continued in the usual manner. Additional, non-hormonal methods of contraception, such as condoms, should also be used by patients using the combined contraceptive patch, both when taking the liver enzyme inducers and for at least 4 weeks after stopping the drug. Using more than one patch is not recommended.

The progestogen-only oral contraceptive is not recommended for use with liver enzyme inducers. Alternative methods of contraception are advised.

The progestogen-only implant may be continued with short courses of enzyme inducers. Additional non-hormonal methods of contraception, such as condoms, should also be used by patients using the progestogen-only implant, both when taking the enzyme inducers and for at least 4 weeks after stopping the drug. Alternatives to the progestogen-only implant should be considered with long-term use of liver enzyme inducers.

The effectiveness of both combined and the progestogen-only emergency hormonal contraceptive will be reduced in women taking liver enzyme inducers. The FPFRHC Clinical Effectiveness Unit states that there appears to be no good evidence on how to manage the interaction between emergency hormonal contraception and enzyme inducers such as St John’s wort, but current clinical practice is to increase the contraceptive dose by approximately 50%.1 The British National Formulary recommends giving a single 3-mg dose of levonorgestrel, although this is unlicensed.14 A copper intrauterine device (IUD) may also be used as an effective alternative.13 In the UK it is possible to buy the progestogen-only emergency hormonal contraception without a prescription; however, it has been advised that patients taking enzyme inducers should not be supplied the emergency hormonal contraceptive but should be referred to a doctor or family planning service.15 Given the potential consequences of an unwanted pregnancy, these seem sensible precautions.

The depot progestogen-only injection, copper and levonorgestrel-releasing IUDs do not appear to be affected by enzyme-inducing drugs, such as St John’s wort, and may be used as alternative contraceptive methods, particularly for women requiring hormonal contraception who are likely to be taking the enzyme inducer in the long term, as these are unaffected by liver enzyme inducers. Although the considerable worldwide popularity of St John’s wort is fairly recent, it is currently the most widely used antidepressant in Germany and has been used for very many years in both Germany and Austria. Yet, there seems to be no published evidence that oral contraceptive failure in those countries is more frequent than anywhere else. This would seem to confirm that contraceptive failure leading to pregnancy occurring as a result of this interaction is very uncommon, or perhaps that it has failed to be identified as a possible cause.

The anti-androgenic effects of ethinylestradiol/norethisterone, utilised in the treatment of hirsutism and acne, do not appear to be significantly affected by St John’s wort. However, as this was a small study, it may be prudent to still monitor the effectiveness of the combined hormonal contraceptive for this indication until further evidence is available.

---

St John’s wort + Ibuprofen

St John’s wort does not affect the pharmacokinetics of ibuprofen.

Clinical evidence
Eight healthy male subjects were given an oral dose of ibuprofen 400 mg before, and at the end of, a 21-day course of St John’s wort 300 mg three times daily. The pharmacokinetics of ibuprofen were unaffected by St John’s wort. The St John’s wort extract was standardised to contain hypericin (probably 0.3%) and a minimum of 4% hyperforin.1

Experimental evidence
No relevant data found.

Mechanism
As ibuprofen is a substrate for the cytochrome P450 isoenzymes CYP2C9 and CYP2C8, the authors of the study suggest that the lack of interaction is evidence that St John’s wort has no significant effects on these isoenzymes. Minor or no significant effects on pharmacokinetics have similarly been reported for rosiglitazone, a substrate for CYP2C8, and gliclazide and tolbutamide, both of which are substrates for CYP2C9. See St John’s wort + Antidiabetics, page 362.

Importance and management
St John’s wort does not appear to interact with ibuprofen and therefore no special precautions seem necessary on concurrent use.


St John’s wort + Imininib

St John’s wort lowers serum imatinib levels.
Clinical evidence
In a study in 12 healthy subjects, the pharmacokinetics of a single dose of imatinib was determined before, and on day 12, of two weeks of treatment with St John’s wort extract (Kira [LI 160], Lichtwer Pharma) 300 mg three times daily. The AUC and maximum plasma level of imatinib was decreased by 30% and 15%, respectively. Imatinib clearance was increased by 43% and its half-life was decreased from 12.8 to 9 hours. Similar results were found in another study.1

Experimental evidence
No relevant data found.

Mechanism
St John’s wort induces intestinal CYP3A4 and it therefore also reduces imatinib levels.

Importance and management
This study suggests that St John’s wort may modestly reduce the exposure to imatinib, which could result in a reduction in its efficacy. The manufacturers suggest that concurrent use of imatinib and potent enzyme-inducing drugs should be avoided.3,4 St John’s wort has smaller effects than other known CYP3A4 inducers, but, nevertheless, some suggested that concurrent use should also be avoided.5 However, if this is not possible it would be prudent to monitor the outcome of concurrent use closely, and increase the imatinib dose as necessary.

St John’s wort + Irinotecan
St John’s wort increases the metabolism of irinotecan, which may decrease its activity.

Clinical evidence
In a randomised, crossover study St John’s wort decreased the plasma levels of the active metabolite of irinotecan, SN-38, by 42%. Myelosuppression was also reduced; with irinotecan alone the leucocyte and neutrophil counts decreased by 56% and 63%, respectively, but in the presence of St John’s wort the decreases were only 8.6% and 4.3%, respectively. In this study, irinotecan was given as a single 350-mg/m² intravenous dose every 3 weeks, and during one cycle a St John’s wort preparation was given three times daily, beginning 14 days before and stopping 4 days after the irinotecan.1

Experimental evidence
In an experimental study in rats, St John’s wort 400 mg/kg given daily for 14 days reduced the maximum levels of irinotecan and its active metabolite, SN-38, by 39.5% and 38.9%, respectively. The AUC of SN-38 was also reduced by 26.3%.2

Mechanism
St John’s wort induces the cytochrome P450 isoenzyme CYP3A4 and P-glycoprotein, which are both involved in the metabolism of irinotecan. The evidence suggests that St John’s wort increases the metabolism of irinotecan to an unknown inactive metabolite, rather than the active SN-38, thereby reducing its effects.1

Importance and management
The evidence appears to be limited. Irinotecan has a narrow therapeutic range and, as irinotecan is a prodrug that is metabolised to its active metabolite SN-38, the lower levels of SN-38 suggest that its activity will be reduced in the presence of St John’s wort. It would therefore seem sensible to warn patients who are about to receive irinotecan to avoid St John’s wort. It seems likely that irinotecan, a related drug that is also a substrate for CYP3A4, will be similarly affected, but evidence for this is currently lacking.1

St John’s wort + Ivabradine
The metabolism of ivabradine is increased by St John’s wort.

Clinical evidence
Twelve healthy subjects were given a single oral dose of ivabradine 10 mg 24 hours before St John’s wort (Jarsin tablets) 300 mg three times daily was given for 14 days. On day 16, they were given a further dose of ivabradine 10 mg with a single 300-mg dose of St John’s wort. The maximum levels and AUC of ivabradine were reduced by more than half by St John’s wort. The maximum levels and AUC of its active metabolite were reduced by 25% and 32%, respectively. No adverse effects were reported, and the heart rate and blood pressure remained unchanged. Similar findings are also reported by the manufacturers of ivabradine.2

Experimental evidence
No relevant data found.

Mechanism
St John’s wort is a known inducer of the cytochrome P450 isoenzyme CYP3A4, by which ivabradine is metabolised. Concurrent use therefore increases the metabolism of ivabradine, which results in a reduction in its plasma levels, and a potential reduction in effects.

Importance and management
Evidence is limited to the study above and, despite the lack of change in pharmacodynamic effects seen in this study, the pharmacokinetic changes may be significant to affect individual patients. Monitor concurrent use for ivabradine efficacy and adjust the dose as necessary. Remember to re-adjust the dose of ivabradine if concurrent use of these drugs is stopped. The UK manufacturer suggests that the use of St John’s wort should be restricted in patients taking ivabradine.2

St John’s wort + Laboratory tests
St John’s wort does not interfere with in vitro assays for carbamazepine, ciclosporin, digoxin, phenobarbital, phenytoin, procainamide, quinidine, tacrolimus, theophylline, tricyclic antidepressants and valproate.

Clinical evidence
No interactions found.

Experimental evidence
In in vitro experiments, St John’s wort added to serum samples did not interfere with a fluorescence polarisation immunoassay (FPIA, Abbott Laboratories) for carbamazepine, digoxin, phenytoin, procainamide, quinidine, theophylline, tricyclic antidepressants and valproate. It also did not interfere with a serum sample microparticle enzyme

Immunobassay (MEIA, Abbott Laboratories) for digoxin, or other assays (exact assays not specified, Roche Diagnostics/Hitachi) for phenobarbital or procainamide. Whole-blood FPIA analysis of ciclosporin levels and whole-blood MEIA analysis of tacrolimus levels were also not affected by the addition of St John’s wort.

Mechanism
No mechanism expected.

Importance and management
St John’s wort does not appear to interfere with various immunoassays used for therapeutic drug monitoring of carbamazepine, ciclosporin, digoxin, phenobarbital, phenytoin, procainamide, quinidine, tacrolimus, theophylline, tricyclics and valproate. 1

A brief report describes mania in a patient taking lithium who also took St John’s wort.

Clinical evidence
A search of Health Canada’s database of spontaneous adverse reactions identified one case in which St John’s wort was suspected of inducing mania in a patient also taking lithium. 1

Experimental evidence
No relevant data found.

Mechanism
Unknown, although it seems likely that the symptoms could be due to the effects of both lithium and St John’s wort on serotonin.

Importance and management
No general conclusions can be drawn from this case as no further details were given.


A case report describes delirium in a woman taking St John’s wort and valerian root who also took loperamide.

Clinical evidence
A 39-year-old woman who had been taking two tablets of St John’s wort with valerian root daily for 6 months (exact products and doses not specified) was hospitalised after becoming disorientated, agitated and confused. The patient had also recently started loperamide for diarrhoea prior to admission. The delirium subsided within two days of stopping these drugs. 1

Experimental evidence
No relevant data found.

Mechanism
Unclear. A MAOI-induced reaction caused by the combination of St John’s wort and loperamide was suggested as a possible cause for the delirium. However, an interaction between St John’s wort and valerian, or valerian and loperamide, cannot be ruled out. 1

Importance and management
This appears to be the only report of delirium associated with the combination of St John’s wort, valerian and loperamide. Its general relevance is therefore unclear.


St John’s wort may decrease the efficacy of methylphenidate in the treatment of attention deficit hyperactivity disorder.

Clinical evidence
A 22-year-old man who had been successfully treated with methylphenidate 20 mg daily for attention deficit hyperactivity disorder (ADHD) for 6 months started to take St John’s wort 600 mg daily. Over the next 4 months the efficacy of the methylphenidate decreased, but, 3 weeks after the St John’s wort was stopped, the methylphenidate became more effective. No adverse effects were seen during the concurrent use of the herbal medicine and drug. 1

Experimental evidence
No relevant data found.

Mechanism
Unknown.

Importance and management
This is an isolated case report and therefore no general recommendations can be made. However, if the efficacy of methylphenidate becomes reduced, it may be worth questioning the patient about St John’s wort use, and giving consideration to stopping the herb.

1. Niederhofer H. St John’s wort may diminish methylphenidate’s efficacy in treating patients suffering from attention deficit hyperactivity disorder. Med Hypotheses (2007) 68, 1189.

St John’s wort does not appear to alter the pharmacokinetics of mycophenolate.

Clinical evidence
In a pharmacokinetic study, 8 stable kidney transplant recipients taking mycophenolate 1 g to 2 g daily and tacrolimus were given 600 mg of St John’s wort extract (Jarsin 300) daily for 14 days. The levels of mycophenolic acid, the main metabolite of mycophenolate, were measured before St John’s wort was started, on day 14, and two weeks after St John’s wort was stopped. The pharmacokinetics of mycophenolic acid were unchanged throughout the study, and no dosage adjustments were needed in any of the 8 patients. 1

Experimental evidence
No relevant data found.

Mechanism
No mechanism. St John’s wort is an inducer of the cytochrome P450 isoenzyme CYP3A4 and P-glycoprotein. As mycophenolate is not significantly metabolised or transported by these routes, an interaction would not be expected.

Importance and management
St John’s wort does not appear to affect the pharmacokinetics of mycophenolate and therefore no additional precautions seem necessary on concurrent use.

There is some evidence to suggest that St John’s wort may decrease the levels of nevirapine. Delavirdine and efavirenz would be expected to be similarly affected.

**Clinical evidence**

Nevirapine levels, obtained by routine monitoring, were noted to be lower in 5 men who were also taking St John’s wort. Based on a pharmacokinetic modelling analysis, it was estimated that St John’s wort increased the oral clearance of nevirapine by about 35%.1

**Experimental evidence**

No relevant data found.

**Mechanism**

This finding supports predictions based on the known metabolism of the NNRTIs delavirdine, efavirenz and nevirapine by the cytochrome P450 isoenzyme CYP3A4, of which St John’s wort is a known inducer.

**Importance and management**

The interaction between St John’s wort and nevirapine confirms advice issued by the CSM in the UK,2 that St John’s wort may decrease blood levels of the NNRTIs with possible loss of HIV suppression. Therefore concurrent use should be avoided.


St John’s wort does not appear to affect the pharmacokinetics of prednisone.

**Clinical evidence**

Eight healthy male subjects were given a single oral dose of prednisone 20 mg before, and at the end of, a 28-day course of St John’s wort 300 mg three times daily. The pharmacokinetics of prednisone, and its metabolite prednisolone, were not significantly affected by St John’s wort. The St John’s wort extract was standardised to contain hypericin 0.3% and a minimum of 4% hyperforin.1

**Experimental evidence**

No relevant data found.

**Mechanism**

It was thought that St John’s wort, a known inducer of the cytochrome P450 isoenzyme CYP3A4, would increase the metabolism of prednisone and prednisolone and reduce their levels. While prednisone and prednisolone are substrates of CYP3A4, it is not a major metabolic pathway as they have been shown to be relatively unaffected by potent CYP3A4 inhibitors in healthy subjects.

**Importance and management**

St John’s wort does not appear to induce the metabolism of a single dose of prednisone, or its metabolite prednisolone, in healthy male subjects; however, further study is needed to clarify significance of this in patients receiving long-term prednisone.


The interaction between St John’s wort and procainamide is based on experimental evidence only.

**Clinical evidence**

No interactions found.

**Experimental evidence**

In a study in mice, a single dose of St John’s wort extract significantly raised the bioavailability of procainamide 100 mg/kg for a period of up to 4 hours. A trend towards an increase in procainamide levels was seen in the mice given St John’s wort for 2 weeks, with the procainamide dose given the day after St John’s wort was stopped; however, this was not statistically significant. Other pharmacokinetic parameters remained unaffected by both single-dose and long-term use of St John’s wort.1

**Mechanism**

Not understood.

**Importance and management**

The evidence for any significant effect of St John’s wort on the pharmacokinetics of procainamide is extremely limited and, although the bioavailability of procainamide may have been raised slightly in mice, its metabolism was unchanged. The clinical significance of this in humans is unknown and further study is needed.

St John’s wort also does not interfere with laboratory assays for procainamide, see St John’s wort + Laboratory tests, page 372.


St John’s wort reduces the plasma concentrations of methadone and withdrawal symptoms may occur.

**Clinical evidence**

In a study in 4 patients taking methadone, St John’s wort (Jarsin) 900 mg daily for 14 to 47 days decreased methadone plasma concentration-to-dose ratios (indicating decreased methadone levels) by 19 to 60%. Two patients reported symptoms that suggested a withdrawal syndrome.1

**Experimental evidence**

No relevant data found.

**Mechanism**

St John’s wort is metabolised in the liver and induces the cytochrome P450 enzyme CYP3A4, and so could affect plasma levels of drugs metabolised in this way, such as methadone.1

**Importance and management**

St John’s wort appears to reduce the plasma levels of methadone causing withdrawal symptoms in some patients. Therefore, concurrent use should be avoided. It may be prudent to follow the same advice for other opioids1 that are mainly metabolised by CYP3A4, such as buprenorphine, fentanyl and alfentanil.


St John’s wort causes a marked reduction in the serum levels of indinavir, which may result in HIV treatment failure. Other protease inhibitors, whether used alone or boosted by ritonavir, are predicted to interact similarly.

Clinical evidence
In a single-drug pharmacokinetic study, 8 healthy subjects were given three 800-mg doses of indinavir on day 1 to achieve steady-state serum levels, and then an 800-mg dose on day 2. For the next 14 days they were given St John’s wort extract 300 mg three times daily. Starting on day 16, the indinavir dosing was repeated. It was found that the St John’s wort reduced the mean AUC of indinavir by 54% and decreased the 8-hour indinavir trough serum level by 81%.1

Experimental evidence
No relevant data found.

Mechanism
Not fully understood, but it seems highly likely that St John’s wort induces the activity of the cytochrome P450 isoenzyme CYP3A4, thereby increasing the metabolism of indinavir and therefore reducing its levels.

Importance and management
Direct information seems to be limited to this study, but the interaction would appear to be established. Such a large reduction in the serum levels of indinavir is likely to result in treatment failures and the development of viral resistance. Therefore St John’s wort should be avoided. There seems to be no direct information about other protease inhibitors, but since they are also metabolised by CYP3A4 it is reasonable to expect that they will be similarly affected.

Clinical evidence
In a single-drug pharmacokinetic study, 12 healthy subjects (6 of the extensive CYP2C19 metaboliser phenotype and 6 of the poor CYP2C19 metaboliser phenotype) were given St John’s wort 300 mg three times daily or placebo for 14 days, followed by a single 20-mg dose of omeprazole on day 15. St John’s wort modestly decreased the AUC of omeprazole in all subjects (by 49% in extensive metabolisers and 41% in poor metabolisers), and also increased the plasma levels of hydroxymeprazole by 35% in those who were extensive metabolisers. It also markedly increased the levels of the inactive CYP3A4 sulfone metabolite of omeprazole in both extensive and poor metabolisers (by 148% and 132%, respectively).1

Experimental evidence
No relevant data found.

Mechanism
St John’s wort increases the metabolism of omeprazole by inducing both CYP2C19 and CYP3A4.1

Importance and management
This appears to be the only study examining the effects of St John’s wort on proton pump inhibitors. However, the reduction seen in the AUC of omeprazole (about 40%) suggest that there is a possibility that omeprazole will be less effective in patients taking St John’s wort. As all PPIs are metabolised by CYP2C19 to varying extents, it is likely that the effects of St John’s wort seen in these studies will be similar with other PPIs, although note that rabeprazole is much less dependent on this route of metabolism than other PPIs.

There is insufficient evidence to suggest that St John’s wort should be avoided in patients taking PPIs. However, the potential reduction in the efficacy of the PPI should be borne in mind, particularly where the consequences may be serious, such as in patients with healing ulcers.


S

Serotonin syndrome has been reported in one patient taking venlafaxine and St John’s wort.

Clinical evidence
An interaction between venlafaxine and St John’s wort was reported to the Centre Régional de Pharmacovigilance de Marseille involving a 32-year-old man who had been taking venlafaxine 250 mg daily for several months. He started taking St John’s wort at a dose of 200 drops three times daily (usual dose up to 160 drops daily) and on the third day felt faint and anxious, and had symptoms of diaphoresis, shivering and tachycardia. St John’s wort was stopped and his symptoms resolved in 3 days without altering the dose of venlafaxine.1 A search of Health Canada’s database of spontaneous adverse reactions for the period 1998 to 2003 also found one case of suspected serotonin syndrome as a result of an interaction between venlafaxine and St John’s wort.2

Experimental evidence
No relevant data found.

Mechanism
A pharmacodynamic interaction may occur between St John’s wort and venlafaxine because they can both inhibit the reuptake of 5-hydroxytryptamine (serotonin). Serotonin syndrome has been seen with St John’s wort alone,1 and so additive serotonergic effects appear to be the explanation for what occurred in the cases described here.
Importance and management

Information appears to be limited to these reports. Duloxetine would be expected to interact similarly and the manufacturers of both duloxetine and venlafaxine generally advise caution if they are given with drugs that affect the serotonergic neurotransmitter systems; a similar caution with St John’s wort would be prudent.


Cases of severe sedation, mania and serotonin syndrome have been reported in patients taking St John’s wort with SSRIs.

Clinical evidence

(a) Fluoxetine

For a report of hypomania that occurred when St John’s wort, ginkgo biloba and melatonin were added to treatment with fluoxetine and buspirone, see St John’s wort + Buspirone, page 365.

For a report of serotonin syndrome when eletriptan, fluoxetine and St John’s wort were used together, see St John’s wort + Triptans, page 379.

(b) Paroxetine

In one report, a woman stopped taking paroxetine 40 mg daily after 8 months, and 10 days later started to take 600 mg of St John’s wort powder daily. No problems occurred until the next night when she took a single 20-mg dose of paroxetine because she thought it might help her sleep. The following day at noon she was found still to be in bed, rousable but incoherent, groggy and slow moving, and almost unable to get out of bed. Two hours later she still complained of nausea, weakness and fatigue, but her vital signs and mental status were normal. Within 24 hours all symptoms had resolved.1

(c) Sertraline

Four elderly patients taking sertraline developed symptoms characteristic of serotonin syndrome within 2 to 4 days of also taking St John’s wort 300 mg, either two or three times daily. The symptoms included dizziness, nausea, vomiting, headache, anxiety, confusion, restlessness and irritability. Two of them were treated with oral cyproheptadine 4 mg either two or three times daily, and the symptoms of all of them resolved within a week. They later resumed treatment with sertraline without problems.2 A search of Health Canada’s database of spontaneous adverse reactions from 1998 to 2003 found two cases of suspected serotonin syndrome as a result of an interaction between sertraline and St John’s wort.3

Mania developed in a 28-year-old man, who continued to take St John’s wort against medical advice while also receiving sertraline 50 mg daily for depression; he was also receiving testosterone replacement post-orchiectomy.4

Experimental evidence

No relevant data found.

Mechanism

A pharmacodynamic interaction may occur between St John’s wort and SSRIs because they can both inhibit the reuptake of 5-hydroxytryptamine (serotonin),5 serotonin syndrome has been seen with St John’s wort alone,6 and so additive serotonergic effects appear to be the explanation for what occurred in the cases described here.

Importance and management

Information appears to be limited to these reports, but interactions between SSRIs and St John’s wort would seem to be established. The incidence is not known but it is probably small; nevertheless because of the potential severity of the reaction it would seem prudent to avoid concurrent use. The advice of the CSM in the UK is that St John’s wort should be stopped if patients are taking any SSRI because of the risk of increased serotonergic effects and an increased incidence of adverse reactions.7


St John’s wort + Statins

St John’s wort modestly decreases the plasma levels of atorvastatin and simvastatin, but not pravastatin.

Clinical evidence

In a placebo-controlled, crossover study, 16 healthy subjects took St John’s wort 300 mg three times daily for 14 days. On day 14 simvastatin 10 mg was given to 8 subjects and pravastatin 20 mg was given to the other 8 subjects. St John’s wort did not affect the plasma concentration of pravastatin, but it tended to reduce the simvastatin AUC and significantly reduce the AUC of its active metabolite, simvastatin hydroxyacid, by 62%.1

In a crossover study in 24 patients with hypercholesterolemia taking long-term simvastatin 10 to 40 mg daily (an average dose of 20.8 mg daily), St John’s wort (Movina) 300 mg twice daily for 4 weeks significantly raised the levels of total cholesterol from 4.56 mmol/L (pre-treatment) to 5.08 mmol/L and LDL-cholesterol from 2.30 mmol/L to 2.72 mmol/L. The authors equate the magnitude of the increased LDL-cholesterol levels to a halving of the effects of simvastatin.2

In a similar study by the same authors, 16 patients with hypercholesterolemia taking long-term atorvastatin 10 to 40 mg daily (an average dose of 14.4 mg daily) were given St John’s wort (Movina) 300 mg twice daily for 4 weeks. St John’s wort significantly raised the levels of total cholesterol from 4.76 mmol/L (pre-treatment) to 5.1 mmol/L and LDL-cholesterol from 2.39 mmol/L to 2.66 mmol/L. The levels of atorvastatin were not measured in this study. The authors equate the magnitude of the increased LDL-cholesterol levels to a loss of a third of the effects of atorvastatin. No adverse effects were reported.3

Experimental evidence

No relevant data found.

Mechanism

The reason for this interaction is unknown, but St John’s wort may reduce the levels of simvastatin and its metabolite, and atorvastatin, by inducing the cytochrome P450 isoenzyme CYP3A4 or by having some effect on P-glycoprotein.
Importance and management

Although the evidence is limited, it appears that St John’s wort may reduce the efficacy of atorvastatin and simvastatin, which may result in a clinically relevant increase in total cholesterol and LDL levels, depending on the patient’s baseline result and medical history. It may be prudent to consider an interaction if lipid-lowering targets are not met, and advise the patient to stop taking St John’s wort or adjust the dose of statin, as needed.

No significant interaction would be expected with pravastatin as it is not primarily metabolised by CYP3A4, and this was demonstrated in the study above. As fluvastatin and rosuvastatin are not significantly metabolised by CYP3A4, a clinically relevant interaction would also not be expected.


St John’s wort + Tacrolimus

St John’s wort decreases tacrolimus levels.

Clinical evidence

In a clinical study, 10 healthy subjects were given a single 100-microgram/kg dose of tacrolimus alone, or after they took St John’s wort 300 mg three times daily for 14 days. On average St John’s wort decreased the maximum blood level of tacrolimus by 65% and its AUC by 32%. However, the decrease in AUC ranged from 15% to 64%, with one patient having a 31% increase in AUC.2 Similar results have been found in a study in 10 kidney transplant recipients given St John’s wort (Jarsin 300) 600 mg daily for 2 weeks. In order to achieve target levels, the tacrolimus dose was reduced to a median of 6.5 mg daily, and then to the original dose of 4.5 mg daily after about 4 weeks.2

A case report describes a 65-year-old patient taking tacrolimus following a kidney transplantation. The patient started to take St John’s wort (Neuroplant) 600 mg daily, and after one month the tacrolimus trough blood levels had dropped from a range of 6 to 10 nanograms/mL down to 1.6 nanograms/mL, with an unexpected improvement in creatinine levels. When the St John’s wort was stopped, tacrolimus levels and creatinine returned to the previous range. Subsequently a lower target range of tacrolimus was set.3

Experimental evidence

No relevant data found.

Mechanism

St John’s wort induces the cytochrome P450 isoenzyme CYP3A4 and affects the transporter protein P-glycoprotein. CYP3A4 and P-glycoprotein are involved in the metabolism and clearance of tacrolimus, so an increase in their effects would be expected to result in a decrease in tacrolimus levels.1,3

Importance and management

Although the evidence currently seems limited to these reports, the interaction between tacrolimus and St John’s wort has been predicted from the pharmacokinetics of these two drugs. Given the unpredictability of the interaction (and the variability in content of St John’s wort products) it would seem prudent to avoid St John’s wort in transplant recipients, and possibly other types of patient taking tacrolimus. If St John’s wort is started or stopped, monitor tacrolimus levels closely and adjust the dose accordingly.

St John’s wort also does not interfere with laboratory assays for tacrolimus, see St John’s wort + Laboratory tests, page 372.


St John’s wort + Talinolol

St John’s wort modestly decreases the plasma levels of talinolol.

Clinical evidence

In a randomised study, a single oral dose of talinolol 50 mg was given to 9 healthy subjects after 12-days of St John’s wort (Jarsin, Lichtwer Pharma) 900 mg daily. St John’s wort was found to reduce the AUC and oral bioavailability of talinolol by about 31% and 25%, respectively. The non-renal clearance of a single dose of talinolol 30 mg given as a 30-minute infusion was increased by about 26%. Other pharmacokinetic parameters of both oral and intravenous talinolol were not significantly affected.1

Experimental evidence

No relevant data found.

Mechanism

Talinolol is a known substrate for P-glycoprotein. This study found that the levels of intestinal P-glycoprotein in the duodenal biopsy samples of 9 subjects were raised by St John’s wort, leading to a reduction in the absorption of talinolol.

Importance and management

Information appears to be limited to this study but it is in line with the known effects of St John’s wort on substrates of P-glycoprotein, such as digoxin. See St John’s wort + Digoxin, page 368. The modest decrease in talinolol levels suggests that, in most patients, this interaction is unlikely to be clinically significant. Nevertheless, consider this interaction if blood pressure is difficult to control.


St John’s wort + Theophylline

A patient needed a marked increase in the dosage of theophylline while taking St John’s wort. In contrast, no pharmacokinetic interaction was found in a 2-week study in healthy subjects.

Clinical evidence

A study in 12 healthy subjects found that a standardised preparation of St John’s wort 300 mg (hypericin 0.27%) three times daily for 15 days had no significant effects on the plasma level of a single 400-mg oral dose of theophylline.1 However, an isolated case has been reported of a woman, who had previously been stable for several months taking theophylline 300 mg twice daily, but was found to need a marked increase in her theophylline dosage to 800 mg twice daily to achieve serum levels of 9.2 mg/L. Two months previously she had started to take 300 mg of a St John’s wort supplement (hypericin 0.3%) each day. When she stopped taking the St John’s wort, her serum theophylline levels doubled within one week to 19.6 mg/L and her theophylline dosage was consequently reduced. This patient was also taking a whole
spectrum of other drugs (amitriptyline, furosemide, ibuprofen, inhaled triamcinolone, morphine, potassium, prednisone, salbutamol (albuterol), valproic acid, zolpidem and zafirlukast) and was also a smoker. No changes in the use of these drugs or altered compliance were identified that might have offered an alternative explanation for the changed theophylline requirements.2

Experimental evidence

*In vitro* data suggest that hypericin can act as an inducer of the cytochrome P450 isoenzyme CYP1A2.2

**Mechanism**

Uncertain. It has been suggested that treatment with St John’s wort for 15 days was unlikely to induce the isoenzymes sufficiently to cause changes in plasma theophylline,1 and St John’s wort is thought to have a rather limited ability to induce CYP1A2. The patient in the case report had been taking St John’s wort for 2 months, although at a lower dose, therefore differences in duration of treatment may account for the discrepancy.

**Importance and management**

Direct information about this apparent interaction between theophylline and St John’s wort appears to be limited. Despite the isolated case report of a marked decrease in theophylline levels, no significant pharmacokinetic interaction was noted in healthy subjects, and any pharmacokinetic interaction appears likely to be minor. Mechanistic studies suggest a modest interaction at most. Furthermore, most clinically significant interactions with St John’s wort are mediated by the cytochrome P450 isoenzyme CYP3A4. However, until further evidence is available, it would be prudent to be aware of the possibility of an interaction. Patients should be warned of the possible effects of concurrent use. In 2000, the CSM in the UK recommended that patients taking theophylline should not take St John’s wort. In those patients already taking the combination, the St John’s wort should be stopped and the theophylline dosage monitored and adjusted if necessary.3,4 However, this guidance was issued before the pharmacokinetic study that suggests that an interaction is generally unlikely.

Note that St John’s wort does not appear to interfere with laboratory assays for theophylline, see St John’s wort + Laboratory tests, page 372.

----------


----------

**St John’s wort + Tricyclic antidepressants**

**The plasma levels of amitriptyline and its active metabolite, nortriptyline, are modestly reduced by St John’s wort.**

**Clinical evidence**

Twelve depressed patients were given amitriptyline 75 mg twice daily and St John’s wort extract (Jarsin, Lichtwer Pharma) 900 mg daily for at least 14 days. The AUC0–12 of amitriptyline was reduced by about 22% and the AUC of nortriptyline (its metabolite) was reduced by about 41%.1

**Experimental evidence**

No relevant data found.

**Mechanism**

Unknown.

**Importance and management**

The general clinical importance of this isolated report is uncertain. Both tibolone and hydroxychloroquine sulfate have been associated with liver toxicity alone but cases with hydroxychloroquine sulfate are quite rare. Therefore the authors of the report suggest that an interaction between tibolone and St John’s wort was to blame for the liver damage in this case; however, both drugs may cause liver damage alone. Both tibolone and St John’s wort are widely used long term, which suggests that this interaction is not common. Nevertheless, it may be prudent to be aware of a possible interaction if symptoms of liver toxicity (fatigue, reduced appetite, dark urine) become apparent.


----------

**St John’s wort + Tobilone**

An isolated case describes liver damage in a woman taking tibilone and St John’s wort.

**Clinical evidence**

A 57-year-old woman who had been taking tibilone 2.5 mg daily for the past 2 years for postmenopausal symptoms, and hydroxychloroquine sulfate 200 mg daily for the past 7 years for rheumatoid arthritis, without complaint, was hospitalised for liver damage after taking a 2-g infusion of St John’s wort daily for 10 weeks for mild jaundice. The patient was suffering from fatigue, reduced appetite and jaundice. Her liver function normalised after about one year of taking ursodesoxycholic acid 250 mg twice daily.1

**Experimental evidence**

No relevant data found.

St John’s wort + Triptans

Serotonin syndrome has been reported in a patient taking eletriptan and St John’s wort.

Clinical evidence
A 28-year-old woman who had been taking fluoxetine 60 mg daily for one year for an eating disorder, and St John’s wort (dose and frequency not stated) for one month, suffered a loss of consciousness, convulsions and mental confusion after eletriptan 40 mg daily was started 3 days earlier for a recurrent migraine. Previous use of eletriptan and fluoxetine had not resulted in any reported adverse effects. After admission to hospital, the patient developed acute rhabdomyolysis and transient mild acute renal failure. Serotonin syndrome was diagnosed, all medications were stopped and the symptoms gradually resolved over 10 days.\(^1\)

Experimental evidence
No relevant data found.

Mechanism
Additive serotonergic effects are the likely explanation for the case report above as serotonin syndrome has been reported with both St John’s wort\(^2\) and with triptans alone.

Importance and management
The CSM/MCA in the UK note that potentiation of serotonergic effects have been identified between triptans and St John’s wort, leading to an increased risk of adverse effects, and they advise that patients taking triptans should not take St John’s wort preparations.\(^3,4\) However, most UK manufacturers of triptans simply warn about the potential increase in undesirable effects. The possible concern is that concurrent use may result in the development of serotonin syndrome.


St John’s wort + Voriconazole

St John’s wort more than halves the AUC of a single dose of voriconazole.

Clinical evidence
In a study in 17 healthy subjects, a single 400-mg dose of oral voriconazole was given alone and on the first and last day of St John’s wort (Jarsin, Lichtwer Pharma) 300 mg three times daily for 15 days. Taking St John’s wort for one day had no effect on the voriconazole AUC\(_{0-\infty}\) but slightly increased the maximum serum level and AUC\(_{0-\infty}\) by 22%. However, when voriconazole was given on day 15 of treatment with St John’s wort, the AUC of voriconazole was decreased by 59% and there was a 2.4-fold increase in oral clearance.\(^1\)

Experimental evidence
No relevant data found.

Mechanism
These results suggest that the short-term effect of St John’s wort is to slightly enhance the absorption of voriconazole, whereas the longer-term effect is to induce absorption-limiting transport proteins, such as P-glycoprotein, and intestinal metabolism via cytochrome P450 isoenzyme CYP3A4.\(^1\)

Importance and management
The slight increase in voriconazole absorption with a single dose of St John’s wort is not clinically relevant. However, the reduction in voriconazole levels after 15 days of St John’s wort could impact on clinical efficacy. This suggests that patients requiring voriconazole should be asked about current or recent use of St John’s wort, since this may indicate the need to use an increased voriconazole dose, at least initially. Patients taking voriconazole should be advised not to take St John’s wort. The manufacturers of voriconazole specifically contraindicate concurrent use of St John’s wort.\(^2\)


St John’s wort + Warfarin and related drugs

St John’s wort can cause a moderate reduction in the anticoagulant effects of phenprocoumon and warfarin.

Clinical evidence
(a) Phenprocoumon
In a randomised, placebo-controlled, crossover study in 10 healthy men,\(^3\) St John’s wort extract (LI 160, Lichtwer Pharma) 900 mg daily for 11 days reduced the AUC of a single 12-mg dose of phenprocoumon by a modest 17.4%. There is also a case report of a 75-year-old woman taking phenprocoumon who had a reduced anticoagulant response (a rise in the Quick value) 2 months after starting to take St John’s wort.\(^3\)

(b) Warfarin
In a randomised, crossover study in 12 healthy subjects, one tablet of St John’s wort three times daily for 3 weeks modestly decreased the AUC of both R- and S-warfarin by about 25% after a single 25-mg dose of warfarin taken on day 14. In this study, the brand of St John’s wort used was Bioglan tablets, each tablet containing an extract equivalent to 1 g of Hypericum perforatum flowering herb top containing 825 micrograms of hypericin and 12.5 mg of hyperforin.\(^3\)

The Swedish Medical Products Agency received 7 case reports over the 1998 to 1999 period of patients stabilised on warfarin who showed decreased INRs when St John’s wort was added. Their INRs fell from the normal therapeutic range of about 2 to 4 to about 1.5. Two patients needed warfarin dosage increases of 6.6% and 15%, respectively, when St John’s wort was added. The INRs of 4 patients returned to their former values when St John’s wort was stopped.\(^4\)

Experimental evidence
No relevant data found.

Mechanism
Uncertain, but it is suggested that the St John’s wort increases the metabolism and clearance of the anticoagulants,\(^1,3,4\) possibly by induction of cytochrome P450 isoenzyme CYP3A4, and possibly also CYP2C9, as both R- and S-warfarin were affected.\(^3\) However, note that St John’s wort had no effect on the metabolism of tolbutamide, which is commonly used as a probe substrate for CYP2C9 activity. See St John’s wort + Antidiabetics, page 362.

Importance and management
Information seems to be limited to these reports, but a modest
pharmacokinetic interaction is established, which might be clinically important in some patients. It would be prudent to monitor the INRs of patients taking phenprocoumon, warfarin or any other coumarin if they start taking St John’s wort, being alert for the need to slightly raise the anticoagulant dosage. However, note that the advice of the CSM in the UK is that St John’s wort should not be used with warfarin. They note that the degree of induction of warfarin metabolism is likely to vary because levels of active ingredients may vary between St John’s wort preparations. If a patient is already taking the combination, they advise checking the INR, stopping the St John’s wort and then monitoring the INR closely and adjusting the anticoagulant dosage as necessary.5

Starflower oil
Borago officinalis L. (Boraginaceae)

**Synonym(s) and related species**
Beebread, Bee plant, Borage, Borage oil, Burrage.

**Pharmacopoeias**
Refined Borage Oil (BP 2009); Refined Borage (Starflower) Oil (Ph Eur 6.4).

**Constituents**
The oil from starflower seeds contains the essential fatty acids of the omega-6 series, linoleic acid (about 30 to 41%) and gamolenic acid (gamma-linolenic acid, about 17 to 27%). Other fatty acids include oleic acid, alpha-linolenic acid, palmitic acid and stearic acid.

Starflower leaves contain potentially hepatotoxic pyrrolizidine alkaloids including lycopsamine, intermedine and their derivatives.

**Use and indications**
Starflower is thought to possess diuretic, expectorant and anti-inflammatory properties. The main use of starflower comes from its seed oil, which contains none of the hepatotoxic pyrrolizidine alkaloids found in the leaves. The oil is used as an alternative to evening primrose oil, page 179, as a source of gamolenic acid.

Infusions of the leaves have traditionally been used for fevers and coughs but it is not recommended that starflower leaves are taken internally, especially if fresh, because they contain small amounts of the hepatotoxic pyrrolizidine alkaloids. The leaves have also been used as an emollient poultice.

**Pharmacokinetics**
No relevant pharmacokinetic data found, but see evening primrose oil, page 179 for information on the pharmacokinetics of cis-linoleic acid.

**Interactions overview**
*Evening primrose oil* contains linoleic acid and gamolenic acid, which are the main active constituents implicated in its interactions. Starflower oil also contains these constituents, and is therefore expected to interact in the same way. See evening primrose oil, page 179.
Tea

Camellia sinensis (L.) Kuntze (Theaceae)

Synonym(s) and related species
Camellia thea Link, Thea sinensis L.

Note that Green tea (predominantly produced in China and Japan) is produced from steam-treated tea leaves. Black tea or Red tea (predominantly produced in India, Sri Lanka and Kenya) is processed by fermentation and heating, whereas Oolong tea is partially fermented.

Pharmacopoeias
Powdered Decaffeinated Green Tea Extract (USP 32).

 Constituents
Tea contains caffeine (around 1 to 5%), with minor amounts of other xanthines such as theophylline and theobromine. Tea also contains flavonoids, the content of which varies between green (unfermented) and black (fermented) tea. Green tea appears to contain greater quantities of the flavonol-type flavonoids than black tea. Black tea also contains theaflavins, which are produced during the fermentation process. Other flavonols present include quercetin and kaempferol. Oolong tea contains some unique flavones known as oolonghomobisflavins. Tea also contains up to 24% tannins.

 Use and indications
The leaf buds and very young leaves of tea are used as a stimulant and diuretic, actions that can be attributed to the caffeine content. They are also used as an astringent for gastrointestinal disorders, which may be attributed to the polyphenols and tannins. Tea is very widely used to make a beverage. Green tea extracts, which are rich in polyphenols, are available as supplements. There is also a prescription-only ointment containing green tea extract (sinecatechins), which is used for the treatment of genital warts.1

Pharmacokinetics
The pharmacokinetics of caffeine are discussed under caffeine, page 97. Black tea does not appear to affect the cytochrome P450 isoenzyme CYP2C9, as shown by the lack of effect on the pharmacokinetics of flurbiprofen, page 385. Similarly green tea catechins do not appear to affect the metabolism of caffeine, page 384, losartan, page 387, dextromethorphan, page 385, or alprazolam, page 383, suggesting a lack of effect on the isoenzymes CYP1A2, CYP2C9, CYP2D6 and CYP3A4, respectively.

For information on the pharmacokinetics of individual flavonoids present in tea, see flavonoids, page 186.

Interactions overview
Tea can contain significant amounts of caffeine, therefore the interactions of caffeine, page 97, are relevant to tea, unless the product is stated as decaffeinated. Black tea appears to reduce the absorption of iron, whereas green tea appears to have much smaller, if any, effects. Both black and green tea may cause a modest increase in blood pressure, which may be detrimental to the treatment of hypertension. Tea, particularly green tea catechins, may have some antiplatelet effects, which may be additive to those of conventional antiplatelet drugs. Case reports suggest that tea may reduce the INR in response to warfarin.

Green tea extracts do not appear to affect the pharmacokinetics of alprazolam, caffeine, ciclosporin, dextromethorphan, irinotecan and losartan, and have only modest effects on the pharmacokinetics of buspirone, but some of these data need confirming in patients. Black tea does not appear to have a clinically relevant effect on the pharmacokinetics of flurbiprofen.

Milk does not appear to affect the absorption of flavonoids or catechins from tea, suggesting that the addition of milk does not impair the antioxidant effects of tea.

For information on the interactions of individual flavonoids present in tea, see under flavonoids, page 186.

Green tea extract does not affect the pharmacokinetics of alprazolam.

Clinical evidence
In a pharmacokinetic study, 10 healthy subjects were given a single 2-mg dose of alprazolam before and after Decaffeinated Super Green Tea Extract 2 capsules twice daily for 14 days. The green tea extract did not affect the pharmacokinetics of alprazolam.

Experimental evidence
Because of the quality of the clinical evidence available, experimental data have not been sought.

Mechanism
These studies provide evidence that green tea catechins, at similar doses to the amount provided by average green tea consumption, are unlikely to affect the metabolism of drugs by the cytochrome P450 isoenzyme CYP3A4.

Importance and management
The available data suggest that no clinically relevant pharmacokinetic interaction would be expected between green tea and alprazolam. Alprazolam is used as a probe drug for CYP3A4 activity, and therefore these results also suggest that a pharmacokinetic interaction as a result of this mechanism between green tea and other CYP3A4 substrates is unlikely.

For the possible pharmacodynamic interaction between caffeine (a constituent of tea) and benzodiazepines, see Caffeine + Benzodiazepines and related drugs, page 100. Tea can contain significant amounts of caffeine, and this interaction should be applied to tea, unless the product is stated to be decaffeinated.


Both black and green tea may cause a modest increase in blood pressure, which may be detrimental to the treatment of hypertension.

Clinical evidence
There is a possibility that the effect of tea on blood pressure might differ from that of pure caffeine. There are few data on the effect of tea on blood pressure in patients treated with antihypertensives. One study in stable hypertensive patients taking beta blockers, calcium-channel blockers, nitrates and ACE inhibitors reported that 450 mL of black tea (containing approximately 190 mg of caffeine) increased systolic blood pressure by 5 mmHg two hours after consumption. This effect was similar to the increase seen with a single dose of 200-mg of caffeine. Drinking 900 mL of black tea daily for 4 weeks had no significant effect on blood pressure. However, the acute effects of tea remained: systolic blood pressure was still increased by 5 mmHg two hours after the patients drank 450 mL of black tea.

There are a number of short-term intervention studies on the effect of tea on blood pressure, mainly in healthy subjects or patients with untreated mild hypertension. In one meta-analysis of 5 randomised studies of the effect of tea consumption for at least 7 days (median 4 weeks) on blood pressure, tea consumption was associated with no change in blood pressure, when compared with the control group (although this group took caffeine in two of the studies). In one of the studies in this review, the acute increase in blood pressure seen with both green tea and black (fermented) tea 30 minutes after consumption was actually higher than that from an equivalent dose of caffeine. However, the increases seen in ambulatory blood pressure after 7 days of regular consumption of green or black tea were small and not different to that of caffeine. In another study by the same research group, the acute effects of black (fermented) tea on blood pressure were not apparent when the tea was taken with a meal (high fat).

The only long-term studies are of epidemiological type. In the Nurses Health prospective cohort study I, tea consumption was not associated with an increased risk of developing hypertension, whereas in the cohort study II, there was a slight trend for increased risk of hypertension with increased caffeinated tea intake. However, in a cohort study in Taiwan, the risk of developing hypertension was reduced by regular tea (green or oolong) consumption. Similarly, in a cross-sectional study, tea intake (mostly black (fermented) tea with added milk) was related to lower blood pressure in older women. There appear to be very few data on the effect of supplements containing tea extracts on blood pressure. In one study, which compared the addition of green tea extract or placebo with a low-energy diet, the green tea extract had no additional benefit on blood pressure over that achieved by modest weight loss. In a single-dose study, a supplement containing black tea extract (polyphenols and caffeine), guarana extract (caffeine), ginger extract, dill weed extract, rutin and vitamin C (TeaLean), there was an average 3.7 mmHg increase in systolic blood pressure in the 2 hours after ingestion, but no increase in diastolic blood pressure.

Experimental evidence
Because of the extensive clinical evidence available, experimental data have not been sought.

Mechanism
Acute intake of caffeine raises blood pressure, but some tolerance to this effect might possibly develop with regular consumption. See also Caffeine + Antihypertensives, page 99. Polyphenolics in tea might improve endothelial function, and might therefore lower blood pressure.

Importance and management
The evidence presented here is conflicting, and it is not possible to be conclusive about the long-term effect of tea intake (green or black) on blood pressure. However, any adverse effect appears to be modest. On acute intake, both green and black (fermented) tea and some herbal supplements (particularly if they contain caffeine) might increase blood pressure, although, from the limited information above, these increases appear to be small and not necessarily sustained during long-term intake. Bear this in mind in patients with poorly controlled hypertension who frequently consume tea, particularly in large quantities. Further study on the effects of tea on antihypertensives is needed. However, note that similar effects are known to occur with caffeine alone, see Caffeine + Anti-hypertensives, page 99.

Tea, particularly green tea catechins, may have some antplatelet effects, which may be additive to those of conventional antplatelet drugs.

Clinical evidence

(a) Pharmacodynamic effects
In studies in healthy medication-free subjects, neither acute1,2 nor chronic3 tea consumption of black (fermented) tea (with or without added milk) affected platelet aggregation, whereas two studies did report a reduction in platelet activation with chronic tea intake.2,4

Another study, in 49 patients with known coronary artery disease taking aspirin 325 mg daily, found no evidence that acute or chronic ingestion of black (fermented) tea affected ADP-induced platelet aggregation.5 There appears to be just one clinical study of green tea, which did not find any significant effect on platelet aggregation.6

(b) Pharmacokinetic effects
A study in 5 healthy subjects found that 200 mL of tea (at a temperature of 50°C) increased the rate of absorption of salicylate from a single 500-mg dose of aspirin, when compared with water, but the maximum concentration of salicylate was not significantly affected. The authors note that this result may have been influenced by the high temperature of the tea and an alkaline pH, both of which can increase the dissolution rate of aspirin.7 Note that caffeine is known to have a modest effect on the absorption of aspirin, see Caffeine + Aspirin or Diclofenac, page 99.

Experimental evidence

Green tea catechins have been reported to inhibit platelet aggregation in mice and in vitro, in a dose-dependent manner. Bleeding time was also prolonged in mice, but aPTT, prothrombin time and thrombin time were not affected by green tea catechins added to human plasma. This suggested an antplatelet rather than an antithrombotic effect.8 Another animal study by the same research group found that oral green tea catechins 25 and 50 mg/kg inhibited arachidonic acid-induced platelet aggregation and the production of thromboxane A2 and prostaglandin D2.9

Mechanism
There is in vitro evidence that flavonoids, and flavanols and procyanidin oligomers in particular, inhibit platelet aggregation, and this has been suggested as a mechanism to explain why some epidemiological studies show that a diet high in these substances is associated with a reduced risk of cardiovascular disease (see also Flavonoids + Antiplatelet, page 188).

Importance and management
In general the evidence appears to suggest that black (fermented) tea does not have a clinically relevant effect on platelet aggregation. However, experimental studies using green tea catechins have found an antplatelet effect, and this effect may, in theory, be additive to those of conventional antplatelet drugs. Concurrent use need not be avoided (indeed combinations of antplatelet drugs are often prescribed together) but it may be prudent to be aware of the potential for increased bleeding if green tea extracts, particularly in high doses, are given with other antplatelet drugs such as aspirin and clopidogrel. Patients should discuss any episode of prolonged bleeding with a healthcare professional. Modest consumption is unlikely to cause any problems.

Experimental evidence
Because of the quality of the clinical evidence available, experimental data have not been sought.

Mechanism
This study provides evidence that green tea catechins (at higher doses than the amount provided by average green tea consumption) are unlikely to affect the metabolism of drugs principally metabolised by the cytochrome P450 isoenzyme CYP1A2.

Importance and management
No pharmacokinetic interaction is expected between decaffeinated green tea and caffeine or other CYP1A2 substrates.

Note that tea usually contains caffeine, and therefore the interactions of caffeine, page 97, (including caffeine found in other medicines, supplements or foods) are relevant. Excess caffeine consumption can cause adverse effects, including headache, jitteriness, restlessness and insomnia. Reduce caffeine intake if problems develop.


Tea + Ciclosporin or Tacrolimus

Green tea catechins do not appear to affect ciclosporin levels, and may protect against the adverse renal effects of ciclosporin and tacrolimus.

Evidence, mechanism, importance and management
In a study in rats, epigallocatechin gallate (a green tea catechin) had no significant effect on ciclosporin levels and also appeared to protect against ciclosporin-induced renal damage.1 In another animal study, pre-treatment with green tea polyphenolic extract, followed by the addition of ciclosporin or tacrolimus, blunted the decrease in glomerular filtration rates seen with these drugs.2 Similar findings were reported in another study in which 7 subjects received a single 30-mg dose of dextromethorphan before and after Decaffeinated Super Green Tea Extract 2 capsules twice daily for 14 days.3

Experimental evidence
Because of the quality of the clinical evidence (controlled pharmacokinetic studies), experimental data have not been sought.

Mechanism
These studies provide evidence that green tea catechins (at similar or higher doses than the amount provided by average green tea consumption) are unlikely to affect the metabolism of dextromethorphan.

Importance and management
Evidence from two well-designed clinical studies suggests that green tea does not affect the pharmacokinetics of dextromethorphan. Dextromethorphan is used as a probe drug for CYP2D6 activity, and therefore these results also suggest that a pharmacokinetic interaction as a result of this mechanism between green tea and other CYP2D6 substrates is unlikely.


Tea + Flurbiprofen

Black tea does not appear to have a clinically relevant effect on the pharmacokinetics of flurbiprofen.

Clinical evidence
In a single-dose study in healthy subjects, brewed black tea (Lipton Brisk tea) had no effect on the clearance of elimination half-life of flurbiprofen.1

Experimental evidence
An in vitro study reported that a sample containing brewed black tea 2.5% inhibited the hydroxylation of flurbiprofen by CYP2C9 by 89%.1

Mechanism
These studies provide evidence that black (fermented) tea is unlikely to affect the metabolism of flurbiprofen.

Importance and management
Although experimental studies suggested that black tea may inhibit the metabolism of flurbiprofen, the study in healthy subjects suggests that any effect is not clinically relevant. No pharmacokinetic interaction is therefore expected between black (fermented) tea and flurbiprofen. Flurbiprofen can be used as a probe drug for CYP2C9 activity, and therefore these results also suggest that a pharmacokinetic interaction as a result of this mechanism between black tea and other CYP2C9 substrates is unlikely.


Tea + Food

Milk does not appear to affect the absorption of flavonoids or catechins from tea, suggesting that the addition of milk does not impair the antioxidant effects of tea.
**Clinical evidence**

In a study in 12 healthy subjects, blood levels of catechins did not differ when black (fermented) tea was taken with the addition of milk (100 mL semi-skimmed plus water 500 mL with 3 g of instant tea) compared with no milk (3 g instant tea with water 600 mL). Similarly, in another study, plasma levels of the flavonoids quercetin and kaempferol did not differ when black (fermented) tea was drunk alone or with the addition of 15 mL of milk to 135 mL of tea. Another study showed similar findings (no difference in increase in total phenols, catechins, quercetin and kaempferol). Conversely, a slight 17% decrease in the AUC of catechins when black tea was taken with the addition of 70 mL milk was reported in another study. As regards the plasma antioxidant effect of tea, three studies found that the addition of milk to black (fermented) tea did not alter the increase in antioxidant potential, whereas one study found that the addition of milk to black tea (3 measures consumed between 9 am and 12 noon) markedly reduced the increase in antioxidant effect at 12 noon, but it was only slightly reduced at 3 pm. The addition of milk also had no effect on the antioxidant effect of green tea in one study.

In another study in 16 healthy women, the addition of milk (to a final concentration of 10%) to black tea completely prevented the increase in endothelial-dependent flow-mediated dilatation seen with black tea alone. However, the increase in endothelial-independent vasodilation was not affected by the addition of milk to tea.

**Experimental evidence**

Because of the extensive clinical evidence available, experimental data have not been sought.

**Mechanism**

It has been suggested that substances in milk (such as casein) might reduce the absorption of catechins and flavonoids from tea, but this has not been demonstrated in many of the studies.

**Importance and management**

Although the evidence is not entirely conclusive, there appears to be no important interaction between milk and black (fermented) tea, suggesting that the addition of milk does not reduce the antioxidant effects of tea. Similar levels of potentially active catechins and flavonoids can be expected, however the tea is taken. This suggests that milk is also unlikely to alter the absorption of catechins from green tea supplements.

---


---

**Tea + Herbal medicines; Pepper**

The interaction between green tea and pepper is based on experimental evidence only.

**Clinical evidence**

No interactions found.

**Experimental evidence**

In a study in *mice*, piperine modestly increased the bioavailability of epigallocatechin-3-gallate (EGCG) from *green tea*, with a 30% increase in the AUC1–5 and maximum plasma levels.

**Mechanism**

Piperine appeared to increase EGCG bioavailability by inhibiting glucuronidation and gastrointestinal transit.

**Importance and management**

The available evidence is from experimental studies only, but it does provide some evidence that piperine (an alkaloid derived from black pepper, page 313) can modestly increase bioavailability of the green tea catechin studied. However, the increases seen are probably unlikely to be clinically important, even if they were to be replicated in a clinical study. Evidence regarding the interactions of other herbal medicines with tea is limited, but the caffeine content of tea suggests that it may interact with other herbal medicines in the same way as caffeine, see Caffeine + Herbal medicines; Bitter orange, page 101, and Ephedra + Caffeine, page 176.

---


---

**Tea + Irinotecan**

The information regarding the use of green tea with irinotecan is based on experimental evidence only.

**Evidence, mechanism, importance and management**

Based on the results of *in vitro* studies, it was considered that usual pharmacological doses of *green tea catechins* were unlikely to inhibit the formation of active metabolites of irinotecan. There was no induction of CYP3A4 metabolism, and just modest and variable induction of glucuronidation (UGT1A1). However, the authors did conclude that these effects require confirmation in patients.

---


---

**Tea + Iron compounds**

Black tea appears to reduce the absorption of iron and may contribute to iron deficiency anaemia. Green tea appears to have much smaller, if any, effects.

**Clinical evidence**

(a) *Black tea*

There are few data on the effect of tea on the absorption of iron from supplements. One case report describes an impaired response to iron, given to correct iron deficiency anaemia, in a patient drinking 2 litres of black tea daily. The patient recovered when the black tea was stopped. This report did not specify whether the black tea was tea without milk, or black (fermented) tea.

Some short-term controlled studies show a marked reduction in the absorption of dietary non-haem iron with black (fermented) tea beverage, some of which are cited for information. In one of these, in a series of studies in healthy subjects, a 275 mL serving of black (fermented, Assam) tea reduced the absorption of radiolabelled iron from a 50 g bread roll by 79 to 94%. The tea was prepared by adding 300 mL of boiling water to 3 g of Assam tea, then infusing for 10 minutes before straining and serving. Milk added to the tea had very little effect on the reduction in iron absorption. A study found that 150 mL of black tea reduced the absorption of radiolabelled iron...
from a test meal by 59% in 10 women with iron deficiency anaemia and by 49% in 10 control subjects without anaemia. When the quantity of tea was increased to 300 mL iron absorption was reduced by about 66% in both groups.6

Whether these reductions in iron absorption are important in the development of iron deficiency anaemia is less clear. Various epidemiological studies have looked at the correlation between tea consumption and iron deficiency in different populations. In one review of 16 of these studies, tea consumption did not influence iron status in people with adequate iron stores (as is common in the West), but there seemed to be a negative association between tea consumption and iron status in people with marginal iron status.7

West), but there seemed to be a negative association between tea consumption and iron deficiency in different populations. In one epidemiological study has looked at the correlation between tea consumption and iron status in people with marginal iron status.8

Note that tea has been used with some success in reducing iron accumulation and the frequency of phlebotomy in patients with iron overload syndromes.13

**Experimental evidence**

Because of the extensive clinical evidence available, experimental data have not been sought.

**Mechanism**

Tannins found in tea are thought to form insoluble complexes with non-haem iron and thus reduce its absorption.3,11 Other polyphenolic compounds found in tea may also reduce the bioavailability of non-haem iron. One study reported that beverages containing 100 to 400 g of polyphenols may reduce iron absorption by 60 to 90%.5

**Importance and management**

The general importance of these findings is uncertain, but be aware that black tea consumption may contribute to iron deficiency anaemia. However, it has been suggested that no restrictions are required in healthy patients not at risk of iron deficiency.14 Conversely, the suggestion is that patients at risk of iron deficiency (which would include those requiring iron supplements) should be advised to avoid tea and meals and for one hour after eating.14 Note that tea is not generally considered to be a suitable drink for babies and children, because of its effects on iron absorption. Milk does not attenuate the effect of black (fermented) tea on iron absorption.

The available data suggest that green tea extracts rich in catechins have less effect on iron absorption than tea beverages from black (fermented) teas.12


**Tea + Losartan**

Green tea extracts do not appear to affect the pharmacokinetics of losartan.

**Clinical evidence**

In a study in 42 healthy subjects, green tea extract for 4 capsules daily for 4 weeks had no effect on the metabolism of a single 25-mg dose of losartan to the metabolite E3174. The green tea catechin extract used in this study, Polyphenon E, contained 80 to 98% total catechins, of which 50 to 75% (200 mg per capsule) was epigallocatechin gallate. It was essentially decaffeinated (0.5% w/w caffeine).1

**Experimental evidence**

Because of the quality of the clinical evidence (controlled pharmacokinetic studies), experimental data have not been sought.

**Mechanism**

This study suggests that green tea catechins do not affect the metabolism of losartan.

**Importance and management**

Evidence is limited to this one study, which suggests that no pharmacokinetic interaction is expected between decaffeinated green tea extract and losartan. Losartan can be used as a probe drug for CYP2C9 activity, and therefore these results also suggest that a pharmacokinetic interaction as a result of this mechanism between green tea extracts and other CYP2C9 substrates is unlikely.


**Tea + Warfarin and related drugs**

Case reports suggest that tea may reduce the INR in response to warfarin.

**Clinical evidence**

A patient taking warfarin had a reduction in his INR from a range of 3.2 to 3.79 down to 1.37, which was attributed to the ingestion of very large quantities of green tea (about 2 to 4 litres each day for one week). This interaction was attributed to the vitamin K content of the tea.1 However, although dried tea, including green tea, is very high in vitamin K1, the brewed liquid made from the tea contains negligible amounts of vitamin K1,2 and is therefore not considered to contribute any vitamin K1 to the diet.2 The reason for this interaction is therefore unclear, unless the patient was eating some of the brewed tea leaves.

Another man stabilised on warfarin was found to have an INR of 4.43 at a routine clinic visit, which was increased from 3.07 six weeks previously. The patient had stopped taking a herbal product named Nature’s Life Greens that month because he did not have enough money to buy it. He had been taking it for the past 7 years as a vitamin supplement because he had previously been instructed to limit his intake of green leafy vegetables. He was eventually
restabilised on warfarin and the same nutritional product. The product label listed 25 vegetables without stating the amounts or concentrations, but at least 5 of the listed ingredients are known to contain high levels of vitamin K, including parsley, green tea leaves, spinach, broccoli and cabbage. It is therefore likely that it contained sufficient vitamin to antagonise the effect of the warfarin so that when it was stopped the warfarin requirements fell and, without an appropriate adjustment in dose, this resulted in an increased INR.

Experimental evidence
Because of the extensive clinical evidence available, experimental data have not been sought.

Mechanism
Unknown. Green and black (fermented) tea do not alter the pharmacokinetics of some CYP2C9 substrates. See losartan, page 387, and flurbiprofen, page 385. Therefore it is unlikely that a pharmacokinetic interaction occurs with warfarin, which is principally metabolised by this isoenzyme.

Importance and management
Evidence for an interaction between tea and warfarin appears to be limited to two case reports. Vitamin K antagonises the effect of warfarin and similar anticoagulants, and this is present in high levels in green tea leaves. However, it is a fat-soluble vitamin, and is therefore not present in brewed tea or water extracts of green tea. In general, a reduction in warfarin effects via this mechanism would be unexpected with tea or tea supplements. Nevertheless, some consider that increased monitoring of INR is advisable when patients taking warfarin want to stop or start any herbal medicine or nutritional supplement. Because of the many other factors influencing anticoagulant control, it is not possible to reliably ascribe a change in INR specifically to a drug interaction in a single case report without other supporting evidence. It may be better to advise patients to discuss the use of any herbal products that they wish to try, and to increase monitoring if this is thought advisable. Cases of uneventful use should be reported, as they are as useful as possible cases of adverse effects.

However, note that it has been suggested that tea, particularly green tea, may have antiplatelet effects. See Tea + Antiplatelet drugs, page 384. There is a well-established small increased risk of bleeding when aspirin at antiplatelet doses is combined with the anticoagulant drug warfarin. Theoretically, very high intake of green tea catechins may be sufficient to increase the risk of bleeding with anticoagulant drugs; however, firm evidence for this is lacking. Modest consumption is unlikely to cause any problems.

Thyme

*Thymus vulgaris* L. (Lamiaceae)

**Synonym(s) and related species**
Common thyme, French thyme, Garden thyme, Rubbed thyme.


Not to be confused with wild thyme, which is *Thymus serpyllum* L.

**Pharmacopoeias**

**Constituents**
The major non-volatile constituents of thyme are the flavonoids including apigenin, eriodictyol, luteolin, naringenin and others. Other non-volatile constituents include caffeic acid, rosmarinic acid, saponins and tannins. The oil contains up to 70% thymol, with carvacrol, p-cymene, linalool, α-terpineol and thujan-4-ol. Other species contain similar constituents, although some varieties contain less thymol and more of the other components.

**Use and indications**
Thyme is used traditionally as a carminative, spasmytic and antimicrobial, particularly for the respiratory system. Thymol is widely used in dentistry as a mouthwash, but it is toxic in high doses and should not be taken internally or applied externally in large amounts. Thyme is commonly used as a flavouring ingredient in foods.

**Pharmacokinetics**
An aqueous extract of thyme has been identified as a potent inhibitor of several cytochrome P450 isoenzymes, namely CYP2C9, CYP2C19, CYP2D6 and CYP3A4, in an *in vitro* study. However, these findings should be interpreted with caution, as the study also found St John’s wort to be a CYP3A4 inhibitor, whereas clinically it is a CYP3A4 inducer.

For information on the pharmacokinetics of individual flavonoids present in thyme, see under flavonoids, page 186.

**Interactions overview**
No interactions with thyme found. Note that thyme is commonly used as a flavouring ingredient in foods.

For information on the interactions of individual flavonoids present in thyme, see under flavonoids, page 186.

**Turmeric**

*Curcuma longa* L. (Zingiberaceae)

**Synonym(s) and related species**

Indian saffron.  
*Curcuma domestica* Valeton is generally accepted to be the same species as *Curcuma longa*.

The related species *Curcuma aromatica* Salisb. is known as wild or aromatic turmeric and *Curcuma xanthorrhiza* D. Dietr. is known as Javanese turmeric.

Not to be confused with *Curcuma zedoaria* (Christmann) Roscoe, which is zedoary.

**Pharmacopeias**

Javanese Turmeric (*BP 2009*, *Ph Eur 6.4*); Turmeric (*USP 32*); Powdered Turmeric (*USP 32*); Powdered Turmeric Extract (*USP 32*).

**Constituents**

The active constituents are curcuminoids, and include a mixture known as curcumin which contains diferuloylmethane (sometimes referred to as curcumin or curcumin I), desmethoxycurcumin (curcumin II), bisdesmethoxycurcumin (curcumin III) and cyclocurcumin (curcumin IV). Most commercially available preparations of ‘curcumin’ are not pure, but also contain desmethoxycurcumin and bisdesmethoxycurcumin. The related species *Curcuma aromatica* and *Curcuma xanthorrhiza* also contain curcuminoids.

The essential oil contains mainly turmerones, including zingiberene.

**Use and indications**

Turmeric has many biological activities, which are mainly attributed to the curcuminoids that it contains. It is widely used as an anti-inflammatory and liver protecting agent, and its chemopreventive effects for cancer (inhibition of tumour formation, promotion, progression and dissemination in many animal models) are the subject of much research. Turmeric is also used for disorders related to the ageing process. Curcumin has an anti-oxidant and anti-inflammatory activity, and has been proposed as a treatment for many degenerative diseases with an inflammatory or oxidative basis, such as cardiovascular diseases, type 2 diabetes, artherosclerosis and arthritis, among others.

Turmeric is also used as a spice in food.

**Pharmacokinetics**

An *in vitro* study suggested that curcumin-containing extracts from *Curcuma longa* may inhibit intestinal CYP3A4;¹ this finding is supported by a study in rats, see midazolam, page 392. A study in rats fed curcumin, found that even large amounts of curcumin (5 g/kg) did not alter the activity of hepatic cytochrome P450 isoenzymes.²

Several *in vitro* studies have suggested that curcumin inhibits or alters the effects of P-glycoprotein.³–⁵ See also beta blockers, page 391. Further study using individual curcumin constituents extracted from turmeric powder found that curcumin I has a greater inhibitory action on P-glycoprotein than curcumin II or curcumin III,⁶ although curcumin III has been shown to have a greater influence on the multidrug resistance gene (of which P-glycoprotein is a product).⁷

**Interactions overview**

Turmeric or its constituent curcumin affects the absorption of some beta blockers, increases the absorption of midazolam, but does not affect the absorption of iron. Piperine, from pepper, enhances the bioavailability of curcumin.

In a clinical study, curcumin, a major constituent of turmeric, decreased the absorption of talinolol, a P-glycoprotein substrate. Curcumin increased the absorption of celiprolol, another P-glycoprotein substrate, in rats.

Clinical evidence
In a randomised study, 12 healthy subjects were given a single 50-mg dose of talinolol after taking curcumin, a major constituent of turmeric, 300 mg daily for 6 days. Curcumin was found to reduce the AUC and maximum plasma level of talinolol by 33% and 28%, respectively, but no clinically significant changes in heart rate or blood pressure occurred."}

Experimental evidence
In a study, rats were given curcumin 60 mg/kg daily for 5 days. Thirty minutes after the last dose of curcumin, a single 30-mg/kg dose of celiprolol was given. Curcumin increased the AUC and maximum plasma concentration of celiprolol by 30% and 90%, respectively. In a parallel single-dose study in rats curcumin 60 mg/kg, given 30 minutes before a single 30-mg/kg dose of celiprolol, had no effect on the pharmacokinetics of celiprolol.

Mechanism
It was thought that curcumin inhibits P-glycoprotein and therefore increases the absorption of P-glycoprotein substrates such as talinolol. This appears to be the case in a rat study, where curcumin had effects similar to (but weaker than) other known, clinically relevant P-glycoprotein inhibitors, that is, it increased the absorption of celiprolol, another P-glycoprotein substrate. However, in a clinical study the absorption of talinolol was unexpectedly decreased by curcumin, although, clinically, the known P-glycoprotein inhibitor verapamil also decreases talinolol absorption. This suggests that there may be other mechanisms involved in talinolol absorption. Differential effects on hepatic and intestinal P-glycoprotein may also be of relevance.

Importance and management
Evidence for an interaction between curcumin (a major constituent of turmeric) and beta blockers is sparse, but the available evidence does suggest that curcumin can modify the absorption of beta blockers that are P-glycoprotein substrates. The findings with talinolol were similar to the effects seen clinically with other P-glycoprotein inhibitors (see Mechanism above). However, the effects on absorption were modest, and beta blockers are generally accepted to have a wide therapeutic margin, so these findings would not be expected to be clinically relevant. It is unclear whether the effects of curcumin on celiprolol in rats will be replicated in humans. However, as with talinolol the effects were modest and are therefore unlikely to be clinically relevant.

---

Piperine, a major constituent of pepper, increases the bioavailability of curcumin, a major constituent of turmeric.

Clinical evidence
In a crossover study, 8 healthy subjects were given a single 2-g dose of curcumin, a major constituent of turmeric, powder alone, or with piperine, a major constituent of pepper, powder 20 mg. When curcumin was given alone, its serum levels were either very low or undetectable. The addition of piperine increased curcumin levels 3-fold over the first 45 minutes, and the relative bioavailability of curcumin was increased 20-fold. Concurrent use was well tolerated.

Experimental evidence
In an experimental study, rats were given a single 2-g/kg dose of curcumin alone, or with piperine 20 mg/kg. Although piperine modestly increased the maximum levels and AUC of curcumin, these changes were not statistically significant. Note that curcumin was reasonably well absorbed in rats, in contrast to humans, where absorption is poor, but this may have been due to the much greater doses given.

Mechanism
Unknown. It was suggested that piperine may inhibit the metabolism of curcumin.

Importance and management
In general the evidence supports the suggestion that piperine (a constituent of pepper) increases the bioavailability of curcumin (a major constituent of turmeric). This interaction may be beneficial because the effects of curcumin may be increased; however, it may also increase the potential for curcumin to interact with other medicines. The effect of piperine on the absorption of curcumin from turmeric extracts does not appear to have been studied, but it seems reasonable to expect a similar increase in bioavailability.

---


---

Consider Turmeric + Herbal medicines; Pepper, below. Turmeric is used as a spice in food.
However, what is known suggests that an interaction would not be expected.


**Turmeric + Midazolam**

The interaction between curcumin, a major constituent of turmeric, and midazolam is based on experimental evidence only.

**Clinical evidence**

No interactions found.

**Experimental evidence**

In a study, *rats* were given curcumin, a major constituent of turmeric, 60 mg/kg daily for 5 days. Thirty minutes after the last dose of curcumin, a single 20-mg/kg dose of midazolam was given. Curcumin increased the AUC of midazolam 3.8-fold and, although the maximum plasma level was approximately doubled, this was not statistically significant.¹

**Mechanism**

Midazolam is a substrate of the cytochrome P450 subfamily CYP3A (specifically the isoenzyme CYP3A4). The authors of the study suggest that curcumin inhibited intestinal CYP3A, resulting in a decrease in the metabolism of midazolam by this route, which led to an increase in its bioavailability.

**Importance and management**

Evidence appears to be limited to this study in *rats*, which demonstrated a large increase in the bioavailability of midazolam. These findings are difficult to reliably extrapolate to humans, but, as the effect was so large, it would seem reasonable to assume that curcumin could cause a clinically relevant increase in the bioavailability of midazolam, which may lead to an increase in the sedative effects of midazolam. It is not clear whether turmeric, of which curcumin is a major constituent, would have similar effects, but if large doses are given an effect seems possible. It would seem prudent to warn patients taking curcumin, and turmeric, about the possible increase in sedative effects.

Midazolam is used as a probe drug for CYP3A4 activity, and therefore these results also suggest that a pharmacokinetic interaction between curcumin (and therefore possibly turmeric) and other CYP3A4 substrates is possible. See the table Drugs and herbs affecting or metabolised by the cytochrome P450 isoenzyme CYP3A4, page 8, for a list of known CYP3A4 substrates.

No interactions have been included for herbal medicines or dietary supplements beginning with the letter U
Valerian

Valeriana officinalis L. (Valerianaceae)

Synonym(s) and related species
All-heal, Belgian valerian, Common valerian, Fragrant valerian, Garden valerian.
Many other Valerian species are used in different parts of the world.

Pharmacopoeias
Powdered Valerian (USP 32); Powdered Valerian Extract (USP 32); Valerian (BP 2009, USP 32); Valerian Dry Aqueous Extract (Ph Eur 6.4); Valerian Dry Hydroalcoholic Extract (BP 2009, Ph Eur 6.4); Valerian Root (Ph Eur 6.4); Valerian Tablets (USP 32); Valerian Tincture (BP 2009, Ph Eur 6.4).

Constituents
Valerian root and rhizome contains a large number of constituents which vary considerably according to the source of the plant material and the method of processing and storage. Many are known to contribute to the activity, and even those that are known to be unstable may produce active decomposition products. The valepotriates include the valerian acids, which are active constituents, but decompose on storage to form other actives including baldrian, and volatile constituents. The volatile oil is composed of valerenic acids and their esters, and other derivatives including isovaleric acids (which is responsible for the odour of valerian), and others. Other constituents present include: the free amino acids γ-aminobutyric acid (GABA); the flavonoids flavone 6-methylapigenin, hesperidin and linarin; alkaloids of the pyridine type including valerianine and valerine; and sterols including β-sitosterol.

Valerian dry hydroalcoholic extract is an extract produced from valerian root and contains a minimum of 0.25% sesquiterpenic acids, expressed as valeric acid.

Use and indications
Valerian is used particularly for stress and insomnia. It has long been used as a hypnotic, sedative, anxiolytic, antispasmodic, carminative and antihypertensive, and for hypochondriasis, migraine, cramp, intestinal colic, rheumatic pains and dysmenorrhoea. Despite many pharmacological studies showing sedative and anxiolytic effects, and binding or modulation of constituents to GABA and other neurotransmitter receptors, the clinical efficacy is not conclusively proven. A recent study suggested that it is safe, but not necessarily effective; however, many analytical reports also show that extracts and products of valerian vary greatly in both chemical composition and biological activity, and it may be that only certain preparations have any therapeutic benefit. Many commercial products use valerian in combination with hops, passiflora and other herbal extracts, and there is some evidence that these may be more efficacious, although again this is not clinically proven. The use of valerian as an aid to benzodiazepine withdrawal has been suggested on the basis of GABA-receptor binding effects, and there is a small study in mice which suggests that it may be useful to a limited extent; again this has not been shown clinically.

Pharmacokinetics
An in vitro study using a number of different valerian root preparations (capsules or tablets of the powdered extract, and teas) found that the products tested inhibited the cytochrome P450 isoenzyme CYP3A4. Other in vitro studies have found no effects, or an inductive effect at levels unlikely to be obtained clinically. Generally, studies suggest that any effect on CYP3A4 is unlikely to be of clinical importance, see benzodiazepines, page 396.

A further in vitro study suggests that valerian has no effect, or weak effects, on CYP1A2 (see also caffeine, page 397), CYP2C9 or CYP2C19. This study also suggests that valerian does not affect CYP2D6, although another in vitro study suggests that valerian may cause induction of CYP2D6, but this was at concentrations that are unlikely to be attained in vivo. These effects are unlikely to be clinically relevant because a study in 12 healthy subjects found that valerian root extract had no significant effects on the metabolism of debrisoquine, a probe substrate for CYP2D6, as did another clinical study using dextromethorphan, page 397). A further clinical study suggests that valerian also has no clinically relevant effect on CYP2E1, see chlorzoxazone, page 397.

In vivo investigations have suggested that valerian may inhibit P-glycoprotein, although the authors of one study concluded that this is unlikely to be clinically relevant, because the concentration at which this occurred is unlikely to be attained in vivo, and the findings of another study suggested that the effects were much weaker than those of verapamil, a known, clinically relevant P-glycoprotein inhibitor.

For information on the pharmacokinetics of individual flavonoids present in valerian, see under flavonoids, page 186.

Interactions overview
Valerian does not appear to affect the metabolism of alprazolam, caffeine, chlorzoxazone, dextromethorphan or midazolam to a clinically relevant extent. Valerian may increase the sleeping time in mice in response to alcohol and barbiturates. Case reports describe possible interactions with ginkgo, see Ginkgo + Herbal medicines; Valerian, page 214,
and St John’s wort and/or loperamide, see St John’s wort + Loperamide, page 373. For information on the interactions of individual flavonoids present in valerian, see under flavonoids, page 186.


Valerian + Alcohol

The interaction between valerian and alcohol is based on experimental evidence only.

Clinical evidence
No interactions found.

Experimental evidence
In a study in mice, a valepotriate extract of valerian, given in high doses, almost doubled the sleeping time in response to alcohol. In contrast, in a separate experiment, the extract appeared to antagonise the effects of alcohol on motor activity.

Mechanism
Additive CNS depressant effects.

Importance and management
The evidence of an interaction between valerian and alcohol appears to be limited to a study in mice. However, valerian is said to have sedative effects, and is used for insomnia, and so additive effects on sedation seem possible. The manufacturers of two herbal products containing valerian that are registered by the MHRA in the UK advise against excessive alcohol intake while taking valerian because the sedative effect of valerian may be potentiated by alcohol. It seems reasonable to suggest that additive sedative effects are possible. It would be prudent to warn patients that they may be more sedated if they drink alcohol while taking valerian and, if this occurs, to avoid undertaking skilled tasks. Note that, in the study in mice, the sedative effects of valepotriates, even in large doses, were more modest than those of diazepam and chlordiazepoxide. Remember that not all the indications of valerian are as anxiolytic/hypnotic.

Valerian + Benzodiazepines

Valerian does not affect the pharmacokinetics of alprazolam or midazolam to a clinically relevant extent. However, additive sedative effects are a possibility.

Clinical evidence
In a crossover study, 12 healthy subjects were given valerian root extract 1 g each night for 14 days, with a single 2-mg dose of alprazolam on the morning of day 15. Valerian increased the maximum plasma concentration of alprazolam by 20%, but there were no other statistically significant changes in the pharmacokinetics of alprazolam. The valerian extract used in this study contained 11 mg of valerenic acid per gram. In another study, 12 healthy subjects were given valerian root extract 125 mg three times daily for 28 days before receiving a single dose of midazolam. Valerian root extract caused no significant changes in the metabolism of midazolam.

Experimental evidence
No relevant data found.

Mechanism
Valerian has been found in some in vitro studies to be an inhibitor of the cytochrome P450 isoenzyme CYP3A4. See Pharmacokinetics, page 394. Alprazolam and midazolam are metabolised by this isoenzyme. The minor pharmacokinetic changes reported therefore suggest that, clinically, valerian has only slight effects on CYP3A4.

Importance and management
Evidence from two well-designed clinical studies suggest that valerian does not have a clinically relevant effect on the pharmacokinetics of either alprazolam or midazolam (the 20% rise in alprazolam levels seen in one study would not be expected to be clinically relevant). Therefore no dosage adjustment of either benzodiazepine would appear to be needed if valerian is also given. However, note that valerian is said to have sedative effects, and is used for insomnia, and so additive effects on sedation seem possible. There seems to be no reason to avoid the concurrent use of valerian with alprazolam or midazolam, but, as with any combination of CNS depressant drugs, warn patients that they be more drowsy, and caution against undertaking skilled tasks if this occurs. Midazolam is used as a probe drug for CYP3A4 activity, and therefore these results also suggest that a pharmacokinetic interaction between valerian and other CYP3A4 substrates is unlikely.

Valerian + Barbiturates

The interaction between valerian and barbiturates is based on experimental evidence only.

Clinical evidence
No interactions found.

Experimental evidence
In a study in mice, valerenic acid (an active constituent of valerian) 50 or 100 mg/kg was found to increase sedation (measured by balance tests), but only at the highest doses. The effect was strongest 10 to 15 minutes after administration. Pentobarbital 60 mg/kg also sedated the mice, but the effects were more pronounced than those with valerenic acid. When both substances were given together, valerenic acid prolonged the sleeping time in response to pentobarbital. The effect was dose dependent, with the higher valerenic acid dose approximately doubling the pentobarbital sleeping time.

Mechanism
Valerenic acid has non-specific central nervous depressant properties, which appear to enhance the effects of pentobarbital.

Importance and management
Evidence for an interaction between valerenic acid and pentobarbital appears to be limited to this study in mice; however, the effects are in line with the known activities of both substances. It is unclear whether the use of valerian would result in an effect of similar magnitude, but some additive sedation seems likely. Other barbiturates do not appear to have been studied, but it seems likely that they will interact similarly. It may therefore be prudent to consider the potential additive sedative effects in any patient taking barbiturates with valerian. This seems most likely to be of importance with the use of phenobarbital (or other barbiturates) for epilepsy, when sedative effects are less desirable. It would be prudent to warn patients that they may be more sedated and, if this occurs, to avoid undertaking skilled tasks. Remember that not all the indications of valerian are as anxiolytic/hypnotic.


Valerian + Goldenseal

Evidence for an interaction between goldenseal root and valerian is limited to experimental evidence only.

Mechanism
Goldenseal root may increase the sedative effects of valerian. When both substances were given together, goldenseal may potentiate the sedative effects of valerian. The evidence of an interaction between valerian and goldenseal appears to be limited to this study in mice, where goldenseal may potentiate the sedative effects of valerian.

Importance and management
Evidence of an interaction between valerian and goldenseal appears to be limited to the study in mice. However, goldenseal root is said to have sedative effects and is used for insomnia, and so additive effects on sedation seem possible. It would be prudent to warn patients that they may be more sedated if they drink alcohol while taking valerian and, if this occurs, to avoid undertaking skilled tasks. Remember that not all the indications of valerian are as anxiolytic/hypnotic.

Valerian + Goldenseal extract contain 11 mg of valerenic acid per gram. In another study, 12 healthy subjects were given valerian root extract 125 mg three times daily for 28 days before receiving a single dose of midazolam. Valerian root extract caused no significant changes in the metabolism of midazolam.

Experimental evidence
No relevant data found.

Mechanism
Valerian has been found in some in vitro studies to be an inhibitor of the cytochrome P450 isoenzyme CYP3A4. See Pharmacokinetics, page 394. Alprazolam and midazolam are metabolised by this isoenzyme. The minor pharmacokinetic changes reported therefore suggest that, clinically, valerian has only slight effects on CYP3A4.

Importance and management
Evidence from two well-designed clinical studies suggest that valerian does not have a clinically relevant effect on the pharmacokinetics of either alprazolam or midazolam (the 20% rise in alprazolam levels seen in one study would not be expected to be clinically relevant). Therefore no dosage adjustment of either benzodiazepine would appear to be needed if valerian is also given. However, note that valerian is said to have sedative effects, and is used for insomnia, and so additive effects on sedation seem possible. There seems to be no reason to avoid the concurrent use of valerian with alprazolam or midazolam, but, as with any combination of CNS depressant drugs, warn patients that they be more drowsy, and caution against undertaking skilled tasks if this occurs. Midazolam is used as a probe drug for CYP3A4 activity, and therefore these results also suggest that a pharmacokinetic interaction between valerian and other CYP3A4 substrates is unlikely.


Valerian + Caffeine

Valerian does not affect the pharmacokinetics of caffeine to a clinically relevant extent. However, the stimulant effects of caffeine may oppose the hypnotic effects of valerian.

Clinical evidence
In a study, 12 non-smoking healthy subjects were given valerian root extract 125 mg three times daily for 28 days with a single 100-mg dose of oral caffeine at the end of supplementation. Valerian root extract caused no significant changes in the metabolism of caffeine.1

Experimental evidence
No relevant data found.

Mechanism
Opposing pharmacological effects.

Importance and management
Although the evidence is limited to one study, it was a well-designed study in healthy subjects. It suggests that the use of valerian will not alter the pharmacokinetics of caffeine. However, the effects of caffeine (a stimulant) are likely to be in direct opposition to the effects of valerian (a hypnotic) and, although this does not appear to have been studied, caffeine has been shown to diminish the effects of other known hypnotic drugs. Therefore patients requiring valerian for its hypnotic properties should probably also consider their caffeine intake.


Valerian + Chlorzoxazone

Valerian does not affect the pharmacokinetics of chlorzoxazone to a clinically relevant extent. However, additive sedative effects are a possibility.

Clinical evidence
In a study, 12 healthy subjects were given valerian root extract 1 g each night for 14 days, with a single 30-mg dose of chlorzoxazone on the morning of day 15. Valerian extract caused no significant changes in the pharmacokinetics of chlorzoxazone. The valerian extract used in this study contained 11 mg of valerenic acid per gram.1

Experimental evidence
See Pharmacokinetics, page 394, for in vitro studies of the possible inducing effects of valerian on the cytochrome P450 1A2 activity.

Mechanism
Although in vitro study suggests that valerian may induce the cytochrome P450 1A2 activity, this effect only occurred at high dose, and the clinical study suggests that this effect does not occur in humans.

Importance and management
Although the evidence is limited to one study, it was a well-designed study in healthy subjects. It suggests that the use of valerian will not alter the pharmacokinetics of dextromethorphan. Dextromethorphan is used as a probe drug for CYP2D6 activity, and therefore these results also suggest that a pharmacokinetic interaction between valerian and other CYP2D6 substrates is unlikely.


Valerian + Dextromethorphan

Valerian does not affect the pharmacokinetics of dextromethorphan to a clinically relevant extent.

Clinical evidence
In a crossover study, 12 healthy subjects were given valerian root extract 1 g each night for 14 days, with a single 30-mg dose of dextromethorphan on the morning of day 15. Valerian extract caused no significant changes in the pharmacokinetics of dextromethorphan. The valerian extract used in this study contained 11 mg of valerenic acid per gram.1

Experimental evidence
See Pharmacokinetics, page 394, for in vitro studies of the possible inducing effects of valerian on the cytochrome P450 1A2 activity.

Mechanism
Although in vitro study suggests that valerian may induce the cytochrome P450 1A2 activity, this effect only occurred at high dose, and the clinical study suggests that this effect does not occur in humans.

Importance and management
Although the evidence is limited to one study, it was a well-designed study in healthy subjects. It suggests that the use of valerian will not alter the pharmacokinetics of dextromethorphan. Dextromethorphan is used as a probe drug for CYP2D6 activity, and therefore these results also suggest that a pharmacokinetic interaction between valerian and other CYP2D6 substrates is unlikely.


Valerian + Food

No interactions found.

Valerian + Herbal medicines

For a report of a possible interaction between valerian and ginkgo, see Ginkgo + Herbal medicines; Valerian, page 214. For a case describing delirium in a patient taking St John’s wort, valerian and loperamide, see St John’s wort + Loperamide, page 373.
Wild yam

*Dioscorea villosa* L. (Dioscoreaceae)

**Synonym(s) and related species**
Colic root, Rheumatism root.

**Constituents**
The major constituents of the root and rhizome are saponins based mainly on diosgenin and other sapogenins; they include dioscin and dioscorin.

**Use and indications**
Traditionally, wild yam was used to treat rheumatism and intestinal colic. However, more recently wild yam extract has found favour as a form of topical hormone replacement therapy for women. It is often claimed that wild yam is a source of ‘natural progesterone’, but this is not the case – it is a source of diosgenin, which is used by the pharmaceutical industry as a chemical precursor for the production of progesterone.

**Pharmacokinetics**
No relevant pharmacokinetic data found.

**Interactions overview**
No interactions with wild yam found.
Willow

*Salix* species (Salicaceae)

**Synonym(s) and related species**


**Pharmacopoeias**

Willow Bark (*BP 2009, Ph Eur 6.4*); Willow Bark Dry Extract (*BP 2009, Ph Eur 6.4*).

**Constituents**

The bark of willow contains the phenolic glycosides salicin (up to 10%), acetylsalicin, salicortin, salireposide, picein, triandrin. Esters of salicylic acid and salicyl alcohol, and flavonoids and tannins are also present. Extracts are sometimes standardised to a minimum of 1.5% of total salicylic derivatives, expressed as salicin (*BP 2009, Ph Eur 6.4*).

**Use and indications**

The bark of willow is reported to have analgesic, anti-inflammatory, antipyretic and astringent properties. It has long been used for treating all kinds of fevers, headache, influenza, rheumatism, gout and arthritis.

**Pharmacokinetics**

In a pharmacokinetic study, 10 healthy subjects were given two oral doses of *Salix purpurea* bark extract, each standardised to contain 120 mg of salicin, 3 hours apart and 30 minutes before meals. Salicylic acid was the most prominent metabolite detected in the serum, with peak levels achieved approximately 1 hour after the dose. The AUC of salicylic acid from the willow bark extract was equivalent to the AUC of salicylic acid from an 87-mg dose of aspirin (given to healthy subjects in another study). However, it is not clear if this amount of salicylic acid has the same antiplatelet effects as aspirin: one study found that taking an extract of the bark of *Salix purpurea* and *Salix daphnoides*, to achieve a salicin dose of 240 mg daily, had a much smaller effect on platelet aggregation than aspirin.

**Interactions overview**

No interactions with willow found. It has been suggested that willow bark is likely to interact with antiplatelet drugs and NSAIDs (which have antiplatelet effects), and increase the risk of bleeding with anticoagulants. This is because one constituent, salicin, is metabolised to salicylic acid, a substance that is also derived from aspirin. Given that pharmacokinetic studies (see above) suggest that doses of willow bark extracts can achieve levels of salicylic acid that are equivalent to an 87-mg dose of aspirin, this seems reasonable. However, other studies suggest that the antiplatelet effects of aspirin are much greater than those of willow bark, which suggests that willow bark extracts may be less likely to interact than aspirin. The antiplatelet effects of willow bark need much more research before any firm recommendations can be made about its potential to interact with antiplatelet drugs, NSAIDs and anticoagulants; however, until more is known some caution is warranted.

The concurrent use of willow bark and antiplatelet drugs (such as aspirin or clopidogrel) need not be avoided: indeed combinations of antiplatelet drugs are often prescribed together, but it may be prudent to be aware of the potential for increased bleeding. Patients should discuss any episode of prolonged bleeding with a healthcare professional.

Clinically, the use of an antiplatelet drug with an anticoagulant should generally be avoided in the absence of a specific indication. It may therefore be prudent to advise against concurrent use with willow bark. However, if concurrent use is felt desirable it would seem sensible to warn patients to be alert for any signs of bruising or bleeding, and report these immediately should they occur.

This advice is probably applicable to any herb with known antiplatelet effects.

No interactions have been included for herbal medicines or dietary supplements beginning with the letter X
Yarrow

*Achillea millefolium* L. (Asteraceae)

**Synonym(s) and related species**
Achillea, Milfoil, Nosebleed.
*Achillea collina* Becker and *Achillea lanulosa* Nutt. are closely related and are also frequently used.

**Pharmacopoeias**
Yarrow (*BP 2009, Ph Eur 6.4*).

**Constituents**
Yarrow contains a volatile oil composed of various monoterpenes (including limonene and α-thujone), and sesquiterpene lactones (including achillicin, achillin, millefin and millefolide). Azulene is the major component in the closely related *Achillea collina* and *Achillea lanulosa* but it is reported to be absent in *Achillea millefolium*. Yarrow also contains pyrrolidine and pyridine alkaloids, flavonoids (including apigenin, quercetin and rutin), tannins and sugars.

**Use and indications**
Yarrow has been used in the treatment of bruises, swellings and strains, and for fevers and colds. It has also been used for essential hypertension, amenorrhoea, dysentery, diarrhoea and specifically for thrombotic conditions. There is little, if any, clinical evidence to support these uses, but extracts and many of the constituents have reported anti-inflammatory and antiplatelet activity.

**Pharmacokinetics**
An *in vitro* study suggests that ethanol extracts of yarrow leaves and flowers markedly inhibit the cytochrome P450 isoenzyme CYP2C19 but have only weak inhibitory effects on CYP3A4. The clinical significance of the effects on CYP2C19 is unknown.1 For information on the pharmacokinetics of individual flavonoids present in yarrow, see under flavonoids, page 186.

**Interactions overview**
No interactions with yarrow found. For information on the interactions of individual flavonoids present in yarrow, see under flavonoids, page 186.

---

No interactions have been included for herbal medicines or dietary supplements beginning with the letter Z.
All of the herbal medicines, dietary supplements, nutraceuticals and drugs included in this book, whether interacting or not, are listed in this index. Drugs may also be listed under the group names if the interaction is thought to apply to the group as a whole, or if several members of the group have been shown to interact. Note that in some circumstances, broad terms (e.g. analgesics) have been used, where the information is insufficient to allow more specific indexing. It is therefore advisable to look up both the individual drug and its group to ensure that all the relevant information is obtained. It may also be advisable to look up both interactants if you don’t initially find what you are looking for as synonyms are also included as lead-ins. You can possibly get a lead on the way unlisted drugs behave if you look up those that are related, but bear in mind that none of them is identical and any conclusions reached should only be tentative.
Aloe barbadensis, 27
Aloe ferox, 27
Aloe gel, see under Aloe vera
Aloe peryi, 27
Aloe vera, 24
  + Antidiabetics, 25
  + Ascorbic acid, see Vitamin C substances
  + dl-alpha tocopherol, see Vitamin E substances
  + General anaesthetics, 25
  + Glibenclamide, 25
  + Glyburide, see Glibenclamide
  + Hypoglycaemic agents, see Antidiabetics
  + Sevoflurane, 25
  + Tocopherols, see Vitamin E substances
  + Vitamin C substances, 25
  + Vitamin E substances, 25

Aloes, 27
  + Cardiac glycosides, see Digitalis glycosides
  + Corticosteroids, 28
  + Digitalis glycosides, 28
  + Digoxin, 28
  + Diuretics, loop, see Loop diuretics
  + Diuretics, thiazide, see Thiazides
  + Liquorice, 29
  + Loop diuretics, 28
  + Quinidine, 29
  + Thiazide diuretics, see Thiazides
  + Thiazides, 28

Alprazolam
  + Garlic, 199
  + Ginkgo, 210
  + Ginseng, 222
  + Green tea, 383
  + Saw palmetto, 345
  + Siberian ginseng, 222
  + St John’s wort, 364
  + Tea, 383
  + Tea, green, see Green tea
  + Valerian, 396

Altamisa, see under Feverfew
American dwarf palm, see under Saw palmetto
American ginseng
  + Coumarins, 225
  + Digoxin, 223
  + Laboratory tests, 223
  + Metformin, 221
  + Oestrone receptor modulators, 224
  + Oral antidiabetics, 221
  + Sulfonylureas, 221
  + Warfarin, 225

American pennyroyal, see under Pennyroyal
American sloe, see under Black haw
Amehopterin, see Methotrexate
Amphetamine
  + Passiflora, 308
Amfetamines (Amphetamines), see also individual drugs
  + Passiflora, 308
Amikacin
  + Ginkgo, 209
2-Amino-2-deoxy-β-D-glucopyranose, 226
5-Aminoolevulinic acid
  + St John’s wort, 362
Aminophenazone
  + Parsley, 305

Aminophylline, consider also
Theophylline
  + Cannabis, 113
  + Capsicum, 118
  + Daidzein, 263
  + Isoflavones, 263
  + Rhodiola, 339
  + St John’s wort, 377

Amitriptyline
  + St John’s wort, 378
Amoxicillin
  + Bromelain, 84
  + Liquorice, 275

Amphetamines, see Amfetamines
Amphicillin
  + Acidophillus, 14

Amprenavir
  + St John’s wort, 375

Anaesthetics general, see General anaesthetics
Ananas comosus, 83

Anastatica, see under Bromelain
Andrographis
  + Anticoagulants
  + Antibacterials (Antibiotics)
  + Antibiotics
  + Antineoplastic
  + Angiotensin-converting enzyme inhibitors, see ACE inhibitors
Anise, see under Aniseed
\(^{33,34}\)

Aniseed
  + Asafoetida, 40
  + Balm of Gilead, 53
  + Carnosic acid, 127
  + Cat’s claw, 121
  + Coffee, 146
  + Caffeine, 99
  + Guarana, 271

Anticoagulants
  + Aspirin, 329
  + Cannabis, 50

Anticoagulants, see also individual drugs and drug groups
Anticoagulants
  + Acetylsalicylic acid, see Aspirin
  + Acetaminophen, 188
  + Apigenin, 188
  + Aspirin, 25
  + Balm of Gilead, 53
  + Cannabis, 50
  + Cannabis, 40

Antidepressants, see under Antiplatelet drugs
Antidepressants, see also individual drugs and drug groups
Antidepressants
  + Acetylsalicylic acid, see Aspirin
  + Acetaminophen, 188
  + Apigenin, 188
  + Aspirin, 25
  + Balm of Gilead, 53
  + Cannabis, 50

Antifungal drugs, see under Anticoagulants

Antihypertensives, see also individual drugs and drug groups
Antihypertensives
  + Acetylsalicylic acid, see Aspirin
  + Acetaminophen, 188
  + Apigenin, 188
  + Aspirin, 25
  + Balm of Gilead, 53
  + Cannabis, 50

Antineoplastic, see under Antiplatelet drugs
Antineoplastic
  + Acetylsalicylic acid, see Aspirin
  + Acetaminophen, 188
  + Apigenin, 188
  + Aspirin, 25
  + Balm of Gilead, 53
  + Cannabis, 50

Antineoplastics, see also individual drugs and drug groups
Antineoplastics
  + Acetylsalicylic acid, see Aspirin
  + Acetaminophen, 188
  + Apigenin, 188
  + Aspirin, 25
  + Balm of Gilead, 53
  + Cannabis, 50

Antioxidants, see also individual drugs and drug groups
Antioxidants
  + Acetylsalicylic acid, see Aspirin
  + Acetaminophen, 188
  + Apigenin, 188
  + Aspirin, 25
  + Balm of Gilead, 53
  + Cannabis, 50

Antiparkinsonian drugs, see under Anticoagulants
Antiparkinsonian drugs
  + Acetylsalicylic acid, see Aspirin
  + Acetaminophen, 188
  + Apigenin, 188
  + Aspirin, 25
  + Balm of Gilead, 53

Antipsychotics, see under Antiplatelet drugs
Antipsychotics
  + Acetylsalicylic acid, see Aspirin
  + Acetaminophen, 188
  + Apigenin, 188
  + Aspirin, 25
  + Balm of Gilead, 53

Antithyroid drugs, see under Antiplatelet drugs
Antithyroid drugs
  + Acetylsalicylic acid, see Aspirin
  + Acetaminophen, 188
  + Apigenin, 188
  + Aspirin, 25
  + Balm of Gilead, 53

Aortic valve replacement, see under Antiplatelet drugs
Aortic valve replacement
  + Acetylsalicylic acid, see Aspirin
  + Acetaminophen, 188
  + Apigenin, 188
  + Aspirin, 25
  + Balm of Gilead, 53
Bearberry, 55
+ Lithium compounds, 305
Bee plant, see under Starflower oil
Bee pollen, 57
Bee bread, see under Starflower oil
Bee, alcohol-free, see Tyramine-rich foods
Beggars buttons, see under Burdock
Belgian valerian, see under Valerian
Benedict’s herb, see under Aven
Benzetonium chloride
+ Warfarin, 238
Benzo diazepines, see also individual drugs
+ Caffeine, 100
+ Garlic, 199
+ Ginkgo, 210
+ Isoflavones, 260
+ Kudzu, 268
+ Melatonin, 286
+ Puerrnin, 260
+ Saw palmetto, 345
+ St John’s wort, 364
+ Valerian, 396
Benzoic acid
+ Peppermint, 322
Benzylpenicillin (Penicillin G)
+ Acidophilus, 14
Berberidis, see under Berberis
Berberine, 58
+ Anxiolytics, 59
+ Buspirone, 59
+ Ciclosporin, 59
+ Cyclosporin, see Ciclosporin
+ Diazepam, 59
+ Hycosine, 59
+ Paclitaxel, 60
+ Scopolamine, see Hyoscine
+ Sedatives, see Anxiolytics
+ Tranquilizers, see Anxiolytics
Berberis, 61
Berberis aquifolium, see under Oregon grape
Berberis aristata, 61
Berberis chilca, see under Berberis
Berberis dumetorum, see under Berberis
Berberis floribunda, see under Berberis vulgaris, 61
Bergamottin
+ Ciclosporin, 300
+ Cyclosporin, see Ciclosporin
+ Felodipine, 300
+ Lovastatin, 301
+ Saquinavir, 301
+ Simvastatin, 301
+ Talinolol, 301
Bergapten, 297
Berghee, see under Honeybush
Besom, see under Broom
Beta blockers, see also individual drugs
+ Hawthorn, 248
+ Isoflavones, 260
+ Kudzu, 268
+ Policosanol, 324
+ Puerrnin, 260
+ Turmeric, 391
Beta-blockers, see Beta blockers
Betacarotene, 62
+ Alcoholic beverages, 63
+ Ciclosporin, 63
+ Citrime, 63
+ Colchicine, 63
+ Colestyramine, 64
+ Cyclosporine, see Ciclosporin
+ Foods, 280
+ Lycopen, 280
+ Niacin, see Nicotinic acid
+ Nicotinic acid, 64
+ Omeprazole, 64
+ Orlistat, 64
+ Probuco, 64
+ Proton pump inhibitors, 64
+ Simvastatin, 64
+ Smoking, see Tobacco
+ Tobacco, 65
Bhang, see under Cannabis
Bhunimba, see under Andrographis
Bigaradier, 78
Black cohosh, 72
+ Caffeine, 73
+ Chloroxazone, 73
+ Cisplatin, 73
+ Digoxin, 73
+ Docetaxel, 73
+ Doxorubicin, 73
+ Midazolam, 74
Black elder, see under Elder
Black haw, 75
Black mint, see under Peppermint
Black pepper, see under Pepper
Black sampson, see under Echinacea
Black snakeroot, see under Black cohosh
Black tang, see under Kelp
Black tea, see Tea
Bladder fucus, see under Kelp
Bladderwrack, see under Kelp
Blueberry, see under Bilberry
Bolkshorn, see under Fenugreek
Boerette, see under Honeybush
Bog rubarb, see under Butterbur
Bogbean, 77
Bogberry, see under Bilberry
Bogshorns, see under Butterbur
Boldia fragrans, see under Boldo
Boldi folium, see under Boldo
Boldo, 78
+ Coumarins, 79
+ Warfarin, 79
Boldo boldus, see under Boldo
Boldus, see under Boldo
Bousseret, 80
Borage, see under Starflower oil
Borage oil, see under Starflower oil
Borage officinalis, 381
Boisest, see under Honeybush
Boswellia, 81
+ Foods, 82
Boswellia serrata, 81
Bovil, see Tyramine-rich foods
Box holly, see under Butcher’s broom
Broom, see under Broom
Bromerg, see under Valerian
Branneria, see under Echinacea
Braueria pallida, see under Echinacea
Brazilian cocoa, see under Guarana
Bridewort, see under Meadowsweet
Bromelain, 83
+ Amoxicillin, 84
+ Tetracycline, 84
Bromocriptine
+ Agnus castus, 17
Broom, 85
Broomtops, see under Broom
Buco, see under Buchu
Buchu, 86
+ Lithium compounds, 305
Buckbean, see under Bogbean
Bugbane, see under Black cohosh
Bupleurum, 88
Bupleurum falcata, 89
Bupleurum fruticosum, see under Bupleurum
Bupleurum scorzonerifolium, see under Bupleurum
Buprenorphine
+ St John’s wort, 374
Bupropion
+ St John’s wort, 364
Butcher’s broom
Burnet, 93
+ Ciproflaxacin, 94
+ Quinolones, 94
Burrage, see under Starflower oil
Bush tea, see under Honeybush
Buspirone
+ Berberine, 59
+ Green tea, 384
+ Melatonin, 286
+ St John’s wort, 365
+ Tea, 384
+ Tea, green, see Green tea
Butcher’s broom, 95
Butterbur, 96
Butterdock, see under Butterbur
Butterfly dock, see under Butterbur
C
Cacao, see under Cocoa
Caffeine, 97
+ Acetaminophen, see Paracetamol
+ Acetylsalicylic acid, see Aspirin
+ Adenosine, 99
Central nervous system depressants, see CNS depressants

Centaurom, see under Centaurom
Chelidonium majus
Cichaemelum nobile
Chamomilla vulgaris
Chamomilla
Chamomilla recutita
Chamomilla vulgaris
Chaparral

Chaste tree, see under Agnus castus
Chaste berry, see under Agnus castus
Chelidonium majus,

Chicken liver, see Tyramine-rich foods

Chili pepper, see under Capsicum
Chili pepper, see under Capsicum

Chinese angelica
+ Coumarins, 131
+ Diazepam, 130
+ Estrogen antagonists, see Oestrogen antagonists
+ Nifedipine, 130
+ Oestrogen antagonists, 130
+ Oestrogen receptor modulators, 130
+ Tamoxifen, 130
+ Tolbutamide, 131
+ Warfarin, 131

Chinese cinnamon, see under Cinnamon
Chinese ginseng, see under Ginseng
Chinese rhubarb, see under Rhabarb
Chinese salvia, see under Danshen
Chinese wolfberry, see under Lycium

Chitosamine, see under Glucosamine

Chitosan, 132
+ Acetaminophen, see Paracetamol
+ Cefalexin, 133
+ Coumarins, 134
+ Griseofulvin, 133
+ Indanediones, 134
+ Indometacin, 133
+ Paracetamol, 133
+ Warfarin, 134

Chittab bark, see under Cascara
Chloramphenicol
+ Acidophilus, 14

Chlorpromazine
+ Cannabis, 109
+ Evening primrose oil, 180

Chloroxzzone
+ Asian ginseng, 222
+ Bitter orange, 69
+ Black cohosh, 73
+ Garlic, 200
+ Ginkgo, 212
+ Ginseng, 222
+ Goldenseal, 231
+ Milk thistle, 294
+ Saw palmetto, 345
+ St John’s wort, 366
+ Valerian, 397

Chocolate, see under Cocoa
Chocolate tree, see under Cocoa
Chondroitin, 135
Chondroitin sulfate sodium, see under Chondroitin
Chondroitin sulphate sodium, 135
Chrysanthemum parthenium

Chrysin
+ Irinotecan, 192
+ Nitrofurantoin, 188
+ Topotecan, 192

Ciclosporin (Cyclosporine)
+ Alfafl, 22
+ Baical skullcap, 52
+ Baicalein, 190
+ Baicalin, 190
+ Berberine, 59
+ Ergamottin, 300
+ Betacarotene, 63
+ Bitter orange, 69
+ Cannabis, 110
+ Cranberry, 153
+ Echinacea, 170
+ Flavonoids, 190
+ Ginkgo, 212
+ Green tea, 385
+ Morin, 190
+ Pepper, 315
+ Peppermint, 315
+ Piperine, 315
+ Quercetin, 190
+ Shatavari, 354
+ St John’s wort, 367
+ Tea, green, see Green tea

Cilostazol
+ Ginkgo, 209

Cimetidine
+ Betacarotene, 63
+ Hypericin, 367
+ Liquorice, 275
+ Melatonin, 287
+ St John’s wort, 367

Cimicifuga, see under Black cohosh
Cimicifuga racemosa, 72
Cinnamomum aromaticum, see under Cinnamon
Cinnamomum burmanni, 136
Cinnamomum burmannii, see under Cinnamon
Cinnamomum cassia, 136
Cinnamomum laureirii, 136
Cinnamomum loureirii, see under Cinnamon
Cinnamomum pseudomelastoma, see under Cinnamon
Cinnamomum verum, 136
Cinnamomum zeylanticum, see under Cinnamon

Cinnamon
+ Antidiabetics, 137
+ Carbamazepine, 137
+ Hypoglycaemic agents, see Antidiabetics
+ Oflloxacin, 137

Ciprofloxacin
+ Burnet, 94
+ Capsicum, 116
+ Dandelion, 160
+ Melatonin, 288

Cisplatin
+ Astragalus, 47
+ Black cohosh, 73
+ Cannabis, 110

Citalopram
+ Melatonin, 288

Citrus aurantium

Citrus bioflavonoids
+ Lovastatin, 194
+ Simvastatin, 194
+ Tamoxifen, 194

Citrus maxima, see under Grapefruit
Citrus paradisi, see under Grapefruit
Citrus sinensis, see under Grapefruit
Citrus x paradisi, 235
Clarithromycin
+ Liquorice, 275

Cleavers, see under Clivers

Climbacyclin
+ Acidophilus, 14

Clivers, 138

Clonazepam
+ Caffeine, 100

Clozapine
+ Caffeine, 100
+ Cannabis, 110

CNS depressants (Central nervous system depressants), see also individual drugs and drug groups
+ Passiflora, 308

Cocaine
+ Hops, 252

Cocklebur, see under Agrimony

Cocoa, 139, see also Caffeine
+ Anticoagulants, 188
+ Antidiabetics, 140
+ Antihypertensives, 140
+ Antiplatelet drugs, 188
+ Anticoagulants, 188
+ Foods, 140
+ Grapefruit juice, 140
+ Hypoglycaemic agents, see Antidiabetics
+ Iron compounds, 140
+ Milk, 140

Codeine
+ Cannabis, 112

Coenzyme Q10, 142
+ Aldosterone, 143
+ Coumarins, 143
+ Doxorubicin, 143
+ Foods, 143
+ Pepper, 143
+ Warfarin, 143

Coffee arabica, see under Coffee
Coffee canephora, see under Coffee
Coffee liberica, see under Coffee
Coffee robusta, see under Coffee
Coffee species, 145

Coffee, 145, see also Caffeine
+ Acetylsalicylic acid, see Aspirin
+ Antidiabetics, 146
+ Antihypertensives, 146
+ Aspirin, 146
+ Hypoglycaemic agents, see Antidiabetics
+ Iron compounds, 147
+ Lysine acetylsalicylate, see Aspirin
+ Nicotine, 147
Diazepam
+ Baicain, 189
+ Berberine, 59
+ Caffeine, 100
+ Chinese angelica, 130
+ Flavonoids, 189
+ Ginkgo, 210
+ Hesperidin, 189
+ Hops, 252
+ St John’s wort, 364

Diaflofenac
+ Caffeine, 99
+ Cannabis, 112
+ Ginger, 206
+ Ginkgo, 214
+ Goldenseal, 231
+ Pepper, 316
+ Resveratrol, 336
+ Trikatu, 316

Dinofenac
+ Caffeine, 99
+ Cannabis, 112
+ Ginger, 206
+ Ginkgo, 214
+ Goldenseal, 231
+ Pepper, 316
+ Resveratrol, 336
+ Trikatu, 316

Dienogest
+ See under Asafoetida

Dilectripant
+ See under St John’s wort

Dietary supplements
+ See under Lycopenes

Digitalis
+ See Digitalis glycosides

Digitalis glycosides
+ Cardiac glycosides, see also individual drugs
  + Aloes, 28
  + Senna, 350

Digoxin
+ Alkaloids, 22
+ Aloes, 28
+ American ginseng, 223
+ Arjuna, 37
+ Ashwagandha, 42
+ Asian ginseng, 223
+ Biochanin A, 261
+ Black cohosh, 73
+ Capsicum, 116
+ Danshen, 162
+ Echinacea, 169
+ Flavonoids, 191
+ Ginkgo, 213
+ Ginseng, 223
+ Goldenseal, 232
+ Hawthorn, 248
+ Horse chestnut, 255
+ Isoflavones, 261

Diltiazem
+ Flavonoids, 189
+ Ginkgo, 211
+ Guggul, 246
+ Morin, 189
+ Naringin, 189

Dioscorea villosa
+ See under Buchu

Dipsacyclin
+ See under Buchu

Disulfiram
+ See under Phenothiazines

Diuretics
+ Loop diuretics
+ Thiazides

Docetaxel
+ Black cohosh, 73
+ Cannabis, 110
+ Garlic, 200

Docorlexin, see Docosahexaenoic acid

Docosahexaenoic acid (Docorlexin)
+ Garlic, 201

Dolichos lobatus, see under Kudzu

Donepezil
+ Ginkgo, 213

Dong quai, see under Chinese angelica

Dopamine agonists, see also individual drugs
+ Agnus castus, 17

Dopamine antagonists, see also individual drugs
+ Agnus castus, 17

Double chamomile, 127

Drugxorubicin
+ Black cohosh, 73
+ Coenzyme Q10, 143
+ Glucosamine, 227

Dragonwort, see under Bistort

Dronabinol
+ Indinavir, 113
+ Nelfinavir, 113

Duloxetine
+ St John’s wort, 375

D缬酮
+ St John’s wort, 375

Devil’s claw, 165
+ Antiinflammatories, 166
+ Antiplatelet drugs, 166
+ Coumarins, 166
+ Nonsteroidal anti-inflammatory drugs, see NSAIDs
+ NSAIDs, 166
+ Warfarin, 166

Devil’s dung, see under Asafoetida

Dexamethasone
+ See also individual drugs

Echinacea
+ See under Echinacea

Echinacea angustifolia
+ See under Echinacea

Echinacea pallida
+ See under Echinacea

Echinacea purpurea
+ See under Echinacea

Eclipta
+ Alba, 171
+ Prostrata, see under Eclipta

Ecstasy, see under Methyleneoxymethylamphetamine

Efavirenz
+ St John’s wort, 374

Eicosapentaenoic acid (Icosapent)
+ Garlic, 201

Elacapamine
+ St John’s wort, 374

Eleutherooccus senticosus
+ See under Ginseng

Emergency hormonal contraceptives
+ St John’s wort, 370

Enalapril
+ Flavonoids, 191
+ Kaempferol, 191
+ Naringenin, 191

English Serpentary
+ See under Bistort

English chamomile
+ See under Chamomile

English rhubarb
+ See under Rhubarb

Ephedra
+ Alkaloids, 175
+ Caffeine, 176
+ Creatine, 157
+ Guarana, 244
+ MAOIs, 175
+ Monoamine oxidase inhibitors, see MAOIs

Ephedra equisetina
+ See under Ephedra

Ephedra gerardiana
+ See under Ephedra

Ephedra sinica
+ See under Ephedra

Epicatechins
+ See under Epimedium

Epimedium brevicornu
+ See under Epimedium

Epimedium koreanum
+ See under Epimedium

Epimedium pubescens
+ See under Epimedium

Ephedra equisetina
+ See under Ephedra

Ephedra gerardiana
+ See under Ephedra

Ephedra sinica
+ See under Ephedra

Epimedium brevicornu
+ See under Epimedium

Epimedium koreanum
+ See under Epimedium

Epimedium pubescens
+ See under Epimedium
Fucus vesiculosus, 265
Furanocoumarins, 68
Furosemide
  + Arjuna, 37
  + Liquorice, 274
  + Senna, 350
G
Galium, see under Clivers
Galium aparine, 138
Gamolenic acid, 179
Gan Jiang, see under Ginger
Ganja, see under Cannabis
Garcinia kola, see under Cola
Garden burnet, see under Burnet
Garden celandine, see under Greater celandine
Garden rhubarb, see under Rhubarb
Garden sage, see under Sage
Garden thyme, see under Thyme
Garden valerian, see under Valerian
Garlic, 198
  + ACE inhibitors, 199
  + Acetaminophen, see Paracetamol
  + Alcohol, 199
  + Alprazolam, 199
  + Antiplatelet drugs, 199
  + Benzdiazepines, 199
  + Caffeine, 199
  + Chloroxazone, 200
  + Coumarins, 203
  + Debrisoquin, see Debrisoquine
  + Debrisoquine, 200
  + Dextromethorphan, 200
  + Dipyridamole, 199
  + Docetaxel, 200
  + Docusxent, see Docosahexaenoic acid
  + Docosahexaenoic acid, 201
  + Eicosapentaenoic acid, 201
  + Epoprostenol, 199
  + Ethanol, see Alcohol
  + Fish oils, 201
  + Flumidone, 203
  + Foods, 201
  + Gentamicin, 201
  + HIV-protease inhibitors, 202
  + Icoxapent, see Eicosapentaenoic acid
  + Indometacin, 199
  + Isoniazid, 201
  + Lisinopril, 199
  + Midazolam, 199
  + Paracetamol, 202
  + Rifampicin, 203
  + Rifampin, see Rifampicin
  + Ritonavir, 202
  + Saquinavir, 202
  + Triazolam, 199
  + Valproate, 203
Ge Gen, see under Kudzu
General anaesthetics
  + Aloe vera, 25
  + St John’s wort, 362
Genistein
  + Nicotine, 261
  + Paclitaxel, 261
  + Tamoxifen, 262
Gentamicin
  + Acidophilus, 14
  + Ashwagandha, 42
  + Garlic, 201
Geranium, see under Pelargonium
Geranium, see under Avens
Garden rhubarb, see under Rhubarb
Garden sage, see under Sage
Garden thyme, see under Thyme
Garden valerian, see under Valerian
Garlic, 198
  + ACE inhibitors, 199
  + Acetaminophen, see Paracetamol
  + Alcohol, 199
  + Alprazolam, 199
  + Antiplatelet drugs, 199
  + Benzdiazepines, 199
  + Caffeine, 199
  + Chloroxazone, 200
  + Coumarins, 203
  + Debrisoquin, see Debrisoquine
  + Debrisoquine, 200
  + Dextromethorphan, 200
  + Dipyridamole, 199
  + Docetaxel, 200
  + Docusxent, see Docosahexaenoic acid
  + Docosahexaenoic acid, 201
  + Eicosapentaenoic acid, 201
  + Epoprostenol, 199
  + Ethanol, see Alcohol
  + Fish oils, 201
  + Flumidone, 203
  + Foods, 201
  + Gentamicin, 201
  + HIV-protease inhibitors, 202
  + Icoxapent, see Eicosapentaenoic acid
  + Indometacin, 199
  + Isoniazid, 201
  + Lisinopril, 199
  + Midazolam, 199
  + Paracetamol, 202
  + Rifampicin, 203
  + Rifampin, see Rifampicin
  + Ritonavir, 202
  + Saquinavir, 202
  + Triazolam, 199
  + Valproate, 203
Ge Gen, see under Kudzu
General anaesthetics
  + Aloe vera, 25
  + St John’s wort, 362
Genistein
  + Nicotine, 261
  + Paclitaxel, 261
  + Tamoxifen, 262
Gentamicin
  + Acidophilus, 14
  + Ashwagandha, 42
  + Garlic, 201
Geranium, see under Pelargonium
German chamomile, see Chamomile, German
Gentamicin
  + Sodium valproate, see Valproate
Ginkgo biloba, see under Ginkgo
Ginseng, 219
  + Acarbose, 221
  + Albendazole, 221
  + Alcoholic beverages, 221
  + Alprazolam, 222
  + Caffeine, 222
  + Carbamazepine, 222
  + Chloroxazone, 222
  + Coumarins, 225
  + Debrisoquin, see Debrisoquine
  + Debrisoquine, 223
  + Dextromethorphan, 223
  + Digoxin, 223
  + Guaran, 223
  + Laboratory tests, 223
  + MAOs, 224
  + Metformin, 221
  + Midazolam, 222
  + Monoamine oxidase inhibitors, see MAOs
  + Oestrogen receptor modulators, 224
  + Olfaxacin, 224
  + Oral anti-diabetics, 221
  + Phelazine, 224
  + Rosiglitazone, 221
  + Sulfonylureas, 221
  + Tamoxifen, 224
  + Tolbutamide, 224
  + Valproate, 225
Glechoma hederacea, 242
Glibenclamide (Glyburide)
  + Aloe vera, 25
Gliclazide
  + Hawthorn, 248
  + St John’s wort, 362
Globe artichoke, see under Artichoke
Glucosamine, 226
  + Acenocoumarol, 228
  + Acetaminophen, see Paracetamol
  + Antidiabetics, 227
  + Coumarins, 228
  + Diuretics, 227
  + Doxorubicin, 227
  + Etoposide, 227
  + Hypoglycaemic agents, see Antidiabetics
  + Oxotremorine, 228
  + Paracetamol, 227
  + Tetracyclines, 228
  + Warfarin, 228
Glucosamine hydrochloride, see under Glucosamine
Glucosamine sulfate potassium chloride, see under Glucosamine
Glucosamine sulfate sodium chloride, see under Glucosamine
Glyburide, see Glibenclamide
Glycine max, 356
Glycine soja, see under Soya
Glycine, 258
Glycine max, 356
Glycine soja, see under Soya
Glycine, 258
Index

Inula helenium, see under Maté
Inula paraguariensis, 282
Insatinh
+ St John’s wort, 371
Imipramine
+ Cannabis, 114
+ Melatonin, 287
Immunosuppressants, see also individual drugs, consider also Corticosteroids
+ Acidiophius, 14
+ Alfalfa, 22
+ Echinacea, 170
Indanediones
+ Alfalfa, 23
+ Asparagus, 45
+ Chitosan, 134
+ Cranberry, 154
+ Green tea, 387
+ Kelp, 266
+ Parsley, 305
+ Soya bean, 358
+ Tea, 387
+ Tea, green, see Green tea
Indian frankincense, see under Boswellia
Indian ginseng, see under Ashwagandha
Indian hemp, see under Cannabis
Indian olibanum, see under Boswellia
Indian pennywort, see under Gotu kola
Indian rhubarb, see under Rhus barb
Indian saffron, see under Turmeric
Indian sena, see under Senna
Indian water navelwort, see under Gotu kola
Indinavir
+ Bitter orange, 70
+ Cannabis, 113
+ Dronabinol, 113
+ Goldenseal, 232
+ Milk thistle, 295
+ St John’s wort, 375
Indometacin
+ Cannabis, 112
+ Chitosan, 133
+ Garlic, 199
+ Ginger, 206
+ Pepper, 316
+ Trikatu, 316
Insulin
+ Hawthorn, 248
+ + Astragalus, 47
+ + Asparagus, 47
+ + Elecampane
+ + Eleutherococcus, see under Elepant
+ + Eupatorium, 197
+ + Foeniculum, 91
+ + Garlic, 192
+ + Green tea, 386
+ + Milk thistle, 294
+ + St John’s wort, 372
+ + Tratka, 316
Irish broom, see under Broom
Iron compounds, see under Broom
Iron compounds, see also individual drugs
+ Capsicum, 117
+ Chamomile, German, 126
+ Cocoa, 140
+ Coffee, 147
+ German chamomile, see Chamomile, German
+ Green tea, 386
+ Liquorice, 274
+ Pennroyal, 312
+ Peppermint, 322
+ Rooibos, 342
+ Tea, 386
+ Tea, green, see Green tea
+ Turmeric, 391
Isoeomuras, 297
Isoflavones, 258
+ Acetyllysalicic acid, see Aspirin
+ Aminophylline, 263
+ Antibacterials, 260
+ Antibiotics, see Antibacterials
+ Anticoagulants, 260
+ Antidiabetics, 260
+ Antiplatelet drugs, 260
+ Aspirin, 260
+ Benzdiazepines, 260
+ Beta blockers, 260
+ Calcium-channel blockers, 260
+ Digoxin, 261
+ Fexofenadine, 261
+ Hypoglycaemic agents, see Antidiabetics
+ Lysine acetylsalicyle, see Aspirin
+ Nicotine, 261
+ Nitrates, 260
+ Pachitxel, 261
+ Tamoxifen, 262
+ Theophylline, 263
Isoflavonoids, 258
Isoniazid
+ Garlic, 201
+ Ginger, 205
+ Pepper, 316
+ Trikatu, 316
Isorhamnetin, 186
Ivabradine
+ St John’s wort, 372
J
Jesus’ Brazil tea, see under Maté
Juniper
+ Lithium compounds, 305
K
Kadsura chinensis, see under Schisandra
Kaempferol
+ Digoxin, 191
+ Enalapril, 191
+ Lovastatin, 194
+ Midazolam, 189
+ Quinidine, 193
Kaffree tea, see under Rooibos
Kalmegh, see under Andrographis
Kava
+ Guarana, 244
+ Passiflora, 308
Kelp, 265
+ Anticoagulants, 266
+ Coumarins, 266
+ Indanediones, 266
Kelpware, see under Kelp
Ketoprofen
+ Senna, 351
+ Shatavari, 354
Ketorolac
+ Cannabis, 112
Kew tree, see under Ginkgo
Khartoum senna, see under Senna
King’s clover, see under Mellilot
King’s cureall, see under Evening primrose oil
Kneeholm, see under Butcher’s broom
Kneeholy, see under Butcher’s broom
Knotted wrack, see under Kelp
Kola, see under Cola
Korean ginseng, see under Ginseng
Kudzu, 267
+ Acetylsalicic acid, see Aspirin
+ Antibacterials, 268
+ Antibiotics, see Antibacterials
+ Anticoagulants, 268
+ Antidiabetics, 268
+ Antiplatelet drugs, 268
+ Aspirin, 268
+ Benzdiazepines, 268
+ Beta blockers, 268
+ Calcium-channel blockers, 268
+ Digoxin, 268
+ Estrogen antagonists, see Oestrogen antagonists
+ Estrogens, see Oestrogens
+ Fexofenadine, 268
+ Hormonal contraceptives, 268
+ Hypoglycaemic agents, see Antidiabetics
+ Lysine acetylsalicyle, see Aspirin
+ Methotrexate, 268
+ Nicotine, 268
+ Nitrates, 260
+ Oestrogen antagonists, 268
+ Oestrogens, 268
+ Paclitaxel, 269
+ Tamoxifen, 268
+ Theophylline, 269
Kwao Kru Kao, see under Kudzu
L
Laboratory tests
+ American ginseng, 223
+ Ashwagandha, 42
+ Asian ginseng, 223
+ Creatine, 157
+ Danshen, 162
+ Ginseng, 223
+ St John’s wort, 373
Lactobacillus acidophilus, 13
Lady’s thistle, see under Milk thistle
Lapacho, 270
+ Anticoagulants, 271
Lappa, see under Burdock
Large cranberry, see under Cranberry
Larrea divaricata, see under Chaparral
Larrea mexicana, see under Chaparral
Larrea tridentate, 128
Leontodon taraxacum, see under Dandelion
Leucanthemum vulgare, see under Feverfew
Levonorgestrel
+ St John’s wort, 370
Levophylthrocine (Thyroxine)
+ Arjuna, 37
+ Pepper, 319
+ Piperine, 319
+ Soya, 357
+ Soy milk, 357
Licorice, see under Liquorice
Index

Methylenedioxymethamphetamine (Ecstasy)
+ Cannabidiol, 111
Methylenedioxymethamphetamine (Methamphetamine)
+ St John’s wort, 373
Metoclopramide
+ Aegus castus, 17
Metronidazole
+ Liquorice, 275
+ Milk thistle, 295
Midazolam
+ Asian ginseng, 222
+ Bitter orange, 70
+ Black cohosh, 74
+ Coffee, 100
+ Cranberry, 153
+ Echinacea, 170
+ Flavonoids, 189
+ Garlic, 199
+ Ginkgo, 210
+ Ginseng, 222
+ Goldenseal, 231
+ Grapeseed, 240
+ Kaempferol, 189
+ Milk thistle, 294
+ Naringenin, 189
+ Quercetin, 189
+ Rooibos, 342
+ Saw palmetto, 345
+ St John’s wort, 364
+ Tangeretin, 189
+ Warfarin, 358
Midsummer daisy, see under Feverfew
Milfoil, see under Yarrow
Milk
+ Cocoa, 140
+ Green tea, 385
+ Tea, 385
+ Tea, green, see Green tea
Milk thistle, 292
+ Caffeine, 294
+ Chloroxazone, 294
+ Digoxin, 294
+ HIV-protease inhibitors, see Protease inhibitors
+ Indinavir, 295
+ Irbuprofen, 294
+ Metronidazole, 295
+ Midazolam, 294
+ Nifedipine, 295
+ Protease inhibitors, 295
+ Pyrazinamide, 296
+ Ranitidine, 296
+ Ritonavir, 295
+ Rosuvastatin, 296
Millepertuis, see under St John’s wort
Mitomycin
+ see under Cranberry
Mountain grape, see under Oregon grape
Mouth root, see under Coptis
Mukul myrrh, see under Guggul
Mycofolate
+ St John’s wort, 373
Myrica, see under Bayberry
Myrica cerifera
Myricin, 186
Myrtillus, see under Bursa-pastoris
Myrtillus
Myricetin
Myrica cerifera

N
N-Acetyl-5-methoxytryptamine, 285
N-(Aminoiminomethyl)-N-methylglycine, 156
Nanny bush, see under Blue haw
Naproxen
+Nabumetone, 260
Narcotic analgesics, see Opioids
Narcotics, see Opioids
Naringenin
+ Caffeine, 189
+ Enalapril, 191
+ Lovastatin, 194
+ Midazolam, 189
+ Quinidine, 193
+ Quinine, 193
+Nimodipine, 189
Natto
+ Acenocoumarol, 358
+ Coumarins, 358
+ Warfarin, 358
Natural coumarins, 297
+ Coumarins, 301
+ Talinolol, 301
Nelfinavir
+ Cannabis, 113
+ Dronabinol, 113
+ St John’s wort, 375
Neomycin
Neomyxin
+Naproxen, 250
+Nepeta glechoma, see under Ground ivy
Nepeta hederacea, see under Ground ivy
Nettle, 302
Neuroleptics, see Antipsychotics
Nevirapine
+ Pepper, 316
+ Piperine, 316
+ St John’s wort, 374
Nicarin, see Nicotinic acid
Nicardipine
+ Ginkgo, 211
Nicotine
+ Alphalfa, 22
+ Caffeine, 103
+ Cannabis, 111
+ Coffee, 147
+ Daidzein, 261
+ Genistein, 261
+ Glycitein, 261
+ Isoflavones, 261
+ Kudzu, 268
+ Soya, 358
Nicotinic acid (Niacin)
+ Betacarotene, 64
Nifedipine
+ Arjuna, 37
+ Chinese angelica, 130
+ Cranberry, 153
+ Danshen, 162
+ Flavonoids, 189
+ Ginger, 205
+ Ginkgo, 212
+ Grapefruit, 237
+ Melatonin, 287
+ Milk thistle, 295
+ Peppermin, 321
+ Ploysocanol, 324
+ Quercetin, 189
+ Schisandra, 348
+ St John’s wort, 365
Nimodipine
+ Flavonoids, 189
+ Morin, 189
Nisoldipine
+ Flavonoids, 189
+ Grapefruit, 237
+ Naringin, 189
Nitrate, see also individual drugs
+ Arjuna, 37
+ Isoflavones, 260
+ Kudzu, 268
+ Puerarin, 260
Nitrofurantoin
+ Chrysir, 188
+ Flavonoids, 188
Nitrous oxide
+ St John’s wort, 362
Nobiletin
+ Cannabidiol, 111
Non-steroidal anti-inflammatory drugs, see NSAIDs
Norethisterone
+ St John’s wort, 370
Nortriptyline
+ Cannabis, 114
Nosebleed, see under Yarrow
NSAIDs (Nonsteroidal anti-inflammatory drugs), see also individual drugs and drug groups
+ Cannabis, 112
+ Devil’s claw, 166
+ Evening primrose oil, 180
+ Feverfew, 185
+ Ginger, 206
+ Ginkgo, 214
+ Willow, 399
Nucleoside reverse transcriptase inhibitors
+ Astragalus, 47
Opioids (Narcotics, Opiates), Oval buchu individual drugs Opiates Oregon grape Orange root Orlistat Oriental ginseng

Ofloxacin contraceptives Oolong tea primrose oil Oestrogen antagonists (Estrogen antagonists), see also individual drugs + Agnus castus, 17 + Alfalfa, 23 + Chinese angelica, 130 + Hops, 252 + Kudzu, 268 + Red clover, 333 + Shatavari, 354 Oestrogen receptor modulators + American ginseng, 224 + Asian ginseng, 224 + Chinese angelica, 130 + Ginseng, 224 Oestrogens (Estrogens), see also individual drugs, consider also Hormonal contraceptives + Agnus castus, 17 + Aniseed, 34 + Hops, 252 + Kudzu, 268 + Melatonin, 287 + Shatavari, 354 Omeprazole + Betacarotene, 64 + Ginkgo, 216 + Liquorice, 275 + St John’s wort, 375 Onagra biennis, see under Evening primrose oil Oolong tea, see under Tea Opiates, see also Opioids Opioids (Narcotics, Opiates), see also individual drugs + Agnus castus, 17 + Cannabis, 112 + St John’s wort, 375 Oral antidiabetics, see Antidiabetics Orange root, see under Goldenseal Oregon grape, 303 Oriental ginseng, see under Ginseng Orlistat + Betacarotene, 64 + Lycopene, 281 Osterick, see under Bistort Oval buchu, see under Buchu Oxazepam + St John’s wort, 364 Oxymorphone + Cannabinoids, 112 OxypHENbutazone + Pepper, 316 + Piperine, 316 OxYtetracycline + Acidophilus, 14 + Glucosamine, 228

+ Pepper, 317 + Piperine, 317 P-P-glycoprotein substrates + Horse chestnut, 255 Paclitaxel + Alfalfa, 22 + Berberine, 60 + Biochanin A, 261 + Flavonoids, 192 + Genistein, 261 + Goldenseal, 232 + Isoflavones, 261 + Kudzu, 269 + Morin, 192 + Naringin, 192 + Quercetin, 192 + Red clover, 333 + Resveratrol, 337 + Soya, 358 Panax ginseng, see under Ginseng Panax notoginseng, see under Ginseng Paullinia cupana Paprika, see under Capsicum Paracetamol (Acetaminophen) + Ashwagandha, 42 + Caffeine, 103 + Cannabis, 112 + Chitosan, 133 + Genistein, 192 + Glucosamine, 227 + Hops, 252 + Parsley, 305 + Senna, 351 + Shatavari, 354 Paraguay tea, see under Maté Paroxetine + St John’s wort, 376 Parsley, 304 + Acetaminophen, see Paracetamol + Aminophenazone, 305 + Coumarins, 305 + Indanediones, 305 + Lithium compounds, 305 + Paracetamol, 305 + Pentobarbital, 305 + Warfarin, 305 Passiflora, 307 + Amfétamine, 308 + Amfétamines, 308 + Amphetamines, see Amfétamines + Central nervous system depressants, see CNS depressants + CNS depressants, 308 + Kava, 308 + Phenobarbital, 308 Passiflora incarnata, 307 Passion flower, see under Passiflora Passion vine, see under Passiflora Pau D’arco, see under Lapacho Paullinia cupana, 243 Paullinia sorbilis, see under Guarana Pelargonidin, 186 Pelargonium, 309 + Coumarins, 310 + Warfarin, 310 Pelargonium reniforme, 309 Pelargonium sidoides, 309 Penicillin G, see Benzylpenicillin Penicillins, see also individual drugs + Acidophilus, 14 Pennroyal, 311 + Iron compounds, 312 Pentobarbital + Capsicum, 117 + Hops, 253 + Parsley, 305 + Pepper, 315 + Piperine, 315 + Valerian, 396 Peonidin, 186 Pepper, 313 + Antithyroid drugs, 319 + Ciclosporin, 315 + Coenzyme Q10, 143 + Cyclosporine, see Ciclosporin + Dichlofenac, 316 + Digoxin, 315 + Diphenylhydantoin, see Phenytion + Fosphenytoin, see Phenytion + Green tea, 386 + Indometacin, 316 + Isomiazid, 316 + Levotheroxine, 319 + Nevirapine, 316 + Oxyphenbutazone, 316 + Oxytetraacycline, 317 + Pentobarbital, 315 + Phenobarbital, 315 + Phenytoin, 317 + Propranolol, 318 + Rhodiola, 339 + Rifampicin, 318 + Rifampin, see Rifampicin + Tea, green, see Green tea + Theophylline, 315 + Thyroxine, see Levothyroxine + Turmeric, 391 + Verapamil, 319 Peppermint, 320 + Benzoic acid, 322 + Caffeine, 321 + Calcium-channel blockers, 321 + Ciclosporin, 321 + Cyclosporine, see Ciclosporin + Digoxin, 322 + Felodipine, 321 + Fluorouracil, 322 + 5-FU, see Fluorouracil + Iron compounds, 322 + Nifedipine, 321 Peppermint oil + Antacids, 321 + Foods, 322 + Histamine H2-receptor antagonists, 321 + Proton pump inhibitors, 321 Persicaria bistorta, see under Bistort Petasites hybridus, 96 Petasites officinalis, see under Butterburr Petasites ovatus, see under Butterburr Petasites sabinus, see under Butterburr Petasites vulgaris, see under Butterburr Pethidine, see under Butcher’s Broom

Petroselinum sativum, 309 PetroseLimum peregrinum, see under Parsley PetroseLimum vulgare, see under Parsley Pettigree, see under Butcher’s Broom
Piperine, 318
Piper nigrum

Peumus boldus, 78

Phenazone (Antipyrine)
+ Capiscum, 117
+ Policosanol, 325

Phencyclidine
+ Cannabis, 112

Phenelzine
+ Ginseng, 224
+ Siberian ginseng, 224

Phenobarbital
+ Ashwagandha, 42
+ Elder, 173
+ Ginkgo, 215
+ Passiflora, 308
+ Pepper, 315
+ Piperine, 315
+ St John’s wort, 364
+ Valerian, 396

Phenothiazines, see also individual drugs,
consider also Antipsychotics, consider also
Dopamine antagonists
+ Evening primrose oil, 180

Phenprocoumon
+ Ginger, 205
+ St John’s wort, 379

4-Phenyloquinones, 297

Phephlyropanolamine
+ Caffeine, 103
+ Coffee, 147

Phenylalanine (Diphenylhydantoin, Fosphenylalanine)
+ Ashwagandha, 42
+ Cannabis, 113
+ Ginkgo, 209
+ Pepper, 317
+ Piperine, 317
+ St John’s wort, 364

Phosphodiesterase type-5 inhibitors
+ Epimidium, 178

Physalis somnifera, see under Ashwagandha

Pimpinella anisum, 33

Pineapple, see under Bromelain

Pinus maritima, see under Pycnogenol

Pinus maritimus, 328

Pinus pinaster, 328

Pogostemon
+ St John’s wort, 362

Piper longum, see under Pepper

Piper methysticum, see Kava

Piper nigrum, 313

Piperine
+ Ciclosporin, 315
+ Cyproheptadine, see Ciclosporin
+ Digoxin, 315
+ Diphenylhydantoin, see Phenytoin
+ Fosphenytoin, see Phenytoin
+ Green tea, 386
+ Levothyroxine, 319
+ Nevirapine, 316
+ Oxycodone, 316
+ Oxetraclavamycin, 317
+ Pentobarbital, 315
+ Pheno-barbital, 315
+ Phenytoin, 317
+ Propranolol, 318
+ Rifampicin, 318
+ Rifampin, see Rifampicin
+ Tea, green, see Green tea
+ Theophylline, 318

Proton pump inhibitors, see also individual drugs
+ Betacarotene, 64
+ Ginkgo, 216
+ Peppermint oil, 321
+ St John’s wort, 375

Provitamin A, see under Betacarotene

Prunus africana, 330

Psoralen, 297

Pueraria hirsuta, see under Kudzu

Pueraria lobata, see under Kudzu

Pueraria mirifica, see under Kudzu

Pueraria montana, 267

Pueraria phaseoloides, see under Kudzu

Pueraria thunbergiana, see under Kudzu

Puerarin
+ Acetylsalicylic acid, see Aspirin
+ Antibacterials, 260
+ Antibiotics, see Antibacterials
+ Anticoagulants, 260
+ Anti-inflammatories, 260
+ Antiplatelet drugs, 260
+ Aspirin, 260
+ Benzodiazepines, 260
+ Calcium-channel blockers, 260
+ Hypoglycaemic agents, see Antidiabetics
+ Lysine acetylsalicylate, see Aspirin
+ Nitrates, 260

Puero, see under Kudzu

Pulegium erectum, see under Pennroyal

Pulegium parviflorum, see under Pennroyal

Pulegium vulgare, see under Pennroyal

Pumello, see under Grapefruit

Pumpkin, 327

Purple clover, see under Red clover

Purple coneflower, see under Echinacea

Purple medick, see under Alfalfa

Pycnogenol, 328
+ Acetylsalicylic acid, see Aspirin
+ Aspirin, 329
+ Lysine acetylsalicylate, see Aspirin

Pygeum, 330

Pygeum africanum, see under Pygeum

Pyranocoumarins, 297

Pyrazinamide
+ Milk thistle, 296

Pyrethrum parthenium, see under Feverfew

Q

Quaker bonnet, see under Skullcap

Quazepam
+ St John’s wort, 364

Queen of the meadow, see under Meadowweet

Quercetin
+ Aceclovin, 188
+ Anticoagulants, 188
+ Antipatelet drugs, 188
+ Calcium-channel blockers, 189
+ Ciclosporin, 190
+ Cyproheptadine, see Ciclosporin
+ CYP2C8 substrates, 193
+ Digoxin, 191
+ Etoposide, 191
+ Midazolam, 189
+ Nifedipine, 189
+ Paclitaxel, 192
+ Quinidine, 193
Quercetin-3-rutinoside, 186
Quercitrin, 186
Quinidine
  + Aloes, 29
  + Baicalin, 193
  + Flavonoids, 193
  + Kaempferol, 193
  + Naringenin, 193
  + Quercetin, 193
  + Senega, 351
  + St John’s wort, 372
Quinine
  + Capsicum, 117
  + Flavonoids, 193
  + Naringenin, 193
  + Naringin, 193
  + Quercetin, 193
Quinolone antibiotics, see Quinolones
  + Quinolones, see also individual drugs
  + Burana, 94
Quinupristin/dalfopristin
  + Acidophilus, 14

R
Rabeprazole
  + St John’s wort, 375
Ranitidine
  + Milk thistle, 296
Rattleroot, see under Black cohosh
Rattleweed, see under Black cohosh
Red Indian paint, see under Bloodroot
Red bush tea, see under Rooibos
Red clover, 332
  + Antibacterials, 333
  + Antibiotics, see Antibacterials
  + Anticoagulants, 333
  + Digoxin, 333
  + Estrogen antagonists, see Oestrogen antagonists
  + Fexofenadine, 333
  + Oestrogen antagonists, 333
  + Paclitaxel, 333
  + Tamoxifen, 333
  + Warfarin, 333
Red pepper, see under Capsicum
Red puccoon, see under Bloodroot
Red root, see under Bloodroot
Red root sage, see under Danshen
Red sage, see under Sage
Red tea, see under Tea
Red vine leaf, 334
Renshen, see under Ginseng
Repaglinide
  + St John’s wort, 362
Resveratrol, 335
  + Anticoagulants, 336
  + Antiplatelet drugs, 336
  + CYP2C19 substrates, 336
  + CYP2C9 substrates, 336
  + Diclofenac, 336
  + Mephentoin, 336
  + Paclitaxel, 337
Retinol, see Vitamin A
Reversible inhibitors of monoamine oxidase type A, see RIMAs
Rhamnus cathartica, see under Frangula
  + Rhamnus frangula, 197
  + Rhamnus purshiana, 119
  + Rheum emodi, see under Rhubarb
  + Rheum officinale, 340
  + Rheum palmatum, 340
  + Rheum rhaponticum, see under Rhubarb
  + Rheum tanguticum, see under Rhubarb
  + Rheumatism root, see under Wild yam
Rhodiola, 338
  + Aminophylline, 339
  + Pepper, 339
  + Theophylline, 339
  + Warfarin, 339
  + Rhodiola rosea, 338
Rhubarb, 340
  + Liquorice, 275
Ribbed meliot, see under Melilot
Rifampicin (Rifampin)
  + Garlic, 203
  + Ginger, 206
  + Pepper, 318
  + Piperine, 318
  + Trikatu, 318
Rifampin, see Rifampicin
RIMAs (Reversible inhibitors of monoamine oxidase type A), see also individual drugs
  + Soya, 358
Risperidone
  + Ginkgo, 216
Ritonavir
  + Cat’s claw, 121
  + Garlic, 202
  + Ginkgo, 215
  + Milk thistle, 295
  + St John’s wort, 375
Robusta coffee, see under Coffee
Rockweed, see under Kelp
Rodiola, see under Rhodiola
Rofecoxib
  + Ginkgo, 214
Roman chamomile, 125
Rooibos, 341
  + CYP3A4 substrates, 342
  + Iron compounds, 342
  + Midazolam, 342
Rose root, see under Rhodiola
Rosiglitazone
  + Asian ginseng, 221
  + Flavonoids, 193
  + Ginseng, 221
  + Quercetin, 193
  + St John’s wort, 362
Rosuvastatin
  + Milk thistle, 296
  + St John’s wort, 376
Round buchu, see under Buchu
Rubbed thyme, see under Thyme
Rudbeckia, see under Echinacea
Rudbeckia hirsuta, see under Echinacea
Rudbeckia purpurea, see under Echinacea
Rudbeckia serotina, see under Echinacea
Ruscus aculeatus, 95
Rutin, 186
S
Sabal, see under Saw palmetto
Sabal serrulata, see under Saw palmetto
Sabal serratatum, see under Saw palmetto
Sacred bark, see under Cascara
Sage, 343
Saiiko, see under Bupleurum
Saiko-ka-ryukotsu-borei-to
  + Carbamazepine, 90
Sairei-to
  + Ofloxacin, 90
Salai guggul, see under Boswellia
Salami, see Tyramine-rich foods
Salicin, 399
Salicylates, see also individual drugs
  + Ashtwagandha, 42
  + Danshen, 163
Salisburia adianthifolia, see under Ginkgo
Salisburia biloba, see under Ginkgo
Salix, see under Willow
Salix alba, see under Willow
Salix cinerea, see under Willow
Salix daphnoides, see under Willow
Salix fragilis, see under Willow
Salix pentandra, see under Willow
Salix purpurea, see under Willow
Salix species, 399
Salvia, see under Sage
Salvia lavandulifolia, see under Sage
Salvia miltiorrhiza, 161
Salvia officinalis, 343
Savita triloba, see under Sage
Sambucus, see under Elder
Sambucus nigra, 172
Samento, see under Cat’s claw
Sanchi ginseng, see under Ginseng
Sanguinaria, see under Bloodroot
Sanguinaria australis, see under Bloodroot
Sanguinaria canadensis, see under Bloodroot
Sanguinaria dilleniana, see under Bloodroot
Sanguisorba, see under Burnet
Sanguisorba officinalis, 93
Sanguisorba polygama, see under Burnet
Saquinavir
  + Bergamottin, 301
  + Cat’s claw, 121
  + Dihydroxybergamottin, 301
  + Flavonoids, 193
  + Garlic, 202
  + Quercetin, 193
  + St John’s wort, 375
Saccharum comosum, see under Broom
Sarothamnus vulgaris, see under Broom
Saw palmetto, 344
  + Alprazolam, 345
  + Anticoagulants, 345
  + Benzodiazepines, 345
  + Caffeine, 345
  + Chloroxazone, 345
  + Dextromethorphan, 346
  + Midazolam, 345
  + Warfarin, 345
Scabwort, see under Elecampane
Scented mayweed, 125
Schisandra, 347
  + Coumarins, 348
  + Nifedipine, 348
  + Tacrolimus, 348
  + Warfarin, 348
Schisandra chinensis, 347
Schisandra sphenanthera, see under Schisandra
Scoparius, see under Broom
Scoparius, see under Broom
Scopolamine, see Hyoscyne
Scopolin, 297
Scotch broom, see under Broom
Scullcap, see under Skullcap
Scutellaria, see under Skullcap
Scutellaria baicalensis, 51
Scutellaria lateriflora, 355
Scutellaria macrantha, see under Baical skullcap
Seawrack, see under Kelp
Sedatives, see Anxiolytics
Sedum rosea, see under Rhodiola
Sedum roseum, see under Rhodiola
Selective serotonin re-uptake inhibitors, see SSRIs
Serrata, see under Senna
Serenoa serrulata, 76
Serenoa, 76
Seritic, 355
Sertraline
SSRIs (Selective serotonin re-uptake inhibitors), see also individual drugs
Seminodium valproate, see Valproate
Senna, 349
+ Acetaminophen, see Paracetamol
  + Cardiac glycosides, see Digitalis glycosides
  + Corticosteroids, 350
  + Digitalis glycosides, 350
  + Digoxin, 350
  + Diuretics, loop, see Loop diuretics
  + Diuretics, thiazide, see Thiazides
  + Estradiol, 350
  + Furosemide, 350
  + Ketoprofen, 351
  + Liquorice, 275
  + Loop diuretics, 350
  + Oestradiol, see Estradiol
  + Paracetamol, 351
  + Propranolol, 351
  + Quinidine, 351
  + Thiazide diuretics, see Thiazides
  + Thiazides, 350
  + Verapamil, 352
Senna alexandrina, see under Senna
Serenoa, see under Saw palmetto
Seronoa repens, 344
Seronoa serrulata, see under Saw palmetto
Serpentine, see under Aristochloia
Sertraline
+ St John’s wort, 376
Seville orange, see under Bitter orange
Sevoflurane
+ Aloe vera, 25
  + St John’s wort, 362
Shatavari, 353
+ Acetaminophen, see Paracetamol
  + Antidiabetics, 354
  + Atovaquone, 354
  + Ciclosporin, 354
  + Cyclosporine, see Ciclosporin
  + Dantrolene, 354
  + Digoxin, 354
  + Estrogen antagonists, see Oestrogen antagonists
  + Estrogens, see Oestrogens
  + Hypoglycaemic agents, see Antidiabetics
  + Ketoprofen, 354
  + Morphine, 354
  + Oestrogen antagonists, 354
  + Oestrogens, 354
  + Paracetamol, 354
  + Tamoxifen, 354
  + Tolbutamide, 354
Sho-saiko-to
+ Caffeine, 90
  + Carbamazepine, 90
  + Ofloxacin, 90
  + Tolbutamide, 90
Short buchu, see under Buchu
Siberian ginseng
+ Alprazolam, 222
+ Dextromethorphan, 223
+ Digoxin, 223
+ Laboratory tests, 223
+ Oral antidiabetics, 221
+ Phenelzine, 224
  + Warfarin, 225
Sildenafil
+ Cannabis, 113
  + Epimedium, 178
Silybum marianum, 292
Silymarin, 292
Sinisetin, 186
Single chamomile, 125
Skullcap, 355
Skullcap, baical
Smallage, see under Single chamomile
Sinensetin
Snakeweed, see under Broom
Sodium nitroprusside
+ Policosanol, 325
Sodium picosulfate
+ Liquorice, 275
Sodium valproate, see Valproate
Soybean isoflavones
Soy milk
+ Levothyroxine, 357
+ Thyroxine, see Levothyroxine
  + Warfarin, 358
Soy isolavones
+ Acidophilus, 14
Soy milk
+ Levothyroxine, 357
+ Thyroxine, see Levothyroxine
  + Warfarin, 358
Spanish sage, see under Sage
Sparrowgrass, see under Asparagus
Spartium scoparium, see under Broom
Spiraea ulmaria, see under Meadowweet
Spirolactone
+ Arjuna, 37
Squash, see under Pumpkin
Squaw mint, see under Pennroyal
Squawroot, see under Black cohosh
SSRIs (Selective serotonin re-uptake inhibitors), see also individual drugs
  + Melatonin, 288
  + St John’s wort, 376
St Bartholomew’s tea, see under Maté
St John’s wort, 360
  + Alfentanil, 374
  + Alprazolam, 364
  + 5-Aminolevulinic acid, 362
  + Aminophylline, 377
  + Am-triptylaine, 378
  + Antidiabetics, 362
  + Atazanavir, 375
  + Ato-vasatin, 376
  + Beer, alcohol-free, see Tyramine-rich foods
  + Benzodiazepeines, 364
  + Buprenorphine, 374
  + Bupropion, 364
  + Buspirone, 365
  + Caffeine, 365
  + Calcium-channel blockers, 365
  + Carbamazepine, 363
  + Chloroxazone, 366
  + Coumarins, 379
  + Ciclosporin, 366
  + Citemedine, 367
  + Combined hormonal contraceptives, 370
  + Cyclosporine, see Ciclosporin
  + Darunavir, 375
  + Debrisoquin, see Debrisoquaine
  + Debrisoquine, 367
  + Delavirdine, 374
  + Dextromethorphan, 367
  + Diazepam, 364
  + Dienogest, 368
  + Digoxin, 368
  + Diphenylhydantoin, see Phenytoin
  + Divalproex, see Valproate
  + Duloxetine, 375
  + Efavirenz, 374
  + Eletriptan, 379
  + Emergency hormonal contraceptives, 370
  + Eplerenone, 369
  + Ethynylestradiol, 370
  + Etoposide, 369
  + Fentanyl, 362
  + Fexofenadine, 369
  + Fluoxetine, 376
Thyroid hormones

Thyroxine

+ Alfalfa, 23
+ Ashwagandha, 42
+ Caffeine, 104
+ Cannabis, 113
+ Capsicum, 118
+ Daidzein, 263
+ Danshen, 163
+ Ginkgo, 206
+ Ginseng, 224
+ Goldenseal, 233
+ Liquorice, 275
+ Shatavari, 354
+ Sho-saiko-to, 90
+ St John’s wort, 362

Toothache tree, see under Prickly ash
Toothed wrack, see under Kelp

Topotecan

+ Chrysin, 192
+ Flavonoids, 192
+ St John’s wort, 372

Trailing ecliptha, see under Eclipta

Tranquilisers, see Anxiolytics

Tranylcypromine

+ Soy sauce, 358

Trazodone

+ Ginkgo, 217

Tree primrose, see under Evening primrose oil

e

Trental, see under Evening primrose oil

Trijolenum borysthenicum, see under Red clover

Trijolenum bracteatum, see under Red clover

Trijolenum lenkoranicum, see under Red clover

Trijolenum pratense, 332

Trijolenum ukrainicum, see under Red clover

Trigonella foenum-graecum, 182

Trigonella upendræ, see under Alfalfa

Trigatu

+ Diclofenac, 316
+ Indometacin, 316
+ Isoniazid, 316
+ Rifampicin, 318
+ Rifampin, see Rifampicin

Triptans, see individual drugs
+ St John’s wort, 379

Tropical kudzu, see under Kudzu

True sage, see under Sage

Tumeric, 390

+ Beta blockers, 391
+ Cetylprolor, 391
+ CYP3A4 substrates, 392
+ Iron compounds, 391
+ Midazolam, 392
+ Pepper, 391
+ Talinolol, 391

Turnera aphrodisiaca, see under Damiana

Turnera diffusa, 158

Turnera microphylla, see under Damiana

Tussilago farfara, 150

Tussilago petasites, see under Butterbur

Tyramine

+ St John’s wort, 369

Tyramine-rich foods (Beer, alcohol-free)
+ St John’s wort, 369

U

Ubidecarenone, see under Coenzyme Q10

Ubiquinone, see under Coenzyme Q10

Umbelliferone, 297

Umbrella plant, see under Butterbur

Uncaria guianensis, 120

Uncaria tomentosa, 120

Urta, see under Nettle

Urta dioica, 302

Urta unens, see under Nettle

Uva-ursi, see under Bearberry

Uña de gato, see under Cat’s claw

V

Vaccinium macrocarpon, 152

Vaccinium myrtillus, 66

Vaccinium oxyccoccus, see under Cranberry

Valerian, 394

+ Alcohol, 396
+ Alprazolam, 396
+ Barbiturates, 396
+ Benzodiazepines, 396
+ Caffeine, 397
+ Chloroxazone, 397
+ CYP2D6 substrates, 397
+ Dextromethorphan, 397
+ Ethanol, see Alcohol
+ Ginkgo, 214
+ Loperamide, 397
+ Midazolam, 396
+ Pentobarbital, 396
+ Phenobarbital, 396
+ St John’s wort, 397

Valeriana officinalis, 394

Valproate (Divalproex, Semisodium valproate, Sodium valproate)
+ Ashwagandha, 42
+ Ginkgo, 209
+ St John’s wort, 372

Valproate semisodium, see Valproate

Valproic acid, see Valproate

Valpromide, see Valproate

Vancomycin

+ Acidophilus, 14

Vardenafil

+ Epimedium, 178

Vasodilators, see individual drugs, see also Nitrites
+ Arjuna, 37

Vegetable gold, see under Coptis

Venlafaxine

+ St John’s wort, 375

Verapamil

+ Flavonoids, 189
+ Naringin, 189
+ Pepper, 319
+ Piperine, 319
+ Quercetin, 189
+ Senna, 352
+ St John’s wort, 365

Viburnum prunifolium, 75

Vinca alkaloids, see also individual drugs
+ Astragalus, 47

Vitamin A (Retinol)

+ Alcohol beverages, 63

Vitamin C substances

+ Alpha tocopherol, 305
+ Wu jia pi, 304

Vitamin C, see Vitamin C substances

Vitamin C substances (Ascorbic acid)
+ Aloe vera, 25

Vitamin E substances (Tocopherols, dl-alpha tocopherol)
+ Aloe vera, 25
Vitex agnus-castus, 16
Vitis vinifera, 239
Voriconazole
  + St John's wort, 379

Warfarin
  + Alfalfa, 23
  + American ginseng, 225
  + Andrographis, 31
  + Asafoetida, 40
  + Asian ginseng, 225
  + Benzethonium chloride, 238
  + Boldo, 79
  + Chamomile, German, 126
  + Chinese angelica, 131
  + Chitosan, 134
  + Coenzyme Q10, 143
  + Cranberry, 154
  + Danshen, 164
  + Devil's claw, 166
  + Evening primrose oil, 181
  + Fennel, 183
  + Garlic, 203
  + German chamomile, see Chamomile, German
  + Ginger, 205
  + Ginkgo, 217
  + Ginseng, 225
  + Glucosamine, 228
  + Grapefruit, 238
  + Green tea, 387
  + Liquorice, 276
  + Lycium, 278
  + Meadowsweet, 284
  + Melatonin, 289
  + Natto, 358
  + Parsley, 305
  + Pelargonium, 310
  + Policosanol, 324
  + Red clover, 333
  + Rhodiola, 339
  + Saw palmetto, 345
  + Schisandra, 348
  + Siberian ginseng, 225
  + Soy protein, 358
  + Soy sauce, 358
  + Soyabean, 358
  + Soy milk, 358
  + St John's wort, 379
  + Tea, 387
  + Tea, green, see Green tea
  + Tofu, 358

Water bugle, see under Bugleweed

Wax myrtle, see under Bayberry

Weissdorn, see under Hawthorn

White mint, see under Peppermint

White pepper, see under Pepper

White willow, see under Willow

Whitethorn, see under Hawthorn

Whortleberry, see under Bilberry

Wild asparagus, see under Shatavari

Wild celery, see under Celery

Wild chamomile, 125

Wild yam, 398

Willow, 399
  + Anticoagulants, 399
  + Antiplatelet drugs, 399
  + Nonsteroidal anti-inflammatory drugs, see NSAIDs
  + NSAIDs, 399

Winter cherry, see under Ashwagandha

Withania somnifera, 41

Wolfberry, see under Lycium

Wood avens, see under Lycium

Wood spider, see under Devil's claw

Wu-Wei-Zi, see under Schisandra

X

Xanthorrhiza simplicissima, see under Goldenseal

Xanthoxylum, see under Prickly ash

Y

Yarrow, 401

Yellow melilot, see under Melilot

Yellow root, see under Goldenseal

Yellow starwort, see under Elecampane

Yellow sweet clover, see under Melilot

Yellow wood, see under Prickly ash

Yerba maté, see under Maté

Yin Yang Huo, see under Epimedium

Z

Zalcitabine
  + Astragalus, 47

Zanthoxylum, see under Prickly ash

Zanthoxylum americanum, 326

Zanthoxylum clava-herculis, 326

Zanzibar aloes, see under Aloes

Zidovudine
  + Astragalus, 47

Zingiber, see under Ginger

Zingiber officinale, 204

Zingiberis rhizoma, 204

Zolpidem
  + Caffeine, 100
  + Melatonin, 286

Zopiclone
  + Caffeine, 100